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Human embryonic stem cells (hESCs) are derived from the inner cell mass of a 
5-day old blastocyst. hESCs possess the cardinal properties of unlimited self-renewal 
and pluripotency which enable them to give rise to the approximately 220 different 
cell types that comprise the human body. Theoretically, harnessing this property of 
hESCs could provide an inexhaustible source of cell therapy material for diseases like 
diabetes, Parkinson’s disease, etc.  
In order to assess the usefulness of hESCs in regenerative medicine, I 
investigated the ability of two cell lines– hES2 and hES3– to generate derivatives of 
mesoderm and endoderm in vitro. Differentiation into these particular lineages was of 
interest to me as hESC-derived β-like cells could be used as cell therapy for Type I 
Diabetes and haematopoietic cells from the same source could possibly be used to 
induce transplantation tolerance in a host receiving the allogeneic hESC-derived cell 
therapy graft. To this end, I evaluated published strategies that used stromal cell 
support or cytokines to differentiate hESCs or hESC-EBs into haematopoietic-like 
cells. Differentiation either on a cell layer of OP9 stroma or in the presence of 
cytokines like SCF, IL-4, TPO and Flt3L generated haematopoietic cells from both 
hES2 and hES3 EBs. The haematopoietic identity of these cells was established by the 
expression of relevant markers like CD45, CD14, CD34, CD83 and CD86 and the 
formation of colony forming units in methylcellulose cultures. The combination and 
concentrations of the cytokines used or the stroma itself seemed to bias the 
differentiation towards a granulocytic fate as no erythroid cells were formed at any 
stage. This finding might also indicate the restricted differentiation potential of hES2 
and hES3. Though not efficient, the differentiation achieved in this study provides 
proof-of-principle that these 2 cells lines can be directed to a haematopoietic fate. 
v 
A simultaneous investigation of the endodermal potential of these cells resulted 
in the development of a three-dimensional differentiation strategy in which hESC-EBs 
embedded in Matrigel were exposed to Activin A and Bmp4 to generate definitive 
endoderm. Differentiation progressed in a developmentally relevant sequence with the 
formation of TBRA-expressing primitive streak-like cells followed by FOXA2- and 
SOX17-expressing endodermal cells. These cells differentiated further in the presence 
of growth factors that promote pancreatic development and maturation to generate 
PDX1+ pancreatic progenitors which gave rise to insulin-secreting β-like cells albeit at 
a low efficiency. The unexpected combinatorial effect of Activin A and Bmp4 on the 
formation of endoderm was investigated in detail using molecular techniques that 
dissected the individual role of these factors in the differentiation. However, no clear 
mechanism of action was evident from these studies. A global view of the 
differentiation was obtained using microarray technology which revealed expression 
of novel genes and novel expression patterns of known genes in this system. 
Expression analysis of a few selected genes in the early mouse embryo showed 
hitherto uncharacterized expression domains some of which may be relevant to 
endoderm formation. The significance of these genes in the specification of endoderm 
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1.1. Embryonic stem cells 
The isolation of mouse and human embryonic stem cells (ES cells) heralded a 
new era in regenerative medicine, raising hopes for effective cellular therapies to treat 
conditions like diabetes and heart disease. Working with the simple goal of replacing 
defective, diseased or lost cell types, embryonic stem cell-based therapy promised the 
repair of damaged tissue/s or organs of the human body. ES cells are derived from the 
inner cell mass (ICM) of the blastocyst-stage pre-implantation embryo which gives 
rise to the approximately 220 specialised cell types in the human body. ES cells 
possess the cardinal properties of self-renewal and pluripotency which enable them to 
give rise to all the cells that comprise the vertebrate body. The first successful 
isolation and study of pluripotent ES cells was accomplished in the mouse in 1981 
(Evans and Kaufman 1981; Martin 1981). The ease with which mouse embryonic 
stem cells (mESCs) can be derived and manipulated has made them an ideal model 
system for the study of developmental biology. In vitro differentiation of mESCs has 
successfully given rise to cells of the various germ layers and provided valuable 
insights into the events in early development of the embryo like hemangioblast 
development (Keller 2005; Keller 1995). mESCs retain their pluripotency despite 
extended in vitro culture and generate all three germ layers and the germ line when re-
introduced into mouse blastocysts (Bradley et al. 1984).  
ES cell research achieved another milestone in 1994 when Bongso et al. (1994) 
reported the isolation and culture of ICM cells with stem cell-like morphology from 
human blastocysts (Fig 1.1A) though cultures failed beyond 2 passages. The first 
long-term culture (4-5 months) of human embryonic stem cells (hESCs) was 
accomplished using mouse fibroblast feeder layers by Thomson et al. (1998) (Fig 
1.1B). These cells show characteristic expression of pluripotency markers like the 
1 
transcription factor OCT4/ POU5F11 and the cell surface antigen Tra1-60 (Fig 1.1 D-
E). Unlike mESCs the pluripotent nature of hESCs cannot be demonstrated through 
chimera formation as there are obvious ethical concerns in generating mosaic human 
embryos that require development in utero. Therefore, in vitro differentiation into the 
three embryonic germ layers– ectoderm, mesoderm and endoderm– and in vivo 
teratoma formation assays are used to substantiate pluripotency of hESCs. For in vitro 
culture of hESCs, mouse or human primary “feeder” monolayers are still popular 
though substrates like Matrigel are also widely used. In addition to the traditional 
method of mechanical dissection, enzymes like Trypsin and Collagenase IV have 
been successfully used for passaging hESCs. Culture media also play an important 
role in maintenance of the undifferentiated state. For example, unlike mouse ES cells, 
hESCs do not require LIF (leukemia inhibitory factor) or Bmp4 (bone morphogenetic 
protein 4) for maintenance of self-renewing, undifferentiated cultures. A combination 
of Activin A/ Nodal and Fgf2 has been shown to be sufficient to maintain hESCs in 
the pluripotent state even in the absence of feeders, fetal bovine serum or Matrigel 
(Xiao et al. 2006; Vallier et al. 2005; James et al. 2005; Beattie et al. 2005). 
If mouse ES cells are grown in suspension cultures on low-attachment surfaces 
in the absence of feeder support, they form aggregates of differentiating cells called 
embryoid bodies or EBs (Fig 1.1C) (Reubinoff et al. 2000; Doetschman et al. 1985; 
Evans 1981). Various precursors representing the three germ layers including 
haematopoietic and endothelial progenitors emerge as these EBs spontaneously 
differentiate (Keller 1995).  
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Figure 1.1. Embryonic origin of human embryonic stem cells and their in vitro 
characterisation. (A) 5-day human blastocyst with inner cell mass (ICM), blastocoel 
cavity (C) and trophectoderm (T). Image from the Advanced Fertility Centre, Chicago 
http://www.advancedfertility.com/blastocystimages.htm. (B) A single hESC colony, 
here hES3, maintained on a mitotically inactivated mouse embryonic fibroblast 
(MEF) monolayer. Typically a hESC colony grown under these conditions has the 
dense, white ‘central button’ surrounded by a thinner halo of cells with a crisp border. 
(C) hESC-derived embryoid bodies (EBs) in suspension culture. (D, E) 
Immunostaining performed on hESC colonies for pluripotency markers. Nuclear 
staining for transcription factor OCT4 (D) and cell surface staining for Tra 1-60 (E) 
show that more than 90% of the cells in all colonies stain positive for these two 
markers. 
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Detailed investigation of the differentiating ES/ EB system suggests that it 
recapitulates to a limited degree the early events of embryonic development (Dvash 
and Benvenisty 2004; Dvash et al. 2004; Rust et al. 2006). EBs derived from hESCs 
organise themselves in a manner reminiscent of the early post-implantation mouse 
embryo, with features like an outer jacket of extraembyonic (visceral) endoderm (Rust 
et al. 2006). These similarities prompted the use of the EB system as a model to 
stimulate in vitro the early events of mammalian axis specification and germ layer 
patterning. Several methods of EB formation– in hanging drops, in low-attachment 
plates, in 3D matrices (synthetic and natural) and the use of various growth factors in 
all or some of these methods– are commonly used to induce differentiation.  
Though they were thought to be equivalent to the ICM, it was suggested that ES 
cells are cell culture artefacts as they adapt well to in vitro growth conditions and 
show properties not usually associated with the embryo such as dependence on 
exogenous cytokines/ growth factors (Buehr et al. 2003; Smith 2001; Rossant 2001). 
Later studies provided evidence that ES cells likely bear closer resemblance to 
embryonic germ (EG) cells as several germ cell markers like Dppa3 (Stella) were 
expressed in ES cells (Zwaka and Thomson 2005). Derivation of pluripotent cell lines 
from the mouse epiblast, called EpiSCs, brought to light similarities between these 
cells and hESCs (Tesar et al. 2007; Brons et al. 2007). EpiSCs and hESCs have the 
ability to give rise to trophectoderm in the presence of Bmp4 which mESCs do not 
possess (Xu et al. 2002; Beddington and Robertson 1989). Another similarity between 
these two cell types is the requirement for Activin A/ Nodal signaling to maintain 
pluripotency, a property that has been previously demonstrated for hESCs (Vallier et 
al. 2005). Inhibition of Activin signaling resulted in rapid downregulation of 
pluripotency genes in both cell types. This may reflect the embryonic stage to which 
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hESCs are equivalent, since Activin/ Nodal signaling is known to be required for 
maintenance of pluripotency in the epiblast of the post-implantation embryo (Brennan 
et al. 2001). The importance of Activin/ Nodal signaling in the maintenance of hESC 
pluripotency has been re-iterated in recent studies detailing the derivation and 
maintenance of induced pluripotent stem (iPS) cells (Takahashi et al. 2007; Takahashi 
and Yamanaka 2006). iPS cells are generated from mouse and human adult fibroblasts 
by nuclear reprogramming using a few critical transcription factors like SOX2, 
OCT3/4, KLF4 and C-MYC. Human iPS cells were found to be similar to hESCs in 
several aspects including morphology, growth kinetics, cell-surface antigen profile 
and gene expression. In addition it has been shown that iPS cells can differentiate into 
the three germ layers in vivo and form teratomas identical to hESCs.  A family tree of 
the various embryonic and extraembryonic lineages summarises these relationships 
(Fig 1.2). The lineage tree emphasizes that as the biology of ES cells continues to be 
unravelled, there is mounting confidence that culture regimes can be developed which 
direct pluripotent ES cells toward a desired cell fate that would be therapeutically 
useful. 
Much progress has been made towards gaining a better understanding of hESC 
biology and translating the technology from the bench to the bedside. However, the 
hESC lines on which most of these studies were performed might have restricted use 
in the clinic, as they have all come in contact with materials or reagents of foreign 
origin (Bongso et al. 2008; Hentze et al. 2007). Recently, this presumed roadblock 
was deemed acceptable when the Food and Drug Administration (FDA), USA granted 
permission for the use of oligodendrocyte cells derived from hESCs for Phase I 
clinical trials to treat patients with spinal cord injury. GRNOPC1, oligodendroglial 
progenitor cells, were derived from the H7 hESC line (Thomson et al. 1998) and have 
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been demonstrated to support re-myelination and nerve growth stimulation in animal 
models of acute spinal cord injury (Kierstead et al. 2005). The current clinical trial 
will be an attempt to demonstrate the safety of using these cells in humans though it 
has been shown to elicit a poor immune response in the immune-deficient animal 
model (Okamura et al. 2007). 
The isolation of clinically compliant hESC lines was recently achieved (Crook 
et al. 2007). Six hESC lines were derived on clinical grade human fibroblasts, Ortec 
143, and maintained in chemically defined medium containing Knockout Serum 
Replacement supplemented with basic fibroblast growth factor (bFGF). None of the 
reagents used during derivation and expansion were of animal origin and the entire 
process was carried out under cGMP (current good manufacturing practice) 
guidelines. Even with derivation of qualified lines and defined culture methods, the 
recurring challenges of directing the differentiation of hESCs to generate cell types in 
numbers sufficient for clinical applications and ensuring acceptance of the transplant 
and preventing rejection by the recipient’s immune system remain. Harnessing and 
understanding the differentiation potential of hESCs and employing that knowledge to 
gain insight into mammalian development is the focus of the thesis. Such studies 
require experimental strategies that are guided by the knowledge of how a vertebrate 
embryo develops and forms a complex organism. Hence it is important to review key 
aspects of the mammalian developmental sequence especially, formation of the three 
























Figure 1.2. Lineage tree of embryo-derived cells and cell lines. The various stages 
of embryonic development from fertilization to E6.5 are represented in this image. 
Embryonic Stem (ES) cells are derived from the inner cell mass while epiblast stem 
cells (EpiSCs) are of epiblast origin. Human ES cells (hESCs) and mouse EpiSCs 
have been found to share several characteristics which imply that hESCs might 
actually be derivatives of epiblast-stage embryos. The extraembryonic endoderm is 
the source of XEN cells while TS cells represent the extraembryonic ectoderm 





1.2. Gastrulation– formation of mesoderm and endoderm in the embryo 
Gastrulation is defined by a series of complex morphogenetic events in 
combination with cell proliferation and differentiation that generate the three 
embryonic germ layers and establish a vertebrate body plan (Arnold and Robertson 
2009; Tam and Loebel 2007; Rossant and Tam 2004). In the mouse embryo 
gastrulation is initiated by the recruitment of epiblast cells to the primitive streak 
around E6.5 (Fig 1.3). There, epiblast cells undergo an epithelial to mesenchymal 
transition (EMT) as they ingress through the primitive streak, emerging as definitive 
endoderm (DE) and the mesoderm (Tam and Beddington 1992; Lawson et al. 1991). 
Mesoderm is formed as an epithelial sheet that expands from either side of the 
primitive streak (Tam and Behringer 1997). Extensive studies on cells of the cardiac 
mesoderm showed that the timing of ingression through the streak and the position of 
these cells in the epiblast determines their lineage fate (Tam and Behringer 1997; Tam 
and Zhou 1996; Lawson et al. 1991). The newly formed motile mesoderm migrates 
laterally between the outer visceral endoderm (VE) layer and the epiblast, while the 
definitive endoderm moves to the outer surface of the embryo by displacing the 
visceral endoderm proximally (Lawson et al. 1986). However, recent work from 
Kwon et al. (2008) suggests that the DE is formed by intercalation of epiblast cells 
with the underlying VE and not by complete displacement of the visceral layer. This 
work is discussed in more detail in section 1.5. Understanding the complex events that 
characterise gastrulation is critical for the creation of experimental strategies to 



























Figure 1.3. Gastrulation and specification of the germ layers. (A) Gastrulation in 
the human embryo results in the specification of the three germ layers. During this 
process, prospective endodermal and mesodermal cells ingress through the primitive 
streak (arrows) to form definitive endoderm and mesoderm respectively. Image used 
with permission from Dias et al. 2004 Neurosurgical Focus. (B) Gastrulation in 
mouse embryo occurs at E6.5 and forms the three germ layers. Image used with 
permission from Tam et al. 2007 Nature Reviews Genetics. (C) Cellular organisation 
of the mouse embryo after the process of gastrulation is complete. Image used with 




1.3. Regenerative medicine and embryonic stem cells 
1.3.1. Diabetes– a candidate disease for cell therapy 
Autoimmune destruction of insulin-secreting pancreatic β-cells within the Islets 
of Langerhans causes Type I diabetes which makes up about 5-10% of all diagnosed 
cases (Fig 1.4). Clinical islet transplantation using cadaveric islets is to date, the most 
successful cell-based therapy that has been used to treat this condition (Shapiro et al. 
2006; Robertson 2004). However, the demand for such islets far exceeds the actual 
supply especially, since the modern procedure called the Edmonton protocol utilises 
approximately 10,000 islet ‘units’ per kilogram of bodyweight. Therefore, alternative 
sources of β-cells need to be identified and hESCs are an appealing source. 
Pluripotent hESCs retain the capability to differentiate into cells representing all three 
embryonic germ layers (Keller 2005).  By directing the differentiation of hESCs to 
generate functional beta (β) cells, one hopes to create an inexhaustible supply of these 
cells for the treatment of Type I Diabetes. This has led to immense interest in the 
differentiation of hESCs into endodermal derivatives. One part of this thesis (Chapter 
4) describes my contribution to the development of in vitro β cell differentiation 
protocols, with particular emphasis on the formation of the definitive endoderm, the 
parental lineage of the pancreas.  
 
1.3.2. Transplantation tolerance of hESC-derived cell therapy 
As research efforts intensify towards deriving transplantable cell therapy 
material like insulin-secreting β-like cells from hESCs, issues pertaining to graft 
acceptance/ rejection must be addressed. Rejection of hESC-derived cell populations 
is a significant concern as their immunological signature is indisputably foreign 
10 
(Draper and Andrews 2002; Drukker et al. 2002). Interestingly, several studies have 
shown that undifferentiated hESCs and their differentiated progeny may in fact be 
immune-privileged or can be transplanted specifically into immune-privileged sites 
like the spleen (Li et al. 2004; Drukker et al. 2006). Transplantation into areas like the 
spleen are under consideration largely due to the low expression of Major 
Histocompatibility Complex (MHC) class I molecules on the surface of hESCs and 
the resultant low immunostimulatory capacity of these cells. Though hESC-
derivatives show increased expression of MHC class I, this does not alter the immune 
response.  
Recently, it was demonstrated that mESCs and their derivatives with similar 
MHC I signatures can induce a potent immunological reaction even with a single 
difference between the donor and host Minor Histocompatibility antigen (mH) 
profiles (Robertson et al. 2007). However, these authors found that the inherent 
immune-privileged status of mESCs could be harnessed with minimal intervention to 
induce tolerance and prevent rejection. Highlighting the differences between the 
mouse and human systems, a very recent study shows that hESCs and their 
derivatives might not be as immune-privileged as previously thought and are capable 
of triggering a severe immune response in a xenogeneic host like the mouse 
(Swijnenburg et al. 2008). In this study, hESCs transduced with a double fusion 
reporter gene consisting of firefly luciferase and enhanced GFP were tracked in vivo 
using bioluminescent imaging. Severe infiltration of the graft 5 days after 
transplantation with immune cells and detectable levels of anti-hESC antibodies in the 
recipient serum together demonstrate active rejection of the graft. However, this 
reaction could be mitigated with the use of immunosuppressive drugs like tacrolimus 
(binds calcineurin and thereby inhibits T-cell signaling ) and sirolimus (blocks 
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activation of T- and B- cells by inhibiting interleukin-2 responsiveness) that 
prolonged hESC graft survival up to 28 days. The disadvantage of 
immunosuppression is the undesirable side-effects that it triggers including 
nephrotoxicity, liver disease, increased risk of infections and a compromised immune 
system. Though much progress has been made, it is clear that more studies are 
required before any of the above strategies can be put to clinical use. Nevertheless, 
one step forward is the recently approved clinical trial for oligodendrocyte precursor 
cells derived from hESCs. The outcome of this safety study is eagerly anticipated as 
longevity of the graft within humans will pave the way for effective cell therapy.   
If the inherent immune-privileged status of hESCs is inadequate to aid 
transplantation, one strategy is to induce tolerance with the use of hESC-derived 
haematopoietic cells (Drukker and Benvenisty 2004). Haematopoietic stem cells 
(HSC) are mesodermal derivatives that serve as progenitors to all cells that circulate 
in the peripheral blood and differentiate into several myeloid or lymphoid lineages 
during development (Fig 1.5). Theoretically, haematopoietic cells derived from the 
same exact source as the therapeutic graft, for example, a given pluripotential hESC 
line, could tolerise the recipient towards the incoming transplant material irrespective 
of its cellular nature (Kaufman and Thomson 2002). Tolerance could either be 
induced (1) through mixed haematopoietic chimerism or (2) through tolerogenic 
dendritic cells (DCs) (Fig 1.6) (Drukker and Benvenisty 2004; Fairchild et al. 2004). 
Mixed haematopoietic chimerism refers to the use of haematopoietic progenitor 
cells to establish a resident donor population in the host. This grants donor-specific 
tolerance to the host and allows any other material from the same donor to be 
accepted with out any adverse reaction. Clinical examples of this phenomenon in 



































Figure 1.4. Pancreas and diabetes. The pancreas consists of Acinar cells which 
perform its exocrine functions and clusters of cells called Islets of Langerhans which 
perform its endocrine functions. Acinar cells secrete digestive enzymes like trypsin 
and chymotrypsin into the small intestine. Islets of Langerhans secrete various 
hormones into blood from its four main cell types which are (1) alpha (α) cells that 
secrete glucagon, (2) beta (β) cells that secrete insulin, (3) Delta (δ) cells that secrete 
somatostatin and (4) PP cells that secrete pancreatic polypeptide. The beta cells sense 
glucose levels in the blood and secrete Insulin to allow uptake of this important 
nutrient. Decreased production of Insulin leads to hyperglycemia and all the 
symptoms associated with the metabolic disease Type I Diabetes. Schematic diagram 




  Kawai et al. (2008) showed that the patient’s immune system accepted solid 
organ transplants from a donor whose haematopoietic cells were previously used to 
treat the same patient after myeloablative chemotherapy. A recent study describes the 
role of mixed chimerism in the successful treatment of type I diabetes in a mouse 
model transplanted with ES cell-derived haematopoietic material (Verda et al. 2008). 
Haematopoietic defects are one of the causes of autoimmune diabetes in the non-
obese diabetic (NOD) mice. Therefore, these authors generated diabetic-resistant 
adult haematopoietic progenitor-like cells from mESCs and transplanted these into 
NOD mice to induce islet cell tolerance and treat diabetes. Though cell surface marker 
analysis showed that full donor chimerism was not established, the low level 
chimerism was significant enough to have an anti-diabetic effect. Importantly, no 
teratomas were formed in mice transplanted with the differentiated cells. Similar 
observations have previously been reported where highly homogenous differentiated 
populations failed to generate teratomas in the animal model (Kroon et al. 2008; 
Okamura et al. 2007). 
Mixed chimerism induces tolerance through the deletion of alloreactive T cells 
that would otherwise activate the host immune system against the incoming graft 
(Sykes 2001). Recently Bonde et al. (2008) demonstrated that tolerance could be 
induced by the stimulation of regulatory T (Treg) cells in the host. This mechanism in 
part can be attributed to the differentiation of the mixed pool of donor haematopoietic 
cells into allogeneic antigen-presenting cells (APCs). DCs are potent antigen 
presenting cells of the immune system that are responsible for priming naïve T cells 
(Banchereau and Steinman 1998). They are identified by the presence of co-
stimulatory cell surface molecules CD80, CD86 and CD83 that enhance the activation 






















Figure 1.5. Haematopoietic development. Pluripotent stem cells give rise to 
multipotent haematopoietic stem cells that differentiate into lymphoid and myeloid 
progenitors. T-cells, B-cells and Natural killer (NK) cells form from lymphoid 
progenitors. Myeloid progenitors differentiate into various lineages including 
erythrocytes, granulocytes and monocytes. The asterisk (*) marks the cell types from 
which dendritic cells can be generated. Schematic diagram adapted with permission 























Figure 1.6. Pluripotent hESCs for cell replacement therapy. Regenerative 
medicine aims to produce therapeutic cell types through the directed differentiation of 
hESCs in vitro. Rejection of hESC-derived grafts is a concern that may be effectively 
addressed by using co-grafts derived from the exact same hESC source. 
Haematopoietic progenitors are known to repopulate myeloablated animals by 
establishing donor-specific chimerism in the host. In much the same way, 
haematopoietic cells differentiated from hESCs can either be used directly to achieve 
a state of mixed haematopoietic chimerism or can be differentiated further to generate 
dendritic cells (esDCs) that tolerise the host to the incoming graft. Schematic diagram 






DCs are also involved in the maintenance of immunologic self-tolerance, 
inducing production of regulatory T cells or anergy/ immune unresponsiveness of 
autoreactive T cells (Steinbrink et al. 2002). Several studies have documented graft 
tolerance induced by donor DCs or host DCs in mice with various immunological 
backgrounds. Pulsing host DCs with alloantigens, using DCs to generate antigen-
specific Treg cells which induce tolerance, targeting DCs using monoclonal antibodies 
and targeting DCs using donor-derived apoptotic cells are some of the methods that 
were used with varying degrees of success (Morelli and Thomson 2007). If hESCs 
could be differentiated in vitro to form tolerogenic DCs, these could be presented to 
the host’s immune system to establish a state of tolerance. Theoretically, these DCs 
would selectively activate Treg cells that induce anergy and attenuate the host’s 
immune response to the graft, even though the introduction of DCs into the host can 
be considered an allogeneic transplantation. The predicted tolerance of this graft sets 
the stage for the delivery and engraftment of other hESC-derived transplant material 
such as cardiomyocytes or beta-like cells. Ideally, this second graft would be 
recognized as ‘self’ as the host’s immune system has encountered and developed prior 
tolerance to a similar set of antigens. 
To generate functional haematopoietic-like cells in vitro, it is critical to 
understand the process of haematopoiesis in vivo during embryogenesis. By closely 
mimicking in vitro the sequence of haematopoietic development, one envisages that 




1.4. Haematopoiesis  
1.4.1. Haematopoietic development in the mouse  
In the mouse, haematopoietic lineages first appear in the form of blood islands 
in the yolk sac, a derivative of the extraembryonic mesoderm by embryonic day E7.5 
of gestation (Russell and van den Engh 1979). This is preceded by the expression of 
key haematopoietic genes like Gata-2, Scl/ Tal-1 in the extraembryonic mesoderm 
which forms the visceral yolk sac (VYS), as revealed by in situ hybridization studies 
on the early embryo (Silver and Palis 1997). This yolk sac haematopoiesis was 
thought to seed the fetal liver and establish bone marrow haematopoiesis in the adult 
(Weissman et al. 1977; Moore and Metcalf 1970). However, this was shown 
otherwise by elegant grafting experiments done mainly in the chick which showed 
that adult haematopoiesis was established by cells from the embryo proper and the 
allantois (Caprioli et al. 2001; Cormier and Dieterlen-Lievre 1988; Dieterlen-Lievre 
1975). By E10-11 of gestation, the yolk sac primitive haematopoiesis declines and 
haematopoietic activity shifts to the embryo proper where HSC emerge from the 
intraembryonic Para-Aortic Splanchnopleura (PAS/P-Sp), which is the presumptive 
aorta-gonad-mesonephros (AGM) (Godin et al. 1993; Medvinsky et al. 1993).  
At E7.5, before circulation has connected the YS with the embryo, the PAS only 
contains stem cells with lymphoid potential (Cumano et al. 1996). Intraembryonic 
HSC emerge autonomously in situ, independently from the precursors emerging in the 
YS (Cumano et al. 1996; Medvinsky and Dzierzak 1996). Particularly, the dorsal 
aorta and the vitelline and umbilical arteries have been shown to contain 
haematopoietic cells between E9.5 to E12 (Garcia-Porrero et al. 1995). In vitro 
culture of segments of the embryo proper demonstrated that the haematopoietic 
precursors were exclusively present in the PAS (Godin et al. 1995). The AGM region 
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is the first site in the murine embryo where multipotential long term repopulating 
stem cells (LTRSCs) are detected (Muller et al. 1994). In this study, the E10 AGM 
injected into irradiated mice showed long-term reconstitution of the haematopoietic 
system. The AGM functions as a haematopoietic site until E11/E12 when it begins to 
degenerate; at the same time there is an increase in fetal liver haematopoietic activity 
(Medvinsky and Dzierzak 1996; Muller et al. 1994; Medvinsky et al. 1993). 
Haematopoiesis in the liver is not de novo but occurs by colonization from other 
tissues like yolk sac, placenta and AGM (Gekas et al. 2005; Kumaravelu et al. 2002; 
Houssaint 1981; Johnson and Moore 1975). The large number of HSC in the fetal 
liver could be the results of these colonisations and expansion of the population by the 
liver itself (Takeuchi et al. 2002). Beyond this point the liver functions as the site of 
haematopoiesis until just before birth when the bone marrow takes over and remains 
the only site of haematopoiesis in the adult (Fig 1.7). 
The emergence of haematopoiesis is influenced by distinct interactions between 
germ layers within the embryo as well as transcription factors and other 
environmental factors. It has been shown that contact with visceral endoderm is 
required for primitive haematopoiesis in mouse yolk sac explants and that the VE can 
impart a haematopoietic fate to prospective neuroectoderm (Dyer et al. 2001; 
Belaoussoff et al. 1998). One of the signals responsible for this effect was found to be 
Indian Hedgehog which was then proven to be essential but not sufficient for effective 
primitive erythropoiesis in the mouse (Byrd et al. 2002). In the chick embryo, 
ventralising factors like vascular endothelial growth factor (VEGF) and bone 
morphogenetic protein 4 (BMP4) promote haematopoiesis while dorsalising factors 
like epidermal growth factor (EGF) and transforming growth factor α (TGF-α) 
antagonize the process (Pardanaud and Dieterlen-Lievre 1999). Similar activity of the 
19 
ventralising factors has been shown in the mouse through ES cell differentiation and 
gene targeting studies (Faloon et al. 2000; Shalaby et al. 1995; Winnier et al. 1995). 
For example, knockout studies showed that BMP4 is important for initiation of 
haematopoiesis in the mouse as Bmp4–/– embryos either die around gastrulation or 
have a smaller yolk sac and decreased erythropoiesis (Winnier et al. 1995). The 
critical requirement for Bmp4 in development of the cardiac mesoderm was also 
shown in studies on Bmp4 homozygous null mutant mice that showed abnormal heart 
formation (Fujiwara et al. 2002). These ventralising factors also regulate expression 
of critical haematopoietic transcription factors like Scl and Gata-1 (Sadlon et al. 
2004). In addition to these Runx1 and Gata-2 are known to be absolutely essential for 
definitive haematopoiesis that originates in the AGM region. Mice lacking Gata-2 
show a complete lack of committed progenitors and HSC and die at E10.5 as there is 
a severe drop in the number of AGM HSC (Tsai et al. 1994). Runx1 deficiency also 
leads to the absence of AGM HSC and all myeloid and lympho-myeloid progenitors 
(Cai et al. 2000). Absence of both transcription factors only marginally impaired 
primitive erythropoiesis thus revealing the specific role of these factors in the 
definitive program. Thus, complex interactions within the embryonic environment 
establish haematopoietic identity in the developing mouse embryo.  
The yolk sac blood islands in the developing embryo consist of primitive 
erythrocytes surrounded by differentiating endothelial cells (Risau 1991). This close 
developmental association of the haematopoietic and endothelial cell lineages within 
the blood islands of the developing embryo has led to the hypothesis that they arise 
























Figure 1.7. Haematopoiesis in the mouse embryo. (A) Haematopoietic cells are first 
visible at E7.5 in the yolk sac blood islands as primitive haematopoiesis is initiated. 
(B) At E8.25 circulation is established in the embryo. The allantois which will fuse 
with the chorion to form the umbilicus is seen at days E7.5 and E8.25. The para-aortic 
splanchnopleura (pSp) which is the prospective Aorta Gonad Mesonephros (AGM) is 
also indicated. (C) At E9.0 the embryo has turned and is enveloped in the yolk sac. 
Colonisation of the liver by haematopoietic progenitors begins at late E9. (D) The 
E10.5 mouse embryo contains haematopoietic clusters in the dorsal aorta in the AGM 
region, the vitelline (V) and umbilical (U) arteries. The first adult haematopoietic 
stem cells are found in these vessels. (E) Timeline of haematopoietic development in 
the mouse embryo. Arrows above indicate formation of specific haematopoietic 
populations. Arrows below show the colonisation of secondary sites of 
haematopoiesis. Schematic diagram adapted with permission from Dzierzak et al. 
2008 Nature Immunology. 
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The concept of a bi-potent hemangioblast was supported by the observation that 
the expression of several genes was common to both haematopoietic and endothelial 
cell populations (Asahara et al. 1997; Kabrun et al. 1997; Young et al. 1995; 
Anagnostou et al. 1994; Kallianpur et al. 1994; Millauer et al. 1993; Yamaguchi et al. 
1993; Fina et al. 1990). Studies on mice deficient in the receptor tyrosine kinase, Flk1 
support the hemangioblast hypothesis as homozygous mutant embryos do not develop 
blood vessels or yolk sac blood islands, and die between E8.5 and E9.5 (Shalaby et al. 
1997; Shalaby et al. 1995). ES cells provide a powerful tool to probe the existence of 
the hemangioblast population in the developing embryo. This is possible because 
haematopoietic and endothelial differentiation of ES cells in vitro is known to follow 
the same developmental sequence observed in the mouse embryo (Vittet et al. 1996; 
Keller 1995; Nakano et al. 1994; Keller et al. 1993; Wiles and Keller 1991; Risau et 
al. 1988). Using mESC-derived EBs, a common precursor for the primitive and 
definitive haematopoietic lineages was identified in vitro (Kennedy et al. 1997). 
When cultured in the presence of vascular endothelial growth factor (VEGF), c-Kit 
ligand and conditioned medium from an endothelial cell line D4T, these precursors 
formed colonies consisting of immature or blast-like cells that expressed a number of 
genes common to both the haematopoietic and endothelial lineages, including Tal-
1/Scl, CD34 and the VEGF receptor, Flk-1. This work was developed further by Choi 
et al. (1998) who established the blast colony assay using mESC-derived EBs to 
prove the presence of BL-CFCs (blast colony forming cells) that could clonally give 
rise to cells of both endothelial and haematopoietic lineages in presence of factors like 
VEGF. Using genetic tools, Chung et al. (2002) determined that haematopoietic cells 
develop from the Flk1+ Scl+ and Flk1– Scl+ population while endothelial cells arise 
from the Flk1+ Scl+ and Flk1+ Scl– population. Applying the blast colony assay to 
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early stage mouse embryos, it was demonstrated that in E7.0 embryos, the 
hemangioblast emerges from the posterior primitive streak and migrates to the 
extraembryonic mesoderm in the yolk sac (Huber et al. 2004). In this study, 
hemangioblasts were found to be most enriched in the Brachyury+ Flk1+ population 
within mESC-derived EBs and were determined to co-express Scl (Fig 1.8). 
Investigations in the zebrafish gastrula also provide evidence for the existence of a 
hemangioblast population (Vogeli et al. 2006). Detailed molecular characterization of 
hemangioblast cells has revealed an important role for the Notch pathway in 
differentiation of this multipotent lineage. Activation of Notch signaling in 
combination with inhibition of Wnt signaling was shown to be responsible in part for 
the formation of cardiac mesoderm from hemangioblasts while the converse was 
found to be important for specification of a primitive haematopoietic fate from 
hemangioblasts (Chen et al. 2008; Cheng et al. 2008). Recently, Lu et al. (2008) 
made improvements to the cell culture protocols to demonstrate that Bmp4 and VEGF 
were necessary and sufficient to induce robust differentiation of hESCs into 
hemangioblasts. Expression of hemangioblast-associated genes like TBRA, FLK-1, 
CD31 and LMO2 was upregulated in the differentiated cells while expression of the 
pluripotency gene OCT4 was downregulated. Hemangioblasts generated using this 
differentiation approach were recently shown to be tripotent cells which could 
differentiate into endothelial cells, haematopoietic cells and smooth muscle-like cells 
(Lu et al. 2009). This shows that functional vasculatures can be developed from such 
differentiated progeny again demonstrating that multipotent progenitors like the 






















Figure 1.8. A model for hemangioblast development. Hemangioblasts are thought 
to arise from the Brachyury (Bry+) expressing mesodermal population of the 
developing embryo. These cells go on to express Flk1 in addition to T and migrate to 
the yolk sac (Bry+/ Flk-1+). At this point the hemangioblast differentiates to form 
progenitors of haematopoietic (H), endothelial (E) and vascular smooth muscle 







1.4.2. Haematopoiesis in the human embryo 
Detectable yolk-sac haematopoiesis and expression of evolutionarily conserved 
haematopoietic genes in the human system closely follows the sequence in mouse 
(Tavian et al. 1999). However, the lack of detectable haematopoietic activity after day 
60 of human development suggests that the duration of yolk sac haematopoiesis in 
human gestation is shorter than that in birds and rodents (Huyhn et al. 1995; 
Dommergues et al. 1992; Migliaccio et al. 1986). Similar to the mouse embryo, the 
human yolk sac is the site of primitive haematopoiesis during which nucleated 
erythrocytes expressing embryonic globin and the surface molecule glycophorin A are 
detected. Primitive haematopoiesis gives way to definitive haematopoiesis in the liver 
where the erythrocytes are enucleated and express fetal globin (Brotherton et al. 
1979). As mentioned earlier studies in chick embryos provided evidence that the yolk 
sac gives rise predominantly to primitive haematopoiesis while the embryo proper is 
the site of definitive haematopoiesis. Haematopoiesis in the embryo proper occurs at 
the embryonic truncal arteries (homologous to the mouse AGM region) in early 
development (Tavian et al. 1996). Other components of the definitive haematopoietic 
lineage, like lymphoid cells, are derived from multipotential cells which can be found 
at either the yolk sac or the embryo proper or both. 
Recently, Tavian et al. (2005) used an in vitro organ culture assay with human 
embryonic explants to show that the aorta as well as the P-Sp is capable of 
establishing long-term haematopoietic cultures. This study also differentiated the 
multi-lineage potential of the yolk-sac and the embryo proper: though both 
contributed myeloid and NK cells, only intraembryonic haematopoiesis generated 
lymphoid cells. As in the mouse, progenitors from the embryo proper are thought to 
be responsible for the establishment of definitive haematopoiesis in the human system 
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(Tavian et al. 2001). Yoder et al. (1997) studied and identified these precursors in the 
embryo as CD34+/ c-Kit+ progenitor populations. CD34 is a cell-surface molecule 
thought to be one of the earliest markers of a haematopoietic cell/ progenitor. Another 
haematopoietic progenitor marker is c-Kit which is the receptor for the cytokine Stem 
Cell Factor (SCF/ Steel Factor). This study demonstrated that the CD34+/ c-Kit+ cells 
isolated from the yolk sac and separately from the P-Sp at the same stage of 
development showed presence of long-term repopulating stem cells (LTRSCs). 
LTRSCs are stem cells that can establish long term haematopoietic cultures and have 
the potency to repopulate an entire animal post irradiation. Beginning in the yolk sac 
and transiting through the liver, the haematopoietic program finally arrives in the 
bone marrow which takes over as the major site of haematopoiesis through out the 
lifetime of the developing adult (Fig 1.9). 
 
1.4.3. Haematopoietic differentiation from mESCs  
Although many aspects of embryonic haematopoiesis have been studied in 
detail, early events regulating the lineage specification and maturation of stem cells 
are still unclear. Studying the mouse embryo immediately after gastrulation and 
before the appearance of blood islands has yielded important insights into these 
processes (Baron 2005; Baron and Fraser 2005). However, unhindered analysis of 
developmental events was made possible with the isolation of embryonic stem cells. 
Extensive investigation of the properties and capabilities of these cells has led to the 
development of several experimental approaches to induce haematopoietic 


















Figure 1.9. Haematopoiesis in the human embryo. Primitive haematopoiesis begins 
in the yolk sac around day 16 and contributes to erythroid and granulo-macrophage 
lineages. Circulation initiates around day 21 of development and mainly involves the 
nucleated erythrocytes found in the yolk sac. Around day 23, the first haematopoietic 
cells in the fetal liver are detected. These cells are thought to be of yolk sac origin. A 
second wave of haematopoiesis occurs at day 27 during which clusters of 
haematopoietic cells are visible in the vitelline and umbilical arteries and the AGM 
region. This definitive haematopoiesis seeds the fetal liver leading to the second 
hepatic colonisation. The fetal liver remains the main site of haematopoiesis until 
after birth when the bone marrow takes over and becomes the only site of 
haematopoiesis throughout adult life. Schematic diagram used with permission from 







One favoured method is the formation of three-dimensional EBs from mESCs as 
described earlier (Evans and Kaufman 1981). Spontaneous mesodermal 
differentiation occurs quite reproducibly within mESC-EBs and has been shown to 
generate cardiac and haematopoietic mesodermal cells (Keller 1995; Doetschman et 
al. 1985). Co-culture on stromal feeder cells is another method employed to generate 
haematopoietic progeny from mESCs. Stromal cells of bone marrow or yolk sac 
origin are known to support the growth and maintenance of haematopoietic 
progenitors in culture (Lu et al. 1996; Wineman et al. 1993). One such cell line OP9 
is a murine macrophage colony stimulating factor (M-CSF)- deficient cell line which 
has been shown extensively to support the maintenance of haematopoietic progenitors 
differentiated from mESCs (Senju et al. 2003; Kitajima et al. 2003; Kyba et al. 2002; 
Nakano et al. 1994). OP9 co-culture mainly gives rise to B lymphocytes.  
Haematopoietic-like cells have also been obtained from mESCs differentiating 
in monolayers on extracellular matrix proteins like collagen (Nishikawa et al. 1998). 
The authors of this study used antibodies against markers like E-cadherin, Flk1/KDR, 
CD45, etc., to define the intermediate stages during differentiation of mESCs to blood 
cells. Gene targeting studies have revealed that transcription factors like Gata-1, 
Gata-2 and Scl that are known to be essential for haematopoietic development in the 
embryo are expressed during in vitro differentiation of mESCs. Gata-1 is necessary 
for primitive erythroid differentiation as mESCs deficient in Gata-1 and EBs derived 
from these showed a complete block in the development of erythroid precursors 
(Weiss et al. 1994). Mice homozygous for Gata-2 and mESCs derived from the same 
have defective primitive erythropoiesis and an absolute lack of definitive erythroid 
precursors (Tsai et al. 1994). Scl/ Tal-1 is critical for haematopoiesis as Tal-1 
deficient mESCs were found not to differentiate into several haematopoietic lineages 
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(Porcher et al. 1996). Though developmentally relevant markers were expressed on 
the differentiated progeny the functional competence of these cells was unclear. Since 
then, several studies have documented that haematopoietic progenitors derived from 
mESCs are capable of long-term repopulation of myeloablated mice (Burt et al. 2004; 
Kyba et al. 2003; Palacios et al. 1995). These studies were done with differentiated 
cells derived using distinct strategies and all of them showed low-level repopulating 
ability. Though these results are highly encouraging, more investigations need to be 
done to determine if these cells are indeed comparable to those found in the fetal liver 
and adult bone marrow.  
 
1.4.4. Haematopoietic differentiation from hESCs  
Although murine haematopoiesis has been extensively described using both 
embryological and gene targeting strategies, knowledge of early developmental 
decisions in the human embryo is limited. The study of human haematopoiesis has 
mainly been limited to primary human tissues like bone marrow, peripheral blood and 
umbilical cord blood. The differentiation of hESCs provides a possible inroad into 
embryonic development especially given the limited availability of human embryonic 
material. Differences in morphology, population doubling time and growth factor 
requirements between mESCs and hESCs point to the likelihood that there might be 
differences in the factors that direct in vitro differentiation of hESCs. Drawing on 
lessons from studies on mouse and human embryos and mESCs, hESCs have been 
subjected to various differentiation strategies in order to develop and establish models 
of human embryonic and haematopoietic development. These approaches are 
expectedly very similar to those used with mESCs despite the differences between the 
















Figure 1.10. Strategies for haematopoietic differentiation from ES cells. Various 
successful strategies have been used in the recent years to differentiate ES cells 
(mouse and human) into cells of the haematopoietic lineage. (A). Differentiation 
within an EB shares similarities with vertebrate development and serves as an in vitro 
model system. However, the three-dimensional structure allows only minimal access 
to monitor selected cell types and hence to guide the differentiation. (B) The use of 
stromal cells allows better access to the differentiating cells and limited guidance of 
the differentiation although it is labour-intensive process. Another disadvantage is the 
low reproducibility as efficiency of differentiation depends on the quality of the 
stromal cells. (C). Differentiation on a matrix like collagen, fibronectin, etc., has the 
advantage of being a selective strategy that allows for maximum access to cells and 
therefore, directed differentiation. However, determination of optimal culture 
conditions is difficult and the cost is extremely high. Schematic diagram adapted with 





A much reported strategy for haematopoietic differentiation from ES cells is the 
use of stromal cells as a supportive feeder layer which promotes the efficient 
production of haematopoietic derivatives in vitro. In addition to various murine cell 
lines including OP9 (described earlier), two immortalised human bone marrow 
stromal cell lines HS-5 and HS-27A have been shown to maintain bone marrow-
derived haematopoietic progenitors in culture (Nakano et al. 1994; Roecklein and 
Torok-Storb 1995). HS-5 secretes large amounts of cytokines; conditioned medium 
from this line supports the ex vivo expansion of both immature and mature 
haematopoietic progenitors. In contrast HS-27A does not secrete cytokines but has 
been shown to support formation of typically haematopoietic “cobblestone areas” 
from progenitor cells of human bone marrow origin (Torok-Storb et al. 1999). One of 
the first reports of hESC-derived haematopoietic colony-forming cells was from 
Kaufman et al. who co-cultured hESCs with either S17, a mouse bone marrow cell 
line, or C166, a mouse endothelial cell line (Kaufman et al. 2001). Few resulting cells 
(1-2%) were CD34+ CD38–, which identifies early haematopoietic cells. The 
haematopoietic potential of these cells at various stages of differentiation was 
demonstrated using the clonal assay for Colony Forming Units (CFUs). In this assay, 
a viscous Methyl Cellulose-based medium supplemented with appropriate cytokines 
is used to enrich the clonal progeny of single haematopoietic progenitor cells called 
colony-forming cells (CFCs) or colony-forming units (CFUs). In the study from 
Kaufman et al. (2001) the expression of evolutionarily conserved genes, GATA-2 and 
TAL-1, and the decline in their expression with a simultaneous decrease in CFU 
numbers confirmed the haematopoietic origin of the differentiated progeny. Although 
haematopoietic cells were successfully derived from hESCs and extensively 
characterized, some inherent problems in the process were brought to light. The 
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differentiation was inefficient as the number of CFUs generated from days 14 to 18 
was low (0.03%). The use of selectively enriched CD34+ cells from the whole 
population resulted in an improved CFU efficiency of 0.27% (equivalent to human 
bone marrow samples). However, no new CFUs (secondary or tertiary) were formed 
during this assay. The lack of new CFUs indicates the absence of LTRSCs that are 
essential for successful engraftment of an irradiated animal. Therefore, the 
haematopoiesis obtained by differentiation is transient and not definitive in nature. In 
another study, hESCs growing on OP9 monolayers were shown to give rise to CD34+ 
CD38– primitive haematopoietic-like cells which were further induced to differentiate 
into a definitive population by culturing on M5 stroma in the presence of cytokines 
(Vodyanik et al. 2005). These cells were enriched in CFUs and expressed 
haematopoietic genes like GATA-1, GATA-2, SCL/ TAL-1 and FLK1. This study was 
used by Slukvin et al. to demonstrate the efficient generation of well characterized 
DCs from hESCs (Slukvin et al. 2006). These authors used OP9 co-culture to 
differentiate hESCs into CD34+ haematopoietic progenitors. These precursors were 
then treated with GM-CSF and other cytokines in a non-feeder based system to 
generate myeloid cells like DCs. The DCs exhibited a typical marker profile (CD80, 
CD86, CD40, etc.,) and gave expected readouts in biological assays in vitro which 
demonstrated that these terminally differentiated cells were functional. 
Another proven method of differentiation from ES cells is the use of pro-
haematopoietic cytokines. Chadwick et al. (2003) demonstrated the successful use of 
cytokines like Stem Cell Factor (SCF), Flt-3 Ligand (Flt-3L), Interleukin-3 (IL-3), 
Interleukin-6 (IL-6) and Granulocyte Colony Stimulating Factor (G-CSF) and Bmp4, 
to direct the differentiation of hESCs to haematopoietic stem cells. In this study, the 
differentiated cells were characterised as CD45+ haematopoietic cells similar to both 
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committed adult haematopoietic tissue and the initial population of definitive 
haematopoietic cells detected within the AGM region of the human embryo around 
day 27 (Oberlin et al. 2002; Labastie et al. 1998). The haematopoietic transcription 
factors GATA-1 and PU.1 were upregulated in these cells, confirming their acquired 
identity. Though it did not significantly affect the efficiency of differentiation, Bmp4 
was found to promote the self-renewal capacity of these hESC-derived 
haematopoietic progenitors.  
An alternative strategy for haematopoietic differentiation of hESCs was 
developed by Zhan et al. (2004) where a combination of cytokines was used to 
generate functional antigen-presenting leukocytes in culture. Using a combination of 
serum stimulation and addition of haematopoietic cytokines to EBs grown in 
suspension, CD34+ CD45+ haematopoietic progenitors were generated in culture. In 
addition, cells expressing CD80, CD86 (dendritic-like cells) and CD40 (antigen 
presenting cells) were detected and confirmed to be of dendritic origin by Wright-
Giemsa staining which allows identification of the different cells in blood or bone 
marrow samples. These immature DC-like cells were shown to be functional antigen 
presenting cells through a mixed leukocyte reaction (MLR). In the MLR assay, the 
cytotoxic T-cell response to antigens is measured as a direct result of the antigen 
presenting activity of the test population. Even though there is extensive proof that in 
vitro differentiation of hESCs can give rise to HSC the functionality of these cells in 
vivo needs to be demonstrated. In a recent study, either a CD34+ CD38– or CD34+/ lin– 
cell population generated using S17 stroma was used to successfully engraft fetal 
sheep via haematopoietic chimerism (Narayan et al. 2006). This is an encouraging 
result that provides proof of principle that differentiated cells derived in vitro retain 
their functional behaviour after transplantation.  
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In Chapter 3 of this thesis, I will present preliminary results from investigations 
on the haematopoietic differentiation potential of two hESC lines, hES2 and hES3, 
which are extensively utilized in our laboratory. I employed two approaches– stromal 
cell co-culture and exposure to cytokines– to induce differentiation of the hESC lines. 
In both strategies, hESC-EBs were used as the starting material as these seemed to 
have a selective advantage over undifferentiated cells in generating differentiated 
progeny. Stromal cells are thought to promote differentiation by providing an 
environment that mimics in vivo conditions. Since the differentiation using stromal 
cells was sporadic it is possibly a spontaneous occurrence. Cytokine-based 
differentiation has the advantage of being a slightly more controlled and defined 
system in which pro-haematopoietic cytokines tightly control the development of the 
relevant cell types in contrast to the inconsistencies accompanying the use of stromal 
cells. This phenomenon was clearly noted in my investigations as cytokine treatment 
gave much more reproducible differentiation from hESCs. Though much 
improvement is needed to improve the efficiency of differentiated, these results 
provide proof that these two cell lines can be directed to a haematopoietic fate in vitro 
(Chapter 3). 
 
1.5. Definitive endoderm formation in the vertebrate embryo 
As a result of segregatory events in the embryo, the DE emerges from the 
anterior part of the primitive streak about 8 to 10 hours after gastrulation and 
incorporates into the visceral endoderm (VE) which covers the basal surface of the 
embryo (Grapin-Botton and Constam 2007; Tam and Beddington 1992; Lawson et al. 
1991). This endodermal layer progressively displaces the VE to a more anterior and 
proximal position and closer to the extraembryonic region of the embryo (Tremblay 
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and Zaret 2005; Kinder et al. 2000; Tam et al. 1993; Lawson et al. 1986). Supporting 
this observation is the expression of VE markers which initially mark the cells 
overlying both embryonic and extraembryonic regions and are subsequently restricted 
to the visceral layer of the yolk sac (Weber et al. 1999; Beddington and Robertson 
1999). By the late streak stage, the endodermal layer overlying the epiblast is 
exclusively DE, except for a region overlying the posterior primitive streak (Tam and 
Beddington 1992; Lawson and Pedersen 1987; Lawson et al. 1986). Soon after the 
emergence of DE, the gut endoderm folds and is internalized to form the gut tube 
from which the respiratory and digestive tracts and associated visceral organs develop 
(Lewis and Tam 2006; Wells and Melton 1999). This model of DE formation was 
arrived at through extensive fate-mapping studies using single-cell labelling and cell 
transplantation techniques. Advances in genetic and imaging tools available for such 
studies have led to a revision of this classical model. Kwon et al. recently put forth an 
‘intercalation’ model in which cells of the DE get integrated into the existing VE 
(Kwon et al.  2008). These authors used three different transgenic lines that expressed 
either Alpha Feto Protein (Afp) or Transthyretin (Ttr), both VE markers, to track these 
cells in vivo. Several findings were made during the course of this study. (1) Cells of 
the VE disperse to accommodate definitive endoderm cells thus leading to cell 
mixing. (2) The external epithelial lining of the embryo consists of both VE and DE 
cells (not exclusively VE). (3) Absence of expression of VE-specific genes is due to 
down regulation and not cell migration. (4) VE-derived cells incorporate into the gut 
tube and hence contribute to the embryo proper. The proposed new model for 










Figure 1.11. Development of endoderm in the vertebrate embryo. Historically, 
definitive endoderm is thought to arise at the anterior primitive streak present at the 
distal end of the embryo near the node. Ingression of definitive endodermal cells 
through the streak is accompanied by proximal movement of the visceral endoderm 
towards the extraembryonic region. In the new model proposed by Kwon et al. the 
visceral endoderm is not completely displaced but becomes dispersed by the 
intercalation of epiblast-derived definitive endodermal cells. Schematic diagram used 




Extensive studies in zebrafish, Xenopus and mouse have shown that members of 
the TGF-β family of molecules play critical roles in early development especially in 
the formation of mesoderm and endoderm (Schier 2003; Stainier 2002; Winnier et al. 
1995; Smith et al. 1993). Nodal and Activin A are two such ligands that signal 
through phosphorylated Smad molecules to initiate transcription of genes important in 
development (Shi and Massague 2003; Moustakas et al. 2001). Receptor Smads– 
Smad2 and Smad3 are integral to the Nodal signalling pathway as these molecules 
mediate the intracellular consequences of ligand binding (Fig 1.12) (Arnold and 
Robertson 2009). Nodal has been shown to be important in determining cell fate and 
cell movements during early vertebrate development (Vincent et al. 2003; Norris et 
al. 2002; Whitman 2001; Schier and Shen 2000; Nomura and Li 1998). Its role in 
patterning is revealed in Nodal mutant mouse embryos that fail to form anterior 
visceral endoderm (AVE) and primitive streak and have no anterior-posterior identity 
(Brennan et al. 2001; Conlon et al. 1994).  In the developing embryo, Nodal is also 
known to influence the formation of mesoderm and endoderm (Lewis and Tam 2006; 
Vincent et al. 2003; Lowe et al. 2001, Jones et al. 1995). Nodal establishes a gradient 
of expression which specifies the endoderm at higher levels and mesoderm at lower 
concentrations (Brennan et al. 2002; Stainier 2002; Chen and Schier 2001; Smith 
1995). Activin A closely mimics Nodal, which is the endogenous ligand, and 
transduces its signals using the same receptor apparatus and Smads with the exception 
of Cripto, a co-receptor which is required for most Nodal signalling (Chen and Shen 
2004; de Caestecker 2004; Schier 2003). This might explain why Activin can 
phosphorylate Smad2 faster than Nodal in Xenopus embryos as Nodal activity is 
limited by the requirement for the co-receptor (Lee et al. 2001). Studies on vertebrate 
embryos have shown that like Nodal, Activin can induce formation of both mesoderm 
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and endoderm in a dose-dependant manner (Okabayashi and Asashima 2003; 
Ninomiya et al. 1999; Gurdon et al. 1995; Gurdon et al. 1994; Smith et al. 1990). 
Though largely considered to be identical, differences between these two molecules 
have been reported. Ramis et al. (2007) showed that Activin and Nodal are expressed 
differently and regulate distinct sets of genes in Xenopus. While Activin was 
ubiquitously expressed, Nodal was restricted to the vegetal and equatorial regions of 
the embryo. 
For in vitro studies the commercially available preparation of Activin A is 
preferred over Nodal as it is more stable and shows better induction of differentiation 
(Tada et al. 2005). The ability of Activin A to generate either mesoderm or endoderm 
in a dose-dependent manner has been demonstrated in ES cells with low levels 
generating mesoderm and a higher concentration of Activin forming endoderm (Kubo 
et al. 2004; Johansson and Wiles 1995). Kubo et al. developed culture conditions in 
which Activin A induced formation of a primitive streak-like population expressing 
Brachury, which further developed into endodermal cells. Since then extensive 
studies have documented the use of Activin A in vitro to induce endoderm formation 
from mESCs and hESCs (McLean et al. 2007; D’Amour et al. 2005; Shi et al. 2005; 
Tada et al. 2005; Yasunaga et al. 2005). Activin A has also been employed 
successfully in generating more specialised and differentiated endoderm cell types 
from ES cells (D’Amour et al. 2006; Gouon-Evans et al. 2006). These observations 
prompted the use of Activin A in our differentiation strategy to induce formation of 
























Figure 1.12. Nodal pathway. Pro Nodal is processed by convertases like Furin or 
PACE4 to generate Nodal which binds to the EGF-CFC co-receptor, Cripto to 
activate signaling. Ligand binding causes phosphorylation of Smad2/3 which enables 
the co-Smad, Smad4 to complex with Smad2/3. This complex then translocates to the 
nucleus and binds to co-factors like Foxh1/ FAST to trigger transcription of 
downstream target genes including Nodal, Foxa2, Gsc, Pitx2 and Lefty1/2. Image 





1.5.1. Differentiation of mESCs to endodermal derivatives  
Endoderm induction has been extensively studied in model systems like 
Xenopus and zebrafish while such investigations in the mouse model have been 
limited due to the restricted accessibility to early stages of development. mESCs 
provide an ideal alternative system that allows extensive interrogation of mammalian 
development in vitro if their differentiation potential can be directed to give rise to 
desired cell types like endodermal cells (Keller 1995). One of the first reports of 
endoderm induction in vitro was from Kubo et al. who used a mESC line with GFP 
targeted to the Brachyury (Tbra) locus to monitor endoderm differentiation (Kubo et 
al. 2004, Fehling et al. 2003). Tbra is a T-box transcription factor that marks the 
primitive streak and nascent mesoderm in vertebrate embryos (Wilkinson et al. 1990). 
These authors used Activin A in serum-free conditions to differentiate mESCs into 
Foxa2 and Sox17-expressing endoderm and Tbra-expressing mesoderm at the 
expense of Gata1-expressing haematopoietic cells and neuroectoderm marked by 
Pax6.  Foxa2 (Forkhead box a2) is a marker of the anterior primitive streak (APS) and 
early endoderm, and is essential for the formation of foregut and midgut endoderm 
(Ang et al. 1993; Monaghan et al. 1993; Sasaki and Hogan 1993). Sox17 (Sry-related 
HMG box transcription factor) is expressed in the APS and DE, and is known to be 
essential for endoderm development as Sox17 null mice show severe depletion of 
definitive endoderm (Kanai-Azuma et al. 2002). The marker genes used most 
commonly to monitor endodermal differentiation as summarized in Table 1.1.  
Kubo et al. (2004) observed, rather unexpectedly, that the endodermal cells 
were specified from Tbra+ cells which also exhibited mesoderm potential at the 
appropriate concentration of Activin A. When used at a high concentration Activin A 
induced endoderm and very little mesoderm, while at lower concentrations only 
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mesoderm formed from Tbra+ cells. In the embryo, Tbra is exclusively expressed in 
the PS and since both mesoderm and endoderm emerge from the PS, these cell types 
would have been Tbra+ at some point during their development. This was 
demonstrated in mouse studies using differentiated mESCs which showed 
development of both mesoderm and endoderm from mESC-derived Tbra+ cells (Kubo 
et al. 2004). The formation of mesoderm and endoderm from the same cell population 
under relevant culture conditions lends support to the existence of the mesendoderm. 
Though the concept of a common progenitor for mesoderm and endoderm, termed 
mesendoderm, had earlier been shown in C. elegans and Xenopus, no direct evidence 
had been found in the mouse system (Rodaway and Patient 2001). In Zebrafish the 
existence of cells expressing markers of both mesoderm (Tbra) and endoderm 
(Gata5) that generate all endoderm but only some part of mesoderm has been shown 
(Rodaway et al. 1999; Kimelman and Griffin 2000). Cell fate studies in the mouse 
have previously pointed to the possible mesendodermal potential of the organizer 
region of the anterior primitive streak as it gives rise to both anterior definitive 
endoderm and axial mesoderm (Kinder et al. 1999; Lawson et al. 1991). Therefore, it 
seems likely that the Tbra+ Foxa2+ cells generated by Kubo et al. are similar to cells 
of the anterior primitive streak that express these markers and give rise to the first 
endodermal cells and may possibly represent mesendoderm (Wilkinson et al. 1990; 
Monaghan et al. 1993; Sasaki and Hogan 1993; Wells and Melton 1999). Though 
Tbra expression was used to define a bi-potent population by Kubo et al. it is not an 
exclusive marker of the mesendoderm. Tbra is expressed in the node and early 
mesodermal cells and does not distinguish between mesendoderm and other cells of 
the mesoderm (Showell et al. 2004).  
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Working on the hypothesis that Goosecoid (Gsc) might be a better marker of the 
mesendoderm, Tada et al. (2005) generated a mESC line with a GFP reporter knocked 
into the Gsc locus and showed that a bi-potent mesendoderm population exists during 
Activin-induced mesodermal and endodermal differentiation of mESCs. Gsc is a 
homeobox transcription factor expressed in the organizer region that forms definitive 
endoderm in the developing mouse embryo (Blum et al. 1992). Using Gsc-GFP 
knock-in mESCs these authors were able to define a Gsc+ E-cadherin+ PDGFR+ 
mesendoderm population that subsequently diverges into Gsc+ E-cadherin+ PDGFR- 
definitive endoderm precursors and Gsc+ E-cadherin– PDGFR+ mesodermal 
precursors. E-cadherin functions as a cell adhesion protein and is expressed in the 
epiblast and endoderm of the early mouse embryo (Takeichi 1995; Damjanov et al. 
1986). The development of mesoderm from the Ecadherin– precursors in the study 
outline above is consistent with the downregulation of E-cadherin expression during 
EMT which is essential for the differentiation and development of mesoderm at 
gastrulation (Burdsal et al. 1993).  PDGFRα (platelet-derived growth factor receptor 
α) is expressed in the presumptive mesoderm of the vertebrate embryo and is induced 
during mesoderm formation by high doses of Activin (Jones et al. 1993; Symes et al. 
1994).  The Gsc+ Ecadherin+ PDGFR– endoderm precursors and the Gsc+ Ecadherin– 
PDGFR+ mesoderm precursors defined in this study further developed into Foxa2 and 
Sox17-expressing definitive endoderm and some mesoderm lineages respectively. 
Though much progress was made in the derivation of endoderm induction in 
vitro it was still difficult to judge whether these differentiated endodermal cells 
represent definitive or visceral endoderm owing to the lack of molecular markers that 
distinguish between the two endodermal lineages (Grapin-Botton and Melton 2000; 









Gene Name Embryonic Expression Relevance 
Tbra Primitive streak, 
Nascent Mesoderm 
Required for posterior 
mesoderm movement and 
somite differentiation 
Gsc Primitive streak,  
Anterior mesoderm 
Role in cell fate specification 
and craniofacial development 
Foxa2 Anterior Primitve Streak, 
Early Endoderm 
Required for formation of 
foregut and midgut endoderm 
Sox17 Anterior Primitve Streak, 
Definitive Endoderm 
Required for formation of 
definitive endoderm 
 
Table 1.1. Marker genes expressed during the differentiation of mouse and            











However, the expression of Tbra (which does not mark the VE) and lack of 
expression of VE markers like Sox7 in the above differentiation strategies suggests 
that it is DE and not VE that is being specified from the Tbra+ and Gsc+ populations 
(Kanai-Azuma et al. 2002). In order to distinguish between formation of DE and VE 
in vitro, Yasunaga et al. (2005) exploited the following observations: (1) Gsc is 
expressed in the anterior visceral endoderm of the mouse embryo (Filosa et al. 1997) 
and (2) Sox17 is expressed in the DE and not in the anterior VE (Kanai-Azuma et al. 
2002). The authors proposed that it will be possible to distinguish between VE-
derived and DE-derived cells by monitoring appearance of mesendoderm markers 
during differentiation, as the DE forms through an intermediate mesendodermal state 
while the VE is derived directly from the ICM. In this study, a mESC line with a 
double knock-in– GFP into the Gsc locus and the human IL2Rα gene (CD25) into the 
Sox17 locus– was generated and used to define and characterize the differentiated 
populations in vitro (Yasunaga et al. 2005).  These authors were able to define 
mesendoderm-derived DE as Gsc+ Sox17+ and VE as Gsc– Sox17+ and used this 
marker profile to identify culture conditions that selectively induced formation of 
either DE (Activin in serum-free medium) or VE (serum-free medium without 
Activin) and not both tissues. An unexpected observation from this study was that the 
cells designated as DE also expressed Tbra, an expression pattern that has rarely been 
described (Kispert and Herrmann 1994). This suggests that the mESCs progress 
through a gastrulation-like stage during differentiation as Tbra is a known marker of 
the same. Activin A could be responsible for this developmental sequence as it is 
known to induce expression of Tbra (D’amour et al. 2006; Rust et al. 2006; Kubo et 
al. 2004; Kimelman and Griffin 2000). To characterize the DE and VE populations, 
further microarray analysis of the differentiations was done to identify cell surface 
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markers. Nine surface markers with 10-fold difference in expression between DE and 
VE were identified. One of these, Cxcr4, is a chemokine receptor for Sdf-1 (stromal 
cell-derived factor 1) which is expressed in the DE and mesoderm but not in the VE 
(McGrath et al. 1999). Under conditions that support DE formation, Yasunaga et al. 
found that Cxcr4 expression was induced simultaneously with Gsc while the Gsc– 
population showed no Cxcr4 expression. As Cxcr4 is not detected in VE or on 
undifferentiated ES cells, it can be used in combination with DE-specific markers to 
designate cells from the DE. These studies and others on mESCs encouraged and 
guided efforts to induce endoderm from hESCs, some of which are described below. 
 
1.5.2. Endodermal differentiation from hESCs   
Encouraged by the success of Activin A in generating definitive endodermal 
derivatives from mESCs when used at a high concentration, this Nodal mimic has 
been used widely to differentiate hESCs into DE. In one such strategy D’Amour et al. 
(2005) induced endodermal differentiation from hESCs in presence of high Activin A 
concentration (100 ng/ml) and low levels of serum. This differentiation resulted in the 
elevated expression of definitive endodermal marker genes like GSC, FOXA2, SOX17 
and CXCR4 (described earlier) while markers of primitive, visceral and parietal 
endoderm like SOX7, Alpha feto protein (AFP) and Thrombomodulin (THBD) were 
not detected (Kanai-Azuma et al. 2002; Weiler-Guettler et al. 1996; Dziadek and 
Andrews 1983). FOXA2 and SOX17 double-positive cells were shown to be derived 
exclusively from the TBRA+ population thus confirming formation of DE as TBRA is 
not detected in the primitive endoderm (Wilkinson et al. 1990). The decreasing 
expression of E-cadherin followed by increasing expression of N-cadherin pointed to 
an EMT-like event and formation of a primitive streak-like intermediate during 
45 
differentiation. Testing the in vivo potential of these cells showed partial 
differentiation into endodermal derivatives. These authors subsequently extended this 
differentiation strategy to produce pancreatic hormone-expressing endocrine-like cells 
from hESCs (D’Amour et al. 2006).  
In the modified protocol, DE was formed by treating cells with Activin A (high) 
and Wnt3 in serum-free conditions, which eliminated the requirement for serum 
stimulation. Sequential exposure of the DE to various other reagents like fibroblast 
growth factor 10 (FGF10), cyclopamine and Retionic Acid resulted in the formation 
of PDX1+ (pancreatic and duodenal homeobox 1) pancreatic endocrine progenitor 
cells which were further differentiated into hormone-expressing cells. Expression of 
the transcription factor Pdx1 in the ventral and dorsal endoderm first specifies the 
pancreatic fate in the embryonic foregut and this precedes the progressive expression 
of more mature markers of the endocrine lineage, including Neurogenin 3 (Ngn3) and 
Islet 1 (Isl1) (Habener et al. 2005; Ashizawa et al. 2004; Jensen 2004). The hormone-
expressing cells formed during the differentiation described by D’Amour et al. (2006) 
responded to a variety of insulin secretagogues, but only showed limited glucose 
responsiveness. In addition, a significant proportion of the insulin+ cells curiously 
displayed immunoreactivity for the additional islet endocrine hormones glucagon 
and/or somatostatin. Thus, these cells resemble the infrequent, doubly hormone-
positive cells observed in the mouse and human embryo that have been shown by 
lineage analysis in the mouse to never give rise to adult endocrine cells (Piper et al. 
2004; Herrera 2002). This emphasized the need for improved protocols for the 
generation of glucose-sensing insulin-secreting cells from hESCs.  
Our lab used a novel hESC differentiation strategy that combines an initial 
three-dimensional (3D) endoderm induction phase with a series of culture conditions 
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originally optimized to trigger formation of endocrine β-cells from adult pancreatic 
epithelial duct cells (Phillips et al. 2007). Unlike the strategies described above, this 
differentiation exploited the hESC-EB system as we hypothesized that effective cell-
cell interactions within the three-dimensional EB may promote better lineage 
specification and cell type allocation in a manner reminiscent of human development. 
Even with the predicted drawbacks of (1) random EB sizes and (2) stochastic internal 
architecture, which may promote counter-productive cell-cell interactions, this system 
was effective in reproducibly generating pancreatic endoderm. Genes characteristic of 
definitive endoderm formation were induced within the first 4 days of differentiation, 
and this was followed by activation of PDX1 on day 12. With extended 
differentiation, a portion of PDX1-expressing pancreatic progenitors became further 
restricted to the endocrine lineage, uniquely expressing the INSULIN gene and 
releasing C-peptide into the culture medium. These β-like cells do not produce other 
pancreatic hormones, show modest glucose responsiveness, and retain their endocrine 
identity when transplanted into diabetic severe combined immunodeficiency (SCID) 
mice.  
In this protocol Activin A and Bmp4 (bone morphogenetic protein 4) were 
shown to synergistically enhance the formation of PDX1-expressing pancreatic 
endoderm in a Matrigel-based medium. Matrigel, a mouse EHS sarcoma-derived 
basement membrane matrix, can function as a supportive scaffold for cellular 
maintenance by mimicking in vivo conditions (Kleinman and Martin 2005). The 
endoderm-inducing effect of Bmp4 when used with Activin A is unexpected as it has 
been previously shown to induce formation of trophoblast, extraembryonic endoderm, 
primordial germ cells, and mesoderm-derived haematopoietic progenitors from 
hESCs but not definitive endoderm (Kee et al. 2006; Valdimarsdottir and Mummery 
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2005; Xu et al. 2002). This ability of Bmp4 to form endoderm is entirely reproducible 
within the EB-based differentiation and can also be implemented to promote 
endoderm differentiation of hESCs in a monolayer (Y. Ali, A. Teo, H. Chipperfield– 
unpublished results). Individually, both Activin A and Bmp4 are known to have 
critical functions in the embryo around the same period of development. However, 
synergistic activity between the two that enables the induction of endoderm has not 
been reported.  
Activin A transduces its signal through a complex of Smad2/3 and Smad4 that 
translocates to the nucleus and binds to FOXH1 (FAST) which activates transcription 
of genes like Goosecoid (GSC), NODAL, PITX2, etc. This leads to downstream 
signaling that results in the formation of mesoderm or endoderm (Schier 2003). In the 
developing mouse embryo, Bmp4 is first expressed in the extraembryonic region 
adjacent to the posterior epiblast at gastrulation (Lawson et al. 1999; Waldrip et al. 
1998). Later in development expression is detectable at the junction of the amnion 
with the posterior PS. Bmp4 signals through Smad1/5/8 to initiate transcription of 
genes that specify its downstream functions (Wu and Hill 2009; Massague and Gomis 
2006; Massague et al. 2005). The requirement for extraembryonic Bmp4 in the 
formation of the node and primitive streak and for epiblast-derived Bmp4 in 
maintaining left-right patterning in the mouse embryo has been clearly shown using 
Bmp4 mutant mice that had defects in these processes (Fujiwara et al. 2002). 
However, not much is known about the relevance of Bmp4 in the formation of DE. 
One study  provides evidence that Bmp receptor 1A (Bmpr1a) is required for 
endodermal morphogenesis in mouse embryos as mutants lacking Bmpr1a in the 
epiblast form mosaic embryos showing abnormal expression of definitive endoderm 
markers (Davis et al. 2004). Though the endoderm cell identity was not affected, the 
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distribution of definitive endoderm was defective as seen by the patchy expression of 
Foxa1 (marks definitive endoderm) and the formation of the gut tube was incomplete. 
In a very recent report Bmp4 has been shown to be necessary and sufficient for the 
specification of ventral endoderm in Xenopus (Wills et al. 2008). In this study, Bmp4 
was overexpressed in Xenopus embryos which resulted in the specific induction of 
ventral endoderm marked by Sox17β, Mixer, VegT, etc., and not dorsal endoderm. The 
importance of Bmp signaling for the formation of ventral and not dorsoanterior 
endoderm was reiterated in experiments employing Bmp antagonists Chordin and 
Noggin, and morpholino knockdown of Bmp2, Bmp4 and Bmp7. A quadruple 
knockdown of Bmp2, Bmp4, Bmp7 and β-Catenin resulted in complete abrogation of 
all endoderm in the embryos, indicating that Bmp and Wnt pathways are essential for 
endoderm formation in Xenopus. These studies suggested that Bmp4 might be acting 
early in endoderm specification. Therefore, a significant focus of this dissertation is 
investigation of the role of Bmp4 in the initial part of this differentiation. 
It is possible that our differentiation protocol creates an environment that reveals 
the effect of Bmp4 on primitive streak patterning and endoderm specification as has 
been reported in other vertebrate systems (Tiso et al. 2002; Song et al. 2007). It has 
been demonstrated that differentiating hESC-EBs form a VE-like layer around 
themselves (Conley et al. 2004). In the mouse embryo, the anterior VE (AVE) is 
known to antagonize formation of the primitive streak by secreting Bmp antagonists 
(Lewis and Tam 2006). Our lab recently demonstrated that Matrigel inhibits VE 
formation during in vitro differentiation of hESCs (Rust et al. 2006). Loss of this 
tissue might therefore be creating an environment which relieves the Bmp4 
antagonism and facilitates its action during differentiation.  
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A more direct effect of Bmp4 could be due to its induction of Tbra expression 
which has been reported in mESCs (Johansson and Wiles 1995). Since definitive 
endoderm derived during in vitro differentiation of mESCs has been shown to arise 
from Tbra+ cells this might be a possible mechanism of Bmp4 action during hESC 
differentiation (Tada et al. 2005; Yasunaga et al. 2005; Kubo et al. 2004). The three-
dimensional differentiation described in Chapter 4 employs extended exposure of EBs 
to Bmp4 which raises the possibility that Bmp4 could act later in the differentiation 
on committed endodermal progenitors, possibly mimicking pancreas-promoting 
signals emanating from the lateral plate mesoderm (Kumar et al. 2003). This is 
supported by a recent study using mESCs which showed that isolating Activin A-
induced endodermal progenitors by cell sorting and subsequently culturing them at 
high density in the presence of Activin A and Bmp4 (and bFGF) promoted both 
hepatocyte differentiation and activation of Pdx1 (Gouon-Evans et al. 2006). 
However, this might not be relevant to my differentiation scheme as Bmp4 seems to 
be acting early to exert an endoderm-specifying effect on the hESCs in Matrigel and 
does not have a similar effect if added later (data not shown). In addition to probing 
the how Bmp4 facilitates or directly influences the formation of definitive endoderm 
it is also important to assess the actual mechanism of endoderm induction by Activin 
A in hESCs. In Chapter 4 of this thesis, I will describe my efforts towards a) the 
detailed characterization of differentiation in the 3D Matrigel system and b) the 
identification of a mechanism for the synergy shown by Activin A and Bmp4 in 





Broad Aims of the Thesis 
1. Test haematopoietic potential of human embryonic stem cells lines– hES2 
and hES3– maintained on various culture platforms. 
 
2. Characterise the early lineage specification events that occur during in vitro 
endoderm differentiation from human embryonic stem cells. 
 
3. Identify a mechanism of action for the observed Activin A and Bmp4 synergy 















































2.1. Cell culture 
2.1.1. Human embryonic stem cell culture 
Human embryonic stem cells lines (hESCs), hES2 and hES3, were cultured as 
described (Reubinoff et al. 2000).  Briefly, hESC lines were grown on a feeder layer 
of mitotically inactivated mouse embryonic fibroblasts (MEFs) derived from day 13.5 
129/Sv mouse embryos and plated at a density of 5 x 104 cells/cm2 in hESC medium 
containing Dulbecco’s Modified Eagle’s Medium (DMEM), 20% Fetal Bovine Serum 
(FBS), 100 μM non-essential amino acids (NEAA), 2 mM L-glutamine, 1% v/v 
Insulin Transferrin Selenium (ITS), 0.5% v/v penicillin/streptomycin, and 0.1 mM β-
mercaptoethanol (β-ME) (ES Cell Culture Lab Manual, ES Cell International Pte 
Ltd).  Alternatively, hESCs were grown on gamma-irradiated human fibroblasts 
CCD919 (ATCC) or Ortec (Crook et al. 2007) fibroblasts in KO medium containing 
Knock-out DMEM (KO-DMEM), 20% Knock-out Serum Replacement (KOSR), 2 
mM L-glutamine, 100 μM NEAA and 25 ng/ml basic Fibroblast Growth Factor 
(bFGF) (Strathmann). For routine passaging, hESC colonies were cut into small 
clumps using a combination of manual and enzymatic methods.  The plate was rinsed 
with Phosphate Buffered Saline (PBS) and treated with 1 mg/ml Type IV Collagenase 
in PBS for 5 minutes at 37°C.  Collagenase was rinsed away with PBS and replaced 
with hESC/ KO medium.  The entire surface area of the plate was streaked with a 
micropipette tip at approximately 2mm intervals.  Cells were then harvested with a 
cell scraper and transferred to fresh feeder plates previously conditioned in hESC/ KO 
medium.  Typical splitting ratios were between 1:3 and 1:6 depending on the density 
of the starting culture.  Morphologically differentiated colonies or cystic regions were 
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removed by aspiration prior to dissociation.  All tissue culture reagents were 
purchased from Invitrogen (Gibco) unless otherwise stated. 
 
2.1.2. Stromal feeder cells 
Human feeder cells HS-5 and HS-27A were obtained from ATCC and cultured 
according to manufacturer’s recommendations. Briefly, HS-5 cells were thawed and 
cultured in growth medium composed of DMEM, 4 mM L-glutamine, 4.5 mg/ml 
Glucose, 1.5 mg/ml Sodium bicarbonate (Na2CO3) and 10% FBS. Splitting ratio was 
1: 3 to 1: 9. HS-27A cells were grown in medium composed of RPMI 1640, 2 mM L-
glutamine, 10 mM HEPES, 1 mM Sodium pyruvate (C3H3NaO3), 4.5 mg/ml Glucose, 
1.5 mg/ml Na2CO3 and 10% FBS. Split ratio was 1: 4 to 1: 5. Mouse stromal cell line 
OP9 was grown in medium composed of Alpha Minimum Essential Medium without 
ribonucleosides and deoxyribonucleosides, 2 mM L-glutamine, 1.5 mg/ml Na2CO3                      
and 20% FBS (Nakano et al. 1994). Split ratio was 1: 4 to 1: 5.  
  
2.2. Differentiation protocols 
2.2.1. Haematopoietic differentiation: Co-culture with stromal cell lines 
Human stromal cell lines HS-5 and HS-27A were seeded onto tissue culture 
dishes at a cell density of 5 x104 cells/ cm2. The next day, hESCs or EBs (defined in 
Chapter 1) were seeded onto the feeder cells.  Briefly, hES2 and hES3 cells grown on 
MEFs were dissociated using Collagenase IV (1 mg/ml). The hESC layer was 
sectioned into small clumps (3-4 mm) and scrapped off using a cell scraper into hESC 
medium. Clumps were spun down at 1200 rpm for 3 minutes and resuspended in the 
appropriate medium, DMEM-based HS-5 medium, RPMI-based HS-27A medium or 
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hESC medium. Clumps in hESC medium were seeded into 6-well Ultra low 
attachment plates (Corning Lifesciences) for EB formation for 2 weeks with medium 
changes every 2 days. Clumps in feeder medium or day 14 EBs were seeded on feeder 
layers at the seeding density used in routine culture of hESCs. Medium changes were 
done every 2 days and culture continued for 2 weeks. By day 3, most hESC clumps 
attached and some seemed to differentiate (change in cell morphology) while others 
remained undifferentiated. By day 10 almost all clumps seemed to have differentiated. 
EBs attached by day 2 and seemed to grow out on the feeders. On day 14, cells were 
detached from the dishes using 0.25% Trypsin and seeded into Methocult H+4435 
(Stem Cell Technologies) for the CFU assay described later. Methocult-containing 
plates were monitored for the appearance of haematopoietic colonies over the next 4 
weeks. 
OP9, a mouse MCF-deficient stromal cell line, was seeded in tissue culture 
dishes at 5 x 104 cells/ cm2. hESCs or day 14 hESC EBs were seeded onto the 
monolayers in OP9 or hESC medium as outlined above. Cultures were continued for 2 
weeks with medium changes every 2 days. At the end of culture, cells were 
dissociated using 0.25% Trypsin and seeded in Methocult for CFU assay as described. 
If cells with dendritic-like protrusions were observed in culture, 20 ng/ml Tumor 
Necrosis Factor alpha (TNF-α) and 1 µg/ml Lipo Poly Saccharide (LPS) were added 
for 90 minutes at 37°C to stimulate maturation of any dendritic-like cells before using 
the cells for immunostaining. 
 
2.2.2. Haematopoietic differentiation: Use of cytokines 
hESC-derived EBs were differentiated in presence of cytokines that are known 
to be functional during haematopoiesis (Zhan et al. 2004). Briefly, hESCs were 
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dissociated using Collagenase IV and EBs were generated in 6-well ultra low 
attachment plates. EBs were formed in hESC medium supplemented with 0.1 mM β-
ME and 20% FBS. After 2 weeks, EBs were transferred to 6-well tissue culture plates 
in a differentiation medium containing KO-DMEM, 2 mM L-glutamine, 0.1 mM 
NEAA, 0.1 mM β-ME and 20% FBS for another 2 weeks. The following cytokines 
were added to the differentiation medium: 100 ng/ml Stem Cell Factor (SCF), 50 
ng/ml Flt3 ligand (Flt3L), and 20 ng/ml Thrombopoietin (TPO) to maintain 
haematopoietic stem cells and to expand committed progenitor cells; 20 ng/ml 
Interleukin 3 (IL-3), 100 ng/ml Granulocyte-Macrophage Colony-Stimulating Factor 
(GM-CSF), and 20 ng/ml Interleukin 4 (IL-4) to enhance maturation of lymphoid 
cells and dendritic cells (Cytokines from Peprotech). After 4 weeks of differentiation 
cells were dissociated using 0.25% Trypsin and either immunostained for flow 
cytometry or seeded in Methocult for CFU assay as described below. If cells with 
dendritic-like protrusions were observed in culture, these were stimulated with 20 
ng/ml TNF-α and 1 µg/ml LPS for 90 minutes at 37°C to induce maturation of any 
dendritic-like cells before dissociating the cells.  
 
2.2.3. Endodermal differentiation: 3D Matrigel protocol 
hESCs cultures were washed with PBS+ (with Ca++, Mg++) and incubated with 
Collagenase IV (1 mg/ml) for 5 minutes at 37°C. Cells were washed again with PBS+ 
after removing the Collagenase IV and growth medium was added. Cell layer was 
sectioned/ streaked into 3-4 mm-sized clumps using a micropipette tip. Differentiated 
regions were aspirated out before Collagenase treatment. Cell clumps were scrapped 
off in the medium and spun down at 1500 rpm for 3 minutes. Clumps were 
resuspended in ice-cold RPMI + 20% KOSR medium containing 1:6 dilution of 
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Growth Factor reduced Matrigel (BD Biosciences, USA). Early factors (EF) Activin 
A and Bmp4 (50 ng/ml each; R & D Systems) were added to the relevant aliquot of 
cells. Clumps were distributed evenly between required number of wells in 6-well 
ultra low attachment plates (day 0) and incubated at 37°C for the duration of the 
experiment. Clumps started aggregating and rounding up by day 1 and were compact 
embryoid bodies by day 2. To accommodate medium evaporation and growth factor 
depletion and to maintain the semi-solid matrix over extended culture, the culture 
medium was supplemented on days 3 and 6 by adding 0.5 ml/well of basal RPMI 
medium (without Matrigel) containing 100 ng/ml Activin A and 100 ng/ml Bmp4. On 
day 10, EBs embedded in Matrigel were treated with the late factors (LF) - HGF (50 
ng/ml), β-cellulin (50 ng/ml) and Exendin-4 (10 ng/ml) (growth factors from R & D 
Systems). Briefly, 2 ml RPMI+ 20% KOSR basal medium was added to each well and 
incubated for 1 hour to wash out the early factors. Without disrupting the Matrigel 
layer 2 ml medium was removed carefully from each well. Medium (0.5 ml) 
containing the appropriate amount of late factors was added to all wells. The culture 
medium was similarly supplemented with these late factors on days 13 and 16.  One 
set of EBs did not receive any growth factors. Cultures were harvested every other 
day till day 20, unless otherwise stated, for expression analysis of PDX1 and other 
assorted markers by Q-PCR.  
A variation of the above protocol was used to investigate in detail the role of 
Activin A and Bmp4 in this system. hESCs were dissociated using Collagenase IV 
and clumps were seeded in RPMI+KOSR medium containing Matrigel as described. 
Early factors were used to create four different conditions for differentiation- (1) 
Activin A (50 ng/ml), (2) Bmp4 (50 ng/ml), (3) Activin A + Bmp4 (50 ng/ml each) 
and (4) No growth factors. The same scheme was followed for medium top-up on 
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days 3 and 6. The second phase of differentiation was identical for all 4 conditions 
with the addition of all three Late Factors. EBs were harvested every other day for 
expression analysis using undifferentiated hESCs as control. Selected samples from 
this differentiation were used for Microarray analysis described later. 
To study the effect of Matrigel on the differentiation, free-floating EBs were 
generated exactly as above without the supporting Matrigel matrix. Growth factors 
were used at a concentration of 50 ng/ml. Differentiation of free-floating EBs was 
done only up to day 10, unless otherwise indicated. 
 
2.3. CFU assay 
CFU assay allows generation of clonal colonies from haematopoietic 
progenitors in a viscous methyl cellulose-based medium supplemented with 
stimulatory cytokines. Cells/ EBs were dissociated using 0.25% Trypsin and seeded in 
Methocult (H+4435, Stem Cell Technologies) to allow formation of haematopoietic 
colonies. Briefly, between 1 x 104 and 2 x 105 cells in 300 μl KO-DMEM was added 
to 2.7 ml Methocult and vortexed. After allowing the cell suspension to settle for 5 
minutes, 1 ml each was seeded into three 35 mm non-treated culture dishes (Stem Cell 
Technologies) specifically designed for CFU assays and incubated at 37°C. These 
plates were monitored over 4 weeks for the appearance of haematopoietic colonies. A 
cluster of at least 50 cells was counted as a colony, and identification was based on 
descriptions given in the Atlas of Human Haematopoietic Colonies (Stem Cell 
Technologies). Since CFU colony morphology was identical for hES2 and hES3, 




2.4. Flow Cytometry 
Cells from the differentiating adherent culture or colonies from the CFU assay 
were immunostained and subjected to Fluorescence Activated Cell Sorting (FACS) 
using a FACScalibur (BD Biosciences). Adherent cells were dissociated using 0.25% 
Trypsin and washed in PBS. Colonies from CFU assays were progressively diluted 
with PBS to allow easy aspiration of the colonies. Colonies were resuspended and 
washed in PBS. Cells in PBS were transferred to FACS tubes and fixed using Cytofix/ 
Cytoperm reagent (BD Biosciences) for 20 minutes on ice. Fixed cells were washed 
and stained with primary antibody for 40 minutes on ice. All washes post- fixation 
were done in 1 x washing solution (BD Biosciences) and cells were spun at 1220 rpm 
for 5 minutes at 4°C. One aliquot of cells was treated with the appropriate isotype 
control or used as control with no primary antibody addition. After 2 washes 
appropriate secondary antibodies were added and incubated for 30 minutes on ice. 
Cells were washed to remove excess secondary antibody and resuspended in PBS + 
1% FBS. Samples were analysed on FACScalibur and quantitated using Cellquest Pro 
software. Normalisation was against the isotype or no primary antibody control. The 
following primary antibodies were used at 1:100 dilutions: CD83-FITC, CD45-PE, 
CD14-PerCP-Cy5.5, CD34- FITC and CD86-Biotin (all from BD Biosciences). 
Isotype controls IgG1k-FITC, IgG1k-PE, IgG2ak-PerCP-Cy5.5 and IgG1k-Biotin 
(BD Biosciences, USA) were used at 1:100 dilutions.  
 
2.5. Immunocytochemistry 
Plated cells/ EBs were washed 2x with PBS and fixed in 4% paraformaldehyde 
(PFA) for 30 minutes at room temperature. After 2 washes, cells/ EBs were blocked 
using blocking solution (10% FBS, 0.05% Triton X-100 in PBS) for 1 hour at room 
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temperature. Diluted primary antibody was added to the cells after removing the 
blocking solution and incubated overnight at 4°C. Cells were washed 3x with PBS. 
Diluted secondary antibody was then added and incubated for 1 hour at room 
temperature. Cells were washed 3x with PBS and incubated for 3 minutes at room 
temperature with 1:10,000 diluted Hoechst 33342 (Molecular Probes). Cells were 
washed 2x in PBS and either observed immediately or the next day using a Zeiss 
Axiovert microscope. All antibody dilutions were performed with blocking solution. 
For haematopoietic cells, fluorophore-conjugated primary antibodies CD34-FITC and 
CD45-PE were diluted 1:100 for use. For endodermal differentiation primary 
antibodies Sox-17, Foxa2 (R&D systems) and Oct4 (Santa Cruz Biotech) were diluted 
1:100 for use. Alexa 488 was the secondary antibody used at a dilution of 1:200. 
  
2.6. Differential staining 
May-Grünwald and Giemsa staining is a differential staining procedure done to 
distinguish between various types of cells in blood. Methocult cultures were 
progressively diluted with PBS to allow easy removal of colonies for staining. 
Colonies collected were pooled and washed in PBS. Cells in 100 μl PBS was spun on 
to poly-lysine-coated slides at 500 rpm for 5 minutes with low acceleration. Slides 
were fixed in absolute Methanol for 20 minutes. Staining solutions were diluted using 
0.2 M phosphate buffer or Sorenson’s buffer (Appendix I). Without washing or 
drying, slides were stained with May-Grünwald stain (diluted 1:1 with Sorenson’s 
buffer) for 10 minutes followed by Giemsa stain (1:10 using Sorenson’s buffer) for 30 
minutes. Slides were rinsed once with Sorenson’s buffer (0.2 M phosphate buffer) and 
washed in running deionised water. Air-dried slides were examined using a Zeiss 
Axiovert Microscope. Blood cell types were identified using published images of 
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2.7. RNA extraction 
EBs or cells collected at different time points were washed in PBS to remove 
medium and lysed in Trizol (Invitrogen) or RLT buffer (RNeasy Kit, Qiagen) for 
RNA extraction. To ensure complete lysis, cells in RLT buffer were first spun through 
Qiashredder columns (Qiagen) at 13,000 rpm for 2 minutes. Lysates from either 
method were stored at -80°C till use. Trizol lysates (500 μl) were thawed on ice, 
mixed well with 150 μl Chloroform and incubated at room temperature for 3 minutes. 
Lysates were spun at 12,000 rpm for 15 minutes at 4°C and the aqueous phase was 
transferred to a fresh tube. RNA was precipitated by adding 375 μl of Isopropanol and 
incubating at room temperature for 10 minutes followed by centrifugation at 12,000 
rpm for 10 minutes at 4°C. The supernatant was discarded and the pellet resuspended 
in 1 ml 70% Ethanol, vortexed and spun at 7,500 rpm for 5 minutes at 4°C. After 
removing the supernatant, the pellet was air-dried and re-suspended in 30 μl RNase-
free water for quantification using Nanodrop. Ethanol, Chloroform and Isopropanol 
were from Sigma Aldrich. RLT buffer lysates were processed using the RNeasy kit 
(Qiagen) according to manufacturer’s instructions. RNA was eluted in 30 μl RNase-
free H2O and quantitated using the Nanodrop.  
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2.8. Quantitative RT-PCR 
5 μg RNA was reverse transcribed to generate cDNA for quantitative PCR. For 
cDNA preparation, 60 μg/ml Random Primers (Invitrogen), 1x MMLV RT Buffer 
(NEBL) and 0.5 mM dNTP mix (Invitrogen) was added to each sample and mixed 
well. An aliquot was removed as the RT negative control (-RT). 1 μl MMLV Reverse 
Transcriptase (NEBL) was added to each sample and incubated at 37°C for 1 hour 
after mixing well. RT was inactivated by heating samples at 95°C for 5 minutes. Each 
Q-PCR consisted of 50 ng cDNA, 2x Sybergreen master mix and 10 mM primer mix 
(forward and reverse). PCR was performed using the iCycler MyiQ (Biorad). 
Quantitation was performed either against a standard curve or according to ΔCt 
relative to β-actin amplification. Primer pairs are listed in Appendix II. 
 
 
2.9. Western blotting 
EBs were harvested and washed in PBS to remove all traces of media. Pellet 
was snap frozen in liquid nitrogen and stored at -80°C till use. For protein extraction, 
the pellet was thawed and lysed in RIPA (Radio Immuno Precipitation Assay) buffer 
with freshly added 1 mM PMSF (phenylmethanesulphonylfluoride) (Sigma) and 1X 
protease inhibitor cocktail (Roche). Lysate was triturated to lyse the EBs efficiently 
and spun down at 13,000 rpm for 10 minutes to remove debris. Supernatant was 
collected and spun a second time at 13,000 rpm for 5 minutes. Total protein content of 
the supernatant was estimated using the BCA protein assay (Pierce) following 
manufacturer’s recommendations. Colorimetric measurements were done using the 
Fluorostar Optima plate reader. For western blot, 20-30 μg total cellular protein was 
loaded in each well along with 1X Laemmli sample buffer. 
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Using the Biorad mini-Protean System, 1.5 mm thick gels (3% stacking and 8% 
running) were run at 100 V for 90 minutes in 1x Tris Glycine SDS (Sodium Dodecyl 
Sulphate) buffer (Biorad).  Pre-stained molecular marker (Biorad) was used to 
identify and assign sizes to the protein bands on the gel. Gels were blotted onto 
Hybond-P PVDF or Hybond C-extra nitrocellulose membrane (Amersham 
Biosciences) under semi-dry conditions in Transfer buffer for 45 minutes at 10 V. 
Blots were stained with Ponceau S to check for transfer and before blocking in either 
5% w/v non-fat dry milk or 5% Bovine Serum Albumin (BSA) (Sigma) in 1X Tris 
Buffered Saline (TBS) + 0.1% Tween-20 (Sigma) (TBST). After one hour of 
blocking, blots were incubated overnight at 4°C with the primary antibody diluted 
appropriately in blocking buffer. Blots were washed 5 times in TBST to remove 
excess and unbound primary antibody. Secondary antibody incubation was performed 
for one hour at room temperature and blots were washed 5 times to remove excess 
secondary antibody. Gel and buffer compositions are given in Appendix I. 
Chemiluminescent detection of proteins was done using the ECL Plus system 
(Amersham Biosciences) according to manufacturer’s recommendations. Protein 
signal was captured on Hyperfilm (Amersham Biosciences) and developed using a 
Kodak film processor. Rabbit polyclonal primary antibodies pSmad2/3 and 
pSmad1/5/8 were diluted 1:1000 before use (Cell Signaling). Monoclonal anti- human 
Actin antibody was diluted 1:4000 for use (Chemicon). Secondary antibodies, anti-
rabbit IgG-HRP (Cell Signaling) was used for the Smad antibodies at 1:1000 dilution. 




hESCs were differentiated using a variation of the 3D Matrigel protocol in 4 
different conditions- (1) Activin A (50 ng/ml), (2) Bmp4 (50 ng/ml), (3) Activin A + 
Bmp4 (50 ng/ml each) and (4) No growth factors. RNA from undifferentiated hESCs 
on day 0 and hESC-EBs harvested on days 4 and 6 was used for microarray using the 
Illumina Sentrix® BeadChip Human Reference 8 Version 2. Two biological replicates 
of each sample were performed. An aliquot of each RNA sample (500 ng) was 
converted to complementary RNA with the Illumina TotalPrep™ RNA Amplification 
Kit (Ambion) according to manufacturer’s recommendations. Purified cRNA samples 
were added to the Illumina BeadChips and loaded into the Hybridization Chamber. 
After overnight incubation at 58ºC on a rocker BeadChips were washed thoroughly, 
blocked and stained with Streptavidin-Cy3. Once the chips were thoroughly washed 
and dried, the staining was detected and measured using an Illumina Bead scanner. 
Data was generated using Illumina Bead Studio software and analysed using 
Genespring software. Statistically relevant data were generated using the paired T-
Test (p≤0.17). 
 
2.11. Whole Mount In Situ Hybridisation (WISH) 
2.11.1. Cloning of genes 
Total Mouse embryonic RNA from E7.5, E8.5 and E9.5 was used for cDNA 
preparation as described earlier. A partial cDNA fragment was amplified by PCR 
using primers spanning the 3’ UTR (variable) region of each specific gene. The PCR 
product was resolved on a 1% agarose gel run at 100V for 40 minutes and visualized 
using 0.5ug/ml Ethidium Bromide added in the gel. Once product size was confirmed, 
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the DNA fragment was cloned into the TOPO PCR II vector according to 
manufacturer’s recommendations (TOPO TA Cloning Kit, Invitrogen). The plasmid 
preparation was used to transform TOP10 (Invitrogen) or XL-Gold (Stratagene) cells 
according to manufacturer’s recommendations. Clones, after selection for Ampicillin 
resistance and lack of X-gal staining were grown up and plasmid DNA was extracted 
subsequently using the Qiaprep Miniprep kit (Qiagen) according to manufacturer’s 
recommendations. DNA was quantitated using Nanodrop and 1 μg of each sample 
was used for restriction enzyme (RE) digest analysis to confirm insertion of specific 
gene fragment. 
RE digest was done using appropriate enzymes that would cut the plasmid at 
sites such that the DNA insert is released as a single fragment. Reactions were carried 
out in recommended buffers at 37°C for 90 minutes. Digested DNA was run on 1% 
agarose gels at 100V for 40 minutes to confirm proper digestion and fragment release. 
Clones containing the correct insert were subsequently sequenced and aligned against 
the expected PCR product gene sequence to confirm the 5’ to 3’ orientation of insert 
in the pCRII vector.   
 
2.11.2. Riboprobe synthesis 
For riboprobe synthesis, 2 μg of the plasmid prep was linearised using an RE 
that cuts only once at the 5’ end of the insert. RE digest was done as described earlier 
in a total volume of 40 µl at 37°C for 2 hours. 2ul of the RE reaction was run on a 1% 
agarose gel to confirm for complete linearization. The remainder was purified using 
the QIAquick PCR Purification kit according to manufacturer’s recommendations 
(Qiagen) and eluted in 40 µl RNase-free H2O. 500 ng of DNA was used for 
subsequent RNA synthesis using either the T7 or SP6 RNA polymerases (Stratagene). 
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RNA synthesis was done in 5X reaction buffer (Roche) + Digoxigenin-NTP (Dig-
NTP) (Roche) + RNasin (Stratagene) + Dithiothreitol (DTT) (Promega) + DNA 
template + appropriate polymerase at 37°C. After 2 hours, 2 μl of the reaction was run 
on a 1.5% agarose gel (90V for 45 mins) to check for the RNA synthesis product. 
.Upon RNA product confirmation, RNA was treated with 2 µl DNase I (Qiagen) at 
37°C for 15 minutes to remove residual DNA template. RNA was precipitated at -
20°C for 30 minutes in 4 M Lithium Chloride (LiCl; 10 µl) and 100% Ethanol (300 
µl). Precipitate was spun down at 16,000 g for 15 minutes at 4°C and washed once in 
100% Ethanol (500 µl). RNA pellet, air-dried and thereafter resuspended in 30 µl 
H2O, was stored at -80°C till use. 
 
2.11.3 Whole-mount In Situ Hybridisation (WISH) 
Mouse embryos previously harvested, fixed and stored in Methanol at E7, E7.5, 
E8.5 and E9.5 were used for WISH. Embryos were rehydrated using a Methanol + 
PBT (PBS + 1% Tween-20) series with decreasing concentration of Methanol. After 2 
rinses in PBT, embryos were bleached in freshly prepared H2O2 in PBT for 1 hour. 
Embryos were washed 3x in PBT and treated with 10 µg/ml Proteinase K/ PBT: 3 
minutes for E7 and E7.5, 4 minutes for E8.5 and 5 minutes for E9.5. Embryos were 
washed in 2 mg/ml Glycine/ PBT for 5 minutes followed by 2 washes in PBT. At this 
point embryos were sorted such that there were at least 2 embryos of each stage per 
in-situ probe. After proteinase K treatment, 4% PFA + 0.2% glutaraldehyde (Sigma) 
was used to re-fix the embryos for 20 minutes at room temperature. After 2 washes in 
PBT, the embryos were rinsed in pre-warmed Hybridisation solution (Hyb). Embryos 
were incubated in Hyb for 2 hours at 70°C. 50 - 100 ng of the earlier synthesized 
RNA in-situ probe was added to the embryos in fresh Hyb and incubated overnight at 
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70°C with gentle rotating. The next day, embryos were first washed in pre-warmed 
Hyb for 5 minutes at 70°C, followed by washes in Formamide wash buffers: Solutions 
I and II at 70°C and 65°C respectively. Embryos were washed 3x in MAB buffer + 
1% Levamisole before blocking for 90 minutes at room temperature in embryo 
blocking solution. Embryo blocking solution was MAB + 2% Boehringer Mannheim 
Blocking Reagent (BBR) + 10% Heat Inactivated Sheep Serum (HIS) + 1% 
Levamisole. This was followed by treatment with the pre-absorbed anti-Dig antibody 
overnight at 4°C with gentle shaking. Pre-absorption was done in antibody block 
solution using acetone powder prepared from grounded E12.5 embryos to block non-
specific hybridisations. Briefly, MAB + 2% BBR + 1% Levamisole + 1 mg mouse 
embryo acetone powder (per probe) were mixed and heated at 70°C for 30 minutes. 
After cooling on ice and vortexing for 5 minutes, 10 µl HIS and 1 µl anti-Dig 
antibody (per probe) were added and samples kept at 4°C for 1 hour with gentle 
shaking. Acetone powder residue was spun down at 13,000 rpm for 10 minutes and 
the supernatant was diluted in embryo block for use. The next day, embryos were 
washed extensively in MAB + 1% Levamisole followed by 3 washes in Alkaline 
Phosphatase (NTMT) buffer. BM Purple staining solution (Roche) was added to the 
embryos and incubated in the dark at room temperature till colour develops. Colour 
reaction was stopped using 2 mM EDTA in PBT and stained embryos were stored at 
4°C indefinitely. Images were obtained on the Olympus MVX10 inverted 



































As described in Chapter 1, the rejection of hESC-derived cell transplant material 
is a significant concern in regenerative medicine as their immunological profile will 
be recognized as foreign (Draper and Andrews 2002; Drukker et al. 2002). Suggested 
strategies to reduce the immunogenicity of such cells include (1) transplanting into 
immune-privileged sites in the body, (2) exploiting the immune-privileged status of 
hESCs imparted by the low expression of MHC class I molecules on their cell surface 
and (3) inducing transplantation tolerance using hESC-derived haematopoietic cells 
(Drukker et al. 2006; Drukker and Benvenisty 2004; Li et al. 2004). Theoretically, 
haematopoietic cells derived from the same exact source as the therapeutic graft, 
specifically a given hESC line, could tolerise the recipient towards the incoming 
transplant material irrespective of its cellular nature (Kaufman and Thomson 2002). 
Existing reports of haematopoietic differentiation from hESCs at the time I initiated 
my dissertation research used either stromal cell co-culture or cytokine treatment to 
induce formation of these mesodermal derivatives (Kaufman et al. 2001, Chadwick et 
al. 2003). Kaufman et al. co-cultured hESCs with a human stromal cell line S17 to 
generate CD34 expressing haematopoietic progenitors. These cells had the capacity to 
form more differentiated cell types like erythroid, myeloid and megakaryocytic 
lineages as evidenced by marker expression. In contrast, Chadwick et al. used a 
selection of cytokines and Bone Morphogenetic Protein 4 (Bmp4) to derive 
haematopoietic progenitors expressing the pan-haematopoietic marker CD45 from 
hESCs. These studies provided the experimental framework for my investigation in 
this chapter into the ability of hESC lines, hES2 and hES3, to undergo haematopoietic 
differentiation. The need for embarking on this series of experiments is further 
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elaborated in Chapter 4, which chronicles my experimental contribution toward our 
laboratory’s overarching goal of generating insulin-secreting beta cells from hESCs. 
This clinical goal prompted concurrent work on haematopoietic differentiation of 
hESCs which could provide a transplantation tool to allow successful engraftment of 
therapeutic grafts (Figure 1.3). In this chapter I will describe the preliminary results 
obtained for differentiation of hESC lines, hES2 and hES3, into cells of the 
haematopoietic lineage using the following two experimental strategies: 
 
1. Co-culture of hESCs with stromal cell lines OP9, HS-5 and HS-27A (Fig 
3.1B). 




































































Figure 3.1. Summary of various protocols tested. (A) Representative images of a 
hESC colony (hES3), day 14 EBs and stromal cell lines (OP9). (B) Schematic of 
differentiation strategy using stromal cell lines OP9, HS-5 and HS-27A. hESC clumps 
seeded onto stromal monolayers were differentiated for 14 days and plated in 
Methocult for CFU assay (Nakano 1994, Kaufman 2001). (C) Schematic of 
haematopoietic differentiation in presence of cytokines. Day 14 hESC-EBs were 
seeded in tissue culture plates with SCF, GM-CSF, TPO, Flt3L, IL-3 and IL-4 and 







3.1. hESC-derived embryoid bodies (EBs) give rise to haematopoietic-like cells 
when co-cultured with stromal cell lines 
Stromal cells of bone marrow or yolk sac origin are known to support the 
growth and maintenance of haematopoietic progenitors in culture (Lu et al. 1996; 
Wineman et al. 1993). In a prior study, the mouse bone marrow-derived cell line S17 
was used successfully to generate mixed populations of haematopoietic cells in vitro 
from hESCs (Kaufman et al. 2001). In contrast, I investigated the ability of OP9, a 
murine macrophage colony stimulating factor (M-CSF)-deficient cell line to promote 
haematopoietic differentiation from hESCs. OP9 has been shown extensively to 
support the maintenance of haematopoietic progenitors differentiated from mESCs in 
vitro (Nakano et al. 1994; Kyba et al. 2002; Kitajima et al. 2003). In addition, I co-
cultured hESCs with immortalised human bone marrow stromal cell lines HS-5 and 
HS-27A, which are known to maintain bone marrow-derived haematopoietic 
progenitors in culture (Roecklein and Torok-Storb 1995). HS-5 secretes large 
amounts of cytokines; conditioned medium from this line supports the ex vivo 
expansion of both immature and mature haematopoietic progenitors. HS-27A does not 
secrete cytokines but has been shown to support formation of typically 
haematopoietic “cobblestone areas” from progenitor cells of human bone marrow 
origin (Torok-Storb et al. 1999). hESC lines and stromal cell lines were maintained as 
described in Chapter 2.1. Briefly, hES2 and hES3 maintained on MEFs were 
dissociated and hESC clumps were seeded on stromal cells OP9, HS-5 and HS-27A 
(Chapter 2.2.1). Previous reports suggested that haematopoietic differentiation of 
mESCs and hESCs is initiated around day 5 and continues for more than 2 weeks 
70 
(Kaufman et al. 2001; Kitajima et al. 2003). Anticipating a similar timeframe, I 
monitored the morphological changes during differentiation over a period of 2 weeks. 
However, none of the typical colony or haematopoietic cell morphologies were 
detectable in culture over this period (Kitajima et al. 2003). Given the possibility that 
the cell lines used in this study might not yield identical results to those described in 
the prior reports, the differentiation was prolonged for another week. Though no 
haematopoietic-like morphological changes were obvious at the end of 3 weeks, the 
differentiation was continued and cells were seeded in Methocult for the CFU assay 
(Chapter 2.3). Plates were monitored for the appearance of colony forming units over 
the next 28 days. Disappointingly, no haematopoietic colonies were observed in this 
first of four independent experiments. Subsequent attempts at this protocol– hESC co-
culture with stromal cells– did not yield any haematopoietic-like cells or colonies in 
Methocult (data not shown). 
Therefore, I employed an alternative approach using the EB system which has 
been shown to generate progenitors of all three germ layers by spontaneous 
differentiation (Schuldiner et al. 2000; Keller 1995). Our lab previously reported that 
the architecture of a human EB bears some resemblance to the pre-gastrulation 
mammalian embryo; it forms an outer layer of visceral (extraembryonic) endoderm 
(VE) and expresses known markers of the VE (Rust et al. 2006). I hypothesized that 
the appropriate combinations of cell culture conditions and cytokines could act on 
spontaneously differentiating EBs and guide the differentiation to form predominantly 
mesoderm. hESC clumps in growth medium were seeded into Ultra low attachment 
plates for EB formation over the next 14 days. This particular time frame was chosen 
based on existing reports of haematopoietic differentiation. After 14 days of 
spontaneous differentiation, EBs were plated on stromal cell monolayers. Co-culture 
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was carried out over the next 14 days during which the EBs readily attached and grew 
out. Following co-culture, cells were seeded in Methocult for the CFU assay. Unlike 
what was seen during the co-culture of hESCs on stromal cells, haematopoietic-like 
colonies of the CFU-GM (colony forming unit-granulocyte macrophage) type were 
visible by day 14 in plates seeded with cells from hES3-EBs co-cultured on OP9 (Fig 
3.2A). CFU-GM colonies were large and relatively homogenous, though some 
colonies had more cells concentrated in the centre. Pooled cells from these colonies 
were cytospun on to slides for Giemsa and May-Grünwald staining. Neutrophils were 
clearly distinguishable by their segmented nuclei (Fig 3.2B).  
In addition, immunostaining of cells from the Methocult colonies was 
performed for CD45 (pan-haematopoietic), CD14 (monocytic), CD86 (antigen 
presenting cells) and CD83 (mature DCs) antigens. The DC-specific marker was 
chosen since many cells showed dendrite-like protrusions. Cells were stimulated with 
LPS and TNF-α prior to staining. Flow cytometry revealed significantly high numbers 
of haematopoietic cells (Fig 3.2C). Staining was detected in the gated population 
(excludes dead cells) of which 66% were CD45+ haematopoietic cells. CD14+ 
monocytes and CD86+ macrophages or antigen presenting cells were also abundant. 
CD83 expression was low indicating the absence of mature dendritic cells. The 
marker profile shows that stromal co-culture induced haematopoietic differentiation in 
cells derived from hESC-EBs but not in differentiating hESCs.  
The presence of haematopoietic colonies in the CFU assay and the marker 
expression profile of these colonies indicate that haematopoietic differentiation has 
occurred from the hESC-EBs. These differentiated cells, which form colonies in semi-
solid media and express CD45, represent committed progenitors with limited 
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Figure 3.2. hESC-EBs co-cultured with OP9 stromal cells give rise to 
haematopoietic colony forming units. Day 14 hESC-EBs were co-cultured on OP9 
stromal layers for 14 days. On day 14, EBs were plated in Methocult for CFU assay 
and incubated for 28 days. (A) Phase contrast image of a CFU-GM (Colony Forming 
Unit-Granulocyte Macrophage) formed in Methocult (5x magnification). These 
colonies were tightly packed. (B) Giemsa and May-Grünwald staining of cells pooled 
from various colonies formed in Methocult (20x magnification). Neutrophils were the 
most common cell type observed (white arrows labelled N). Inset shows magnified 
image of a neutrophil. (C) FACS analysis of pooled cells immunostained for CD45, 
CD14, CD83 and CD86. The green line represents isotype control while the purple 
filled area indicates stained cells. Expression of each marker within the marker region 
(M1) is indicated as percentage of the gated live population. Expression of the pan-
leukocyte marker CD45 and the monocytic marker CD14 was high. This is not 
surprising since colonies in Methocult were mainly of granulocytic origin. CD86 
(marker of antigen presenting cells) was extremely high suggesting that some of the 
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It is possible that this strategy does not support the formation of more versatile multi-
potent progenitors with a wider differentiation capability due to culture conditions 
including the choice of cytokines.  Most of the differentiated haematopoietic cells 
were monocytic (CD14+) with a significant percentage becoming antigen presenting 
cells or macrophages (CD86+), though few were mature dendritic-like cells (CD83). 
Therefore the differentiation seems to be biased towards the formation of leukocytes 
(CD45+), most of which are monocytic and immature antigen-presenting cells. The 
human stromal cell lines HS-5 and HS-27A did not support haematopoietic 
differentiation of hES2 and hES3 in any of the conditions described above. The 
results are summarized in Table 3.1. 
 
3.2. hESCs form haematopoietic-like cells when differentiated in presence of pro-
haematopoietic- cytokines  
The use of haematopoietic cytokines to promote haematopoietic differentiation 
from hESCs has been clearly demonstrated in the literature. In one of the earliest 
successful studies, Chadwick et al. used cytokines SCF, G-CSF, Flt3L, IL-3, and IL-6 
in the presence of Bmp4 to generate self-renewing CD45+ CD34+ haematopoietic 
progenitor cells in vitro (Chadwick et al. 2003). A slightly different combination of 
haematopoietic cytokines was used by Zhan et al. to produce functional antigen 
presenting cells and leucocytes from hESCs (Zhan et al. 2004). As mentioned earlier, 
antigen-presenting cells (APCs; DC-like cells) may be preferable over a mixed pool 
of haematopoietic cells for transplantation studies. This prompted me to adapt this 
strategy for the in vitro differentiation of hES2 and hES3 into cells of the 
haematopoietic lineage. The cytokines used in this study and their known functions 
are summarized in Table 3.2.  
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EBs were generated from hES2 and hES3 cells in Ultra low attachment plates as 
described in Chapter 2.2.2. After 14 days, EBs were plated onto tissue culture plates 
in Differentiation medium with the addition of SCF, Flt3L, TPO, IL-4, GM-CSF and 
IL-3. Most EBs attached in two days and generated cellular outgrowths (day 6) in 
culture. After two weeks of culture two wells of cells were used for CFU assay while 
the rest were left to differentiate further. Extended differentiation generated floating 
or loosely attached spherical cells (Fig 3.3A) and cells with dendrite-like protrusions 
(Fig 3.3B) on day 20 of culture. Interestingly, these cells were only observed in hES2 
cultures, alluding to differences between hESC lines in their potential to differentiate 
into haematopoietic cells. The two cell types observed in culture increased in number 
over the next 4 days. To confirm their haematopoietic identity, cells were 
immunostained for haematopoietic, monocytic and dendritic markers after stimulation 
with TNF-α and LPS. Flow cytometric analysis of immunostaining showed 44% 
CD45+ cells in the gated live population (Fig 3.3C). CD14 expression was high 
indicating the presence of monocytes. Low CD83 staining shows that mature dendritic 
cells were not formed in culture. The marker expression profile suggests that 
haematopoietic differentiation in the presence of these particular cytokines generates 
cells which are very similar to those seen when OP9 was used as stromal support. 
As described earlier, 2 wells of cells from the adherent culture (day 14) were 
seeded in Methocult for the CFU assay (~150,000 cells per plate). Colony forming 
units appeared in these plates by day 17– mainly CFU-GM (Fig 3.4A) and CFU-M 
(Fig 3.4B) types. While CFU-GM colonies were large and tightly packed with small 
sized cells, CFU-M colonies were smaller and consisted of sparsely arranged cells. 
Colonies pooled from the CFU assay plates were used for immunostaining and for 






Stem Cell Factor (SCF) or 
c-kit ligand 
Required for self-renewal, growth and differentiation of 
the more primitive haematopoietic progenitors and for 
some early lineage progenitors. 
 
Granulocyte Macrophage 
Colony Stimulating Factor 
(GM-CSF) 
Growth factor for several lineage progenitors and 
differentiation factor acting on granulocytes, 
macrophages and dendritic cells. 
 
Thrombopoietin (TPO) Regulates the production of platelets by bone marrow 
by stimulating the production and differentiation of 
megakaryocytes. 
 
Flt3 Ligand (Flt3L) Ligand for the FLT3 tyrosine kinase receptor. Belongs 
to a small group of growth factors that regulate 
proliferation of early haematopoietic cells. 
 
Interleukin- 3 (IL-3) Multipotent haematopoietic growth factor; induces 
proliferation, maturation and probably self-renewal of 
pluripotent haematopoietic stem cells and cells of 
myeloid, erythroid and megakaryocytic lineages. 
 
Interleukin- 4 (IL-4) Stimulates activated B-cell and T-cell proliferation. 
Induces the differentiation of naive helper T cells (Th0 
cells) to Th2 cells. 
 
 
Table 3.2.  Cytokines used in haematopoietic differentiation of hESC-derived 
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Figure 3.3. hESC-EBs treated with cytokines give rise to haematopoietic-like 
cells in culture. Day 14 hESC-EBs were differentiated for 14 days in presence of 
haematopoietic cytokines. (A, B) Distinct areas with spherical haematopoietic-like 
cells and cells with dendrite-like projections (white arrows labelled DC in B) were 
observed in culture (10x and 20x magnification respectively). (C) FACS analysis of 
these cells immunostained for CD45, CD14 and CD83. Cells were stimulated with 
LPS and TNF-α for 90 minutes prior to staining to induce maturation of DCs. The 
green line represents isotype control while the purple filled area indicates stained 
cells. Expression of each marker within the marker region (M1) is indicated as 
percentage of the gated live population. High expression of CD45 and CD14 shows 
that granulocytic differentiation has occurred in the cultures. CD83 staining was not 
significant enough to conclude the presence of mature DCs. CD86 was not used due 
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Differential staining showed the presence of neutrophils, eosinophils, basophils 
and monocytes (Fig 3.4C). Flow cytometric analysis of immunostaining with 
antibodies to CD45, CD14, CD83 and CD86 revealed an expression profile similar to 
that of cells in adherent culture. Ninety-six percent of the gated live cell population 
was found to be CD45+. Presence of CD14high cells indicates significant monocytic 
differentiation (Fig 3.4D).  
Using cytokines to differentiate hESCs gave rise mainly to CD45+ leukocytes, 
which included a high number of CD14+ monocytic cells. Expression of co-
stimulatory molecules CD86 and CD83 (specific to dendritic cells) was low indicating 
that differentiation did not progress beyond a certain progenitor stage. In contrast to 
the OP9-based differentiation, CD86 expression was very low indicating that antigen 
presenting cells or macrophages were more efficiently formed in the stromal co-
culture. Though Zhan et al. (2004) generated very high numbers of haematopoietic 
cells using the combination of EB formation and cytokines, hES2 produced relatively 
low numbers of these cells in a similar protocol. hES3 did not form CFUs or stain for 
haematopoietic markers. The reasons for this are unclear, but tailoring the protocol to 
the specific differentiation requirements of hES2 and hES3, for example, optimising 
the concentration of cytokines, would likely help to address this shortfall.  
 
3.3. hESCs maintained on human feeder cells are amenable to haematopoietic 
differentiation  
Historically hESCs have been grown on feeder cells of murine origin. This 
particular culture platform can have an impact on the differentiation potential of these 
hESCs.  
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Figure 3.4. hESC-EBs differentiated in presence of cytokines generate 
haematopoietic colony forming units in Methocult. hESC-EBs differentiating in 
presence of cytokines (shown in Fig. 6) were plated in Methocult for CFU assay. (A, 
B) Representative images of CFU-GM (Granulocyte Macrophage) and CFU-M 
(Monocyte) colonies (5x magnification). (C) Giemsa and May-Grünwald staining of 
pooled cells from colonies (20x magnification). Neutrophils (brown arrow heads), 
eosinophils (blue arrowheads), basophils (green arrowheads) and monocytes (red 
arrowheads) are shown. (D) FACS analysis of pooled cells immunostained for CD45, 
CD14, CD86 and CD83. The green line represents the isotype control while the 
purple filled area indicates the stained cells. Expression within the marker region 
(M1) is indicated as percentage of the gated live population. As seen in the OP9 
differentiation, CD45 and CD14 expression was high, though the CD86 expression 
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Studies in our lab have shown that hESCs tend to form largely stable cultures on 
human feeder cells (Crook et al. 2007) compared to mouse feeders. For example, the 
rate and frequency of spontaneous differentiation are comparatively lower when 
human feeders like CCD919 and Ortec143 are used. To analyse the impact of the 
human feeder culture platform on the haematopoietic potential of the hESCs, EBs 
derived from hES2 and hES3 cells grown on either CCD919 or Ortec143 were 
differentiated in presence of cytokines.  
 
3.3.1. hESCs maintained on CCD919 cells 
CCD919 is a fibroblast cell line derived from normal human adult mammary 
epithelial tissue and has been proven to support undifferentiated growth of hESCs 
(Crook et al. 2007). For differentiation, hESC-EBs were formed in ultra low 
attachment plates. At days 5, 11 and 15, EBs were plated onto tissue culture plates in 
Differentiation medium containing SCF, Flt3L, TPO, IL-4, GM-CSF and IL-3. Most 
EBs attached in 2 days and generated outgrowths (day 6) in culture. After 2 weeks of 
culture 2 wells of cells were seeded in Methocult for CFU assay (50,000 cells/ plate). 
Only cells from EBs treated with cytokines on days 5 and 11 of differentiation gave 
rise to haematopoietic colonies in Methocult. Colonies were CFU-GM (Fig 3.5A) and 
CFU-M (Fig 3.5B) types, similar to those obtained using MEF-based hESCs for 
differentiation. Giemsa and May Grünwald staining showed presence of neutrophils, 
eosinopihls and monocytes (Fig 3.5C). Unlike MEF-grown hESCs which gave rise to 
CFUs only from day 14 EBs, human feeder-grown hESCs generated CFUs even from 
5-day old EBs. However, the frequency of colony formation– 0.008% for CFU-GM 
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Figure 3.5. hESC grown on CCD919 human feeders differentiate in presence of 
cytokines to generate haematopoietic colonies. (A, B) Representative images of 
CFU-GM (Granulocyte Macrophage) and CFU-M (Monocyte) colonies (5x 
magnification). (C) Giemsa and May-Grünwald staining of pooled cells from colonies 
(20x magnification). Neutrophils (brown arrow heads), eosinophils (blue arrowheads) 
and monocytes (red arrowheads) are shown. (D) Gene expression during 
differentiation. Only Brachyury (T) showed an increase which could be due to 
spontaneous differentiation since its activation preceded addition of cytokines. FLK-1, 
was expressed in undifferentiated cells and persisted through out the differentiation. 
β-GLOBIN was not expressed. Exposure to cytokines does not seem to have a 
significant effect on expression of these genes. (E) Human adult bone marrow RNA 
was used as positive control for gene expression; only GATA-1 and β-GLOBIN were 
detected in the BM-RNA sample (high Y-axis values necessitated a separate graph). 
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Though inefficient, the data suggests that hESCs grown on CCD919 show 
slightly better haematopoietic differentiation than hESCs maintained on MEFs. This 
could be due to a variety of reasons including (1) a more homogeneous culture 
platform provided by the human feeders, which ensures that a higher percentage of 
cells are pluripotent at the onset and are poised to differentiate, (2) differences in 
medium formulation, (3) expression of cell surface receptors specific to the cytokines 
used and (4) expression of developmentally relevant genes in the differentiating cells.  
A more thorough characterization of the differentiation especially with regards 
to gene expression will not only help to precisely establish the differentiation status 
but also to identify areas that could be targeted to improve efficiency. It is also of 
interest to study whether the in vitro differentiation regime, especially in the early 
commitment stages, follows patterns that are established in embryonic development. 
To this end expression of haematopoietic genes including SCL, FLK1 and GATA-1 
was determined in the differentiating cells. hES3 which showed better CFU formation 
than hES2 was differentiated as described and hES3-EBs were treated with cytokines 
from day 5 of differentiation. Samples were collected at various time points during 
EB differentiation and adherent culture. Trizol was used to generate RNA from the 
samples and quantitative RT-PCR was performed as described.  Expression of the 
haematopoietic transcription factors SCL (Elefanty et al. 1997, Robb et al. 1996) and 
GATA-1 (Suwabe et al. 1998; Fujiwara et al. 1996), mesodermal/ hemangioblast 
markers FLK1 and T/BRACHYURY (TBRA) (Kennedy et al. 2007; Huber et al. 2004), 
and β-GLOBIN (Lanyon et al. 1975) was compared to control commercially available 
bone marrow total RNA (Clontech). Curiously, FLK1 expression was high in 
undifferentiated hESCs and did not vary much over the entire duration of 
differentiation (Fig 3.5D). However, this is not surprising as there are studies which 
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have clearly demonstrated that FLK1 is expressed in undifferentiated hESCs 
(Zambidis et al. 2005; Wang et al. 2004). This is in contrast to undifferentiated 
mESCs that do not express FLK1 until the cells progressively differentiate into the 
mesodermal/ hemangioblast population (Chung et al. 2002; Choi et al. 1998). TBRA 
levels which increased by day 5, remained steady through day 8 and then dropped 
precipitously. SCL, GATA-1 and β-GLOBIN were not significantly upregulated at any 
point in the differentiation. Human adult bone marrow RNA used as control, showed 
the predicted expression of GATA-1 and β-GLOBIN but not of any of the other genes 
(Fig 3.5E). Since TBRA levels increased before the addition of cytokines, this can be 
attributed to gastrulation-like events triggered within the spontaneously differentiating 
EBs. However, the differentiation seems not to have progressed beyond this point as 
the addition of cytokines did not have any significant effect on expression of the other 
genes. Perhaps it is not surprising then that an aliquot of these differentiating cells 
seeded in Methocult did not generate any colonies. Therefore, if the relevant genes are 
not activated at the right stages, differentiation does not progress beyond a certain 
developmental point. The above data suggest that CFUs seen in earlier experiments 
might have been the result of a spontaneous differentiation event. 
 
3.3.2. hESCs maintained on Ortec143 cells 
Though CCD919 cells promote haematopoietic differentiation from hESCs, the 
low efficiency and poor reproducibility prompted further trials using alternative 
culture platforms. Ortec143 is a human feeder cell line derived under clinically 
compliant conditions from neo-natal foreskin tissue (Ortec International). These cells 
support undifferentiated culture of hESCs over numerous passages with an extremely 
low frequency of spontaneous differentiation (Crook et al. 2007). To assess the 
85 
haematopoietic potential hESCs grown on Ortec cells, hES2 and hES3 were 
differentiated in the presence of cytokines. 
Briefly, hESC-EBs were formed in Ultra low attachment plates. On day 14, EBs 
were plated onto tissue culture plates in Differentiation medium containing SCF, 
Flt3L, TPO, IL-4, GM-CSF and IL-3. After 2 weeks of culture an aliquot of the 
differentiating population was seeded in Methocult for CFU assay while some were 
left to differentiate further. On day 29 of differentiation, both hES2 and hES3 showed 
presence of numerous spherical cells restricted to certain areas in the plates (Fig 
3.6A). To confirm the haematopoietic nature of these cells, plate-based 
immunostaining was done for CD34 (haematopoietic progenitors) and CD45 (pan-
haematopoietic) markers. Almost all the spherical cells were positive for CD45 (Fig 
3.6B) and negative for CD34. This suggests that these cells are more mature 
progenitors expressing only CD45 and not early precursor cells which are CD34+ 
CD45–. A merged image of cells stained for CD45 (red) and DAPI (blue) to mark the 
nuclei is shown (Fig 3.6C). An aliquot of the differentiating culture was also 
immunostained for CD45, CD14, CD83 and CD86 and analysed by flow cytometry. 
Only CD45 was expressed at very low levels– 17% of the gated live population (Fig 
3.6D). All other markers were negative. This suggests that differentiation was 
inefficient and did not progress beyond the CD45+ progenitor stage. 
As mentioned earlier, two wells of differentiating cells were seeded in 
Methocult for the CFU assay. These cells generated haematopoietic colonies mainly 
of CFU-GM (Fig 3.7A) and CFU-M (Fig 3.7B) types. The frequency of colony 
formation was 0.02% for CFU-GM and 0.05% for CFU-M respectively. Giemsa and 
May Grünwald staining of cells from the colonies showed presence of neutrophils, 
eosinophils and monocytes (Fig 3.7C). 
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Figure 3.6. hESCs cells grown on Ortec143 differentiated in presence of 
cytokines to give rise to haematopoietic-like cells. (A) Distinct areas with spherical 
haematopoietic-like observed in culture (10x magnification). (B, C) Cells shown in 
(A) stained with CD45-PE, CD34-FITC and Hoechst (10x magnification). (B) Cells 
stained positive for CD45 while no CD34 was detected. (C) Hoechst was used to 
mark the nuclei of stained cells. (D) FACS analysis of pooled cells immunostained for 
CD45, CD14, CD86 and CD83. The green line represents isotype control while the 
purple filled area indicates stained cells. Expression within the marker region (M1) is 
indicated as percentage of the gated live population. Only CD45 was detected and at 
extremely low levels even though the culture had high numbers of spherical cells 


























hES3-derived cells showed more efficient differentiation and formed 4 times 
more colonies than hES2 cells. hESCs grown on Ortec cells generated 40 times more 
CFU-GM and 10 times more CFU-M colonies than the CCD919-based cultures. 
These results suggest that Ortec cells provide a culture platform more supportive of 
efficient haematopoietic differentiation than even the CCD919 human feeders.   
For a detailed characterisation of haematopoietic differentiation obtained using 
hESCs maintained on Ortec cells, gene expression analysis was performed. EBs/ cells 
harvested every 4 days during differentiation were processed using the RNAeasy kit 
according to the manufacturer’s recommendations. Quantitative RT-PCR was 
performed to detect expression of assorted marker genes (Fig 3.7D). As seen in the 
case of hESCs maintained on CCD919 cells, FLK1 was expressed even in the 
undifferentiated cells and showed a very slight increase on exposure to cytokines (day 
18). TBRA was low through out the EB differentiation phase and was upregulated 
transiently upon cytokine treatment. MIXL1, an early marker of the developing 
mesoderm (Willey et al. 2006; Hart et al. 2002) and PU.1 a haematopoietic 
transcription factor (Fisher and Scott 1998) did not show any variation in expression 
compared to undifferentiated control. GATA-2 is a mesodermal marker known to be 
expressed in haematopoietic progenitors (Tsai et al. 1994) and is expressed at high 
levels through out the differentiation. HOXB4, a critical haematopoiesis-specific 
transcription factor (Kyba et al. 2002; Antonchuk et al. 2001) responded specifically 
to the addition of cytokines and showed increased levels of expression. However, the 
expression of GATA-2 and HOXB4 in the untreated control (–GF) was also high 
suggesting that this might not be a specific response to the cytokines. GATA-1, SCL 
and LMO2 were not expressed at any stage tested. 
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Though TBRA was upregulated upon cytokine treatment, the very slight increase 
in FLK1 expression might not be significant enough to infer the presence of a 
hemangioblast-like (common progenitor for haematopoietic and endothelial cells) 
population. The high levels of GATA-2 and HOXB4 in the untreated control indicates 
that expression of these genes is not triggered exclusively by the cytokines. Due to 
these reasons, the gene expression analysis was not conclusive enough to show if 
differentiation is a specific response to the addition of cytokines. As seen in the case 
of CCD919-based hESCs, differentiation does not seem to activate developmentally 
relevant genes. This roadblock in differentiation is also evident from the 
immunostaining seen in Figure 3.6D which shows extremely low levels of only 
CD45+ expression. It would seem that the CFUs generated in Methocult (Fig 3.7A 

























































































































































































































Figure 3.7. hESCs grown on Ortec feeders differentiate in presence of cytokines 
to generate haematopoietic colonies. (A, B) Representative images of CFU-GM 
(Granulocyte Macrophage) and CFU-M (Monocyte) colonies formed in Methocult. 
(C) Giemsa and May-Grünwald staining of pooled cells from colonies. Neutrophils 
(brown arrow heads), eosinophils (blue arrowheads) and monocytes (red arrowheads) 
are shown. (D) Increased expression of marker genes TBRA, FLK1 and HOXB4 in 
response to cytokine treatment (day 18 onwards) shows the induction of a low degree 
of mesodermal differentiation in this system. Surprisingly, PU.1 is not significantly 
upregulated even though granulocytic differentiation is known to be characterised by 
the expression of this gene. Grey bars indicate differentiation during the EB formation 
phase in absence of cytokines. Dotted line represents day 0 normalisation. 
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CONCLUSION and DISCUSSION 
 
Several factors including the derivation, feeders used, epigenetic status, etc., can 
influence the amenability of hESCs to differentiate (Pekkanen-Mattila et al. 2009; 
Aiba et al. 2008; Catalina et al. 2008; Chang et al. 2008; Adewumi et al. 2007). As 
part of my preliminary studies to test the multipotential differentiation capability of 
hESC lines, hES2 and hES3, I used strategies that were known to induce 
haematopoietic differentiation. 
Using bone marrow-derived cell lines as supportive stroma, hESC-EBs could be 
differentiated to generate haematopoietic-like cells. However, hESCs did not show a 
similar capacity, suggesting that differentiation needed to be ‘kick started’ as a 
spontaneous event within EBs. The source and support capability of the stroma were 
also important factors as only OP9, a murine cell line, supported haematopoietic 
differentiation from hESCs while human stromal cell lines HS-5 and HS-27A did not. 
Reproducibility of differentiation using co-culture was quite low indicating that it 
may be a spontaneous event or that the outcome may be easily affected by slight 
changes in culture conditions. Efficient differentiation may also be hESC line 
dependent as hES2 subjected to identical conditions did not yield similar results as 
hES3. The use of OP9 for haematopoietic differentiation from hESC lines H1 and H9 
was reported by Vodyanik et al. (2005) around the same time as my work was 
underway. In contrast to results obtained with hES3, these authors reported generation 
of haematopoietic cells from hESCs in a monolayer differentiation and not from 
hESC-EBs. They reported low CD45 (3.4%) and high CD34 (19.3%) expression and 
a wider range of colonies in the CFU assay. This suggests that the haematopoietic 
cells they obtained in culture are more naïve and have a wider developmental capacity 
in contrast to the more differentiated CD45+ population I obtained. These differences 
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could be attributed to several factors including hESC line variation, quality of OP9 
monolayers and sampling points within experiments. 
Differentiation in presence of human recombinant cytokines was another 
favoured strategy as this approach eliminates the foreign (murine) stromal cells in 
culture. A cocktail of haematopoiesis-promoting cytokines acted on hESC-derived 
EBs to give cells mainly of the granulocytic lineage. No erythroid differentiation was 
detected at any time. The bias towards granulocytes was expected since the cytokines 
used are known to promote differentiation of this particular lineage (Zhan et al. 2004). 
An interesting observation was that hES3 did not seem to differentiate as well as 
hES2 in the presence of cytokines. This is in contrast to the OP9-based differentiation 
where only hES3 gave rise to differentiated haematopoietic-like cells. Though these 
two cell lines were derived under identical conditions, inherent differences between 
the two are highlighted by such observations. 
With the aim of adapting hESCs to clinically compliant culture regimes, our lab 
began using human feeder cells to maintain hESCs in the undifferentiated state. Since 
hESC culture platforms can significantly affect the differentiation capability of these 
cells, I decided to test if the new culture conditions alter this potential. EBs derived 
from hESCs grown on CCD919 or Ortec feeders were differentiated in presence of 
cytokines in a manner similar to hESCs grown on MEFs. In general, expression of 
haematopoietic cell surface markers was not as dramatic or high in the human feeder 
based differentiation as it was with the use of MEFs (FACS data). Another difference 
seems to be the efficiency of differentiation. Though Ortec-based hESCs formed a 
significantly higher number of colonies in the CFU assay than the CCD919 cultures, 
the frequency was much lesser than in the MEF-based cultures. Since the protocol 
used was optimized for hESCs grown on MEFs, slight modifications may be required 
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to adapt this protocol to hESCs grown on human feeders. Though the human feeder-
based hESC system generated CFUs in Methocult, they did not seem to activate 
expression of genes known to be important in haematopoietic development. TBRA 
upregulation shows that a gastrulation-like event initiated but this did not advance to 
give rise to haematopoietic mesoderm in this system. The lack of GATA-1 expression 
in the differentiating population supports the observation that no erythroid colonies 
were formed in the CFU assay, since GATA-1 is critical for the formation of the 
erythroid lineage (Suwabe et al. 1998). The extremely low percentage of CFUs and 
lack of corroborative gene expression data suggests that the CFUs formed in 
Methocult were most likely the result of spontaneous differentiation events. It is also 
possible that the sampling points chosen for my gene expression analysis might have 
missed important events in the differentiation. This emphasizes the need for more 
thorough analysis of the differentiation process by increasing the frequency of 
sampling. 
My experimental observations point towards a certain degree of haematopoietic 
differentiation albeit spontaneous, occurring in this system. Immunostaining revealed 
that cells formed were mainly haematopoietic progenitors which did not develop 
further into more terminally differentiated cell types. Differentiation was mainly 
towards cells of the myeloid lineage which is not surprising since the cytokines used 
were pro-granulocytic. Gene expression analysis proved inconclusive as either genes 
were not expressed or did not show specific response to cytokine treatment. This 
makes it almost impossible to conclude if in vitro differentiation using hES2 and 
hES3 with the strategies described, mirrors haematopoietic development in the 
embryo (Kennedy et al. 2007). However, these results constitute proof-of-principle 
that haematopoietic differentiation from hESCs can be obtained with the use of 
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cytokines on differentiating embryoid bodies. Better tailoring of this differentiation 
strategy might help resolve the current issues.  
Since this work was done numerous innovations have been reported resulting in 
improved methods for generation of haematopoietic cells from ES cells. One 
particular gene of interest is HOXB4 which has been reported to be expressed in 
haematopoietic progenitors and has been shown to enhance the repopulating ability of 
haematopoietic stem cells (Sauvageau et al. 1995; Sauvageau et al. 1994). In addition, 
recombinant HOXB4 protein has been used to achieve expansion of human and 
murine haematopoietic stem cell populations (Amsellem et al. 2003; Krosl et al. 
2003). Taking cues from these studies Bowles et al. reported that over-expression of 
HOXB4 in hESCs led to the expansion of haematopoietic progenitors and their 
derivative populations (Bowles et al. 2006). Clonogenic progenitors expressing 
markers like CD34, CD45 and Glycophorin A were generated in this differentiation. 
Another recent study demonstrated that HOXB4, and not Bmp4, confers self-renewal 
properties to haematopoietic progenitors derived from ES cells (Bonde et al. 2008). 
These authors found that the ES-derived haematopoiesis induced by Bmp4 leads only 
to transient mixed chimerism. However, HOXB4 transduced mESCs generated 
haematopoietic progenitors with enhanced self-renewal and long-term engraftment 
capability. This latest study is encouraging as it provides a strategy to generate a 
source of haematopoietic cells that could induce transplantation tolerance. 
Concurrent investigations on endodermal differentiation from hESCs proved to 
be more successful than the mesodermal differentiation. These experiments yielded 
differentiated progeny with a much greater efficiency. Therefore, studies of 
endodermal differentiation constitute the bulk of my dissertation work and are 






























In Chapter 3, I described my results on differentiation of hESCs into 
haematopoietic-like cells which could theoretically be used as a transplantation aid for 
hESC-derived cell therapy products. In this chapter, I focus on the efficient 
differentiation of hESCs into definitive endoderm as a first step towards the in vitro 
production of insulin-secreting β cells for the treatment of diabetes. As outlined in 
Chapter 1, our lab developed an EB-based differentiation strategy that begins with an 
initial endoderm induction phase and is followed by pancreatic and endocrine cell 
specification phases (Phillips et al. 2007). In this protocol, a known inducer of 
endoderm, Activin A was used to initiate differentiation towards a definitive 
endodermal fate. Genes characteristic of definitive endoderm (DE) formation are 
induced within the first 4 days of differentiation, with activation of the pancreatic 
homeobox gene PDX1 about one week later.  
During the course of developing our EB-based differentiation regime, we 
discovered that the combined use of Activin A and Bmp4 led to greater expression of 
genes characteristic of definitive endoderm. The extent of endoderm induction was 
found to be concentration-dependent as only a certain range of growth factor 
concentrations efficiently gave rise to the desired progeny from differentiating hESCs. 
The enhanced induction of endoderm in the presence of Bmp4 is surprising as this 
growth factor is known to be involved in a variety of developmental events including 
bone formation, mesoderm induction and primordial germ cell generation, but is not a 
well-established endoderm inducer.  
Several models can be proposed and tested for the unexpected role of Bmp4 
during DE formation in vitro. (1) Bmp4 might signal directly to cells that receive the 
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Activin A patterning signal and potentiate their endodermal differentiation. (2) Bmp4 
may facilitate the transduction of locally produced Nodal signals emanating from the 
hESCs by directly impacting the signaling pathway. (3) Bmp4 may induce the 
formation of an unrelated cell type that indirectly, for example, influences DE 
formation and expansion. In this Chapter, I will describe my efforts to characterize 
DE differentiation in detail and to arrive at a possible mechanism for the collaborative 
effect of Activin A and Bmp4, using a variety of molecular methods. In depth analysis 
of the differentiation revealed that Activin A induces formation of DE in Matrigel-
embedded EBs and this induction is augmented with the addition of Bmp4 to the 
differentiation. Detailed investigation of the Activin A and Bmp4 signaling pathways 
and the pleiotropic roles of Bmp4 did not bring to light a clear mechanism for the 
combinatorial activity of these two growth factors. By studying changes in global 
gene expression during differentiation, I identified novel genes that were upregulated 
during the formation of DE. The expression domains of these genes during mouse 
embryonic development were investigated to establish their relevance to the 













4.1. Formation of definitive endoderm within embryoid bodies derived from 
hESCs 
Our lab previously developed an empirical protocol for the differentiation of 
hESCs into pancreatic progenitor cells. A summary of this Matrigel-based three-
dimensional differentiation is given in Figure 4.1. Briefly, hESC clumps grown on 
mouse feeders (MEFs) were embedded in Matrigel-containing medium either with or 
without Activin A and Bmp4, as described in Chapter 2.2.3 (Fig 4.1A). Spherical EBs 
of various sizes were formed by day 2 of differentiation. As differentiation progressed 
some of the EBs developed cystic areas, while a few fused to form larger structures. 
On day 10, the early factors were replaced with the late factors Exendin-4, β-cellulin 
and HGF. Differentiation was discontinued on day 20, since from previous trials it 
was known that pancreatic progenitors are formed by this time. PDX1, the earliest 
marker of the pancreas, is detectable by day 12 (Fig 4.1B) and decreases thereafter 
with a simultaneous increase in markers of mature pancreatic progenitors like 
INSULIN, NGN3 and PTF1a (Fig 4.1B and C). Therefore, in the presence of 
Matrigel, an initial stimulus of Activin A and Bmp4 seems to induce formation of a 
pancreatic progenitor population from hESCs. 
As pancreatic tissue is known to arise from DE during development, I examined 
if markers of DE could be detected in the differentiation cultures by immunostaining. 
Briefly, EBs embedded in Matrigel with the early factors were plated on fibronectin-
coated plates to enable staining against endodermal markers Sox17 and Foxa2 and the 
pluripotency marker Oct4. Addition of Activin A and Bmp4 triggered downregulation 
of the pluripotency marker Oct4, while simultaneously upregulating the expression of 
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endodermal markers Foxa2 and Sox17 (Fig 4.2). In the absence of growth factors, 
Oct4 expression remained high in all EBs. There were a few cells in some untreated 
EBs that stained for Foxa2 and Sox17, which suggests that a certain degree of 
spontaneous differentiation occurs in this differentiation system. These results suggest 
that DE cells form during hESC differentiation in response to growth factor treatment 
and most likely give rise to PDX1+ pancreatic progenitors. 
 
4.1.1. Bmp4 enhances the endoderm-inducing potential of Activin A in Matrigel 
Since they have distinct roles in development, Activin A and Bmp4 acting 
together to specify or enhance the formation of endoderm in vitro came as a surprise. 
In the 3D Matrigel differentiation, the combination of these growth factors 
reproducibly gives enhanced endoderm differentiation (N=7). This effect was 
irrespective of the hESC culture platform used, as hESCs grown on MEFs and HFs 
gave similar results. Since HFs and KOSR-based culture medium provide a stable 
culture platform for hESCs in our hands, I adopted this method for all experiments 
described henceforth (Crook et al. 2007). To investigate molecularly the Activin A 
and Bmp4 collaboration in detail, I used the following iterations of the 3D 
differentiation protocol. In the standard Matrigel embedding conditions, I added either 
Activin A alone (AA) or Bmp4 alone (Bmp4) or both (+GF) or neither (–GF) and 
allowed differentiation to proceed through the endoderm phase onto the pancreatic 
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Figure 4.1. Three dimensional differentiation in the presence of Activin A and 
Bmp4.  (A) Schematic representation of differentiation strategy. hESC colonies were 
enzymatically dissociated to create clumps that formed EBs of various sizes in 
Matrigel-containing medium. Differentiation was carried out in the presence of the 
indicated growth factors. As differentiation progressed many EBs formed cystic areas, 
giving them a bubble-like appearance (white arrowhead). (B) A critical marker of 
pancreatic differentiation, Pdx1 (red), is activated around day 10 of differentiation. 
Insulin expression (blue) is detected by day 16 and continues to rise with a 
simultaneous decrease in the levels of Pdx1, which is consistent with the known 
pattern of Pdx1 expression during pancreatic development (Jensen 2004). (C) Other 
pancreatic markers like Ngn3 (red) and Ptf1a (blue) are detected following Pdx1 
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Figure 4.2. Activin A and Bmp4 induce upregulation of endodermal markers and 
simultaneous downregulation of pluripotency markers. hESCs were differentiated 
using the 3D Matrigel protocol either with (+GF) or without (–GF) both Activin A 
and Bmp4. On day 4 of differentiation, EBs were seeded on Fibronectin-coated plates 
and allowed to attach for 2 days before staining. Oct4, Foxa2 and Sox17 were 
detected using Alexa 488 conjugated secondary antibodies. The number of Oct4+ cells 
in the –GF condition were significantly greater than EBs exposed to growth factors. 
Few Foxa2+ and Sox17+ cells were observed in the –GF EBs but the population 
increased dramatically in EBs treated with Activin A and Bmp4. The low number of 
endodermal cells in the –GF condition can be attributed to spontaneous 






Markers of pluripotency, OCT4 and NANOG, were rapidly downregulated in 
+GF and Bmp4 (Fig 4.3A and 4B). However, Activin A when added alone sustained 
expression of OCT4 and NANOG for a short time. This finding supports the reported 
role of Activin A in maintaining the pluripotency of hESCs and mEpiSCs (Tesar et al. 
2007; Vallier et al. 2005). In the absence of growth factor stimulation (–GF), 
expression of these markers was maintained for a few days before being 
downregulated. This decrease in expression is expected as spontaneous differentiation 
occurs even when EBs are cultured in differentiation medium rich in KOSR (20%).  
Directed differentiation was measured as changes in the expression of TBRA, 
FOXA2 and SOX17. In general, all three genes were upregulated in presence of 
Activin A + Bmp4 (+GF) and Activin A; the expression was always higher in the 
+GF condition (Fig 4.3C-E). The lack of expression of all three genes in –GF 
suggests that there was little spontaneous differentiation toward DE in this system.  
As expected from what is known from previous work, Bmp4 alone induced 
expression of TBRA (Johansson and Wiles 1995). No expression of FOXA2 and 
SOX17 was detected in the presence of Bmp4 alone. Taken together these 
observations imply that the growth factors used here specifically and rapidly 
downregulate pluripotency genes and set the stage for differentiation. The progress of 
differentiation was measured by PDX1 expression, which was detected by day 10 in 
the presence +GF and Activin A (Fig 4.3F). The significantly higher PDX1 
expression in +GF suggests that the endoderm-inducing synergistic activity of Activin 
A and Bmp4 might significantly impact the pancreatic differentiation phase of the 
protocol, most likely by providing a greater initial pool of DE that can undergo 
pancreatic commitment. 
 102
Detailed analysis of the differentiation under the 4 different conditions stated 
above has revealed that both conditions, Activin A and Activin A + Bmp4 (+GF), 
specifically induce endoderm differentiation. However, the +GF condition always 
elicited a higher expression of the marker genes than Activin A alone. This confirms 
the earlier observation that the presence of Bmp4 enhances the ability of Activin A to 
promote endodermal differentiation. 
 
4.1.2. Matrigel affects the extent, not the outcome of differentiation 
The 3D differentiation protocol uses the growth factor-reduced formulation of 
Matrigel to induce endoderm differentiation from hESC-EBs. Since Matrigel contains 
biologically active components, including trace amounts of potent growth factors, it is 
important to examine the influence of this substrate on differentiation. hESCs were 
dissociated using collagenase as described and seeded in RPMI/KOSR medium 
without Matrigel. EBs formed by day 2 and were more varied in size than in Matrigel- 
based culture. Differentiation was initiated identically to the 3D protocol described 
earlier. Quantitative RT-PCR analysis was performed on free-floating EBs harvested 
every other day and compared against those embedded in Matrigel (adapted from 
Figure 4.3). In free-floating EBs, growth factor addition caused only a slight decrease 
in OCT4 expression, which was similar to the –GF condition (Fig 4.4A). This is in 
contrast to the Matrigel-based differentiation where addition of growth factors triggers 
a rapid drop in OCT4 levels, while expression is maintained in the –GF condition (Fig 
4.4E). In the free-floating EBs, expression of TBRA, FOXA2 and SOX17 was induced 
in the +GF condition, though the levels of expression were roughly 10 times lower 
than in the Matrigel-based platform (Fig 4.4B-D and F-H). As expected, Bmp4 when 











































































































































































Figure 4.3. Activin A and Bmp4 together are more effective in inducing 
endodermal differentiation than either growth factor alone. hESCs were 
differentiated using the 3D Matrigel protocol under the 4 conditions indicated. Gene 
expression data were generated by quantitative RT-PCR with samples collected every 
other day from day 0 to day 20. (A, B) Expression of pluripotency markers OCT4 (A) 
and NANOG (B) decreases during the course of differentiation as expected. The 
continued expression of these markers in the –GF condition shows that decreasing 
expression in all other conditions is a direct effect of growth factor addition. (C) The 
gastrulation marker BRACHYURY (TBRA) is expressed in response to all growth 
factor treatments. Bmp4, which is known to induce TBRA, stimulated the highest 
expression followed by +GF and Activin A. (D, E) Genes specific to the endodermal 
lineage, FOXA2 and SOX17, are expressed in response to the growth factors and seem 
to follow the known developmental sequence of gene expression. Activin A alone 
does expectedly induce some amount of endodermal differentiation but much lower 
than +GF (~3 fold). Bmp4 when used alone does not seem to efficiently differentiate 
hESCs into endoderm. (F) To confirm if the differentiation progressed as expected to 
generate pancreatic progenitors, PDX1 expression was determined. PDX1 is 
detectable by day 10 and shows higher expression in +GF than in Activin A alone. 
These expression data suggest that undifferentiated cells downregulate pluripotency 
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Figure 4.4. Absence of Matrigel adversely affects the extent of endodermal 
differentiation. hESCs were differentiated using the 3D protocol without Matrigel 
under the 4 conditions indicated. Gene expression data were generated by quantitative 
RT-PCR with samples collected every other day from day 0 to day 10 and compared 
against the data from Matrigel-embedded EBs (adapted from Figure 4.3).  (A, E) 
Expression of OCT4 was low but persistent in the free-floating EBs. In presence of 
Matrigel, all conditions except –GF showed rapid downregulation of OCT4, while 
expression remained constant in –GF. (B-D, F-H) In the absence of Matrigel, Activin 
A alone does not seem to induce endodermal differentiation. When free-floating EBs 
are treated with both Activin A and Bmp4, there is expression of the gastrulation 
marker TBRA, followed by the endodermal genes SOX17 and FOXA2, though 10 
times lower than in the Matrigel-based differentiation. Induction of endoderm seems 
to be slower than in the Matrigel differentiation as expression of SOX17 and FOXA2 
is delayed. Bmp4 alone has no effect on gene expression except in the case of TBRA 











Strikingly, Activin A alone did not seem to induce endodermal differentiation in 
the absence of Matrigel (Figure 4.4). This suggests that Matrigel enhances the ability 
of Activin A to bring about differentiation. There could be a Bmp4-like activity in 
Matrigel, which causes an effect similar to the +GF condition. Eliminating Matrigel 
possibly abrogates this Bmp4-like activity thus rendering recombinant Activin A 
inefficient in inducing endodermal differentiation in this system. Alternatively, 
Activin A when used alone could be acting to maintain pluripotency or to resist 
differentiation and the addition of Matrigel possibly overcomes this block.  
An alternative explanation for this observation is the potent anti-differentiation 
activity present in KOSR which can be attributed mainly to Insulin/ IGF-like activity 
(Bendall et al. 2007). Since Matrigel- and free-floating- EBs are differentiated in 
KOSR-containing medium, this IGF-like activity is present in all conditions. 
However, the presence of Matrigel seems to serve as a protective barrier to the anti-
differentiation effect of KOSR. In the absence of this buffer, free-floating EBs are 
exposed to extremely high concentrations of IGF which hampers and delays the 
differentiation or even eliminates it when Activin A is used alone. Another interesting 
observation is that the absence of Matrigel seems to prolong the gastrulation-like 
phase (TBRA expression) and delay the expression of FOXA2 and SOX17. This 
suggests that Matrigel renders the EB more amenable to differentiation. These data 
also reiterate the importance of Bmp4 in inducing endodermal differentiation. 
 
4.1.3. Cells expressing FOXA2 and SOX17 are of definitive endodermal origin as 
visceral endoderm is suppressed during differentiation 
Both FOXA2 and SOX17 are known to be expressed in the definitive and 
visceral endoderm (Dufort et al. 1998, Kanai-Azuma et al. 2002). Therefore, it is 
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important to verify that FOXA2 and SOX17 expression during in vitro differentiation 
specifically identifies DE-like cells. This is especially relevant in light of 
experimental evidence that hESC-EBs form a VE-like layer during in vitro 
differentiation (Conley et al. 2004).  
Since the outer VE-like layer is expected to form quite rapidly during EB 
organization, the expression of VE genes is predicted during the earliest stages of in 
vitro differentiation. Molecular analysis of the differentiation shows that the 
expression of FOXA2 and SOX17 always follows TBRA expression (Fig 4.3). This 
indicates that the differentiation closely mimics development and gives rise to a 
TBRA+ primitive streak-like population from which the FOXA2+ SOX17+ DE cells 
emerge. In addition, RT-PCR analysis of samples from Matrigel-based and free-
floating differentiations shows that gene expression of markers unique to the VE like 
Transthyretin (TTR), Alpha Feto Protein (AFP) and H19 expression is suppressed in 
the early part of differentiation (Fig 4.5A-D). The effect on gene expression seemed 
to be irrespective of Matrigel unlike what has been reported previously. H19 
expression was insignificant in all conditions except in the presence of Bmp4 alone. 
TTR and AFP expression is detectable later in differentiation and is coincident with 
the expression of PDX1 (Fig 4.3). As TTR and AFP resolve to the liver later in 
development, the similar timeline of expression of these genes suggests that multiple 
derivatives of the DE are being generated during differentiation. Taken together, these 
data strongly suggest that FOXA2 and SOX17 expression marks cells of the DE that 
are derived from a primitive streak-like population and are therefore not indicative of 
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Figure 4.5. Markers of visceral endoderm are suppressed during the definitive 
endoderm formation phase of differentiation. Cells were differentiated using the 
3D protocol with or without Matrigel under the 4 conditions indicated. Gene 
expression data were generated by quantitative RT-PCR with samples collected every 
other day from day 0 to day 10. In general, markers of visceral endoderm– TTR, AFP 
and H19– are suppressed in endoderm-forming conditions irrespective of the presence 
of Matrigel. (A, B) TTR and AFP are specifically suppressed during the initial 
endoderm-forming phase of differentiation in both free-floating and Matrigel-EBs. 
+GF and Bmp4 alone induce gene expression later in the differentiation following the 
activation of TBRA, FOXA2 and SOX17 (between days 2 and 6 in Fig 3). These data 
strongly argue that these markers have resolved to the definitive endoderm. (C) H19 
was expressed only when Bmp4 was used alone.  
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The above data (Section 4.1) show that reproducible, directed differentiation of 
hESCs to DE can be achieved by exposing EBs embedded in Matrigel to Activin A 
and that this induction can be enhanced with the addition of Bmp4. Analysis of gene 
expression suggests that the growth factors generate specifically DE and suppress the 
formation of VE in vitro. However, it is entirely possible that certain VE-like cells 
exist in these cultures and this has been shown later in this chapter. It is important to 
note that by day 20 of differentiation a variety of cell types reside within the EBs– not 
every cell is Pdx1+. This observation is consistent with QPCR analysis of the 
differentiation which is given in the various sections of this chapter. 
 
4.2. Detailed analysis of the role played by Bmp4 in the formation of definitive 
endoderm in vitro 
The initial investigations outlined in Section 4.1 show that in our differentiation 
strategy, Activin A expectedly induces the formation of DE in Matrigel-embedded 
EBs. Strikingly, the addition of Bmp4 to this differentiation significantly increases the 
expression of DE-specific genes. This unexpected synergy is consistent between 
various hESC culture platforms and is highly reproducible. To address the role of 
Bmp4 in the formation of DE in vitro, it is important to draw lessons from Bmp4’s 
role during vertebrate development.  
As alluded to in the general introduction and earlier in this chapter, Bmp4 is 
known to play pleiotropic roles in development but is not known to be an inducer of 
endoderm. However, there are a few possible mechanisms by which Bmp4 could 
enhance endodermal differentiation in vitro. (1) Activin A utilizes the Nodal signaling 
machinery and potentially induces transcription of Nodal and other genes that locally 
influence the formation of DE. Binding of Activin A to its receptor initiates 
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phosphorylation of Smad2, which in a complex with Smad4 induces transcription. 
Phosphorylated Smad2 (p-Smad2) is known to activate transcription of Nodal by 
binding to the Asymmetric Enhancer (ASE) element within the Nodal gene (Saijoh et 
al. 2005; Adachi et al. 1999). It is therefore conceivable that endogenous Nodal 
production also leads to transcription of genes essential for generation of DE. Both 
signaling events could result in increased Nodal activity as the Nodal gene is known 
to establish a positive feedback loop for its own induction. Consequently there might 
be greater levels of DE formation in the differentiation. Bmp4 might be enhancing 
this differentiation (Activin A-induced + Nodal-induced endoderm formation) by 
activating expression of Cripto, the co-receptor required for Nodal function. Bmp4 is 
known to induce Cripto in embryonic explants (Beck et al. 2002) which mirrors hESC 
differentiation in vitro. The above hypothesis is represented in Figure 4.6. (2) Bmp4 
induces expression of brachyury (Tbra) during endodermal differentiation from 
mESCs and could be acting similarly in hESCs to exert a direct effect on 
differentiation (Johansson and Wiles 1995). The expression of TBRA indicates the 
presence of a primitive streak-like population which forms DE. This is supported by 
gene expression data that shows the expression of TBRA followed by FOXA2 and 
SOX17 (Fig 4.3). As is evident from the data, Bmp4 induces expression of TBRA 
which could increase the pool of primitive streak-like cells primed for allocation to 
the DE lineage. (3) Our lab has previously demonstrated that Matrigel inhibits VE 
formation associated with in vitro differentiation of hESCs. Since the VE is known to 
secrete Bmp antagonists like Noggin and Chordin, the use of Matrigel might create an 
environment that reveals a previously masked function of Bmp4 in endoderm 
specification in vitro (Song et al. 2007; Rust et al. 2006; Tiso et al. 2002). It is also 
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important to note that the formation of anterior primitive streak derivatives such as the 
node is impaired in Bmp4 mutant mouse embryos (Fujiwara et al. 2002).  
In order to address these possibilities and interrogate the collaborative activity of 
Activin A and Bmp4 during DE formation from hESC, I undertook the studies 
outlined below. 
 
4.2.1. Activin A signaling leads to the expression of known target genes during 
differentiation 
Activin A binding to its receptor initiates phosphorylation of Smad2/3, which 
ultimately leads to transcriptional activation of target genes. Gene expression analysis 
showed that NODAL was upregulated specifically in response to Activin A treatment 
as the –GF and Bmp4 alone conditions did not show any change in expression levels 
(Fig 4.7). This shows that Activin A is able to induce NODAL transcription over and 
above the endogenous levels seen at day 0 and in the –GF condition. When Activin A 
and Bmp4 were added together, there was only a slight upregulation of NODAL 
expression which disappeared by day 6 of differentiation, indicating a rapid signaling 
event in the presence of these two growth factors. This is in contrast to the sustained 
expression of NODAL in the presence of Activin A alone. The effector Smad 
molecules phosphorylated by Activin A and Bmp4 compete for the same co-Smad 
(Smad4) which might affect gene expression. This could be an alternative explanation 
for the lower expression of NODAL in the presence of both growth factors. If this 
were true, it would suggest that both signaling pathways are active in the same cell 
and that Bmp4 has a direct effect on DE formation. Along with several other targets, 
NODAL is known to induce transcription of its own inhibitor LEFTYA (LEFTY2) in a 
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Figure 4.6. Proposed model for synergistic activity of Activin A and Bmp4.  
(A) Nodal binding to its receptor causes phosphorylation of Smad2, which complexes 
with Smad4 and translocates to the nucleus to initiate transcription of downstream 
target genes including Nodal itself and Lefty1/2. (B) Activin mimics Nodal signaling 
in vitro and results in the expression of genes like Foxa2 and Sox17 which are 
required for DE formation. (C) Activin A signaling potentially leads to the expression 
of genes like Nodal as p-Smad2 is known to activate Nodal expression through the 
Asymmetric Enhancer (ASE) element within the Nodal gene. This addition activation 
of Nodal transcription could lead to increased expression of genes essential for DE 
formation. (D) A combinatorial effect of these various events is highly likely in the 
Matrigel-based differentiation in which Activin and p-Smad2 separately induce 
expression of genes including Nodal. This along with the positive feedback loop 
induced by Nodal increases the endogenous pool of Nodal that leads to activation of 
genes that influence DE formation in vitro. Bmp4 might be enhancing Nodal 
signaling locally by inducing Cripto, a co-receptor essential for Nodal function. The 





In the differentiation, expression of LEFTYA followed the peak expression of 
NODAL in the presence of Activin A alone and in the +GF condition (Fig 4.7B). This 
pattern suggests that NODAL could be inducing LEFTYA at levels relative to its own 
expression. In addition to this, Smad2 could be directly activating LEFTY as there is a 
Smad-responsive ASE element within the LEFTY gene (Saijoh et al. 2000; Adachi et 
al. 1999). The Nodal co-receptor CRIPTO was expressed at low levels in –GF and in 
both conditions where Activin A was present (Fig 4.7C). Since –GF represents the 
expression, if any, in the spontaneously differentiating population any equivalent 
expression cannot be considered significant. Interestingly, Bmp4, which is known to 
induce CRIPTO in explant cultures did not exhibit the same effect in this Matrigel-
based differentiation when Bmp4 was used alone. The homeobox transcription factor 
Goosecoid (GSC) is expressed in the epiblast region that later forms DE and is a 
known target of Nodal/ Activin signaling (Schier 2003). As expected, GSC is 
activated specifically in response to the addition of Activin A alone or Activin A + 
Bmp4, and not Bmp4 alone (Fig 4.7D). These data indicate that Activin A might be 
inducing transcription of Nodal through p-Smad2, resulting in endoderm formation as 
proposed in Figure 4.5D. It is important to note that though Activin A was 
supplemented during the course of differentiation this did not seem to have any 
specific effect on gene expression. The above data indicate that induction of CRIPTO 
might not be the mechanism by which Bmp4 enhances endodermal differentiation. 
Activin A transduces its signal by phosphorylating Smad2 to mediate the 
downstream effects. Therefore, I monitored phosphorylation of Smad proteins by SDS 
PAGE and western blotting as detailed in Chapter 2.9. Phosphorylated Smad2 
(pSmad2) was detected in all conditions though sustained expression was seen only in 
presence of Activin A alone (Fig 4.8A). The sustained pSmad2 expression in the 
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presence of Activin A alone could be attributed to the robust endogenous NODAL 
expression seen in the QPCR analysis. Supplementing Activin A at various time 
points during the differentiation did not seem to increase or sustain the p-Smad2 
expression in any other condition including Activin A + Bmp4. This was inconsistent 
with the QPCR data which shows induction of Nodal at those time points. High p-
Smad2 expression on day 2 and a sharp drop in expression by day 4 is consistent with 
the idea of a short but rapid signaling in the presence of both growth factors. 
As phosphorylation of Smad2 is a relatively quick response to ligand binding, I 
tested early time points during growth factor treatment. Samples were collected as 
indicated and phosphorylation status analysed (Fig 4.8B). Smad2 phosphorylation 
levels were almost identical for all conditions tested; starting at 15 minutes there was 
a clear increase which continued up to 3 hours after which it decreased. This suggests 
that Activin A is depleted by this time in the differentiation resulting in lower levels 
of pSmad2. This aligns with the reported kinetics of Smad2 phosphorylation in 
response to Activin A treatment (Mavrakis et al. 2007). However, identical pSmad2 
levels in all conditions indicate that any specific response to growth factor addition 
does not occur this early in the differentiation. Taken together these data strongly 
argue that Activin A triggers a signaling cascade that involves phosphorylated Smads 
and NODAL gene expression to induce endoderm formation. Sustained 
phosphorylation of Smad2 in the presence of Activin A alone might be a consequence 
of NODAL expression, which possibly increases the pool of p-Smad2 protein. The 
increased expression of endodermal genes in the presence of Activin A and Bmp4 is 
most likely the consequence of a rapid and short signaling event induced by these 

































































































Figure 4.7. Genes characteristic of Nodal/ Activin A signaling. 
Cells were differentiated using the 3D Matrigel protocol under the 4 conditions 
indicated. Gene expression data was generated by quantitative RT-PCR with samples 
collected every other day from day 0 to day 10. (A) NODAL is expressed during 
differentiation and is upregulated as a specific response to Activin A. The presence of 
Bmp4 seems to be dampening Nodal expression in the +GF condition. (B) A potent 
inhibitor of NODAL, LEFTY A is highly expressed in presence of Activin A and both 
growth factors. The more NODAL in the system, the more LEFTY A is generated, 
indicating a self-regulatory negative feedback loop that is induced by NODAL. (C) 
The Nodal co-receptor, Cripto, shows a modest upregulation in all conditions except 
in presence of Bmp4 alone. The expression is possibly insignificant since –GF 
represents the background levels of differentiation. Though Bmp4 is a known inducer 
of Cripto, there does not seem to be a specific effect of Bmp4 on the same in this 
instance. (D) Goosecoid (GSC) is a direct target of Activin signaling and is robustly 
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Figure 4.8. Phosphorylation of Smad2/3 in response to the Activin A signal. 
Cells were differentiated using the 3D Matrigel protocol under the 4 conditions 
indicated and SDS-PAGE performed as described. (A) Western blot for pSmad2 
which is phosphorylated specifically in response to Activin A/ Nodal. In Activin A 
alone, there is sustained phosphorylation of the Smad2. In all the other conditions, the 
expression is significantly high only till day 2 and seems to decrease/ disappear 
thereafter. Bmp4 seems to be squelching the phosphorylation of Smad2 which could 
result in lower Nodal levels. Xen denotes stage 10 Xenopus embryos lysed and run as 
control. Blots were stained for Actin as the loading control. (B) Western blot to assess 
the timing of Smad phosphorylation upon exposure to differentiating conditions. 
Samples were collected at the times indicated (‘– minutes, hrs – hours). Smad2 
showed almost identical pattern of phosphorylation in all conditions indicating that 
any specific response to growth factor addition was not occurring this early in the 
differentiation. Since the same activity is seen even in absence of all growth factor 
treatment, this could be considered background levels of phosphorylation. 
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4.2.3. Bmp4 signaling and its downstream effects 
Bmp4 phosphorylates Smad1/5/8 to initiate a signaling cascade which results in 
transcription of relevant genes like the inhibitor of differentiation (Id) genes in ES 
cells (Ying et al. 2003; Hollnagel et al. 1999). To check whether components of this 
pathway were induced during differentiation, I employed RT-PCR analysis and 
western blotting. All three ID genes ID1, ID2 and ID3 were expressed in the presence 
of Activin A + Bmp4 and Bmp4 alone. ID2 expression was significantly higher than 
the other two genes and seems to be a specific response to growth factor treatment 
(Fig 4.9B). However, ID1 and ID3 were also expressed in the –GF condition which 
indicates that these genes were induced irrespective of growth factor addition thus 
rendering the data inconclusive (Fig 4.9A, C). The homeobox genes MSX1 and MSX2 
are functional in multiple tissues during embryogenesis and are important in 
craniofacial development and limb patterning (Chen et al. 2008; Han et al. 2007; Ishii 
et al. 2005; Brugger et al. 2004; van den Boogaard et al. 2000; Bei and Mas 1998). 
Since these genes are known downstream targets of Bmp4 signaling, I monitored their 
expression during differentiation. In the presence of Activin A + Bmp4 only MSX2 
was expressed, at very low levels (Fig 4.9D, E). As the MSX genes are expressed in 
the primitive streak, this data supports the presence of a primitive streak-like 
population as identified by TBRA expression earlier. When cells were exposed to 
Bmp4 alone, both MSX1 and MSX2 were significantly upregulated as expected. The 
inhibitory Smads (I-Smads) SMAD6 and SMAD7 are induced by TGF-β signaling and 
regulate both Activin and Bmp4 signals differently (Imamura et al. 1997; Nakao et al. 
1997). While Smad7 regulates both Activin and Bmp4 signaling, Smad6 is more 
effective in inhibiting the Bmp4 pathway (Hanyu et al. 2001; Hata et al. 1998; Itoh et 
al. 1998). Analysis of gene expression during in vitro differentiation shows that 
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SMAD7 is not significantly upregulated (Fig 4.9G). Curiously, SMAD6 is 
significantly high in the +GF condition while low level expression is detected in the 
presence of either growth factor (Fig 4.9F). This is an unexpected observation as only 
p-Smad1/5 is known to induce SMAD6 and expression was anticipated to be high in 
the presence of Bmp4 alone with low level expression in the +GF condition (Ishida et 
al. 2000).  
Phosphorylation of Smad1/5/8 molecules as a consequence of Bmp4 signaling 
was detected employing western blotting. Phosphorylated Smad1/5/8 (p-Smad1/5/8) 
expression was high in all conditions throughout the differentiation and even in 
undifferentiated hESCs (Fig 4.10A). Expression of p-Smad1/5/8 was high even at 
very early time points and identical between the 4 differentiation conditions (Fig 
4.10B). These data suggest that Smad1/5/8 phosphorylation occurs in undifferentiated 
cells and is not a direct and exclusive response to growth factor addition in this 
differentiation. This supports the speculation that a Bmp4-like activity exists in 



































































































































































































Figure 4.9. Genes expressed in response to Bmp4 signaling. Cells were 
differentiated using the 3D Matrigel protocol under the 4 conditions indicated. Gene 
expression data were generated by quantitative RT-PCR with samples collected every 
other day from day 0 to day 10. (A-C) A direct consequence of Bmp4 binding its 
receptor is the induction of Id genes. ID2 is expressed robustly when Bmp4 alone is 
added to the culture system. In presence of Activin A and Bmp4, the ID2 expression 
is delayed and short-lived. Expression patterns of ID1 and ID3 were inconclusive. (D, 
E) MSX genes, which are induced by Bmp4, are not expressed at significantly high 
levels during endoderm differentiation (+GF). However these genes are induced 
specifically in response to Bmp4 addition. (F, G)  SMAD6 and SMAD7 are inhibitory 
Smads induced by TGF-β signaling. SMAD6 is expressed in presence of Activin A 
and Bmp4 individually but highest levels are seen in presence of both growth factors 
showing a combinatorial effect on gene expression. Higher SMAD6 expression could 







































Figure 4.10. Phosphorylation status of Smad1/5/8 in response to the Bmp4 signal.  
(A) Western blot for p-Smad1/5/8. Phosphorylation of the Smad protein is high in all 
conditions, irrespective of growth factor addition. (B) Western blot to estimate the 
timeline of Smad phosphorylation upon exposure to differentiating conditions. 
Samples were collected at the times indicated (‘ – minutes, hrs – hours). P-Smad1/5/8 
showed almost identical pattern of phosphorylation in all conditions with no specific 
response to growth factor treatment. Since the same activity is seen even in absence of 
all growth factor treatment, this could be considered background levels of 
phosphorylation.  
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4.2.4. Bmp4 shows inefficient formation of cell types associated with its pleiotropic 
activities 
Bmp4 is known for its pleiotropic activities during development including its 
roles in the formation of primordial germ cells and mesoderm. In addition, Bmp4 is 
known to induce trophoblast differentiation from ES cells in vitro. I used a candidate 
gene approach to evaluate the expression of these lineage markers in order to assess if 
Bmp4 functions along known pathways and induces expression of known target 
genes. 
 
Primordial Germ Cells (PGCs) 
It has been shown that Bmp4 is an absolute requirement for the formation of 
PGCs in the mouse embryo (Lawson et al. 1999). Bmp4 and other related proteins 
have also been implicated in germ cell differentiation from hESCs in vitro (Kee et al. 
2006). BLIMP1, STELLA, FRAGILIS and VASA were chosen as the markers to test for 
the presence of the germ cell lineage during differentiation. In conditions favouring 
endodermal differentiation (Activin A + Bmp4 and Activin A) only STELLA and 
BLIMP1 were upregulated slightly (Fig 4.11A and C). VASA and FRAGILIS did not 
show any significant expression (Fig 4.11B and D). Interestingly, Bmp4 alone did not 
induce expression of any of these genes. Therefore, a germ cell-like population is not 
a significant part of the differentiating milieu in Matrigel. Moreover, no cells were 
found that show the characteristics of PGCs after staining for endogenous alkaline 





























































































 No growth factors (-GF) Activin A + Bmp4 (+GF) Activin A (AA) Bmp4 (B4) 
 
 
Figure 4.11. Primordial Germ Cell markers are expressed transiently at 
extremely low levels. Cells were differentiated using the 3D Matrigel protocol under 
the 4 conditions indicated. Gene expression data was generated by quantitative RT-
PCR with samples collected every other day from day 0 to day 10. (A-D) Blimp1 and 
Stella are expressed in presence of Activin A and when the growth factor combination 
is used. Fragilis is induced slightly in presence of Activin A alone. VASA does not 
show any induction. Therefore, the germ cell lineage does not seem to be induced as 






Bmp4 has also been successfully used to generate trophoblast cells in vitro from 
hESCs (Xu et al. 2002). Quantitative RT-PCR for marker genes BMP4, ELF5, CDX2, 
SPC4, FGFR2 and ESRRB was used to investigate for signs of trophoblast 
differentiation. These markers are all detected in the extraembryonic ectoderm (ExE) 
of the developing mouse embryo between E6.5 and E7.5 (Donnison et al. 2005; 
Pettersson et al. 1996). All genes showed significant upregulation when Bmp4 was 
the only growth factor (Fig 4.12A-F). No gene expression was detected when Activin 
A and Bmp4 were added together. From this data it would seem that conditions that 
give rise to endoderm do not encourage trophoblast differentiation.   
 
Haematopoietic Cells 
Bmp4 is known to induce formation of self-renewing haematopoietic cells from 
hESCs (Chadwick et al. 2003). Haematopoietic markers SCL (stem cell leukemia 
gene) and PU.1 (purine-rich box.1) were significantly upregulated during 
differentiation in presence of Bmp4 alone (Fig 4.12C and D). SCL was also induced 
in the +GF condition which shows that whenever Bmp4 was added, it led to low level 
haematopoietic differentiation in this system. In presence of Activin A alone there 
was only a modest increase in SCL. The coincident expression of SCL and TBRA in 
Activin A + Bmp4 and Activin A suggests that there might be a hemangioblast-like 
population forming in the differentiating culture (Chung et al. 2002). Hemangioblasts 
cells are multipotent precursors that can give rise to haematopoietic and endothelial 
cells. The presence of this bi-potent population might explain the expression of the 
endothelial cell marker, VWF (Von Willebrand Factor) in cells differentiating in the 
+GF condition and in the presence of Activin A alone (Fig 4.12E).  
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Figure 4.12. Trophoblast markers are expressed at extremely low levels, mainly 
in response to Bmp4. Cells were differentiated using the 3D Matrigel protocol under 
the 4 conditions indicated. Gene expression data was generated by quantitative RT-
PCR with samples collected every other day from day 0 to day 10. (A-F) All six 
markers, including Bmp4 itself, were expressed specifically in response to Bmp4 
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Figure 4.13. Differentiation does not induce significant mesodermal gene 
expression. hESCs were differentiated using the 3D Matrigel protocol under the 4 
conditions indicated. Gene expression data was generated by quantitative RT-PCR 
with samples collected every other day from day 0 to day 10. (A, B) Haematopoietic 
markers PU.1 and Scl were induced in presence of Bmp4 alone as expected. Scl was 
upregulated transiently in presence of both growth factors but in general 
haematopoietic differentiation was negligible. (C) Endothelial cell marker VWF was 
significantly upregulated in presence of Activin A and when both Activin A and 
Bmp4 were added. This is not entirely unexpected as endothelial cells are known to 
be closely associated with the developing endoderm. These cells may be 





4.2.5. Negligible formation of alternate lineages during DE differentiation  
Given the sub-optimal efficiency of pancreatic differentiation it must be 
assumed that other lineages are also being formed in the differentiating cultures. 
These cell types could arise as a result of spontaneous differentiation or as a direct 
response to growth factor treatment.  
hESCs are known to readily form cells with a neuronal phenotype either through 
directed or spontaneous differentiation in vitro (Itskovitz-Eldor et al. 2000). However, 
in this system, little neuronal differentiation was observed, as evidenced by negligible 
levels of NESTIN, TUBB4, OTX2, SOX1 and SOX2 (Fig 4.14A-D). High SOX2 
expression in the –GF condition is similar to the expression of OCT4 and NANOG 
shown earlier (Fig. 4.3). This is not entirely unexpected as these genes are expressed 
in the epiblast and might be maintained in hESCs that are not exposed to 
differentiation signals (Wood and Episkopou 1999). OTX2 was specifically 
upregulated to significant levels in presence of Activin A alone and Activin A + 
Bmp4 as early as day 2 and expression was maintained till day 10  (Fig 4.14E). This 
expression might indicate the persistence of epiblast-like cells in the differentiation as 
OTX2 is known to be expressed in the epiblast (Ang et al. 1994). Another alternative 
is that Activin signaling triggers a synthetic induction of OTX2 as Smad2 is known to 
regulate the expression of OTX2 (supported by microarray data shown later in the 
chapter). 
The mesenchyme is known to be important for pancreatic development and has 
recently been shown to regulate beta cell differentiation in rat embryonic explants 
(Attali et al. 2007; Gittes et al. 1996).  I tested the differentiation for expression of 
VIMENTIN a marker of mesenchyme but found that there is a meagre response only 
to Bmp4 addition (Fig 4.14F).  
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Figure 4.14. No significant expression of neuronal markers during 
differentiation. hESCs were differentiated using the 3D Matrigel protocol under the 4 
conditions indicated. Gene expression data was generated by quantitative RT-PCR 
with samples collected every other day from day 0 to day 10. (A-D) Markers of the 
neurectodermal lineage NESTIN, TUBB4, SOX1 and SOX2 were not significantly 
upregulated in conditions that gave rise to endoderm during the differentiation. High 
SOX2 expression in the –GF is consistent with expression of this marker in the 
epiblast. As cells in the –GF condition do not encounter massive differentiation 
signals there might be persistence of epiblast-like characteristics. (E) OTX2 was 
specifically upregulated to high levels in presence of Activin A alone and Activin A + 
Bmp4. As OTX2 is known to be expressed in epiblast tissue this expression might 
indicate persistence of epiblast-like cells in the differentiation. Another explanation is 
that Activin A-induced p-Smad2 causes synthetic regulation of gene expression as 
Smad2 is known to regulate OTX2. (F) Vimentin which marks mesenchymal cells or 











In an effort to understand the differentiation process and to define a mechanism 
for the combinatorial activity of Activin A and Bmp4 that leads to reproducible 
formation of DE from hESCs, I undertook the investigations detailed in sections 4.2.1 
to 4.2.5. These studies showed that the endoderm induction by Activin A was 
enhanced significantly by Bmp4. However, monitoring gene expression and Smad 
phosphorylation status of members of Activin and Bmp4 signaling pathways did not 
reveal a direct impact of Bmp4 on the Activin pathway to potentiate DE formation. 
Supplementing Activin A in the differentiation did not seem to have a pronounced 
effect on the expression of target genes and p-Smad2. This suggests that Activin A 
might not be inducing significantly higher levels of NODAL as suggested, that results 
in increased formation of DE. Gene expression analysis of markers indicative of 
Bmp4’s known pleiotropic activities showed that there was little formation of those 
specific lineages known to be induced by Bmp4. Taken together these data suggest 
that Bmp4 impacts DE formation in a novel manner which is not captured in any of 
the above experimental strategies. In light of these observations, I chose to adopt a 
global view of the differentiation which is outlined below. 
 
4.2.6. Gene Expression Analysis of Differentiation Using Microarray Technology 
My quest to deduce a potential mechanism for the synergistic activity of Activin 
A and Bmp4 led me to undertake the studies described in Sections 4.2.1 to 4.2.5. 
Since these strategies did not yield any significant clues about the role of Bmp4, I 
analysed global gene expression patterns during differentiation using microarray 
technology. Briefly, hES3 cells were differentiated as Matrigel-embedded EBs in 
presence of Activin A and Bmp4 either individually or in combination. RNA samples 
were generated at various time points as described earlier and found to express genes 
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indicative of efficient DE formation by QPCR analysis (Fig 4.3).  Complementary 
RNA (cRNA) was synthesized from these samples as detailed in Chapter 2.10. cRNA 
from selected time points were hybridized to Illumina BeadChips as shown in Figure 
4.15. Days 4 and 6 were chosen as the preferred sampling points as the expression of 
key endodermal genes like SOX17 and FOXA2 was high on these particular days of 
the differentiation (Fig 4.3). After normalizations and statistical analysis, genes whose 
expression was altered in comparison to day 0 undifferentiated cells on day 4 were 
chosen for further investigation. Heat map shows changing expression of genes when 
treated with the relevant growth factor (s) (Fig 4.16). Genes upregulated in 
undifferentiated hESCs are significantly downregulated in cells treated with Activin A 
alone (AA) or with Activin A + Bmp4 (+GF). Alterations in gene expression are 
similar between the treated samples though the +GF condition shows robust 
expression as seen by the colour intensity (*). Gene list is given in Appendix III.  
To assess if the microarray is a true representation of the in vitro 
differentiation I analysed the expression of genes known to be upregulated during 
endoderm formation and previously characterized by QPCR analysis in the day 4 
samples. Key indicators of endodermal development in the vertebrate embryo 
including FOXA2, SOX17, EOMES and CXCR4 were detected in the presence of 
Activin A alone and in the presence of Activin A + Bmp4 thus validating the 
endoderm induction mediated by these two conditions in the differentiation (Table 
4.1). As was seen in the QPCR analysis, expression of key genes was significantly 
higher in Activin A + Bmp4 than when Activin A was used alone as evident from the 
fold change data (Appendix III). There was evidence of some mesendodermal and 
ectodermal differentiation as genes representing these two germ layers including 
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Day 0 undiff: Undifferentiated cells  
-GF: No growth factors 
 +GF: Activin A + Bmp4 
AA: Activin A  
B4: Bmp4  
 
 
Figure 4.15. Samples loaded on Illumina BeadChip for microarray analysis. 
hESCs were differentiated using the 3D Matrigel protocol under the 4 conditions 
indicated. RNA samples from days 0, 4 and 6 of differentiation were converted to 
































Figure 4.16. Heat map shows global changes in gene expression corresponding to 
growth factor treatment. Heat map shows clustering of genes expressed 
differentially between undifferentiated hESCs (Undiff), Activin A treated cells (AA) 
and Activin A + Bmp4 treated cells (+GF). Genes upregulated in undifferentiated 
cells (red) are significantly downregulated upon growth factor treatment (green) and 
vice versa. Gene expression changes are similar between AA and +GF as expected 
since these two conditions give rise to endoderm during differentiation. However, 
there is a more robust induction of gene expression in the +GF condition as seen by 















































Table 4.1. Genes expressed during gastrulation in the mouse and/ or associated 
with the formation of DE. Genes known to be expressed during gastrulation and 
others known to be critical for endoderm formation are upregulated as expected in day 
4 Activin A alone and day 4 Activin + Bmp4. Most genes showed higher expression 
in presence of both factors than in presence of Activin A alone. The induction of 





The presence of other germ layers was not clearly captured in the QPCR 
analysis described earlier as only a small subset of genes was chosen for analysis. 
Among the various data sets, I chose to look more closely at conditions that promote 
endoderm formation, i.e. Activin A alone and Activin A + Bmp4 on day 4 of 
differentiation as that is my primary area of interest (Fig 4.17 A, B). Genes altered by 
2-fold or above and 10-fold or above were compared between the treated conditions 
in Venn diagrams. Gene lists are given in Appendix III. Gene Ontology analysis was 
performed to distinguish these gene lists on the basis of molecular function. The pie 
charts show that in general, genes altered during differentiation fall into the following 
main categories– binding, catalytic activity, signal transducer activity, transcription 
regulator activity and transporter activity (Fig 4.17C).  
Genes in the data set d4 [AA] + [+GF] that showed a difference in expression 
of 2-fold or more compared to undifferentiated cells were chosen for further analysis 
(Fig 4.17 A*). In these conditions, several genes not previously associated with or 
characterized in the context of the endoderm and its formation were highly 
upregulated. These genes were interrogated in two ways (1) expression analysis of the 
murine homologues in the developing embryo and (2) QPCR corroboration of 
candidate gene expression in an independent hESC differentiation experiment. 
Though these genes were upregulated under conditions that specify endoderm it is 
important to establish their expression domain (s) in the developing embryo and to 
analyse if it is relevant to the formation of endoderm. I chose to use the mouse as a 
model system to study gene expression during development. After eliminating those 
genes known to be related to endoderm formation and those that are well 
characterized in other contexts, I chose a total of 26 genes to test in the mouse system 
(Table 4.2).   
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Figure 4.17. Genes expressed in conditions that form DE were chosen for further 
analysis. (A, B) The conditions that gave rise to endoderm– Activin A alone (AA) 
and Activin A + Bmp4 (+GF) – were compared in a Venn diagram. (A) The number 
of genes altered by 2 fold or more in these conditions is shown. (B) The number of 
genes altered by 10 fold or more is shown. As the subset of genes available for 
analysis was not significant in the +GF list, genes common to both conditions which 
were altered by 2 fold or more (936 in the intersect marked by *) were studied in 
detail. This represents the subset of genes that induce formation of DE. (C) Gene 
Ontology analysis was performed for the indicated conditions taken from (A) and 
results are represented as pie charts. Distribution of genes was similar between the 




























































Table 4.2. Preliminary list of genes for detailed analysis. After eliminating genes 
that are known to be associated with gastrulation, endoderm formation and those 
novel genes that are common between two very distinct differentiation strategies– 3D 
and monolayer differentiation (mentioned later in this chapter), a selection of genes 
hitherto uncharacterised in the context of definitive endoderm formation was chosen 














As mentioned in Chapter 1 endoderm development in the mouse commences 
around E6.5. Therefore, I chose embryos at early stages of development for the 
studies outlined below.  Since these genes were shortlisted on the basis of expression 
in differentiating hESCs, it was important to establish that genes are indeed expressed 
in the mouse system. This was by performing Q-PCR analysis on mouse embryo 
samples at embryonic days E7.5, E8.5 and E9.5. cDNA preparation and PCR 
conditions are described in Chapter 2.7 and 2.8 respectively. Expression values were 
normalized to Actin using the ∆∆Ct method and PCR product size was confirmed by 
agarose gel electrophoresis (Fig 4.18A). Results show that some of the genes are 
either not expressed at all or are expressed in a pattern that does not seem relevant to 
my investigation (Fig 4.18B). After careful analysis of these results, 15 genes were 
chosen for Whole mount In Situ Hybridisation (WISH) (Table 4.3). WISH was 
performed to obtain knowledge about the expression of these genes in the developing 
mouse embryo. Cloning of these genes, riboprobe synthesis and the WISH protocol 
are described in Chapter 2.11. Of the 15 genes only one, Rcor3, did not yield a PCR 
product for cloning and is therefore not included in the WISH analysis. 
Among the 14 genes tested, 8 showed tissue-specific staining and are described 
below (Table 4.4). (1) As the major component of high density lipoprotein (HDL), 
apolipoprotein 1 (Apoa1) promotes cholesterol efflux from tissues to the liver for 
excretion. A recent study showed the expression of Apoa1 in the extraembryonic 
hypoblast and endoblast and restricted expression in the endoderm of the developing 
chick embryo (Bertocchini and Stern 2008). A similar expression pattern was seen in 
the mouse embryo as hybridisation with in situ probes shows that Apoa1 strongly 
marks the extraembryonic visceral endoderm between E7.0 and E9.5 (Fig 4.19A). 
However, Apoa1 is restricted entirely to the extraembryonic tissue in the mouse 
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unlike in the chick embryo. (2) Edg3 (sphingolipid G-protein coupled receptor 3/ 
S1P3) is known to mediate the effects of its ligand, sphingosine-1-phosphate (S1P), 
during embryonic angiogenesis and bone homeostasis (Ishii et al. 2009; Kono et al. 
2004). A recent report shows that S1P activity indirectly promotes budding of the 
pancreatic endoderm by stimulating pancreatic mesenchymal cell proliferation by 
(Edsbagge et al. 2005). This ligand is also known to induce proliferation and 
morphological changes in neural progenitor cells (Harada et al. 2004). Expression in 
the mouse embryo was mainly in the somites, neural tissue and the allantois (Fig 
4.19B). (3) Gatm (glycine amidinotranferase) is a creatine synthesis enzyme which is 
known to be imprinted in the mouse placenta and the yolk sac but not in embryonic 
tissues (Sandell et al. 2003). However, here I show expression in the somites, the 
brachial arch and possibly in neural tissue (Fig 4.19C). (4) Previously known to be 
expressed in neural tissue, Homer2, was strongly expressed in the developing heart 
and in the 1st brachial arch (Fig 4.19D). Homer2 expression in cardiac tissue was 
previously reported in adult rats but not in embryonic tissue (Schweitzer et al. 2006). 
This is the first report of Homer2 expression in the developing vertebrate heart. (5) 
Another gene that was expressed in the extraembryonic/ chorionic ectoderm is Irx3 
(Iroquois related homeobox 3) which progressively resolved to the anterior region of 
the embryo (Fig 4.19E). Irx3 belongs to a family of genes involved in patterning and 
regionalization of differentiation within the embryo. It has been implicated in neural 
development and is known to be expressed in the foregut at E10.5 in the epithelial 
layer of lung buds and bronchia (Houweling et al. 2001). In the stained embryos, Irx3 
was also seen in the anterior neuroectoderm and the neural tube from E7.0 to E9.5. In 
addition, this gene seems to be expressed in the early DE which resolves to the 












































































































































































































Figure 4.18. Quantitative PCR in mouse embryo samples for genes shortlisted 
from microarray. (A) PCR product sizes of the genes were confirmed by agarose gel 
electrophoresis. Some genes like Amhr2 in lane 1 (*) were eliminated from further 
analysis as their expression patterns are known and might not be relevant to my 
investigation. (B) Q-PCR revealed varied expression patterns of the selected genes in 
mouse embryo samples at embryonic days E7.5, E8.5 and E9.5. Some genes like 
Has2 showed high but sustained expression while others like Apoa1 showed 







































Table 4.3. Genes chosen for riboprobe synthesis and whole mount in situ 
hybridisation. Based on expression in the mouse embryo 14 genes were selected for 
detailed characterisation. These were cloned into bacterial vector to generate DNA 
template for riboprobe synthesis. Probes were used for whole mount in situ 

































 HOMER2 RHOBTB3 EDG3 
 GATM IRX3 NR0B1 
RHOBTB3 NUAK1 GATM IRX3 
HOMER2 IRX3 EDG3 APOA1 














Table 4.4. Expression domains of key genes identified by WISH in the mouse 
embryo. While some genes like Apoa1 showed restricted areas of expression, others 












(6) Nr0b1 (Nuclear receptor subfamily 0, group B, member 1) is the gene that 
encodes DAX1 (dosage sensitive sex-reversal (DSS), adrenal hypoplasia congenita 
(AHC)), a nuclear receptor protein which is essential for vertebrate development. 
DAX1 is expressed on preimplantation mouse blastocysts and mouse ES cells and is 
known to be regulated by Oct3/4 and Stat3 to promote maintenance of the 
undifferentiated state of ES cells (Sun et al. 2008; Niakan et al. 2006; Clipsham and 
McCabe 2003). Nr0b1 has recently been identified as one of the possible target genes 
of the homeodomain protein Hex, which marks the anterior DE and anterior VE 
(Zamparini et al. 2006; Thomas et al. 1998). In support of this observation, Nr0b1 
was strongly expressed in the chorionic/ extraembryonic ectoderm only in early 
embryos at E7.0 and E7.5 in a pattern reminiscent of Hex expression (Fig 4.19F). (7) 
Nuak1 is an SNF1-like kinase known to be suppressor of apoptosis induced by 
nutrient starvation (Suzuki et al. 2005; Suzuki et al. 2003). This kinase promotes 
survival by triggering the Akt/ PKB (protein kinase B) pathway upon encountering 
metabolic stress. In early mouse embryos there seems to be weak primitive streak 
expression that becomes progressively restricted to the foregut and then to the 
pharyngeal endoderm (Fig 4.19). Nuak1 was also detected in the brachial arches and 
brain. (8) Rhobtb3 (Rho related BTB domain containing 3) is a member of the Rho 
GTPase family known to be expressed strongly in adult mouse neural and cardiac 
tissues by Northern blot analysis (Ramos et al. 2002). The in situ data shows for the 
first time expression of this gene in the embryonic component of the early embryo and 
in the neural tissue of the later stage embryo (Fig 4.19H). Five genes– Edg3, Gatm, 
Homer2, Nuak1 and Rhobtb3– were also expressed in the primitive streak (PS) and 
may impact DE formation as this germ layer arises from the PS. These will be studied 
in detail in further experiments outlined in Chapter 5. Three genes– Apoa1, Irx3 and 
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Nr0b1– showed specific expression in the extraembryonic ectoderm. Of these, Apoa1 
was robustly expressed in the extraembryonic VE indicating the formation of low 
levels of VE for which Bmp4 could be solely responsible. Six other probes that were 
used for WISH either showed no tissue-specific expression or were not expressed at 
all. These need to be re-visited to resolve the discrepancy between QPCR data and 
WISH observations. 
The second approach to validate the microarray results was QPCR analysis of 
gene expression during in vitro differentiation (Fig 4.20). Samples from an 
independent Matrigel-based differentiation were used to assess gene expression. In 
general, all genes tested showed increased expression in conditions favouring 
endodermal differentiation (AA and +GF) compared to untreated control (–GF). 
APOA1, GATM, IRX3, NR0B1 and RHOBTB3 showed significant upregulation in the 
+GF condition compared to the other conditions while EDG3, HOMER2 and NUAK1 
showed higher expression when Activin A was used alone (Fig 4.20 A-H). In 
addition, some genes like EDG3, RHOBTB3 and NR0B1 were also upregulated in the 
presence of Bmp4 alone. APOA1 in particular was significantly upregulated only 
when both Activin A and Bmp4 were used (Fig 4.20A). The late expression (post day 
4) of APOA1 was similar to that of AFP and TTR (Fig 4.4). As these markers resolve 
to the liver, it is possible that the APOA1 expression detected here marks the 
precocious formation of hepatic cell types during differentiation. IRX3 expression in 
the +GF condition shows that it is involved in endodermal development (Fig 4.20E). 
This is consistent with the staining seen in the early DE and the foregut of the mouse 
embryo. Upregulation of NUAK1 in the +GF and AA conditions, validates the 
staining observed in the foregut and pharyngeal endoderm (Fig 4.20G). Significant 
levels of IRX3, NR0B1 and RHOBTB3 on day 2 of differentiation aligns with the 
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expression seen in the early embryo (Fig 4.20E, F, H). However, APOA1 is an 
exception as it is detected in the early embryo but not in initial part of differentiation. 
It is possible that APOA1 specifically marks the VE unlike the other early markers 
and is inhibited along with the other VE markers like H19 during the differentiation. 
As the QPCR analysis was done on an independent hESC differentiation, these data 
serve to validate the microarray results. Concurrent to this work our lab developed a 
differentiation strategy in monolayer culture using the combination of Activin A and 
Bmp4 to generate in phases, definitive endoderm and pancreatic progenitors. 
Microarray analysis of this two-dimensional differentiation revealed genes that were 
common between the two experimental regimes (Table 4.5). These genes are 





























































Figure 4.19. Whole mount in-situ hybridisation in mouse embryos. Mouse 
embryos at E7.0-E7.5, E8.5 and E9.5-10.5 were used for WISH using specific RNA 
probes created against genes of interest. (A) Apoa1 exclusively marks the 
extraembryonic visceral endoderm. In the E9.5 embryo staining is clearly visible only 
in the remnants of the allantois (black arrowhead). (B) Edg3 is not detected in the 
early stage embryos which is consistent with the PCR data. Expression in the later 
stage embryos seems restricted to the somites, anterior and posterior neural tissues. In 
E8.5 the allantois retains some staining. (C) Gatm was expressed in the somites and 
neural tissue in the E8.5 and in the somites, first brachial arch and possibly heart 
traberculae in E9.5. (D) Homer2 is first detected in E8.5 embryos where it stains the 
somites and the forming heart. By E9.5 staining is clearly visible in the heart and in 
the first brachial arch. (E) Irx3 is expressed in the hat/ bonnet of the extraembryonic 
(chorionic) ectoderm in early allantoic bud (EB+), late allantoic bud (LB) and late 
head fold stage embryos. Between E7.5 to E8.0 the expression resolves to the anterior 
region and is excluded from the node and the posterior primitive streak. In the late 
head fold embryo (E8.0), Irx3 was also detected in the neural folds, midline 
(notochordal plate) and possibly in the definitive endoderm. At the 1-2 somite stage, 
Irx3 resolves to the anterior neuroectoderm (hindbrain, midbrain and forebrain) and 
the anterior endoderm represented by the foregut pocket. In E10.5 embryos staining is 
detectable in the midbrain, hindbrain, midline neural tissue and lateral plate 
mesoderm. (F) Nr0b1 is expressed in a ring-like form at the junction where the 
visceral endoderm meets the chorionic ectoderm. Expression is highest in the early 
embryos, decreases by E7.5 and is not present in E8.5 and E9.5 embryos. (G) Nuak1 
weakly stains the posterior primitive streak in E7.5 embryos and shows specific 
staining at the foregut entrance in E8.5 embryos. By E10.5 this gene is expressed in 
the brachial arches and the limb bud. (H) Rhobtb3 is weakly expressed through out 
the embryonic component of the early stage embryos (E7.5 to E8.5). In E8.5 




































































































































































































Figure 4.20. Expression of genes characterised by WISH during in vitro 
differentiation of hESCs. Cells were differentiated using the 3D Matrigel protocol 
under the 4 conditions indicated. Gene expression data was generated by quantitative 
RT-PCR with samples collected every other day from day 0 to day 10. All genes 
analysed here show increased expression in conditions favouring endoderm formation 
when compared to untreated control (–GF).  A subset of the genes showed higher 
expression in response to Activin A alone and some to Bmp4 alone. (E, F, H) IRX3, 
NR0B1 and RHOBTB3 gene expression was detected in the first few days of 
differentiation mirroring the staining in very early stage embryos. (A) APOA1 was the 
exception as gene expression was absent early in the differentiation while strong 
staining was seen in the early stage embryos. The specific response to +GF condition 
and the late expression suggests that APOA1 might be an endodermal marker which 























































Table 4.5. Novel genes potentially involved in endoderm differentiation of 
hESCs. Several novel genes that showed altered expression were common between 
the 3D approach and a parallel monolayer differentiation strategy developed in our lab 
for the generation of pancreatic progenitors from hESCs. These are currently being 




CONCLUSION and DISCUSSION 
 
In an effort to develop effective cell therapy for diabetes our lab devised an in 
vitro differentiation strategy that allows the sequential formation of DE and pancreatic 
progenitor cells from hESCs. This differentiation employed the combination of a 
known endoderm inducer Activin A and the pleiotropic factor, Bmp4 to generate DE-
like cells marked by FOXA2 and SOX17. These cells further developed into PDX1+ 
pancreatic progenitors which gave rise to more mature cell types that expressed 
INSULIN, NGN3 and PTF1A in the presence of appropriate growth and maturation 
factors. Though inefficient with regard to β cell output, this three-dimensional 
protocol reproducibly led to the production of definitive endoderm and pancreatic 
progenitors (Phillips et al. 2007). Detailed investigation of the differentiation revealed 
that the gene activation pattern closely mimics what is known in the vertebrate 
embryo. The onset of differentiation led to an increase in expression of the 
gastrulation marker TBRA. This was followed by sequential expression of FOXA2 and 
SOX17 (DE) and PDX1 and other endocrine markers. Immunocytochemistry showed 
that as differentiation progresses, there are reciprocal changes in the expression of 
pluripotency and differentiation markers.  
Though Activin A is a known endoderm inducer, Bmp4 is better known for its 
pleiotropic activities like mesoderm induction and PGC formation. The unexpected 
synergy between Activin A and Bmp4 that induces endoderm prompted detailed 
characterization of the differentiation in the presence of either factor singly or 
together. Gene expression profiles of TBRA, FOXA2, SOX17 and PDX1 suggested 
that Activin A either used alone or with Bmp4 gave rise to endodermal derivatives 
though the combination of the two factors always induced higher levels of 
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differentiation. However, removal of Matrigel from the system abrogated this ability 
of Activin A to induce endoderm formation. This suggests that a Bmp4-like activity 
exists in Matrigel that might be mimicking the environment created by the 
combination of Activin A and Bmp4. An alternative explanation is that Activin A 
used in the differentiation maintains the pluripotency of the hESCs and only the 
differentiation signals from Matrigel/ Bmp4 allow it to overcome that block. Another 
possibility is that Matrigel buffers the EBs against the anti-differentiation activity of 
IGF in the medium formulation, thereby allowing differentiation to proceed. Delayed 
and lower level gene expression in free-floating EBs even in the presence of both 
growth factors also support the observation that removal of Matrigel creates sub-
optimal conditions for differentiation.  
In order to elucidate the mechanism of Activin A + Bmp4 synergy, I 
investigated the expression of components of the individual signaling pathways. Since 
Activin is an able mimic of Nodal signaling, it is possible that recombinant Activin 
activates transcription of genes relevant to DE formation through the phosphorylation 
of Smad2. Since Smad2 is known to activate Nodal directly through the ASE element 
in the Nodal gene, p-Smad2 could increase the endogenous levels of Nodal leading to 
enhanced DE formation. To test this hypothesis, I monitored p-Smad2 levels and 
expression of target genes. Disappointingly, there seemed to be no specific 
upregulation of pSmad2 levels as a direct response to Activin addition. Expression 
analysis of target genes also did not yield any clues to deciphering the mechanism of 
the Activin A + Bmp4 synergy. Similar analysis of the Bmp4 pathway did not 
generate significant findings. These results strongly argue that there is no direct 
impact of Bmp4 on the Activin signaling machinery to influence DE formation. Bmp4 
does not seem to facilitate the transduction of the Activin patterning signal either 
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directly or by enhancing local Nodal signaling. Since Bmp4 is known to have 
pleiotropic effects in the developing embryo and in ES cells I tested the ability of this 
growth factor to execute these functions during the differentiation. Using a candidate 
gene approach, I found that though there was low level expression of some markers, 
none were significantly high to conclude the presence of any other major cell lineage 
including trophoblast, mesodermal or primordial germ cell lineages. Since the 
differentiation only generates between 5-20% PDX1+ cells, it is possible that there are 
other lineages being formed in the differentiating population. Using a candidate gene 
approach, I determined that neural or mesenchymal cells were also not generated 
robustly. Curiously, the expression of OTX2 was high in conditions where Activin A 
was present, suggesting that there is persistence of some epiblast-like cells in the 
differentiating culture. The studies outlined above suggest that Bmp4 enhances DE 
formation by Activin A through a novel mechanism. None of my investigations have 
shed light on a possible mode of action. It is important to note that gene expression 
analysis was the preferred method of investigation in the studies summarized above, 
as immunostaining and flow cytometry were extremely difficult to perform on the 
extracellular matrix-rich EBs.  
An entirely different role for Bmp4 was suggested by a recent study using 
mESCs showed that Activin A and Bmp4 (and bFGF) promoted both hepatocyte 
differentiation and activation of Pdx1 from endoderm progenitors (Gouon-Evans et al. 
2006). Though this indicates a possible role for Bmp4 later in pancreatic 
development, my focus was on the impact of Bmp4 in the early developmental stages 
as seen using the three-dimensional Matrigel-based differentiation.  
Since none of the above experimental approaches yielded significant clues about 
the mechanism of the synergy between these growth factors, I chose to obtain a more 
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global view of the differentiation using genetic tools like Microarray technology to 
analyse gene expression. Expression of genes known to be important for endodermal 
development established the validity of this technique. Among the various data sets, I 
chose to look closely at a subset of these genes upregulated on day 4 of differentiation 
in presence of Activin A alone and Activin A + Bmp4 i.e. conditions that favour 
endoderm differentiation. In this data set there were numerous genes strongly 
upregulated which have not been characterized in the context of endoderm formation; 
some relatively unknown. A few of these genes were chosen for further analysis. 
Validation of results from the microarray screen was done by (1) in vivo analysis in 
the mouse embryo using whole mount in situ hybridization after establishing 
expression in the early mouse embryo by QPCR and (2) in vitro endoderm 
differentiation of hESCs. Analysis of embryos subjected to WISH revealed tissue-
restricted and stage-specific expression of several genes. Irx3 and Nuak1 were 
expressed in the foregut region which suggests that these might be markers of the 
definitive endoderm. Though some reports exist that associate these markers with the 
endoderm, detailed studies are required to characterize these further. Five of the 
genes– Edg3, Gatm, Homer2, Nuak1 and Rhobtb3 were expressed in the primitive 
streak, and although not exclusive to DE, may impact the formation of this lineage. 
Various genetic strategies that will be used to define the role of these genes in the 
development of DE are outlined in Chapter 5. Several genes like Gatm, Edg3, Irx3 
and Rhobtb3 were expressed in neural tissue which indicates that some neural 
differentiation occurs in the three-dimensional strategy. This is not entirely 
unexpected as the low efficiency of pancreatic differentiation suggests that other 
lineages are being formed from the differentiating hESCs. Nr0b1, Apoa1 and Irx3 
were expressed in the extraembryonic component of the embryo while Homer2 
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specifically marked the heart. These genes have not been previously associated with 
the mentioned embryonic regions and might serve as novel markers of the same. 
Apoa1 specifically marked the VE and indicates that there is a low percentage of VE 
formed during differentiation which might be due to Bmp4 signaling. In addition to 
these genes that showed specific domains of expression, there were others that 
showed non-specific or no expression. This discrepancy between the expression 
detected in Q-PCR and in WISH could be due to sub-optimal PCR primers or 
riboprobes and will be addressed in future experiments.  
Genes that showed specific patterns of expression were validated in the hESC 
differentiation system that confirmed significant induction of most of these genes in 
presence of both Activin A and Bmp4 compared to the other conditions on day 4. 
While some were significantly upregulated in the presence of Activin A alone, other 
showed a similar response to the presence of Bmp4 alone. Interestingly all the genes 
that showed expression in the early embryo were upregulated during the first 2 days 
of differentiation with the exception of APOA1 which was only detected later. The 
gene expression pattern of APOA1 was similar to that of VE-specific markers like 
AFP, TTR and H19 which are suppressed during the early stages of in vitro 
differentiation. Though QPCR analysis showed that formation of VE was suppressed 
during differentiation, it is not entirely eliminated. This is evident from the microarray 
data as genes like Apoa1 were upregulated in differentiation conditions that formed 
endoderm but marked the extraembryonic VE in the mouse embryo. The 
differentiation creates a synthetic environment by suppressing VE formation. This 
possibly allows Bmp4, which is restricted to the node, to impact the formation and 
specification of another lineage like the DE.  
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Though significant progress has been made in understanding the in vitro 
differentiation programme that generates definitive endoderm from hESCs, an actual 
mechanism of action for Activin A and Bmp4 is still not obvious. In depth analysis of 
































































































The inner cell mass of a developing embryo gives rise to all organs and tissues 
in the adult vertebrate. Embryonic stem cells are derivatives of the ICM which 
recapitulate this pluripotent ability in vitro. The isolation of these cells from the 
developing blastocyst has added a new dimension to the field of regenerative 
medicine. Various strategies have been proposed and used successfully to 
differentiate ES cells into derivatives of the three germ layers as part of efforts to 
develop cell replacement therapy for various diseases or conditions like diabetes, 
heart disease, Parkinson’s disease etc. Our lab aims to derive effective cell therapy 
reagents by differentiating human embryonic stem cells (hESCs) into mesoderm-
derived cardiomyocytes and definitive endoderm-derived β-like cells. Increasing 
concerns about the immunogenicity of such therapeutic grafts has focused attention 
on the development of immunotolerance mechanisms which could prevent outright 
rejection of the transplant. Immunotolerance can be induced either using a pool of 
haematopoietic cells to create a state of mixed haematopoietic chimerism in the host 
or using terminally differentiated dendritic cells (DCs) to induce a state of tolerance 
towards the donor antigens. Deriving such tolerance-inducing cells from the exact 
same source (hESCs) as the cardiomyocyte or β-cell graft would help to minimize the 
immune reaction. Therefore I focused my research efforts on the directed 
differentiation of hESCs into cells of the haematopoietic and definitive endodermal 
lineages employing adaptations of various published strategies used to differentiate 





5.1. Haematopoietic Differentiation 
At the time I initiated work on this dissertation, there were few reports of 
haematopoietic differentiation from hESCs. I sought to obtain the cell types of my 
interest by a step-wise differentiation of hESCs first into haematopoietic progenitor 
cells and then into terminally differentiated dendritic-like cells. As described in 
Chapter 3 of this thesis, I chose to use either stromal feeder cells or pro-
haematopoietic cytokines which have been shown to support the differentiation and 
maintenance of haematopoietic cells derived from peripheral blood and/or bone 
marrow to induce differentiation. Both approaches gave rise to cells of the 
granulocytic and monocytic lineages marked by the pan leukocyte marker CD45 and 
the monocyte marker CD14. No erythroid differentiation was detected in any of the 
conditions. This was not surprising as the successful differentiation strategies were 
originally reported to promote formation of granulocytic cells. Employing various 
markers to characterize the cells further I observed that differentiation did not 
progress much beyond this stage of progenitor cells. Sporadically immature dendritic-
like cells expressing CD86 were detected when stromal feeder cells were used for 
differentiation. However, these did not seem to mature into functional DCs as their 
marker profile remained unchanged upon stimulation with maturation factors. Though 
several alternate and additional approaches could be used to refine these 
differentiations, I limited my investigations to the generation of progenitor cells. 
These serve as proof-of-principle experiments which show that hESCs could be 
differentiated into haematopoietic progenitor cells in presence of stromal feeder cells 
or appropriate cytokines. Recent work in this field, e.g., overexpression of 
developmentally relevant genes like HOXB4, has led to vast improvements in the 
generation of functional haematopoietic cells from hESCs. 
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5.2. Endoderm Differentiation 
The major focus of my dissertation work was on the differentiation of hESCs 
into definitive endodermal cells and further into pancreatic β-like cells. At the time 
our lab had developed a strategy to differentiate hESCs into PDX1+ pancreatic 
progenitor cells with the sequential use of factors known to 1) promote formation of 
definitive endoderm and 2) promote differentiation and maturation of these cells into 
an endocrine fate. In order to characterize the differentiation in detail and to obtain a 
better understanding of the developmentally relevant events, if any, that occur during 
the process, I used a candidate gene approach. As detailed in Chapter 4, gene 
expression studies showed that hESCs rapidly downregulated pluripotency markers 
and upregulated markers of differentiation when treated with factors like Activin A 
and Bmp4. Expression of gastrulation and definitive endodermal markers in a 
sequential manner showed that hESCs were closely mimicking a developmentally 
relevant pattern during the differentiation.  These cells further developed into 
pancreatic progenitor cells which matured into the endocrine lineage as seen by 
marker analysis. Differentiation was most efficient in presence of both Activin A and 
Bmp4 though Activin A alone also seemed to induce endoderm formation. Since a 
candidate gene approach to define active members of the Activin and Bmp4 signaling 
pathways did not yield any clues, an overview of gene expression was obtained using 
microarray technology.  
Along with the known and expected genes that showed altered expression, there 
were numerous genes that were previously not known to be associated with endoderm 
formation. I investigated the expression of these in the vertebrate embryo using mouse 
as the model system. Whole mount in situ hybridization studies revealed the varied 
expression domains of these genes including extraembryonic ectoderm, mesoderm, 
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endoderm, primitive streak, etc. Expression of these genes was analysed in 
differentiation samples which validated the microarray data. Five genes– Edg3, Gatm, 
Homer2, Nuak1 and Rhobtb3– that were expressed in the primitive streak are of 
interest to our lab as these could impact DE formation. Available data on the mouse 
knock-out (KO) phenotypes for these genes are given in Table 5.1. Future studies 
involving these four genes will include the following approaches. (1) Analysis of 
expression in early embryos (E6.5) employing whole mount in-situ hybridisation (2) 
gain of function studies in independent model systems like Xenopus and Zebrafish 
and (3) loss of function studies in Xenopus and Zebrafish. 
Though my primary aim was to elucidate a role for Bmp4 in promoting 
endoderm formation, the gene list (+GF) – (AA), which should have been the most 
informative, did not highlight many genes of interest (based on the available data 
from various databases). Hence, I chose to conduct detailed studies on genes 
upregulated only in conditions favouring endoderm formation which are outlined in 
this dissertation. There are several clusters of genes that could be investigated further 
including 1) genes downregulated during endoderm formation, 2) genes differentially 
expressed between Activin A alone and Activin A + Bmp4 and 3) genes expressed 
differentially as differentiation progresses. Detailed study of these data could reveal 
novel genes involved in the negative regulation of endoderm formation. In addition, 
charaterisation of genes expressed during various stages of differentiation could 
enhance the study of endoderm development in the embryo. 
Ultimately, extensive analysis of the microarray data may provide clues to investigate 
and reveal a mechanism for the synergy between Activin A and Bmp4 that induces 


















Gene Name Knock-Out Phenotype Reference 
Edg3 lethality/prenatal-perinatal, 
cardiovascular, reproductive, 
nervous system, behaviour, 
hearing/vestibular/ear, 
homeostasis, skin/coat/nails 
Ishii et al. 2001 J Biol Chem 
Ishii et al. 2002 J Biol Chem 
Kono et al. 2004 J Biol Chem 
Gatm None None 
Homer2 None None 
Nuak1 None None 




Table 5.1. Available information on knock-out phenotypes in the mouse. Whole 
mount in-situ hybridization (WISH) of mouse embryos showed the expression of 
Edg3, Gatm, Homer2, Nuak1 and Rhobtb3 in the primitive streak. Since the 
expression pattern suggests that these might impact DE formation, detailed studies 
will be performed on the five genes. Currently knock-out (KO) phenotype information 
is available only for Edg3 which does not seem to correlate with the primitive streak 
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I. Buffers and Gels 
 
Sorenson’s Buffer pH 6.8 
 
24.5 ml 0.2M dibasic sodium phosphate  
25.5 ml 0.2M monobasic sodium phosphate  
 
Make volume up to 100 ml with distilled water. 
 
 
Radio Immuno Precipitation Assay (RIPA) Buffer  
 
20 mM Tris, pH 8.0 
1 mM EDTA 
0.1% NP-40 
10% Glycerol 
1 mM Sodium orthovanadate (Na3VO4) 
1 mM PMSF 





8% resolving gel (10 ml) 
 
Distilled H2O       4.6 ml 
30% Acrylamide      2.7 ml 
1.5 M Tris pH 8.8      2.5 ml 
10% Sodium Dodecyl Sulphate (SDS)   100 μl 
10% Ammonium per Sulphate (APS)   100 μl 
Tetramethylethylenediamine (TEMED)   6 μl 
 
 
Stacking gel (3 ml) 
 
Distilled H2O       2.1 ml 
30% Acrylamide      500 μl 
1 M Tris pH 6.8       380 μl 
10% SDS        30 μl 
10% APS        30 μl 





Sample buffer- 5X Laemmli Buffer 
 
1 M Tris, pH 6.8       15.6 ml 
Glycerol         25 ml 
β-mercaptoethanol      12.5 ml 
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SDS         5 g 
Bromophenol Blue      0.05% 
 
 
Protein Transfer Buffer 
 
For nitrocellulose membranes 
 
Trizma Base       6 g 
Glycine        3 g 
Methanol        100 ml 
10% Triton X       2 ml 
10% SDS        2 ml 
 
Make volume up to 1 Litre with distilled water.  
 
For PVDF membranes 
 
Trizma base       6 g 
Glycine        3 g 
Methanol        100 ml 
 
Make volume up to 1 Litre with distilled water. 
 
 
Tris Buffered Saline with Tween-20 (TBST) 
 
Tris base        12.1 g 
Sodium Chloride (NaCl)     8.76 g 
Tween-20        1 ml 
 
Make volume up to 1 Litre with distilled water and adjust pH to 7.4. 
 
 




Paraformaldehyde      4 g 
Phosphate Buffered Saline (PBS)     100 ml 
 
In a water bath, warm solution to 65°C to dissolve the powder.  
 
 
Phosphate Buffered Saline with Tween-20 (PBT) 
 
10x PBS        100 ml 
Tween-20        1 ml 
H2O         898 ml 
DEPC        1 ml 
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Deionised Formamide      250 ml 
20x SSC (DEPC)      125 ml 
Tween-20        500 μl 
20% SDS        2.5 ml 
50 mg/ml Heparin (in 4x SSC)    0.5 ml 
10 mg/ml Yeast tRNA      2.5 ml 
1 M Citric acid       30 ml 
 





Formamide       75 ml 
20x SSC        37.5 ml 
1 M Citric acid       9 ml 
20% SDS        7.5 ml 





Formamide       75 ml 
20x SSC        15 ml 
1 M Citric acid       3.6 ml 
20% SDS        1.5 ml 
Tween-20        150 μl 
DEPC- H2O       55 ml 
 
 
200 mM Levamisole (100x) 
 





Maleic Acid       11.61 g 
NaCl         17.4 g 
Sodium Hydroxide (NaOH) pellets   7 g 
Tween-20        1 ml 
 
Adjust pH to 7.5 using NaOH pellets and 5M NaOH. Add 1% v/v 100x Levamisole 
prior to use. 
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Boehringer Mannheim Blocking Reagent (BBR) (2%) 
 
Boehringer blocking reagent (DIG detection kit) 1 g 
MAB        50 ml 
 
Heat solution to 70°C to dissolve powder. Add 1% v/v Levamisole prior to use. 
 
 
Alkaline Phosphatase (NTMT) Buffer 
 
1 M Tris-HCl pH 9.5      10 ml 
5 M NaCl        2 ml 
1 M MgCl2       5 ml 
Tween-20        0.1 ml 
H2O          82.9 ml 
 





























II. PCR Primer Sequences 
 
HUMAN Q-PCR 
PRIMERS FORWARD REVERSE 
ACTIN caatgtggccgaggactttg  cattctccttagagagaagtgg 
PDX1 cctttcccatggatgaagtc ggaactccttctccagctcta 
NGN3 ctattcttttgcgccggtag ctccctcttccgcctctg 
INSULIN ggggaacgaggcttcttcta cacaatgccacgcttctg 
PTF1A tgagtttgtgtcctgagaagtcc acatgtacaatatgcacagagacataa 
BRACHYURY aattggtccagccttggaat cgttgctcacagaccacag 
FOXA2 ggagcggtgaagatggaa tacgtgttcatgccgttcat 
SOX17 cagaatccagacctgcacaa ctctgcctcctccacgaa 
OCT4 ggcaacctggagaatttgtt gccggttacagaaccacact 
NANOG tacctcagcctccagcagat tgcgtcacaccattgctatt 
TTR tagatgctgtccgaggcagt ccatgcagctctccagactc 
AFP gtagcgctgcaaacaatgaa tccaacaggcctgagaaatc 
ALBUMIN tcagctctggaagtcgatga ttcacgagctcaacaagtgc 
H19 ttacttcctccacggagtcg  gctgggtagcaccatttctt 
NODAL agggcgagtgtcctaatcct caacaagtggaagggactcg 
CRIPTO agatggcccgcttctctta gagatggacgagcaaattcc 
LEFTY2 aggttcagccagagcttcc caccagcaggtgtgtgct 
ID2 atatcagcatcctgtccttgc aaagaaatcatgaacaccgctta 
FRAGILIS ccctgttcaacaccctcttc gccaaccatcttcctgtcc 
BLIMP1 acgtgtgggtacgaccttg ctgccaatccctgaaacct 
STELLA gttactgggcggagttcgta tgaagtggcttggtgtcttg 
SPC4 ggtggtacagacctcgaagc gccatatgagtggctcacttt 
FGFR2 cctgcggagacaggtaacag cggggtgttggagttcat 
BMP4 ctgcaaccgttcagaggtc tgctcgggatggcactac 
CDX2 atcaccatccggaggaaag tgcggttctgaaaccagatt 
ELF5 cctcctctttggacctagcc acatcaggggatcgcaga 
ESRRB agagaggcaggcagatctca gtgagccagagatgctttcc 
CSH2  tagaggaaggcatccaaacg tcagcgccttactgctaaaa 
SCL (TAL-1) cctatgagatggagattactgatgg gtgtggggatcagcttgc 
PU.1 caggggatctgaccgactc aggtcttctgatggctgagg 
VWF agtgcagacccaacttcacc gtggggacactcttttgcac 
VIMENTIN aaagtgtggctgccaagaac agcctcagagaggtcagcaa 
NESTIN gccctgaccactccagttta ggagtcctggatttccttcc 
TUBB4 gcggatcagcgtctactaca atgtccaaaggcccctgag 
APOA1 ccttgggaaaacagctaaacc ccagaactcctgggtcaca 
EDG3 tgatgagatgaaacctatttgtaagg caagaaggcaacagaaatgct 
GATM tgaccgaccatgtcacca ggatgatcgtctgggatga 
HOMER2 gacctcaagtaatcattcccaag tgagaggccttttcatcgtc 
IRX3 aaaagttactcaagacagctttcca ggatgaggagagagccgata 
NR0B1 aagccatcaagtgctttctttc cctgaatgtacttcacgcactg 
NUAK1 gtcaatgggagaccttaccg ccataaacaagagtgtaaagcaaca 
RHOBTB3 gccgatgttgtcttcgaaat ggctgccatcacttcacaa 
GSC gcgaggagaaagtggaggt cgttctccgactcctctgat 
ID3 catctccaacgacaaaaggag cttccggcaggagaggtt 
ID1 ccagaaccgcaaggtgag ggtccctgatgtagtcgatga 
OTX2 ctggctatttggaatttaaaggat ggtttggagcagtggaactt 
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SOX1 gagattcatctcaggattgagattcta ggcctactgtaatcttttctccact 
SOX2 ttgctgcctctttaagactagga ctggggctcaaacttctctc 
MSX1 ctcgtcaaagccgagagc cggttcgtcttgtgtttgc 
MSX2 tcggaaaattcagaagatgga caggtggtagggctcatatgtc 
SMAD6 tgcaacccctaccacttca cgaggagacagccgagagt 
SMAD7 cgatggattttctcaaaccaa attcgttccccctgtttca 
FLK1 gaacatttgggaaatctcttgc cggaagaacaatgtagtctttgc 
GATA-1 cactgagcttgccacatcc atggagcctctggggatta 
GATA-2 aaggctcgttcctgttcaga ggcattgcacaggtagtgg 
β-GLOBIN acacaactgtgttcactagc agtgatgggccagcacacag 
HOXB4 tggatgcgcaaagttcac gaaattccttctccagctcca 
MIXL1 ggtaccccgacatccactt gcctgttctggaaccatacct 
   
 
MOUSE Q-PCR 
PRIMERS   
Amhr2 cccaacatcccatccact cttccaggagctccctcag 
Ankkd1a tgtggacgacgtggactc tctgcaagtggccaaacc 
Apoa1 tatgtggatgcggtcaaaga tgaacccagagtgtcccagt 
Apoc1 tgggaacactttggaagaca actttgccaaatgcctctga 
Bhlhb5 acacttgcagggcaaacaa gaatgtccggtttgtctctga 
C6orf60 ccaaagagcccaagacattt gggtctggagaagccactg 
Calcr ggttccttctcgtgaacaggt agaactggagttgggctcac 
Cmkor1 cagccacatgtccatcagac cacagctcgctgacacctaa 
Col9a2 agggcagtgcaggacaagt tccttttgttccaggctgac 
Ddit4l gagcaagatccactttgccta aggcgggtacaataacagca 
Edg3 agatgcgccttgcagaac agagtggtggtgggttcct 
Flj23514 agttgatggaccgcttgg gagctctttgtgcagcaagtt 
Gatm ttttcaagaaagcaggatgga tgacatccagaggggatgat 
Has2 ggcggaggacgagtctatg acacatagaaacctctcacaatgc 
Homer2 ggaacagctatcggatcatca tcggggtgatagtgctgttt 
Irx3 aaaagttactcaagacagctttcca cgatttaaaaatggttgaaaagttaag 
Kcnf1 caacaagcttccaggtacagc gttcaaagccattttgtggatt 
Lrrc3 accccgacttgagtgttcc gagccatgtggcaaaaataaa 
Manea agatgatcaaaacatgcatcaaa gcccagtcctggtcttgtat 
Mgst2 acatatacgcccgtcacaagta cagtcggaaaccggtgat 
Myct1 tgggaatgaaaaccgttcc gccaaacagctaaatgaacca 
Nppb gtcagtcgtttgggctgtaac agacccaggcagagtcagaa 
Nr0b1 accgtgctctttaacccaga ccggatgtgctcagtaagg 
Nuak1 ccttaccgagggccagag gaagggcatcgttccataaa 
Pcdh7 ctaccaccagccaacacattt tgtatggatgtacacgcatctg 
Rcor3 agtcctgtttgaacaagccttt tgcaattgtcttatctggaagc 
Rhobtb3 cagctccttccatgggatt tgatgcctcagctttcaaga 
S100a14 atgggacagtgtcggtcag gtgtctcaatggccctctct 
Slc5a9 agtcgagggaccgttggt ccacattgctggacattagaga 
Slco2a1 ctttatgggatgttccacacc ggctgcggatgtatagaacttg 
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MOUSE 3' UTR 
PRIMERS 
Apoa1 acccagactgtcggagagc ggtttattgtaagaaagccaatgc 
Apoc1 cctcctgagagatccttagatcc ttttattggtctgtgatgaagagg 
Calcr atactctgattgtcatggctgtgt aagcacatacaaggttcagatcaa 
Ddit4l actgtctgtccagatcaaagca tcattgcagtaagaggcacact 
Edg3 tgtgttcattgcctgttggt ctggcttttctgtggctttc 
Gatm ttctttgagtaccgagcgtaca aaggttaggaccgacatctcaa 
Homer2 cttctatgatgtcaccaggaacag tttttgagtgtgaactttgtggtt 
Irx3 catcaccaagatgaccctca acagacatgcttgcaactcg 
Lrrc3 tctgaaactagacgccaacaga cttcagtccctcctctttctga 
Manea acactcagaacacccggaac ctctggctgtcctggaactc 
Nr0b1 tcctgtaccgcagctatgtg tttatttggcggggttaatg 
Nuak1 gaaaaagacccagcagagagaa aaggtccaggagcaaattaaca 
Pcdh7 tacagtgttagcgacagacagtga tttgcacataaagccaaaatctta 
Rhobtb3 tgctcaaaaaggccaagttt gaactgggggagtgtttcaa 




































Q-PCR products resolved on 2% Agarose gels to confirm product sizes. The lowest 

























































































































































































































































Change Common Genbank Description 
CYP26A1 90.12 CP26; CYP26; P450RAI; P450RAI1 NM_000783 
cytochrome P450, family 26, subfamily A, 
polypeptide 1 
EOMES 81.1 TBR2 NM_005442 eomesodermin homolog (Xenopus laevis) 
CXCR4 79.35 
FB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; 
LESTR; NPY3R; NPYRL; HSY3RR; NPYY3R; 
D2S201E NM_003467 chemokine (C-X-C motif) receptor 4 
CXCR4 74.17 
FB22; HM89; LAP3; LCR1; NPYR; WHIM; CD184; 
LESTR; NPY3R; NPYRL; HSY3RR; NPYY3R; 
D2S201E NM_001008540 chemokine (C-X-C motif) receptor 4 
CER1 71.97 DAND4; MGC96951; MGC119894; MGC119895 NM_005454 
cerberus 1, cysteine knot superfamily, 
homolog (Xenopus laevis) 
FOXA2 71.79 HNF3B; TCF3B; MGC19807 NM_021784 forkhead box A2 
APOA2 65.95 APOA2 NM_001643 apolipoprotein A-II 
FGF17 61.28 FGF-13 NM_003867 fibroblast growth factor 17 
SOX17 54.05 FLJ22252 NM_022454 SRY (sex determining region Y)-box 17 
CYP26A1 52.32 CP26; CYP26; P450RAI; P450RAI1 NM_057157 
cytochrome P450, family 26, subfamily A, 
polypeptide 1 
GYPE 52.25 GPE; MNS; MiIX NM_002102 glycophorin E 
CCKBR 43.4 GASR; CCK-B NM_176875 cholecystokinin B receptor 
FLJ23514 43.05 FLJ16339; FLJ23514 NM_021827 coiled-coil domain containing 81 
FREM1 41.77 QBRICK; C9orf154; FLJ25461; RP11-439N12.3 NM_144966 FRAS1 related extracellular matrix 1 
GYPB 39.64 
SS; GPB; MNS; GYPA; CD235b; GPB.NY; 
GYPHe.NY NM_002100 glycophorin B (MNS blood group) 
APOA1 33.79 MGC117399 NM_000039 apolipoprotein A-I 
FOXQ1 31.93 HFH1 NM_033260 forkhead box Q1 
LRIG3 31.01 FLJ26573; FLJ90440; KIAA3016 NM_153377 
leucine-rich repeats and immunoglobulin-like 
domains 3 
FRZB 30.38 
FRE; FZRB; hFIZ; FRITZ; FRP-3; FRZB1; SFRP3; 
SRFP3; FRZB-1; FRZB-PEN NM_001463 frizzled-related protein 
MIXL1 27.57 MIX; MIXL; MILD1; MGC138179 NM_031944 Mix1 homeobox-like 1 (Xenopus laevis) 
SLCO2A1 27.55 PGT; OATP2A1; SLC21A2 NM_005630 
solute carrier organic anion transporter family, 
member 2A1 
GSC 26.62 GSC NM_173849 goosecoid 
EPSTI1 26.6 BRESI1; MGC29634 NM_033255 epithelial stromal interaction 1 (breast) 
TMOD1 25.98 TMOD; ETMOD; D9S57E NM_003275 tropomodulin 1 
FLRT3 22.63 FLRT3 NM_013281 
fibronectin leucine rich transmembrane 
protein 3 
NPPB 22.17 BNP NM_002521 natriuretic peptide precursor B 
VWF 20.32 VWD; F8VWF NM_000552 von Willebrand factor 
CALCR 19.91 CRT; CTR; CTR1 NM_001742 calcitonin receptor 
GRP 19.53 BN; GRP-10; proGRP; preproGRP NM_002091 gastrin-releasing peptide 
OTX2 18.26 MCOPS5; MGC45000 NM_172337 orthodenticle homolog 2 (Drosophila) 
DACT2 18.04 
DAPPER2; C6orf116; FLJ31232; MGC133141; 
MGC133142; bA503C24.7; RP11-503C24.7 NM_214462 
dapper, antagonist of beta-catenin, homolog 2 
(Xenopus laevis) 
LHX1 16.62 LIM1; LIM-1; MGC126723; MGC138141 NM_005568 LIM homeobox 1 
CRIP1 16.6 CRHP; CRIP; CRP1 NM_001311 cysteine-rich protein 1 (intestinal) 
ANKS1B 14.81 
AIDA; EB-1; ANKS2; AIDA-1; MGC26087; cajalin-
2 NM_181670 
ankyrin repeat and sterile alpha motif domain 
containing 1B 
PDZK1 14.4 CAP70; CLAMP; PDZD1 NM_002614 PDZ domain containing 1 
CPE 13.44 CPE NM_001873 carboxypeptidase E 
COL9A2 13.26 MED; EDM2; DJ39G22.4 NM_001852 collagen, type IX, alpha 2 
BMP2 13.1 BMP2A NM_001200 bone morphogenetic protein 2 
RHOBTB3 12.5 KIAA0878 NM_014899 Rho-related BTB domain containing 3 
ERBB4 12.35 HER4; MGC138404; p180erbB4 NM_005235 
v-erb-a erythroblastic leukemia viral oncogene 
homolog 4 (avian) 
MGST2 12.28 GST2; MGST-II; FLJ27438; MGC14097 NM_002413 microsomal glutathione S-transferase 2 
HHEX 12.07 HEX; PRH; HMPH; PRHX; HOX11L-PEN NM_002729 homeobox, hematopoietically expressed 
ST8SIA4 12.03 




C6ORF60 12 FLJ13942 NM_024581 chromosome 6 open reading frame 60 
C1ORF61 11.95 CROC4; FLJ38303; RP11-139I14.3 NM_006365 chromosome 1 open reading frame 61 
ROR2 11.53 BDB; BDB1; NTRKR2 NM_004560 receptor tyrosine kinase-like orphan receptor 2 
HP 11.44 MGC111141; hp2-alpha NM_005143 haptoglobin 
EDG3 11.39 LPB3; S1P3; EDG-3; S1PR3; FLJ37523; MGC71696 NM_005226 
endothelial differentiation, sphingolipid G-
protein-coupled receptor, 3 
KCNK12 11.39 THIK2; THIK-2 NM_022055 potassium channel, subfamily K, member 12 
CMKOR1 11.11 RDC1; GPR159 NM_020311 chemokine orphan receptor 1 
KCNG1 10.63 K13; kH2; KCNG; KV6.1; MGC12878 NM_002237 
potassium voltage-gated channel, subfamily 
G, member 1 
OXTR 10.54 OT-R NM_000916 oxytocin receptor 
COLEC12 10.43 CLP1; NSR2; SRCL; SCARA4 NM_130386 collectin sub-family member 12 
GATA4 10.41 MGC126629 NM_002052 GATA binding protein 4 
ACOX3 10.39 HBA2 NM_003501 acyl-Coenzyme A oxidase 3, pristanoyl 
HAS2 10.33 MGC126241; MGC126242 NM_005328 hyaluronan synthase 2 
LEPREL1 10.25 P3H2; MLAT4; FLJ10718 NM_018192 leprecan-like 1 
OTX2 10.12 MCOPS5; MGC45000 NM_021728 orthodenticle homolog 2 (Drosophila) 
MYL7 10.05 MYL2A; MYLC2A NM_021223 myosin, light polypeptide 7, regulatory 
Intersect of (d4AA and d4+GF) 
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BHLHB5 9.742 Beta3; CAGL85; TNRC20 NM_152414 
basic helix-loop-helix domain containing, 
class B, 5 
ADAM19 9.66 MLTNB; FKSG34; MADDAM NM_033274 
ADAM metallopeptidase domain 19 (meltrin 
beta) 
MFAP4 9.529 MFAP4 NM_002404 microfibrillar-associated protein 4 
GATM 9.516 AGAT NM_001482 
glycine amidinotransferase (L-
arginine:glycine amidinotransferase) 
LEFTY2 9.403 EBAF; LEFTA; TGFB4; LEFTYA; MGC46222 NM_003240 left-right determination factor 2 
MXRA5 9.365 DKFZp564I1922 NM_015419 matrix-remodelling associated 5 
ANKDD1A 9.185 FLJ25870; MGC120305; MGC120306; MGC120307 NM_182703 
ankyrin repeat and death domain containing 
1A 
FZD8 9.061 FZ-8; hFZ8 NM_031866 frizzled homolog 8 (Drosophila) 
ST8SIA4 9.055 




AMHR2 8.828 AMHR; MISRII NM_020547 anti-Mullerian hormone receptor, type II 
AGTRL1 8.811 APJ; FLJ90771; MGC45246 NM_005161 angiotensin II receptor-like 1 
KRT19 8.679 K19; CK19; K1CS; MGC15366 NM_002276 keratin 19 
C1ORF97 8.674 FLJ27347; FLJ27348; MGC14801; RP11-318L16.3 NM_032705 chromosome 1 open reading frame 97 
HLXB9 8.43 HB9; SCRA1; HOXHB9 NM_005515 homeobox HB9 
SFRP1 8.336 FRP; FRP1; FrzA; FRP-1; SARP2 NM_003012 secreted frizzled-related protein 1 
S100A14 8.249 BCMP84; S100A15 NM_020672 S100 calcium binding protein A14 
TMEM46 8.239 C13orf13; PRO28631; WGAR9166; bA398O19.2 NM_001007538 transmembrane protein 46 
SLITRK2 8.22 
CXorf2; SLITL1; KIAA1854; MGC129912; 
MGC129913; DKFZp451E1911 NM_032539 SLIT and NTRK-like family, member 2 
DIO3 8.202 D3; 5DIII; TXDI3; DIOIII NM_001362 deiodinase, iodothyronine, type III 
RNASE1 8.176 RIB1; RNS1; MGC12408 NM_198232 ribonuclease, RNase A family, 1 (pancreatic) 
FOXA1 8.161 HNF3A; TCF3A; MGC33105 NM_004496 forkhead box A1 
GATA6 8.042 GATA6 NM_005257 GATA binding protein 6 
STMN2 7.99 SCG10; SGC10; SCGN10 NM_007029 stathmin-like 2 
DDIT4L 7.93 REDD2; Rtp801L NM_145244 DNA-damage-inducible transcript 4-like 
LRRC3 7.757 C21orf102 NM_030891 leucine rich repeat containing 3 
SERHL2 7.715 MGC149508; dJ222E13.1 NM_014509 serine hydrolase-like 2 
MYCT1 7.469 MTLC; FLJ21269 NM_025107 myc target 1 
KCNF1 7.426 IK8; kH1; KCNF; KV5.1; MGC33316 NM_002236 
potassium voltage-gated channel, subfamily F, 
member 1 
APOC1 7.089 TOMM40 NM_001645 apolipoprotein C-I 
S100Z 7.039 Gm625; S100-zeta NM_130772 S100 calcium binding protein Z 
TDRD7 7.003 TRAP; KIAA1529; PCTAIRE2BP; RP11-508D10.1 NM_014290 tudor domain containing 7 
SLC5A9 6.982 SGLT4; MGC132517; MGC132523 NM_001011547 
solute carrier family 5 (sodium/glucose 
cotransporter), member 9 
GPR37 6.865 PAELR; EDNRBL; hET(B)R-LP NM_005302 
G protein-coupled receptor 37 (endothelin 
receptor type B-like) 
SEMA3E 6.862 
SEMAH; coll-5; M-SEMAH; M-SemaK; KIAA0331; 
M-sema H NM_012431 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3E 
NR0B1 6.818 
AHC; AHX; DSS; GTD; HHG; AHCH; DAX1; 
DAX-1; NROB1 NM_000475 
nuclear receptor subfamily 0, group B, 
member 1 
H2AFY2 6.816 macroH2A2 NM_018649 H2A histone family, member Y2 
GCNT1 6.778 
G6NT; C2GNT; C2GNT1; NACGT2; NAGCT2; 
C2GNT-L; MGC126335; MGC126336 NM_001490 
glucosaminyl (N-acetyl) transferase 1, core 2 
(beta-1,6-N-acetylglucosaminyltransferase) 
MANEA 6.673 hEndo; FLJ12838; DKFZp686D20120 NM_024641 mannosidase, endo-alpha 
MATN3 6.615 HOA; EDM5 NM_002381 matrilin 3 
MAPK10 6.484 
JNK3; JNK3A; PRKM10; p493F12; FLJ12099; 
FLJ33785; MGC50974; p54bSAPK NM_138980 mitogen-activated protein kinase 10 
FZD5 6.444 HFZ5; C2orf31; MGC129692; DKFZP434E2135 NM_003468 frizzled homolog 5 (Drosophila) 
SMAD6 6.434 MADH6; MADH7; HsT17432 NM_005585 
SMAD, mothers against DPP homolog 6 
(Drosophila) 
DNMT3L 6.399 MGC1090 NM_175867 DNA (cytosine-5-)-methyltransferase 3-like 
ELOVL2 6.307 Ssc2; FLJ20334 NM_017770 
elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3, yeast)-like 2 
ITGA9 6.086 RLC; ITGA4L; ALPHA-RLC NM_002207 integrin, alpha 9 
IRX3 6.079 IRX-1 NM_024336 iroquois homeobox protein 3 
PCDH7 6.06 BHPCDH; BH-Pcdh NM_002589 BH-protocadherin (brain-heart) 
FZD4 5.91 
EVR1; FEVR; Fz-4; FzE4; GPCR; FZD4S; 
MGC34390 NM_012193 frizzled homolog 4 (Drosophila) 
ENC1 5.788 NRPB; CCL28; ENC-1; PIG10; TP53I10; FLJ39259 NM_003633 
ectodermal-neural cortex (with BTB-like 
domain) 
IL18R1 5.695 IL1RRP; CDw218a; IL-1Rrp NM_003855 interleukin 18 receptor 1 
VIPR2 5.66 VPAC2; FLJ16511 NM_003382 vasoactive intestinal peptide receptor 2 
CLDN1 5.652 CLD1; SEMP1; ILVASC NM_021101 claudin 1 
RCOR3 5.644 FLJ10876; RP11-318L16.1 NM_018254 REST corepressor 3 
EPHA4 5.634 SEK; HEK8; TYRO1 NM_004438 EPH receptor A4 
ANKRD1 5.631 
ALRP; CARP; C-193; CVARP; MCARP; 
bA320F15.2 NM_014391 ankyrin repeat domain 1 (cardiac muscle) 
HAS2 5.625 MGC126241; MGC126242 NM_005328 hyaluronan synthase 2 
NUAK1 5.586 ARK5; KIAA0537 NM_014840 NUAK family, SNF1-like kinase, 1 
C9ORF66 5.479 FLJ31158; RP11-59O6.1 NM_152569 chromosome 9 open reading frame 66 
FAM89A 5.416 C1orf153; MGC15887; RP11-423F24.2 NM_198552 family with sequence similarity 89, member A 
HOMER2 5.415 
CPD; ACPD; Vesl-2; HOMER-2; HOMER2A; 
HOMER2B NM_004839 homer homolog 2 (Drosophila) 
SP8 5.384 BTD NM_182700 Sp8 transcription factor 
CDH2 5.362 CDHN; NCAD; CDw325 NM_001792 cadherin 2, type 1, N-cadherin (neuronal) 
ARSE 5.355 CDPX; CDPX1; CDPXR NM_000047 arylsulfatase E (chondrodysplasia punctata 1) 
COL4A6 5.35 MGC88184 NM_001847 collagen, type IV, alpha 6 
PRSS2 5.328 TRY2; TRY8; TRYP2; MGC111183; MGC120174 NM_002770 protease, serine, 2 (trypsin 2) 




TNNC1 5.287 TNC; TNNC NM_003280 troponin C type 1 (slow) 
VIL1 5.262 VIL; D2S1471 NM_007127 villin 1 
CST1 5.257 CST4 NM_001898 cystatin SN 
SP5 5.212 FAM5B NM_001003845 Sp5 transcription factor 
MGC39900 5.183 MGC39900 NM_194324 hypothetical protein MGC39900 
AGL 5.149 GDE NM_000645 
amylo-1, 6-glucosidase, 4-alpha-
glucanotransferase (glycogen debranching 
enzyme, glycogen storage disease type III) 
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ARHGAP28 5.147 FLJ10312; DKFZp686A2038 NM_001010000 Rho GTPase activating protein 28 
SLC2A14 5.12 GLUT14 NM_153449 
solute carrier family 2 (facilitated glucose 
transporter), member 14 
BHLHB2 5.119 DEC1; STRA13; Stra14; SHARP-2 NM_003670 
basic helix-loop-helix domain containing, 
class B, 2 
CA2 5.084 CAII; Car2; CA II; CA-II NM_000067 carbonic anhydrase II 
SMARCD3 5.036 Rsc6p; BAF60C; CRACD3; MGC111010 NM_003078 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
d, member 3 
IGFBP5 5.006 IBP5 NM_000599 insulin-like growth factor binding protein 5 
BCAR3 4.949 NSP2; SH2D3B; KIAA0554 NM_003567 breast cancer anti-estrogen resistance 3 
COL4A5 4.922 ATS; ASLN; CA54; MGC42377 NM_033381 collagen, type IV, alpha 5 (Alport syndrome) 
ARL4D 4.909 ARL6; ARF4L NM_001661 ADP-ribosylation factor-like 4D 
OR52A1 4.869 HPFH1OR NM_012375 
olfactory receptor, family 52, subfamily A, 
member 1 
CNTNAP2 4.851 CDFE; NRXN4; CASPR2; DKFZp781D1846 NM_014141 contactin associated protein-like 2 
LZTS1 4.844 F37; FEZ1 NM_021020 leucine zipper, putative tumor suppressor 1 
FLJ38451 4.844 FLJ38451; MGC117233; MGC119731 NM_175872 zinc finger protein 792 
SAMD11 4.838 MGC45873 NM_152486 sterile alpha motif domain containing 11 
EYA2 4.837 EAB1; MGC10614 NM_172112 eyes absent homolog 2 (Drosophila) 
MOBP 4.794   NM_006501   
LOC56901 4.764 NUOMS; FLJ26118 NM_020142 
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 4-like 2 
PITX2 4.762 
RS; RGS; ARP1; Brx1; IDG2; IGDS; IHG2; PTX2; 
RIEG; IGDS2; IRID2; Otlx2; RIEG1; MGC20144; 
MGC111022 NM_153426 
paired-like homeodomain transcription factor 
2 
ARMC7 4.76 FLJ22160 NM_024585 armadillo repeat containing 7 
TCF2 4.734 
FJHN; HNF2; LFB3; HNF1B; MODY5; VHNF1; 
HNF1beta NM_000458 
transcription factor 2, hepatic; LF-B3; variant 
hepatic nuclear factor 
CAPN12 4.734 MGC20576 NM_144691 calpain 12 
KEL 4.705 ECE3; CD238 NM_000420 Kell blood group, metalloendopeptidase 
NDRG4 4.678 
SMAP-8; FLJ30586; FLJ42011; KIAA1180; 
MGC19632; DKFZp686I1615 NM_022910 NDRG family member 4 
FBXO34 4.653 
Fbx34; CGI-301; FLJ20725; MGC126434; 
MGC126435; DKFZp547C162 NM_017943 F-box protein 34 
LAMA1 4.644 LAMA NM_005559 laminin, alpha 1 
GATS 4.617 GATS; DKFZp686B07267 NM_178831 opposite strand transcription unit to STAG3 
JUP 4.608 DP3; PDGB; PKGB; CTNNG; DPIII NM_021991 junction plakoglobin 
LEFTY1 4.607 LEFTB; LEFTYB NM_020997 left-right determination factor 1 
GPX2 4.592 GPRP; GI-GPx; GSHPx-2; GSHPX-GI NM_002083 glutathione peroxidase 2 (gastrointestinal) 
AJAP1 4.55 MOT8; SHREW1; SHREW-1; RP3-426F10.1 NM_018836 adherens junction associated protein 1 
SPHK2 4.531 DBP NM_020126 sphingosine kinase 2 
RARB 4.499 HAP; RRB2; NR1B2 NM_000965 retinoic acid receptor, beta 
LIFR 4.494 SWS; SJS2; STWS; CD118 NM_002310 leukemia inhibitory factor receptor alpha 
KIT 4.457 SCFR; C-Kit; CD117 NM_000222 
v-kit Hardy-Zuckerman 4 feline sarcoma viral 
oncogene homolog 
C5 4.457 CPAMD4; MGC142298 NM_001735 complement component 5 
ELMO1 4.435 
CED12; CED-12; ELMO-1; KIAA0281; 
MGC126406 NM_014800 engulfment and cell motility 1 
TSPAN12 4.397 NET-2; TM4SF12 NM_012338 tetraspanin 12 
DSCR6 4.357 RIPPLY3 NM_018962 Down syndrome critical region gene 6 
ABCC4 4.348 MRP4; MOATB; MOAT-B; EST170205 NM_005845 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 4 
LGALS12 4.328 GRIP1; GALECTIN-12 NM_033101 
lectin, galactoside-binding, soluble, 12 
(galectin 12) 
PDZK1 4.323 CAP70; CLAMP; PDZD1 NM_002614 PDZ domain containing 1 
DUSP4 4.311 TYP; HVH2; MKP2; MKP-2 NM_001394 dual specificity phosphatase 4 
PRSS1 4.31 TRP1; TRY1; TRY4; TRYP1; MGC120175 NM_002769 protease, serine, 1 (trypsin 1) 
ST8SIA1 4.275 GD3S; SIAT8; SIAT8A; ST8SiaI; ST8Sia I NM_003034 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 1 
PLCG2 4.209 PLCG2 NM_002661 
phospholipase C, gamma 2 
(phosphatidylinositol-specific) 
NBLA10383 4.199 FLJ36674; MGC33988; NBLA10383 NM_173622 CMT1A duplicated region transcript 4 
SORCS1 4.189 FLJ41758; FLJ43475; FLJ44957 NM_001013031 
sortilin-related VPS10 domain containing 
receptor 1 
SLC3A2 4.148 
4F2; CD98; MDU1; 4F2HC; 4T2HC; NACAE; 
CD98HC NM_001013251 
solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
NOG 4.144 SYM1; SYNS1 NM_005450 noggin 
MGC13057 4.118 MGC13057 NM_032321 hypothetical protein MGC13057 
MCC 4.106 MCC1; FLJ46755 NM_002387 mutated in colorectal cancers 
SAMD3 4.105 FLJ34563; MGC35163 NM_001017373 sterile alpha motif domain containing 3 
EPHB3 4.076 ETK2; HEK2; TYRO6 NM_004443 EPH receptor B3 
CUGBP2 4.03 ETR-3; NAPOR; BRUNOL3 NM_006561 CUG triplet repeat, RNA binding protein 2 
WDR22 4.029 
BCRG2; BCRP2; KIAA1824; D14S1461E; 
DKFZp434A035 NM_003861 WD repeat domain 22 
LOC349136 3.988 MGC129839 NM_198285 WD repeat domain 86 
RNASE4 3.976 RNS4; MGC9306 NM_194430 ribonuclease, RNase A family, 4 
FAM18B2 3.966 MGC8763 NM_145301 
family with sequence similarity 18, member 
B2 
RBM24 3.959 
RNPC6; FLJ26355; FLJ30829; FLJ37697; 
dJ259A10.1 NM_153020 RNA binding motif protein 24 
LOC400451 3.943 LOC400451; MGC102891 NM_207446 
hypothetical gene supported by AK075564; 
BC060873 
ANKS1B 3.939 
AIDA; EB-1; ANKS2; AIDA-1; MGC26087; cajalin-
2 NM_020140 
ankyrin repeat and sterile alpha motif domain 
containing 1B 
SLC35A3 3.938 DKFZp781P1297 NM_012243 
solute carrier family 35 (UDP-N-
acetylglucosamine (UDP-GlcNAc) 
transporter), member A3 
PLCE1 3.938 PLCE; FLJ23659; KIAA1516 NM_016341 phospholipase C, epsilon 1 
FRAS1 3.922 
FLJ14927; FLJ22031; KIAA1500; 
DKFZp686I05113; DKFZp686P08111 NM_025074 Fraser syndrome 1 
RGS11 3.886 RS11 NM_183337 regulator of G-protein signalling 11 
RAP2A 3.881 KREV; RAP2; K-REV; RbBP-30 NM_021033 RAP2A, member of RAS oncogene family 
EDA 3.876 
ED1; HED; EDA1; EDA2; XHED; XLHED; ED1-
A1; ED1-A2 NM_001005615 ectodysplasin A 




ARP9; CEM15; MDS019; FLJ12740; bK150C2.7; 
dJ494G10.1 NM_021822 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3G 
IGFBP3 3.823 IBP3; BP-53 NM_001013398 insulin-like growth factor binding protein 3 
EPHA2 3.82 ECK NM_004431 EPH receptor A2 
FGFR3 3.795 ACH; CEK2; JTK4; CD333; HSFGFR3EX NM_000142 
fibroblast growth factor receptor 3 
(achondroplasia, thanatophoric dwarfism) 
UPK1B 3.792 UPIB; UPK1; TSPAN20 NM_006952 uroplakin 1B 
KCNG1 3.779 K13; kH2; KCNG; KV6.1; MGC12878 NM_172318 
potassium voltage-gated channel, subfamily 
G, member 1 
C12ORF34 3.776 FLJ14721 NM_032829 chromosome 12 open reading frame 34 
PFKFB4 3.748 PFKFB4 NM_004567 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4 
KIAA1409 3.72 FLJ43337 NM_020818 KIAA1409 
NT5DC3 3.72 FLJ11266; TU12B1-TY NM_016575 5'-nucleotidase domain containing 3 
DENND2C 3.696 
FLJ37099; dJ1156J9.1; RP5-1156J9.1; 
DKFZp686G0351; DKFZp686N1631; 
DKFZp779P1149 NM_198459 DENN/MADD domain containing 2C 
PCDH20 3.691 PCDH13; FLJ22218 NM_022843 protocadherin 20 
PRDM1 3.677 
BLIMP1; PRDI-BF1; MGC118922; MGC118923; 
MGC118924; MGC118925 NM_001198 PR domain containing 1, with ZNF domain 
FAM89A 3.664 C1orf153; MGC15887; RP11-423F24.2 NM_198552 family with sequence similarity 89, member A 
SULF2 3.612 
HSULF-2; FLJ90554; KIAA1247; MGC126411; 
DKFZp313E091 NM_018837 sulfatase 2 
CTXN1 3.605 CTXN; FLJ25968 NM_206833 cortexin 1 
LRRN1 3.587 NLRR-1; KIAA1497 NM_020873 leucine rich repeat neuronal 1 
ATPAF2 3.56 ATP12; ATP12p; LP3663; MGC29736 NM_145691 
ATP synthase mitochondrial F1 complex 
assembly factor 2 
DACH1 3.553 DACH; FLJ10138 NM_080759 dachshund homolog 1 (Drosophila) 
SLC1A1 3.54 EAAC1; EAAT3 NM_004170 
solute carrier family 1 (neuronal/epithelial 
high affinity glutamate transporter, system 
Xag), member 1 
LOC441268 3.528 LOC441268 NM_001013725 hypothetical gene supported by BC044942 
CFLAR 3.503 
CASH; FLIP; MRIT; CLARP; FLAME; Casper; c-
FLIP; FLAME-1; I-FLICE; USURPIN; c-FLIPL; c-
FLIPR; c-FLIPS; CASP8AP1 NM_003879 CASP8 and FADD-like apoptosis regulator 
VASH1 3.502 KIAA1036 NM_014909 vasohibin 1 
FXYD6 3.5 FXYD6 NM_022003 
FXYD domain containing ion transport 
regulator 6 
APBB3 3.488 SRA; FE65L2; MGC87674 NM_006051 
amyloid beta (A4) precursor protein-binding, 
family B, member 3 
C10ORF114 3.475 bA418C1.3 NM_001010911 chromosome 10 open reading frame 114 
ANKRD6 3.474 VAPA NM_014942 ankyrin repeat domain 6 
BTG2 3.46 PC3; TIS21; MGC126063; MGC126064 NM_006763 BTG family, member 2 
ANKRD37 3.44 Lrp2bp; MGC111507 NM_181726 ankyrin repeat domain 37 
RAB20 3.422 FLJ20429 NM_017817 RAB20, member RAS oncogene family 
MERTK 3.394 MER; c-mer; MGC133349 NM_006343 c-mer proto-oncogene tyrosine kinase 
PPAPDC1A 3.374 PPAPDC1; MGC120300 NM_001030059 
phosphatidic acid phosphatase type 2 domain 
containing 1A 
GREM2 3.373 PRDC; DAND3; CKTSF1B2 NM_022469 
gremlin 2, cysteine knot superfamily, homolog 
(Xenopus laevis) 
KIAA1688 3.336 KIAA1688 NM_025251 KIAA1688 protein 
ZNF664 3.291 ZFOC1; MGC126579; DKFZp761B128 NM_152437 zinc finger protein 664 
ABCA1 3.288 TGD; ABC1; CERP; ABC-1; HDLDT1; FLJ14958 NM_005502 
ATP-binding cassette, sub-family A (ABC1), 
member 1 
KIAA1161 3.284 BCORL2 NM_020702 KIAA1161 
KCNH8 3.266 ELK; ELK1; Kv12.1 NM_144633 
potassium voltage-gated channel, subfamily H 
(eag-related), member 8 
TMEM100 3.233 FLJ10970; FLJ37856 NM_018286 transmembrane protein 100 
KIAA1729 3.226 KIAA1729 NM_053042 KIAA1729 protein 
EFS 3.226 SIN; EFS1; EFS2; HEFS NM_005864 embryonal Fyn-associated substrate 
RTN4RL1 3.212 NgR3; NGRH2; DKFZp547J144 NM_178568 reticulon 4 receptor-like 1 
CAP2 3.203 RAB11FIP1 NM_006366 
CAP, adenylate cyclase-associated protein, 2 
(yeast) 
B3GNT1 3.202 




SAMD3 3.19 FLJ34563; MGC35163 NM_152552 sterile alpha motif domain containing 3 
AIRE 3.186   NM_000659   
PCDH10 3.178 
PCDH19; OL-PCDH; KIAA1400; MGC133344; 
DKFZP761O2023 NM_032961 protocadherin 10 
HSPB8 3.174 H11; HMN2; CMT2L; DHMN2; E2IG1; HSP22 NM_014365 heat shock 22kDa protein 8 
SERPINB9 3.143 PI9; CAP3; CAP-3 NM_004155 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 9 
WWOX 3.136   NM_018560   
MLLT6 3.134 AF17; FLJ23480 NM_005937 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated 
to, 6 
PPT2 3.13 G14; NG3; C6orf8; DKFZp564P1516 NM_138717 palmitoyl-protein thioesterase 2 
CEP70 3.107 BITE; FLJ13036 NM_024491 centrosomal protein 70kDa 
ZNF702 3.106 FLJ12985 NM_024924 zinc finger protein 702 
FAM84B 3.101 NSE2; BCMP101 NM_174911 family with sequence similarity 84, member B 
PARP6 3.099   NM_020213   
AADAT 3.093 KAT2; KATII NM_182662 aminoadipate aminotransferase 
RNF125 3.074 FLJ20456; MGC21737 NM_017831 ring finger protein 125 
FGF8 3.068 AIGF; HBGF-8 NM_033164 fibroblast growth factor 8 (androgen-induced) 
PPM1K 3.004 
PTMP; UG0882E07; DKFZp667B084; 
DKFZp761G058 NM_152542 
protein phosphatase 1K (PP2C domain 
containing) 
GMPR 2.988 GMPR NM_006877 guanosine monophosphate reductase 
DSCR5 2.988 DCRC; DSRC; DSCR5; DCRC-S NM_153682 
phosphatidylinositol glycan anchor 
biosynthesis, class P 
WSB1 2.986   NM_134264   
CHST3 2.985 C6ST; C6ST1 NM_004273 
carbohydrate (chondroitin 6) sulfotransferase 
3 
PLEKHB1 2.984 KPL1; PHR1; PHRET1 NM_021200 
pleckstrin homology domain containing, 
family B (evectins) member 1 
KIAA1443 2.983 HOMEZ NM_020834 KIAA1443 
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ZNF614 2.982 FLJ21941; MGC120638 NM_025040 zinc finger protein 614 
AD031 2.971 AD031; MGC138255 NM_032021 transmembrane protein 133 
CAMK2D 2.97 CAMKD; MGC44911 NM_172115 
calcium/calmodulin-dependent protein kinase 
(CaM kinase) II delta 
LYPD2 2.968 LYPDC2; UNQ430; MGC148106 NM_205545 LY6/PLAUR domain containing 2 
PIK3CB 2.968 
PI3K; PIK3C1; PI3Kbeta; MGC133043; p110-
BETA; DKFZp779K1237 NM_006219 
phosphoinositide-3-kinase, catalytic, beta 
polypeptide 
BTK 2.958 
AT; ATK; BPK; XLA; IMD1; AGMX1; PSCTK1; 
MGC126261; MGC126262 NM_000061 Bruton agammaglobulinemia tyrosine kinase 
PKP2 2.95 ARVD9 NM_004572 plakophilin 2 
PCTP 2.945 STARD2 NM_021213 phosphatidylcholine transfer protein 
TLN2 2.93 ILWEQ; KIAA0320; DKFZp451B1011 NM_015059 talin 2 
GPC4 2.91 K-glypican NM_001448 glypican 4 
GRM2 2.897 GLUR2; mGlu2; GPRC1B; MGLUR2 NM_000839 glutamate receptor, metabotropic 2 
ITLN2 2.888 HL2; HL-2 NM_080878 intelectin 2 
PAX6 2.885 AN; AN2; MGDA; WAGR; D11S812E; MGC17209 NM_000280 paired box gene 6 (aniridia, keratitis) 
TMEM27 2.881 NX17; NX-17 NM_020665 transmembrane protein 27 
DOCK8 2.864 ZIR8; FLJ00026; FLJ00152; FLJ00346 NM_203447 dedicator of cytokinesis 8 
FAM11A 2.856 CXorf13; MGC118844; MGC118845 NM_032508 family with sequence similarity 11, member A 
TYRO3 2.85 BYK; Brt; Dtk; RSE; Sky; Tif NM_006293 TYRO3 protein tyrosine kinase 
AMOT 2.842 KIAA1071 NM_133265 angiomotin 
TPK1 2.84 PP20; HTPK1 NM_022445 thiamin pyrophosphokinase 1 
LGR5 2.837 FEX; HG38; GPR49; GPR67; GRP49; MGC117008 NM_003667 
leucine-rich repeat-containing G protein-
coupled receptor 5 
BTBD3 2.829 KIAA0952; MGC130038; MGC130039; dJ742J24.1 NM_014962 BTB (POZ) domain containing 3 
C3ORF32 2.823 C3orf32 NM_015931 chromosome 3 open reading frame 32 
GNAL 2.817 GNAL NM_182978 
guanine nucleotide binding protein (G 
protein), alpha activating activity polypeptide, 
olfactory type 
GATA3 2.814 HDR; MGC2346; MGC5199; MGC5445 NM_002051 GATA binding protein 3 
DPPA3 2.811 STELLA NM_199286 developmental pluripotency associated 3 
CTSH 2.804 CPSB; MGC1519; minichain; DKFZp686B24257 NM_004390 cathepsin H 
CDKN1B 2.802 KIP1; CDKN4; P27KIP1 NM_004064 
cyclin-dependent kinase inhibitor 1B (p27, 
Kip1) 
TMEM88 2.77 FLJ20025; MGC71744 NM_203411 transmembrane protein 88 
MDK 2.768 MK; NEGF2; FLJ27379 NM_002391 midkine (neurite growth-promoting factor 2) 
TLE2 2.763 ESG; ESG2; GRG2; FLJ41188 NM_003260 
transducin-like enhancer of split 2 (E(sp1) 
homolog, Drosophila) 
PAQR5 2.744 MPRG; FLJ20190 NM_017705 
progestin and adipoQ receptor family member 
V 
GNG2 2.742 G protein NM_053064 
guanine nucleotide binding protein (G 
protein), gamma 2 
YPEL2 2.742 FKSG4; DKFZp761C2021 NM_001005404 yippee-like 2 (Drosophila) 
CUGBP2 2.737 ETR-3; NAPOR; BRUNOL3 NM_001025077 CUG triplet repeat, RNA binding protein 2 
ZNF124 2.728 HZF16; HZF-16; MGC117046 NM_003431 zinc finger protein 124 
ARHGAP28 2.726 FLJ10312; DKFZp686A2038 NM_030672 Rho GTPase activating protein 28 
FST 2.723 FS NM_006350 follistatin 
KIFC2 2.716 C19orf25 NM_145754 kinesin family member C2 
APOBEC3F 2.707 KA6; ARP8; MGC74891; BK150C2.4.MRNA NM_145298 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3F 
ARHGAP28 2.706 FLJ10312; DKFZp686A2038 NM_030672 Rho GTPase activating protein 28 
DDX58 2.702 
RIG-I; FLJ13599; DKFZp434J1111; 
DKFZp686N19181 NM_014314 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
58 
CTDSP1 2.7 SCP1; NLIIF NM_021198 
CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase 1 
NPL 2.699 NPL1; c112; C1orf13 NM_030769 
N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) 
C9ORF52 2.687 FLJ33868 NM_152574 chromosome 9 open reading frame 52 
CEP55 2.646 URCC6; C10orf3; FLJ10540 NM_018131 centrosomal protein 55kDa 
FBN2 2.644 CCA NM_001999 
fibrillin 2 (congenital contractural 
arachnodactyly) 
C18ORF19 2.635 HsT2329; MGC24180 NM_152352 chromosome 18 open reading frame 19 
MEIS3 2.63 MRG2; DKFZp547H236 NM_001009813 
Meis1, myeloid ecotropic viral integration site 
1 homolog 3 (mouse) 
ZIC2 2.628 HPE5 NM_007129 
Zic family member 2 (odd-paired homolog, 
Drosophila) 
PRND 2.622 DPL; PrPLP; DOPPEL; MGC41841; dJ1068H6.4 NM_012409 prion protein 2 (dublet) 
C16ORF57 2.62 FLJ13154 NM_024598 chromosome 16 open reading frame 57 
FLJ11155 2.619 FLJ11155 NM_018342 transmembrane protein 144 
COL23A1 2.611 DKFZp434K0621 NM_173465 collagen, type XXIII, alpha 1 
TRAF5 2.61 RNF84; MGC:39780 NM_004619 TNF receptor-associated factor 5 
PRSS3 2.609 MTG; TRY3; TRY4; PRSS4 NM_002771 protease, serine, 3 (mesotrypsin) 
DTWD2 2.605 FLJ33977; MGC138579; MGC138580 NM_173666 DTW domain containing 2 
HRBL 2.589 RABR NM_006076 HIV-1 Rev binding protein-like 
FBN3 2.578 KIAA1776 NM_032447 fibrillin 3 
PCDH10 2.567 
PCDH19; OL-PCDH; KIAA1400; MGC133344; 
DKFZP761O2023 NM_020815 protocadherin 10 
OGT 2.566   NM_003605   
SSBP3 2.562 CSDP; SSDP; SSDP1; FLJ10355 NM_145716 single stranded DNA binding protein 3 
LAMA1 2.557 LAMA NM_005559 laminin, alpha 1 
C15ORF17 2.555 FLJ00005 NM_020447 chromosome 15 open reading frame 17 
MBNL3 2.553 CHCR; MBLX; MBXL; MBLX39; FLJ11316 NM_133486 muscleblind-like 3 (Drosophila) 
RIPK4 2.549 
DIK; PKK; RIP4; ANKK2; ANKRD3; MGC129992; 
MGC129993 NM_020639 receptor-interacting serine-threonine kinase 4 
FMO5 2.546 FMO5 NM_001461 flavin containing monooxygenase 5 
RNF19 2.533 DORFIN; DKFZp566B1346 NM_015435 ring finger protein 19 
TANC1 2.523 TANC; ROLSB; KIAA1728 NM_033394 
tetratricopeptide repeat, ankyrin repeat and 
coiled-coil containing 1 
ZNF342 2.507 MAF NM_145288 zinc finger protein 342 
NGFRAP1 2.495 Bex; BEX3; NADE; HGR74; DXS6984E NM_014380 
nerve growth factor receptor (TNFRSF16) 
associated protein 1 
TMEM74 2.491 FLJ30668 NM_153015 transmembrane protein 74 
GSTA1 2.488 GST2; GTH1; GSTA1-1; MGC131939 NM_145740 glutathione S-transferase A1 
LOC442578 2.475 LOC442578 NM_001013739 similar to Cohesin subunit SA-3 (Stromal 
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antigen 3) (Stromalin 3) (SCC3 homolog 3) 
RGS16 2.455 RGS-R; A28-RGS14; A28-RGS14P NM_002928 regulator of G-protein signalling 16 
SLC25A29 2.452 CACL; C14orf69; FLJ38975 NM_152333 solute carrier family 25, member 29 
HAK 2.446 HAK; FLJ34875; FLJ43253 NM_052947 alpha-kinase 2 
SORCS1 2.398 FLJ41758; FLJ43475; FLJ44957 NM_052918 
sortilin-related VPS10 domain containing 
receptor 1 
HOXD13 2.396 BDE; SPD; HOX4I NM_000523 homeobox D13 
UTX 2.385 MGC141941; bA386N14.2; DKFZp686A03225 NM_021140 
ubiquitously transcribed tetratricopeptide 
repeat, X chromosome 
PIP5K1B 2.374 MSS4; STM7 NM_003558 
phosphatidylinositol-4-phosphate 5-kinase, 
type I, beta 
PLSCR1 2.372 MMTRA1B NM_021105 phospholipid scramblase 1 
SULF2 2.356 
HSULF-2; FLJ90554; KIAA1247; MGC126411; 
DKFZp313E091 NM_018837 sulfatase 2 
DDIT3 2.355 CHOP; CEBPZ; CHOP10; GADD153; MGC4154 NM_004083 DNA-damage-inducible transcript 3 
ZBTB40 2.348 KIAA0478; MGC133098 NM_014870 zinc finger and BTB domain containing 40 
BSPRY 2.345 FLJ20150 NM_017688 B-box and SPRY domain containing 
MAPK7 2.34 BMK1; ERK4; ERK5; PRKM7 NM_139034 mitogen-activated protein kinase 7 
SLC36A1 2.337 PAT1; LYAAT1; TRAMD3 NM_078483 
solute carrier family 36 (proton/amino acid 
symporter), member 1 
AMMECR1 2.337 AMMERC1 NM_015365 
Alport syndrome, mental retardation, midface 
hypoplasia and elliptocytosis chromosomal 
region, gene 1 
TMEM56 2.335 FLJ31842; MGC102912 NM_152487 transmembrane protein 56 
SLC4A2 2.328 AE2; HKB3; BND3L; NBND3; EPB3L1 NM_003040 
solute carrier family 4, anion exchanger, 
member 2 (erythrocyte membrane protein 
band 3-like 1) 
LRRC54 2.322 TSK; E2IG4 NM_015516 leucine rich repeat containing 54 
ZNF160 2.318 
F11; HZF5; KR18; HKr18; FLJ00032; KIAA1611; 
DKFZp686B16128 NM_033288 zinc finger protein 160 
VCX2 2.316 
VCXB; VCX2R; VCX-2r; MGC118977; 
MGC125729; MGC125794; MGC125795 NM_016378 variable charge, X-linked 2 
FLJ45187 2.313 FLJ45187; DLN-1; DKFZp761J229 NM_207371 hypothetical protein LOC387640 
ICOSLG 2.312 
B7H2; GL50; B7-H2; B7RP1; CD275; ICOSL; 
LICOS; B7RP-1; ICOS-L; KIAA0653 NM_015259 inducible T-cell co-stimulator ligand 
NCR1 2.31 LY94; CD335; NKP46; NK-p46 NM_004829 natural cytotoxicity triggering receptor 1 
FLJ35725 2.304 FLJ12891; FLJ35725 NM_152544 chromosome 4 open reading frame 23 
ACVR1B 2.293 ALK4; SKR2; ACTRIB; ACVRLK4 NM_004302 activin A receptor, type IB 
C1ORF63 2.281   NM_207035   
AXIN2 2.268 AXIL; MGC126582; DKFZp781B0869 NM_004655 axin 2 (conductin, axil) 
C22ORF8 2.264 C22orf8; FLJ20635 NM_017911 
family with sequence similarity 118, member 
A 
MDK 2.253 MK; NEGF2; FLJ27379 NM_001012333 midkine (neurite growth-promoting factor 2) 
MGC33302 2.246 MGC33302 NM_152778 hypothetical protein MGC33302 
GSTA2 2.244 GST2; GTA2; GTH2; GSTA2-2; MGC10525 NM_000846 glutathione S-transferase A2 
ATHL1 2.244 FLJ22635; MGC129858; MGC129859 NM_025092 ATH1, acid trehalase-like 1 (yeast) 
ZNF358 2.238 ZFEND; FLJ10390 NM_018083 zinc finger protein 358 
UBAP2 2.227 FLJ22435; KIAA1491; bA176F3.5 NM_018449 ubiquitin associated protein 2 
KIAA0980 2.217 KIAA0980; NLP; FLJ11792; dJ691N24.1 NM_025176 KIAA0980 protein 
C1QTNF6 2.211 CTRP6; ZACRP6 NM_031910 
C1q and tumor necrosis factor related protein 
6 
NRXN3 2.206 KIAA0743 NM_004796 neurexin 3 
COL4A6 2.203 MGC88184 NM_033641 collagen, type IV, alpha 6 
DLK1 2.199 FA1; ZOG; pG2; PREF1; Pref-1 NM_003836 delta-like 1 homolog (Drosophila) 
SNX16 2.199 DKFZp666H147 NM_022133 sorting nexin 16 
HS6ST1 2.195 HS6ST; MGC116899; MGC116901 NM_004807 heparan sulfate 6-O-sulfotransferase 1 
PICALM 2.195 LAP; CALM; CLTH NM_007166 
phosphatidylinositol binding clathrin assembly 
protein 
H2AFY 2.194 
H2A.y; H2A/y; H2AFJ; mH2A1; H2AF12M; 
MACROH2A1.1; macroH2A1.2 NM_004893 H2A histone family, member Y 
TRO 2.187   NM_177557   
IGSF4 2.172 
BL2; ST17; NECL2; RA175; TSLC1; IGSF4A; 
Necl-2; SYNCAM; sTSLC-1; synCAM1; 
DKFZp686F1789 NM_014333 immunoglobulin superfamily, member 4 
PLEKHG2 2.17 CLG; FLJ00018; FLJ22458 NM_022835 
pleckstrin homology domain containing, 
family G (with RhoGef domain) member 2 
GP1BB 2.17 CD42c NM_000407 glycoprotein Ib (platelet), beta polypeptide 
C8ORF34 2.167 VEST1; vest-1; FLJ36872; DKFZp547E186 NM_052958 chromosome 8 open reading frame 34 
MAGED2 2.164 
11B6; BCG1; HCA10; JCL-1; MAGED; MAGE-D2; 
MGC8386 NM_177433 melanoma antigen family D, 2 
RCOR2 2.163 RCOR2 NM_173587 REST corepressor 2 
SLC9A5 2.159 NHE5 NM_004594 
solute carrier family 9 (sodium/hydrogen 
exchanger), member 5 
ZNF193 2.158 PRD51; ZSCAN9 NM_006299 zinc finger protein 193 
ARL6IP2 2.158 ATL2; ARL3IP2; FLJ23293; atlastin2 NM_022374 
ADP-ribosylation factor-like 6 interacting 
protein 2 
LPGAT1 2.155 FAM34A; FAM34A1 NM_014873 lysophosphatidylglycerol acyltransferase 1 
FMN2 2.152 ROR2 NM_020066 formin 2 
PTP4A3 2.132 PRL3; PRL-3; PRL-R NM_007079 
protein tyrosine phosphatase type IVA, 
member 3 
MAGED4 2.131 MAGE1; MAGE-E1; MGC3210; MGC88639 NM_177535 melanoma antigen family D, 4 
FEZ1 2.123 FEZ1 NM_022549 
fasciculation and elongation protein zeta 1 
(zygin I) 
EFNB3 2.119 EFL6; EPLG8; LERK8 NM_001406 ephrin-B3 
PCBP4 2.114 LIP4; MCG10 NM_033008 poly(rC) binding protein 4 
ISOC1 2.113 CGI-111 NM_016048 isochorismatase domain containing 1 
AGPAT4 2.107 
1-AGPAT4; dJ473J16.2; LPAAT-delta; RP3-
473J16.2 NM_001012734 
1-acylglycerol-3-phosphate O-acyltransferase 
4 (lysophosphatidic acid acyltransferase, 
delta) 
WDR72 2.1 FLJ38736; MGC126663; MGC126665 NM_182758 WD repeat domain 72 
SETBP1 2.098 SEB; KIAA0437 NM_015559 SET binding protein 1 
MTSS1 2.087 MIM; MIMA; MIMB; FLJ44694; KIAA0429 NM_014751 metastasis suppressor 1 
SOX10 2.076 DOM; WS4; MGC15649 NM_006941 SRY (sex determining region Y)-box 10 
LASS6 2.073 MGC129949; MGC129950 NM_203463 
LAG1 longevity assurance homolog 6 (S. 
cerevisiae) 
LOC91461 2.065 LOC91461; MGC125960 NM_138370 hypothetical protein BC007901 
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C9ORF47 2.064 C9orf108; FLJ37523; bA791O21.3 NM_001001938 chromosome 9 open reading frame 47 
ELAVL4 2.056 HUD; PNEM NM_021952 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D) 
C3ORF58 2.051 MGC33365 NM_173552 chromosome 3 open reading frame 58 
DDHD2 2.041 SAMWD1; KIAA0725 NM_015214 DDHD domain containing 2 
CAMTA1 2.035 KIAA0833 NM_015215 calmodulin binding transcription activator 1 
DKK4 2.034 DKK-4; MGC129562; MGC129563 NM_014420 dickkopf homolog 4 (Xenopus laevis) 
KIAA0895 2.034 KIAA0895 NM_015314 KIAA0895 protein 
LONRF1 2.02 RNF191; FLJ23749 NM_152271 
LON peptidase N-terminal domain and ring 
finger 1 
TMC7 2.019 FLJ21240; DKFZp781O2274 NM_024847 transmembrane channel-like 7 
PILRB 2.017 FDFACT1; FDFACT2 NM_175047 paired immunoglobin-like type 2 receptor beta 
GCNT2 2.013 
II; IGNT; ULG3; GCNT5; GCNT2C; NACGT1; 
NAGCT1; bA421M1.1; bA360O19.2 NM_145655 
glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme (I blood group) 
ZNF615 2.012 FLJ33710; FLJ39372; DKFZp686O1554 NM_198480 zinc finger protein 615 
COL22A1 2.011 COL22A1 NM_152888 collagen, type XXII, alpha 1 
ERF 2.008 PE-2 NM_006494 Ets2 repressor factor 
ZNF608 2.006 NY-REN-36; DKFZp781C0723 NM_020747 zinc finger protein 608 
DHCR24 1.999 KIAA0018; SELADIN1; Nbla03646; seladin-1 NM_014762 24-dehydrocholesterol reductase 
ZNF611 1.997 MGC5384 NM_030972 zinc finger protein 611 
MOBP 1.995 MGC87379 NM_182935 
myelin-associated oligodendrocyte basic 
protein 
SLC16A5 1.991 MCT5; MCT6 NM_004695 
solute carrier family 16, member 5 
(monocarboxylic acid transporter 6) 
AHSA2 1.989 Hch1; DKFZp564C236 NM_152392 
AHA1, activator of heat shock 90kDa protein 
ATPase homolog 2 (yeast) 
ARHGEF2 1.989 
GEF; P40; GEFH1; LFP40; GEF-H1; KIAA0651; 
DKFZp547L106; DKFZp547P1516 NM_004723 
rho/rac guanine nucleotide exchange factor 
(GEF) 2 
RAX 1.983 RX NM_013435 retina and anterior neural fold homeobox 
MLLT10 1.982 AF10; MGC75086; DKFZp686E10210 NM_004641 
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated 
to, 10 
PDLIM7 1.979 PDLIM7 NM_213636 PDZ and LIM domain 7 (enigma) 
C6ORF213 1.977 C6orf212; bA160A10.4 NM_001010852 chromosome 6 open reading frame 213 
PPP1R13B 1.973 p85; ASPP1; KIAA0771; p53BP2-like NM_015316 
protein phosphatase 1, regulatory (inhibitor) 
subunit 13B 
SRRP35 1.972 SRrp35; RP11-63L7.3 NM_080743 serine-arginine repressor protein (35 kDa) 
MMP15 1.968 MTMMP2; SMCP-2; MT2-MMP NM_002428 
matrix metallopeptidase 15 (membrane-
inserted) 
DNAJB9 1.967 
MDG1; ERdj4; MST049; MSTP049; 
DKFZP564F1862 NM_012328 
DnaJ (Hsp40) homolog, subfamily B, member 
9 
RXRG 1.962 RXRC; NR2B3 NM_006917 retinoid X receptor, gamma 
TRIM36 1.955 RNF98; HAPRIN; RBCC728 NM_018700 tripartite motif-containing 36 
ZCCHC3 1.952 C20orf99; MGC104290 NM_033089 zinc finger, CCHC domain containing 3 
GALNT10 1.944 
FLJ00205; FLJ11715; GalNAcT10; 





DKFZP761I2123 1.936 DKFZp761I2123; KIAA1886 NM_031449 hypothetical protein DKFZp761I2123 
SPATA6 1.933 SRF1; SRF-1; FLJ10007 NM_019073 spermatogenesis associated 6 
LASS4 1.933 Trh1; FLJ12089 NM_024552 
LAG1 longevity assurance homolog 4 (S. 
cerevisiae) 
LOC130576 1.93 LOC130576 NM_177964 hypothetical protein LOC130576 
RUNDC1 1.922 DKFZp761H0421 NM_173079 RUN domain containing 1 
ZNF154 1.918   NM_003444   
CDK5RAP3 1.911 C53; IC53; HSF-27; MST016; OK/SW-cl.114 NM_176095 CDK5 regulatory subunit associated protein 3 
RP3-473B4.1 1.908 RP3-473B4.1 NM_138819 family with sequence similarity 122C 
KLF12 1.908 AP2REP; AP-2rep; HSPC122 NM_007249 Kruppel-like factor 12 
ENTPD7 1.903 LALP1; FLJ30978; RP11-483F11.1 NM_020354 
ectonucleoside triphosphate 
diphosphohydrolase 7 
ID1 1.901 ID NM_181353 
inhibitor of DNA binding 1, dominant 
negative helix-loop-helix protein 
RNF122 1.899 FLJ12526; MGC126622 NM_024787 ring finger protein 122 
LCMT2 1.895 PPM2; TYW4; MGC9534; KIAA0547 NM_014793 leucine carboxyl methyltransferase 2 
RAB15 1.89 RAB15 NM_198686 RAB15, member RAS onocogene family 
MSI1 1.888 MSI1 NM_002442 musashi homolog 1 (Drosophila) 
TRIM2 1.887 RNF86; KIAA0517 NM_015271 tripartite motif-containing 2 
WDR27 1.885 MGC43690 NM_182552 WD repeat domain 27 
PHACTR2 1.883 C6orf56; KIAA0680; DKFZp686F18175 NM_014721 phosphatase and actin regulator 2 
COBLL1 1.88 KIAA0977 NM_014900 COBL-like 1 
MRPS25 1.879 RPMS25; MRP-S25; FLJ00023; DKFZp313H0817 NM_022497 mitochondrial ribosomal protein S25 
PIP5K1B 1.876 MSS4; STM7 NM_003558 
phosphatidylinositol-4-phosphate 5-kinase, 
type I, beta 
GPM6A 1.87 M6A; GPM6 NM_201592 glycoprotein M6A 
STRN3 1.853 SG2NA NM_014574 striatin, calmodulin binding protein 3 
DPP10 1.848 DPL2; DPPY; DPRP3 NM_001004360 dipeptidyl-peptidase 10 
DVL2 1.845 DVL2 NM_004422 dishevelled, dsh homolog 2 (Drosophila) 
TRIM17 1.845 RBCC; terf; RNF16 NM_016102 tripartite motif-containing 17 
ACVR2A 1.839 ACVR2; ACTRII NM_001616 activin A receptor, type IIA 
ZC3HAV1 1.835 
ZAP; ZC3H2; FLB6421; ZC3HDC2; FLJ13288; 
MGC48898; DKFZp686F2052; DKFZp686H1869; 
DKFZp686O19171 NM_024625 zinc finger CCCH-type, antiviral 1 
RFFL 1.835 RNF189; RNF34L NM_001017368 
ring finger and FYVE-like domain containing 
1 
UNG2 1.833 UDG2; FLJ22422 NM_021147 uracil-DNA glycosylase 2 
LMX1A 1.833 LMX1; LMX-1; LMX1.1; MGC87616 NM_177398 LIM homeobox transcription factor 1, alpha 
TSPAN14 1.833 TM4SF14; DC-TM4F2; MGC11352 NM_030927 tetraspanin 14 
C9ORF7 1.83 D9S2135 NM_017586 chromosome 9 open reading frame 7 
E2F5 1.83 E2F-5 NM_001951 E2F transcription factor 5, p130-binding 
MIDN 1.823 DKFZp547M072 NM_177401 midnolin 
MGC39518 1.812 MGC39518 NM_173822 
family with sequence similarity 126, member 
B 
TMEM92 1.811 FLJ33318 NM_153229 transmembrane protein 92 
SORCS1 1.805 FLJ41758; FLJ43475; FLJ44957 NM_001013031 
sortilin-related VPS10 domain containing 
receptor 1 
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FLJ39155 1.805 FLJ39155 NM_152403 
EGF-like, fibronectin type III and laminin G 
domains 
MAPK10 1.804 
JNK3; JNK3A; PRKM10; p493F12; FLJ12099; 
FLJ33785; MGC50974; p54bSAPK NM_002753 mitogen-activated protein kinase 10 
C1ORF91 1.799 
AASL548; PRO1105; FLJ90779; RP4-622L5; 
dJ622L5.7; RP4-622L5.3 NM_019118 chromosome 1 open reading frame 91 
FARP1 1.798 CDEP; PLEKHC2; MGC87400 NM_001001715 
FERM, RhoGEF (ARHGEF) and pleckstrin 
domain protein 1 (chondrocyte-derived) 
WNT3 1.795 INT4; MGC131950; MGC138321; MGC138323 NM_030753 
wingless-type MMTV integration site family, 
member 3 
OVOL1 1.794 HOVO1 NM_004561 ovo-like 1(Drosophila) 
TSC1 1.793 LAM; TSC; KIAA0243; MGC86987 NM_000368 tuberous sclerosis 1 
RXRG 1.79 RXRC; NR2B3 NM_001009598 retinoid X receptor, gamma 
USP49 1.788 MGC20741 NM_018561 ubiquitin specific peptidase 49 
VEGF 1.788 VPF; VEGFA; MGC70609 NM_001025366 vascular endothelial growth factor 
UNC93A 1.785 
MGC119395; MGC119397; dJ366N23.1; 
dJ366N23.2 NM_018974 unc-93 homolog A (C. elegans) 
C8ORF72 1.766 FAM110B; MGC39325 NM_147189 chromosome 8 open reading frame 72 
TREM1 1.764 TREM-1 NM_018643 
triggering receptor expressed on myeloid cells 
1 
C14ORF101 1.762 FLJ20392 NM_017799 chromosome 14 open reading frame 101 
WNK3 1.761 PRKWNK3; KIAA1566 NM_001002838 WNK lysine deficient protein kinase 3 
ELMO1 1.76 
CED12; CED-12; ELMO-1; KIAA0281; 
MGC126406 NM_014800 engulfment and cell motility 1 
MESP1 1.758 MGC10676 NM_018670 mesoderm posterior 1 homolog (mouse) 
EML4 1.756 
C2orf2; ELP120; ROPP120; FLJ10942; FLJ32318; 
DKFZp686P18118 NM_019063 
echinoderm microtubule associated protein 
like 4 
LOC283932 1.756   NM_175901   
LOC389289 1.756 LOC389289 NM_001014279 similar to annexin II receptor 
CRHBP 1.755 CRFBP; CRF-BP NM_001882 
corticotropin releasing hormone binding 
protein 
MUS81 1.748 FLJ21012; FLJ44872 NM_025128 MUS81 endonuclease homolog (S. cerevisiae) 
RFP2 1.744 CAR; LEU5; DLEU5; RNF77; TRIM13 NM_001007278 ret finger protein 2 
TAL2 1.743 TAL2 NM_005421 T-cell acute lymphocytic leukemia 2 
SPAG4 1.742 SPAG4 NM_003116 sperm associated antigen 4 
ESRRG 1.741 
ERR3; NR3B3; FLJ16023; KIAA0832; 
DKFZp781L1617 NM_206595 estrogen-related receptor gamma 
ZNF513 1.74 FLJ32203; HMFT0656 NM_144631 zinc finger protein 513 
ZNF558 1.74 FLJ30932 NM_144693 zinc finger protein 558 
LOC388969 1.738 LOC388969; FLJ14112; FLJ35653; MGC131675 NM_001013649 hypothetical LOC388969 
ZNF135 1.737 pT3; ZNF61; pHZ-17; ZNF78L1 NM_003436 zinc finger protein 135 
ALPK3 1.735 MAK; MIDORI; FLJ21176; KIAA1330 NM_020778 alpha-kinase 3 
ZBTB10 1.721 RINZF; FLJ12752 NM_023929 zinc finger and BTB domain containing 10 
LAMC3 1.72 DKFZp434E202 NM_006059 laminin, gamma 3 
TMEM50B 1.717 C21orf4; HCVP7TP3; DKFZp686C2482 NM_006134 transmembrane protein 50B 
ZC3H12B 1.717 CXorf32 NM_001010888 zinc finger CCCH-type containing 12B 
ABHD4 1.716 FLJ12816 NM_022060 abhydrolase domain containing 4 
LOC125893 1.713 LOC125893; MGC125619 NM_001031665 hypothetical protein LOC125893 
ZNF436 1.712 ZNF; KIAA1710 NM_030634 zinc finger protein 436 
C1ORF63 1.71 NPD014; DJ465N24.2.1; RP3-465N24.4 NM_020317 chromosome 1 open reading frame 63 
RFPL3 1.71 RFPL3 NM_006604 ret finger protein-like 3 
C9ORF40 1.709 FLJ10110; FLJ25795 NM_017998 chromosome 9 open reading frame 40 
DGCR8 1.705 Gy1; DGCRK6; C22orf12 NM_022720 DiGeorge syndrome critical region gene 8 
LMOD3 1.703 DKFZp313F0135 NM_198271 leiomodin 3 (fetal) 
FOXA2 1.703 HNF3B; TCF3B; MGC19807 NM_021784 forkhead box A2 
ZNF662 1.701 FLJ45880 NM_207404 zinc finger protein 662 
SLC22A15 1.699 FLIPT1; PRO34686; DKFZp761G0313 NM_018420 
solute carrier family 22 (organic cation 
transporter), member 15 
ALG14 1.699 MGC19780 NM_144988 
asparagine-linked glycosylation 14 homolog 
(yeast) 
LMBRD1 1.698 C6orf209; FLJ11240; bA810I22.1; RP11-810I22.1 NM_018368 LMBR1 domain containing 1 
HSD11B2 1.697 AME; AME1; HSD2; HSD11K NM_000196 hydroxysteroid (11-beta) dehydrogenase 2 
LOC399744 1.696 LOC399744 NM_001013665 hypothetical LOC399744 
NETO2 1.695 NEOT2; FLJ10430; FLJ14724; FLJ90456 NM_018092 neuropilin (NRP) and tolloid (TLL)-like 2 
ZNF235 1.694 HZF6; ZFP93; ANF270; ZNF270 NM_004234 zinc finger protein 235 
LIPG 1.686 EL; EDL; PRO719 NM_006033 lipase, endothelial 
SNAI1 1.685 SNA; SNAH; SLUGH2; dJ710H13.1 NM_005985 snail homolog 1 (Drosophila) 
FLJ13236 1.681 FLJ13236 NM_024902 hypothetical protein FLJ13236 
MED12 1.677 
HOPA; OPA1; CAGH45; TNRC11; TRAP230; 
KIAA0192 NM_005120 
mediator of RNA polymerase II transcription, 
subunit 12 homolog (S. cerevisiae) 
EFNA4 1.675 EFL4; EPLG4; LERK4; MGC125826 NM_005227 ephrin-A4 
PTPRD 1.675 
HPTP; PTPD; HPTPD; MGC119750; MGC119751; 
MGC119752; MGC119753; HPTP-DELTA; R-PTP-
DELTA NM_130391 protein tyrosine phosphatase, receptor type, D 
DDX17 1.674 P72; RH70; DKFZp761H2016 NM_030881 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
17 
SLC5A3 1.673 SMIT; SMIT2 NM_006933 
solute carrier family 5 (inositol transporters), 
member 3 
RBM33 1.672 KIAA1604 NM_001008408 RNA binding motif protein 33 
ZDHHC11 1.669 ZNF399; FLJ13153 NM_024786 zinc finger, DHHC-type containing 11 
MDM4 1.663 MDMX; MRP1; MGC132766; DKFZp781B1423 NM_002393 
Mdm4, transformed 3T3 cell double minute 4, 
p53 binding protein (mouse) 
CHD7 1.663 FLJ20357; FLJ20361; KIAA1416 NM_017780 
chromodomain helicase DNA binding protein 
7 
CDC42 1.662 G25K; CDC42Hs NM_044472 
cell division cycle 42 (GTP binding protein, 
25kDa) 
STK32A 1.661 YANK1; MGC22688 NM_145001 serine/threonine kinase 32A 
FLJ39827 1.657 FLJ39827; RP11-403E24.2 NM_152424 family with sequence similarity 123B 
MSMB 1.656 
MSP; PSP; IGBF; MSPB; PN44; PRPS; PSP57; 
PSP94; PSP-94 NM_002443 microseminoprotein, beta- 
FLJ38717 1.654 FLJ38717; FLJ40915 NM_001004322 FLJ38717 protein 
AFG3L1 1.653 AFG3; FLJ45200 NM_001031805 
AFG3 ATPase family gene 3-like 1 (S. 
cerevisiae) 
SH3BGRL2 1.651 FLJ90025 NM_031469 
SH3 domain binding glutamic acid-rich 
protein like 2 
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SLC25A24 1.65 APC1; SCAMC-1; DKFZp586G0123 NM_013386 
solute carrier family 25 (mitochondrial carrier; 
phosphate carrier), member 24 
AGXT2L1 1.65 GALC NM_031279 alanine-glyoxylate aminotransferase 2-like 1 
MCF2L2 1.649 FLJ42509; KIAA0861; DKFZp686K0690 NM_015078 
MCF.2 cell line derived transforming 
sequence-like 2 
MGC35048 1.647 FLJ20115; FLJ36575; MGC35048 NM_153208 IQ motif containing K 
ZFX 1.646 ZFX NM_003410 zinc finger protein, X-linked 
PFKFB3 1.645 PFK2; IPFK2 NM_004566 
6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 
C17ORF80 1.643 MIG3; HLC-8; FLJ20721 NM_017941 chromosome 17 open reading frame 80 
ANKFY1 1.641 
ANKHZN; ZFYVE14; KIAA1255; 
DKFZp686M19106 NM_020740 
ankyrin repeat and FYVE domain containing 
1 
ZNF446 1.633 ZSCAN30; FLJ20626 NM_017908 zinc finger protein 446 
ARHGEF11 1.631 GTRAP48; KIAA0380; PDZ-RHOGEF NM_014784 
Rho guanine nucleotide exchange factor 
(GEF) 11 
RFXAP 1.626 RFXAP NM_000538 regulatory factor X-associated protein 
EMB 1.625 MGC71745 NM_198449 embigin homolog (mouse) 
ST8SIA2 1.624 
STX; SIAT8B; HsT19690; MGC116854; 
MGC116857; ST8SIA-II NM_006011 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 2 
COL4A3BP 1.62 CERT; GPBP; CERTL; STARD11 NM_005713 
collagen, type IV, alpha 3 (Goodpasture 
antigen) binding protein 
GPR89A 1.615 GPR89; SH120 NM_016334 G protein-coupled receptor 89A 
C1ORF106 1.609 FLJ10901; MGC125608 NM_018265 chromosome 1 open reading frame 106 
CAMK2D 1.606 CAMKD; MGC44911 NM_001221 
calcium/calmodulin-dependent protein kinase 
(CaM kinase) II delta 
DKFZP547C195 1.603 DKFZp547C195 NM_207343 hypothetical protein DKFZp547C195 
DKFZP781I1119 1.6 
FLJ35954; DKFZP781I1119; DKFZp781G1119; 
DKFZp781I1119; DKFZp686L09111 NM_152622 
mesoderm induction early response 1, family 
member 3 
VIPR1 1.598 
II; HVR1; RDC1; VIPR; VIRG; VAPC1; VPAC1; 
PACAP-R-2 NM_004624 vasoactive intestinal peptide receptor 1 
ICA1 1.598   NM_022308   
SEMA6D 1.593 FLJ11598; KIAA1479 NM_024966 
sema domain, transmembrane domain (TM), 
and cytoplasmic domain, (semaphorin) 6D 
OCLN 1.592 OCLN NM_002538 occludin 
ATP1B1 1.59 ATP1B; MGC1798 NM_001677 
ATPase, Na+/K+ transporting, beta 1 
polypeptide 
PIP5K2B 1.586 Pip4k2B; PIP5KIIB NM_138687 
phosphatidylinositol-4-phosphate 5-kinase, 
type II, beta 
FUT8 1.585 MGC26465 NM_178154 
fucosyltransferase 8 (alpha (1,6) 
fucosyltransferase) 
NBLA04196 1.585 
C7orf12; FLJ21213; FLJ21879; FLJ41901; 
NBLA04196 NM_022900 CAS1 domain containing 1 
GGT2 1.583 GGT NM_002058 gamma-glutamyltransferase 2 
ETV3 1.58 PE1; METS; PE-1; bA110J1.4 NM_005240 ets variant gene 3 
GTPBP3 1.578 MSS1; MTGP1; THDF1; GTPBG3; FLJ14700 NM_133644 GTP binding protein 3 (mitochondrial) 
HOOK3 1.577 HK3 NM_032410 hook homolog 3 (Drosophila) 
PARP6 1.573   NM_020213   
MGC21830 1.569 MGC21830 NM_182563 chromosome 16 open reading frame 79 
C17ORF55 1.563 FLJ39421; MGC120553; MGC120556 NM_178519 chromosome 17 open reading frame 55 
GPHN 1.563 GPH; GEPH; GPHRYN; KIAA1385 NM_020806 gephyrin 
FLJ10815 1.562 FLJ10815; FLJ12724 NM_018231 amino acid transporter 
LBR 1.558 PHA; LMN2R; DHCR14B; MGC9041 NM_002296 lamin B receptor 
IQCA 1.557 FLJ22527; 4930465P12Rik NM_024726 IQ motif containing with AAA domain 
DBN1 1.557 D0S117E; DKFZp434D064 NM_004395 drebrin 1 
KIAA1618 1.557 SPAG16 NM_020954 KIAA1618 
LOC349338 1.555 FLJ00038 NM_182905 CXYorf1-related protein 
WAC 1.551 Wwp4; BM-016; PRO1741; MGC10753; bA48B24.1 NM_100264 
WW domain containing adaptor with coiled-
coil 
ZNF343 1.547 FLJ39592; MGC10715; MGC20504; dJ734P14.5 NM_024325 zinc finger protein 343 
SOAT1 1.547 
ACAT; SOAT; STAT; ACACT; ACAT1; RP11-
215I23.2 NM_003101 
sterol O-acyltransferase (acyl-Coenzyme A: 
cholesterol acyltransferase) 1 
TFF1 1.544 pS2; BCEI; HPS2; HP1.A; pNR-2; D21S21 NM_003225 
trefoil factor 1 (breast cancer, estrogen-
inducible sequence expressed in) 
ZNF33A 1.543 
KOX2; KOX5; KOX31; ZNF11; ZNF33; ZZAPK; 
ZNF11A; FLJ23404; KIAA0065 NM_006974 zinc finger protein 33A 
EFNA4 1.539 EFL4; EPLG4; LERK4; MGC125826 NM_182690 ephrin-A4 
LRCH3 1.537 MGC4126 NM_032773 
leucine-rich repeats and calponin homology 
(CH) domain containing 3 
SLC30A1 1.53 ZNT1; ZRC1 NM_021194 
solute carrier family 30 (zinc transporter), 
member 1 
ATP2B1 1.529 PMCA1 NM_001001323 
ATPase, Ca++ transporting, plasma 
membrane 1 
RBM8A 1.529 
Y14; RBM8; ZNRP; RBM8B; ZRNP1; BOV-1A; 
BOV-1B; BOV-1C; MDS014 NM_005105 RNA binding motif protein 8A 
LOC440925 1.528 LOC440925 NM_001013712 hypothetical gene supported by AK123485 
HSA277841 1.524 ELG; HSA277841 NM_018553 chromosome 17 open reading frame 85 
ZNF548 1.523 FLJ32932 NM_152909 zinc finger protein 548 
PLEKHO1 1.522 OC120; CKIP-1; RP11-458I7.3 NM_016274 
pleckstrin homology domain containing, 
family O member 1 
MSX2 1.521 FPP; MSH; PFM; CRS2; HOX8; PFM1 NM_002449 msh homeobox homolog 2 (Drosophila) 
CTGLF1 1.521 MRIP2; CTGLF5 NM_133446 centaurin, gamma-like family, member 1 
RGS8 1.519 MGC119067; MGC119068; MGC119069 NM_033345 regulator of G-protein signalling 8 
MAP2K4 1.519 
JNKK; MEK4; MKK4; SEK1; JNKK1; SERK1; 
MAPKK4; PRKMK4 NM_003010 mitogen-activated protein kinase kinase 4 
PDLIM5 1.513 L9; ENH; LIM NM_006457 PDZ and LIM domain 5 
ASAM 1.509 ASAM; ACAM; CLMP; FLJ22415 NM_024769 adipocyte-specific adhesion molecule 
SMARCE1 1.507 BAF57 NM_003079 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
e, member 1 
C21ORF66 1.505 GCFC; BM-020; FLJ90561 NM_016631 chromosome 21 open reading frame 66 
WBSCR18 1.505 MGC12943 NM_032317 
Williams Beuren syndrome chromosome 
region 18 
PCDHA12 1.502 MGC138485; MGC141932; PCDH-ALPHA12 NM_031864 protocadherin alpha 12 
ING3 1.5 Eaf4; ING2; p47ING3; FLJ20089 NM_198267 inhibitor of growth family, member 3 
TRIM6 1.5 RNF89 NM_058166 tripartite motif-containing 6 
FGF13 1.494 FGF2; FHF2 NM_033642 fibroblast growth factor 13 
 205
CYP4X1 1.494 MGC40051 NM_178033 
cytochrome P450, family 4, subfamily X, 
polypeptide 1 
ZNF660 1.49 FLJ36870 NM_173658 zinc finger protein 660 
AACS 1.488 SUR-5; FLJ12389; FLJ41251 NM_023928 acetoacetyl-CoA synthetase 
SLC25A34 1.483 RP11-169K16.2; DKFZp781A10161 NM_207348 solute carrier family 25, member 34 
ARMC8 1.483 S863-2; HSPC056; MGC4880; MGC10058 NM_015396 armadillo repeat containing 8 
BIRC2 1.482 API1; MIHB; HIAP2; RNF48; cIAP1; Hiap-2 NM_001166 baculoviral IAP repeat-containing 2 
YTHDC1 1.48 YT521; YT521-B; KIAA1966 NM_133370 YTH domain containing 1 
PLAC8 1.48 C15; onzin NM_016619 placenta-specific 8 
BRD2 1.476 
NAT; RNF3; FSRG1; RING3; D6S113E; FLJ31942; 
KIAA9001; DKFZp686N0336 NM_005104 bromodomain containing 2 
OLR1 1.474 LOX1; CLEC8A; SCARE1 NM_002543 
oxidised low density lipoprotein (lectin-like) 
receptor 1 
STAT4 1.473 STAT4 NM_003151 
signal transducer and activator of transcription 
4 
CCDC45 1.47 DKFZp667E1824 NM_138363 coiled-coil domain containing 45 
HSD17B7 1.467 PRAP; MGC12523; MGC75018 NM_016371 hydroxysteroid (17-beta) dehydrogenase 7 
PDZRN3 1.465 LNX3; SEMACAP3 NM_015009 PDZ domain containing RING finger 3 
CSNK1G1 1.465 FIBP NM_022048 casein kinase 1, gamma 1 
CNR1 1.465 CB1; CNR; CB-R; CB1A; CANN6; CB1K5 NM_016083 cannabinoid receptor 1 (brain) 
PARD3 1.463 
ASIP; PAR3; SE2-5T2; FLJ21015; SE2-5L16; SE2-
5LT1; PAR3alpha NM_019619 
par-3 partitioning defective 3 homolog (C. 
elegans) 
AHR 1.459 AHR NM_001621 aryl hydrocarbon receptor 
MFSD7 1.457 LP2561; FLJ22269 NM_032219 
major facilitator superfamily domain 
containing 7 
MAX 1.45 
orf1; MGC10775; MGC11225; MGC18164; 
MGC34679; MGC36767 NM_197957 MYC associated factor X 
NPY1R 1.45 NPYR NM_000909 neuropeptide Y receptor Y1 
GUCY2D 1.449 
LCA; CYGD; LCA1; CORD5; CORD6; GUC2D; 
retGC; GUC1A4; RETGC-1; ROS-GC1 NM_000180 
guanylate cyclase 2D, membrane (retina-
specific) 
CYP20A1 1.447 CYP-M; MGC22229 NM_177538 
cytochrome P450, family 20, subfamily A, 
polypeptide 1 
FLJ40113 1.446 FLJ40113; FLJ35171 NM_198079 golgi autoantigen, golgin subfamily a-like 
RICS 1.445 
RICS; GRIT; GC-GAP; MGC1892; p250GAP; 
KIAA0712; p200RhoGAP NM_014715 Rho GTPase-activating protein 
ZNF480 1.434 MGC32104 NM_144684 zinc finger protein 480 
ZNF223 1.434 ZNF223 NM_013361 zinc finger protein 223 
ZNF740 1.431 Zfp740; MGC61706 NM_001004304 zinc finger protein 740 
LAMP3 1.427 LAMP; CD208; DCLAMP; TSC403; DC-LAMP NM_014398 lysosomal-associated membrane protein 3 
RABL2A 1.427 MGC117180 NM_013412 
RAB, member of RAS oncogene family-like 
2A 
GNL3 1.423 NS; E2IG3; C77032; MGC800 NM_206825 
guanine nucleotide binding protein-like 3 
(nucleolar) 
MLR2 1.422 MLR2; FLJ38026; KIAA1795; RP11-175O19.1 NM_032440 ligand dependent nuclear receptor corepressor 
RNF19 1.417 DORFIN; DKFZp566B1346 NM_015435 ring finger protein 19 
FLJ34443 1.417 FLJ34443 NM_175918 cysteine-rich PAK1 inhibitor 
PIP5K2B 1.417 Pip4k2B; PIP5KIIB NM_138687 
phosphatidylinositol-4-phosphate 5-kinase, 
type II, beta 
FRAS1 1.415   NM_206841   
NSUN3 1.412 MST077; MSTP077; FLJ22109; FLJ22609 NM_022072 NOL1/NOP2/Sun domain family, member 3 
TBC1D2 1.41 
PARIS1; PARIS-1; TBC1D2A; FLJ10702; 
FLJ16244; FLJ42782; DKFZp761D1823 NM_018421 TBC1 domain family, member 2 
PHF21B 1.41 PHF4; BHC80L; FLJ34161 NM_138415 PHD finger protein 21B 
FLJ13946 1.407 FLJ13946 NM_152275 tetratricopeptide repeat domain 30A 
DMD 1.406 
BMD; CMD3B; DXS142; DXS164; DXS206; 
DXS230; DXS239; DXS268; DXS269; DXS270; 
DXS272 NM_004019 
dystrophin (muscular dystrophy, Duchenne 
and Becker types) 
RIPK1 1.403 RIP; FLJ39204 NM_003804 
receptor (TNFRSF)-interacting serine-
threonine kinase 1 
TAF9L 1.398 DN7; DN-7; TAF9L; TAFII31L; TFIID-31 NM_015975 
TAF9B RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
31kDa 
SLC29A2 1.396 ENT2; DER12; HNP36 NM_001532 
solute carrier family 29 (nucleoside 
transporters), member 2 
TTC10 1.39 
TG737; TTC10; hTg737; MGC26259; D13S1056E; 
RP11-172H24.2 NM_175605 
intraflagellar transport 88 homolog 
(Chlamydomonas) 
ZNF579 1.388 FLJ35453 NM_152600 zinc finger protein 579 
CXORF1 1.388 MGC142160; MGC142164 NM_004709 chromosome X open reading frame 1 
TDRD1 1.38 FLJ21082 NM_198795 tudor domain containing 1 
PDIA2 1.378 PDI; PDA2; PDIP; PDIR NM_006849 
protein disulfide isomerase family A, member 
2 
EGLN2 1.369 EIT6; PHD1; HIFPH1; DKFZp434E026 NM_080732 egl nine homolog 2 (C. elegans) 
ZNF311 1.368 zf31 NM_001010877 zinc finger protein 311 
ZNF184 1.368 ZNF184 NM_007149 zinc finger protein 184 
TUBB4Q 1.364 TUBB4Q NM_020040 tubulin, beta polypeptide 4, member Q 
ZNF690 1.362 
Zfp690; ZSCAN29; FLJ35867; MGC129894; 
MGC129895 NM_152455 zinc finger protein 690 
MYRIP 1.362 
SLAC2C; SLAC2-C; FLJ44025; MGC130034; 
MGC130035; DKFZp586F1018 NM_015460 myosin VIIA and Rab interacting protein 
LANCL2 1.361 TASP; GPR69B; MGC87139 NM_018697 
LanC lantibiotic synthetase component C-like 
2 (bacterial) 
FLJ30990 1.359 FLJ30990 NM_152517 tetratricopeptide repeat domain 30B 
PBX2 1.354 G17; HOX12; PBX2MHC NM_002586 pre-B-cell leukemia transcription factor 2 
PLEKHA6 1.35 PEPP3; KIAA0969 NM_014935 
pleckstrin homology domain containing, 
family A member 6 
DDX26 1.345 
HDB; INT6; DBI-1; DDX26; DICE1; DDX26A; 
Notchl2; DKFZP434B105 NM_012141 integrator complex subunit 6 
DKFZP564K142 1.343 
DKFZp564K142; PRO0756; FLJ14726; MGC64926; 
bA217H1.1; RP11-217H1.1 NM_032121 implantation-associated protein 
PIP5K2C 1.341 FLJ22055 NM_024779 
phosphatidylinositol-4-phosphate 5-kinase, 
type II, gamma 
KCNV1 1.339 HNKA; KCNB3; KV2.3; KV8.1 NM_014379 potassium channel, subfamily V, member 1 
FLJ36874 1.33 FLJ36874; MGC125671; MGC125672 NM_152716 FLJ36874 protein 
PMFBP1 1.328 FLJ40146; DKFZP434G131 NM_031293 
polyamine modulated factor 1 binding protein 
1 
ADAR 1.326 DSH; G1P1; IFI4; p136; ADAR1; DRADA; NM_001025107 adenosine deaminase, RNA-specific 
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DSRAD; IFI-4; K88dsRBP 
NR6A1 1.325 RTR; GCNF; NR61; GCNF1 NM_033334 
nuclear receptor subfamily 6, group A, 
member 1 
STK31 1.317 TDRD8; FLJ16102 NM_031414 serine/threonine kinase 31 
MLSTD1 1.317 FAR2; FLJ10462 NM_018099 male sterility domain containing 1 
ZNF45 1.312 KOX5; ZNF13 NM_003425 zinc finger protein 45 
RHBDD3 1.31 PTAG; C22orf3; HS984G1A NM_012265 rhomboid domain containing 3 
CEP350 1.31 gm133; CAP350; FLJ38282; FLJ44058; KIAA0480 NM_014810 centrosomal protein 350kDa 
RBM9 1.309 RTA; HRNBP2 NM_014309 RNA binding motif protein 9 
ZNF79 1.308 pT7 NM_007135 zinc finger protein 79 
CD200 1.307 MRC; MOX1; MOX2; OX-2 NM_001004196 CD200 molecule 
NFASC 1.303   NM_001005389   
BARX1 1.3 BARX1 NM_021570 BarH-like homeobox 1 
FNBP1L 1.299 TOCA1; C1orf39 NM_001024948 formin binding protein 1-like 
PGBD1 1.298 SCAND4; HUCEP-4; dJ874C20.4 NM_032507 piggyBac transposable element derived 1 
POGZ 1.298 SUHW5; ZNF635; KIAA0461; MGC71543 NM_145796 pogo transposable element with ZNF domain 
TGIF2 1.294 TGIF2 NM_021809 
TGFB-induced factor 2 (TALE family 
homeobox) 
ZNF670 1.287 FLJ12606; MGC12466 NM_033213 zinc finger protein 670 
FLJ40504 1.284 FLJ40504; MGC138231; MGC138233 NM_173624 hypothetical protein FLJ40504 
BTAF1 1.283 
MOT1; TAF172; KIAA0940; TAFII170; 
MGC138406; TAF(II)170 NM_003972 
BTAF1 RNA polymerase II, B-TFIID 
transcription factor-associated, 170kDa (Mot1 
homolog, S. cerevisiae) 
ATP11A 1.283 ATPIH; ATPIS NM_015205 ATPase, Class VI, type 11A 
IIP45 1.282 IIP45; FLJ12438; FLJ38609 NM_001025374 invasion inhibitory protein 45 
ZNF345 1.281 HZF10 NM_003419 zinc finger protein 345 
CHMP6 1.28 VPS20; FLJ11749 NM_024591 chromatin modifying protein 6 
TIAM1 1.279 DTNA NM_003253 T-cell lymphoma invasion and metastasis 1 
GOLGA8A 1.273 GM88 NM_181077 golgi autoantigen, golgin subfamily a, 8A 
ABCC3 1.271   NM_020038   
CDAN1 1.266 CDA1; CDAI; CDA-I; PRO1295; codanin NM_138477 congenital dyserythropoietic anemia, type I 
USF2 1.265 FIP NM_003367 
upstream transcription factor 2, c-fos 
interacting 
CC2D1B 1.264 KIAA1836; RP11-155O18.2 NM_032449 coiled-coil and C2 domain containing 1B 
GPR111 1.264 PGR20; hGPCR35 NM_153839 G protein-coupled receptor 111 
LOC149134 1.264 
LOC149134; MGC120210; MGC120211; 
MGC120212; MGC120213 NM_207326 hypothetical protein LOC149134 
ZNF137 1.259 pHZ-30; MGC119990; MGC119991 NM_003438 zinc finger protein 137 
ZFP95 1.257 FLJ39233; KIAA1015; MGC33710 NM_014569 zinc finger protein 95 homolog (mouse) 
RANBP6 1.256 FREM2 NM_012416 RAN binding protein 6 
ZDHHC13 1.252 HIP14L; HIP3RP; FLJ10852; FLJ10941; MGC64994 NM_019028 zinc finger, DHHC-type containing 13 
HYAL4 1.252 HYAL4 NM_012269 hyaluronoglucosaminidase 4 
LHB 1.251 CGB4; hLHB; LSH-B NM_000894 luteinizing hormone beta polypeptide 
EPIM 1.25 EPM; EPIM; STX2A; STX2B; STX2C; MGC51014 NM_194356 syntaxin 2 
PCDHA10 1.24 CNR8; CNRN8; CNRS8; CRNR8; PCDH-ALPHA10 NM_031859 protocadherin alpha 10 
FLJ35801 1.238 FLJ35801 NM_153044 chromosome 22 open reading frame 27 
ZNF510 1.238 KIAA0972; MGC33740 NM_014930 zinc finger protein 510 
BRD9 1.236 PRO9856; LAVS3040; DKFZp686L0539 NM_023924 bromodomain containing 9 
DHX57 1.235   NM_144995   
AADAT 1.234 KAT2; KATII NM_016228 aminoadipate aminotransferase 
GAD1 1.232 GAD NM_013445 glutamate decarboxylase 1 (brain, 67kDa) 
ZNF306 1.23 
ZF47; Zfp47; ZFP306; ZSCAN13; FLJ33906; 
KIAA0426 NM_024493 zinc finger protein 306 
SON 1.228 
SON3; BASS1; DBP-5; NREBP; C21orf50; 
FLJ21099; FLJ33914; KIAA1019 NM_032195 SON DNA binding protein 
ZNF140 1.228 pHZ-39 NM_003440 zinc finger protein 140 
ZNF582 1.227 FLJ30927 NM_144690 zinc finger protein 582 
FLJ39653 1.224 FLJ39653 NM_152684 hypothetical protein FLJ39653 
ZNF473 1.221 ZN473; HZFP100 NM_015428 zinc finger protein 473 
MLH3 1.22 HNPCC7; MGC138372 NM_014381 mutL homolog 3 (E. coli) 
KCNAB1 1.218 
hKvb3; AKR6A3; KCNA1B; Kvb1.3; hKvBeta3; 
KV-BETA-1 NM_003471 
potassium voltage-gated channel, shaker-
related subfamily, beta member 1 
NXF5 1.217 NXF5 NM_033155 nuclear RNA export factor 5 
JUB 1.215 Ajuba; MGC15563 NM_032876 jub, ajuba homolog (Xenopus laevis) 
MGC24975 1.212 MGC24975 NM_153359 hypothetical protein MGC24975 
GAD1 1.205 GAD NM_013445 glutamate decarboxylase 1 (brain, 67kDa) 
PNMA6A 1.204 MGC15827 NM_032882 paraneoplastic antigen like 6A 
DUSP10 1.201 MKP5; MKP-5 NM_144728 dual specificity phosphatase 10 
MDC1 1.197 NFBD1; KIAA0170; DKFZp781A0122 NM_014641 mediator of DNA damage checkpoint 1 
DNMT3A 1.188 DNMT3A2; M.HsaIIIA NM_153759 DNA (cytosine-5-)-methyltransferase 3 alpha 
LPP 1.185 LPP NM_005578 
LIM domain containing preferred 
translocation partner in lipoma 
MAOA 1.183 MAOA NM_000240 monoamine oxidase A 
MVK 1.178 LRBP; MVLK NM_000431 mevalonate kinase (mevalonic aciduria) 
ASB7 1.176 FLJ22551 NM_024708 ankyrin repeat and SOCS box-containing 7 
RAPGEF6 1.172 
PDZGEF2; KIA001LB; PDZ-GEF2; RA-GEF-2; 
DKFZp686I15116 NM_016340 
Rap guanine nucleotide exchange factor 
(GEF) 6 
SLC13A3 1.17 NADC3; SDCT2 NM_022829 
solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 
ADAMTS7 1.168 ADAM-TS7; DKFZp434H204 NM_014272 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 7 
PRPF4B 1.167 
PR4H; PRP4; PRP4H; PRP4K; KIAA0536; 
dJ1013A10.1 NM_003913 
PRP4 pre-mRNA processing factor 4 homolog 
B (yeast) 
SHPRH 1.166 
FLJ37625; FLJ45012; FLJ90837; KIAA2023; 
MGC134886; bA545I5.2 NM_173082 SNF2 histone linker PHD RING helicase 
DPY19L3 1.165 DKFZp686J17135 NM_207325 dpy-19-like 3 (C. elegans) 
TRPV6 1.161 
CAT1; CATL; ZFAB; ECAC2; ABP/ZF; LP6728; 
HSA277909 NM_018646 
transient receptor potential cation channel, 
subfamily V, member 6 
UBE2J2 1.16   NM_194316   
C14ORF49 1.159 FLJ25605; c14_5734 NM_152592 chromosome 14 open reading frame 49 
PARP8 1.158 FLJ21308; MGC42864 NM_024615 
poly (ADP-ribose) polymerase family, 
member 8 
RAB12 1.157 FLJ45927; MGC104724 NM_001025300 RAB12, member RAS oncogene family 
RECQL5 1.155 RECQ5; FLJ90603 NM_004259 RecQ protein-like 5 
CASC5 1.153 D40; AF15Q14; KIAA1570 NM_170589 cancer susceptibility candidate 5 
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FLJ45445 1.15 FLJ45445 NM_001004321 FLJ45445 protein 
ZNF285 1.148 FLJ30747 NM_152354 zinc finger protein 285 
PTEN 1.141 BZS; MHAM; TEP1; MMAC1; PTEN1; MGC11227 NM_000314 
phosphatase and tensin homolog (mutated in 
multiple advanced cancers 1) 
CLEC9A 1.141 UNQ9341 NM_207345 C-type lectin domain family 9, member A 
PMS2L3 1.141 PMS5; PMSR3; PMS2L9; MGC126647 NM_001003686 postmeiotic segregation increased 2-like 3 
FLJ23322 1.138 FLJ23322; FLJ33734 NM_024955 
FAD-dependent oxidoreductase domain 
containing 2 
MSH5 1.132 G7; NG23; MutSH5; MGC2939; DKFZp434C1615 NM_002441 mutS homolog 5 (E. coli) 
ZNF96 1.129   NM_014724   
FLJ46688 1.122 FLJ46688 NM_001004330 FLJ46688 protein 
TMED8 1.105 FAM15B; MGC126559 NM_213601 
transmembrane emp24 protein transport 
domain containing 8 
ZNF74 1.101 Cos52; ZNF520; Zfp520 NM_003426 zinc finger protein 74 
LOC388692 1.087 LOC388692 NM_001013644 hypothetical gene supported by AK123662 
ZNF20 1.085 KOX13; FLJ39241 NM_021143 zinc finger protein 20 
ANKRD5 1.08 FLJ21669; dJ839B4.6 NM_022096 ankyrin repeat domain 5 
SMARCC2 1.07 Rsc8; BAF170; CRACC2 NM_003075 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
c, member 2 
SLC35C2 1.069 
CGI-15; OVCOV1; C20orf5; FLJ37039; 
MGC20633; MGC32079; MGC39183; BA394O2.1 NM_173179 solute carrier family 35, member C2 
PCDHA3 1.057 PCDH-ALPHA3 NM_031497 protocadherin alpha 3 
FGFBP1 1.056 FGFBP; HBP17 NM_005130 fibroblast growth factor binding protein 1 
FABP2 1.052 FABPI; I-FABP; MGC133132 NM_000134 fatty acid binding protein 2, intestinal 
GIPC1 0.944 
NIP; GIPC; IIP-1; TIP-2; SEMCAP; C19orf3; 
Hs.6454; MGC3774; GLUT1CBP; MGC15889; 
RGS19IP1; SYNECTIIN NM_202468 
GIPC PDZ domain containing family, 
member 1 
KIAA1005 0.922 KIAA1005; DKFZp686C0668 NM_015272 KIAA1005 protein 
HOXB2 0.916 K8; HOX2; HOX2H; Hox-2.8 NM_002145 homeobox B2 
ANK1 0.915 ANK; SPH1; SPH2 NM_020480 ankyrin 1, erythrocytic 
ZCCHC5 0.902 Mar3; ZHC5; Mart3; FLJ38865 NM_152694 zinc finger, CCHC domain containing 5 
DGKI 0.897 DGK-IOTA NM_004717 diacylglycerol kinase, iota 
NPTXR 0.89 NPTXR NM_058178 Neuronal pentraxin receptor 
ATG12 0.889 APG12; APG12L; HAPG12 NM_004707 
ATG12 autophagy related 12 homolog (S. 
cerevisiae) 
GABRB3 0.888 MGC9051 NM_000814 
gamma-aminobutyric acid (GABA) A 
receptor, beta 3 
LSS 0.885 OSC NM_001001438 
lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
TEKT3 0.872 LRRC23 NM_031898 tektin 3 
STXBP1 0.861 UNC18; hUNC18; rbSec1; MUNC18-1 NM_003165 syntaxin binding protein 1 
ZFHX2 0.861 KIAA1762 NM_033400 zinc finger homeobox 2 
CPSF3L 0.856 
RC68; INT11; RC-68; INTS11; CPSF73L; 
FLJ13294; FLJ20542 NM_032179 
cleavage and polyadenylation specific factor 
3-like 
NRGN 0.854 RC3; hng NM_006176 neurogranin (protein kinase C substrate, RC3) 
ZNF706 0.85 HSPC038; PNAS-106; PNAS-113 NM_016096 zinc finger protein 706 
TINAGL1 0.849 ARG1; LCN7; LIECG3; TINAGRP NM_022164 tubulointerstitial nephritis antigen-like 1 
NR2F1 0.844 
EAR3; EAR-3; NR2F2; SVP44; ERBAL3; 
TFCOUP1; COUP-TFI; TCFCOUP1 NM_005654 
nuclear receptor subfamily 2, group F, 
member 1 
OGDH 0.841 E1k; OGDC; AKGDH NM_001003941 
oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) 
MRE11A 0.836 ATLD; HNGS1; MRE11; MRE11B NM_005590 
MRE11 meiotic recombination 11 homolog A 
(S. cerevisiae) 
BIRC5 0.835 API4; EPR-1 NM_001012271 baculoviral IAP repeat-containing 5 (survivin) 
WDR76 0.834 FLJ12973 NM_024908 WD repeat domain 76 
SHD 0.829 MAP2 NM_020209 
Src homology 2 domain containing 
transforming protein D 
BOLA1 0.828 CGI-143; MGC75015; RP11-196G18.18 NM_016074 bolA-like 1 (E. coli) 
ZNRF2 0.827 RNF202 NM_147128 zinc and ring finger 2 
BTD 0.827 BTD NM_000060 biotinidase 
PXK 0.824 MONaKA; FLJ20335 NM_017771 PX domain containing serine/threonine kinase 
SPESP1 0.824 SP-ESP; MGC24663 NM_145658 sperm equatorial segment protein 1 
TIE1 0.821 TIE; JTK14 NM_005424 
tyrosine kinase with immunoglobulin-like and 
EGF-like domains 1 
FLJ33167 0.817 FLJ33167 NM_152683 coiled-coil domain containing 111 
EZH2 0.816 EZH1; ENX-1; MGC9169 NM_004456 enhancer of zeste homolog 2 (Drosophila) 
LYPD5 0.814 PRO4356; FLJ30469 NM_001031749 LY6/PLAUR domain containing 5 
PIGZ 0.811 SMP3; FLJ12768; MGC52163 NM_025163 
phosphatidylinositol glycan anchor 
biosynthesis, class Z 
SUHW4 0.81 ZNF634; MGC21637; MGC61687 NM_001002844 
suppressor of hairy wing homolog 4 
(Drosophila) 
MPG 0.806 
AAG; MDG; APNG; Mid1; anpg; PIG11; PIG16; 
CRA36.1 NM_001015054 N-methylpurine-DNA glycosylase 
CTSF 0.802 CATSF NM_003793 cathepsin F 
DKFZP686K16132 0.801 DKFZp686K16132 NM_001012987 similar to BMP2 inducible kinase 
UEV3 0.8 ATTP; UEV3; FLJ11068 NM_018314 
UEV and lactate/malate dehyrogenase 
domains 
MUC1 0.8 EMA; PEM; PUM; MAM6; PEMT; CD227; H23AG NM_001018021 mucin 1, cell surface associated 
THAP10 0.8 THAP10 NM_020147 THAP domain containing 10 
SCYL1 0.796 
GKLP; NKTL; NTKL; P105; TAPK; TEIF; TRAP; 
HT019 NM_020680 SCY1-like 1 (S. cerevisiae) 
LOC88523 0.796 LOC88523 NM_033111 CG016 
GCK 0.795 GK; GLK; HK4; HHF3; HKIV; HXKP; MODY2 NM_033508 
glucokinase (hexokinase 4, maturity onset 
diabetes of the young 2) 
EPB41L1 0.794 4.1N; KIAA0338; MGC11072; DKFZp686H17242 NM_012156 erythrocyte membrane protein band 4.1-like 1 
C6ORF204 0.791 
NY-BR-15; MGC131785; bA57K17.2; RP11-
57K17.2 NM_206921 chromosome 6 open reading frame 204 
WDR70 0.791 FLJ10233 NM_018034 WD repeat domain 70 
WHSC1 0.791 
WHS; NSD2; TRX5; MMSET; REIIBP; FLJ23286; 
KIAA1090 NM_133331 Wolf-Hirschhorn syndrome candidate 1 
WFDC1 0.784 PS20 NM_021197 WAP four-disulfide core domain 1 
SEMA4F 0.783 
SEMAM; SEMAW; M-SEMA; PRO2353; m-Sema 
M; m-Sema-M NM_004263 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4F 
SMOX 0.783   NM_019025   
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LRRC3B 0.78 LRP15; MGC102927 NM_052953 leucine rich repeat containing 3B 
LOC92691 0.78 FLJ34263; DKFZp781L2456 NM_138390 transmembrane protein 169 
GPR175 0.779 TPRA40; FLJ32197 NM_016372 G protein-coupled receptor 175 
PCDH11Y 0.779 PCDHY; PCDH22; PCDH11X NM_032971 protocadherin 11 Y-linked 
PTER 0.778 RPR-1 NM_030664 phosphotriesterase related 
FSD1 0.777 MIR1; GLFND; MGC3213 NM_024333 
fibronectin type III and SPRY domain 
containing 1 
GRTP1 0.776 TBC1D6; FLJ22474; MGC138328; MGC138330 NM_024719 growth hormone regulated TBC protein 1 
KIAA1244 0.772 RP3-422G23.4 NM_020340 KIAA1244 
GBP2 0.771 PRDM2 NM_004120 
guanylate binding protein 2, interferon-
inducible 
KLHDC1 0.769 MST025; MGC126644; MGC126646 NM_172193 kelch domain containing 1 
KIF17 0.769 KIF3X; KIF17B; KIAA1405 NM_020816 kinesin family member 17 
TNFRSF10B 0.767 
DR5; CD262; KILLER; TRICK2; TRICKB; 
ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-
R2; KILLER/DR5 NM_003842 
tumor necrosis factor receptor superfamily, 
member 10b 
DOPEY2 0.767 C21orf5 NM_005128 dopey family member 2 
TNFAIP8L3 0.767 FLJ41287 NM_207381 
tumor necrosis factor, alpha-induced protein 
8-like 3 
TGM2 0.765 TG2; TGC NM_198951 
transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
ABCC2 0.763 DJS; MRP2; cMRP; ABC30; CMOAT; KIAA1010 NM_000392 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 2 
TRIM3 0.763 BERP; HAC1; RNF22; RNF97 NM_006458 tripartite motif-containing 3 
PLK3 0.762 CNK; FNK; PRK NM_004073 polo-like kinase 3 (Drosophila) 
ATPBD1C 0.761 MGC14560; MGC32810 NM_016301 ATP binding domain 1 family, member C 
IL19 0.76 MDA1; NG.1; ZMDA1; IL-10C NM_153758 interleukin 19 
GTF2H2 0.758 BTF2; TFIIH; BTF2P44; MGC102806; T-BTF2P44 NM_001515 
general transcription factor IIH, polypeptide 2, 
44kDa 
PDCD6IP 0.756 AIP1; Alix; HP95; DRIP4; MGC17003 NM_013374 programmed cell death 6 interacting protein 
MFAP5 0.756 MP25; MAGP2 NM_003480 microfibrillar associated protein 5 
FAM14A 0.754 TLH29; MGC44913 NM_032036 family with sequence similarity 14, member A 
C10ORF72 0.754 FLJ31737; MGC44086 NM_001031746 chromosome 10 open reading frame 72 
QTRTD1 0.754 FLJ12960 NM_024638 
queuine tRNA-ribosyltransferase domain 
containing 1 
ADAMTSL1 0.753 ADAMTSR1; MGC40193 NM_139238 ADAMTS-like 1 
ARL4 0.753 ARL4 NM_005738 ADP-ribosylation factor-like 4A 
C2ORF11 0.75 FLJ30574; MGC117313 NM_144629 chromosome 2 open reading frame 11 
NGB 0.75 NGB NM_021257 neuroglobin 
CCDC51 0.749 FLJ12436 NM_024661 coiled-coil domain containing 51 
ANXA4 0.748 ANX4; PIG28; MGC75105; DKFZp686H02120 NM_001153 annexin A4 
ADCY4 0.748 ADCY4 NM_139247 adenylate cyclase 4 
GNB1L 0.746 
GY2; FKSG1; WDR14; WDVCF; DGCRK3; 
KIAA1645 NM_053004 
guanine nucleotide binding protein (G 
protein), beta polypeptide 1-like 
C9ORF72 0.745 MGC23980; RP11-27J8.2 NM_145005 chromosome 9 open reading frame 72 
AK5 0.745 AK6; MGC33326 NM_012093 adenylate kinase 5 
INHBB 0.745 INHBB NM_002193 inhibin, beta B (activin AB beta polypeptide) 
POLD4 0.745 p12; POLDS NM_021173 polymerase (DNA-directed), delta 4 
ARSJ 0.744 FLJ23548 NM_024590 arylsulfatase family, member J 
SLC25A16 0.743 
GDA; GDC; ML7; hML7; HGT.1; D10S105E; 
MGC39851 NM_152707 
solute carrier family 25 (mitochondrial carrier; 
Graves disease autoantigen), member 16 
CYLD 0.743 
EAC; CDMT; CYLD1; CYLDI; USPL2; HSPC057; 
FLJ20180; FLJ31664; KIAA0849 NM_015247 cylindromatosis (turban tumor syndrome) 
PEX6 0.741 PAF2; PAF-2; PXAAA1 NM_000287 peroxisomal biogenesis factor 6 
C1QTNF5 0.74 LORD; CTRP5; DKFZp586B0621 NM_015645 
C1q and tumor necrosis factor related protein 
5 
ITPKA 0.74 ITPKA NM_002220 inositol 1,4,5-trisphosphate 3-kinase A 
ASPH 0.738 BAH; HAAH; JCTN; junctin; CASQ2BP1 NM_004318 aspartate beta-hydroxylase 
NME1-NME2 0.737 NME1-NME2; NME2 NM_001018136 NM23-LV 
CITED1 0.735 MSG1 NM_004143 
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 1 
PTPN22 0.735 LYP; PEP; Lyp1; Lyp2; PTPN8 NM_012411 
protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid) 
C9ORF85 0.734 MGC61599; RP11-346E17.2 NM_182505 chromosome 9 open reading frame 85 
ACSM3 0.733 SA; SAH NM_005622 
acyl-CoA synthetase medium-chain family 
member 3 
CSGLCA-T 0.733 CSGlcA-T; KIAA1402 NM_019015 chondroitin sulfate glucuronyltransferase 
HERC4 0.733 KIAA1593; DKFZP564G092 NM_022079 hect domain and RLD 4 
PLEKHH3 0.733 FLJ21019 NM_024927 
pleckstrin homology domain containing, 
family H (with MyTH4 domain) member 3 
PHF19 0.729 PCL3; MGC23929; MGC131698 NM_001009936 PHD finger protein 19 
PPP2R5C 0.729 B56G; MGC23064 NM_002719 
protein phosphatase 2, regulatory subunit B 
(B56), gamma isoform 
CCDC3 0.728 FLJ20925; DKFZP761F241; RP11-347I22.1 NM_031455 coiled-coil domain containing 3 
TAF13 0.727 TAF2K; TAFII18; MGC22425 NM_005645 
TAF13 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
18kDa 
REEP2 0.727 C5orf19; SGC32445 NM_016606 receptor accessory protein 2 
PRDM8 0.727 PFM5 NM_020226 PR domain containing 8 
NDP 0.725 ND; EVR2; FEVR NM_000266 Norrie disease (pseudoglioma) 
C10ORF67 0.724 MGC46732; RP11-792P23.2 NM_153714 chromosome 10 open reading frame 67 
ARNTL 0.722 
TIC; JAP3; MOP3; BMAL1; PASD3; BMAL1c; 
MGC47515 NM_001178 
aryl hydrocarbon receptor nuclear 
translocator-like 
PLCB2 0.722 FLJ38135 NM_004573 phospholipase C, beta 2 
TMEM117 0.722 DKFZp434K2435 NM_032256 transmembrane protein 117 
HIST1H4K 0.721 H4/d; H4FD; dJ160A22.1 NM_003541 histone 1, H4k 
LOC51334 0.718 DSC54; MGC104614 NM_016644 proline rich 16 
ANXA2 0.718 
P36; ANX2; LIP2; LPC2; CAL1H; LPC2D; 
ANX2L4; PAP-IV NM_001002857 annexin A2 
FBXO4 0.717 FBX4; FLJ10141; DKFZp547N213 NM_012176 F-box protein 4 
PIP 0.716 GPIP4; GCDFP15; GCDFP-15 NM_002652 prolactin-induced protein 
RDH12 0.716 LCA3; FLJ30273 NM_152443 
retinol dehydrogenase 12 (all-trans/9-cis/11-
cis) 
LMTK2 0.715 
BREK; KPI2; LMR2; cprk; KPI-2; AATYK2; 
KIAA1079 NM_014916 lemur tyrosine kinase 2 
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FBXO2 0.715 FBG1; FBX2; Fbs1; NFB42 NM_012168 F-box protein 2 
HPCAL1 0.713 BDR1; HLP2; VILIP-3 NM_134421 hippocalcin-like 1 
FBXL17 0.711 Fbl17; Fbx13; FBXO13; DKFZp434C1715 NM_022824 F-box and leucine-rich repeat protein 17 
HOXA9 0.71 HOX1; ABD-B; HOX1G; HOX1.7; MGC1934 NM_152739 homeobox A9 
SERPIND1 0.71 HC2; LS2; HCF2; HCII; HLS2; D22S673 NM_000185 
serpin peptidase inhibitor, clade D (heparin 
cofactor), member 1 
XG 0.709 
PBDX; MGC118758; MGC118759; MGC118760; 
MGC118761 NM_175569 Xg blood group 
SHC4 0.707 RaLP; MGC34023 NM_203349 
SHC (Src homology 2 domain containing) 
family, member 4 
ELF4 0.707 MEF; ELFR NM_001421 
E74-like factor 4 (ets domain transcription 
factor) 
RET 0.705 
PTC; MTC1; HSCR1; MEN2A; MEN2B; RET51; 
CDHF12; RET-ELE1 NM_020630 
ret proto-oncogene (multiple endocrine 
neoplasia and medullary thyroid carcinoma 1, 
Hirschsprung disease) 
TOX 0.704 TOX; KIAA0808 NM_014729 thymus high mobility group box protein TOX 
C17ORF76 0.703 FLJ35696 NM_207387 chromosome 17 open reading frame 76 
FREQ 0.703 FLUP; NCS1; NCS-1; DKFZp761L1223 NM_014286 frequenin homolog (Drosophila) 
TAC3 0.701 NKB; NKNB; PRO1155; ZNEUROK1 NM_001006667 tachykinin 3 (neuromedin K, neurokinin beta) 
OGDH 0.7 E1k; OGDC; AKGDH NM_001003941 
oxoglutarate (alpha-ketoglutarate) 
dehydrogenase (lipoamide) 
PANX2 0.698 hPANX2; MGC119432 NM_052839 pannexin 2 
RLTPR 0.697 RLTPR NM_001013838 
RGD, leucine-rich repeat, tropomodulin and 
proline-rich containing protein 
CDKN2A 0.696 
ARF; MLM; p14; p16; p19; CMM2; INK4; MTS1; 
TP16; CDK4I; CDKN2; INK4a; p14ARF; p16INK4; 
p16INK4a NM_058197 
cyclin-dependent kinase inhibitor 2A 
(melanoma, p16, inhibits CDK4) 
LMO2 0.694 TTG2; RBTN2; RHOM2; RBTNL1 NM_005574 LIM domain only 2 (rhombotin-like 1) 
ZFP64 0.693 MGC940; ZNF338 NM_199427 zinc finger protein 64 homolog (mouse) 
UBE2H 0.693 UBC8; UBCH; UBCH2; E2-20K NM_182697 
ubiquitin-conjugating enzyme E2H (UBC8 
homolog, yeast) 
LOC161931 0.693 LOC161931 NM_139174 testis nuclear RNA-binding protein-like 
HSPB2 0.692 MKBP; HSP27; Hs.78846; MGC133245 NM_001541 heat shock 27kDa protein 2 
ALDH3B1 0.691 ALDH4; ALDH7; FLJ26433 NM_001030010 aldehyde dehydrogenase 3 family, member B1 
KIAA0247 0.691 TMEM101 NM_014734 KIAA0247 
STOML1 0.691 SLP-1; STORP; hUNC-24; FLJ36370 NM_004809 stomatin (EPB72)-like 1 
ZMYND15 0.69 DKFZp434N127 NM_032265 zinc finger, MYND-type containing 15 
PODN 0.69 PCAN; SLRR5A; MGC24995 NM_153703 podocan 
MSRA 0.686 MSRA NM_012331 methionine sulfoxide reductase A 
TAGLN3 0.686 NP22; NP25 NM_001008273 transgelin 3 
SYTL4 0.684 FLJ40960; DKFZp451P0116 NM_080737 synaptotagmin-like 4 (granuphilin-a) 
COG5 0.684 GTC90; GOLTC1 NM_006348 component of oligomeric golgi complex 5 
CINP 0.683 CINP; MGC849 NM_032630 cyclin-dependent kinase 2-interacting protein 
DKFZP686O24166 0.681 DKFZp686O24166; DKFZp686I21167 NM_001009913 hypothetical protein DKFZp686O24166 
ICAM2 0.68 CD102 NM_000873 intercellular adhesion molecule 2 
HLA-F 0.679 HLAF; HLA-5.4; HLA-CDA12 NM_018950 major histocompatibility complex, class I, F 
FBXL16 0.678 Fbl16; C16orf22; FLJ33735; MGC33974; c380A1.1 NM_153350 F-box and leucine-rich repeat protein 16 
FLJ14054 0.677 FLJ14054 NM_024563 chromosome 5 open reading frame 23 
IFIT1 0.676 G10P1; IFI56; IFI-56; IFNAI1; RNM561; GARG-16 NM_001548 
interferon-induced protein with 
tetratricopeptide repeats 1 
CARD9 0.676 hCARD9 NM_052813 caspase recruitment domain family, member 9 
CACNA2D3 0.676 HSA272268 NM_018398 
calcium channel, voltage-dependent, alpha 
2/delta 3 subunit 
GABRB3 0.676 MGC9051 NM_000814 
gamma-aminobutyric acid (GABA) A 
receptor, beta 3 
RNH1 0.675 RAI; RNH; MGC4569; MGC18200; MGC54054 NM_203384 ribonuclease/angiogenin inhibitor 1 
NLGN4Y 0.675 KIAA0951 NM_014893 neuroligin 4, Y-linked 
ACTN4 0.674 FSGS; FSGS1; DKFZp686K23158 NM_004924 actinin, alpha 4 
FLJ35258 0.673 FLJ35258 NM_182571 hypothetical protein 284297 
MGC35212 0.673 gs129; MGC35212 NM_152764 chromosome 16 open reading frame 73 
FIBCD1 0.673 FLJ14810 NM_032843 fibrinogen C domain containing 1 
C3 0.671 ASP; CPAMD1 NM_000064 complement component 3 
IL1R1 0.671 P80; IL1R; IL1RA; CD121A; D2S1473; IL-1R-alpha NM_000877 interleukin 1 receptor, type I 
ASB13 0.67 FLJ13134; MGC19879 NM_024701 ankyrin repeat and SOCS box-containing 13 
FLJ20273 0.67 FLJ20273; DKFZp686F02235 NM_019027 RNA-binding protein 
SGCD 0.669 
SGD; DAGD; 35DAG; CMD1L; SGCDP; 
MGC22567; SG-delta NM_000337 
sarcoglycan, delta (35kDa dystrophin-
associated glycoprotein) 
KITLG 0.668 SF; MGF; SCF; KL-1; Kitl; DKFZp686F2250 NM_000899 KIT ligand 
TPCN1 0.668 TPC1; FLJ20612; KIAA1169 NM_017901 two pore segment channel 1 
HSD3B7 0.667 PFIC4 NM_025193 
hydroxy-delta-5-steroid dehydrogenase, 3 
beta- and steroid delta-isomerase 7 
ACOT7 0.667 
ACT; ACH1; BACH; LACH; LACH1; hBACH; 
CTE-II; MGC1126; RP1-120G22.10 NM_181864 acyl-CoA thioesterase 7 
ABHD14B 0.667 CIB; MGC15429 NM_032750 abhydrolase domain containing 14B 
KRTHA4 0.666 HA4; Ha-4; hHa4; KRTHA4 NM_021013 keratin 34 
C13ORF21 0.666 MGC35505; bA269C23.1; RP11-269C23.1 NM_001010897 chromosome 13 open reading frame 21 
AKAP1 0.665 
AKAP; PRKA1; AKAP84; AKAP121; AKAP149; 
D-AKAP1; MGC1807; SAKAP84 NM_003488 A kinase (PRKA) anchor protein 1 
TAPBPL 0.664 TAPBPR; TAPBP-R; FLJ10143 NM_018009 TAP binding protein-like 
MNS1 0.664 FLJ11222 NM_018365 meiosis-specific nuclear structural 1 
SPFH1 0.664 KE04; KEO4; C10orf69; RP11-316M21.1 NM_006459 SPFH domain family, member 1 
CPEB4 0.663 KIAA1673 NM_030627 
cytoplasmic polyadenylation element binding 
protein 4 
CALB2 0.662 CAL2 NM_001740 calbindin 2, 29kDa (calretinin) 
CBX7 0.661 STOML1 NM_175709 chromobox homolog 7 
C1ORF45 0.661 KATNAL1 NM_001025231 chromosome 1 open reading frame 45 
SERINC2 0.66 TDE2; TDE2L; FKSG84; PRO0899; MGC90340 NM_178865 serine incorporator 2 
C16ORF52 0.66   NM_173501   
PPAPDC3 0.658 
C9orf67; FLJ14662; KIAA0515; MGC12921; RP11-
643E14.1 NM_032728 
phosphatidic acid phosphatase type 2 domain 
containing 3 
Mar-04 0.657 RNF174; MARCH-IV; MGC104908 NM_020814 membrane-associated ring finger (C3HC4) 4 
PLA2G10 0.656 
SPLA2; GXPLA2; GXSPLA2; MGC119918; 
MGC119919; MGC133367 NM_003561 phospholipase A2, group X 
NFKBIZ 0.652 IKBZ; INAP; MAIL; FLJ30225; FLJ34463 NM_031419 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 
 210
GLRB 0.652 MDM2 NM_000824 glycine receptor, beta 
LOC200810 0.652 LOC200810 NM_001015050 
similar to beta-1,4-mannosyltransferase; beta-
1,4 mannosyltransferase 
ME3 0.652 FLJ34862 NM_006680 
malic enzyme 3, NADP(+)-dependent, 
mitochondrial 
ERN1 0.65 IRE1; IRE1P; FLJ30999 NM_152461 endoplasmic reticulum to nucleus signalling 1 
FCHSD2 0.65 NWK; SH3MD3; KIAA0769 NM_014824 FCH and double SH3 domains 2 
CDC25C 0.65 CDC25 NM_001790 cell division cycle 25C 
IFT57 0.649 HIPPI; MHS4R2; ESRRBL1; FLJ10147 NM_018010 
intraflagellar transport 57 homolog 
(Chlamydomonas) 
MGC52057 0.649 MGC52057 NM_194317 LY6/PLAUR domain containing 6 
CYB5R3 0.648 B5R; DIA1 NM_007326 cytochrome b5 reductase 3 
NAP1L5 0.648 DRLM NM_153757 nucleosome assembly protein 1-like 5 
PCNXL2 0.648 FLJ11383; KIAA0435 NM_024938 pecanex-like 2 (Drosophila) 
PLD3 0.647 HU-K4 NM_001031696 phospholipase D family, member 3 
IL1F7 0.646 
FIL1; FIL1Z; IL1H4; IL-1F7; IL-1H4; IL1RP1; IL-
1RP1; FIL1(ZETA) NM_014439 interleukin 1 family, member 7 (zeta) 
TRHDE 0.645 PAP-II; PGPEP2; TRH-DE; FLJ22381 NM_013381 
thyrotropin-releasing hormone degrading 
enzyme 
FUBP1 0.644 FBP; FUBP NM_003902 
far upstream element (FUSE) binding protein 
1 
C5ORF14 0.644 UNQ335; FLJ22625 NM_024715 chromosome 5 open reading frame 14 
C3ORF52 0.644 TTMP; FLJ23186 NM_024616 chromosome 3 open reading frame 52 
FGF5 0.641 HBGF-5; Smag-82 NM_004464 fibroblast growth factor 5 
FAM70B 0.64 MGC20579; RP11-199F6.1 NM_182614 family with sequence similarity 70, member B 
RAB27A 0.64 GS2; RAM; RAB27; HsT18676; MGC117246 NM_004580 RAB27A, member RAS oncogene family 
DOCK5 0.637 DKFZp451J181; DKFZp779M164; DKFZp781J211 NM_024940 dedicator of cytokinesis 5 
MYO1E 0.636 MYO1C; MGC104638 NM_004998 myosin IE 
SDCBP2 0.636 ST-2; SITAC18 NM_080489 syndecan binding protein (syntenin) 2 
SERPINB3 0.636 SCC; T4-A; SCCA1; SCCA-1; HsT1196; SCCA-PD NM_006919 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 3 
DNPEP 0.635 DAP; ASPEP NM_012100 aspartyl aminopeptidase 
NEDD4 0.635 KIAA0093 NM_198400 
neural precursor cell expressed, 
developmentally down-regulated 4 
GNG3 0.635 GNG3 NM_012202 
guanine nucleotide binding protein (G 
protein), gamma 3 
CCT3 0.635 CCTG; PIG48; TRIC5; CCT-gamma; TCP-1-gamma NM_001008800 
chaperonin containing TCP1, subunit 3 
(gamma) 
TANK 0.634 TRAF2; I-TRAF NM_004180 
TRAF family member-associated NFKB 
activator 
COL2A1 0.633 AOM; SEDC; COL11A3; MGC131516 NM_001844 
collagen, type II, alpha 1 (primary 
osteoarthritis, spondyloepiphyseal dysplasia, 
congenital) 
ILDR1 0.633 MGC50831; ILDR1beta; ILDR1alpha NM_175924 
immunoglobulin-like domain containing 
receptor 1 
NOTCH2 0.632 hN2; AGS2 NM_024408 Notch homolog 2 (Drosophila) 
MMAA 0.632 
MGC120010; MGC120011; MGC120012; 
MGC120013 NM_172250 
methylmalonic aciduria (cobalamin 
deficiency) cblA type 
TIP39 0.632 TIP39 NM_178449 
tuberoinfundibular 39 residue protein 
precursor 
SH2D4A 0.632 SH2A; FLJ20967 NM_022071 SH2 domain containing 4A 
EDN1 0.631 ET1 NM_001955 endothelin 1 
STEAP3 0.63 STMP3; TSAP6; dudlin-2 NM_018234 STEAP family member 3 
AR 0.629 
KD; AIS; TFM; DHTR; SBMA; NR3C4; SMAX1; 
HUMARA NM_000044 
androgen receptor (dihydrotestosterone 
receptor; testicular feminization; spinal and 
bulbar muscular atrophy; Kennedy disease) 
URB 0.629 URB; DRO1; SSG1; MGC131805; MGC134851 NM_199511 coiled-coil domain containing 80 
HES3 0.629 LOC339977 NM_001024598 hairy and enhancer of split 3 (Drosophila) 
STK39 0.627 DCHT; SPAK; DKFZp686K05124 NM_013233 
serine threonine kinase 39 (STE20/SPS1 
homolog, yeast) 
FLJ10178 0.626 FLJ10178; FLJ14191; RP11-647M7.1 NM_018015 chromosome X open reading frame 57 
MCTP1 0.626 FLJ22344 NM_001002796 multiple C2 domains, transmembrane 1 
AKR1A1 0.625 ALR; ALDR1; MGC1380; MGC12529 NM_006066 
aldo-keto reductase family 1, member A1 
(aldehyde reductase) 
SNCA 0.624 PD1; NACP; PARK1; PARK4; MGC110988 NM_000345 
synuclein, alpha (non A4 component of 
amyloid precursor) 
C6ORF65 0.623 FLJ30162; bA203B9.1 NM_152731 chromosome 6 open reading frame 65 
CHURC1 0.623 chch; My015; C14orf52; FLJ33064 NM_145165 churchill domain containing 1 
C1ORF78 0.623 FLJ10647; RP11-268J15.2 NM_018166 chromosome 1 open reading frame 78 
PPARD 0.622 
FAAR; NUC1; NUCI; NR1C2; NUCII; PPARB; 
MGC3931; PPAR-beta NM_006238 
peroxisome proliferative activated receptor, 
delta 
PDGFC 0.622 SCDGF NM_016205 platelet derived growth factor C 
ANTXR1 0.62 ATR; TEM8; FLJ10601; FLJ11298; FLJ21776 NM_032208 anthrax toxin receptor 1 
EIF1AX 0.62 EIF1A; EIF4C; eIF-1A; eIF-4C NM_001412 
eukaryotic translation initiation factor 1A, X-
linked 
DYRK4 0.618 RPGRIP1 NM_003845 
dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 4 
PH-4 0.617 PH-4 NM_177939 hypoxia-inducible factor prolyl 4-hydroxylase 
SYN2 0.616 SYNII; SYNIIa; SYNIIb NM_133625 synapsin II 
MDFIC 0.616 HIC NM_199072 MyoD family inhibitor domain containing 
WNT2 0.616 IRP; INT1L1 NM_003391 
wingless-type MMTV integration site family 
member 2 
SCNN1G 0.615 PHA1; ENaCg; SCNEG; ENaCgamma NM_001039 sodium channel, nonvoltage-gated 1, gamma 
C16ORF45 0.615 FLJ32618 NM_033201 chromosome 16 open reading frame 45 
TFB1M 0.615 CGI75; mtTFB; CGI-75 NM_016020 transcription factor B1, mitochondrial 
MGC13040 0.615 MGC13040 NM_032930 chromosome 11 open reading frame 70 
NEXN 0.614 NELIN; MGC138865; MGC138866 NM_144573 nexilin (F actin binding protein) 
PHKA1 0.613 PHKA; MGC132604 NM_002637 phosphorylase kinase, alpha 1 (muscle) 
ERCC1 0.613 UV20 NM_202001 
excision repair cross-complementing rodent 
repair deficiency, complementation group 1 
(includes overlapping antisense sequence) 
MAGEH1 0.612 APR1; APR-1 NM_014061 melanoma antigen family H, 1 
RGS4 0.612 RGP4; SCZD9; MGC2124; MGC60244 NM_005613 regulator of G-protein signalling 4 
IER3IP1 0.61 HSPC039; PRO2309 NM_016097 
immediate early response 3 interacting protein 
1 
FLJ21062 0.61   NM_024788   
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OPN3 0.609 ECPN NM_014322 opsin 3 (encephalopsin, panopsin) 
PPIF 0.608 CYP3; Cyp-D; FLJ90798; MGC117207 NM_005729 peptidylprolyl isomerase F (cyclophilin F) 
MR1 0.607 HLALS NM_001531 
major histocompatibility complex, class I-
related 
ST3GAL3 0.607 ST3N; SIAT6; ST3GALII; ST3GalIII; ST3Gal III NM_006279 
ST3 beta-galactoside alpha-2,3-
sialyltransferase 3 
PDE7B 0.606 MGC88256; bA472E5.1 NM_018945 phosphodiesterase 7B 
HIVEP2 0.605 MBP-2; MIBP1; HIV-EP2 NM_006734 
human immunodeficiency virus type I 
enhancer binding protein 2 
MFN2 0.605 
HSG; MARF; CMT2A; CPRP1; CMT2A2; 
KIAA0214 NM_014874 mitofusin 2 
LOXL1 0.603 LOL; LOXL NM_005576 lysyl oxidase-like 1 
ARFIP1 0.603 HSU52521; MGC117369 NM_001025595 
ADP-ribosylation factor interacting protein 1 
(arfaptin 1) 
TRIM55 0.602 RNF29; MURF-2 NM_184086 tripartite motif-containing 55 
KHK 0.602 TRAP1 NM_000221 ketohexokinase (fructokinase) 
FLJ10159 0.601 FLJ10159 NM_018013 hypothetical protein FLJ10159 
CNTN1 0.601 F3; GP135 NM_001843 contactin 1 
ARHGAP9 0.601 10C; RGL1; MGC1295; FLJ16525 NM_032496 Rho GTPase activating protein 9 
HIST1H2BC 0.601 H2B.1; H2B/l; H2BFL; dJ221C16.3 NM_003526 histone 1, H2bc 
LOC196394 0.6 LOC196394 NM_207337 hypothetical protein LOC196394 
SLC7A10 0.598 asc-1; HASC-1; FLJ20839 NM_019849 
solute carrier family 7, (neutral amino acid 
transporter, y+ system) member 10 
DDX46 0.598 MGC9936; FLJ25329; KIAA0801 NM_014829 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 
46 
ZNF451 0.598 
COASTER; FLJ90693; KIAA0576; MGC26701; 
dJ417I1.1 NM_001031623 zinc finger protein 451 
ATP6V1G2 0.598 NG38; ATP6G; VMA10; ATP6G2 NM_130463 
ATPase, H+ transporting, lysosomal 13kDa, 
V1 subunit G2 
LOC92689 0.598 LOC92689 NM_138389 hypothetical protein BC001096 
SCIN 0.597 KIAA1905 NM_033128 scinderin 
JAG1 0.597 
AGS; AHD; AWS; HJ1; CD339; JAGL1; 
MGC104644 NM_000214 jagged 1 (Alagille syndrome) 
SYN3 0.597 SYN3 NM_133633 synapsin III 
ASCC3L1 0.595 BRR2; HELIC2; U5-200KD NM_014014 
activating signal cointegrator 1 complex 
subunit 3-like 1 
ADAM9 0.595 MCMP; MDC9; Mltng; KIAA0021 NM_003816 
ADAM metallopeptidase domain 9 (meltrin 
gamma) 
IGF2 0.595 INSIGF; pp9974; C11orf43; FLJ22066; FLJ44734 NM_000612 insulin-like growth factor 2 (somatomedin A) 
SERPINF1 0.594 PEDF; EPC-1; PIG35 NM_002615 
serpin peptidase inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium derived 
factor), member 1 
ETFDH 0.593 MADD; ETFQO NM_004453 
electron-transferring-flavoprotein 
dehydrogenase 
SH2D3C 0.593 CHAT; NSP3; FLJ39664; PRO34088 NM_170600 SH2 domain containing 3C 
Mar-06 0.592 TEB4; RNF176; KIAA0597; MARCH-VI NM_005885 membrane-associated ring finger (C3HC4) 6 
NIP30 0.592 NIP30; CDA10; CDA018; FLJ21799; MGC74898 NM_024946 NEFA-interacting nuclear protein NIP30 
IFNAR2 0.592 IFN-R; IFNABR; IFNARB; IFN-alpha-REC NM_207584 interferon (alpha, beta and omega) receptor 2 
EFEMP1 0.591 
DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; 
FBLN3; FLJ35535; MGC111353 NM_004105 
EGF-containing fibulin-like extracellular 
matrix protein 1 
LRRC8C 0.591 AD158; FAD158; MGC138551; DKFZp586J1119 NM_032270 
leucine rich repeat containing 8 family, 
member C 
RASGRP2 0.59 CDC25L; CALDAG-GEFI NM_005825 
RAS guanyl releasing protein 2 (calcium and 
DAG-regulated) 
GRIN1 0.59 NR1; NMDA1; NMDAR1 NM_007327 
glutamate receptor, ionotropic, N-methyl D-
aspartate 1 
SNAP23 0.589 SNAP23A; SNAP23B; HsT17016 NM_130798 synaptosomal-associated protein, 23kDa 
NRXN2 0.589 KIAA0921 NM_015080 neurexin 2 
CAST 0.589 BS-17; MGC9402 NM_173060 calpastatin 
C9ORF123 0.589 MGC4730 NM_033428 chromosome 9 open reading frame 123 
CAMK2N2 0.589 CAM-KIIN NM_033259 
calcium/calmodulin-dependent protein kinase 
II inhibitor 2 
STARD5 0.588 MGC10327 NM_181900 START domain containing 5 
ACSBG1 0.588 
BG1; BGM; hBG1; hsBG; GR-LACS; FLJ30320; 
KIAA0631; MGC14352 NM_015162 
acyl-CoA synthetase bubblegum family 
member 1 
RNF39 0.587 HZF; HZFW; LIRF; HZFw1 NM_025236 ring finger protein 39 
FCHO1 0.586 KIAA0290 NM_015122 FCH domain only 1 
BCAP29 0.585 BAP29; DKFZp686M2086 NM_001008406 B-cell receptor-associated protein 29 
TRPV2 0.585 VRL; VRL1; VRL-1; MGC12549 NM_016113 
transient receptor potential cation channel, 
subfamily V, member 2 
ADAMTS2 0.584 
NPI; PCINP; PCPNI; hPCPNI; ADAM-TS2; 
ADAMTS-3 NM_021599 
ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
DUSP16 0.583 
MKP7; MKP-7; KIAA1700; MGC129701; 
MGC129702 NM_030640 dual specificity phosphatase 16 
GPC3 0.583 SGB; DGSX; SDYS; SGBS; SGBS1 NM_004484 glypican 3 
KIAA1033 0.583 KIAA1033 NM_015275 KIAA1033 
VPS24 0.583 NEDF; CHMP3; CGI-149 NM_016079 
vacuolar protein sorting 24 homolog (S. 
cerevisiae) 
KCTD8 0.582 C3orf57 NM_198353 
potassium channel tetramerisation domain 
containing 8 
ABLIM3 0.582 HMFN1661 NM_014945 actin binding LIM protein family, member 3 
C1QTNF1 0.581 GIP; CTRP1; ZSIG37; FLJ90694 NM_030968 
C1q and tumor necrosis factor related protein 
1 
P2RX5 0.579 P2X5; P2X5R; MGC47755 NM_175081 
purinergic receptor P2X, ligand-gated ion 
channel, 5 
HESX1 0.579 RPX; MGC138294 NM_003865 homeobox, ES cell expressed 1 
PCAF 0.579 CAF; GCN5; GCN5L; P/CAF; GCN5L1 NM_003884 p300/CBP-associated factor 
SYNGR1 0.578 MGC:1939 NM_145731 synaptogyrin 1 
PRRX1 0.578 PMX1; PRX1; PHOX1 NM_006902 paired related homeobox 1 
HMFN0839 0.577 LPAAT-THETA; MGC11324 NM_032717 lysophosphatidic acid acyltransferase theta 
FLJ32028 0.577 FLJ32028 NM_152680 transmembrane protein 154 
PTHR2 0.576 PTHR2 NM_005048 parathyroid hormone receptor 2 
ABHD7 0.576 EPHXRP; FLJ90341 NM_173567 abhydrolase domain containing 7 
EGFL9 0.576 MGC2487; MGC111055 NM_023932 EGF-like-domain, multiple 9 
FOXF1 0.576 FKHL5; FREAC1; MGC105125 NM_001451 forkhead box F1 
MAF 0.575 MGC71685 NM_005360 v-maf musculoaponeurotic fibrosarcoma 
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oncogene homolog (avian) 
CD99L2 0.575 MIC2L1; DKFZp761H2024 NM_134446 CD99 molecule-like 2 
CORO1A 0.574 
p57; TACO; CLABP; HCORO1; CLIPINA; 
FLJ41407; MGC117380 NM_007074 coronin, actin binding protein, 1A 
LOC492311 0.574 LOC492311 NM_001007189 similar to bovine IgA regulatory protein 
HRASLS 0.573 A-C1; HSD28; HRASLS1; H-REV107 NM_020386 HRAS-like suppressor 
OSMR 0.573 OSMRB; MGC75127 NM_003999 oncostatin M receptor 
COL16A1 0.572 447AA; FP1572 NM_001856 collagen, type XVI, alpha 1 
QSCN6 0.572 Q6; QSOX1 NM_002826 quiescin Q6 
NOV 0.572 CCN3; NOVH; IGFBP9 NM_002514 nephroblastoma overexpressed gene 
GABRA5 0.569 MGC138184 NM_000810 
gamma-aminobutyric acid (GABA) A 
receptor, alpha 5 
CDS1 0.568 CDS NM_001263 
CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
MMP24 0.567 MMP25; MT-MMP5; MT5-MMP NM_006690 
matrix metallopeptidase 24 (membrane-
inserted) 
SYT4 0.567 HsT1192; KIAA1342 NM_020783 synaptotagmin IV 
RAB40B 0.566 RAR; SEC4L; FLJ42385 NM_006822 RAB40B, member RAS oncogene family 
GDF15 0.566 
PDF; MIC1; PLAB; MIC-1; NAG-1; PTGFB; GDF-
15 NM_004864 growth differentiation factor 15 
CLYBL 0.565 CLB; bA134O15.1 NM_206808 citrate lyase beta like 
EMR2 0.565 CD312; DKFZp781B135 NM_013447 
egf-like module containing, mucin-like, 
hormone receptor-like 2 
IL13RA1 0.564 NR4; CD213A1; IL-13Ra NM_001560 interleukin 13 receptor, alpha 1 
C20ORF19 0.564 
HT013; MGC102941; MGC141930; 
DKFZP586H021 NM_018474 chromosome 20 open reading frame 19 
KYNU 0.563 DLK1 NM_003937 kynureninase (L-kynurenine hydrolase) 
AIG1 0.563 
AIG-1; FLJ10485; dJ95L4.1; RP1-95L4.1; 
DKFZp686F03136 NM_016108 androgen-induced 1 
MTHFD2L 0.563 FLJ13105; MGC45532; MGC72244 NM_001004346 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 2-like 
METRN 0.562 MGC2601; C16orf23; c380A1.2 NM_024042 meteorin, glial cell differentiation regulator 
MAP2K5 0.562 MEK5; MAPKK5; PRKMK5; HsT17454 NM_002757 mitogen-activated protein kinase kinase 5 
LPPR4 0.562 
LPPR4; PHP1; PRG1; PRG-1; KIAA0455; RP4-
788L13.1 NM_014839 plasticity related gene 1 
SPHK1 0.562 SPHK NM_021972 sphingosine kinase 1 
SYT15 0.562 sytXV; CHR10SYT; syt XV-a NM_181519 synaptotagmin XV 
DOCK11 0.56 ZIZ2; FLJ32122; FLJ43653; bB128O4.1 NM_144658 dedicator of cytokinesis 11 
IRAK3 0.559 IRAK-M NM_007199 interleukin-1 receptor-associated kinase 3 
PPAP2B 0.557 
LPP3; VCIP; Dri42; PAP-2b; PAP2-b; MGC15306; 
PAP2-beta NM_003713 phosphatidic acid phosphatase type 2B 
TMEM42 0.557 MGC29956 NM_144638 transmembrane protein 42 
HAGHL 0.557 MGC2605 NM_032304 hydroxyacylglutathione hydrolase-like 
CX3CL1 0.556 
NTN; NTT; CXC3; CXC3C; SCYD1; ABCD-3; 
C3Xkine; fractalkine; neurotactin NM_002996 chemokine (C-X3-C motif) ligand 1 
GPR176 0.555 GPR; Gm1012 NM_007223 G protein-coupled receptor 176 
LY96 0.554 MD-2 NM_015364 lymphocyte antigen 96 
ZNF25 0.554 Zfp9; KOX19; FLJ31890; DKFZp564C206 NM_145011 zinc finger protein 25 
TMEM54 0.553 BCLP; CAC1; CAC-1; MGC10137 NM_033504 transmembrane protein 54 
NALP1 0.553 
CARD7; DEFCAP; PP1044; KIAA0926; DEFCAP-
L/S; DKFZp586O1822 NM_001033053 
NACHT, leucine rich repeat and PYD (pyrin 
domain) containing 1 
FKBP5 0.553 
P54; FKBP51; FKBP54; PPIase; Ptg-10; 
MGC111006 NM_004117 FK506 binding protein 5 
GNE 0.552 NM; DMRV; IBM2; Uae1; GLCNE NM_005476 
glucosamine (UDP-N-acetyl)-2-epimerase/N-
acetylmannosamine kinase 
TMEM106C 0.552 MGC5576; MGC111210 NM_024056 transmembrane protein 106C 
TNFRSF14 0.551 TR2; ATAR; HVEA; HVEM; LIGHTR NM_003820 
tumor necrosis factor receptor superfamily, 
member 14 (herpesvirus entry mediator) 
NEK6 0.55 SID6-1512 NM_014397 
NIMA (never in mitosis gene a)-related kinase 
6 
LOC221091 0.549 LOC221091; MGC61707 NM_203422 similar to hypothetical protein 
XPO6 0.549 EXP6; RANBP20; FLJ22519; KIAA0370 NM_015171 exportin 6 
CNIH3 0.549 FLJ38993 NM_152495 cornichon homolog 3 (Drosophila) 
PRAF2 0.549 JM4 NM_007213 PRA1 domain family, member 2 
CDH13 0.549 CDHH NM_001257 cadherin 13, H-cadherin (heart) 
VEPH1 0.548 
FLJ12604; KIAA1692; MGC111426; MGC126709; 
MGC142115 NM_024621 
ventricular zone expressed PH domain 
homolog 1 (zebrafish) 
EBF3 0.547 COE3; O/E-2 NM_001005463 early B-cell factor 3 
CXCL12 0.547 
PBSF; SDF1; SDF1A; SDF1B; TPAR1; SCYB12; 
SDF-1a; SDF-1b; TLSF-a; TLSF-b NM_000609 
chemokine (C-X-C motif) ligand 12 (stromal 
cell-derived factor 1) 
RECQL 0.543 RecQ1; RECQL1 NM_032941 RecQ protein-like (DNA helicase Q1-like) 
BLVRA 0.543 BLVR; BVRA NM_000712 biliverdin reductase A 
ATP8B3 0.542 ATPIK NM_138813 ATPase, Class I, type 8B, member 3 
C12ORF23 0.541 FLJ11721; FLJ13959; MGC17943 NM_152261 chromosome 12 open reading frame 23 
PRRG1 0.541 PRGP1 NM_000950 proline rich Gla (G-carboxyglutamic acid) 1 
TPBG 0.541 5T4; M6P1; 5T4-AG NM_006670 trophoblast glycoprotein 
NFIC 0.541 CTF; NFI; CTF5; NF-I; MGC20153 NM_005597 
nuclear factor I/C (CCAAT-binding 
transcription factor) 
BCAN 0.54 BEHAB; CSPG7; MGC13038 NM_021948 brevican 
GPRC5B 0.539 RAIG2; RAIG-2 NM_016235 
G protein-coupled receptor, family C, group 5, 
member B 
C6ORF117 0.539 RP11-51G5.2 NM_138409 chromosome 6 open reading frame 117 
LDHD 0.538 MGC57726 NM_194436 lactate dehydrogenase D 
UNQ3045 0.538 UNQ3045 NM_207409 AAAL3045 
C1R 0.537 VIM NM_001733 complement component 1, r subcomponent 
HEY1 0.535 CHF2; OAF1; HERP2; HESR1; HRT-1; MGC1274 NM_012258 
hairy/enhancer-of-split related with YRPW 
motif 1 
NIFUN 0.535 ISCU; ISU2; NIFU; MGC74517; 2310020H20Rik NM_014301 NifU-like N-terminal domain containing 
LOC285989 0.535 LOC285989 NM_001013258 zinc finger protein 789 
KCTD10 0.535 ULRO61; MSTP028; FLJ41739 NM_031954 
potassium channel tetramerisation domain 
containing 10 
FKBP10 0.535 FKBP65; hFKBP65; FLJ22041 NM_021939 FK506 binding protein 10, 65 kDa 
PTX3 0.534 TSG-14; TNFAIP5 NM_002852 
pentraxin-related gene, rapidly induced by IL-
1 beta 
RBP7 0.534 CRBP4; CRBPIV; MGC70641 NM_052960 retinol binding protein 7, cellular 
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STAT5A 0.534 MGF; STAT5 NM_003152 
signal transducer and activator of transcription 
5A 
KNTC2 0.534 HEC; HEC1 NM_006101 kinetochore associated 2 
CYP27B1 0.533 
VDR; CP2B; CYP1; PDDR; VDD1; VDDR; 
VDDRI; CYP27B; P450c1; CYP1alpha NM_000785 
cytochrome P450, family 27, subfamily B, 
polypeptide 1 
RUNX1 0.533 
AML1; CBFA2; EVI-1; AMLCR1; PEBP2aB; 
AML1-EVI-1 NM_001754 
runt-related transcription factor 1 (acute 
myeloid leukemia 1; aml1 oncogene) 
EGFR 0.531 ERBB; mENA; ERBB1 NM_201283 
epidermal growth factor receptor 
(erythroblastic leukemia viral (v-erb-b) 
oncogene homolog, avian) 
TEX14 0.531 TEX14 NM_031272 testis expressed sequence 14 
GPR177 0.531 
MRP; WLS; C1orf139; FLJ23091; MGC14878; 
MGC131760 NM_001002292 G protein-coupled receptor 177 
CUZD1 0.53 ERG-1; UO-44 NM_022034 CUB and zona pellucida-like domains 1 
CRAT 0.529 CAT1 NM_000755 carnitine acetyltransferase 
CPNE3 0.527 CPN3; PRO1071; KIAA0636 NM_003909 copine III 
OSBPL5 0.527 ORP5; OBPH1; FLJ42929 NM_020896 oxysterol binding protein-like 5 
SEMA3C 0.526 SemE; SEMAE NM_006379 
sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3C 
CD36 0.525 FAT; GP4; GP3B; GPIV; PASIV; SCARB3 NM_001001548 CD36 molecule (thrombospondin receptor) 
VAMP4 0.525   NM_201994   
FLJ20105 0.524 FLJ20105; MGC131695 NM_017669 FLJ20105 protein 
KIAA0367 0.524 BMCC1; BNIPXL; A214N16.3; bA214N16.3 NM_015225 KIAA0367 
ANTXR1 0.522 ATR; TEM8; FLJ10601; FLJ11298; FLJ21776 NM_053034 anthrax toxin receptor 1 
SPOCK2 0.522 testican-2 NM_014767 
sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan (testican) 2 
NINJ1 0.521 NIN1; NINJURIN NM_004148 ninjurin 1 
NAV3 0.52 POMFIL1; unc53H3; KIAA0938; STEERIN3 NM_014903 neuron navigator 3 
ZDHHC19 0.518   NM_144637   
MGLL 0.518 MGL; HU-K5 NM_001003794 monoglyceride lipase 
MGC72104 0.518 MGC72104 NM_207350 
similar to FRG1 protein (FSHD region gene 1 
protein) 
DUSP6 0.518 MKP3; PYST1 NM_001946 dual specificity phosphatase 6 
CYBASC3 0.517 MGC20446 NM_153611 cytochrome b, ascorbate dependent 3 
PRG2 0.515 MBP; BMPG; MGC14537 NM_002728 
proteoglycan 2, bone marrow (natural killer 
cell activator, eosinophil granule major basic 
protein) 
DGKA 0.513 
DAGK; DAGK1; MGC12821; MGC42356; DGK-
alpha NM_201554 diacylglycerol kinase, alpha 80kDa 
SNTB2 0.513 SNT3; SNTL; SNT2B2; EST25263; D16S2531E NM_006750 
syntrophin, beta 2 (dystrophin-associated 
protein A1, 59kDa, basic component 2) 
ARHGAP22 0.512 RhoGAP2 NM_021226 Rho GTPase activating protein 22 
DIDO1 0.511 
BYE1; DIO1; DATF1; DIDO2; DIDO3; DIO-1; 
FLJ11265; KIAA0333; MGC16140; C20orf158; 
dJ885L7.8; DKFZp434P1115 NM_080796 death inducer-obliterator 1 
TLOC1 0.511 HTP1; Dtrp1; SEC62; FLJ32803 NM_003262 translocation protein 1 
EVI5L 0.511 EVI5L NM_145245 ecotropic viral integration site 5-like 
EMILIN1 0.51 gp115; EMILIN; EMILIN-1; DKFZP586M121 NM_007046 elastin microfibril interfacer 1 
C14ORF149 0.51 FLJ25436 NM_144581 chromosome 14 open reading frame 149 
CHST8 0.51 CDKN2C NM_022467 
carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 8 
RGL1 0.509 RGL; KIAA0959 NM_015149 
ral guanine nucleotide dissociation stimulator-
like 1 
BCL6 0.509 BCL5; LAZ3; BCL6A; ZNF51; ZBTB27 NM_001706 
B-cell CLL/lymphoma 6 (zinc finger protein 
51) 
CAPN2 0.509 mCANP; CANPL2; CANPml NM_001748 calpain 2, (m/II) large subunit 
PCSK9 0.509 FH3; NARC1; NARC-1; HCHOLA3 NM_174936 proprotein convertase subtilisin/kexin type 9 
CLIC6 0.508 CLIC1L NM_053277 chloride intracellular channel 6 
SSSCA1 0.508 p27 NM_006396 Sjogren's syndrome/scleroderma autoantigen 1 
GPR177 0.508 
MRP; WLS; C1orf139; FLJ23091; MGC14878; 
MGC131760 NM_001002292 G protein-coupled receptor 177 
SGCD 0.507 
SGD; DAGD; 35DAG; CMD1L; SGCDP; 
MGC22567; SG-delta NM_172244 
sarcoglycan, delta (35kDa dystrophin-
associated glycoprotein) 
CALCB 0.506 CALC2; CGRP2; CGRP-II; FLJ30166 NM_000728 calcitonin-related polypeptide, beta 
ATCAY 0.506 CLAC; BNIP-H; KIAA1872 NM_033064 ataxia, cerebellar, Cayman type (caytaxin) 
C9ORF125 0.506 MGC12992 NM_032342 chromosome 9 open reading frame 125 
ATP6V0A4 0.506 
A4; STV1; VPH1; VPP2; RTA1C; RTADR; 
ATP6N2; RDRTA2; ATP6N1B; MGC130016; 
MGC130017 NM_130840 
ATPase, H+ transporting, lysosomal V0 
subunit a4 
SFXN3 0.505 SFX3; BA108L7.2 NM_030971 sideroflexin 3 
EHD2 0.505 PAST2 NM_014601 EH-domain containing 2 
MOBKL2C 0.504 MOB3C; MGC26743 NM_201403 
MOB1, Mps One Binder kinase activator-like 
2C (yeast) 
FUCA2 0.503 MGC1314; dJ20N2.5; RP1-20N2.5 NM_032020 fucosidase, alpha-L- 2, plasma 
PRICKLE2 0.503 
DKFZp686D143; DKFZp686M031; 
DKFZp686H1748 NM_198859 prickle-like 2 (Drosophila) 
DDEF2 0.503 
PAP; PAG3; AMAP2; SHAG1; KIAA0400; Pap-
alpha NM_003887 
development and differentiation enhancing 
factor 2 
TJP3 0.503 ZO-3; MGC119546 NM_014428 tight junction protein 3 (zona occludens 3) 
MORC4 0.502 ZCW4; ZCWCC2; FLJ11565; dJ75H8.2 NM_024657 MORC family CW-type zinc finger 4 
ACSL3 0.502 ACS3; FACL3; PRO2194 NM_004457 
acyl-CoA synthetase long-chain family 
member 3 
HSD11B1 0.501 
HDL; 11-DH; HSD11; HSD11B; HSD11L; 
MGC13539; 11-beta-HSD1 NM_005525 hydroxysteroid (11-beta) dehydrogenase 1 
CFH 0.501 
FH; HF; HF1; HF2; HUS; FHL1; CFHL3; 
MGC88246 NM_001014975 complement factor H 
ZAK 0.5 ZAK; AZK; MLT; MRK; MLK7; MLTK; mlklak NM_133646 
sterile alpha motif and leucine zipper 
containing kinase AZK 
PARP12 0.5 ZC3H1; PARP-12; ZC3HDC1; FLJ22693 NM_022750 
poly (ADP-ribose) polymerase family, 
member 12 
PNCK 0.5   NM_198452   
HTR7 0.499 5-HT7 NM_000872 
5-hydroxytryptamine (serotonin) receptor 7 
(adenylate cyclase-coupled) 
FLJ34922 0.498 SLFN8/9; FLJ34922 NM_152270 schlafen family member 11 
MGC15476 0.498 MGC15476 NM_145056 thymus expressed gene 3-like 
NPY 0.496 PYY4 NM_000905 neuropeptide Y 
 214
CALCA 0.494 




FHOD3 0.493 FHOS2; Formactin2 NM_025135 formin homology 2 domain containing 3 
FLJ20160 0.492 FLJ20160 NM_017694 FLJ20160 protein 
PPM2C 0.492 PDH; PDP; PDP1; PDPC; FLJ32517; MGC119646 NM_018444 
protein phosphatase 2C, magnesium-
dependent, catalytic subunit 
FBLN5 0.491 EVEC; UP50; ARMD3; DANCE; FLJ90059 NM_006329 fibulin 5 
CRYL1 0.491 MGC149525; MGC149526 NM_015974 crystallin, lambda 1 
PIP5K2A 0.491 PIPK; PIP5KII-alpha NM_005028 
phosphatidylinositol-4-phosphate 5-kinase, 
type II, alpha 
TXNDC5 0.491 ERP46; UNQ364; EndoPDI; MGC3178 NM_030810 thioredoxin domain containing 5 
SIRT1 0.49 SIR2L1 NM_012238 
sirtuin (silent mating type information 
regulation 2 homolog) 1 (S. cerevisiae) 
GNPDA2 0.49 SB52 NM_138335 glucosamine-6-phosphate deaminase 2 
C14ORF106 0.49 FLJ11186; KIAA1903; HSA242977 NM_018353 chromosome 14 open reading frame 106 
GNLY 0.49 
519; LAG2; NKG5; LAG-2; D2S69E; TLA519; 
lymphokine NM_012483 granulysin 
MATN2 0.489 MATN2 NM_030583 matrilin 2 
FLJ22746 0.488 FLJ22746 NM_024785 family with sequence similarity 124B 
RGC32 0.487 RGC32; KIAA0564; MGC87338; bA157L14.2 NM_014059 response gene to complement 32 
HPCAL1 0.487 BDR1; HLP2; VILIP-3 NM_002149 hippocalcin-like 1 
Sep-03 0.486 SEP3; MGC133218; bK250D10.3 NM_019106 septin 3 





SLC15A3 0.485 OCTP; PHT2; PTR3; hPTR3; FLJ26631 NM_016582 solute carrier family 15, member 3 
ABTB1 0.485 BPOZ; EF1ABP; PP2259; MGC20585 NM_172027 
ankyrin repeat and BTB (POZ) domain 
containing 1 
SP110 0.485 VODI; IFI41; IFI75; FLJ22835 NM_004510 SP110 nuclear body protein 
C7ORF10 0.485 ORF19; DERP13; FLJ11808 NM_024728 chromosome 7 open reading frame 10 
MCOLN2 0.484 TRPML2; FLJ36691 NM_153259 mucolipin 2 
TMEM30A 0.484 CDC50A; C6orf67; FLJ10856 NM_018247 transmembrane protein 30A 
RGS3 0.483 
C2PA; RGP3; FLJ20370; FLJ31516; FLJ90496; 
PDZ-RGS3 NM_144489 regulator of G-protein signalling 3 
FAM19A3 0.482 TAFA3; TAFA-3; MGC138473; RP11-426L16.6 NM_182759 
family with sequence similarity 19 
(chemokine (C-C motif)-like), member A3 
NTNG1 0.481 Lmnt1; KIAA0976 NM_014917 netrin G1 
SH3GL3 0.48 
CNSA3; EEN-B2; SH3D2C; SH3P13; HsT19371; 
EEN-2B-L3 NM_003027 SH3-domain GRB2-like 3 
EGFR 0.479 ERBB; mENA; ERBB1 NM_005228 
epidermal growth factor receptor 
(erythroblastic leukemia viral (v-erb-b) 
oncogene homolog, avian) 
MEF2D 0.479 DKFZp686I1536 NM_005920 
MADS box transcription enhancer factor 2, 
polypeptide D (myocyte enhancer factor 2D) 
FNDC6 0.479 MGC34923 NM_144717 fibronectin type III domain containing 6 
CELSR2 0.479 
EGFL2; MEGF3; CDHF10; FLJ34118; FLJ42737; 
FLJ45143; KIAA0279; Flamingo1 NM_001408 
cadherin, EGF LAG seven-pass G-type 
receptor 2 (flamingo homolog, Drosophila) 
BPGM 0.478 BPGM NM_001724 2,3-bisphosphoglycerate mutase 
NPDC1 0.477 CAB; CAB-; CAB1; CAB-1; DKFZP586J0523 NM_015392 
neural proliferation, differentiation and 
control, 1 
SIPA1 0.474 SPA1; MGC17037; MGC102688 NM_153253 signal-induced proliferation-associated gene 1 
PHLDA3 0.474 TIH1 NM_012396 
pleckstrin homology-like domain, family A, 
member 3 
TEX2 0.474 HT008; TMEM96; KIAA1738; DKFZp781G0721 NM_018469 testis expressed sequence 2 
LGALS3 0.473 GAL3; MAC2; CBP35; GALBP; LGALS2 NM_002306 
lectin, galactoside-binding, soluble, 3 (galectin 
3) 
PLCL2 0.473 PLCE2; FLJ13484; KIAA1092 NM_015184 phospholipase C-like 2 
ARL4 0.473 ARL4 NM_005738 ADP-ribosylation factor-like 4A 
RBPSUH 0.472 
csl; CBF1; KBF2; RBP-J; RBPJK; IGKJRB; 
IGKJRB1; MGC61669 NM_005349 
recombining binding protein suppressor of 
hairless (Drosophila) 
NMNAT2 0.472 PNAT2; PNAT-2; C1orf15; MGC2756; KIAA0479 NM_015039 nicotinamide nucleotide adenylyltransferase 2 
ACSM3 0.469 SA; SAH NM_202000 
acyl-CoA synthetase medium-chain family 
member 3 
CARD11 0.469 BIMP3; CARMA1; MGC133069 NM_032415 
caspase recruitment domain family, member 
11 
ELAVL2 0.468 HUB; HELN1; HEL-N1 NM_004432 
ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 2 (Hu antigen B) 
TCEAL7 0.468 MGC23947; MPMGp800C04260Q003 NM_152278 transcription elongation factor A (SII)-like 7 
DEPDC6 0.466 DEP.6; FLJ12428; FLJ13854; DKFZp564B1778 NM_022783 DEP domain containing 6 
GLI3 0.465 
PHS; ACLS; GCPS; PAPA; PAPB; PAP-A; PAPA1; 
PPDIV NM_000168 
GLI-Kruppel family member GLI3 (Greig 
cephalopolysyndactyly syndrome) 
FYCO1 0.464 
RUFY3; ZFYVE7; FLJ13335; MGC126517; 
MGC126519 NM_024513 FYVE and coiled-coil domain containing 1 
C14ORF138 0.464 FLJ13920 NM_024558 chromosome 14 open reading frame 138 
EVC 0.463   NM_014556   
BTN3A2 0.463 BTF4; BT3.2; BT3.3 NM_007047 butyrophilin, subfamily 3, member A2 
AMPH 0.463 AMPH1 NM_001635 
amphiphysin (Stiff-Man syndrome with breast 
cancer 128kDa autoantigen) 
SCARA3 0.463 CSR; APC7; CSR1; MSLR1; MSRL1 NM_016240 scavenger receptor class A, member 3 
GLI2 0.462 THP2 NM_005270 GLI-Kruppel family member GLI2 
DKFZP586H2123 0.461 DKFZP586H2123; RAMP; FP938 NM_001001991 regeneration associated muscle protease 
TSPAN33 0.461 PEN; MGC50844 NM_178562 tetraspanin 33 
COL6A3 0.461 FLJ34702; DKFZp686D23123; DKFZp686K04147 NM_057164 collagen, type VI, alpha 3 
ACVRL1 0.461 
HHT; ALK1; HHT2; ORW2; SKR3; ALK-1; 
ACVRLK1 NM_000020 activin A receptor type II-like 1 
PSG2 0.461 CEA; PSG1; PSBG2; PSGGB NM_031246 pregnancy specific beta-1-glycoprotein 2 
HSA9761 0.46 DIMT1; HSA9761 NM_014473 
DIM1 dimethyladenosine transferase 1-like 
(S. cerevisiae) 




HIST1H2AC 0.459 H2A/l; H2AFL; MGC99519; dJ221C16.4 NM_003512 histone 1, H2ac 
ERAF 0.459 AHSP; EDRF NM_016633 erythroid associated factor 
PGBD5 0.459 FLJ11413; DKFZp761A0620 NM_024554 piggyBac transposable element derived 5 




H2B; GL105; H2B.1; H2B/q; H2BFQ; MGC129733; 
MGC129734 NM_003528 histone 2, H2be 
SDSL 0.458 SDS-RS1 NM_138432 serine dehydratase-like 
C5ORF21 0.457 DKFZP564D172 NM_032042 chromosome 5 open reading frame 21 
NCALD 0.457 MGC33870; MGC74858 NM_032041 neurocalcin delta 
INPP1 0.456 MGC110984 NM_002194 inositol polyphosphate-1-phosphatase 
WIG1 0.455 WIG1; WIG-1; PAG608; FLJ12296; MGC10613 NM_152240 zinc finger, matrin type 3 
LRCH2 0.455 KIAA1495; dA204F4.4 NM_020871 
leucine-rich repeats and calponin homology 
(CH) domain containing 2 
BDNF 0.455 MGC34632 NM_001709 brain-derived neurotrophic factor 
PRSS23 0.455 SIG13; SPUVE; ZSIG13; MGC5107 NM_007173 protease, serine, 23 
APOD 0.454 APOD NM_001647 apolipoprotein D 
PBX1 0.454 MGC126627; DKFZp686B09108 NM_002585 pre-B-cell leukemia transcription factor 1 
GAS1 0.452 HAS3 NM_002048 growth arrest-specific 1 
CLIPR-59 0.452 CLIPR-59; CLIPR59; FLJ33413; DKFZp586N1922 NM_015526 CLIP-170-related protein 
SLC16A10 0.451 TAT1; PRO0813 NM_018593 
solute carrier family 16, member 10 (aromatic 
amino acid transporter) 
SLC25A12 0.45 ARALAR; ARALAR1 NM_003705 
solute carrier family 25 (mitochondrial carrier, 
Aralar), member 12 
OBFC2A 0.45   NM_022837   
LTBP2 0.45 LTBP3; MSTP031; C14orf141 NM_000428 
latent transforming growth factor beta binding 
protein 2 
C9ORF127 0.45 NGX6; NAG-5; MGC120460; RP11-112J3.10 NM_016446 chromosome 9 open reading frame 127 
PRG1 0.45 PPG; PRG; MGC9289; FLJ12930; SERGLYCIN NM_002727 proteoglycan 1, secretory granule 
SPG3A 0.45 ATL1; FSP1; GBP3; SPG3; AD-FSP; atlastin1 NM_181598 spastic paraplegia 3A (autosomal dominant) 
FOSL1 0.449 FRA1; fra-1 NM_005438 FOS-like antigen 1 
KLK6 0.449 
hK6; Bssp; Klk7; SP59; ZYME; PRSS9; PRSS18; 
MGC9355; NEUROSIN NM_002774 kallikrein 6 (neurosin, zyme) 
RAB13 0.448 GIG4 NM_002870 RAB13, member RAS oncogene family 
FADS3 0.447 CYB5RP; LLCDL3 NM_021727 fatty acid desaturase 3 
C1ORF94 0.446 MGC15882 NM_032884 chromosome 1 open reading frame 94 
SHC3 0.446 NSHC; SHCC; N-Shc NM_016848 
SHC (Src homology 2 domain containing) 
transforming protein 3 
GRIA3 0.445 GLUR3; GLURC; gluR-C; GLUR-K3 NM_181894 glutamate receptor, ionotrophic, AMPA 3 
CAPN5 0.445 HTRA3; nCL-3; FLJ46245 NM_004055 calpain 5 
NUDT6 0.445 
gfg; bFGF; FGF-2; gfg-1; ASFGF2; FGF-AS; 
FGF2AS NM_007083 
nudix (nucleoside diphosphate linked moiety 
X)-type motif 6 
LACTB2 0.444 CGI-83 NM_016027 lactamase, beta 2 
ALOX5 0.444 5-LO; 5LPG; LOG5 NM_000698 arachidonate 5-lipoxygenase 
MYO5A 0.444 
GS1; MYO5; MYH12; MYR12; MYOXIN; myosin 
V; myosin Va NM_000259 myosin VA (heavy polypeptide 12, myoxin) 
NRIP3 0.443 C11orf14; NY-SAR-105 NM_020645 nuclear receptor interacting protein 3 
RABGAP1L 0.443 
HHL; EVI5; TBC1D18; RP1-102G20.1; 
DKFZp686E1450 NM_014857 RAB GTPase activating protein 1-like 
LRFN5 0.443 FLJ30803; C14orf146; DKFZp686G0210 NM_152447 
leucine rich repeat and fibronectin type III 
domain containing 5 
FLJ21986 0.441 FLJ21986; FLJ26813 NM_024913 hypothetical protein FLJ21986 
KISS1R 0.441 GPR54; AXOR12; HOT7T175 NM_032551 KISS1 receptor 
PHLDA1 0.439 PHRIP; TDAG51; DT1P1B11; MGC131738 NM_007350 
pleckstrin homology-like domain, family A, 
member 1 
UBE2E2 0.439 UBCH8; FLJ25157 NM_152653 
ubiquitin-conjugating enzyme E2E 2 (UBC4/5 
homolog, yeast) 
NPAL3 0.437 DJ462O23.2; RP3-462O23.3; DKFZp686E22155 NM_020448 NIPA-like domain containing 3 
C6ORF192 0.436 dJ55C23.6 NM_052831 chromosome 6 open reading frame 192 
HSPA4 0.434 
RY; APG-2; hsp70; hsp70RY; HS24/P52; 
MGC131852 NM_002154 heat shock 70kDa protein 4 
RECQL 0.434 RecQ1; RECQL1 NM_002907 RecQ protein-like (DNA helicase Q1-like) 
PAPPA 0.434 
PAPA; DIPLA1; PAPP-A; PAPPA1; ASBABP2; 
IGFBP-4ase NM_002581 
pregnancy-associated plasma protein A, 
pappalysin 1 
SV2A 0.433 SV2; KIAA0736 NM_014849 synaptic vesicle glycoprotein 2A 
ITGA2 0.432 BR; GPIa; CD49B; VLA-2; VLAA2 NM_002203 
integrin, alpha 2 (CD49B, alpha 2 subunit of 
VLA-2 receptor) 
KIAA1913 0.432 TTMC NM_052913 KIAA1913 
COPZ2 0.432 COPZ2 NM_016429 coatomer protein complex, subunit zeta 2 
GLS2 0.431 GA; GLS; LGA; hLGA; MGC71567 NM_013267 glutaminase 2 (liver, mitochondrial) 
AFP 0.431 FETA; HPAFP NM_001134 alpha-fetoprotein 
MGC17330 0.431 MGC17330; HGFL; hHGFL(S) NM_052880 HGFL gene 
GOLPH4 0.43 P138; GIMPC; GPP130 NM_014498 golgi phosphoprotein 4 
GPR137B 0.428 TM7SF1 NM_003272 G protein-coupled receptor 137B 
CAST 0.428 BS-17; MGC9402 NM_001750 calpastatin 
HYAL1 0.427 NAT6; LUCA1; HYAL-1; MGC45987 NM_153281 hyaluronoglucosaminidase 1 
ARHGDIB 0.427 D4; GDIA2; GDID4; LYGDI; Ly-GDI; RAP1GN1 NM_001175 Rho GDP dissociation inhibitor (GDI) beta 
CASP1 0.426 ICE; P45; IL1BC NM_033294 
caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 
STS-1 0.426 STS-1; p70; KIAA1959; MGC15437 NM_032873 Cbl-interacting protein Sts-1 
LPPR2 0.425 LPPR2; PRG-4; FLJ13055; DKFZp761E1121 NM_022737 
lipid phosphate phosphatase-related protein 
type 2 
NIN 0.425 KIAA1565 NM_020921 ninein (GSK3B interacting protein) 
KCNS3 0.425 KV9.3; MGC9481 NM_002252 
potassium voltage-gated channel, delayed-
rectifier, subfamily S, member 3 
UGCG 0.424 GCS NM_003358 UDP-glucose ceramide glucosyltransferase 
OSBPL10 0.424 ORP10; OSBP9; FLJ20363 NM_017784 oxysterol binding protein-like 10 
CCND3 0.423 CCND3 NM_001760 cyclin D3 
KDELR3 0.423 ERD2L3 NM_016657 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 
TNFRSF1B 0.422 
p75; TBPII; TNFBR; TNFR2; CD120b; TNFR80; 
TNF-R75; p75TNFR; TNF-R-II NM_001066 
tumor necrosis factor receptor superfamily, 
member 1B 
PPP1R3C 0.422 PPP1R5 NM_005398 
protein phosphatase 1, regulatory (inhibitor) 
subunit 3C 
ACOX2 0.421 BCOX; BRCOX; THCCox; BRCACOX NM_003500 acyl-Coenzyme A oxidase 2, branched chain 
SLC16A2 0.421 AHDS; MCT7; MCT8; XPCT; DXS128; DXS128E NM_006517 
solute carrier family 16, member 2 
(monocarboxylic acid transporter 8) 
MASP1 0.419 
MASP; RaRF; CRARF; PRSS5; CRARF1; 
FLJ26383; MGC126283; MGC126284; NM_001031849 
mannan-binding lectin serine peptidase 1 
(C4/C2 activating component of Ra-reactive 
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DKFZp686I01199 factor) 
transporter 2, ATP-binding cassette, sub-
family B (MDR/TAP) TAP2 0.418 APT2; PSF2; ABC18; ABCB3; RING11; D6S217E NM_000544 
G0S2 0.417 RP1-28O10.2 NM_015714 G0/G1switch 2 
TBC1D23 0.417 NS4ATP1; FLJ11046; DKFZp667G062 NM_018309 TBC1 domain family, member 23 
SLC30A3 0.417 ZNT3 NM_003459 
solute carrier family 30 (zinc transporter), 
member 3 
FCRLM2 0.416 FcRY; FCRL2; FCRLY; FREB-2; RP11-474I16.6 NM_001002901 Fc receptor-like and mucin-like 2 
SDC1 0.415 SDC; CD138; SYND1 NM_002997 syndecan 1 
DDB2 0.415 DDB2 NM_000107 
damage-specific DNA binding protein 2, 
48kDa 
DIRAS3 0.414 ARHI; NOEY2 NM_004675 DIRAS family, GTP-binding RAS-like 3 
SLIT3 0.413 MEGF5; SLIL2; SLIT1; slit2; Slit-3; FLJ10764 NM_003062 slit homolog 3 (Drosophila) 
GLS 0.413 GLS1; FLJ10358; KIAA0838; DKFZp686O15119 NM_014905 glutaminase 
ISG20 0.412 CD25; HEM45 NM_002201 interferon stimulated exonuclease gene 20kDa 
FOLR3 0.41 FR-G; FR-gamma; gamma-hFR NM_000804 folate receptor 3 (gamma) 
FAM43A 0.41 FLJ90022 NM_153690 family with sequence similarity 43, member A 
CREB5 0.407 CRE-BPA NM_182898 cAMP responsive element binding protein 5 
ANTXR2 0.407 
ISH; JHF; CMG2; CMG-2; FLJ31074; MGC45856; 
MGC111533 NM_058172 anthrax toxin receptor 2 
EXO1 0.406 HEX1; hExoI NM_003686 exonuclease 1 
NRP1 0.406 
NRP; CD304; VEGF165R; DKFZp781F1414; 
DKFZp686A03134 NM_003873 neuropilin 1 
IRX2 0.406 MARK2 NM_033267 iroquois homeobox protein 2 
GNG12 0.405 FLJ31352; FLJ34695 NM_018841 
guanine nucleotide binding protein (G 
protein), gamma 12 
C9ORF88 0.405 
OC58; MEG-3; FLJ13518; FLJ22151; FLJ22298; 
bA356B19.6; DKFZP434H0820; RP11-356B19.6 NM_022833 chromosome 9 open reading frame 88 
MYLK 0.404 
KRP; MLCK; MLCK108; MLCK210; MSTP083; 
FLJ12216; DKFZp686I10125 NM_005965 myosin, light polypeptide kinase 
CDCP1 0.402 CD318; TRASK; SIMA135 NM_022842 CUB domain containing protein 1 
PEA15 0.402 
PED; MAT1; HMAT1; MAT1H; PEA-15; 
HUMMAT1H NM_003768 phosphoprotein enriched in astrocytes 15 
C6ORF32 0.4 PL48; DIFF40; DIFF48; FAM65B; KIAA0386 NM_015864 chromosome 6 open reading frame 32 
TGFBR2 0.399 
AAT3; FAA3; MFS2; RIIC; TAAD2; HNPCC6; 
TGFR-2; TGFbeta-RII NM_001024847 
transforming growth factor, beta receptor II 
(70/80kDa) 
RPS26 0.399 MGC104292 NM_001029 ribosomal protein S26 
CTHRC1 0.399 GIMAP5 NM_138455 collagen triple helix repeat containing 1 
PDSS2 0.399 hDLP1; C6orf210; bA59I9.3 NM_020381 
prenyl (decaprenyl) diphosphate synthase, 
subunit 2 
MASP1 0.397 
MASP; RaRF; CRARF; PRSS5; CRARF1; 
FLJ26383; MGC126283; MGC126284; 
DKFZp686I01199 NM_001031849 
mannan-binding lectin serine peptidase 1 
(C4/C2 activating component of Ra-reactive 
factor) 
NID2 0.397 NID2 NM_007361 nidogen 2 (osteonidogen) 
IRXL1 0.396 IFRX; IRXL1; C10orf48; MGC39616 NM_173576 mohawk homeobox 
IL32 0.396 
NK4; TAIF; TAIFa; TAIFb; TAIFc; TAIFd; IL-
32beta; IL-32alpha; IL-32delta; IL-32gamma NM_001012632 interleukin 32 
C21ORF7 0.396 TAK1L NM_020152 chromosome 21 open reading frame 7 
ITGB1 0.394 CD29; FNRB; MDF2; VLAB; GPIIA; MSK12 NM_133376 
integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
CCBL1 0.393 GTK; KATI; MGC29624 NM_004059 
cysteine conjugate-beta lyase; cytoplasmic 
(glutamine transaminase K, kyneurenine 
aminotransferase) 
TNFRSF19 0.392 TAJ; TROY; TRADE; TAJ-alpha NM_148957 
tumor necrosis factor receptor superfamily, 
member 19 
ART5 0.391 MGC22848 NM_053017 ADP-ribosyltransferase 5 
TBC1D4 0.39 AS160; DKFZp779C0666 NM_014832 TBC1 domain family, member 4 
CADPS2 0.389 FLJ40851; KIAA1591 NM_017954 
Ca2+-dependent activator protein for secretion 
2 
LAYN 0.389 FLJ30977; FLJ31092 NM_178834 layilin 
MAP3K5 0.389 ASK1; MEKK5; MAPKKK5 NM_005923 
mitogen-activated protein kinase kinase kinase 
5 
SNCAIP 0.388 SYPH1; MGC39814 NM_005460 synuclein, alpha interacting protein (synphilin) 
LRRC33 0.388 GARPL1; UNQ3030; MGC50789 NM_198565 leucine rich repeat containing 33 
IL12A 0.387 CLMF; NFSK; NKSF1; IL-12A NM_000882 
interleukin 12A (natural killer cell stimulatory 
factor 1, cytotoxic lymphocyte maturation 
factor 1, p35) 
PSG6 0.387 PSG10 NM_001031850 pregnancy specific beta-1-glycoprotein 6 
MAFF 0.386 U-MAF NM_012323 
v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog F (avian) 
CPT1A 0.384 CPT1; CPT1-L; L-CPT1 NM_001876 carnitine palmitoyltransferase 1A (liver) 
C9ORF26 0.384 
IL33; DVS27; NF-HEV; NFEHEV; 
DKFZp586H0523; RP11-575C20.2 NM_033439 
chromosome 9 open reading frame 26 (NF-
HEV) 
DKFZP564O0823 0.384 DKFZP564O0823 NM_015393 DKFZP564O0823 protein 
S100A3 0.383 S100E NM_002960 S100 calcium binding protein A3 
ASAHL 0.383 PLT; NAAA NM_014435 
N-acylsphingosine amidohydrolase (acid 
ceramidase)-like 
ACTN3 0.382 MGC117002; MGC117005 NM_001104 actinin, alpha 3 
AKR1C3 0.381 
DD3; HAKRB; HAKRe; HA1753; HSD17B5; 
hluPGFS; KIAA0119 NM_003739 
aldo-keto reductase family 1, member C3 (3-
alpha hydroxysteroid dehydrogenase, type II) 
SHRM 0.381 SHRM; APXL3; ShrmL; MSTP013; KIAA1481 NM_020859 shroom family member 3 
ST7 0.381 
HELG; RAY1; SEN4; TSG7; ETS7q; FAM4A1; 
DKFZp762O2113 NM_021908 suppression of tumorigenicity 7 
MAP1A 0.38 MAP1L; MTAP1A NM_002373 microtubule-associated protein 1A 
ENG 0.38 END; ORW; HHT1; ORW1; CD105; FLJ41744 NM_000118 endoglin (Osler-Rendu-Weber syndrome 1) 
CYBRD1 0.378 DCYTB; FRRS3; FLJ23462 NM_024843 cytochrome b reductase 1 
HPS3 0.377 SUTAL; FLJ22704; DKFZp686F0413 NM_032383 Hermansky-Pudlak syndrome 3 
SCHIP1 0.377 SCHIP-1; FLJ39160 NM_014575 schwannomin interacting protein 1 
MAT2B 0.376 TGR; MAT-II; MGC12237; MATIIbeta; Nbla02999 NM_182796 methionine adenosyltransferase II, beta 
CTSB 0.376 APPS; CPSB NM_001908 cathepsin B 
PLAUR 0.376 CD87; UPAR; URKR NM_001005376 plasminogen activator, urokinase receptor 
ATP5G2 0.375 RNASE1 NM_001002031 
ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit C2 (subunit 9) 
LMNA 0.375 
FPL; IDC; LFP; CDDC; EMD2; FPLD; HGPS; 
LDP1; LMN1; LMNC; PRO1; CDCD1; CMD1A; NM_005572 lamin A/C 
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CMT2B1; LGMD1B 
RGS10 0.374 RGS10 NM_001005339 regulator of G-protein signalling 10 
COL12A1 0.374 COL12A1L; BA209D8.1; DJ234P15.1 NM_080645 collagen, type XII, alpha 1 
SLC1A5 0.374 
R16; AAAT; ATBO; M7V1; RDRC; ASCT2; 
M7VS1; FLJ31068 NM_005628 
solute carrier family 1 (neutral amino acid 
transporter), member 5 
LMNA 0.374 
FPL; IDC; LFP; CDDC; EMD2; FPLD; HGPS; 
LDP1; LMN1; LMNC; PRO1; CDCD1; CMD1A; 
CMT2B1; LGMD1B NM_005572 lamin A/C 
RRM2B 0.373 
p53R2; MGC42116; MGC102856; 
DKFZp686M05248 NM_015713 
ribonucleotide reductase M2 B (TP53 
inducible) 
PVRL3 0.373 
PPR3; PRR3; PVRR3; CDw113; FLJ90624; nectin-
3; DKFZP566B0846 NM_015480 poliovirus receptor-related 3 
ACSL4 0.371 ACS4; FACL4; LACS4; MRX63; MRX68 NM_004458 
acyl-CoA synthetase long-chain family 
member 4 
PTGS1 0.371 
COX1; COX3; PHS1; PCOX1; PGHS1; PTGHS; 
PGG/HS; PGHS-1 NM_000962 
prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and 
cyclooxygenase) 
FLJ43339 0.37 FLJ43339; DKFZp686N1468 NM_207380 FLJ43339 protein 
ERBB3 0.37 
HER3; ErbB-3; c-erbB3; erbB3-S; MDA-BF-1; 
MGC88033; c-erbB-3; p180-ErbB3; p45-sErbB3; 
p85-sErbB3 NM_001982 
v-erb-b2 erythroblastic leukemia viral 
oncogene homolog 3 (avian) 
TACC1 0.37 Ga55; KIAA1103; DKFZp686K18126 NM_006283 
transforming, acidic coiled-coil containing 
protein 1 
SELM 0.37 SELM; SEPM; MGC40146 NM_080430 selenoprotein M 
CDH11 0.37 OB; CAD11; CDHOB; OSF-4 NM_001797 cadherin 11, type 2, OB-cadherin (osteoblast) 
ARNT2 0.369 KIAA0307 NM_014862 
aryl-hydrocarbon receptor nuclear translocator 
2 
KIAA0773 0.368 KIAA0773 NM_014690 KIAA0773 gene product 
RHBDL3 0.368 
VRHO; RHBDL4; FLJ45582; MGC119300; 
MGC119301 NM_138328 rhomboid, veinlet-like 3 (Drosophila) 
SOCS1 0.367 JAB; CIS1; SSI1; TIP3; CISH1; SSI-1; SOCS-1 NM_003745 suppressor of cytokine signaling 1 
LHFP 0.366 MGC22429 NM_005780 lipoma HMGIC fusion partner 
WNT5B 0.366 MGC2648 NM_032642 
wingless-type MMTV integration site family, 
member 5B 
CBX6 0.366 ALDOA NM_014292 chromobox homolog 6 
ZNF483 0.366 ZNF483 NM_001007169 zinc finger protein 483 
LITAF 0.365 
PIG7; CMT1C; SIMPLE; TP53I7; FLJ38636; 
MGC116698; MGC116700; MGC116701; 
MGC125274; MGC125275; MGC125276 NM_004862 lipopolysaccharide-induced TNF factor 
PPM1E 0.364 POPX1; PP2CH; KIAA1072; DKFZp781F1422 NM_014906 
protein phosphatase 1E (PP2C domain 
containing) 
CD68 0.364 GP110; SCARD1; DKFZp686M18236 NM_001251 CD68 molecule 
IL15 0.363 IL-15; MGC9721 NM_172174 interleukin 15 
BZRP 0.363 
DBI; IBP; MBR; PBR; BZRP; PKBS; PTBR; 
mDRC; pk18 NM_000714 translocator protein (18kDa) 
NFIX 0.362 NF1A NM_002501 
nuclear factor I/X (CCAAT-binding 
transcription factor) 
DDR2 0.362 TKT; NTRKR3; TYRO10 NM_006182 discoidin domain receptor family, member 2 
SYT13 0.362 KIAA1427 NM_020826 synaptotagmin XIII 
HCP5 0.362 P5-1; D6S2650E NM_006674 HLA complex P5 
RRAGD 0.361 RAGD; bA11D8.2.1; DKFZP761H171 NM_021244 Ras-related GTP binding D 
SYTL2 0.361 
SLP2; SGA72M; CHR11SYT; KIAA1597; 
MGC102768 NM_206930 synaptotagmin-like 2 
DOCK2 0.361 KIAA0209 NM_004946 dedicator of cytokinesis 2 
SAMD4A 0.361 
SMG; SMGA; SAMD4; Smaug; Smaug1; 
KIAA1053; DKFZp434H0350 NM_015589 sterile alpha motif domain containing 4A 
MGC20983 0.36 MGC20983; FLJ31801 NM_145045 hypothetical protein MGC20983 
C18ORF17 0.36 HsT2697; FLJ33761 NM_153211 chromosome 18 open reading frame 17 
CXCL16 0.359 SRPSOX; CXCLG16; SR-PSOX NM_022059 chemokine (C-X-C motif) ligand 16 
KDELR3 0.359 ERD2L3 NM_016657 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 
SLC1A3 0.356 EA6; EAAT1; GLAST; GLAST1; FLJ25094 NM_004172 
solute carrier family 1 (glial high affinity 
glutamate transporter), member 3 
LTBR 0.356 
CD18; TNFCR; D12S370; TNFR-RP; TNFRSF3; 
TNFR2-RP; LT-BETA-R; TNF-R-III NM_002342 
lymphotoxin beta receptor (TNFR 
superfamily, member 3) 
ITGA3 0.356 
VL3A; CD49C; GAPB3; MSK18; VCA-2; VLA3a; 
GAP-B3; FLJ34631 NM_002204 
integrin, alpha 3 (antigen CD49C, alpha 3 
subunit of VLA-3 receptor) 
OPN3 0.355 ECPN NM_001030012 opsin 3 (encephalopsin, panopsin) 
INA 0.355 NEF5; NF-66; TXBP-1; MGC12702 NM_032727 
internexin neuronal intermediate filament 
protein, alpha 
TUBA1 0.354 FLJ30169; H2-ALPHA NM_006000 tubulin, alpha 1 
TSRC1 0.354 TSRC1 NM_025008 ADAMTS-like 4 
LCE2C 0.354 LEP11 NM_178429 late cornified envelope 2C 
LRRC20 0.354 FLJ10751; FLJ10844 NM_207119 leucine rich repeat containing 20 
PAM 0.353 PAL; PHM NM_138821 
peptidylglycine alpha-amidating 
monooxygenase 
ATP1A2 0.352 FHM2; MHP2; MGC59864 NM_000702 
ATPase, Na+/K+ transporting, alpha 2 (+) 
polypeptide 
ZDHHC22 0.351 C14orf59 NM_174976 zinc finger, DHHC-type containing 22 
HEBP1 0.351 HBP; HEBP NM_015987 heme binding protein 1 
HCLS1 0.35 HS1 NM_005335 hematopoietic cell-specific Lyn substrate 1 
TBX2 0.349 FLJ10169 NM_005994 T-box 2 
CHGB 0.349 SCG1 NM_001819 chromogranin B (secretogranin 1) 
RGS20 0.348 RGSZ1; ZGAP1 NM_170587 regulator of G-protein signalling 20 
DHDH 0.348 HUM2DD NM_014475 dihydrodiol dehydrogenase (dimeric) 
KCTD12 0.348 PFET1; C13orf2; KIAA1778 NM_138444 
potassium channel tetramerisation domain 
containing 12 
BNC2 0.348 BSN2; FLJ20043; FLJ34928; DKFZp686A01127 NM_017637 basonuclin 2 
CLEC11A 0.348 P47; SCGF; LSLCL; CLECSF3 NM_002975 C-type lectin domain family 11, member A 
GRIA3 0.347 GLUR3; GLURC; gluR-C; GLUR-K3 NM_181894 glutamate receptor, ionotrophic, AMPA 3 
MRGPRF 0.344 RTA; mrgF; GPR140; GPR168; MGC21621 NM_145015 MAS-related GPR, member F 
GAP43 0.343 B-50; PP46 NM_002045 growth associated protein 43 
EDIL3 0.343 DEL1; MGC26287 NM_005711 
EGF-like repeats and discoidin I-like domains 
3 
EFEMP1 0.343 
DHRD; DRAD; FBNL; MLVT; MTLV; S1-5; 
FBLN3; FLJ35535; MGC111353 NM_004105 
EGF-containing fibulin-like extracellular 
matrix protein 1 
 218




ADORA2A 0.341 RDC8; hA2aR; ADORA2 NM_000675 adenosine A2a receptor 
LAMC2 0.34 
B2T; EBR2; BM600; EBR2A; LAMB2T; LAMNB2; 
MGC138491; MGC141938 NM_005562 laminin, gamma 2 
PHLDA2 0.34 IPL; BRW1C; BWR1C; HLDA2; TSSC3 NM_003311 
pleckstrin homology-like domain, family A, 
member 2 
LOXL4 0.34 LOXC; FLJ21889 NM_032211 lysyl oxidase-like 4 
MYBPH 0.34 MYBPH NM_004997 myosin binding protein H 
BNC1 0.338 BNC; BSN1; HsT19447 NM_001717 basonuclin 1 
PLA2G4A 0.337 PLA2G4; MGC126350; cPLA2-alpha NM_024420 
phospholipase A2, group IVA (cytosolic, 
calcium-dependent) 
PTHB1 0.337 PTHB1; B1; D1; C18; BBS9; MGC118917 NM_001033604 parathyroid hormone-responsive B1 
IGFBP7 0.337 PSF; FSTL2; MAC25; IGFBP-7; IGFBP-7v NM_001553 insulin-like growth factor binding protein 7 
DUSP1 0.337 HVH1; CL100; MKP-1; PTPN10 NM_004417 dual specificity phosphatase 1 
ASB9 0.336 MGC4954; FLJ20636; DKFZp564L0862 NM_024087 ankyrin repeat and SOCS box-containing 9 
GPR19 0.335 GPR19 NM_006143 G protein-coupled receptor 19 
ZNF537 0.334 TSH3; ZNF537; KIAA1474 NM_020856 teashirt family zinc finger 3 
DAZL 0.334 DAZH; DAZL1; DAZLA; SPGYLA; MGC26406 NM_001351 deleted in azoospermia-like 
KCNS1 0.334 KV9.1 NM_002251 
potassium voltage-gated channel, delayed-
rectifier, subfamily S, member 1 
TXNRD2 0.334   NM_145748   
NPTX1 0.332 NP1; MGC105123; DKFZp686J2446 NM_002522 neuronal pentraxin I 
TRERF1 0.331 
RAPA; TReP-132; HSA277276; dJ139D8.5; RP1-
139D8.5 NM_033501 transcriptional regulating factor 1 
RPS4Y1 0.33 RPS4Y; MGC5070; MGC119100 NM_001008 ribosomal protein S4, Y-linked 1 
ASMTL 0.33 ASTML; ASMTLX; ASMTLY NM_004192 acetylserotonin O-methyltransferase-like 
EEF2K 0.329 eEF-2K; HSU93850; MGC45041 NM_013302 eukaryotic elongation factor-2 kinase 
KDELR3 0.329 ERD2L3 NM_006855 
KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 
PRKCA 0.328 
AAG6; PKCA; PRKACA; MGC129900; 
MGC129901; PKC-alpha NM_002737 protein kinase C, alpha 
MGC34830 0.327 MGC34830 NM_152314 chromosome 11 open reading frame 69 
FILIP1 0.327 FILIP; KIAA1275 NM_015687 filamin A interacting protein 1 
CYFIP2 0.326 PIR121 NM_014376 cytoplasmic FMR1 interacting protein 2 
LOC205251 0.326   NM_174925   
Sep-03 0.325 SEP3; MGC133218; bK250D10.3 NM_019106 septin 3 
CD59 0.324 
EJ16; EJ30; EL32; G344; MIN1; MIN2; MIN3; 
MIC11; MSK21; 16.3A5; p18-20; MGC2354; 
PROTECTIN NM_203329 
CD59 molecule, complement regulatory 
protein 
HIST2H2AC 0.324 H2A; H2A/q; H2AFQ; MGC74460; H2A-GL101 NM_003517 histone 2, H2ac 
DOCK10 0.324 ZIZ3; DRIP2; Nbla10300; DKFZp781A1532 NM_014689 dedicator of cytokinesis 10 
ARRDC4 0.323 FLJ36045 NM_183376 arrestin domain containing 4 
HGF 0.322 SF; HGFB; HPTA; F-TCF NM_001010931 
hepatocyte growth factor (hepapoietin A; 
scatter factor) 
CD47 0.322   NM_001025080   
TAPBP 0.322 TPN; TAPA; TPSN; NGS17 NM_003190 TAP binding protein (tapasin) 
MSRB3 0.321 FLJ36866; DKFZp686C1178 NM_198080 methionine sulfoxide reductase B3 
HIST1H1C 0.32 H1.2; H1F2; MGC3992 NM_005319 histone 1, H1c 
UGT8 0.319 CGT NM_003360 
UDP glycosyltransferase 8 (UDP-galactose 
ceramide galactosyltransferase) 
TSRC1 0.319 TSRC1 NM_025008 ADAMTS-like 4 
SRPX2 0.318 SRPX; SRPUL NM_014467 sushi-repeat-containing protein, X-linked 2 
VAMP4 0.317 VAMP24 NM_003762 vesicle-associated membrane protein 4 
CSEN 0.317 CSEN; DREAM; KCHIP3; MGC18289 NM_013434 Kv channel interacting protein 3, calsenilin 
CD82 0.317 
R2; 4F9; C33; IA4; ST6; GR15; KAI1; SAR2; 
TSPAN27 NM_001024844 CD82 molecule 
PLXDC2 0.315 TEM7R; FLJ14623 NM_032812 plexin domain containing 2 
STAMBPL1 0.314 
AMSH-FP; AMSH-LP; ALMalpha; FLJ31524; 
KIAA1373; bA399O19.2 NM_020799 STAM binding protein-like 1 
ZDHHC14 0.314 NEW1CP; FLJ20984 NM_024630 zinc finger, DHHC-type containing 14 
FLJ11259 0.313 DRAM; FLJ11259 NM_018370 damage-regulated autophagy modulator 
GLT8D2 0.313 FLJ31494 NM_031302 glycosyltransferase 8 domain containing 2 
AXL 0.312 UFO NM_001699 AXL receptor tyrosine kinase 
LIPA 0.311 LAL; CESD NM_000235 
lipase A, lysosomal acid, cholesterol esterase 
(Wolman disease) 
DPYSL3 0.31 DRP3; ULIP; CRMP4; DRP-3; CRMP-4 NM_001387 dihydropyrimidinase-like 3 
CSRP1 0.31 
CRP; CRP1; CSRP; CYRP; D1S181E; 
DKFZp686M148 NM_004078 cysteine and glycine-rich protein 1 
LIF 0.31 CDF; HILDA; D-FACTOR NM_002309 
leukemia inhibitory factor (cholinergic 
differentiation factor) 
MGLL 0.31 MGL; HU-K5 NM_007283 monoglyceride lipase 
NR4A2 0.307 NOT; RNR1; HZF-3; NURR1; TINUR NM_006186 
nuclear receptor subfamily 4, group A, 
member 2 
PLAU 0.305 ATF; UPA; URK; u-PA NM_002658 plasminogen activator, urokinase 
NMI 0.304 NMI NM_004688 N-myc (and STAT) interactor 
COL1A1 0.304 OI4 NM_000088 collagen, type I, alpha 1 
CAT 0.303 MGC138422; MGC138424 NM_001752 catalase 
PROCR 0.302 
CCCA; EPCR; CCD41; CD201; MGC23024; 
bA42O4.2 NM_006404 protein C receptor, endothelial (EPCR) 
THBS1 0.302 TSP; THBS; TSP1 NM_003246 thrombospondin 1 
GPD1L 0.301 KIAA0089 NM_015141 glycerol-3-phosphate dehydrogenase 1-like 
SLC22A4 0.3 OCTN1; MGC34546; MGC40524 NM_003059 
solute carrier family 22 (organic cation 
transporter), member 4 
MBNL1 0.3 
EXP; MBNL; EXP35; EXP40; EXP42; KIAA0428; 
DKFZp686P06174 NM_207293 muscleblind-like (Drosophila) 
TFAP2C 0.3 ERF1; TFAP2G; hAP-2g; AP2-GAMMA NM_003222 
transcription factor AP-2 gamma (activating 
enhancer binding protein 2 gamma) 
TXNDC5 0.3 ERP46; UNQ364; EndoPDI; MGC3178 NM_030810 thioredoxin domain containing 5 
WNT5A 0.3 hWNT5A NM_003392 
wingless-type MMTV integration site family, 
member 5A 
TERF1 0.3 TRF; PIN2; TRF1; TRBF1; t-TRF1; hTRF1-AS NM_003218 
telomeric repeat binding factor (NIMA-
interacting) 1 
TGM3 0.299 TGE; MGC126249; MGC126250 NM_003245 
transglutaminase 3 (E polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
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PRRX2 0.298 PMX2; PRX2; MGC19843 NM_016307 paired related homeobox 2 
LCE2A 0.297 LEP9 NM_178428 late cornified envelope 2A 
SP110 0.297 VODI; IFI41; IFI75; FLJ22835 NM_004510 SP110 nuclear body protein 
SPOCD1 0.297 FLJ25348; FLJ39908; RP11-84A19.1 NM_144569 SPOC domain containing 1 
SLC16A6 0.297 MCT6; MCT7 NM_004694 
solute carrier family 16, member 6 
(monocarboxylic acid transporter 7) 
MOCOS 0.296 MOS; HMCS; FLJ20733 NM_017947 molybdenum cofactor sulfurase 




APT1; PSF1; ABC17; ABCB2; RING4; TAP1N; 
D6S114E; FLJ26666; TAP1*0102N NM_000593 
transporter 1, ATP-binding cassette, sub-
family B (MDR/TAP) 
FLJ90805 0.293 FLJ90805 NM_173633 transmembrane protein 145 
TMEM22 0.291 MGC3295; DKFZp564K2464 NM_025246 transmembrane protein 22 
FAM101B 0.291 MGC45871 NM_182705 
family with sequence similarity 101, member 
B 
ZNF488 0.289 FLJ32104 NM_153034 zinc finger protein 488 
MME 0.288 
NEP; CD10; CALLA; MGC126681; MGC126707; 
DKFZp686O16152 NM_007288 
membrane metallo-endopeptidase (neutral 
endopeptidase, enkephalinase, CALLA, 
CD10) 
MOBKL2B 0.287 MOB3B; FLJ13204; FLJ23916; MGC32960 NM_024761 
MOB1, Mps One Binder kinase activator-like 
2B (yeast) 
HLA-E 0.285 MHC; EA1.2; EA2.1; HLA-6.2; DKFZp686P19218 NM_005516 major histocompatibility complex, class I, E 
SGNE1 0.285 7B2; SgV; P7B2; SGNE1 NM_003020 secretogranin V (7B2 protein) 
KLF9 0.285 BTEB; BTEB1 NM_001206 Kruppel-like factor 9 
S100A6 0.285 2A9; PRA; 5B10; CABP; CACY NM_014624 S100 calcium binding protein A6 
STEAP2 0.284 STMP; IPCA1; PUMPCn; STAMP1; PCANAP1 NM_152999 
six transmembrane epithelial antigen of the 
prostate 2 
COTL1 0.283 CLP; FLJ43657; MGC19733 NM_021149 coactosin-like 1 (Dictyostelium) 
PRPS2 0.283 PRSII; PRS II NM_002765 phosphoribosyl pyrophosphate synthetase 2 
CD97 0.282 TM7LN1 NM_078481 CD97 molecule 
TFPI2 0.282 PP5; TFPI-2; FLJ21164 NM_006528 tissue factor pathway inhibitor 2 
ITGB1 0.281 CD29; FNRB; MDF2; VLAB; GPIIA; MSK12 NM_133376 
integrin, beta 1 (fibronectin receptor, beta 
polypeptide, antigen CD29 includes MDF2, 
MSK12) 
APOBEC3B 0.281 
ARP4; ARCD3; PHRBNL; APOBEC1L; FLJ21201; 
bK150C2.2; DJ742C19.2 NM_004900 
apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3B 
DSCR1 0.28 CSP1; DSC1; RCN1; MCIP1; ADAPT78 NM_203417 Down syndrome critical region gene 1 
CTSK 0.28 
CTSO; PKND; PYCD; CTS02; CTSO1; CTSO2; 
MGC23107 NM_000396 cathepsin K (pycnodysostosis) 
METTL7A 0.279 AAM-B; DKFZP586A0522 NM_014033 methyltransferase like 7A 
CXCL12 0.279 
PBSF; SDF1; SDF1A; SDF1B; TPAR1; SCYB12; 
SDF-1a; SDF-1b; TLSF-a; TLSF-b NM_199168 
chemokine (C-X-C motif) ligand 12 (stromal 
cell-derived factor 1) 
PRKCB1 0.277 PKCB; PRKCB; PRKCB2; MGC41878; PKC-beta NM_002738 protein kinase C, beta 1 
FLJ13391 0.276 FLJ13391 NM_032181 transmembrane protein 166 
ANKRD35 0.275 FLJ25124; MGC126667; MGC126669 NM_144698 ankyrin repeat domain 35 
SOX3 0.274 MRGH; SOXB NM_005634 SRY (sex determining region Y)-box 3 
FGF2 0.274 BFGF; FGFB; HBGH-2 NM_002006 fibroblast growth factor 2 (basic) 
SQRDL 0.272 CGI-44 NM_021199 sulfide quinone reductase-like (yeast) 
RCN3 0.271 RLP49 NM_020650 
reticulocalbin 3, EF-hand calcium binding 
domain 
UNC5A 0.27 UNC5H1; FLJ16449; KIAA1976 NM_133369 unc-5 homolog A (C. elegans) 
ARID5B 0.27 MRF2; FLJ21150; RP11-341A19.1 NM_032199 AT rich interactive domain 5B (MRF1-like) 
COL3A1 0.269 EDS4A NM_000090 
collagen, type III, alpha 1 (Ehlers-Danlos 
syndrome type IV, autosomal dominant) 
PRNP 0.269 
CJD; GSS; PrP; ASCR; PRIP; PrPc; CD230; 
MGC26679; PrP27-30; PrP33-35C NM_183079 
prion protein (p27-30) (Creutzfeldt-Jakob 
disease, Gerstmann-Strausler-Scheinker 
syndrome, fatal familial insomnia) 
STEAP1 0.268 STEAP; PRSS24; MGC19484 NM_012449 
six transmembrane epithelial antigen of the 
prostate 1 
FLNC 0.267 
ABPA; ABPL; FLN2; ABP-280; ABP280A; 
FLJ10186 NM_001458 filamin C, gamma (actin binding protein 280) 
PRRX1 0.267 PMX1; PRX1; PHOX1 NM_022716 paired related homeobox 1 
MX1 0.267 MX; MxA; IFI78; IFI-78K NM_002462 
myxovirus (influenza virus) resistance 1, 
interferon-inducible protein p78 (mouse) 
DPP4 0.266 CD26; ADABP; ADCP2; DPPIV; TP103 NM_001935 
dipeptidyl-peptidase 4 (CD26, adenosine 
deaminase complexing protein 2) 
PSMB8 0.266 LMP7; D6S216; RING10; D6S216E; MGC1491 NM_004159 
proteasome (prosome, macropain) subunit, 
beta type, 8 (large multifunctional peptidase 7) 
SRPX 0.265 DRS; ETX1 NM_006307 sushi-repeat-containing protein, X-linked 
CYP26B1 0.265 
CYP26A2; MGC129613; P450RAI-2; 
DKFZp686G0638 NM_019885 
cytochrome P450, family 26, subfamily B, 
polypeptide 1 
EIF1AY 0.262 EIF1AY NM_004681 
eukaryotic translation initiation factor 1A, Y-
linked 
RND3 0.262 ARHE; Rho8; RhoE; memB NM_005168 Rho family GTPase 3 
OAF 0.262 MGC52117; NS5ATP13TP2 NM_178507 OAF homolog (Drosophila) 
CDC42EP5 0.261 CEP5; Borg3; MGC21945; MGC71153 NM_145057 
CDC42 effector protein (Rho GTPase 
binding) 5 
GPR114 0.26 PGR27 NM_153837 G protein-coupled receptor 114 
LAMA4 0.259 LAMA3; DKFZp686D23145 NM_002290 laminin, alpha 4 
G1P3 0.259 6-16; G1P3; FAM14C; IFI616; IFI-6-16 NM_002038 interferon, alpha-inducible protein 6 
SMARCA2 0.256 
BRM; hBRM; Sth1p; BAF190; SNF2L2; SNF2LA; 
hSNF2a; FLJ36757; MGC74511 NM_139045 
SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily 
a, member 2 
PMAIP1 0.255 APR; NOXA NM_021127 
phorbol-12-myristate-13-acetate-induced 
protein 1 
HERC5 0.255 CEB1; CEBP1 NM_016323 hect domain and RLD 5 
TRIM22 0.254 RNF94; STAF50; GPSTAF50 NM_006074 tripartite motif-containing 22 
CHST4 0.254 LSST NM_005769 
carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 4 
CDKN1A 0.254 
P21; CIP1; SDI1; WAF1; CAP20; CDKN1; MDA-6; 
p21CIP1 NM_078467 
cyclin-dependent kinase inhibitor 1A (p21, 
Cip1) 
RGS10 0.254 RGS10 NM_002925 regulator of G-protein signalling 10 
SERPINE1 0.254 PAI; PAI1; PAI-1; PLANH1 NM_000602 
serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type 1), 
member 1 
GLIPR1 0.253 GLIPR; RTVP1; CRISP7 NM_006851 GLI pathogenesis-related 1 (glioma) 
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GNG11 0.251 GNGT11 NM_004126 
guanine nucleotide binding protein (G 
protein), gamma 11 
CD248 0.251 TEM1; CD164L1; MGC119478; MGC119479 NM_020404 CD248 molecule, endosialin 
MGLL 0.25 MGL; HU-K5 NM_007283 monoglyceride lipase 
KIAA1576 0.249 KIAA1576 NM_020927 KIAA1576 protein 
PNPO 0.249 PDXPO; FLJ10535 NM_018129 pyridoxamine 5'-phosphate oxidase 
SLIT2 0.247 SLIL3; Slit-2; FLJ14420 NM_004787 slit homolog 2 (Drosophila) 
CBR3 0.247 hCBR3 NM_001236 carbonyl reductase 3 
EBI3 0.246 MSX2 NM_005755 Epstein-Barr virus induced gene 3 
PCSK5 0.246 PC5; PC6; PC6A; SPC6 NM_006200 proprotein convertase subtilisin/kexin type 5 
COMT 0.246 COMT NM_000754 catechol-O-methyltransferase 
LUM 0.245 LDC; SLRR2D NM_002345 lumican 
MVP 0.245 LRP; VAULT1 NM_005115 major vault protein 
TNFRSF11B 0.245 OPG; TR1; OCIF; MGC29565 NM_002546 
tumor necrosis factor receptor superfamily, 
member 11b (osteoprotegerin) 
CAMK2N1 0.245 
PRO1489; MGC22256; ICAP-1alpha; 
CaMKIINalpha; RP11-401M16.1 NM_018584 
calcium/calmodulin-dependent protein kinase 
II inhibitor 1 
C20ORF108 0.243 5A3; dJ1167H4.1; DKFZP434A1114 NM_080821 chromosome 20 open reading frame 108 
CAV2 0.239 CAV; MGC12294 NM_001233 caveolin 2 
CLDN10 0.239 OSP-L; CPETRL3 NM_006984 claudin 10 
LRAT 0.236 MGC33103 NM_004744 
lecithin retinol acyltransferase 
(phosphatidylcholine--retinol O-
acyltransferase) 
MLKL 0.234 FLJ34389 NM_152649 mixed lineage kinase domain-like 
NNMT 0.234 NNMT NM_006169 nicotinamide N-methyltransferase 
CAV2 0.234 CAV; MGC12294 NM_001233 caveolin 2 
CCL8 0.234 HC14; MCP2; MCP-2; SCYA8; SCYA10 NM_005623 chemokine (C-C motif) ligand 8 
POU2F2 0.232 OCT2; OTF2; Oct-2 NM_002698 POU domain, class 2, transcription factor 2 
GLS2 0.23 GA; GLS; LGA; hLGA; MGC71567 NM_013267 glutaminase 2 (liver, mitochondrial) 
CITED4 0.23 CITED4 NM_133467 
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 4 
C20ORF42 0.23 URP1; KIND1; DTGCU2; FLJ20116; FLJ23423 NM_017671 chromosome 20 open reading frame 42 
ACTA2 0.228 ACTSA NM_001613 actin, alpha 2, smooth muscle, aorta 
VEGFC 0.227 VRP; Flt4-L NM_005429 vascular endothelial growth factor C 
DAB2 0.226 DOC2; DOC-2 NM_001343 
disabled homolog 2, mitogen-responsive 
phosphoprotein (Drosophila) 
C2ORF32 0.224 DKFZp566K1924 NM_015463 chromosome 2 open reading frame 32 
MASP1 0.222 
MASP; RaRF; CRARF; PRSS5; CRARF1; 
FLJ26383; MGC126283; MGC126284; 
DKFZp686I01199 NM_139125 
mannan-binding lectin serine peptidase 1 
(C4/C2 activating component of Ra-reactive 
factor) 
PTGS1 0.222 
COX1; COX3; PHS1; PCOX1; PGHS1; PTGHS; 
PGG/HS; PGHS-1 NM_080591 
prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and 
cyclooxygenase) 
COL8A1 0.221 MGC9568 NM_020351 collagen, type VIII, alpha 1 
PIPOX 0.22 LPIPOX NM_016518 pipecolic acid oxidase 
SERPINB7 0.218 
MEGSIN; MGC120014; MGC120015; 
DKFZp686D06190 NM_003784 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 7 
CHN1 0.218 CHN; ARHGAP2; RHOGAP2 NM_001822 chimerin (chimaerin) 1 
GK 0.216 GKD NM_000167 glycerol kinase 
FLJ20647 0.215 FLJ20647 NM_017918 coiled-coil domain containing 109B 
UTF1 0.214 UTF1 NM_003577 
undifferentiated embryonic cell transcription 
factor 1 
LPXN 0.212 LDPL NM_004811 leupaxin 
CSF3 0.209 GCSF; G-CSF; MGC45931 NM_000759 colony stimulating factor 3 (granulocyte) 
MT1JP 0.209   NM_175622   
DSCR1 0.206 CSP1; DSC1; RCN1; MCIP1; ADAPT78 NM_203418 Down syndrome critical region gene 1 
FOXD1 0.204 FKHL8; FREAC4 NM_004472 forkhead box D1 
HIST2H2AA 0.203 
H2A; H2A.2; H2A/O; H2A/q; H2AFO; H2a-615; 
HIST2H2AA NM_003516 histone 2, H2aa3 
MMP12 0.203 HME; MME; MGC138506 NM_002426 
matrix metallopeptidase 12 (macrophage 
elastase) 
NPTX2 0.201 NP2; NARP; NP-II NM_002523 neuronal pentraxin II 
HSPB3 0.201 HSPL27 NM_006308 heat shock 27kDa protein 3 
NT5E 0.198 NT; eN; NT5; NTE; eNT; CD73; E5NT NM_002526 5'-nucleotidase, ecto (CD73) 
EGR1 0.198 
TIS8; AT225; G0S30; NGFI-A; ZNF225; KROX-24; 
ZIF-268 NM_001964 early growth response 1 
PTRF 0.194 FKSG13 NM_012232 polymerase I and transcript release factor 
SERPINB4 0.192 PI11; SCCA1; SCCA2; LEUPIN; SCCA-2 NM_002974 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 4 
KIAA1199 0.191 CCSP1; TMEM2L NM_018689 KIAA1199 
CA4 0.191 CAIV; Car4 NM_000717 carbonic anhydrase IV 
THBS2 0.191 TSP2 NM_003247 thrombospondin 2 
RAFTLIN 0.19 RAFTLIN; MIG2; PIG9; PIB10; KIAA0084 NM_015150 raft-linking protein 
MICA 0.19 PERB11.1; MGC111087; truncated NM_000247 MHC class I polypeptide-related sequence A 
C20ORF127 0.189   NM_080757   
RDH5 0.188 RDH1 NM_002905 retinol dehydrogenase 5 (11-cis/9-cis) 
CXCL6 0.187 GCP2; CKA-3; GCP-2; SCYB6 NM_002993 
chemokine (C-X-C motif) ligand 6 
(granulocyte chemotactic protein 2) 
NFKBIZ 0.186 IKBZ; INAP; MAIL; FLJ30225; FLJ34463 NM_001005474 
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 
EPAS1 0.184 HLF; MOP2; HIF2A; PASD2 NM_001430 endothelial PAS domain protein 1 
PSG4 0.183 PSG9 NM_002780 pregnancy specific beta-1-glycoprotein 4 
CRADD 0.18 RAIDD; MGC9163 NM_003805 
CASP2 and RIPK1 domain containing adaptor 
with death domain 
PROM1 0.18 AC133; CD133; PROML1; MSTP061 NM_006017 prominin 1 
EMP1 0.179 TMP; CL-20; EMP-1 NM_001423 epithelial membrane protein 1 
CAV1 0.179 CAV; VIP21; MSTP085 NM_001753 caveolin 1, caveolae protein, 22kDa 
INDO 0.176 IDO; CD107B NM_002164 indoleamine-pyrrole 2,3 dioxygenase 
CLDN10 0.174 OSP-L; CPETRL3 NM_006984 claudin 10 
PSG9 0.174 PSG11 NM_002784 pregnancy specific beta-1-glycoprotein 9 
LOX 0.172 MGC105112 NM_002317 lysyl oxidase 
FCRLM1 0.171 
FCRL; FREB; FCRLX; FCRLa; FCRLb; FCRLd; 
FCRLe; FCRLc1; FCRLc2; MGC4595; RP11-
474I16.5 NM_032738 Fc receptor-like and mucin-like 1 
C10ORF116 0.169 APM2 NM_006829 chromosome 10 open reading frame 116 
 221
D4S234E 0.166 D4S234E; P21; NSG1; D4S234; NEEP21 NM_014392 
DNA segment on chromosome 4 (unique) 234 
expressed sequence 
UGP2 0.161 UDPG; UGPP2; UDPGP2; pHC379 NM_006759 UDP-glucose pyrophosphorylase 2 
PSG7 0.159 PSG1 NM_002783 pregnancy specific beta-1-glycoprotein 7 
PSG1 0.157 
SP1; B1G1; PBG1; CD66f; PSBG1; PSGGA; 
DHFRP2; PSGIIA; FLJ90598; FLJ90654 NM_006905 pregnancy specific beta-1-glycoprotein 1 
MT1H 0.155 MT1; MGC70702 NM_005951 metallothionein 1H 
COL10A1 0.154 COL10A1 NM_000493 
collagen, type X, alpha 1(Schmid metaphyseal 
chondrodysplasia) 
MOXD1 0.152 MOX; PRO5780; dJ248E1.1; DKFZP564G202 NM_001031699 monooxygenase, DBH-like 1 
PSG5 0.149 PSG; FL-NCA-3 NM_002781 pregnancy specific beta-1-glycoprotein 5 
ANPEP 0.143 APN; CD13; LAP1; PEPN; gp150 NM_001150 
alanyl (membrane) aminopeptidase 
(aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) 
DDAH1 0.142 DDAH; FLJ21264; FLJ25539 NM_012137 dimethylarginine dimethylaminohydrolase 1 
MT1F 0.141 MT1; MGC32732 NM_005949 metallothionein 1F (functional) 
IL13RA2 0.14 IL-13R; IL13BP; CD213A2 NM_000640 interleukin 13 receptor, alpha 2 
OLFML3 0.137 OLF44; HNOEL-iso NM_020190 olfactomedin-like 3 
SGK 0.13 SGK1 NM_005627 serum/glucocorticoid regulated kinase 
CYR61 0.125 CCN1; GIG1; IGFBP10 NM_001554 cysteine-rich, angiogenic inducer, 61 
SERPINB2 0.124 PAI; PAI2; PAI-2; PLANH2; HsT1201 NM_002575 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
ANXA1 0.124 ANX1; LPC1 NM_000700 annexin A1 
     
CXCL5 0.124 SCYB5; ENA-78 NM_002994 chemokine (C-X-C motif) ligand 5 
FLJ14834 0.12 FLJ14834; MGC126673; MGC126675 NM_032849 chromosome 13 open reading frame 33 
CAMKV 0.115 1G5; MGC8407; VACAMKL NM_024046 CaM kinase-like vesicle-associated 
GNA14 0.112 GNA14 NM_004297 
guanine nucleotide binding protein (G 
protein), alpha 14 
CXCL2 0.108 
GRO2; GROb; MIP2; MIP2A; SCYB2; MGSA-b; 
MIP-2a; CINC-2a; MGSA beta NM_002089 chemokine (C-X-C motif) ligand 2 
LECT1 0.105 CHM1; CHM-I; BRICD3 NM_007015 leukocyte cell derived chemotaxin 1 
PSG11 0.0956 PSG13; PSG14; MGC22484 NM_002785 pregnancy specific beta-1-glycoprotein 11 
PLAT 0.0947 TPA; T-PA; DKFZp686I03148 NM_000930 plasminogen activator, tissue 
MT1M 0.0929 MT1; MT1K; MGC40498; MGC118949 NM_176870 metallothionein 1M 
THY1 0.0901 CD90; FLJ33325 NM_006288 Thy-1 cell surface antigen 
MOXD1 0.0888 MOX; PRO5780; dJ248E1.1; DKFZP564G202 NM_015529 monooxygenase, DBH-like 1 
CSF2 0.0836 GMCSF; MGC131935; MGC138897 NM_000758 
colony stimulating factor 2 (granulocyte-
macrophage) 
VGF 0.0781 VGF NM_003378 VGF nerve growth factor inducible 
CCL7 0.07 
FIC; MARC; MCP3; NC28; MCP-3; SCYA6; 
SCYA7; MGC138463; MGC138465 NM_006273 chemokine (C-C motif) ligand 7 
ACTG2 0.0613 ACT; ACTE; ACTA3; ACTL3; ACTSG NM_001615 actin, gamma 2, smooth muscle, enteric 
TM4SF1 0.0455 L6; H-L6; M3S1; TAAL6 NM_014220 transmembrane 4 L six family member 1 
SPP1 0.0419 OPN; BNSP; BSPI; ETA-1; MGC110940 NM_000582 
secreted phosphoprotein 1 (osteopontin, bone 
sialoprotein I, early T-lymphocyte activation 
1) 
MT1G 0.0401 MT1; MT1K; MGC12386 NM_005950 metallothionein 1G 





































































Common Genbank Description 
HAND1 12.38 Hxt; eHand; Thing1 NM_004821 heart and neural crest derivatives expressed 1 
C20ORF
75 
10.26 NLRR4; FLJ23994; MGC25027; dJ1056H1.1 NM_152611 chromosome 20 open reading frame 75 
GYPE 9.316 GPE; MNS; MiIX NM_002102 glycophorin E 
ANGPT
2 
8.428 ANG2; AGPT2 NM_001147 angiopoietin 2 
HAPLN
1 
6.167 CRTL1 NM_001884 hyaluronan and proteoglycan link protein 1 
PPFIBP2 5.367 Cclp1; MGC42541; DKFZp781K06126 NM_003621 PTPRF interacting protein, binding protein 2 (liprin beta 2) 
HES4 5.147 FGF23 NM_021170 hairy and enhancer of split 4 (Drosophila) 
ANG 5.135 RNASE4; RNASE5; MGC71966 NM_001145 angiogenin, ribonuclease, RNase A family, 5 
LTB4D
H 
5.129 MGC34943 NM_012212 leukotriene B4 12-hydroxydehydrogenase 
MANEA 4.855 hEndo; FLJ12838; DKFZp686D20120 NM_024641 mannosidase, endo-alpha 
CDC42E
P4 
4.714 CEP4; BORG4; MGC3740; KAIA1777; 
MGC17125 
NM_012121 CDC42 effector protein (Rho GTPase binding) 4 
MYL4 4.588 GT1; ALC1; AMLC; PRO1957 NM_002476 myosin, light polypeptide 4, alkali; atrial, embryonic 
KRT8 4.515 K8; KO; CK8; CYK8; K2C8; CARD2 NM_002273 keratin 8 
SIPA1L
2 
4.383 SPAL2; FLJ23126; FLJ23632; KIAA1389 NM_020808 signal-induced proliferation-associated 1 like 2 
DLK1 4.217 FA1; ZOG; pG2; PREF1; Pref-1 NM_003836 delta-like 1 homolog (Drosophila) 
CYP27A
1 
4.153 CTX; CP27; CYP27 NM_000784 cytochrome P450, family 27, subfamily A, polypeptide 1 
BST2 4.127 CD317 NM_004335 bone marrow stromal cell antigen 2 
GREB1 3.952 GREB1; KIAA0575 NM_014668 GREB1 protein 
SOX21 3.797 SOX25 NM_007084 SRY (sex determining region Y)-box 21 
CTSL2 3.763 CTSU; CTSV; CATL2; MGC125957 NM_001333 cathepsin L2 
HLA-
DRB4 
3.73 DRB4; HLA DRB1; HLA-DR4B NM_021983 major histocompatibility complex, class II, DR beta 4 
GAB2 3.616 KIAA0571 NM_080491 GRB2-associated binding protein 2 
HDC 3.616 HDC NM_002112 histidine decarboxylase 
SLC7A5 3.603 E16; CD98; LAT1; 4F2LC; MPE16; hLAT1; 
D16S469E 
NM_003486 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 5 
GPSM2 3.582 LGN; Pins NM_013296 G-protein signalling modulator 2 (AGS3-like, C. elegans) 
RAB17 3.553 FLJ12538 NM_022449 RAB17, member RAS oncogene family 
DAAM1 3.544 KIAA0666 NM_014992 dishevelled associated activator of morphogenesis 1 
VAMP8 3.483 EDB; VAMP5 NM_003761 vesicle-associated membrane protein 8 (endobrevin) 
FEZ1 3.43 FEZ1 NM_005103 fasciculation and elongation protein zeta 1 (zygin I) 
PDLIM3 3.385 ALP; DKFZp686L0362 NM_014476 PDZ and LIM domain 3 
KCNK1 3.373 DPK; HOHO; TWIK1; TWIK-1 NM_002245 potassium channel, subfamily K, member 1 
PCBP4 3.354 LIP4; MCG10 NM_033008 poly(rC) binding protein 4 
DUSP4 3.351 TYP; HVH2; MKP2; MKP-2 NM_057158 dual specificity phosphatase 4 
FUT2 3.311 SE; Se2; sej NM_000511 fucosyltransferase 2 (secretor status included) 
CAMKK
2 
3.299 CAMKK; CAMKKB; KIAA0787; MGC15254 NM_172215 calcium/calmodulin-dependent protein kinase kinase 2, beta 
ARHGE
F16 
3.281 NBR; GEF16 NM_014448 Rho guanine exchange factor (GEF) 16 
ARHGE
F4 





Alport syndrome, mental retardation, midface hypoplasia and 
elliptocytosis chromosomal region, gene 1 
CLDN18 3.23 CLDN18 NM_016369 claudin 18 
HIPK2 3.184 PRO0593 NM_022740 homeodomain interacting protein kinase 2 
RNU3IP
2 
3.183 U3-55K NM_004704 RNA, U3 small nucleolar interacting protein 2 
MBD6 3.171 KIAA1887 NM_052897 methyl-CpG binding domain protein 6 
APOE 3.138 AD2; MGC1571; apoprotein NM_000041 apolipoprotein E 
FOXA3 3.121 FKHH3; HNF3G; TCF3G; MGC10179 NM_004497 forkhead box A3 
AHNAK 3.088 AHNAKRS; MGC5395 NM_001620 AHNAK nucleoprotein (desmoyokin) 
ZNF521 3.081 EHZF; Evi3; MGC142182; MGC142208; 
DKFZp564D0764 
NM_015461 zinc finger protein 521 
FLJ2247
1 
3.042 FLJ22471 NM_025140 coiled-coil domain containing 92 
DDAH2 3.01 G6a; DDAH; NG30; DDAHII NM_013974 dimethylarginine dimethylaminohydrolase 2 
RASL12 2.999 RIS NM_016563 RAS-like, family 12 
ZFP260 2.973 ozrf1; ZFP260 NM_001012
756 
zinc finger protein 260 
CMTM3 2.971 BNAS2; CKLFSF3; FLJ31762; MGC51956 NM_181555 CKLF-like MARVEL transmembrane domain containing 3 
SLC9A3
R1 
2.966 EBP50; NHERF NM_004252 solute carrier family 9 (sodium/hydrogen exchanger), member 3 
regulator 1 
DSCR5 2.959 DCRC; DSRC; DSCR5; DCRC-S NM_153681 phosphatidylinositol glycan anchor biosynthesis, class P 
NFKBIA 2.95 IKBA; MAD-3; NFKBI NM_020529 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
LIX1L 2.947 MGC46719; DKFZp762F237 NM_153713 Lix1 homolog (mouse) like 
SRC 2.945 ASV; SRC1; c-SRC; p60-Src NM_005417 v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog 
(avian) 
RHPN2 2.944 RhoBP; p76RBE NM_033103 rhophilin, Rho GTPase binding protein 2 
HK2 2.935 HKII; HXK2; DKFZp686M1669 NM_000189 hexokinase 2 
SOX18 2.923 HLTS NM_018419 SRY (sex determining region Y)-box 18 






2.913 FLJ46072 NM_198488 family with sequence similarity 83, member H 
COL5A2 2.901 MGC105115 NM_000393 collagen, type V, alpha 2 
BNIP3 2.889 NIP3 NM_004052 BCL2/adenovirus E1B 19kDa interacting protein 3 
WARS 2.861 IFI53; IFP53; GAMMA-2 NM_213646 tryptophanyl-tRNA synthetase 
ZD52F1
0 
2.859 UNQ729; ZD52F10 NM_033317 dermokine 
YRDC 2.854 IRIP; SUA5; DRIP3; FLJ23476; FLJ26165; RP11-
109P14.4 
NM_024640 yrdC domain containing (E. coli) 
C3ORF3
6 
2.847 FLJ22173; MGC125760; MGC125761 NM_025041 chromosome 3 open reading frame 36 
C9ORF6
1 
2.839 X123; MGC142243; MGC142245; RP11-548B3.1 NM_004816 chromosome 9 open reading frame 61 
FARP1 2.828 CDEP; PLEKHC2; MGC87400 NM_005766 FERM, RhoGEF (ARHGEF) and pleckstrin domain protein 1 
(chondrocyte-derived) 
NMU 2.815 NMU NM_006681 neuromedin U 
OTX1 2.81 FLJ38361; MGC15736 NM_014562 orthodenticle homolog 1 (Drosophila) 
DSC2 2.788 DG2; DSC3; CDHF2; DGII/III; DKFZp686I11137 NM_004949 desmocollin 2 
DHRS10 2.781 retSDR3 NM_016246 dehydrogenase/reductase (SDR family) member 10 
EHHAD
H 




2.78 GDN; PI7; PN1; PNI NM_006216 serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 2 
TNFRSF
21 
2.767 DR6; BM-018; MGC31965 NM_014452 tumor necrosis factor receptor superfamily, member 21 
PDLIM7 2.766 PDLIM7 NM_213636 PDZ and LIM domain 7 (enigma) 
MLYCD 2.753 MCD; MGC59795 NM_012213 malonyl-CoA decarboxylase 
MRPL22 2.749 RPML25; HSPC158; MRP-L25; DKFZp781F1071 NM_001014
990 
mitochondrial ribosomal protein L22 
SOX11 2.748 SOX11 NM_003108 SRY (sex determining region Y)-box 11 
FZD7 2.744 FzE3 NM_003507 frizzled homolog 7 (Drosophila) 
ZNF467 2.723 EZI; Zfp467 NM_207336 zinc finger protein 467 
HIC2 2.721 HRG22; ZBTB30; KIAA1020 NM_015094 hypermethylated in cancer 2 
TMSL8 2.716 TMSNB NM_021992 thymosin-like 8 
NPPA 2.696 ANF; ANP; PND; CDD-ANF NM_006172 natriuretic peptide precursor A 
PALM 2.695 KIAA0270 NM_002579 paralemmin 
B4GAL
T4 
2.682 B4Gal-T4; beta4Gal-T4 NM_003778 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, 
polypeptide 4 
FEZ1 2.677 FEZ1 NM_022549 fasciculation and elongation protein zeta 1 (zygin I) 
COL4A1 2.676 arresten NM_001845 collagen, type IV, alpha 1 
SALL1 2.676 TBS; HSAL1; ZNF794 NM_002968 sal-like 1 (Drosophila) 
MCCC1 2.659 MCCA; MCC-B; FLJ25545; DKFZp686B20267 NM_020166 methylcrotonoyl-Coenzyme A carboxylase 1 (alpha) 
GRB10 2.65 RSS; IRBP; MEG1; GRB-IR; KIAA0207 NM_005311 growth factor receptor-bound protein 10 
DNAJB2 2.649 HSJ1; HSPF3 NM_006736 DnaJ (Hsp40) homolog, subfamily B, member 2 
PKM2 2.643 PK3; PKM; TCB; OIP3; CTHBP; THBP1; 
MGC3932 
NM_002654 pyruvate kinase, muscle 
CAPN13 2.631 FLJ23523 NM_144575 calpain 13 
TP53BP
2 
2.628 BBP; 53BP2; ASPP2; p53BP2; PPP1R13A NM_001031
685 
tumor protein p53 binding protein, 2 
UNC50 2.605 URP; GMH1; UNCL; HSD23; hGMH1p; 
DKFZp564G0222 
NM_014044 unc-50 homolog (C. elegans) 
STX3A 2.59 STX3A NM_004177 syntaxin 3 
REEP6 2.584 DP1L1; TB2L1; C19orf32; FLJ25383 NM_138393 receptor accessory protein 6 
ST6GAL
NAC5 
2.578 SIAT7E; MGC3184; ST6GalNAcV NM_030965 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5 
SERTA
D2 
2.577 TRIP-Br2; MGC126688; MGC126690 NM_014755 SERTA domain containing 2 
KCTD15 2.554 MGC2628; MGC25497 NM_024076 potassium channel tetramerisation domain containing 15 
ST3GAL
5 
2.547 SIAT9; ST3GalV; SIATGM3S NM_003896 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 
KIF13B 2.529 GAKIN; KIAA0639 NM_015254 kinesin family member 13B 
C17ORF
59 
2.52 PRO2472; FLJ20014 NM_017622 chromosome 17 open reading frame 59 
LHX2 2.518 LH2; hLhx2; MGC138390 NM_004789 LIM homeobox 2 
ALAD 2.505 PBGS; ALADH; MGC5057 NM_001003
945 
aminolevulinate, delta-, dehydratase 
ZNF395 2.502 PBF; PRF1; HDBP2; PRF-1; Si-1-8-14; 
DKFZp434K1210 
NM_018660 zinc finger protein 395 
FHOD1 2.492 FHOS NM_013241 formin homology 2 domain containing 1 
S100A1
6 
2.469 AAG13; S100F; DT1P1A7; MGC17528 NM_080388 S100 calcium binding protein A16 
CRB3 2.461 DEFB106A NM_139161 crumbs homolog 3 (Drosophila) 
USP3 2.451 UBP; SIH003; MGC129878; MGC129879 NM_006537 ubiquitin specific peptidase 3 
NXN 2.449 TRG-4; FLJ12614 NM_022463 Nucleoredoxin 
RARB 2.446 HAP; RRB2; NR1B2 NM_000965 retinoic acid receptor, beta 
MAP3K
9 
2.444 MLK1; PRKE1 NM_033141 mitogen-activated protein kinase kinase kinase 9 
BCAT2 2.423 BCAM; BCT2 NM_001190 branched chain aminotransferase 2, mitochondrial 
TRIM32 2.42 HT2A; BBS11; TATIP; LGMD2H NM_012210 tripartite motif-containing 32 
H2AFY 2.418 H2A.y; H2A/y; H2AFJ; mH2A1; H2AF12M; 
MACROH2A1.1; macroH2A1.2 
NM_004893 H2A histone family, member Y 
MST1 2.409 MSP; HGFL; NF15S2; D3F15S2; DNF15S2 NM_020998 macrophage stimulating 1 (hepatocyte growth factor-like) 
CNKSR
3 
2.405 MAGI1; FLJ31349; RP11-486M3.1 NM_173515 CNKSR family member 3 
ACSL1 2.403 ACS1; LACS; FACL1; FACL2; LACS1; LACS2 NM_001995 acyl-CoA synthetase long-chain family member 1 
PLEKH
C1 
2.402 MIG2; KIND2; mig-2; UNC112 NM_006832 pleckstrin homology domain containing, family C (with FERM 
domain) member 1 
DIABL
O 
2.4 SMAC; SMAC3; DIABLO-S; FLJ10537; 
FLJ25049 
NM_138930 diablo homolog (Drosophila) 
ANKM
Y2 
2.398 ZMYND20; DKFZP564O043 NM_020319 ankyrin repeat and MYND domain containing 2 
GPR161 2.395 RE2; FLJ33952 NM_007369 G protein-coupled receptor 161 
NUDT1
4 
2.383 UGPP NM_177533 nudix (nucleoside diphosphate linked moiety X)-type motif 14 
NODAL 2.378 MGC138230 NM_018055 nodal homolog (mouse) 
 224
ZFPM2 2.374 DIH3; FOG2; ZNF89B; hFOG-2; MGC129663; 
MGC129664 
NM_012082 zinc finger protein, multitype 2 
TCP11L
1 
2.371 FLJ11336; FLJ11386; dJ85M6.3 NM_018393 t-complex 11 (mouse) like 1 
CGNL1 2.368 JACOP; FLJ14957; KIAA1749; MGC138254 NM_032866 cingulin-like 1 
WSB1 2.361   NM_134264   




Kruppel-like factor 6 
CYGB 2.36 HGB; STAP NM_134268 Cytoglobin 
PTPRM 2.355 RPTPM; RPTPU; PTPRL1; hR-PTPu; R-PTP-MU NM_002845 protein tyrosine phosphatase, receptor type, M 
AES 2.353 GRG; ESP1; GRG5; TLE5; AES-1; AES-2 NM_198969 amino-terminal enhancer of split 
GADD4
5G 
2.351 CR6; DDIT2; GRP17; GADD45gamma NM_006705 growth arrest and DNA-damage-inducible, gamma 
RAB25 2.35 CATX-8 NM_020387 RAB25, member RAS oncogene family 
MASK 2.349 MST4; MASK NM_016542 serine/threonine protein kinase MST4 





chromosome 8 open reading frame 58 
STT3B 2.338 SIMP; STT3-B; FLJ90106 NM_178862 STT3, subunit of the oligosaccharyltransferase complex, homolog 
B (S. cerevisiae) 
MDK 2.336 MK; NEGF2; FLJ27379 NM_001012
334 
midkine (neurite growth-promoting factor 2) 
BMPR2 2.336 BMR2; BMPR3; BRK-3; T-ALK; BMPR-II NM_001204 bone morphogenetic protein receptor, type II (serine/threonine 
kinase) 
IL17R 2.334 IL17R; CDw217; IL-17RA; hIL-17R; MGC10262 NM_014339 interleukin 17 receptor A 
DYNC1I
1 
2.329 DNCI1; DNCIC1 NM_004411 dynein, cytoplasmic 1, intermediate chain 1 
COCH 2.326 DFNA9; DFNA31; COCH5B2; COCH-5B2 NM_004086 coagulation factor C homolog, cochlin (Limulus polyphemus) 
PTPN21 2.321 PTPD1; PTPRL10 NM_007039 protein tyrosine phosphatase, non-receptor type 21 
SLC26A
11 
2.317 MGC46523 NM_173626 solute carrier family 26, member 11 
TMEM5
1 
2.317 C1orf72; FLJ10199 NM_018022 transmembrane protein 51 
PLXNA
2 
2.312 OCT; PLXN2; FLJ11751; FLJ30634; KIAA0463 NM_025179 plexin A2 
ZNF319 2.305 ZFP319; MGC126816 NM_020807 zinc finger protein 319 
ZNF69 2.304 Cos5; MGC59928 NM_021915 zinc finger protein 69 
BAMBI 2.304 NMA NM_012342 BMP and activin membrane-bound inhibitor homolog (Xenopus 
laevis) 
ISL1 2.299 Isl-1 NM_002202 ISL1 transcription factor, LIM/homeodomain, (islet-1) 
CGI-38 2.284 CGI-38 NM_015964 brain specific protein 
C21ORF
91 
2.281 YG81; C21orf14; C21orf38; DKFZp781D1223 NM_017447 chromosome 21 open reading frame 91 
SNAPC3 2.28   NM_003084   
RASSF7 2.278 HRC1; HRAS1; C11orf13; MGC126069; 
MGC126070 
NM_003475 Ras association (RalGDS/AF-6) domain family 7 
RPRM 2.276 REPRIMO; FLJ90327 NM_019845 reprimo, TP53 dependent G2 arrest mediator candidate 
INPPL1 2.274 SHIP2 NM_001567 inositol polyphosphate phosphatase-like 1 
PRSS35 2.274 C6orf158; MGC46520; dJ223E3.1 NM_153362 protease, serine, 35 
SERTA
D3 
2.272 RBT1 NM_203344 SERTA domain containing 3 
SERAC1 2.268 FLJ14917; FLJ30544 NM_032861 serine active site containing 1 
MXI1 2.267 MXI; MAD2; MXD2; MGC43220 NM_130439 MAX interactor 1 
FZD2 2.266 FZD2 NM_001466 frizzled homolog 2 (Drosophila) 
SPRED2 2.264 Spred-2; FLJ21897; FLJ31917 NM_181784 sprouty-related, EVH1 domain containing 2 




solute carrier family 3 (activators of dibasic and neutral amino 
acid transport), member 2 
C11ORF
56 
2.254 FLJ22665; KIAA1759; DKFZP566M1046 NM_032127 chromosome 11 open reading frame 56 
PELI1 2.254 MGC50990 NM_020651 pellino homolog 1 (Drosophila) 






S100 calcium binding protein A13 
EDG4 2.248 LPA2; EDG-4; LPAR2 NM_004720 endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 4 
MLLT11 2.244 AF1Q; RP11-316M1.10 NM_006818 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 11 
LBX2 2.243 LP3727 NM_001009
812 
ladybird homeobox homolog 2 (Drosophila) 
TBC1D9 2.24 MDR1; KIAA0882 NM_015130 TBC1 domain family, member 9 (with GRAM domain) 
ETFB 2.24 MADD; FP585 NM_001014
763 
electron-transfer-flavoprotein, beta polypeptide 
MORN2 2.239 MOPT; BLOCK27; MGC126130; MGC126131; 
MGC126132 
NM_194270 MORN repeat containing 2 
C9ORF1
9 
2.232 GAPR-1; GLIPR2 NM_022343 chromosome 9 open reading frame 19 
PDLIM1 2.231 CLIM1; CLP36; ELFIN; CLP-36; hCLIM1 NM_020992 PDZ and LIM domain 1 (elfin) 
GATA5 2.23 bB379O24.1 NM_080473 GATA binding protein 5 
MYO3A 2.229 DFNB30 NM_017433 myosin IIIA 
DIRC2 2.229 RCC4; FLJ14784 NM_032839 disrupted in renal carcinoma 2 




2.228 HSPC265; MGC131656 NM_138493 chromosome 6 open reading frame 129 
KRAS 2.222 NS3; KRAS1; KRAS2; RASK2; KI-RAS; C-K-
RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-
RAS4B 
NM_004985 v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 
PLEKH
G4 
2.215 DKFZP434I216; puratrophin1 NM_015432 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 4 
ARHGE
F3 
2.215 GEF3; STA3; XPLN; MGC118905; 
DKFZP434F2429 
NM_019555 Rho guanine nucleotide exchange factor (GEF) 3 
FOLR1 2.214 FBP; FOLR; MOv18; FR-alpha NM_016724 folate receptor 1 (adult) 
GADD4
5A 
2.214 DDIT1; GADD45 NM_001924 growth arrest and DNA-damage-inducible, alpha 
SPATA7 2.209 HSD3; HSD-3.1; MGC102934; NM_018418 spermatogenesis associated 7 
 225
DKFZp686D07199 
CLDN23 2.207 CLDNL NM_194284 claudin 23 
SH3MD
2 
2.206 POSH; RNF142; SH3MD2; FLJ21602; KIAA1494 NM_020870 SH3 domain containing ring finger 1 
B3GAL
T6 
2.206 beta3GalT6 NM_080605 UDP-Gal:betaGal beta 1,3-galactosyltransferase polypeptide 6 
EGF 2.198 URG NM_001963 epidermal growth factor (beta-urogastrone) 
DNAL4 2.193 PIG27 NM_005740 dynein, axonemal, light chain 4 
ENSA 2.193 MGC4319; MGC8394; MGC78563 NM_207168 endosulfine alpha 
C21ORF
2 
2.191 A2; YF5 NM_004928 chromosome 21 open reading frame 2 
PNMA1 2.183 MA1 NM_006029 paraneoplastic antigen MA1 
ARHGA
P24 




Rho GTPase activating protein 24 
C6ORF2
11 
2.182 FLJ12910; DKFZp566I174 NM_024573 chromosome 6 open reading frame 211 
SLC25A
13 
2.177 CTLN2; CITRIN; ARALAR2 NM_014251 solute carrier family 25, member 13 (citrin) 
PPP1R3
B 
2.172 GL; PPP1R4; FLJ14005 NM_024607 protein phosphatase 1, regulatory (inhibitor) subunit 3B 
SGPL1 2.168 SPL; FLJ13811; KIAA1252 NM_003901 sphingosine-1-phosphate lyase 1 
MSMB 2.167 MSP; PSP; IGBF; MSPB; PN44; PRPS; PSP57; 
PSP94; PSP-94 
NM_002443 microseminoprotein, beta- 
NFASC 2.164   NM_001005
389 
  
SH3BP4 2.16 TTP; BOG25 NM_014521 SH3-domain binding protein 4 
CDH12 2.156 CDHB; FLJ34857 NM_004061 cadherin 12, type 2 (N-cadherin 2) 
PTPLA 2.154 APOBEC3F NM_014241 protein tyrosine phosphatase-like (proline instead of catalytic 
arginine), member A 
NFATC
1 
2.152 NFAT2; NFATc; NF-ATC; MGC138448 NM_172390 nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1 
ZAP70 2.151 SRK; STD; TZK; ZAP-70 NM_207519 zeta-chain (TCR) associated protein kinase 70kDa 
PIK3R5 2.15 FOAP-2; P101-PI3K; F730038I15Rik NM_014308 phosphoinositide-3-kinase, regulatory subunit 5, p101 
TEAD2 2.144 ETF; TEF4; TEF-4 NM_003598 TEA domain family member 2 
ZHX2 2.138 KIAA0854 NM_014943 zinc fingers and homeoboxes 2 
SEMA5
B 
2.136 SemG; SEMAG; FLJ10372; KIAA1445 NM_001031
702 
sema domain, seven thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 5B 
TM7SF2 2.135 ANG1; DHCR14A NM_003273 transmembrane 7 superfamily member 2 
LOC375
133 
2.13 LOC375133 NM_199345 similar to phosphatidylinositol 4-kinase alpha 
DUSP18 2.128 DUSP20; LMWDSP20; MGC32658; bK963H5.1 NM_152511 dual specificity phosphatase 18 
DSCR1L
2 
2.127 RCN3; MCIP3; hRCN3 NM_013441 Down syndrome critical region gene 1-like 2 
PROS1 2.115 PSA; PROS; PS21; PS22; PS23; PS24; PS25; PS 
26; Protein S; protein Sa 
NM_000313 protein S (alpha) 
RPIA 2.115 RPI NM_144563 ribose 5-phosphate isomerase A (ribose 5-phosphate epimerase) 
LGR6 2.114 GPCR; FLJ14471; VTS20631 NM_001017
403 
leucine-rich repeat-containing G protein-coupled receptor 6 
RFWD2 2.112 COP1; RNF200; FLJ10416; RP11-318C24.3 NM_022457 ring finger and WD repeat domain 2 
MGC26
885 
2.102 MGC26885 NM_152339 chromosome 16 open reading frame 76 
PGM1 2.099 PGM1 NM_002633 phosphoglucomutase 1 
CLCNK
A 
2.098 CLCK1; ClC-K1; hClC-Ka; MGC61490 NM_004070 chloride channel Ka 
KLF6 2.098 GBF; ZF9; BCD1; CPBP; PAC1; ST12; COPEB; 
DKFZp686N0199 
NM_001300 Kruppel-like factor 6 
LOC124
491 
2.098 FLJ37611 NM_145254 transmembrane protein 170 
REC8L1 2.088 REC8; Rec8p NM_005132 REC8-like 1 (yeast) 
DSP 2.087 DPI; DPII NM_001008
844 
Desmoplakin 
PLD5 2.087 FLJ40773; MGC120565; MGC120566; 
MGC120567 
NM_152666 phospholipase D family, member 5 
SEMA5
A 
2.08 semF; SEMAF NM_003966 sema domain, seven thrombospondin repeats (type 1 and type 1-
like), transmembrane domain (TM) and short cytoplasmic 
domain, (semaphorin) 5A 
ENPEP 2.077 APA; CD249; gp160 NM_001977 glutamyl aminopeptidase (aminopeptidase A) 
NEDD9 2.071 CASL; HEF1; CAS-L; dJ49G10.2; dJ761I2.1 NM_182966 neural precursor cell expressed, developmentally down-regulated 
9 
EFHD2 2.071 MGC4342; RP3-467K16.3 NM_024329 EF-hand domain family, member D2 
GUCA2
A 
2.069 GUCA2; STARA; GUANYLIN NM_033553 guanylate cyclase activator 2A (guanylin) 
PTMS 2.064 PTMS NM_002824 Parathymosin 
BMP4 2.062 ZYME; BMP2B; BMP2B1 NM_001202 bone morphogenetic protein 4 
ASXL1 2.062 KIAA0978; MGC71111; MGC117280 NM_015338 additional sex combs like 1 (Drosophila) 
CDC42E
P1 
2.06 CEP1; BORG5; MSE55; MGC15316 NM_007061 CDC42 effector protein (Rho GTPase binding) 1 
DERA 2.058 DEOC; CGI-26 NM_015954 2-deoxyribose-5-phosphate aldolase homolog (C. elegans) 
RGMA 2.053 RGM NM_020211 RGM domain family, member A 
GPR161 2.053 RE2; FLJ33952 NM_153832 G protein-coupled receptor 161 
CDK6 2.05 PLSTIRE; MGC59692 NM_001259 cyclin-dependent kinase 6 
PRG2 2.05 PRG2 NM_024888 plasticity-related gene 2 
ZC3HA
V1 
2.042 ZAP; ZC3H2; FLB6421; ZC3HDC2; FLJ13288; 
MGC48898; DKFZp686F2052; DKFZp686H1869; 
DKFZp686O19171 
NM_020119 zinc finger CCCH-type, antiviral 1 
PKM2 2.039 PK3; PKM; TCB; OIP3; CTHBP; THBP1; 
MGC3932 
NM_182470 pyruvate kinase, muscle 
SERTA
D3 
2.034 RBT1 NM_203344 SERTA domain containing 3 
ANKFY
1 
2.032 ANKHZN; ZFYVE14; KIAA1255; 
DKFZp686M19106 
NM_016376 ankyrin repeat and FYVE domain containing 1 
RORA 2.026 ROR1; ROR2; ROR3; RZRA; NR1F1; 
MGC119326; MGC119329 
NM_002943 RAR-related orphan receptor A 
STMN1 2.025 Lag; SMN; OP18; PP17; PP19; PR22; LAP18 NM_203401 stathmin 1/oncoprotein 18 





2.014 LOC349114 NM_198284 hypothetical protein LOC349114 
RXRA 2.009 NR2B1; MGC102720 NM_002957 retinoid X receptor, alpha 
GTF2IR
D1 
2.005 GTF3; RBAP2; CREAM1; MUSTRD1; 
WBSCR11; WBSCR12; hMusTRD1alpha1 
NM_005685 GTF2I repeat domain containing 1 
CREBB
P 
2.004 CBP; RTS; RSTS NM_004380 CREB binding protein (Rubinstein-Taybi syndrome) 
FRS3 2.001 SNT2; FRS2B; SNT-2; FRS2beta; MGC17167 NM_006653 fibroblast growth factor receptor substrate 3 
LRRC56 1.998 FLJ00101; DKFZp761L1518 NM_198075 leucine rich repeat containing 56 
EGLN3 1.997 PHD3; HIFPH3; FLJ21620; MGC125998; 
MGC125999 
NM_022073 egl nine homolog 3 (C. elegans) 
CHL1 1.987 CALL; L1CAM2; FLJ44930; MGC132578 NM_006614 cell adhesion molecule with homology to L1CAM (close 
homolog of L1) 
ZNF553 1.984 FLJ31751; MGC43952; DKFZp762K013 NM_152652 zinc finger protein 553 
SALL4 1.977 DRRS; HSAL4; ZNF797; MGC133050; 
dJ1112F19.1 
NM_020436 sal-like 4 (Drosophila) 
NELL1 1.976 NRP1; IDH3GL NM_006157 NEL-like 1 (chicken) 
TCN2 1.972 TC2; D22S676; D22S750 NM_000355 transcobalamin II; macrocytic anemia 
LOC220
686 
1.971 LOC220686 NM_199283 hypothetical protein LOC220686 
ZNF114 1.969 MGC17986 NM_153608 zinc finger protein 114 
ANKRD
13 
1.965 ANKRD13; NY-REN-25 NM_033121 ankyrin repeat domain 13A 
CDKN1
C 
1.965 BWS; WBS; p57; BWCR; KIP2 NM_000076 cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
SCT 1.964 SCT NM_021920 Secretin 
C10ORF
39 
1.954 FLJ37857 NM_194303 chromosome 10 open reading frame 39 
KCNN1 1.947 SK1; hSK1; SKCA1; KCa2.1 NM_002248 potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 1 
DKFZP4
34I1020 
1.945 FLJ45937; DKFZp434I1020 NM_194295 chromosome 15 open reading frame 51 
CDS2 1.944 STMN1 NM_003818 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 
2 





chromosome 8 open reading frame 61 
TMEM2
8 
1.939 TED; bB57D9.1 NM_015686 transmembrane protein 28 
PAPLN 1.938 MGC50452; DKFZp434F053 NM_173462 papilin, proteoglycan-like sulfated glycoprotein 
KIAA15
98 
1.936 MGC40476; DKFZp686A0439 NM_018330 KIAA1598 
BRDT 1.934 BRD6 NM_001726 bromodomain, testis-specific 
FLNB 1.932 AOI; FH1; SCT; TAP; LRS1; TABP; FLN1L; 
ABP-278; filamin B; DKFZp686O033; 
DKFZp686A1668 
NM_001457 filamin B, beta (actin binding protein 278) 
PCYT2 1.93 ET NM_002861 phosphate cytidylyltransferase 2, ethanolamine 
BRPF3 1.93 VKORC1L1 NM_015695 bromodomain and PHD finger containing, 3 
SEC14L
2 
1.927 SPF; TAP; TAP1; C22orf6; KIAA1186; 
KIAA1658; MGC65053 
NM_012429 SEC14-like 2 (S. cerevisiae) 
FLJ3593
4 
1.927 FLJ35934 NM_207453 FLJ35934 protein 
FGF11 1.923 FHF3; FLJ16061; MGC45269; MGC102953 NM_004112 fibroblast growth factor 11 
LOC555
65 
1.92 LOC55565 NM_017530 hypothetical protein LOC55565 
LOC113
179 
1.919 LOC113179; FWP005; MST121; S863-5; 
MSTP121 
NM_138422 hypothetical protein BC011824 
ZNF364 1.918 RNF115 NM_014455 zinc finger protein 364 
USP54 1.916 C10orf29; FLJ37318; bA137L10.3; bA137L10.4 NM_152586 ubiquitin specific peptidase 54 
APLP2 1.916 APPH; APPL2; CDEBP NM_001642 amyloid beta (A4) precursor-like protein 2 
RKHD1 1.915 TINO; RNF193; KIAA2031; OK/SW-cl.4 NM_203304 ring finger and KH domain containing 1 
APOBE
C3F 
1.912 KA6; ARP8; MGC74891; BK150C2.4.MRNA NM_001006
666 
apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like 3F 
DSCAM 1.912 CHD2-42; CHD2-52 NM_206887 Down syndrome cell adhesion molecule 
RAB5B 1.912 RAB5B NM_002868 RAB5B, member RAS oncogene family 
TP53BP
1 
1.911 p202; 53BP1; MGC138366 NM_005657 tumor protein p53 binding protein, 1 
C1ORF5
1 
1.911 FLJ25889 NM_144697 chromosome 1 open reading frame 51 
INPP5E 1.907 PPI5PIV; MGC117201 NM_019892 inositol polyphosphate-5-phosphatase, 72 kDa 
NCOA5 1.905 CIA; bA465L10.6 NM_020967 nuclear receptor coactivator 5 
TFG 1.901 TF6; TRKT3 NM_006070 TRK-fused gene 
PPP1R1
5A 
1.9 GADD34 NM_014330 protein phosphatase 1, regulatory (inhibitor) subunit 15A 
C14ORF
58 
1.897 FLVCR2; FLJ20371 NM_017791 chromosome 14 open reading frame 58 
TMC6 1.896 EV1; EVER1; EVIN1; LAK-4P NM_007267 transmembrane channel-like 6 
C10ORF
125 





chromosome 8 open reading frame 49 
CRMP1 1.886 DRP1; DRP-1; DPYSL1 NM_001313 collapsin response mediator protein 1 
LOC285
989 
1.884 LOC285989 NM_213603 zinc finger protein 789 
EFHD1 1.883 MST133; PP3051; MSTP133; FLJ13612; 
DKFZp781H0842 
NM_025202 EF-hand domain family, member D1 
PRKCQ 1.877 PRKCT; MGC126514; MGC141919; nPKC-theta NM_006257 protein kinase C, theta 
NRCAM 1.876 KIAA0343; MGC138845; MGC138846 NM_005010 neuronal cell adhesion molecule 
ENO3 1.875 MSE NM_001976 enolase 3 (beta, muscle) 
ABR 1.872 MDB; FLJ45954 NM_021962 active BCR-related gene 
MBD2 1.871 DMTase; NY-CO-41; DKFZp586O0821 NM_015832 methyl-CpG binding domain protein 2 
OBSCN 1.87 UNC89; FLJ14124; KIAA1556; MGC120409; 
MGC120410; MGC120411; MGC120412; 
MGC138590; DKFZp666E245 
NM_052843 obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF 
BCORL 1.87 FLJ11362; B930011H20Rik NM_021946 BCL6 co-repressor-like 1 
 227
1 
RNF165 1.866 RNF165 NM_152470 ring finger protein 165 
FLJ3577
3 





SAM domain containing 1 
LOC388
886 
1.861 LOC388886; MGC131773 NM_207644 similar to hypothetical protein LOC192734 
VEZT 1.858 VEZATIN; DKFZp761C241 NM_017599 vezatin, adherens junctions transmembrane protein 
ARID1A 1.853 B120; P270; BM029; BAF250; C1orf4; BAF250a; 
SMARCF1 
NM_139135 AT rich interactive domain 1A (SWI- like) 
SLC7A6 1.85 LAT3; LAT-2; y+LAT-2; KIAA0245; 
DKFZp686K15246 
NM_003983 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 6 
ZMYM3 1.85 MYM; XFIM; ZNF261; DXS6673E; KIAA0385; 
ZNF198L2 
NM_005096 zinc finger, MYM-type 3 
SLC7A7 1.849 LPI; LAT3; Y+LAT1; y+LAT-1 NM_003982 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 7 
ABCA7 1.847 ABCX; ABCA-SSN; FLJ40025 NM_019112 ATP-binding cassette, sub-family A (ABC1), member 7 
NCOA6 1.846 NRC; AIB3; ASC2; PRIP; TRBP; RAP250; 
KIAA0181 
NM_014071 nuclear receptor coactivator 6 
ARHGE
F15 
1.846 ARGEF15; FLJ13791; KIAA0915; MGC44868; 
Vsm-RhoGEF 
NM_173728 Rho guanine nucleotide exchange factor (GEF) 15 
MGC42
630 
1.844   NM_175923   
FARP1 1.837 CDEP; PLEKHC2; MGC87400 NM_001001
715 




1.837 FLJ10916 NM_018271 hypothetical protein FLJ10916 
REP15 1.835 REP15 NM_001029
874 
Rab15 effector protein 
JUP 1.834 DP3; PDGB; PKGB; CTNNG; DPIII NM_002230 junction plakoglobin 
LOC128
439 
1.834 AKAP13 NM_139016 chromosome 20 open reading frame 198 
CLCN2 1.834 CLC2; ECA3; EGI3; EGMA; CIC-2 NM_004366 chloride channel 2 
CRB3 1.831 DEFB106A NM_139161 crumbs homolog 3 (Drosophila) 
PDE6B 1.828 rd1; PDEB; CSNB3 NM_000283 phosphodiesterase 6B, cGMP-specific, rod, beta (congenital 
stationary night blindness 3, autosomal dominant) 
DUSP5 1.825 DUSP; HVH3 NM_004419 dual specificity phosphatase 5 
TNNT1 1.824 ANM; MGC104241 NM_003283 troponin T type 1 (skeletal, slow) 
PIGQ 1.821 GPI1; hGPI1; MGC12693; c407A10.1 NM_004204 phosphatidylinositol glycan anchor biosynthesis, class Q 
ZC3HA
V1 
1.821 ZAP; ZC3H2; FLB6421; ZC3HDC2; FLJ13288; 
MGC48898; DKFZp686F2052; DKFZp686H1869; 
DKFZp686O19171 
NM_024625 zinc finger CCCH-type, antiviral 1 
HSPA1
A 
1.82 HSP72; HSPA1; HSPA1B; HSP70-1 NM_005345 heat shock 70kDa protein 1A 
PPFIA1 1.819 LIP1; LIP.1; LIPRIN; MGC26800 NM_003626 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 1 
PCDHB
5 
1.819 PCDH-BETA5; DKFZP586B0217 NM_015669 protocadherin beta 5 
SERINC
3 
1.819 TDE; TDE1; AIGP1; TMS-1; DIFF33; SBBI99 NM_006811 serine incorporator 3 
LOC400
657 
1.816 LOC400657; FLJ10991 NM_001008
234 
hypothetical gene supported by BC036588 
JMJD1A 1.814 TSGA; JMJD1; JHMD2A; KIAA0742; 
DKFZp686A24246; DKFZp686P07111 
NM_018433 jumonji domain containing 1A 
RAD54L
2 
1.814 HSPC325; FLJ21396; FLJ22400; KIAA0809; 
SRISNF2L 
NM_015106 RAD54-like 2 (S. cerevisiae) 
ZNF613 1.811 FLJ13590 NM_001031
721 
zinc finger protein 613 
SKI 1.811 SKV NM_003036 v-ski sarcoma viral oncogene homolog (avian) 
ENTPD1 1.81 CD39; ATPDase; NTPDase-1 NM_001776 ectonucleoside triphosphate diphosphohydrolase 1 
DDX17 1.81 P72; RH70; DKFZp761H2016 NM_006386 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 
MLCK 1.81 MLCK; MLCK2; MGC126319; MGC126320 NM_182493 MLCK protein 
LOC283
537 
1.81 LOC283537; FKSG16 NM_181785 hypothetical protein LOC283537 
FLJ1415
4 
1.81 FLJ14154 NM_024845 hypothetical protein FLJ14154 
AKAP13 1.808 BRX; LBC; HA-3; Ht31; c-lbc; AKAP-Lbc; 
FLJ11952; FLJ43341; PROTO-LB; PROTO-LBC 
NM_007200 A kinase (PRKA) anchor protein 13 
TUBB3 1.806 MC1R; TUBB4; beta-4 NM_006086 tubulin, beta 3 
GCH1 1.806 GCH; DYT5; GTPCH1; GTP-CH-1 NM_001024
024 
GTP cyclohydrolase 1 (dopa-responsive dystonia) 
SLC25A
18 
1.803 GC2 NM_031481 solute carrier family 25 (mitochondrial carrier), member 18 
LHFPL2 1.798 KIAA0206; DKFZp781E0375 NM_005779 lipoma HMGIC fusion partner-like 2 
ITGB5 1.798 FLJ26658 NM_002213 integrin, beta 5 
HYAL3 1.795 LUCA3; LUCA-3; LUCA14; Minna14 NM_003549 hyaluronoglucosaminidase 3 
FAM105
B 
1.792 FLJ34884 NM_138348 family with sequence similarity 105, member B 
SUHW2 1.791 ZNF279; ZNF632; 5'OY11.1; D87009.C22.3 NM_080764 suppressor of hairy wing homolog 2 (Drosophila) 
GAL3ST
4 
1.789 FLJ12116; GAL3ST-4 NM_024637 galactose-3-O-sulfotransferase 4 
PER2 1.787 FASPS; KIAA0347 NM_022817 period homolog 2 (Drosophila) 
CNNM1 1.782 ACDP1; FLJ31632 NM_020348 cyclin M1 
C12ORF
49 
1.781 FLJ21415 NM_024738 chromosome 12 open reading frame 49 
ATP12A 1.781 ATP1AL1 NM_001676 ATPase, H+/K+ transporting, nongastric, alpha polypeptide 
ALDH2 1.779 ALDM; ALDHI; ALDH-E2; MGC1806 NM_000690 aldehyde dehydrogenase 2 family (mitochondrial) 
DAPK1 1.778 DAPK; DKFZp781I035 NM_004938 death-associated protein kinase 1 
GYPE 1.778 GPE; MNS; MiIX NM_198682 glycophorin E 
COL9A3 1.777 IDD; MED; EDM3; DJ885L7.4.1 NM_001853 collagen, type IX, alpha 3 
BRD1 1.773 BRL; BRPF1; BRPF2; DKFZp686F0325 NM_014577 bromodomain containing 1 
FOXI1 1.771 HFH3; FKHL10; FREAC6; MGC34197 NM_012188 forkhead box I1 




exocyst complex component 6 
C10ORF 1.764 MGC33547 NM_144661 chromosome 10 open reading frame 82 
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82 
ZNF694 1.759 ZSCAN31; FLJ23199 NM_001012
981 
zinc finger protein 694 
FOXJ2 1.758 FHX NM_018416 forkhead box J2 
FAM89
B 
1.756 MTVR1 NM_152832 family with sequence similarity 89, member B 
RAD51L
3 
1.755 Trad; R51H3; HsTRAD; RAD51D NM_002878 RAD51-like 3 (S. cerevisiae) 
RASGR
P1 
1.755 V; RASGRP; hRasGRP1; MGC129998; 
MGC129999; CALDAG-GEFI; CALDAG-GEFII 
NM_005739 RAS guanyl releasing protein 1 (calcium and DAG-regulated) 
MCM8 1.754 MGC4816; MGC12866; C20orf154; MGC119522; 
MGC119523; dJ967N21.5 
NM_032485 MCM8 minichromosome maintenance deficient 8 (S. cerevisiae) 
SELI 1.753 SELI; KIAA1724 NM_033505 selenoprotein I 
OPLAH 1.752 OPLA; 5-Opase; DKFZP434H244 NM_017570 5-oxoprolinase (ATP-hydrolysing) 
GPR128 1.75 FLJ14454; FLJ29035; MGC142011 NM_032787 G protein-coupled receptor 128 
KIFC3 1.749 DKFZp686D23201 NM_005550 kinesin family member C3 
DRD1IP 1.747 RP11-122K13.5 NM_015722 dopamine receptor D1 interacting protein 
FLJ2522
2 
1.742 FLJ25222 NM_199163 CXYorf1-related protein 
DKFZP4
34A0131 
1.741 DKFZP434A0131; MGC40269 NM_018991 DKFZp434A0131 protein 
GALC 1.74 TRIM5 NM_000153 Galactosylceramidase 




1.739 C9orf28; FLJ00001 NM_033446 family with sequence similarity 125, member B 
PFKL 1.738 PFK-B; FLJ30173; DKFZp686G1648; 
DKFZp686L2097 
NM_002626 phosphofructokinase, liver 
GPRC5
C 








1.735 NME8; SPTRX2; Sptrx-2 NM_016616 thioredoxin domain containing 3 (spermatozoa) 
TMPRS
S2 
1.735 PRSS10 NM_005656 transmembrane protease, serine 2 
TTC3 1.735 DCRR1; RNF105; TPRDIII; DKFZp686M0150 NM_003316 tetratricopeptide repeat domain 3 
ADCY8 1.733 ADCY3; HBAC1 NM_001115 adenylate cyclase 8 (brain) 
HTR1E 1.733 5-HT1E NM_000865 5-hydroxytryptamine (serotonin) receptor 1E 
RALGD
S 
1.731 RGF; RalGEF; FLJ20922 NM_006266 ral guanine nucleotide dissociation stimulator 
CRMP1 1.73 DRP1; DRP-1; DPYSL1 NM_001014
809 
collapsin response mediator protein 1 
NKX2-5 1.729 CSX; CSX1; NKX2E; NKX2.5 NM_004387 NK2 transcription factor related, locus 5 (Drosophila) 
ZFPM1 1.728 FOG; FOG1; ZNF408; ZNF89A NM_153813 zinc finger protein, multitype 1 
CDK5R
1 
1.728 p23; p25; p35; CDK5R; NCK5A; CDK5P35; 
MGC33831; p35nck5a 
NM_003885 cyclin-dependent kinase 5, regulatory subunit 1 (p35) 
ATP1B1 1.727 ATP1B; MGC1798 NM_001001
787 
ATPase, Na+/K+ transporting, beta 1 polypeptide 
TMEM9
7 
1.726 MAC30 NM_014573 transmembrane protein 97 
STK38 1.724 NDR; NDR1 NM_007271 serine/threonine kinase 38 
RELN 1.724 RL NM_005045 Reelin 
ADNP 1.722 KIAA0784 NM_181442 activity-dependent neuroprotector 
ZCCHC
12 
1.72 SIZN; FLJ16123 NM_173798 zinc finger, CCHC domain containing 12 
LYL1 1.719 LYL1 NM_005583 lymphoblastic leukemia derived sequence 1 
TRIP10 1.719 STP; CIP4; HSTP; STOT NM_004240 thyroid hormone receptor interactor 10 
INPP4A 1.718 INPP4 NM_001566 inositol polyphosphate-4-phosphatase, type I, 107kDa 
FLJ2005
4 
1.715 FLJ20054; DKFZp547O0715 NM_019049 hypothetical protein FLJ20054 
EPHX1 1.712 MEH; EPHX; EPOX NM_000120 epoxide hydrolase 1, microsomal (xenobiotic) 
SACM1
L 
1.708 SAC1; KIAA0851; DKFZp686A0231 NM_014016 SAC1 suppressor of actin mutations 1-like (yeast) 
AP3B2 1.706 NAPTB; DKFZp686D17136 NM_004644 adaptor-related protein complex 3, beta 2 subunit 
SH3BG
R 
1.705 21-GARP NM_007341 SH3 domain binding glutamic acid-rich protein 
RUSC1 1.704 NESCA; DKFZp761A1822 NM_014328 RUN and SH3 domain containing 1 
GRIN3B 1.703 NR3B NM_138690 glutamate receptor, ionotropic, N-methyl-D-aspartate 3B 




filamin binding LIM protein 1 
MGC70
863 
1.7 MGC70863 NM_203302 similar to RPL23AP7 protein 
PLCD1 1.7 NCOA3 NM_006225 phospholipase C, delta 1 
FLJ3753
8 
1.7 FLJ37538 NM_173564 hypothetical protein FLJ37538 
MAGED
2 
1.699 11B6; BCG1; HCA10; JCL-1; MAGED; MAGE-
D2; MGC8386 
NM_201222 melanoma antigen family D, 2 
ZNF432 1.699 ZNF432 NM_014650 zinc finger protein 432 
KIAA02
32 
1.698 KIAA0232 NM_014743 KIAA0232 gene product 
TLE6 1.697 GRG6; FLJ14009; MGC14966 NM_024760 transducin-like enhancer of split 6 (E(sp1) homolog, Drosophila) 





family with sequence similarity 27, member E1 
VENTX 1.696 NA88A; HPX42B; VENTX2; MGC119910; 
MGC119911 
NM_014468 VENT homeobox homolog (Xenopus laevis) 
BMP5 1.695 MGC34244 NM_021073 bone morphogenetic protein 5 
SEMA6
C 
1.693 SEMAY; m-Sema Y; m-Sema Y2 NM_030913 sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6C 
CACNA
1E 
1.689 BII; CACH6; Cav2.3; CACNL1A6 NM_000721 calcium channel, voltage-dependent, alpha 1E subunit 
JAG2 1.685 HJ2 NM_002226 jagged 2 
ZNF181 1.683 HHZ181; MGC44316 NM_001029
997 
zinc finger protein 181 
RAI17 1.681 MIZ; Zimp10; FLJ13541; KIAA1224 NM_020338 retinoic acid induced 17 
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LZIC 1.68 MGC15436 NM_032368 leucine zipper and CTNNBIP1 domain containing 
TRIM11 1.678 BIA1; RNF92 NM_145214 tripartite motif-containing 11 
PPFIA4 1.678 PPFIA4 NM_015053 protein tyrosine phosphatase, receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), alpha 4 
ITPKB 1.677 IP3K; PIG37; IP3K-B NM_002221 inositol 1,4,5-trisphosphate 3-kinase B 
LOH11C
R2A 
1.674 BCSC-1 NM_014622 loss of heterozygosity, 11, chromosomal region 2, gene A 
ARHGA
P27 
1.671 CAMGAP1; FLJ43547; MGC120624 NM_199282 Rho GTPase activating protein 27 
MLLT10 1.67 AF10; MGC75086; DKFZp686E10210 NM_004641 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 10 
ZDHHC
2 
1.668 ZNF372 NM_016353 zinc finger, DHHC-type containing 2 
SLPI 1.667 ALP; MPI; ALK1; BLPI; HUSI; WAP4; WFDC4; 
HUSI-I 
NM_003064 secretory leukocyte peptidase inhibitor 
PLOD2 1.664 LH2; TLH NM_182943 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
TNFRSF
25 
1.664   NM_148973   
THRAP
2 
1.663 MED13L; FLJ21627; KIAA1025; TRAP240L; 
PROSIT240; DKFZp781D0112 
NM_015335 thyroid hormone receptor associated protein 2 
C14ORF
79 
1.662 C14orf79 NM_174891 chromosome 14 open reading frame 79 
JUND 1.661 JUND NM_005354 jun D proto-oncogene 
HYPB 1.661   NM_012271   
TLE1 1.658 ESG; ESG1; GRG1 NM_005077 transducin-like enhancer of split 1 (E(sp1) homolog, Drosophila) 
C1ORF1
65 
1.658 FLJ11588 NM_024603 chromosome 1 open reading frame 165 
C8ORF4
8 
1.655   NM_001007
090 
  
NME5 1.655 NM23H5; NM23-H5 NM_003551 non-metastatic cells 5, protein expressed in (nucleoside-
diphosphate kinase) 
NCOA1 1.654 SRC1; NCoA-1; RIP160; F-SRC-1; MGC129719; 
MGC129720 
NM_147223 nuclear receptor coactivator 1 
PPP1R3
F 
1.654 Hb2E NM_033215 protein phosphatase 1, regulatory (inhibitor) subunit 3F 
LOC196
752 
1.652 LOC196752; FLJ34302 NM_001010
864 
similar to CG32542-PA 
TBL2 1.651   NM_032988   
MTNR1
A 






RTN1 1.648 NSP; MGC133250 NM_206857 reticulon 1 
ACVR2
B 
1.647 ActR-IIB; MGC116908 NM_001106 activin A receptor, type IIB 
GCGR 1.645 GGR; MGC138246 NM_000160 glucagon receptor 
UBE2Q1 1.644 GTAP; UBE2Q; NICE-5; PRO3094 NM_017582 ubiquitin-conjugating enzyme E2Q (putative) 1 
ARSD 1.642 ARSD NM_009589 arylsulfatase D 
KCNJ13 1.642 KIR1.4; KIR7.1; MGC33328 NM_002242 potassium inwardly-rectifying channel, subfamily J, member 13 
LBH 1.642 LBH; MGC104312; DKFZP566J091 NM_030915 hypothetical protein DKFZp566J091 
CECR6 1.642 GATS NM_031890 cat eye syndrome chromosome region, candidate 6 
SUHW1 1.641 ZNF280; ZNF636; 3'OY11.1 NM_080740 suppressor of hairy wing homolog 1 (Drosophila) 
PTPN13 1.64 PNP1; FAP-1; PTP1E; PTPL1; PTPLE; PTP-BL; 
PTP-BAS; DKFZp686J1497 









1.639 MBNT; Mtrp; LAPTM4; HUMORF13; KIAA0108 NM_014713 lysosomal-associated protein transmembrane 4 alpha 
PLA2G4
B 
1.638 FLJ42498; HsT16992; cPLA2-beta NM_005090 phospholipase A2, group IVB (cytosolic) 
CA9 1.636 MN; CAIX NM_001216 carbonic anhydrase IX 
ZNF578 1.635   NM_152472   
PIK3R1 1.633 GRB1; p85-ALPHA NM_181504 phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha) 
NCAM1 1.629 CD56; NCAM; MSK39 NM_181351 neural cell adhesion molecule 1 
L1CAM 1.628 S10; HSAS; MASA; MIC5; SPG1; CAML1; 
CD171; HSAS1; N-CAML1 
NM_000425 L1 cell adhesion molecule 
TBL1X
R1 
1.628 C21; DC42; IRA1; TBLR1; FLJ12894 NM_024665 transducin (beta)-like 1X-linked receptor 1 
TMEM3
7 
1.627 PR; PR1; CACNG5 NM_183240 transmembrane protein 37 
TMPO 1.627 TP; LAP2; CMD1T; PRO0868; MGC61508 NM_003276 Thymopoietin 
C1ORF1
88 
1.627 FLJ32096 NM_173795 chromosome 1 open reading frame 188 
IGSF3 1.626 V8; EWI-3; MGC117164 NM_001542 immunoglobulin superfamily, member 3 
DGKB 1.626 DGK; DAGK2; DGK-BETA; KIAA0718 NM_004080 diacylglycerol kinase, beta 90kDa 
ZNF653 1.626 ZIP67; E430039K05Rik NM_138783 zinc finger protein 653 
MGC13
138 
1.626 MGC13138 NM_033410 zinc finger protein 764 





1.625 cent-b; HSA272195 NM_018404 centaurin, alpha 2 
ZNF701 1.624 FLJ10891 NM_018260 zinc finger protein 701 
ELF1 1.624 ELF1 NM_172373 E74-like factor 1 (ets domain transcription factor) 
CAMK1 1.623 CAMKI; MGC120317; MGC120318 NM_003656 calcium/calmodulin-dependent protein kinase I 
GAL3ST
1 
1.622 CST NM_004861 galactose-3-O-sulfotransferase 1 
TIGD5 1.622 FLJ14926; MGC44883 NM_032862 tigger transposable element derived 5 
DOPEY
1 
1.622 FLJ35610; KIAA1117; dJ202D23.2 NM_015018 dopey family member 1 
FBXO11 1.62 VIT1; FBX11; PRMT9; FLJ12673; MGC44383; 
UG063H01 
NM_018693 F-box protein 11 
MGC52
000 
1.62 MGC52000; CXYorf1; MGC90409; MGC104889; 
MGC111476; MGC117230 
NM_198943 CXYorf1-related protein 
ADD3 1.619 ADDL NM_016824 adducin 3 (gamma) 





1.617 LOC113386; FLJ44718; FLJ46452 NM_138781 similar to envelope protein 
ZBTB33 1.617 ZNF348; ZNF-kaiso NM_006777 zinc finger and BTB domain containing 33 
TGIF 1.616 HPE4; MGC5066; MGC39747 NM_003244 TGFB-induced factor (TALE family homeobox) 
ZNF14 1.616 KOX6; GIOT-4 NM_021030 zinc finger protein 14 
MYT1 1.615 MTF1; MYTI; PLPB1; C20orf36 NM_004535 myelin transcription factor 1 
COL4A2 1.615 FLJ22259; DKFZp686I14213 NM_001846 collagen, type IV, alpha 2 




1.614 CVID; TACI; CD267; FLJ39942; MGC39952; 
MGC133214; TNFRSF14B 
NM_012452 tumor necrosis factor receptor superfamily, member 13B 
CLDN11 1.614 OSP; OTM NM_005602 claudin 11 (oligodendrocyte transmembrane protein) 
KLKB1 1.614 KLK3 NM_000892 kallikrein B, plasma (Fletcher factor) 1 
CEP192 1.612 CEP192 NM_032142 centrosomal protein 192kDa 
RGS19 1.61 GAIP; RGSGAIP NM_005873 regulator of G-protein signalling 19 
DMTF1 1.606 DMP1; DMTF; hDMP1; FLJ41265 NM_021145 cyclin D binding myb-like transcription factor 1 
HNF4A 1.604 TCF; HNF4; MODY; MODY1; NR2A1; TCF14; 
HNF4a7; HNF4a8; HNF4a9; NR2A21; FLJ39654 
NM_178850 hepatocyte nuclear factor 4, alpha 



















chromosome 1 open reading frame 53 
LOC128
977 
1.597 LOC128977; MGC74441 NM_173793 hypothetical protein LOC128977 
CACNA
1H 
1.595 CACNA1HB; FLJ90484 NM_021098 calcium channel, voltage-dependent, alpha 1H subunit 
FGFRL1 1.592 FHFR; FGFR5 NM_001004
358 
fibroblast growth factor receptor-like 1 
P2RY11 1.591 P2Y11 NM_002566 purinergic receptor P2Y, G-protein coupled, 11 
DIP 1.588 DIP; KIAA0767; MGC90497; dA59H18.1; 
dJ439F8.1 
NM_015124 death-inducing-protein 
STK36 1.587 FU; KIAA1278; DKFZp434N0223 NM_015690 serine/threonine kinase 36 (fused homolog, Drosophila) 
NIPSNA
P3A 
1.585 HSPC299; FLJ13953; MGC14553; 
DKFZp564D177 
NM_015469 nipsnap homolog 3A (C. elegans) 
EXOC7 1.585 EX070; EXO70; EXOC1; 2-5-3p; Exo70p; 
YJL085W; FLJ46415; DKFZp686J04253 
NM_015219 exocyst complex component 7 
DDEFL1 1.585 UPLC1; FLJ20199 NM_017707 development and differentiation enhancing factor-like 1 
NEO1 1.584 NGN; HsT17534 NM_002499 neogenin homolog 1 (chicken) 
LOC388
389 
1.583 FLJ13094; FLJ34211 NM_213607 coiled-coil domain containing 103 
DYRK1
B 
1.582 MIRK NM_006484 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 
DUSP8 1.58 HB5; HVH8; HVH-5 NM_004420 dual specificity phosphatase 8 
CSNK2
A1 
1.578 CKII; CK2A1; CKII alpha NM_177559 casein kinase 2, alpha 1 polypeptide 
ZNF91 1.578 HPF7; HTF10 NM_003430 zinc finger protein 91 
SEMA3
F 
1.577 SEMA4; SEMAK; SEMA-IV; sema IV NM_004186 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3F 
POGK 1.575 BASS2; LST003; KIAA1513; KIAA15131 NM_017542 pogo transposable element with KRAB domain 
C15ORF
39 
1.572 FLJ46337; MGC117209; DKFZP434H132 NM_015492 chromosome 15 open reading frame 39 
SMAD5 1.571 Dwfc; JV5-1; MADH5; DKFZp781C1895; 
DKFZp781O1323 
NM_005903 SMAD, mothers against DPP homolog 5 (Drosophila) 
KIAA19
84 
1.568   NM_032874   
ATP8A1 1.568 ATPIA; ATPP2; ATPASEII; MGC26327; 
MGC130042; MGC130043 
NM_006095 ATPase, aminophospholipid transporter (APLT), Class I, type 
8A, member 1 
LIMS2 1.567 PINCH-2; FLJ10044 NM_017980 LIM and senescent cell antigen-like domains 2 
POGZ 1.567 SUHW5; ZNF635; KIAA0461; MGC71543 NM_145796 pogo transposable element with ZNF domain 
NUDT1
8 
1.566 FLJ22494 NM_024815 nudix (nucleoside diphosphate linked moiety X)-type motif 18 
ZNF42 1.565 MZF-1; MZF1B; ZNF42; Zfp98; ZSCAN6 NM_198055 myeloid zinc finger 1 
ZNF236 1.561 ZNF236A; ZNF236B NM_007345 zinc finger protein 236 
ZNF627 1.56 FLJ90365 NM_145295 zinc finger protein 627 
GBGT1 1.56 FS; A3GALNT; UNQ2513; MGC44848; RP11-
326L24.6 
NM_021996 globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 
ZNF24 1.56 KOX17; RSG-A; ZNF191; ZSCAN3; Zfp191 NM_006965 zinc finger protein 24 
RBM15
B 





RUN domain containing 2B 
SLC16A
3 




1.555 6.3; SEX; PLXN3; PLXN4; XAP-6; 
HSSEXGENE; PLEXIN-A3 
NM_017514 plexin A3 
NOTUM 1.555 HMGA1 NM_178493 notum pectinacetylesterase homolog (Drosophila) 
CRAMP
1L 
1.555 TCE4 NM_020825 Crm, cramped-like (Drosophila) 
PPP1R1
4A 
1.551 CPI-17; PPP1INL NM_033256 protein phosphatase 1, regulatory (inhibitor) subunit 14A 
KIAA09
99 
1.551 KIAA0999; L19; FLJ12240 NM_025164 KIAA0999 protein 
ZNF438 1.551 FLJ32761; MGC126671; bA330O11.1; RP11-
330O11.1 
NM_182755 zinc finger protein 438 




1.55 FLJ36794; DKFZp727G131 NM_145111 chromosome 7 open reading frame 38 





1.548 CG7943; MGC14836 NM_033412 mitochondrial carrier triple repeat 1 
S100A8 1.546 P8; MIF; NIF; CAGA; CFAG; CGLA; L1Ag; 
MRP8; CP-10; MA387; 60B8AG 
NM_002964 S100 calcium binding protein A8 
MTA2 1.546 PID; MTA1L1; DKFZp686F2281 NM_004739 metastasis associated 1 family, member 2 







1.543 KBRAS2; MGC74742; kappaB-Ras2; 
DKFZP434N1526 
NM_017595 NFKB inhibitor interacting Ras-like 2 
NTN4 1.543 PRO3091; FLJ23180 NM_021229 netrin 4 
C17ORF
68 
1.543 FLJ22170; MGC133331 NM_025099 chromosome 17 open reading frame 68 
DDX31 1.539 FLJ13633; FLJ14578; FLJ23349; helicain A; 
helicain B; helicain C 
NM_022779 DEAD (Asp-Glu-Ala-Asp) box polypeptide 31 
PCNT2 1.539 KEN; PCN; PCNT2; PCNTB; PCTN2 NM_006031 pericentrin (kendrin) 
SLC6A9 1.536 GLYT1; DKFZp547A1118 NM_006934 solute carrier family 6 (neurotransmitter transporter, glycine), 
member 9 
SMG7 1.535 EST1C; SMG-7; SGA56M; C1orf16; FLJ23717; 
KIAA0250 




1.534 DKFZp547B1713 NM_152379 chromosome 1 open reading frame 131 
LOC158
160 
1.533   NM_001031
744 
  
ALPP 1.532 ALP; PLAP NM_001632 alkaline phosphatase, placental (Regan isozyme) 




1.53 HUR; Hua; MelG; ELAV1 NM_001419 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 
(Hu antigen R) 
NIPA1 1.529 FSP3; SPG6; MGC35570; MGC102724 NM_144599 non imprinted in Prader-Willi/Angelman syndrome 1 
MAFG 1.529 MGC13090; MGC20149 NM_002359 v-maf musculoaponeurotic fibrosarcoma oncogene homolog G 
(avian) 
CNN2 1.528 WDR18 NM_201277 calponin 2 
ZNF703 1.528 ZNF503L; FLJ14299 NM_025069 zinc finger protein 703 
PPP1R1
0 
1.526 FB19; CAT53; PNUTS NM_002714 protein phosphatase 1, regulatory subunit 10 
ZNF499 1.525 FLJ14486; DKFZp547H249 NM_032792 zinc finger protein 499 
GYS1 1.524 GSY; GYS NM_002103 glycogen synthase 1 (muscle) 
ELMO3 1.523 CED12; CED-12; ELMO-3; FLJ13824 NM_024712 engulfment and cell motility 3 
UNQ467 1.522 UNQ467 NM_207392 KIPV467 
SSTR2 1.522 SSTR2 NM_001050 somatostatin receptor 2 
PPP1R1
6A 
1.52 MYPT3; MGC14333 NM_032902 protein phosphatase 1, regulatory (inhibitor) subunit 16A 
TULP4 1.518 TUSP; KIAA1397; RP3-442A17.1 NM_020245 tubby like protein 4 
HRASL
S5 
1.518 HRLP5 NM_054108 HRAS-like suppressor family, member 5 
LSR 1.517 LISCH7; MGC10659; MGC48312; MGC48503 NM_015925 lipolysis stimulated lipoprotein receptor 
LDLRA
D3 
1.517 SLC41A1 NM_174902 low density lipoprotein receptor class A domain containing 3 
PRSS8 1.516 CAP1; PROSTASIN NM_002773 protease, serine, 8 (prostasin) 
KCNH3 1.515 BEC1; ELK2; Kv12.2; KIAA1282 NM_012284 potassium voltage-gated channel, subfamily H (eag-related), 
member 3 
GGTL3 1.514   NM_178025   
C6ORF8
4 
1.513 QN1; C6orf84; FLJ13551 NM_014895 KIAA1009 
PLXNB
1 
1.512 SEP; PLXN5; KIAA0407; PLEXIN-B1 NM_002673 plexin B1 
PHF23 1.511 MGC2941; FLJ16355; FLJ22884; hJUNE-1b NM_024297 PHD finger protein 23 
MGC70
863 
1.51 MGC70863 NM_203477 similar to RPL23AP7 protein 
MGC10
992 
1.51 MGC10992; MGC13119 NM_033212 coiled-coil domain containing 102A 
FAM103
A1 
1.51 MGC2560; C15orf18; HsT19360; MGC102778 NM_031452 family with sequence similarity 103, member A1 
ZNF200 1.509 MGC45293 NM_198088 zinc finger protein 200 
MMP23
A 





hypothetical protein LOC339344 
C12ORF
36 
1.506 FLJ33810; MGC120140 NM_182558 chromosome 12 open reading frame 36 
WDFY3 1.506 ALFY; ZFYVE25; KIAA0993; MGC16461 NM_178583 WD repeat and FYVE domain containing 3 
ZNF264 1.505 KIF1B NM_003417 zinc finger protein 264 
FLJ1421
3 
1.505 FLJ14213; MGC16218 NM_024841 hypothetical protein FLJ14213 
PDZRN
4 
1.502 LNX4; SAMCAP3L NM_013377 PDZ domain containing RING finger 4 
SLC2A8 1.502 GLUT8; GLUTX1 NM_014580 solute carrier family 2, (facilitated glucose transporter) member 8 
CRKL 1.502 CRKL NM_005207 v-crk sarcoma virus CT10 oncogene homolog (avian)-like 
HYOU1 1.501 ORP150; DKFZp686N08236 NM_006389 hypoxia up-regulated 1 
APOLD
1 
1.498 FLJ25138; DKFZP434F0318 NM_030817 apolipoprotein L domain containing 1 
RAB3IL
1 
1.497 GRAB NM_013401 RAB3A interacting protein (rabin3)-like 1 
ZFAND
2B 
1.494 CHFR NM_138802 zinc finger, AN1-type domain 2B 
OSBPL6 1.494 ORP6; FLJ36583; MGC59642 NM_145739 oxysterol binding protein-like 6 
C1ORF1
02 
1.494 NOR1; OSCP1; MGC26685 NM_206837 chromosome 1 open reading frame 102 
HRAS 1.493 HRAS1; K-ras; N-ras; RASH1; c-bas/has NM_176795 v-Ha-ras Harvey rat sarcoma viral oncogene homolog 
RPH3A
L 
1.493 NOC2 NM_006987 rabphilin 3A-like (without C2 domains) 
ODF2 1.493 ODF84; ODF2/1; ODF2/2; MGC9034; FLJ44866; 
MGC111096 
NM_153437 outer dense fiber of sperm tails 2 
BTBD4 1.49 RINZF; ZNF340; FLJ13502; dJ583P15.7; 
dJ583P15.8 




1.49 KIAA1706 NM_030636 KIAA1706 protein 
ALS2CR
13 
1.488 FAM117B; FLJ38771; DKFZp686H01244 NM_173511 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, 
candidate 13 
ZNF189 1.488 PRKCBP1 NM_003452 zinc finger protein 189 
FLJ2253
1 
1.486 FLJ22531 NM_024650 hypothetical protein FLJ22531 
SIDT2 1.486   NM_015996   
ASB18 1.486 ASB-18 NM_212556 ankyrin repeat and SOCS box-containing 18 
ALS2 1.484 ALSJ; PLSJ; IAHSP; ALS2CR6; FLJ31851; 
KIAA1563; MGC87187 
NM_020919 amyotrophic lateral sclerosis 2 (juvenile) 
ZNF93 1.483 TF34; HPF34; HTF34; ZNF505 NM_001004
126 
zinc finger protein 93 
PRPH 1.483 NEF4 NM_006262 Peripherin 
NR3C1 1.483 GR; GCR; GRL; GCCR NM_001020
825 




1.481 dyf-13; FLJ12571 NM_024926 tetratricopeptide repeat domain 26 
FES 1.48 FPS NM_002005 feline sarcoma oncogene 
TBC1D1
3 
1.479 FLJ10743; RP11-545E17.5 NM_018201 TBC1 domain family, member 13 
C1ORF1
02 
1.478 NOR1; OSCP1; MGC26685 NM_206837 chromosome 1 open reading frame 102 
HES6 1.478 HES6 NM_018645 hairy and enhancer of split 6 (Drosophila) 
AGPAT
3 
1.478 MGC4604; LPAAT-GAMMA1 NM_020132 1-acylglycerol-3-phosphate O-acyltransferase 3 
NUTF2 1.477 NTF2; PP15 NM_005796 nuclear transport factor 2 
TP53IN
P1 
1.477 SIP; Teap; FLJ22139; p53DINP1; TP53DINP1; 
TP53INP1A; TP53INP1B; DKFZp434M1317 
NM_033285 tumor protein p53 inducible nuclear protein 1 
FGA 1.477 Fib2; MGC119422; MGC119423; MGC119425 NM_021871 fibrinogen alpha chain 
WDR20 1.477 DMR; FLJ33659; MGC33177; MGC33183 NM_181308 WD repeat domain 20 
PLEKHJ
1 
1.477 GNRPX; FLJ10297 NM_018049 pleckstrin homology domain containing, family J member 1 
FBXW4 1.476 DAC; FBW4; FBWD4; SHFM3; SHSF3 NM_022039 F-box and WD-40 domain protein 4 
PGAP1 1.476 PGAP1; FLJ42774; ISPD3024 NM_024989 GPI deacylase 
ZNF214 1.475 BAZ1 NM_013249 zinc finger protein 214 
TMEM2
0 
1.475 C10orf60; FLJ33990 NM_153226 transmembrane protein 20 
PSKH2 1.474 PSKH2 NM_033126 protein serine kinase H2 
ADD3 1.474 ADDL NM_016824 adducin 3 (gamma) 
SNX26 1.473 TCGAP; FLJ39019 NM_052948 sorting nexin 26 
ET 1.473 ET NM_024311 hypothetical protein ET 
SAP30B
P 
1.472 HTRG; HTRP; HCNGP; DKFZp586L2022 NM_013260 SAP30 binding protein 
MRPL28 1.472 p15; MAAT1; MGC8499 NM_006428 mitochondrial ribosomal protein L28 
MMP11 1.472 ST3; SL-3; STMY3 NM_005940 matrix metallopeptidase 11 (stromelysin 3) 
MEST 1.471 PEG1; MGC8703; MGC111102; 
DKFZp686L18234 
NM_177524 mesoderm specific transcript homolog (mouse) 
HS3ST1 1.469 3OST; 3OST1 NM_005114 heparan sulfate (glucosamine) 3-O-sulfotransferase 1 
CCDC47 1.469 GK001; MSTP041 NM_020198 coiled-coil domain containing 47 
WDR60 1.467 FLJ10300; FLJ23575 NM_018051 WD repeat domain 60 
RABL5 1.467 FLJ13225; FLJ14117; DKFZp761N0823 NM_022777 RAB, member RAS oncogene family-like 5 
COL18A
1 
1.467 KNO; FLJ27325; MGC74745 NM_030582 collagen, type XVIII, alpha 1 
SLC2A4
RG 
1.467 GEF; HDBP1; Si-1-2; Si-1-2-19 NM_020062 SLC2A4 regulator 
GDPD1 1.467 GDE4; UGPQ; FLJ27503; FLJ37451; MGC35046 NM_182569 glycerophosphodiester phosphodiesterase domain containing 1 
ZNF205 1.466 ZNF205 NM_001031
686 
synonym: ZNF210; zinc finger protein 210; Homo sapiens zinc 
finger protein 205 (ZNF205), transcript variant 1, mRNA. 
TP53IN
P2 
1.465 PINH; FLJ21759; FLJ23500; C20orf110; 
dJ1181N3.1; DKFZp434B2411; DKFZp434O0827 
NM_021202 tumor protein p53 inducible nuclear protein 2 
CBS 1.465 HIP4 NM_000071 cystathionine-beta-synthase 
KIAA12
85 
1.464 KIAA1285 NM_015694 zinc finger protein 777 
EDARA
DD 





hypothetical protein DKFZp666G057 
SETD8 1.461 SET8; SET07; PR-Set7 NM_020382 SET domain containing (lysine methyltransferase) 8 
MGAT4
A 
1.46 GNT-IV; GNT-IVA NM_012214 mannosyl (alpha-1,3-)-glycoprotein beta-1,4-N-
acetylglucosaminyltransferase, isozyme A 
C21ORF
55 
1.459 C21orf78 NM_017833 chromosome 21 open reading frame 55 
PODXL 1.458 PCLP; Gp200; MGC138240 NM_005397 podocalyxin-like 
ASB7 1.456 FLJ22551 NM_024708 ankyrin repeat and SOCS box-containing 7 
ATN1 1.456 B37; NOD; DRPLA; D12S755E NM_001007
026 
atrophin 1 
CLSTN2 1.455 CS2; CSTN2; FLJ39113; FLJ39499; MGC119560; 
alcagamma 
NM_022131 calsyntenin 2 
TMEM1
6H 
1.455 KIAA1623 NM_020959 transmembrane protein 16H 
C11ORF
17 
1.454 BCA3; AKIP1 NM_182901 chromosome 11 open reading frame 17 
RUFY1 1.454 RABIP4; ZFYVE12; FLJ22251 NM_025158 RUN and FYVE domain containing 1 
C1ORF2
6 
1.453 FLJ20121; FLJ35944 NM_017673 chromosome 1 open reading frame 26 
ST8SIA
6 
1.452 SIAT8F; ST8SIA-VI; ST8Sia VI NM_001004
470 
ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 
FLJ2029
4 
1.451 FLJ20294; KIAA1736; MGC33725 NM_017749 hypothetical protein FLJ20294 
CD163 1.451 M130; MM130 NM_203416 CD163 molecule 
RARA 1.45 RAR; NR1B1 NM_001024
809 
retinoic acid receptor, alpha 
CTBP1 1.449 BARS; MGC104684 NM_001012
614 
C-terminal binding protein 1 
NDRG4 1.449 SMAP-8; FLJ30586; FLJ42011; KIAA1180; NM_020465 NDRG family member 4 
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MGC19632; DKFZp686I1615 
CPSF1 1.449 CPSF160; P/cl.18; HSU37012 NM_013291 cleavage and polyadenylation specific factor 1, 160kDa 
GLTSC
R1 
1.448 GLTSCR1 NM_015711 glioma tumor suppressor candidate region gene 1 
C9ORF9
8 
1.447 DDX31; FLJ32704; RP11-143F18.1 NM_152572 chromosome 9 open reading frame 98 
CPS1 1.446 CPS1 NM_001875 carbamoyl-phosphate synthetase 1, mitochondrial 
SLC22A
17 
1.446 BOCT; BOIT; hBOIT NM_016609 solute carrier family 22 (organic cation transporter), member 17 
ZNF618 1.446 ZNF618 NM_133374 zinc finger protein 618 
SPRED1 1.446 FLJ33903 NM_152594 sprouty-related, EVH1 domain containing 1 
FAM65
A 
1.445 FLJ13725; KIAA1930 NM_024519 family with sequence similarity 65, member A 
PTPN14 1.444 PEZ; PTP36; MGC126803 NM_005401 protein tyrosine phosphatase, non-receptor type 14 
ITPR1 1.443 IP3R; IP3R1; Insp3r1 NM_002222 inositol 1,4,5-triphosphate receptor, type 1 
C20ORF
46 
1.442 FLJ11190 NM_018354 chromosome 20 open reading frame 46 
NFRKB 1.441 DKFZp547B2013 NM_006165 nuclear factor related to kappaB binding protein 
MAT2B 1.441 TGR; MAT-II; MGC12237; MATIIbeta; 
Nbla02999 
NM_013283 methionine adenosyltransferase II, beta 
SEPP1 1.44 SeP; SELP NM_005410 selenoprotein P, plasma, 1 
HLA-
DRB3 
1.439 HLA-DR3B; MGC117330 NM_022555 major histocompatibility complex, class II, DR beta 3 
CYP3A4
3 
1.439 MGC119315; MGC119316 NM_057096 cytochrome P450, family 3, subfamily A, polypeptide 43 
FOXJ1 1.438 HFH4; HFH-4; FKHL13; MGC35202 NM_001454 forkhead box J1 
ZNF671 1.437 FLJ23506 NM_024833 zinc finger protein 671 
ASRGL
1 
1.437 ALP; ALP1; FLJ22316 NM_025080 asparaginase like 1 
IGSF4D 1.436 NECL3; Necl-3; synCAM2; MGC104534; 
MGC138341; MGC138343 
NM_153184 immunoglobulin superfamily, member 4D 
KIAA12
02 
1.435 KIAA1202 NM_020717 shroom family member 4 
TAOK2 1.434 PSK; PSK1; TAO1; TAO2; MAP3K17; 
KIAA0881 
NM_016151 TAO kinase 2 





ankyrin repeat domain 30B 
PCTK1 1.433 PCTAIRE; FLJ16665; PCTAIRE1; PCTGAIRE NM_033018 PCTAIRE protein kinase 1 
ZNF161 1.433 DB1; ZNF161 NM_007146 vascular endothelial zinc finger 1 
HYI 1.43 HT036; MGC20767; RP11-506B15.5 NM_031207 hydroxypyruvate isomerase homolog (E. coli) 
CNTN4 1.43 AXCAM; BIG-2; CNTN4A; MGC33615 NM_175613 contactin 4 
GYPA 1.43 MN; GPA; MNS; GPSAT; CD235a; GPErik; 
HGpMiV; HGpMiX; GpMiIII; HGpMiXI; 
HGpMiIII; HGpSta(C) 
NM_002099 glycophorin A (MNS blood group) 
FADS2 1.43 D6D; DES6; TU13; FADSD6; LLCDL2; SLL0262 NM_004265 fatty acid desaturase 2 
VTN 1.43 VN; V75; VNT NM_000638 vitronectin 
FOXN4 1.427 FLJ35967 NM_213596 forkhead box N4 
KIAA03
50 
1.427 MGC111457 NM_015226 KIAA0350 
FLJ2174
2 
1.427 FLJ21742 NM_032207 chromosome 19 open reading frame 44 
RASSF6 1.426 DKFZp686K23225 NM_177532 Ras association (RalGDS/AF-6) domain family 6 
SLC44A
2 
1.426 CTL2; PP1292; FLJ44586; DKFZp666A071 NM_020428 solute carrier family 44, member 2 
KIAA06
49 
1.425 RP11-426A6.6 NM_014811 KIAA0649 
GALNT
4 
1.425 GalNAcT4; GALNAC-T4 NM_003774 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4 (GalNAc-T4) 
SLC29A
4 
1.424 ENT4; PMAT; FLJ34923 NM_153247 solute carrier family 29 (nucleoside transporters), member 4 
LOC552
891 
1.424 LOC552891 NM_004125 hypothetical protein LOC552891 
LOC906
93 
1.424 FLJ23031; MGC104248 NM_138771 coiled-coil domain containing 126 
ENPP4 1.424 NPP4; KIAA0879 NM_014936 ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative 
function) 
PRSS16 1.423 TSSP; FLJ40714 NM_005865 protease, serine, 16 (thymus) 
MGC39
900 





family with sequence similarity 116, member B 
CLIC3 1.42 CLIC3 NM_004669 chloride intracellular channel 3 
CXORF
44 
1.42 CXorf44; FLJ20434 NM_138362 family with sequence similarity 104, member B 
C12ORF
61 
1.419 FLJ25590 NM_175895 chromosome 12 open reading frame 61 
FOXH1 1.419 FAST1; FAST-1 NM_003923 forkhead box H1 
MTHFR 1.418 MTHFR NM_005957 5,10-methylenetetrahydrofolate reductase (NADPH) 
STRA6 1.418 PP14296; FLJ12541 NM_022369 stimulated by retinoic acid gene 6 homolog (mouse) 
ACSS2 1.417 ACS; ACSA; ACAS2; AceCS; MYH7B; 
dJ1161H23.1; DKFZp762G026 
NM_139274 acyl-CoA synthetase short-chain family member 2 
CADPS 1.415 CAPS; CAPS1; KIAA1121 NM_183394 Ca2+-dependent secretion activator 
PHF2 1.414 GRC5; KIAA0662 NM_024517 PHD finger protein 2 
FUK 1.414 FLJ39408; 1110046B12Rik NM_145059 fucokinase 
APOB 1.414 FLDB NM_000384 apolipoprotein B (including Ag(x) antigen) 
NUAK2 1.413 SNARK; FLJ90349; DKFZP434J037; 
DKFZp686F01113 
NM_030952 NUAK family, SNF1-like kinase, 2 
HHAT 1.411 Skn; ski; GUP2; SKI1; MART2; MART-2; 
FLJ10724; FLJ34867 
NM_018194 hedgehog acyltransferase 
BANP 1.41 SMAR1; SMARBP1; FLJ10177; FLJ20538; 
DKFZp761H172 
NM_079837 BTG3 associated nuclear protein 
ALDH6
A1 
1.41 MMSDH; MMSADHA; MGC40271 NM_005589 aldehyde dehydrogenase 6 family, member A1 
C1ORF6
0 
1.409 INT3; C1orf60; FLJ21919; DKFZp686E1950; 
DKFZp781I1253; RP11-216N14.2; 
NM_023015 integrator complex subunit 3 
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DKFZp686O20115 
JAK2 1.408 JAK2 NM_004972 Janus kinase 2 (a protein tyrosine kinase) 
TCF2 1.407 FJHN; HNF2; LFB3; HNF1B; MODY5; VHNF1; 
HNF1beta 




1.406 ZNF495; MGC4161 NM_024303 zinc finger and SCAN domain containing 5 
MGC16
385 
1.406 MGC16385; FLJ23771; FLJ31569; MGC13198 NM_145039 hypothetical protein MGC16385 
PHYHIP
L 
1.405 KIAA1796 NM_032439 phytanoyl-CoA 2-hydroxylase interacting protein-like 
RORA 1.405 ROR1; ROR2; ROR3; RZRA; NR1F1; 
MGC119326; MGC119329 
NM_134262 RAR-related orphan receptor A 
SLC30A
4 
1.404 ZNT4 NM_013309 solute carrier family 30 (zinc transporter), member 4 
CCBP2 1.403 D6; hD6; CCR9; CCR10; CMKBR9; 
MGC126678; MGC138250 
NM_001296 chemokine binding protein 2 
INADL 1.402 Cipp; PATJ; FLJ26982 NM_176878 InaD-like (Drosophila) 
DCHS1 1.402 FIB1; CDH25; PCDH16; FLJ11790; KIAA1773 NM_003737 dachsous 1 (Drosophila) 
FNDC5 1.402 FRCP2 NM_153756 fibronectin type III domain containing 5 
ZNF354
A 
1.402 EZNF; HKL1; KID1; KID-1; TCF17 NM_005649 zinc finger protein 354A 
FIGNL1 1.401 FIGNL1 NM_022116 fidgetin-like 1 
C14ORF
80 
1.4 MGC16771 NM_173608 chromosome 14 open reading frame 80 
VPS37C 1.399 FLJ20847 NM_017966 vacuolar protein sorting 37 homolog C (S. cerevisiae) 
DMWD 1.399 DMRN9; DMR-N9; gene59; D19S593E NM_004943 dystrophia myotonica-containing WD repeat motif 
ARHGA
P24 
1.398 p73; FLJ33877; RC-GAP72; p73RhoGAP; 
DKFZP564B1162 
NM_031305 Rho GTPase activating protein 24 





1.397 Fmip; PK1.3; C22orf19 NM_001002
878 
THO complex 5 
OAS1 1.397 OIAS; IFI-4; OIASI NM_002534 2',5'-oligoadenylate synthetase 1, 40/46kDa 
HCN3 1.397 KIAA1535 NM_020897 hyperpolarization activated cyclic nucleotide-gated potassium 
channel 3 
CPLX2 1.397 CPX2; 921-L; CPX-2; MGC138492 NM_006650 complexin 2 
MGC43
99 
1.396 BMSC-MCP; MGC4399 NM_032315 PNC1 protein 
FLJ3677
9 
1.396 FLJ36779 NM_152571 chromosome 9 open reading frame 163 
KBTBD
2 
1.395 BKLHD1 NM_015483 kelch repeat and BTB (POZ) domain containing 2 
HOXD1 1.395 HOX4; HOX4G; Hox-4.7 NM_024501 homeobox D1 
AGL 1.395 GDE NM_000028 amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen 
debranching enzyme, glycogen storage disease type III) 
PCSK4 1.394 PC4; SPC5; MGC34749; DKFZp434B217 NM_017573 proprotein convertase subtilisin/kexin type 4 
BCL6B 1.394 BAZF; ZNF62; ZBTB28 NM_181844 B-cell CLL/lymphoma 6, member B (zinc finger protein) 
TTYH3 1.394 KIAA1691 NM_025250 tweety homolog 3 (Drosophila) 
PLEKH
G3 
1.393 KIAA0599 NM_015549 pleckstrin homology domain containing, family G (with RhoGef 
domain) member 3 
TOP3B 1.393 TOP3B NM_003935 topoisomerase (DNA) III beta 
GALNT
3 
1.393 HHS; HFTC; MGC61909; GalNAc-T3; 
DKFZp686C10199 
NM_004482 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3) 
GYG2 1.392 GN2; GN-2 NM_003918 glycogenin 2 
KIAA03
23 
1.389 KIAA0323 NM_015299 KIAA0323 
ZNF322
A 
1.388 ZNF322; ZNF388; ZNF489; FLJ23393; 
bA457M11.3 
NM_024639 zinc finger protein 322A 
TCF2 1.388 FJHN; HNF2; LFB3; HNF1B; MODY5; VHNF1; 
HNF1beta 




1.388 DKFZp686F01145; DKFZp686G24132 NM_001010
915 
protein tyrosine phosphatase-like A domain containing 2 
SLC25A
36 
1.387 FLJ10618 NM_018155 solute carrier family 25, member 36 
RBMS2 1.386 SCR3 NM_002898 RNA binding motif, single stranded interacting protein 2 
FAM13
C1 
1.386 MGC33233 NM_198215 family with sequence similarity 13, member C1 




1.384 RAP1GA1; KIAA0474; rap1GAPII NM_002885 RAP1 GTPase activating protein 
COL27A
1 
1.383 FLJ11895; KIAA1870; MGC11337; RP11-82I1.1 NM_032888 collagen, type XXVII, alpha 1 
UMODL
1 
1.383 DICER1 NM_173568 uromodulin-like 1 
LOC317
671 
1.382 LOC317671 NM_173362 Rieske (Fe-S) domain containing 
CBX2 1.382 M33; CDCA6; MGC10561 NM_005189 chromobox homolog 2 (Pc class homolog, Drosophila) 
PEX13 1.382 ZWS; NALD NM_002618 peroxisome biogenesis factor 13 
ZNF606 1.381 ZNF328; FLJ14260; KIAA1852 NM_025027 zinc finger protein 606 
GGA1 1.38 GGA1 NM_001001
561 
golgi associated, gamma adaptin ear containing, ARF binding 
protein 1 
IL18 1.38 IGIF; IL-18; IL-1g; IL1F4; MGC12320 NM_001562 interleukin 18 (interferon-gamma-inducing factor) 
ZNF566 1.38 FLJ14779; MGC12515 NM_032838 zinc finger protein 566 
APOA4 1.38 MGC142154; MGC142156 NM_000482 apolipoprotein A-IV 
ARPC4 1.379 ARC20; p20-Arc; MGC13544 NM_005718 actin related protein 2/3 complex, subunit 4, 20kDa 
PRMT1 1.378 ANM1; HCP1; IR1B4; HRMT1L2 NM_198319 protein arginine methyltransferase 1 
FLJ1099
6 
1.378 FLJ10996; FLJ25197; MGC13033 NM_019044 coiled-coil domain containing 93 
SEC10L
1 
1.378 SEC10; HSEC10; SEC10P; PRO1912; SEC10L1; 
DKFZp666H126 
NM_006544 exocyst complex component 5 
GCN5L2 1.378 GCN5; hGCN5; MGC102791 NM_021078 GCN5 general control of amino-acid synthesis 5-like 2 (yeast) 
KIAA09
61 
1.376 ZNF745; KIAA0961 NM_014898 zinc finger protein 30 homolog (mouse) 
JPH3 1.376 JP3; HDL2; JP-3; TNRC22; CAGL237; FLJ44707 NM_020655 junctophilin 3 
ZNF503 1.375 NOLZ-1; MGC2555; FLJ45745 NM_032772 zinc finger protein 503 
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LSM14B 1.375 FT005; LSM13; FAM61B; C20orf40; FLJ25473; 
bA11M20.3 
NM_144703 LSM14 homolog B (SCD6, S. cerevisiae) 
KIAA19
06 
1.375 KIAA1786; KIAA1906 NM_052907 transmembrane protein 132B 
EPM2AI
P1 
1.373 FLJ11207; KIAA0766 NM_014805 EPM2A (laforin) interacting protein 1 
TRIM41 1.372 MGC1127; MGC31991 NM_201627 tripartite motif-containing 41 
DHX8 1.371 DDX8; HRH1; PRP22; PRPF22 NM_004941 DEAH (Asp-Glu-Ala-His) box polypeptide 8 
KHDRB
S2 
1.371 SLM1; SLM-1; MGC26664; bA535F17.1 NM_152688 KH domain containing, RNA binding, signal transduction 
associated 2 




1.371 PP3856 NM_145201 nicotinate phosphoribosyltransferase domain containing 1 
C14ORF
135 
1.369 FBP2; FLJ12799; FLJ38170 NM_022495 chromosome 14 open reading frame 135 
CNTFR 1.368 MGC1774 NM_147164 ciliary neurotrophic factor receptor 
RAB24 1.367 RAB24 NM_130781 RAB24, member RAS oncogene family 
MAP1L
C3A 
1.366 MAP1ALC3; MAP1BLC3 NM_181509 microtubule-associated protein 1 light chain 3 alpha 
TMPO 1.366 TP; LAP2; CMD1T; PRO0868; MGC61508 NM_003276 thymopoietin 
ZNF297
B 
1.366 ZNF-X; ZBTB22B; ZNF297B NM_014007 zinc finger and BTB domain containing 43 
RTN4R 1.366 NGR; NOGOR NM_023004 reticulon 4 receptor 
SIRT4 1.366 SIR2L4; MGC57437; MGC130046; MGC130047; 
sirtuin 4 
NM_012240 sirtuin (silent mating type information regulation 2 homolog) 4 
(S. cerevisiae) 
LMLN 1.366 Msp; Gp63 NM_033029 leishmanolysin-like (metallopeptidase M8 family) 
ZNF136 1.365 pHZ-20 NM_003437 zinc finger protein 136 
HBG1 1.365 HBGA; HBGR; HSGGL1; PRO2979 NM_000559 hemoglobin, gamma A 
FLCN 1.364 BHD; FLCL; MGC17998; MGC23445 NM_144606 folliculin 
ZNF429 1.364 ZNF429 NM_001001
415 
zinc finger protein 429 
FLVCR 1.364 FLVCR; FLVCR1 NM_014053 feline leukemia virus subgroup C cellular receptor 
PIM3 1.363 pim-3 NM_001001
852 
pim-3 oncogene 
CD300A 1.362 IRC1; IRC2; IRp60; IGSF12; CMRF35H; CMRF-
35H; CMRF35H9; CMRF-35-H9 
NM_007261 CD300a molecule 
MGC34
713 
1.362 MGC34713 NM_173665 hypothetical protein MGC34713 
HLRC1 1.361 HLRC1; MGC4293 NM_031304 deoxyhypusine hydroxylase/monooxygenase 
FLJ4571
7 
1.361 FLJ45717 NM_207401 FLJ45717 protein 
CLASP1 1.361 MAST1; FLJ33821; KIAA0622; MGC131895; 
DKFZp686D1968; DKFZp686H2039 
NM_015282 cytoplasmic linker associated protein 1 
ZBTB8
OS 
1.361 ARCH; ARCH2; MGC62007 NM_178547 zinc finger and BTB domain containing 8 opposite strand 
CDCA7 1.361 JPO1; FLJ14722; FLJ14736; MGC34109 NM_031942 cell division cycle associated 7 
VASP 1.359 PTH NM_003370 vasodilator-stimulated phosphoprotein 
MLL3 1.358 HALR; FLJ12625; FLJ38309; KIAA1506; 
DKFZp686C08112 
NM_170606 myeloid/lymphoid or mixed-lineage leukemia 3 
OVCH2 1.358 OVTN NM_198185 ovochymase 2 
AGRN 1.358 AGRN; FLJ45064 NM_198576 agrin 
CCRK 1.357 p42; CDCH NM_178432 cell cycle related kinase 
MGC40
93 
1.355 MGC4093 NM_030578 hypothetical protein MGC4093 
PB1 1.355 PB1; BAF180 NM_181042 polybromo 1 
LOC197
336 
1.355 FLJ36483; FLJ44660; KIAA1924 NM_145294 WD repeat domain 90 
PTCD1 1.354 KIAA0632 NM_015545 pentatricopeptide repeat domain 1 
AGL 1.354 GDE NM_000642 amylo-1, 6-glucosidase, 4-alpha-glucanotransferase (glycogen 
debranching enzyme, glycogen storage disease type III) 
PIK3C2
A 
1.353 CPK; MGC142218; PI3-K-C2A; DKFZp686L193; 
PI3-K-C2(ALPHA) 
NM_002645 phosphoinositide-3-kinase, class 2, alpha polypeptide 
CTNNA
2 
1.353 CAPR; CTNR; CAP-R; DKFZp686H02198 NM_004389 catenin (cadherin-associated protein), alpha 2 
C9ORF5
8 
1.351 IBA2; FLJ12783; MGC29466; RP11-544A12.2 NM_031426 chromosome 9 open reading frame 58 
C15ORF
38 
1.351 MGC61550 NM_182616 chromosome 15 open reading frame 38 
ZNF707 1.35 ZNF707 NM_173831 zinc finger protein 707 
YWHAE 1.35 MDS; MDCR; KCIP-1; 14-3-3E; FLJ45465 NM_006761 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, epsilon polypeptide 
TRAF4 1.348 CART1; MLN62; RNF83 NM_004295 TNF receptor-associated factor 4 
FLJ1040
4 
1.347 FLJ10404; KIAA1931; DKFZp313I142 NM_019057 hypothetical protein FLJ10404 
LOC124
751 
1.347 LOC124751 NM_213597 KRAB-A domain containing 2 
KLHL9 1.347 RP11-380P16.6 NM_018847 kelch-like 9 (Drosophila) 
C10ORF
119 
1.346 FLJ13081; FLJ36756 NM_024834 chromosome 10 open reading frame 119 
Sep-05 1.346 H5; CDCREL; PNUTL1; CDCREL1; CDCREL-1 NM_002688 septin 5 
SORBS3 1.346 SH3D4; SCAM-1; vinexin NM_005775 sorbin and SH3 domain containing 3 
RPRC1 1.345 PARCC1; FLJ10350; MGC117315 NM_018067 arginine/proline rich coiled-coil 1 
BRWD3 1.344 BRODL; FLJ38568 NM_153252 bromodomain and WD repeat domain containing 3 
EVI1 1.343 EVI-1; PRDM3; MDS1-EVI1; AML1-EVI-1 NM_005241 ecotropic viral integration site 1 
ADPN 1.343 ADPN; C22orf20; iPLA(2)epsilon NM_025225 patatin-like phospholipase domain containing 3 
CKM 1.342 CKMM; M-CK NM_001824 creatine kinase, muscle 
BTBD2 1.341 BTBD2 NM_017797 BTB (POZ) domain containing 2 
IL28RA 1.339 IFNLR; LICR2; IFNLR1; CRF2/12 NM_170743 interleukin 28 receptor, alpha (interferon, lambda receptor) 
GAS8 1.339 GAS11; MGC138326 NM_001481 growth arrest-specific 8 
JMJD4 1.339 FLJ12517; MGC129896 NM_023007 jumonji domain containing 4 
FGF12 1.339 FHF1; FGF12B NM_021032 fibroblast growth factor 12 
HEXDC 1.338 FLJ23825 NM_173620 hexosaminidase (glycosyl hydrolase family 20, catalytic domain) 
containing 





1.336 DKFZp686D12126 NM_015091 KIAA0423 
ACRC 1.336 NAAR1 NM_052957 acidic repeat containing 
CNOT7 1.335 CAF1; hCAF-1 NM_054026 CCR4-NOT transcription complex, subunit 7 
RGS5 1.334 MST092; MST106; MST129; MSTP032; 
MSTP092; MSTP106; MSTP129 
NM_003617 regulator of G-protein signalling 5 
COLEC
11 
1.334 MGC3279; DKFZp686N1868 NM_024027 collectin sub-family member 11 
CMTM3 1.333 BNAS2; CKLFSF3; FLJ31762; MGC51956 NM_181553 CKLF-like MARVEL transmembrane domain containing 3 
MMAB 1.333 ATR; MGC20496 NM_052845 methylmalonic aciduria (cobalamin deficiency) cblB type 
NAPB 1.332 MGC26066; MGC48335; SNAP-BETA NM_022080 N-ethylmaleimide-sensitive factor attachment protein, beta 
DNASE
1L2 
1.332 DNAS1L2 NM_001374 deoxyribonuclease I-like 2 
PLA2G1
2B 
1.331 FKSG71; PLA2G13; MGC138151; GXIIIsPLA2 NM_032562 phospholipase A2, group XIIB 
MBD3 1.331 MBD3 NM_003926 methyl-CpG binding domain protein 3 
NNAT 1.33 Peg5; MGC1439 NM_005386 neuronatin 
NPB 1.33 PPL7; PPNPB NM_148896 neuropeptide B 
TRRAP 1.33 Tra1; TR-AP; PAF400; STAF40; FLJ10671; 
PAF350/400 
NM_003496 transformation/transcription domain-associated protein 
C20ORF
177 
1.329 dJ551D2.5 NM_022106 chromosome 20 open reading frame 177 
CMTM4 1.329 CKLFSF4 NM_178818 CKLF-like MARVEL transmembrane domain containing 4 
PARD6
B 
1.327 PAR6B NM_032521 par-6 partitioning defective 6 homolog beta (C. elegans) 
CEP164 1.327 KIAA1052 NM_014956 centrosomal protein 164kDa 
GATAD
1 
1.326 ODAG; FLJ22489; RG083M05.2 NM_021167 GATA zinc finger domain containing 1 
RAB11F
IP3 
1.325 KIAA0665; Rab11-FIP3 NM_014700 RAB11 family interacting protein 3 (class II) 
THAP8 1.324 FLJ32891 NM_152658 THAP domain containing 8 
FLJ2386
1 
1.324 FLJ23861 NM_152519 hypothetical protein FLJ23861 
ABCB6 1.322 ABC; PRP; umat; ABC14; MTABC3; EST45597; 
FLJ22414 
NM_005689 ATP-binding cassette, sub-family B (MDR/TAP), member 6 
GDPD3 1.322 MGC4171; FLJ22603 NM_001031
718 
glycerophosphodiester phosphodiesterase domain containing 3 
BBS1 1.321 BBS2L2; FLJ23590; MGC51114; MGC126183; 
MGC126184 
NM_024649 Bardet-Biedl syndrome 1 





1.319 MGC75238 NM_203374 zinc finger protein 784 
ZNF573 1.319 FLJ30921 NM_152360 zinc finger protein 573 
HLX1 1.318 HB24 NM_021958 H2.0-like homeobox 1 (Drosophila) 
HEMK1 1.318 HEMK; MTQ1; FLJ22320 NM_016173 HemK methyltransferase family member 1 
KIAA04
46 








1.317 FLJ13449; FLJ25774; DKFZp686A01276; 
DKFZp686N15250; DKFZp686O03173 
NM_024546 chromosome 13 open reading frame 7 
RCBTB
1 
1.316 GLP; CLLD7; CLLL7; MGC33184; RP11-
185C18.1 
NM_018191 regulator of chromosome condensation (RCC1) and BTB (POZ) 
domain containing protein 1 
FBXO11 1.313 VIT1; FBX11; PRMT9; FLJ12673; MGC44383; 
UG063H01 
NM_012167 F-box protein 11 
UBTF 1.312 UBF; NOR-90 NM_014233 upstream binding transcription factor, RNA polymerase I 
TCF7L1 1.312 TCF3; TCF-3 NM_031283 transcription factor 7-like 1 (T-cell specific, HMG-box) 
KIAA00
40 
1.312 MGC133301 NM_014656 KIAA0040 
PCYOX
1 
1.311 PCL1; KIAA0908 NM_016297 prenylcysteine oxidase 1 
XYLB 1.31 FLJ10343; FLJ12539; FLJ22075 NM_005108 xylulokinase homolog (H. influenzae) 
CXORF
39 
1.307 C10orf18 NM_207318 chromosome X open reading frame 39 
HM13 1.307 H13; SPP; IMP1; PSL3; IMPAS; PSENL3; 
MSTP086; dJ324O17.1 
NM_178582 histocompatibility (minor) 13 
SEMA3
D 
1.307 coll-2; Sema-Z2; MGC39708 NM_152754 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3D 
FLJ3156
8 
1.307 FLJ31568; MGC126046; MGC126047 NM_152509 FLJ31568 protein 
DIO1 1.305 5DI; TXDI1; MGC130050; MGC130051 NM_000792 deiodinase, iodothyronine, type I 
SLCO1
A2 
1.303 OATP; OATP-A; OATP1A2; SLC21A3 NM_005075 solute carrier organic anion transporter family, member 1A2 
ACE2 1.303 ACEH; DKFZP434A014 NM_021804 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 
NUP98 1.302 ADIR2; NUP196 NM_139131 nucleoporin 98kDa 
DOCK7 1.301 ZIR2; KIAA1771 NM_033407 dedicator of cytokinesis 7 
LOC375
449 
1.301 LOC375449 NM_198828 similar to microtubule associated testis specific serine/threonine 
protein kinase 
C4ORF8 1.301 RES4-22 NM_003704 chromosome 4 open reading frame 8 
C20ORF
195 
1.3 MGC5356 NM_024059 chromosome 20 open reading frame 195 
NPAL1 1.3 DKFZp686A06115 NM_207330 NIPA-like domain containing 1 
TPM2 1.3 DA1; TMSB; AMCD1 NM_003289 tropomyosin 2 (beta) 
HRK 1.3 DP5; HARAKIRI NM_003806 harakiri, BCL2 interacting protein (contains only BH3 domain) 
DIAPH3 1.299 DRF3; diap3; FLJ34705; DKFZP434C0931; 
DKFZp686A13178 
NM_030932 diaphanous homolog 3 (Drosophila) 
JAKMIP
1 
1.299 JAMIP1; MARLIN1; FLJ31564; Gababrbp NM_144720 janus kinase and microtubule interacting protein 1 
SLC27A
6 




solute carrier family 27 (fatty acid transporter), member 6 
NFIB 1.298 NFIB2; NFIB3; NFI-RED NM_005596 nuclear factor I/B 
CACNA
2D2 
1.297 CACNA2D; gene 26; KIAA0558; LUAC11.1 NM_001005
505 
calcium channel, voltage-dependent, alpha 2/delta subunit 2 
C9ORF9
3 
1.296 FLJ39267; FLJ46740; MGC50805; bA536D16.1; 
bA778P13.1 




1.296 CLP1; EDG1; HIS1; MAQ1 NM_006460 hexamethylene bis-acetamide inducible 1 
CLCN6 1.294 CLC-6; KIAA0046 NM_021737 chloride channel 6 
MAP1B 1.294 MAP5; FUTSCH; FLJ38954; DKFZp686E1099; 
DKFZp686F1345 
NM_005909 microtubule-associated protein 1B 




PKD2 interactor, golgi and endoplasmic reticulum associated 1 
ULK1 1.293 ATG1; UNC51; Unc51.1; FLJ38455 NM_003565 unc-51-like kinase 1 (C. elegans) 
RGS12 1.293 DKFZp761K1617; DKFZp761K1817 NM_002926 regulator of G-protein signalling 12 
SLC25A
24 
1.293 APC1; SCAMC-1; DKFZp586G0123 NM_013386 solute carrier family 25 (mitochondrial carrier; phosphate carrier), 
member 24 
CD37 1.292 GP52-40; TSPAN26; MGC120234 NM_001774 CD37 molecule 
PDE4D 1.292 DPDE3; STRK1; HSPDE4D; PDE4DN2 NM_006203 phosphodiesterase 4D, cAMP-specific (phosphodiesterase E3 
dunce homolog, Drosophila) 
SPAG1 1.291 SP75; TPIS; HSD-3.8; FLJ32920 NM_172218 sperm associated antigen 1 
SLC44A
1 
1.291 CTL1; CDW92; CHTL1; RP11-287A8.1 NM_022109 solute carrier family 44, member 1 
PHF20L
1 
1.29 CGI-72; MGC64923 NM_016018 PHD finger protein 20-like 1 
ZNF689 1.29 TIPUH1; FLJ90415; DKFZp762C173 NM_138447 zinc finger protein 689 
CYP2R1 1.29 MGC4663 NM_024514 cytochrome P450, family 2, subfamily R, polypeptide 1 
HPX 1.29 HBA2 NM_000613 hemopexin 
IRF6 1.29 LPS; PIT; PPS; VWS; OFC6 NM_006147 interferon regulatory factor 6 
SOSTD
C1 
1.289 USAG1; CDA019; ECTODIN; DKFZp564D206 NM_015464 sclerostin domain containing 1 
ZNF543 1.289 DKFZp434H055 NM_213598 zinc finger protein 543 
GSDML 1.285 PP4052; PRO2521 NM_018530 gasdermin-like 
DOK6 1.285 DOK5L; HsT3226; MGC20785 NM_152721 docking protein 6 
ZNF549 1.285 FLJ34917 NM_153263 zinc finger protein 549 
C21ORF
29 
1.284 TSPEAR; MGC11251 NM_144991 chromosome 21 open reading frame 29 
NPEPPS 1.284 PSA; MP100 NM_006310 aminopeptidase puromycin sensitive 
SLC38A
5 
1.284 SN2; JM24; pp7194 NM_033518 solute carrier family 38, member 5 
RGS6 1.284 GAP; MGC142132 NM_004296 regulator of G-protein signalling 6 
PMF1 1.284 IL8RA NM_007221 polyamine-modulated factor 1 
PDK1 1.284 PTPRF NM_002610 pyruvate dehydrogenase kinase, isozyme 1 
C1ORF1
04 
1.283   NM_173639   
PSEN1 1.283   NM_007319   
MRPL43 1.283 bMRP36a; MGC17989; MGC48892 NM_176794 mitochondrial ribosomal protein L43 
SCTR 1.282 SR NM_002980 secretin receptor 
SLC2A6 1.282 GLUT6; GLUT9; HSA011372 NM_017585 solute carrier family 2 (facilitated glucose transporter), member 6 
STAU 1.282 STAU; FLJ25010 NM_017453 staufen, RNA binding protein, homolog 1 (Drosophila) 
GGA1 1.282 GGA1 NM_001001
561 
golgi associated, gamma adaptin ear containing, ARF binding 
protein 1 




1.281 ZNF400; FLJ14524; MGC13153; MGC54050 NM_032799 zinc finger, DHHC-type containing 12 
SPINK5 1.28 NS; NETS; LEKTI; LETKI; VAKTI; FLJ21544 NM_006846 serine peptidase inhibitor, Kazal type 5 
DMGD
H 
1.279 DMGDHD; ME2GLYDH NM_013391 dimethylglycine dehydrogenase 
CCDC7 1.279 FLJ32762; DKFZp686N0559; RP11-479G22.1 NM_145023 coiled-coil domain containing 7 
BAZ1A 1.279 ACF1; WALp1; hACF1; WCRF180; FLJ14383; 
DKFZP586E0518 
NM_182648 bromodomain adjacent to zinc finger domain, 1A 
CAPN10 1.278 CAPN10 NM_021251 calpain 10 
FLJ4113
1 
1.278 FLJ41131; MGC103014 NM_198476 chromosome 19 open reading frame 54 
NANP 1.278 HDHD4; MGC26833; C20orf147; dJ694B14.3 NM_152667 N-acetylneuraminic acid phosphatase 
FGF13 1.277 FGF2; FHF2 NM_004114 fibroblast growth factor 13 
FKBP2 1.277 PPIase; FKBP-13 NM_057092 FK506 binding protein 2, 13kDa 
UBXD8 1.277 ETEA; KIAA0887 NM_014613 UBX domain containing 8 
NCOA1 1.276 SRC1; NCoA-1; RIP160; F-SRC-1; MGC129719; 
MGC129720 
NM_147223 nuclear receptor coactivator 1 
FLJ1008
1 
1.276 FLJ10081; FLJ23799; KIAA1310 NM_017991 hypothetical protein FLJ10081 
REPS2 1.275 POB1 NM_004726 RALBP1 associated Eps domain containing 2 
ONECU
T1 
1.274 HNF6; HNF-6; HNF6A NM_004498 one cut domain, family member 1 
SAMD1
4 
1.274 FLJ36890 NM_174920 sterile alpha motif domain containing 14 
CIC 1.274 KIAA0306 NM_015125 capicua homolog (Drosophila) 
NOXA1 1.273 p51NOX; FLJ25475; NY-CO-31; SDCCAG31; 
MGC131800 
NM_006647 NADPH oxidase activator 1 
KRTAP
17-1 
1.273 KAP17.1; KRTAP16.1; KRTAP17.1 NM_031964 keratin associated protein 17-1 
PLAGL2 1.273 FLJ23283 NM_002657 pleiomorphic adenoma gene-like 2 
TAF6L 1.273 PAF65A; MGC4288; FLJ11136 NM_006473 TAF6-like RNA polymerase II, p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa 
FZR1 1.272 FZR; CDH1; FZR2; HCDH; HCDH1; CDC20C; 
KIAA1242 
NM_016263 fizzy/cell division cycle 20 related 1 (Drosophila) 
TMEPAI 1.272 STAG1; PMEPA1 NM_199171 transmembrane, prostate androgen induced RNA 
IFT81 1.271 CDV1; CDV-1; CDV1R; CDV-1R; MGC4027; 
MGC102777 
NM_031473 intraflagellar transport 81 homolog (Chlamydomonas) 
MGC52
423 
1.271 MGC52423 NM_182517 chromosome 1 open reading frame 210 
KLC4 1.27 KNSL8; MGC111777; bA387M24.3 NM_138343 kinesin light chain 4 
TTC25 1.27 DKFZP434H0115 NM_031421 tetratricopeptide repeat domain 25 
ITK 1.269 EMT; LYK; PSCTK2; MGC126257; MGC126258 NM_005546 IL2-inducible T-cell kinase 
ZNF334 1.269 CDCA8 NM_018102 zinc finger protein 334 
TSSC4 1.269 TSSC4 NM_005706 tumor suppressing subtransferable candidate 4 
GMPPB 1.269 KIAA1851 NM_013334 GDP-mannose pyrophosphorylase B 
ZNF440
L 
1.269 ZNF; ZNF440L NM_001012
753 
zinc finger protein 763 
CHMP6 1.269 VPS20; FLJ11749 NM_024591 chromatin modifying protein 6 
 238
BRCC2 1.268 BRCC2 NM_001001
786 
BRCC2 
FBXL11 1.268 FBL7; CXXC8; FBL11; JHDM1A; LILINA; 
FLJ00115; FLJ46431; KIAA1004; 
DKFZP434M1735 
NM_012308 F-box and leucine-rich repeat protein 11 
LMO1 1.266 TTG1; RBTN1; RHOM1; MGC116692 NM_002315 LIM domain only 1 (rhombotin 1) 
BCAM 1.265 AU; LU; CD239; MSK19 NM_001013
257 
basal cell adhesion molecule (Lutheran blood group) 
MYO9A 1.264 FLJ11061; FLJ13244; MGC71859 NM_006901 myosin IXA 
C1ORF2
01 
1.264 FLJ33340 NM_178122 chromosome 1 open reading frame 201 
PAK4 1.264 CRMP1 NM_001014
832 
p21(CDKN1A)-activated kinase 4 
C3ORF1
9 
1.264 FLJ33839 NM_016474 chromosome 3 open reading frame 19 
C10ORF
85 
1.263 FLJ37402; MGC131689 NM_001012
711 
chromosome 10 open reading frame 85 
ZFAND
3 
1.263 TEX27; FLJ13222 NM_021943 zinc finger, AN1-type domain 3 
GAB1 1.262 GAB1 NM_207123 GRB2-associated binding protein 1 
PCDH17 1.262   NM_014459   
SMARC
A4 
1.261 BRG1; BAF190; SNF2L4; SNF2LB; hSNF2b; 
SNF2-BETA 
NM_003072 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
OATL1 1.261 MGC126866; MGC126868 NM_001006
113 
ornithine aminotransferase-like 1 
AKT2 1.261 PRKBB; PKBBETA; RAC-BETA NM_001626 v-akt murine thymoma viral oncogene homolog 2 
PSMA7 1.26   NM_152255   
CPNE8 1.259 MGC129645; MGC129646 NM_153634 copine VIII 
UBE3B 1.259   NM_183414   
RNF32 1.259 HSD15; FKSG33 NM_030936 ring finger protein 32 
PAOX 1.259 PAO; MGC45464; DKFZp434J245; RP11-
122K13.11 
NM_152911 polyamine oxidase (exo-N4-amino) 
TMLHE 1.259 TMLH; BBOX2; XAP130; FLJ10727 NM_018196 trimethyllysine hydroxylase, epsilon 
CLMN 1.258 FLJ12383; KIAA1188 NM_024734 calmin (calponin-like, transmembrane) 
RNF24 1.258 G1L NM_007219 ring finger protein 24 
SLC4A1
AP 
1.257 HLC3; FLJ10624; MGC120646; MGC120648 NM_018158 solute carrier family 4 (anion exchanger), member 1, adaptor 
protein 
UBE2D2 1.257 UBC4; PUBC1; UBC4/5; UBCH5B; E2(17)KB2 NM_181838 ubiquitin-conjugating enzyme E2D 2 (UBC4/5 homolog, yeast) 
ARG99 1.257   NM_031920   
CDKL4 1.255 IL20 NM_001009
565 
cyclin-dependent kinase-like 4 
RCOR1 1.255 RCOR; COREST; KIAA0071 NM_015156 REST corepressor 1 
C19ORF
23 
1.254 MGC39338 NM_152480 chromosome 19 open reading frame 23 
IER5 1.254 SBBI48; MGC102760 NM_016545 immediate early response 5 
C6ORF4
8 
1.254   NM_016947   
OR2T8 1.254 OR2T8P NM_001005
522 
olfactory receptor, family 2, subfamily T, member 8 
SIX5 1.254 DMAHP NM_175875 sine oculis homeobox homolog 5 (Drosophila) 
ATF5 1.253 ATFX; FLJ34666; HMFN0395 NM_012068 activating transcription factor 5 
VEGFB 1.253 VRF; VEGFL NM_003377 vascular endothelial growth factor B 
FLNA 1.252 FLN; FMD; MNS; OPD; ABPX; FLN1; NHBP; 
OPD1; OPD2; ABP-280; filamin A; 
DKFZp434P031 
NM_001456 filamin A, alpha (actin binding protein 280) 
THRAP
5 
1.252 MED16; DRIP92; TRAP95 NM_005481 thyroid hormone receptor associated protein 5 
CLK4 1.252 DKFZp686A20267 NM_020666 CDC-like kinase 4 
LRRC35 1.252 El; FLJ14177; MGC10233 NM_152715 leucine rich repeat containing 35 
B3GAL
T3 
1.251 P; P1; GLOB; GLCT3; galT3; Gb4Cer; 
B3GALT3; beta3Gal-T3 
NM_033169 beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood 
group) 
ZFP95 1.251 FLJ39233; KIAA1015; MGC33710 NM_014569 zinc finger protein 95 homolog (mouse) 
PCDH1 1.25 PC42; PCDH42; MGC45991 NM_032420 protocadherin 1 (cadherin-like 1) 
TTMB 1.25 TTMB; MGC90489; MGC102864 NM_001003
682 
TTMB protein 
GGPS1 1.25 GGPPS; GGPPS1 NM_004837 geranylgeranyl diphosphate synthase 1 
FLJ3815
9 
1.249 FLJ38159 NM_152723 coiled-coil domain containing 89 
MTRR 1.249 MSR; MGC129643 NM_024010 5-methyltetrahydrofolate-homocysteine methyltransferase 
reductase 
CD163 1.249 M130; MM130 NM_004244 CD163 molecule 
ZMYND
10 
1.247 BLU; FLU NM_015896 zinc finger, MYND-type containing 10 
ABC1 1.246 ABC1; FLJ22087; MGC148096; 
DKFZp686D22141 
NM_022070 amplified in breast cancer 1 
NALP9 1.246 NOD6 NM_176820 NACHT, leucine rich repeat and PYD containing 9 
RFFL 1.246 RNF189; RNF34L NM_001017
368 
ring finger and FYVE-like domain containing 1 
L3MBT
L 
1.246 L3MBTL1; KIAA0681; H-L(3)MBT; dJ138B7.3; 
DKFZp586P1522 
NM_032107 l(3)mbt-like (Drosophila) 
SSX7 1.245 SSX2 NM_173358 synovial sarcoma, X breakpoint 7 
ALK 1.245 CD246 NM_004304 anaplastic lymphoma kinase (Ki-1) 
MKL2 1.245 MRTF-B; NPD001; FLJ31823; DKFZp686J1745 NM_014048 MKL/myocardin-like 2 
HCK 1.245 JTK9 NM_002110 hemopoietic cell kinase 
ITIH5 1.245 pp14776; MGC10848; DKFZp686F0145 NM_032817 inter-alpha (globulin) inhibitor H5 
LOC944
31 
1.244   NM_145237   
DDN 1.243 KIAA0749 NM_015086 dendrin 
TREML
2 
1.242 TLT2; C6orf76; FLJ13693; dJ238O23.1 NM_024807 triggering receptor expressed on myeloid cells-like 2 





hypothetical gene supported by AK127120 
CNNM4 1.242 ACDP4; KIAA1592 NM_020184 cyclin M4 
FLJ3828
8 




1.241 C9orf54; FLJ00199; FLJ14596 NM_032809 family with sequence similarity 73, member B 
REPS2 1.24 POB1 NM_004726 RALBP1 associated Eps domain containing 2 
BAT3 1.24 G3; D6S52E NM_080703 HLA-B associated transcript 3 
TMTC2 1.238 DKFZp762A217 NM_152588 transmembrane and tetratricopeptide repeat containing 2 
PXMP2 1.238 PMP22 NM_018663 peroxisomal membrane protein 2, 22kDa 
AHDC1 1.236 CL23945; DJ159A19.3; RP1-159A19.1 NM_001029
882 
AT hook, DNA binding motif, containing 1 
LONRF
3 
1.236 RNF127; FLJ22612; MGC119463; MGC119465 NM_024778 LON peptidase N-terminal domain and ring finger 3 
NOS3 1.236 eNOS; ECNOS; NOS III NM_000603 nitric oxide synthase 3 (endothelial cell) 
CRLF3 1.236 FRWS; CREME9; CYTOR4; MGC20661 NM_015986 cytokine receptor-like factor 3 
SSX8 1.236 SSX8 NM_174961 synovial sarcoma, X breakpoint 8 
PDGFB 1.234 SIS; SSV; PDGF2; c-sis; FLJ12858 NM_033016 platelet-derived growth factor beta polypeptide (simian sarcoma 
viral (v-sis) oncogene homolog) 
MORF4
L1 
1.234 Eaf3; MRG15; FWP006; S863-6; HsT17725; 
MGC10631; MORFRG15 
NM_206839 mortality factor 4 like 1 
FLG 1.232 FLG NM_002016 filaggrin 
PLCXD
2 
1.232 FLJ31579 NM_153268 phosphatidylinositol-specific phospholipase C, X domain 
containing 2 
KIF5B 1.232 KNS; KINH; KNS1; UKHC; U-KHC NM_004521 kinesin family member 5B 
ZNF136 1.231 pHZ-20 NM_003437 zinc finger protein 136 






ZP1 1.23 MGC87693 NM_207341 zona pellucida glycoprotein 1 (sperm receptor) 
ZNF268 1.229 HZF3; MGC126498 NM_152943 zinc finger protein 268 
RGPD5 1.228 RGP5; BS-63; DKFZp686I1842 NM_032260 RANBP2-like and GRIP domain containing 5 
KRTAP
10-12 
1.228 KAP10.12; KRTAP18-12; KRTAP18.12 NM_198699 keratin associated protein 10-12 
TMEM1
04 
1.228 FLJ00021; FLJ20255 NM_017728 transmembrane protein 104 
LOC401
622 





1.226 FLJ33496 NM_182587 chromosome 2 open reading frame 21 
PPEF1 1.226 PP7; PPEF; PPP7C NM_006240 protein phosphatase, EF-hand calcium binding domain 1 
TRIAD3 1.226   NM_019011   
DAB1 1.225 EIF4G1 NM_021080 disabled homolog 1 (Drosophila) 
ARL4C 1.225 LAK; ARL7 NM_005737 ADP-ribosylation factor-like 4C 
ADPRH
L1 
1.225 ARH2 NM_199162 ADP-ribosylhydrolase like 1 
TSNAXI
P1 
1.225 TXI1; MGC111443 NM_018430 translin-associated factor X interacting protein 1 
PHCA 1.224 APHC; FLJ11238 NM_018367 phytoceramidase, alkaline 
C10ORF
61 
1.222 TECT3; DKFZp564D116 NM_015631 chromosome 10 open reading frame 61 
CTNND
1 
1.222 CAS; p120; CTNND; P120CAS; P120CTN; 
KIAA0384 
NM_001331 catenin (cadherin-associated protein), delta 1 
PPHLN1 1.222 HSPC206; HSPC232; MGC48786 NM_016488 periphilin 1 
RGS9BP 1.222 RGS9BP; FLJ45744 NM_207391 RGS9 anchor protein 
MXI1 1.221 MXI; MAD2; MXD2; MGC43220 NM_001008
541 
MAX interactor 1 
CDH20 1.22 Cdh7; CDH7L3; FLJ37047 NM_031891 cadherin 20, type 2 
DAPK3 1.219 ZIP; ZIPK; FLJ36473 NM_001348 death-associated protein kinase 3 
TROAP 1.219 TASTIN NM_005480 trophinin associated protein (tastin) 
FLAD1 1.218 FAD1; PP591; MGC31803; MGC40255; RP11-
307C12.7 
NM_025207 FAD1 flavin adenine dinucleotide synthetase homolog (S. 
cerevisiae) 
CPT1B 1.217 CPT1-M; M-CPT1; KIAA1670 NM_152247 carnitine palmitoyltransferase 1B (muscle) 
ADPRH 1.217 ARH1 NM_001125 ADP-ribosylarginine hydrolase 
KCNK1
0 
1.216 TREK2; TREK-2 NM_138318 potassium channel, subfamily K, member 10 
ESRRG 1.216 ERR3; NR3B3; FLJ16023; KIAA0832; 
DKFZp781L1617 
NM_206594 estrogen-related receptor gamma 
POLE 1.216 POLE1; FLJ21434; DKFZp434F222 NM_006231 polymerase (DNA directed), epsilon 
SMAD9 1.215 MADH6; MADH9; SMAD8A; SMAD8B NM_005905 SMAD, mothers against DPP homolog 9 (Drosophila) 
CRYBA
2 
1.215 C6orf25 NM_057093 crystallin, beta A2 
STRN4 1.215 ZIN; zinedin; FLJ35594 NM_013403 striatin, calmodulin binding protein 4 
MGC42
105 
1.214 MGC42105 NM_153361 hypothetical protein MGC42105 
PKHD1
L1 
1.213 PKHDL1; DKFZp586C1021 NM_177531 polycystic kidney and hepatic disease 1 (autosomal recessive)-
like 1 
TBX6 1.213 TBX6 NM_080758 T-box 6 
ALDH8
A1 
1.213 ALDH12; MGC138650; DJ352A20.2; 
DKFZp779D2315 
NM_022568 aldehyde dehydrogenase 8 family, member A1 
SNAPC4 1.213 SNAP190; FLJ13451; PTFalpha NM_003086 small nuclear RNA activating complex, polypeptide 4, 190kDa 
SLC22A
3 




1.212 ANKHZN; ZFYVE14; KIAA1255; 
DKFZp686M19106 
NM_020740 ankyrin repeat and FYVE domain containing 1 
GPR123 1.211 GPR123 NM_032422 G protein-coupled receptor 123 
C6ORF6
8 
1.211 MGC7199; MGC:7199; MGC117249 NM_138459 chromosome 6 open reading frame 68 
SF1 1.211 ZFM1; ZNF162; D11S636 NM_201997 splicing factor 1 
BRF1 1.21 BRF; hBRF; GTF3B; TAF3C; TAF3B2; TF3B90; 
FLJ42674; TAFIII90; TFIIIB90; MGC105048 
NM_145696 BRF1 homolog, subunit of RNA polymerase III transcription 
initiation factor IIIB (S. cerevisiae) 
KCTD11 1.21 REN; C17orf36; MGC129844; REN/KCTD11 NM_001002
914 
potassium channel tetramerisation domain containing 11 
SLCO1
A2 
1.209 OATP; OATP-A; OATP1A2; SLC21A3 NM_134431 solute carrier organic anion transporter family, member 1A2 
MGC47
28 
1.209 ZNF773; MGC4728 NM_198542 zinc finger protein 419B 
ZFYVE1 1.209 DFCP1; TAFF1; ZNFN2A1; KIAA1589 NM_021260 zinc finger, FYVE domain containing 1 
PTPN9 1.209 MEG2 NM_002833 protein tyrosine phosphatase, non-receptor type 9 




1.208 FLJ40217; MGC120446; MGC120448 NM_201520 solute carrier family 25, member 35 
EHD1 1.208 PAST; PAST1; H-PAST; HPAST1; FLJ42622; 
FLJ44618 
NM_006795 EH-domain containing 1 
DRD1 1.207 DADR; DRD1A NM_000794 dopamine receptor D1 
KRTAP
20-2 
1.207 KAP20.2; MGC133104 NM_181616 keratin associated protein 20-2 
ZNF418 1.206 FLJ31551; KIAA1956; MGC138449 NM_133460 zinc finger protein 418 
PBX4 1.205 PBX4 NM_025245 pre-B-cell leukemia transcription factor 4 
ZCWPW
1 
1.205 ZCW1; FLJ10057; DKFZp434N0510 NM_017984 zinc finger, CW type with PWWP domain 1 
DCUN1
D2 






DiGeorge syndrome critical region gene 13 
LOC916
89 
1.203 dJ186O1.1 NM_033318 chromosome 22 open reading frame 32 
KIAA12
71 
1.203 VISA; MAVS; Ips-1; FLJ27482; FLJ41962; 
KIAA1271; DKFZp666M015 
NM_020746 virus-induced signaling adapter 
CSPP1 1.203 CSPP; FLJ22490; FLJ38886 NM_024790 centrosome and spindle pole associated protein 1 
FLJ2547
6 
1.202 FLJ25476; MGC138318; RP11-415J8.1 NM_152493 FLJ25476 protein 
RBP3 1.201 IRBP; RBPI; D10S64; D10S65; D10S66 NM_002900 retinol binding protein 3, interstitial 
FLJ3756
2 
1.201 FLJ37562 NM_152409 chromosome 5 open reading frame 24 
PDE4C 1.2 DPDE1; MGC126222; PDE4C-791 NM_000923 phosphodiesterase 4C, cAMP-specific (phosphodiesterase E1 
dunce homolog, Drosophila) 
VGLL2 1.199 VGL2; VITO1 NM_153453 vestigial like 2 (Drosophila) 
LYZL2 1.199 ZNF294 NM_183058 lysozyme-like 2 
JPH2 1.199 JP2; JP-2; FLJ40969 NM_020433 junctophilin 2 
NOTCH
3 
1.199 CASIL; CADASIL NM_000435 Notch homolog 3 (Drosophila) 
SLC29A
3 
1.199 ENT3; FLJ11160 NM_018344 solute carrier family 29 (nucleoside transporters), member 3 
C1ORF1
10 





potassium channel tetramerisation domain containing 21 
CRYGS 1.198 CRYG8 NM_017541 crystallin, gamma S 
MTA1 1.198 MTA1 NM_004689 metastasis associated 1 
STX16 1.197 SYN16; hsyn16; MGC90328 NM_001001
433 
syntaxin 16 
ZNF605 1.196 FLJ14967 NM_183238 zinc finger protein 605 
C2ORF1
0 
1.195 C2orf10 NM_194250 chromosome 2 open reading frame 10 
TRIM67 1.195 TNL; FLJ44831 NM_001004
342 
tripartite motif-containing 67 
TRPC5 1.195 TRP5 NM_012471 transient receptor potential cation channel, subfamily C, member 
5 
ZNF473 1.195 ZN473; HZFP100 NM_015428 zinc finger protein 473 
BMF 1.195 FLJ00065 NM_033503 Bcl2 modifying factor 
TRPM7 1.195 CHAK; CHAK1; LTRPC7; FLJ20117; FLJ25718; 
TRP-PLIK 




1.194 RPC8; KIAA1665; MGC29654; MGC111097 NM_138338 polymerase (RNA) III (DNA directed) polypeptide H (22.9kD) 
A2BP1 1.193 A2BP1; FOX1; HRNBP1 NM_018723 ataxin 2-binding protein 1 
ZNF623 1.193 MGC103965; MGC104128 NM_014789 zinc finger protein 623 
COBL 1.192 KIAA0633; DKFZp686G13227 NM_015198 cordon-bleu homolog (mouse) 
BCL2L1
4 
1.191 BCLG NM_138723 BCL2-like 14 (apoptosis facilitator) 
LYCAT 1.191 ALCAT1; UNQ1849; FLJ37965 NM_182551 lysocardiolipin acyltransferase 
OSGEP 1.191 KAE1; GCPL1; OSGEP1; PRSMG1; FLJ20411 NM_017807 O-sialoglycoprotein endopeptidase 
PPP1R1
5B 
1.19 FLJ14744 NM_032833 protein phosphatase 1, regulatory (inhibitor) subunit 15B 
MECP2 1.19 RTS; RTT; PPMX; MRX16; MRX79; AUTSX3; 
DKFZp686A24160 
NM_004992 methyl CpG binding protein 2 (Rett syndrome) 
IL2RA 1.19 CD25; IL2R; TCGFR; IDDM10 NM_000417 interleukin 2 receptor, alpha 
AK3L1 1.19 AK3; AK4 NM_001005
353 
adenylate kinase 3-like 1 
TMOD2 1.19 NTMOD; MGC39481 NM_014548 tropomodulin 2 (neuronal) 
OPN1S
W 




1.188 LOC284361; INM02; MGC33203 NM_175063 hematopoietic signal peptide-containing 
RGR 1.187 RGR NM_001012
722 
retinal G protein coupled receptor 
SLC5A1
0 
1.186 SGLT5; FLJ25217 NM_152351 solute carrier family 5 (sodium/glucose cotransporter), member 
10 
NBPF14 1.186 NBPF; FLJ35032; RP3-328E19.1; DJ328E19.C1.1 NM_015383 neuroblastoma breakpoint family, member 14 
HIF3A 1.186 IPAS; MOP7; PASD7; HIF-3A; HIF-3A4 NM_022462 hypoxia inducible factor 3, alpha subunit 
FLJ3698
0 
1.186   NM_182598   
TMEM7
0 
1.186 FLJ20533 NM_017866 transmembrane protein 70 





chromosome 1 open reading frame 213 
ZNF384 1.184 NP; CIZ; NMP4; CAGH1; ERDA2; TNRC1; 
CAGH1A 
NM_133476 zinc finger protein 384 
DGKZ 1.184 DAGK5; DAGK6; DGK-ZETA; hDGKzeta NM_003646 diacylglycerol kinase, zeta 104kDa 
ARHGE
F1 
1.182 GEF1; LBCL2; SUB1.5; P115-RHOGEF NM_199002 Rho guanine nucleotide exchange factor (GEF) 1 
SIPA1L
1 
1.181 E6TP1; KIAA0440; DKFZp686G1344 NM_015556 signal-induced proliferation-associated 1 like 1 
AP1G2 1.181 G2AD NM_080545 adaptor-related protein complex 1, gamma 2 subunit 





1.179 FLJ32130 NM_152458 zinc finger protein 785 
AIFL 1.179 AIFL; FLJ30473 NM_144704 apoptosis-inducing factor like 
P2RY2 1.179 P2U; HP2U; P2U1; P2UR; P2Y2; P2RU1; P2Y2R; 
MGC20088; MGC40010 
NM_176071 purinergic receptor P2Y, G-protein coupled, 2 
SYVN1 1.179 HRD1; KIAA1810; MGC40372 NM_032431 synovial apoptosis inhibitor 1, synoviolin 
DDC 1.179 AADC NM_000790 dopa decarboxylase (aromatic L-amino acid decarboxylase) 
TMEM1
6B 
1.178 C12orf3; DKFZp434P102 NM_020373 transmembrane protein 16B 
TNRC6
B 
1.178 KIAA1093 NM_015088 trinucleotide repeat containing 6B 
FLJ9075
7 





1.175 KIAA0954; MGC10781 NM_013279 chromosome 11 open reading frame 9 
ZNF624 1.175 KIAA1349; MGC119602; MGC119603; 
MGC119605 
NM_020787 zinc finger protein 624 
USP11 1.175 UHX1 NM_004651 ubiquitin specific peptidase 11 
KIAA07
89 
1.174 KIAA0789; MGC117165 NM_014653 KIAA0789 gene product 
OR4C12 1.174 OR11-259 NM_001005
270 
olfactory receptor, family 4, subfamily C, member 12 
NDST4 1.173 VCX3A NM_022569 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 4 
SRCAP 1.173 SRCAP; KIAA0309 NM_006662 Snf2-related CBP activator protein 
TCF7L2 1.173 TCF4; TCF-4 NM_030756 transcription factor 7-like 2 (T-cell specific, HMG-box) 
C19ORF
25 
1.173 FLJ36666 NM_152482 chromosome 19 open reading frame 25 
AKAP4 1.172 HI; p82; FSC1; AKAP82; hAKAP82 NM_139289 A kinase (PRKA) anchor protein 4 
C10ORF
99 
1.171 UNQ1833; FLJ21763 NM_207373 chromosome 10 open reading frame 99 
VPS16 1.171 hVPS16 NM_022575 vacuolar protein sorting 16 (yeast) 
PLEKH
B2 
1.171 EVT2; FLJ20783 NM_017958 pleckstrin homology domain containing, family B (evectins) 
member 2 
IGF1R 1.171 CD221; IGFIR; JTK13; MGC142170; 
MGC142172 
NM_000875 insulin-like growth factor 1 receptor 




Src homology 2 domain containing E 
MAGEB
3 
1.17 MAGEB3 NM_002365 melanoma antigen family B, 3 
CYSLT
R1 
1.17 HG55; CYSLT1; CYSLTR; CYSLT1R; 
HMTMF81; MGC46139 
NM_006639 cysteinyl leukotriene receptor 1 
GCNT3 1.17 GnT-M; C2GnT2; C2/4GnT; C2GnT-M NM_004751 glucosaminyl (N-acetyl) transferase 3, mucin type 
CDK3 1.169 CDK3 NM_001258 cyclin-dependent kinase 3 
C20ORF
116 
1.169 MGC2592; dJ1187M17.3 NM_023935 chromosome 20 open reading frame 116 
SCAND
2 
1.168 SCAND2 NM_033633 SCAN domain containing 2 
PIP5K3 1.168 CFD; PIP5K; PIKfyve; KIAA0981; MGC40423 NM_152671 phosphatidylinositol-3-phosphate/phosphatidylinositol 5-kinase, 
type III 
NR2E1 1.168 TLL; TLX; XTLL NM_003269 nuclear receptor subfamily 2, group E, member 1 
VSIG2 1.168 CTH; CTXL; 2210413P10Rik NM_014312 V-set and immunoglobulin domain containing 2 
ANKRD
19 
1.167 FLJ36178; bA526D8.2 NM_001010
925 
ankyrin repeat domain 19 
KIAA02
65 
1.167 KIAA0265 NM_014997 KIAA0265 protein 
CHRM2 1.166 HM2; FLJ43243; MGC120006; MGC120007 NM_001006
626 
cholinergic receptor, muscarinic 2 
PLXNA
1 





dysferlin interacting protein 1 (toonin) 
CP110 1.166 CP110; KIAA0419; DKFZp781G1416 NM_014711 CP110 protein 
FLJ2750
5 
1.166 FLJ27505 NM_207408 FLJ27505 protein 
LRRC37
B 
1.165 LRRC37B NM_052888 leucine rich repeat containing 37B 
AMAC1
L2 
1.163 AMAC NM_054028 acyl-malonyl condensing enzyme 1-like 2 
FDX1 1.163 ADX; FDX; LOH11CR1D NM_004109 ferredoxin 1 
GLYCT
K 
1.163 GLYCTK; HBeAgBP4A NM_145262 glycerate kinase 
B3GAT2 1.162 GLCATS; GlcAT-S; KIAA1963; MGC138535 NM_080742 beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S) 
ZNF10 1.162 KOX1 NM_015394 zinc finger protein 10 
TNK1 1.162 MGC46193 NM_003985 tyrosine kinase, non-receptor, 1 
C17ORF
81 
1.161 DERP6; MST071; HSPC002; MSTP071 NM_203414 chromosome 17 open reading frame 81 
MPPED
1 
1.161 239AB; FAM1A; C22orf1; MGC88045 NM_001585 metallophosphoesterase domain containing 1 
FLJ2506
7 
1.16 FLJ25067; RP4-784N16.1 NM_152504 chromosome 20 open reading frame 196 
POLR2
A 
1.16 RPB1; RPO2; POLR2; POLRA; RPBh1; RPOL2; 
RpIILS; hsRPB1; hRPB220; MGC75453 
NM_000937 polymerase (RNA) II (DNA directed) polypeptide A, 220kDa 
BAP1 1.159 hucep-6; FLJ35406; FLJ37180; HUCEP-13; 
KIAA0272; DKFZp686N04275 
NM_004656 BRCA1 associated protein-1 (ubiquitin carboxy-terminal 
hydrolase) 
IFNB1 1.159 IFB; IFF; IFNB; MGC96956 NM_002176 interferon, beta 1, fibroblast 
C1ORF8
8 
1.158 FLJ23853; MGC126550; RP5-1125M8.4 NM_181643 chromosome 1 open reading frame 88 
DGKQ 1.158 DAGK; DAGK4; DAGK7 NM_001347 diacylglycerol kinase, theta 110kDa 
HEXIM
2 
1.158 L3; FLJ32384 NM_144608 hexamthylene bis-acetamide inducible 2 
RPS6KA
6 
1.158 RSK4 NM_014496 ribosomal protein S6 kinase, 90kDa, polypeptide 6 
LNX1 1.157 LNX; MPDZ; PDZRN2 NM_032622 ligand of numb-protein X 1 
FIGLA 1.156 DOCK8 NM_001004
311 




1.156 PFM15; ZNF298; C21orf83 NM_022115 PR domain containing 15 
HNRPF 1.156 HNRNPF; mcs94-1; MGC110997 NM_004966 heterogeneous nuclear ribonucleoprotein F 
HSPG2 1.156 PLC; SJA; SJS; SJS1 NM_005529 heparan sulfate proteoglycan 2 (perlecan) 
RAD54
B 
1.155 FSBP NM_012415 RAD54 homolog B (S. cerevisiae) 
TXNRD
2 
1.155   NM_145748   
OR2A2 1.155 OR2A2P; OR7-11; OST008; OR2A17P NM_001005
480 
olfactory receptor, family 2, subfamily A, member 2 
CYFIP1 1.155 SHYC; FLJ45151; P140SRA-1 NM_014608 cytoplasmic FMR1 interacting protein 1 
AMDH
D1 
1.154 HMFT1272; MGC35366 NM_152435 amidohydrolase domain containing 1 
KCNH7 1.154 ERG3; HERG3; Kv11.3; MGC45986 NM_173162 potassium voltage-gated channel, subfamily H (eag-related), 
member 7 
R7BP 1.154 R7BP NM_001029
875 
R7 binding protein 
AQP12A 1.153 AQP12 NM_198998 aquaporin 12A 
EMP2 1.153 XMP; MGC9056 NM_001424 epithelial membrane protein 2 
OR9Q2 1.153 OR9Q2P NM_001005
283 
olfactory receptor, family 9, subfamily Q, member 2 
MCOLN
1 
1.152 ML4; MLIV; MST080; TRPML1; MSTP080; 
TRP-ML1 
NM_020533 mucolipin 1 
GOLGA
7 
1.152 GCP16; HSPC041; MGC4876; MGC21096; 
GOLGA3AP1 
NM_016099 golgi autoantigen, golgin subfamily a, 7 
C6ORF1
52 
1.152 C6orf152 NM_181714 chromosome 6 open reading frame 152 
ZNF167 1.151 ZFP; ZNF64; FLJ12738 NM_025169 zinc finger protein 167 
FRS2 1.151 SNT; SNT1; FRS2A; SNT-1; FRS2alpha NM_006654 fibroblast growth factor receptor substrate 2 
ELK4 1.151 SAP1 NM_001973 ELK4, ETS-domain protein (SRF accessory protein 1) 
FKBPL 1.151 NG7; DIR1; WISP39 NM_022110 FK506 binding protein like 
ZNF491 1.151 FLJ34791; MGC126639; MGC126641 NM_152356 zinc finger protein 491 
C20ORF
118 
1.151 dJ132F21.2 NM_080628 chromosome 20 open reading frame 118 
ARMCX
4 
1.15 FLJ43051; MGC40053; DKFZp781M0415 NM_152583 armadillo repeat containing, X-linked 4 
GHSR 1.15 GHSR NM_198407 growth hormone secretagogue receptor 
TGFBR1 1.15 SKR4; ALK-5; TGFR-1; ACVRLK4 NM_004612 transforming growth factor, beta receptor I (activin A receptor 
type II-like kinase, 53kDa) 
WDR81 1.149 FLJ23776; FLJ33817 NM_152348 WD repeat domain 81 
GREB1 1.149 GREB1; KIAA0575 NM_148903 GREB1 protein 
ACTN2 1.149 ACTN2 NM_001103 actinin, alpha 2 
DMPK 1.149 DM; DM1; DMK; DM1PK NM_004409 dystrophia myotonica-protein kinase 
HIST1H
4B 
1.149 H4/I; H4FI NM_003544 histone 1, H4b 
S100A9 1.148 MIF; NIF; P14; CAGB; CFAG; CGLB; L1AG; 
LIAG; MRP14; 60B8AG; MAC387 
NM_002965 S100 calcium binding protein A9 
C14ORF
119 
1.148 FLJ20671; MGC74723 NM_017924 chromosome 14 open reading frame 119 
LRRC4
C 
1.148 NGL1; NGL-1; KIAA1580 NM_020929 leucine rich repeat containing 4C 
RSN 1.148 CLIP; CLIP1; CYLN1; CLIP170; CLIP-170; 
MGC131604 
NM_002956 restin (Reed-Steinberg cell-expressed intermediate filament-
associated protein) 
OS9 1.148 OS9 NM_001017
956 
amplified in osteosarcoma 
PPARBP 1.148 PBP; MED1; CRSP1; RB18A; TRIP2; CRSP200; 
DRIP205; DRIP230; PPARGBP; TRAP220; 
MGC71488 
NM_004774 PPAR binding protein 
ZNF354
B 
1.147 KID2; FLJ25008; MGC138316 NM_058230 zinc finger protein 354B 
ING4 1.147   NM_198287   
IHPK1 1.147 PiUS; IP6K1; MGC9925 NM_153273 inositol hexaphosphate kinase 1 
CASKIN
2 
1.147 ANKS5B; FLJ21609; KIAA1139 NM_020753 CASK interacting protein 2 
PRKRIP
1 
1.146 C114; FLJ13902 NM_024653 PRKR interacting protein 1 (IL11 inducible) 
CASP8 1.145   NM_033357   
DEFB32 1.145 DEFB32; UNQ827 NM_207469 defensin, beta 32 (UNQ827) (DEFB32) 
GCC2 1.145 GCC185; KIAA0336 NM_181453 GRIP and coiled-coil domain containing 2 
ATF3 1.144 ATF3 NM_004024 activating transcription factor 3 
DGKD 1.144 dgkd-2; DGKdelta; KIAA0145 NM_152879 diacylglycerol kinase, delta 130kDa 
C5ORF3 1.144 133K02 NM_018691 chromosome 5 open reading frame 3 
GIF 1.143 IF; INF; IFMH; TCN3 NM_005142 gastric intrinsic factor (vitamin B synthesis) 
KRTAP
21-1 
1.143 KAP21.1 NM_181619 keratin associated protein 21-1 




neurotrophic tyrosine kinase, receptor, type 1 
CATSPE
R1 
1.141 CATSPER; MGC33335; MGC33368 NM_053054 cation channel, sperm associated 1 
MAGEA
12 
1.141 MAGE12 NM_005367 melanoma antigen family A, 12 
EMCN 1.14 EMCN2; MUC14 NM_016242 endomucin 
SUMO4 1.14 IDDM5; SMT3H4; SUMO-4; dJ281H8.4 NM_001002
255 
SMT3 suppressor of mif two 3 homolog 4 (S. cerevisiae) 
TICAM1 1.139 TRIF; PRVTIRB; TICAM-1; MGC35334 NM_014261 toll-like receptor adaptor molecule 1 
ZNF574 1.139 FP972; FLJ22059 NM_022752 zinc finger protein 574 
ZNF563 1.139 FLJ34797 NM_145276 zinc finger protein 563 
NEK7 1.138 JMJD1B NM_133494 NIMA (never in mitosis gene a)-related kinase 7 
FASTK 1.138 FAST NM_006712 Fas-activated serine/threonine kinase 
DDA1 1.138 DDA1; PCIA1; MGC2594 NM_024050 chromosome 19 open reading frame 58 
KRT20 1.136 K20; CK20; KRT21; MGC35423 NM_019010 keratin 20 
DHX57 1.136   NM_144995   
WISP1 1.136 CCN4; WISP1c; WISP1i; WISP1tc NM_080838 WNT1 inducible signaling pathway protein 1 









1.136 YT521; YT521-B; KIAA1966 NM_001031
732 
YTH domain containing 1 
RNF146 1.135 dJ351K20.1; RP3-351K20.1; DKFZP434O1427 NM_030963 ring finger protein 146 
LOC512
33 
1.134 LOC51233; MGC33025; MGC75009 NM_016449 hypothetical protein LOC51233 
FLJ3379
0 
1.133   NM_173583   
KRTAP
12-4 
1.133 KRTAP12.4 NM_198698 keratin associated protein 12-4 
OXGR1 1.133 GPR80; GPR99; P2Y15; P2RY15; MGC119206; 
MGC119207; MGC119208 
NM_080818 oxoglutarate (alpha-ketoglutarate) receptor 1 
BTBD12 1.133 KIAA1784; KIAA1987 NM_032444 BTB (POZ) domain containing 12 
CS 1.133 CS NM_198324 citrate synthase 
TSGA10 1.131 CEP4L NM_025244 testis specific, 10 
MSH5 1.131 G7; NG23; MutSH5; MGC2939; 
DKFZp434C1615 
NM_025259 mutS homolog 5 (E. coli) 
MRM1 1.13 FLJ22578 NM_024864 mitochondrial rRNA methyltransferase 1 homolog (S. cerevisiae) 
LRRCC
1 
1.129 SAP2; KIAA1764 NM_033402 leucine rich repeat and coiled-coil domain containing 1 
GOLGB
1 
1.129 GCP; GCP372; GIANTIN NM_004487 golgi autoantigen, golgin subfamily b, macrogolgin (with 
transmembrane signal), 1 
OR10A5 1.128 JCG6; OR10A1; OR11-403 NM_178168 olfactory receptor, family 10, subfamily A, member 5 
MSR1 1.128 SR-A; CD204; phSR1; phSR2; SCARA1 NM_138715 macrophage scavenger receptor 1 
REXO1 1.127 REX1; ELOABP1; EloA-BP1; KIAA1138; 
TCEB3BP1 
NM_020695 REX1, RNA exonuclease 1 homolog (S. cerevisiae) 
FAIM 1.127 FAIM1 NM_018147 Fas apoptotic inhibitory molecule 
FLJ1439
7 
1.127 FLJ14397 NM_032779 hypothetical protein FLJ14397 
C17ORF
57 
1.127 FLJ40342 NM_152347 chromosome 17 open reading frame 57 
HTR2A 1.127 HTR2; 5-HT2A NM_000621 5-hydroxytryptamine (serotonin) receptor 2A 
SERINC
3 
1.126 TDE; TDE1; AIGP1; TMS-1; DIFF33; SBBI99 NM_198941 serine incorporator 3 
COL11A
2 
1.126 HKE5; PARP; STL3; DFNA13; DFNB53 NM_080680 collagen, type XI, alpha 2 
PCDHB
15 
1.124 PCDH-BETA15 NM_018935 protocadherin beta 15 
MC5R 1.124 MC5R NM_005913 melanocortin 5 receptor 





hypothetical gene supported by AK056895 
GLIS1 1.123 FLJ36155 NM_147193 GLIS family zinc finger 1 
TXNDC
11 
1.123 EFP1 NM_015914 thioredoxin domain containing 11 
SVOP 1.122 DKFZp761H039 NM_018711 SV2 related protein homolog (rat) 
IFNA16 1.122 IFNA21 NM_002173 interferon, alpha 16 
FBXL22 1.122 Fbl22; FLJ39626; MGC75496 NM_203373 F-box and leucine-rich repeat protein 22 
DCT 1.122 TYRP2 NM_001922 dopachrome tautomerase (dopachrome delta-isomerase, tyrosine-
related protein 2) 
LILRB1 1.122 CD85; ILT2; LIR1; MIR7; CD85J; LIR-1; MIR-7 NM_006669 leukocyte immunoglobulin-like receptor, subfamily B (with TM 
and ITIM domains), member 1 
SUPT6H 1.121 SPT6; SPT6H; emb-5; KIAA0162; MGC87943 NM_003170 suppressor of Ty 6 homolog (S. cerevisiae) 
KIAA09
63 
1.121 FLJ00173 NM_014963 KIAA0963 
TIAM2 1.12 STEF; FLJ41865 NM_012454 T-cell lymphoma invasion and metastasis 2 
TRIM7 1.119 GNIP; RNF90 NM_203297 tripartite motif-containing 7 
DUX4C 1.119 DUX4C NM_001023
569 
double homeobox 4c 
SLC35E
2 
1.119 KIAA0447; MGC104754; MGC117254; 
MGC126715; MGC138494; DKFZp686M0869 
NM_182838 solute carrier family 35, member E2 
HGF 1.118 SF; HGFB; HPTA; F-TCF NM_001010
934 
hepatocyte growth factor (hepapoietin A; scatter factor) 
ZNF682 1.118 FLJ90362; BC39498_3 NM_033196 zinc finger protein 682 
GARNL
4 





family with sequence similarity 69, member A 
LASS2 1.117 L3; SP260; TMSG1; MGC987; FLJ10243 NM_013384 LAG1 longevity assurance homolog 2 (S. cerevisiae) 
CNR2 1.117 CB2; CX5 NM_001841 cannabinoid receptor 2 (macrophage) 
INVS 1.117 INV; NPH2; NPHP2; KIAA0573; MGC133080; 
MGC133081 
NM_183245 inversin 
KRT16 1.116 K16; CK16; K1CP; NEPPK; KRT16A NM_005557 keratin 16 (focal non-epidermolytic palmoplantar keratoderma) 
LRRC39 1.116 MGC14816; DKFZp313O1122 NM_144620 leucine rich repeat containing 39 
CCDC27 1.115 FLJ32825; MGC138313; MGC138317; RP1-
286D6.1 
NM_152492 coiled-coil domain containing 27 
RBKS 1.114 RBSK; DKFZp686G13268 NM_022128 ribokinase 
DPM2 1.114   NM_152690   
ZNF625 1.113 LOC136263 NM_145233 zinc finger protein 625 
RNF148 1.113 MGC35222 NM_198085 ring finger protein 148 
F2 1.113 PT NM_000506 coagulation factor II (thrombin) 
RHOBT
B2 
1.111 DBC2; KIAA0717 NM_015178 Rho-related BTB domain containing 2 
ZNF595 1.111 FLJ31740 NM_182524 zinc finger protein 595 
ZNF567 1.11 MGC45586 NM_152603 zinc finger protein 567 
CCDC62 1.11 aaa; TSP-NY; FLJ40344 NM_032573 coiled-coil domain containing 62 
SCN8A 1.109 MED; Nav1.6 NM_014191 sodium channel, voltage gated, type VIII, alpha 
ZNF642 1.109 Zfp69; FLJ16030; RP11-656D10.2 NM_198494 zinc finger protein 642 
OR1D2 1.109 OLFR1; OR17-4; MGC119942; MGC119943 NM_002548 olfactory receptor, family 1, subfamily D, member 2 





similar to chromosome 14 open reading frame 166B 




1.108 MCL; MPCL; CLEC6; CLEC-6; CLECSF8; 
MGC40078 
NM_080387 C-type lectin domain family 4, member D 





1.108 FLJ41046 NM_207479 FLJ41046 protein 
ZNF471 1.107 ERP1; Z1971; KIAA1396 NM_020813 zinc finger protein 471 
MGC39
715 
1.106 MGC39715 NM_152628 hypothetical protein MGC39715 
L3MBT
L3 
1.106 MBT1; MBT-1; RP11-73O6.1 NM_032438 l(3)mbt-like 3 (Drosophila) 
ANKH 1.105 ANK; CMDJ; HANK; MANK; CCAL2; CPPDD; 
FLJ27166 
NM_054027 ankylosis, progressive homolog (mouse) 








1.105 MHS5; HOKPP; hypoPP; CCHL1A3; CACNL1A3 NM_000069 calcium channel, voltage-dependent, L type, alpha 1S subunit 
ZNF132 1.105 pHZ-12; MGC126390; MGC126391 NM_003433 zinc finger protein 132 
GABRB
3 
1.104 MGC9051 NM_021912 gamma-aminobutyric acid (GABA) A receptor, beta 3 
C21ORF
124 
1.103 PRED79; FLJ31940; MGC15873 NM_032920 chromosome 21 open reading frame 124 
TSC1 1.103 LAM; TSC; KIAA0243; MGC86987 NM_001008
567 
tuberous sclerosis 1 
OR4K14 1.102 OR14-18; OR14-22 NM_001004
712 
olfactory receptor, family 4, subfamily K, member 14 
TIGD4 1.102 MGC43837 NM_145720 tigger transposable element derived 4 
U1SNR
NPBP 
1.102 U1SNRNPBP; HM-1; MGC138160 NM_180699 U11/U12 snRNP 35K 
GPR133 1.101 PGR25; FLJ16770; MGC138512; MGC138514; 
DKFZp434B1272 
NM_198827 G protein-coupled receptor 133 
NKX2-8 1.101 NKX2H; NKX2.8; Nkx2-9 NM_014360 NK2 transcription factor related, locus 8 (Drosophila) 
PRKCB
P1 
1.101 RACK7; ZMYND8; PRO2893; MGC31836 NM_183047 protein kinase C binding protein 1 
RFX3 1.1 MGC87155; bA32F11.1 NM_134428 regulatory factor X, 3 (influences HLA class II expression) 
OR5AT1 1.099 OR5W2 NM_001001
966 
olfactory receptor, family 5, subfamily AT, member 1 
ZDHHC
5 
1.098 ZNF375; KIAA1748; DKFZP586K0524 NM_015457 zinc finger, DHHC-type containing 5 
LOC510
57 
1.098 LOC51057; DKFZp686C12204 NM_015910 hypothetical protein LOC51057 
CBWD5 1.097 RPL9 NM_001024
916 
COBW domain containing 5 
LRMP 1.097 JAW1 NM_006152 lymphoid-restricted membrane protein 
FUT6 1.096 FT1A; FLJ40754 NM_000150 fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 
THAP3 1.095 MGC33488 NM_138350 THAP domain containing, apoptosis associated protein 3 
WNT16 1.095 PRKCBP1 NM_057168 wingless-type MMTV integration site family, member 16 
IRF4 1.095 MUM1; LSIRF NM_002460 interferon regulatory factor 4 
LIG3 1.094 LIG3 NM_002311 ligase III, DNA, ATP-dependent 
OR4F4 1.094 OR4F18; OLA-7501 NM_001004
195 
olfactory receptor, family 4, subfamily F, member 4 
CNIH2 1.094 Cnil; MGC50896 NM_182553 cornichon homolog 2 (Drosophila) 
FLJ3574
0 
1.094 FLJ35740; ANKRD18A; FLJ40632 NM_147195 FLJ35740 protein 
LOC613
266 





1.092   NM_024826   
C6ORF1
5 
1.092 STG NM_014070 chromosome 6 open reading frame 15 
KRTAP
9-3 
1.091 KAP9.3; KRTAP9.3 NM_031962 keratin associated protein 9-3 
AMELX 1.09 AMG; AIH1; ALGN; AMGL; AMGX NM_001142 amelogenin (amelogenesis imperfecta 1, X-linked) 
USP21 1.09 USP16; USP23; MGC3394 NM_012475 ubiquitin specific peptidase 21 
ZNF406 1.09 KIAA1485; MGC126815; MGC126817 NM_020863 zinc finger protein 406 
GNG13 1.089 h2-35; G(gamma)13 NM_016541 guanine nucleotide binding protein (G protein), gamma 13 
BTNL3 1.089 BTNLR NM_197975 butyrophilin-like 3 
CD33 1.088 p67; SIGLEC3; FLJ00391; SIGLEC-3 NM_001772 CD33 molecule 
POLR1
A 
1.087 RPA1; RPO1-4; FLJ21915; MGC87965; 
DKFZP586M0122 
NM_015425 polymerase (RNA) I polypeptide A, 194kDa 
COL17A
1 
1.087 BP180; BPAG2; LAD-1; KIAA0204; BA16H23.2 NM_000494 collagen, type XVII, alpha 1 
C18ORF
1 
1.087 C18orf1 NM_181481 chromosome 18 open reading frame 1 
MARK2 1.085 EMK1; PAR-1; MGC99619 NM_017490 MAP/microtubule affinity-regulating kinase 2 
MYEF2 1.084 MEF-2; MST156; MSTP156; FLJ11213; 
HsT18564; KIAA1341; MGC87325 
NM_016132 myelin expression factor 2 
FBXW1
2 
1.084 Fbw12; FBXO35; MGC120385; MGC120386; 
MGC120387 
NM_207102 F-box and WD-40 domain protein 12 
RBM35
B 
1.084 FLJ21918; FLJ22248 NM_024939 RNA binding motif protein 35B 
CDSN 1.083 S; HTSS; D6S586E NM_001264 corneodesmosin 
C9ORF5
0 
1.083 FLJ35803 NM_199350 chromosome 9 open reading frame 50 
KIAA05
56 
1.083 KIAA0556 NM_015202 KIAA0556 
OR2M7 1.083 OR1-58 NM_001004
691 
olfactory receptor, family 2, subfamily M, member 7 
CMIP 1.081 CMIP; KIAA1694 NM_030629 c-Maf-inducing protein 
NEIL1 1.08 NEI1; hFPG1; FLJ22402 NM_024608 nei endonuclease VIII-like 1 (E. coli) 
RAB33B 1.079 MGC138182; DKFZP434G099 NM_031296 RAB33B, member RAS oncogene family 
GNRH1 1.079 GRH; GNRH; LHRH; LNRH NM_000825 gonadotropin-releasing hormone 1 (luteinizing-releasing 
hormone) 
PDZD7 1.079 PDZK7 NM_024895 PDZ domain containing 7 
PRH1 1.079 Pa NM_006250 proline-rich protein HaeIII subfamily 1 
TIAF1 1.078 MAJN; MYO18A; MYSPDZ; SPR210 NM_004740 TGFB1-induced anti-apoptotic factor 1 
TAOK2 1.078 PSK; PSK1; TAO1; TAO2; MAP3K17; 
KIAA0881 
NM_004783 TAO kinase 2 
XKR3 1.077 XRG3; XTES; MGC57211 NM_175878 XK, Kell blood group complex subunit-related family, member 3 
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USP16 1.073 UBP-M NM_001032
410 
ubiquitin specific peptidase 16 
ARPP-
21 
1.073 ARPP-21 NM_198399 cyclic AMP-regulated phosphoprotein, 21 kD 
ABCG1 1.072 ABC8; WHITE1; MGC34313 NM_004915 ATP-binding cassette, sub-family G (WHITE), member 1 
AIM2 1.071 PYHIN4 NM_004833 absent in melanoma 2 





family with sequence similarity 47, member C 
BIRC8 1.07 ILP2; ILP-2; hILP2 NM_033341 baculoviral IAP repeat-containing 8 
C5ORF4 1.07 FLJ13758 NM_032385 chromosome 5 open reading frame 4 
TRIM54 1.069 MURF; RNF30; MURF-3 NM_187841 tripartite motif-containing 54 
RXRG 1.069 RXRC; NR2B3 NM_001009
598 
retinoid X receptor, gamma 
IFNA10 1.068 MGC119878; MGC119879 NM_002171 interferon, alpha 10 
AICDA 1.068 AID; ARP2; CDA2; HIGM2 NM_020661 activation-induced cytidine deaminase 
ZYG11
A 







cytochrome P450, family 4, subfamily A, polypeptide 22 
SEC24B 1.066 SEC24; MGC48822 NM_006323 SEC24 related gene family, member B (S. cerevisiae) 
CCNB3 1.066 CCNB3 NM_033031 cyclin B3 
NTN1 1.065 NTN1L NM_004822 netrin 1 
FLJ3837
7 
1.065 FLJ38377 NM_152698 hypothetical protein FLJ38377 
CABP2 1.064 CABP2 NM_031204 calcium binding protein 2 
KIAA07
03 
1.059 KIAA0703; SPCA2; ATP2C2; DKFZp686H22230 NM_014861 KIAA0703 gene product 












discs, large (Drosophila) homolog-associated protein 1 
OR4F5 1.057 OR2T3 NM_001005
484 
olfactory receptor, family 4, subfamily F, member 5 
CCDC67 1.055 FLJ25393 NM_181645 coiled-coil domain containing 67 
NDUFC
2 
1.055 B14.5b; NADHDH2 NM_004549 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 
14.5kDa 
POU2F1 1.054 OCT1; OTF1 NM_002697 POU domain, class 2, transcription factor 1 
KCTD2 1.049 KIAA0176 NM_015353 potassium channel tetramerisation domain containing 2 
KIAA17
54L 
1.049 KIAA1754L NM_178495 KIAA1754-like 
COL14A
1 
1.048 UND NM_021110 collagen, type XIV, alpha 1 (undulin) 
C3ORF3
5 
1.039   NM_178343   
AAK1 1.035 KIAA1048; MGC138170 NM_014911 AP2 associated kinase 1 
HCN4 1.033 HCN4 NM_005477 hyperpolarization activated cyclic nucleotide-gated potassium 
channel 4 
APBB1 1.032 RIR; FE65; MGC:9072 NM_001164 amyloid beta (A4) precursor protein-binding, family B, member 1 
(Fe65) 
LCE1D 1.032 LEP4 NM_178352 late cornified envelope 1D 
IL17C 1.025 CX2; IL-21; IL-17C; MGC126884; MGC138401 NM_013278 interleukin 17C 
TCEAL4 1.008 NPD017; FLJ21174; DKFZp686M0279 NM_024863 transcription elongation factor A (SII)-like 4 
TBC1D1
0C 
0.97 FLJ00332; MGC46488 NM_198517 TBC1 domain family, member 10C 
BPESC1 0.968   NM_021812   
TMEM1
30 
0.967 FLJ42643; DKFZp761L1417 NM_152913 transmembrane protein 130 
WNT2B 0.964 WNT13; XWNT2 NM_004185 wingless-type MMTV integration site family, member 2B 
FLJ9057
5 
0.96 FLJ90575; MGC138479 NM_153376 coiled-coil domain containing 96 
KLK9 0.954 KLK8; KLKL3; KLK-L3 NM_012315 kallikrein 9 
HRB2 0.948 HRB2; RIP-1 NM_007043 KRR1, small subunit (SSU) processome component, homolog 
(yeast) 
CDIPT 0.947 PIS; PIS1; MGC1328 NM_006319 CDP-diacylglycerol--inositol 3-phosphatidyltransferase 
(phosphatidylinositol synthase) 
SYT12 0.942 SRG1; SYT11 NM_177963 synaptotagmin XII 
SENP3 0.942 SSP3; SMT3IP1; DKFZp762A152; 
DKFZP586K0919 
NM_015670 SUMO1/sentrin/SMT3 specific peptidase 3 
ZNF667 0.94 FLJ14011; DKFZp686O111 NM_022103 zinc finger protein 667 
IPO7 0.939 RANBP7; MGC138673 NM_006391 importin 7 
MADCA
M1 
0.938 MACAM1 NM_130760 mucosal vascular addressin cell adhesion molecule 1 
KIAA19
00 





0.933 FLJ25390 NM_145028 chromosome 6 open reading frame 81 
ACYP1 0.932 ACYPE NM_203488 acylphosphatase 1, erythrocyte (common) type 
GMCL1 0.931 GCL; GCL1; BTBD13 NM_178439 germ cell-less homolog 1 (Drosophila) 
TDRKH 0.931 TDRD2 NM_006862 tudor and KH domain containing 
TRPC6 0.928 TRP6; FSGS2; FLJ11098; FLJ14863 NM_004621 transient receptor potential cation channel, subfamily C, member 
6 
NR2C1 0.928 TR2; TR2-11 NM_001032
287 
nuclear receptor subfamily 2, group C, member 1 
RETNL
B 
0.927 XCP2; FIZZ1; FIZZ2; HXCP2; RELMb; 
RELMbeta; RELM-beta 
NM_032579 resistin like beta 
PON3 0.927 PON3 NM_000940 paraoxonase 3 
CDON 0.925 CDO; ORCAM; MGC111524 NM_016952 Cdon homolog (mouse) 
KCNH2 0.922 ERG1; HERG; LQT2; SQT1; HERG1; Kv11.1 NM_172057 potassium voltage-gated channel, subfamily H (eag-related), 
member 2 
PARVB 0.922 CGI-56 NM_013327 parvin, beta 
TGM1 0.919 LI; KTG; LI1; TGK; ICR2; TGASE NM_000359 transglutaminase 1 (K polypeptide epidermal type I, protein-
glutamine-gamma-glutamyltransferase) 
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GIMAP8 0.917 IANT; hIAN6; MGC129545; DKFZp667I133 NM_175571 GTPase, IMAP family member 8 
MCOLN
3 
0.913 TRPML3; FLJ11006; MGC71509 NM_018298 mucolipin 3 
CLYBL 0.912 CLB; bA134O15.1 NM_138280 citrate lyase beta like 
C1S 0.911 MSR1 NM_201442 complement component 1, s subcomponent 
PRDM1
0 
0.909 PFM7; KIAA1231; MGC131802 NM_020228 PR domain containing 10 
MATN4 0.909 FLJ14417; HE6WCR54 NM_030590 matrilin 4 
ZNF347 0.905 ZNF1111 NM_032584 zinc finger protein 347 
ATXN3 0.904 AT3; JOS; MJD; ATX3; MJD1; SCA3 NM_030660 ataxin 3 
TPM4 0.903 TPM4 NM_003290 tropomyosin 4 
C1ORF1
60 
0.902 MGC111002; DKFZP564D0478; RP11-4K3__A.4 NM_032125 chromosome 1 open reading frame 160 
SLC1A6 0.902 EAAT4; MGC33092; MGC43671 NM_005071 solute carrier family 1 (high affinity aspartate/glutamate 
transporter), member 6 
AGTRA
P 
0.902 ATRAP; MGC29646 NM_020350 angiotensin II receptor-associated protein 
ABCA3 0.902 ABC3; ABC-C; LBM180; MGC72201; 
EST111653 
NM_001089 ATP-binding cassette, sub-family A (ABC1), member 3 
CACNG
5 
0.902 MGC126656; MGC126682 NM_014404 calcium channel, voltage-dependent, gamma subunit 5 
CCDC74
A 
0.901 FLJ40345 NM_138770 coiled-coil domain containing 74A 
CABP7 0.901 MGC57793 NM_182527 calcium binding protein 7 
DRD4 0.899 D4DR NM_000797 dopamine receptor D4 
GRHL1 0.899 MGR; LBP32; LBP-32; TFCP2L2 NM_198182 grainyhead-like 1 (Drosophila) 
BCCIP 0.898 TOK-1 NM_078469 BRCA2 and CDKN1A interacting protein 
Sep-06 0.897 SEP2; KIAA0128; MGC16619; MGC20339; RP5-
876A24.2 
NM_145802 septin 6 
CALCR
L 
0.897 CRLR; CGRPR NM_005795 calcitonin receptor-like 
HSP90A
B6P 
0.895   NM_001014
441 
  
TRAK1 0.894 OIP106 NM_014965 trafficking protein, kinesin binding 1 
BCL2L1
1 
0.892   NM_138625   
ADAM1
2 
0.887 MCMP; MLTN; MLTNA; MCMPMltna NM_003474 ADAM metallopeptidase domain 12 (meltrin alpha) 
IQCD 0.886 4933433C09Rik NM_138451 IQ motif containing D 
DGCR1
4 
0.886 ES2; DGSI; DGS-I; Ese2el NM_022719 DiGeorge syndrome critical region gene 14 
KCNK4 0.883 TRAAK; TRAAK1 NM_033310 potassium channel, subfamily K, member 4 
PSCD3 0.882 GRP1; ARNO3 NM_004227 pleckstrin homology, Sec7 and coiled-coil domains 3 
CARD4 0.88 NOD1 NM_006092 caspase recruitment domain family, member 4 
LOC116
236 
0.88 LOC116236 NM_198147 hypothetical protein LOC116236 
GDF11 0.879 BMP11; BMP-11 NM_005811 growth differentiation factor 11 
PPWD1 0.878 KIAA0073 NM_015342 peptidylprolyl isomerase domain and WD repeat containing 1 
TAC1 0.874 NK2; NKNA; TAC2; Hs.2563 NM_013998 tachykinin, precursor 1 (substance K, substance P, neurokinin 1, 






sterile alpha motif domain containing 13 
TBC1D1 0.873 TBC; TBC1; KIAA1108 NM_015173 TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1 
TCF19 0.873 SC1; SC1-1 NM_007109 transcription factor 19 (SC1) 
FAHD2
A 
0.873 CGI-105; MGC131995 NM_016044 fumarylacetoacetate hydrolase domain containing 2A 
SULT1C
1 
0.871 ST1C1; ST1C2; SULT1C#1; humSULTC2 NM_001056 sulfotransferase family, cytosolic, 1C, member 1 
ZYX 0.871 ESP-2; HED-2 NM_003461 zyxin 
SYCP1 0.871 SCP1; MGC104417; HOM-TES-14 NM_003176 synaptonemal complex protein 1 
SYNE2 0.87 NUA; NUANCE; SYNE-2; FLJ11014; FLJ43727; 
FLJ45710; FLJ46790; KIAA1011; Nesprin-2; 
DKFZP434H2235; DKFZp686H1931 
NM_015180 spectrin repeat containing, nuclear envelope 2 
MME 0.87 NEP; CD10; CALLA; MGC126681; MGC126707; 
DKFZp686O16152 
NM_007287 membrane metallo-endopeptidase (neutral endopeptidase, 





hypothetical gene supported by AK091454 
SNTG2 0.869 SYN5; G2SYN NM_018968 syntrophin, gamma 2 
FLJ3977
9 
0.869 FLJ39779 NM_207442 FLJ39779 protein 
CEP68 0.869 KIAA0582 NM_015147 centrosomal protein 68kDa 
MTMR9 0.868 MTMR8; C8orf9; LIP-STYX; MGC126672; 
DKFZp434K171 
NM_015458 myotubularin related protein 9 
CASP3 0.868 CPP32; SCA-1; CPP32B NM_004346 caspase 3, apoptosis-related cysteine peptidase 
SCAP2 0.867 PRAP; RA70; SAPS; SKAP55R; MGC10411; 
MGC33304; SKAP-HOM 
NM_003930 src family associated phosphoprotein 2 
MC1R 0.867 MSH-R; MGC14337 NM_002386 melanocortin 1 receptor (alpha melanocyte stimulating hormone 
receptor) 
EVA1 0.866 EVA; MPZL2 NM_144765 epithelial V-like antigen 1 
TTLL5 0.866 KIAA0998; MGC117189 NM_015072 tubulin tyrosine ligase-like family, member 5 
KLHL18 0.866 FLJ13703; KIAA0795 NM_025010 kelch-like 18 (Drosophila) 
SMARC
A3 
0.865 HLTF; ZBU1; HLTF1; RNF80; HIP116; SNF2L3; 
HIP116A 
NM_003071 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 3 
VMD2 0.864 BMD; BEST; TU15B NM_004183 vitelliform macular dystrophy 2 (Best disease, bestrophin) 
CNFN 0.864 PLAC8L2 NM_032488 cornifelin 
CBFA2T
3 




0.863 PIGU; MGC40420 NM_080476 CDC91 cell division cycle 91-like 1 (S. cerevisiae) 
FSIP1 0.862 HSD10; FLJ35989 NM_152597 fibrous sheath interacting protein 1 




0.86 PGCC1; KIAA0183; KIAA1838; dJ894D12.1 NM_032448 family with sequence similarity 120B 
MRPS23 0.86 CGI-138; HSPC329; MRP-S23 NM_016070 mitochondrial ribosomal protein S23 
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NUBP2 0.859 CFD1; NUBP1 NM_012225 nucleotide binding protein 2 (MinD homolog, E. coli) 
A2ML1 0.858 CPAMD9; FLJ16045; FLJ25179; FLJ39129; 




NM_144670 alpha-2-macroglobulin-like 1 
PAQR4 0.857 FLJ30002 NM_152341 progestin and adipoQ receptor family member IV 
WAS 0.857 THC; IMD2; WASP NM_000377 Wiskott-Aldrich syndrome (eczema-thrombocytopenia) 
POLM 0.856 Tdt-N NM_013284 polymerase (DNA directed), mu 
NKX3-1 0.854 NKX3A; NKX3.1 NM_006167 NK3 transcription factor related, locus 1 (Drosophila) 
SMARC
D1 
0.853 Rsc6p; BAF60A; CRACD1 NM_003076 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily d, member 1 
VPS53 0.853 hVps53L; pp13624; FLJ10979; MGC39512 NM_018289 vacuolar protein sorting 53 (S. cerevisiae) 
TES 0.852 TESS; TESS-2; TESTIN; MGC1146; 
DKFZP586B2022 
NM_015641 testis derived transcript (3 LIM domains) 
DOK5 0.851 MGC16926; C20orf180 NM_018431 docking protein 5 
SPTBN1 0.851 ELF; SPTB2; betaSpII NM_003128 spectrin, beta, non-erythrocytic 1 
RND1 0.85 ARHS; RHO6; FLJ42294 NM_014470 Rho family GTPase 1 
WDR45 0.849 JM5; WDRX1; WIPI4; WIPI-4 NM_001029
896 
WD repeat domain 45 
PLOD2 0.849 LH2; TLH NM_182943 procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 
GRIK5 0.849 KA2; EAA2; GRIK2 NM_002088 glutamate receptor, ionotropic, kainate 5 
SDCCA
G33 
0.849 TSH1; NY-CO-33; SDCCAG33 NM_005786 teashirt family zinc finger 1 
IQSEC1 0.846 KIAA0763 NM_014869 IQ motif and Sec7 domain 1 
GIMAP4 0.846 IAN1; IMAP4; hIAN1; HIMAP4; MSTP062; 
FLJ11110 
NM_018326 GTPase, IMAP family member 4 
ATF7IP
2 
0.845 MCAF2; FLJ12668 NM_024997 activating transcription factor 7 interacting protein 2 
CYP19A
1 
0.844 ARO; ARO1; CPV1; CYAR; CYP19; 
MGC104309; P-450AROM 
NM_031226 cytochrome P450, family 19, subfamily A, polypeptide 1 
TMEM6
2 
0.844 FLJ23375 NM_024956 transmembrane protein 62 
C10ORF
96 
0.844 MGC35062 NM_198515 chromosome 10 open reading frame 96 
CPNE4 0.843 CPN4; COPN4; MGC15604 NM_130808 copine IV 
ADAM2
2 
0.842 MDC2 NM_004194 ADAM metallopeptidase domain 22 
TGFB2 0.842 MGC116892; TGF-beta2 NM_003238 transforming growth factor, beta 2 
YIF1B 0.841 FinGER8 NM_033557 Yip1 interacting factor homolog B (S. cerevisiae) 
SMCY 0.841 HY; HYA; JARID1D; KIAA0234 NM_004653 Smcy homolog, Y-linked (mouse) 
CLTCL1 0.84 CLTD; CHC22; CLH22; CLTCL NM_007098 clathrin, heavy polypeptide-like 1 
C1ORF1
09 
0.84 FLJ20508 NM_017850 chromosome 1 open reading frame 109 
IMPAC
T 
0.839 MGC33718 NM_018439 Impact homolog (mouse) 
ZNF569 0.839 ZNF; ZAP1; FLJ32053 NM_152484 zinc finger protein 569 
FLT1 0.839 FLT; VEGFR1 NM_002019 fms-related tyrosine kinase 1 (vascular endothelial growth 
factor/vascular permeability factor receptor) 
GPR63 0.838 PSP24B; PSP24(beta) NM_030784 G protein-coupled receptor 63 
PAK2 0.838 PAK65; PAKgamma NM_002577 p21 (CDKN1A)-activated kinase 2 
ULBP1 0.837 RAET1I NM_025218 UL16 binding protein 1 
MGC19
604 
0.837 MGC19604; MGC74760 NM_001031
734 
similar to RIKEN cDNA B230118G17 gene 
NPM3 0.835 PORMIN; TMEM123 NM_006993 nucleophosmin/nucleoplasmin, 3 
PRKCE 0.835 PKCE; MGC125656; MGC125657; nPKC-epsilon NM_005400 protein kinase C, epsilon 
NOL6 0.835 NRAP; UTP22; FLJ21959; MGC14896; 
MGC14921; MGC20838; bA311H10.1 
NM_022917 nucleolar protein family 6 (RNA-associated) 
SPARC
L1 
0.835 SC1; PIG33 NM_004684 SPARC-like 1 (mast9, hevin) 
KIAA13
33 
0.834 FLJ20333 NM_017769 KIAA1333 
NBEA 0.832 BCL8B; LYST2 NM_015678 neurobeachin 
HOXC8 0.83 HOX3; HOX3A NM_022658 homeobox C8 
HNMT 0.83 HMT; HNMT-S1; HNMT-S2 NM_001024
074 
histamine N-methyltransferase 
CPLX1 0.83 CPX1; CPX-I NM_006651 complexin 1 
NGEF 0.83 EPHEXIN NM_019850 neuronal guanine nucleotide exchange factor 
GMIP 0.829 GMIP NM_016573 GEM interacting protein 
CA11 0.829 CARP2; CA-RP XI NM_001217 carbonic anhydrase XI 
HMGN2 0.828 HMG17; MGC5629; MGC88718 NM_005517 high-mobility group nucleosomal binding domain 2 
CXORF
23 
0.828 IGL@ NM_198279 chromosome X open reading frame 23 
FLJ1361
1 
0.828 FLJ13611; MGC48585 NM_024941 hypothetical protein FLJ13611 
MAP3K
6 
0.827 ASK2; MAPKKK6; MGC20114; MGC125653 NM_004672 mitogen-activated protein kinase kinase kinase 6 
JPH4 0.826 JPHL1; hJP-4; KIAA1831 NM_032452 junctophilin 4 
CXXC4 0.826 IDAX; MGC149872 NM_025212 CXXC finger 4 
THAP9 0.825 FLJ23320; FLJ34093 NM_024672 THAP domain containing 9 
BSN 0.825 ZNF231 NM_003458 bassoon (presynaptic cytomatrix protein) 
B3GAT1 0.825 CD57; LEU7; NK-1; HNK-1; GLCATP; GlcAT-P; 
GlcUAT-P 
NM_054025 beta-1,3-glucuronyltransferase 1 (glucuronosyltransferase P) 
USP13 0.824 ISOT3; IsoT-3 NM_003940 ubiquitin specific peptidase 13 (isopeptidase T-3) 
TMEM1
06B 
0.824 FLJ11273; MGC33727 NM_018374 transmembrane protein 106B 
COPG2 0.824 2-COP; FLJ11781 NM_012133 coatomer protein complex, subunit gamma 2 
VPS13D 0.824 FLJ23066 NM_015378 vacuolar protein sorting 13 homolog D (S. cerevisiae) 
CNTNA
P3 
0.823 CASPR3; CNTNAP3A; RP11-290L7.1; RP11-
138L21.1 
NM_033655 contactin associated protein-like 3 
SALL3 0.823 ZNF796 NM_171999 sal-like 3 (Drosophila) 
SCARA
3 
0.822 CSR; APC7; CSR1; MSLR1; MSRL1 NM_182826 scavenger receptor class A, member 3 
TSN 0.821 TRSLN; BCLF-1; REHF-1 NM_004622 translin 
FAM20
C 




0.821 HMGB4 NM_199461 nanos homolog 1 (Drosophila) 
LRRN3 0.821 NLRR3; NLRR-3; FLJ11129 NM_018334 leucine rich repeat neuronal 3 
EZH2 0.821 EZH1; ENX-1; MGC9169 NM_152998 enhancer of zeste homolog 2 (Drosophila) 
LSAMP 0.82 LAMP NM_002338 limbic system-associated membrane protein 
PIAS3 0.82 FLJ14651 NM_006099 protein inhibitor of activated STAT, 3 
TNRC6
A 
0.82 GW182; TNRC6; CAGH26; FLJ22043; 
KIAA1460; MGC75384; DKFZp666E117 
NM_014494 trinucleotide repeat containing 6A 
MED25 0.82 P78; ACID1; ARC92; MGC70671; TCBAP0758; 
DKFZp434K0512 
NM_030973 mediator of RNA polymerase II transcription, subunit 25 





chromosome 10 open reading frame 59 
MAST1 0.818 SAST; SAST170; KIAA0973 NM_014975 microtubule associated serine/threonine kinase 1 
DNAJA
5 
0.818 DNAJA5 NM_194283 DnaJ homology subfamily A member 5 
TAF15 0.817 Npl3; RBP56; TAF2N; TAFII68; hTAFII68 NM_003487 TAF15 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 68kDa 
SPINK2 0.816 HUSI-II NM_021114 serine peptidase inhibitor, Kazal type 2 (acrosin-trypsin inhibitor) 
TRIM5 0.815 RNF88; TRIM5alpha NM_033092 tripartite motif-containing 5 
ZMYND
12 
0.815 DKFZp434N2435 NM_032257 zinc finger, MYND-type containing 12 
RFC2 0.814 A1; RFC40; MGC3665 NM_002914 replication factor C (activator 1) 2, 40kDa 
SH3GL1 0.813 EEN; CNSA1; SH3P8; SH3D2B; MGC111371 NM_003025 SH3-domain GRB2-like 1 
SLC35A
5 
0.813 FLJ11130; FLJ20730; FLJ25973; DKFZp434E102 NM_017945 solute carrier family 35, member A5 
TMF1 0.813 ARA160 NM_007114 TATA element modulatory factor 1 
C6ORF2
03 
0.813 PRED31; HSPC230; RP11-59I9.1 NM_016487 chromosome 6 open reading frame 203 
SLC32A
1 
0.812 VGAT; VIAAT NM_080552 solute carrier family 32 (GABA vesicular transporter), member 1 
LRRC8E 0.811 FLJ23420 NM_025061 leucine rich repeat containing 8 family, member E 
C16ORF
30 
0.808 CLP24; FLJ20898; MGC111564 NM_024600 chromosome 16 open reading frame 30 
PET112
L 
0.808 PET112; HSPC199 NM_004564 PET112-like (yeast) 
PROM2 0.808 PROM-2; MGC138714 NM_144707 prominin 2 









0.804 RPC1; RPC155; hRPC155 NM_007055 polymerase (RNA) III (DNA directed) polypeptide A, 155kDa 
TSPAN7 0.804 A15; MXS1; CD231; MRX58; CCG-B7; TM4SF2; 
TALLA-1; TM4SF2b; DXS1692E 
NM_004615 tetraspanin 7 
HECA 0.804 HDC; HDCL; HHDC; dJ225E12.1 NM_016217 headcase homolog (Drosophila) 
KIAA10
18 
0.804 DKFZp451H236; DKFZp686K16147 NM_014967 KIAA1018 
CCK 0.803 MGC117187 NM_000729 cholecystokinin 
WDR69 0.802 FLJ25955 NM_178821 WD repeat domain 69 
CD8A 0.801 CD8; MAL; p32; Leu2 NM_001768 CD8a molecule 
C9ORF2
4 
0.801 CBE1; MGC32921; MGC33614; NYD-SP22; 
bA573M23.4 
NM_147168 chromosome 9 open reading frame 24 
ABHD9 0.799 FLJ22408; MGC131519 NM_024794 abhydrolase domain containing 9 
TRAIP 0.798 TRIP; RNF206 NM_005879 TRAF interacting protein 
GALNT
2 
0.798 GalNAc-T2 NM_004481 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2 (GalNAc-T2) 
FLJ1443
7 
0.798 MYOP NM_032578 myopalladin 
TNPO3 0.797 IPO12; TRNSR; MTR10A; TRN-SR; TRN-SR2 NM_012470 transportin 3 
MTUS1 0.797 ATIP; MP44; MTSG1; FLJ14295; KIAA1288; 
DKFZp586D1519; DKFZp686F20243 
NM_020749 mitochondrial tumor suppressor 1 
FRMD5 0.797 FRMD5 NM_001031
729 
synonyms: FLJ41022, MGC14161; isoform 2 is encoded by 
transcript variant 2; Homo sapiens FERM domain containing 5 
(FRMD5), transcript variant 2, mRNA. 
RUSC2 0.797 KIAA0375 NM_014806 RUN and SH3 domain containing 2 
PCP4 0.796 PEP-19 NM_006198 Purkinje cell protein 4 
BAALC 0.795 FLJ12015 NM_024812 brain and acute leukemia, cytoplasmic 
MRE11
A 
0.793 ATLD; HNGS1; MRE11; MRE11B NM_005590 MRE11 meiotic recombination 11 homolog A (S. cerevisiae) 
F2R 0.793 TR; HTR; CF2R; PAR1 NM_001992 coagulation factor II (thrombin) receptor 
KEAP1 0.793 INrf2; KLHL19; MGC1114; MGC4407; 
MGC9454; KIAA0132; MGC10630; MGC20887 
NM_012289 kelch-like ECH-associated protein 1 
FLJ1084
7 
0.793 FLJ10847; MATE1; MATE2; MGC64822 NM_018242 hypothetical protein FLJ10847 
FBXO4 0.793 FBX4; FLJ10141; DKFZp547N213 NM_012176 F-box protein 4 
E2F4 0.793 E2F-4 NM_001950 E2F transcription factor 4, p107/p130-binding 
LCE2B 0.793 XP5; LEP10; SPRL1B NM_014357 late cornified envelope 2B 
KIRREL
2 
0.793 NLG1; NEPH3; FILTRIN; MGC15718; 
DKFZP564A1164 
NM_199180 kin of IRRE like 2 (Drosophila) 
TNPO1 0.792 MIP; TRN; IPO2; MIP1; KPNB2 NM_153188 transportin 1 
AP1M1 0.792 AP47; CLTNM; MU-1A; CLAPM2 NM_032493 adaptor-related protein complex 1, mu 1 subunit 
RARRE
S1 
0.791 TIG1 NM_002888 retinoic acid receptor responder (tazarotene induced) 1 
BCL2A1 0.791 GRS; BFL1; ACC-1; ACC-2; HBPA1; BCL2L5 NM_004049 BCL2-related protein A1 
SLC25A
17 
0.79 PMP34 NM_006358 solute carrier family 25 (mitochondrial carrier; peroxisomal 
membrane protein, 34kDa), member 17 
RNPEP 0.79 DKFZP547H084 NM_020216 arginyl aminopeptidase (aminopeptidase B) 
FBXO18 0.79 FBH1; Fbx18; FLJ14590; MGC131916; 
MGC141935; MGC141937 
NM_032807 F-box protein, helicase, 18 
RSC1A1 0.789 RS1 NM_006511 regulatory solute carrier protein, family 1, member 1 
SGCD 0.789 SGD; DAGD; 35DAG; CMD1L; SGCDP; 
MGC22567; SG-delta 
NM_172244 sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 
CEPT1 0.789 MGC45223; DKFZp313G0615 NM_006090 choline/ethanolamine phosphotransferase 1 
ZRANB
3 
0.789 MGC75012; MGC105033 NM_032143 zinc finger, RAN-binding domain containing 3 
GNB5 0.789 GB5; FLJ37457 NM_006578 guanine nucleotide binding protein (G protein), beta 5 
DKFZP5 0.788 DKFZP564J102; MST119; MSTP119 NM_015398 DKFZP564J102 protein 
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64J102 
EFHC2 0.787 FLJ22601; FLJ22843; dJ1158H2.1; 
DKFZp686G08235 
NM_025184 EF-hand domain (C-terminal) containing 2 
CDON 0.787 CDO; ORCAM; MGC111524 NM_016952 Cdon homolog (mouse) 
ZNF215 0.787 BAZ2 NM_013250 zinc finger protein 215 
ZBTB24 0.786 BIF1; ZNF450 NM_014797 zinc finger and BTB domain containing 24 
NAALA
D2 
0.786 MGC26353; MGC116996; NAADALASE2; 
NAALADASE2 
NM_005467 N-acetylated alpha-linked acidic dipeptidase 2 
TCERG
1L 
0.786 MGC126584 NM_174937 transcription elongation regulator 1-like 
LETM1 0.786 LETM1 NM_012318 leucine zipper-EF-hand containing transmembrane protein 1 
HCN1 0.785 BCNG1; HAC-2; BCNG-1 NM_021072 hyperpolarization activated cyclic nucleotide-gated potassium 
channel 1 
POLD1 0.785 POLD NM_002691 polymerase (DNA directed), delta 1, catalytic subunit 125kDa 
CHD5 0.785 KIAA0444; DKFZp434N231 NM_015557 chromodomain helicase DNA binding protein 5 
PLAC1 0.784 RPL41 NM_021796 placenta-specific 1 
A2M 0.784 CPAMD5; FWP007; S863-7; alpha 2M; 
DKFZp779B086 
NM_000014 alpha-2-macroglobulin 
SRP72 0.783 SRP72 NM_006947 signal recognition particle 72kDa 
PSMD5 0.783 S5B; KIAA0072; MGC23145 NM_005047 proteasome (prosome, macropain) 26S subunit, non-ATPase, 5 
LOC388
799 
0.782 LOC388799; C20orf107; MGC104273 NM_001013
646 
similar to dJ1153D9.4 (novel protein) 
AMPD3 0.781 DUT NM_001025
389 
adenosine monophosphate deaminase (isoform E) 
SOX13 0.781 ICA12; Sox-13; MGC117216; SRY-box 13 NM_005686 SRY (sex determining region Y)-box 13 
NOVA2 0.781 ANOVA; NOVA3 NM_002516 neuro-oncological ventral antigen 2 
CEP63 0.781 FLJ13386; MGC78416 NM_025180 centrosomal protein 63kDa 
WDR62 0.781 C19orf14; FLJ33298; DKFZP434J046; 
DKFZp686G1024 
NM_173636 WD repeat domain 62 
ZHX3 0.781 TIX1; KIAA0395 NM_015035 zinc fingers and homeoboxes 3 
SYNJ2 0.781 INPP5H; KIAA0348; MGC44422 NM_003898 synaptojanin 2 
PLCL3 0.781 PLCL3; PLCeta1; MGC117152; DKFZp434C1372 NM_014996 phospholipase C, eta 1 
GALK2 0.78 GK2; MGC1745 NM_002044 galactokinase 2 
ATP6V0
A1 
0.78 a1; Stv1; VPP1; Vph1; ATP6N1; ATP6N1A; 
DKFZp781J1951 
NM_005177 ATPase, H+ transporting, lysosomal V0 subunit a1 
STK17B 0.78 DRAK2 NM_004226 serine/threonine kinase 17b (apoptosis-inducing) 
TOR1AI
P2 
0.779 LULL1; MGC126581; MGC138430; RP11-
12M5.5 
NM_145034 torsin A interacting protein 2 
2'-PDE 0.779 2'-PDE NM_177966 2'-phosphodiesterase 
CCDC76 0.779 FLJ10287; FLJ11219 NM_019083 coiled-coil domain containing 76 
FLJ2268
8 
0.778 FY; FLJ22688 NM_025129 fuzzy homolog (Drosophila) 
WNT10
B 
0.778 WNT-12 NM_003394 wingless-type MMTV integration site family, member 10B 
SLC35E
3 
0.778 BLOV1 NM_018656 solute carrier family 35, member E3 
ABCA4 0.778 FFM; RMP; ABCR; RP19; STGD; ABC10; 
CORD3; STGD1; DKFZp781N1972 
NM_000350 ATP-binding cassette, sub-family A (ABC1), member 4 
FAM26
A 
0.777 bA225H22.7 NM_182494 family with sequence similarity 26, member A 
CREB5 0.777 CRE-BPA NM_001011
666 
cAMP responsive element binding protein 5 
FLJ1066
1 
0.777 FLJ10661; FLJ27199; MGC45068 NM_152563 family with sequence similarity 86, member C 
GART 0.777 AIRS; GARS; PAIS; PGFT; PRGS; GARTF; 
MGC47764 
NM_175085 phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
PLAA 0.777 PLAP; PLA2P; FLJ11281; FLJ12699 NM_001031
689 
phospholipase A2-activating protein 
ZNF651 0.777 KIAA1190; DKFZp434N0615 NM_145166 zinc finger protein 651 
DAAM2 0.776 KIAA0381; MGC90515; dJ90A20A.1; RP1-
278E11.1 
NM_015345 dishevelled associated activator of morphogenesis 2 
MYCBP
2 
0.776 PAM; FLJ10106; FLJ13826; FLJ21597; 
FLJ21646; KIAA0916; DKFZp686M08244 
NM_015057 MYC binding protein 2 
PRKAC
B 
0.775 PKACB; MGC9320; MGC41879; 
DKFZp781I2452 
NM_207578 protein kinase, cAMP-dependent, catalytic, beta 
RP1-
32F7.2 
0.775 RP1-32F7.2 NM_173698 hypothetical protein FLJ37659 
SRGAP1 0.774 ARHGAP13; FLJ22166; KIAA1304 NM_020762 SLIT-ROBO Rho GTPase activating protein 1 
ZNF691 0.773 Zfp691; RP11-342M1.5 NM_015911 zinc finger protein 691 
RAB3G
AP1 
0.772 P130; WARBM1; RAB3GAP; KIAA0066; 
RAB3GAP130; DKFZp434A012 
NM_012233 RAB3 GTPase activating protein subunit 1 (catalytic) 
PRKDC 0.772 HYRC; p350; DNAPK; DNPK1; HYRC1; XRCC7 NM_006904 protein kinase, DNA-activated, catalytic polypeptide 
PIK4CB 0.772 PI4Kbeta; PI4K-BETA; PI4KIIIbeta NM_002651 phosphatidylinositol 4-kinase, catalytic, beta polypeptide 
CASC4 0.772 H63; MGC74708; DKFZp459F1927 NM_138423 cancer susceptibility candidate 4 
NFKBIL
2 
0.772 IKBR NM_013432 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor-like 2 
BAIAP2 0.772 BAP2; IRSP53 NM_006340 BAI1-associated protein 2 
NPR3 0.772 NPRC; ANPRC NM_000908 natriuretic peptide receptor C/guanylate cyclase C 
(atrionatriuretic peptide receptor C) 
CHRM3 0.772 HM3 NM_000740 cholinergic receptor, muscarinic 3 
CDC26 0.771 C9orf17 NM_139286 cell division cycle 26 
FLJ2202
8 
0.771 FLJ22028 NM_024854 hypothetical protein FLJ22028 
FDPS 0.771 FPS NM_002004 farnesyl diphosphate synthase (farnesyl pyrophosphate 
synthetase, dimethylallyltranstransferase, geranyltranstransferase) 
C3ORF6
3 
0.77 RAP140; se89-1; KIAA1105; DKFZp686C2456 NM_015224 chromosome 3 open reading frame 63 
HELB 0.769 HELB NM_033647 helicase (DNA) B 




cold shock domain containing E1, RNA-binding 
CCNB1I
P1 
0.769 HEI10; C14orf18 NM_182852 cyclin B1 interacting protein 1 
THAP4 0.768 CGI-36 NM_015963 THAP domain containing 4 
SHQ1 0.768 FLJ10539; DKFZp686H07226 NM_018130 SHQ1 homolog (S. cerevisiae) 
PIB5PA 0.768 PIPP; INPP5; MGC129984 NM_014422 phosphatidylinositol (4,5) bisphosphate 5-phosphatase, A 
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PLEK2 0.768 FMNL2 NM_016445 pleckstrin 2 
LYPLA3 0.767 ACS; LLPL; LPLA2; DKFZp564A0122 NM_012320 lysophospholipase 3 (lysosomal phospholipase A2) 
CALD1 0.767 CDM; H-CAD; L-CAD; NAG22; MGC21352 NM_033138 caldesmon 1 
ABHD2 0.767 HS1-2; LABH2; PHPS1-2; MGC26249; 
MGC111112 
NM_007011 abhydrolase domain containing 2 
SLC27A
2 
0.767 VLCS; FATP2; VLACS; ACSVL1; FACVL1; 
hFACVL1; HsT17226 
NM_003645 solute carrier family 27 (fatty acid transporter), member 2 
KCNJ8 0.766 KIR6.1; uKATP-1 NM_004982 potassium inwardly-rectifying channel, subfamily J, member 8 
GALNA
C4S-6ST 
0.765 GALNAC4S-6ST; BRAG; KIAA0598; 
MGC34346; RP11-47G11.1; DKFZp781H1369 
NM_015892 B cell RAG associated protein 
FKBP3 0.765 PPIase; FKBP-25 NM_002013 FK506 binding protein 3, 25kDa 
IFT80 0.765 WDR56; KIAA1374; MGC126543 NM_020800 intraflagellar transport 80 homolog (Chlamydomonas) 
RELB 0.764 I-REL NM_006509 v-rel reticuloendotheliosis viral oncogene homolog B, nuclear 
factor of kappa light polypeptide gene enhancer in B-cells 3 
(avian) 
AKAP12 0.764 AKAP250; DKFZp686M0430; DKFZp686O0331 NM_005100 A kinase (PRKA) anchor protein (gravin) 12 














hypothetical protein LOC441168 
CDCP1 0.763 CD318; TRASK; SIMA135 NM_178181 CUB domain containing protein 1 
MDM2 0.763 hdm2; MGC71221 NM_002392 Mdm2, transformed 3T3 cell double minute 2, p53 binding 
protein (mouse) 
PRAC 0.762 PRAC; MGC32520 NM_032391 small nuclear protein PRAC 
TMEM6
8 
0.762 FLJ32370; MGC87778 NM_152417 transmembrane protein 68 
RAD1 0.762 REC1; HRAD1 NM_133377 RAD1 homolog (S. pombe) 
LGP1 0.761 LGP1; D11LGP1 NM_032484 GH3 domain containing 
FBXO27 0.761 FBG5; Fbx27 NM_178820 F-box protein 27 
DENND
1A 
0.761 FAM31A; FLJ38464; KIAA1608; RP11-230L22.3 NM_024820 DENN/MADD domain containing 1A 
SH3KBP
1 
0.761 CIN85; GIG10; MIG18 NM_031892 SH3-domain kinase binding protein 1 
PDCD11 0.758 NFBP; ALG-4; KIAA0185 NM_014976 programmed cell death 11 
MON1A 0.758 SAND1; MGC13272 NM_032355 MON1 homolog A (yeast) 
SDCCA
G1 
0.758 NY-CO-1; FLJ10051 NM_004713 serologically defined colon cancer antigen 1 




0.757 TSPAN NM_130783 tetraspanin 18 
C21ORF
51 
0.757 C21orf51 NM_058182 chromosome 21 open reading frame 51 
ARHGA
P18 
0.756 MacGAP; FLJ25728; MGC126757; MGC138145; 
bA307O14.2 
NM_033515 Rho GTPase activating protein 18 
ATP5S 0.756 ATPW; HSU79253 NM_015684 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit s (factor B) 
FAM105
A 
0.755 FLJ11127 NM_019018 family with sequence similarity 105, member A 
SLC13A
4 
0.755 SUT1; SUT-1 NM_012450 solute carrier family 13 (sodium/sulfate symporters), member 4 
LOC387
921 




similar to RIKEN cDNA 8030451K01 
CD79B 0.755 B29; IGB NM_000626 CD79b molecule, immunoglobulin-associated beta 
WDR77 0.754 MEP50; MGC2722; HKMT1069; Nbla10071; 
RP11-552M11.3 
NM_024102 WD repeat domain 77 
NFX1 0.754 NFX2; MGC20369 NM_147134 nuclear transcription factor, X-box binding 1 
DZIP3 0.753 DZIP3; UURF2; FLJ13327; KIAA0675 NM_014648 zinc finger DAZ interacting protein 3 
RPL34 0.753 MGC111005 NM_000995 ribosomal protein L34 
RALBP1 0.752 RIP; RIP1; RLIP76 NM_006788 ralA binding protein 1 
BAG4 0.752 SODD; BAG-4 NM_004874 BCL2-associated athanogene 4 
NAT9 0.752 EBSP; DKFZP564C103 NM_015654 N-acetyltransferase 9 
RNF10 0.752 RIE2; KIAA0262; MGC126758; MGC126764 NM_014868 ring finger protein 10 
SLC16A
4 
0.752 MCT4; MCT5 NM_004696 solute carrier family 16, member 4 (monocarboxylic acid 
transporter 5) 
DDX25 0.751 GRTH NM_013264 DEAD (Asp-Glu-Ala-Asp) box polypeptide 25 
KIAA17
94 
0.751 FLJ10719 NM_018193 KIAA1794 
FAM107
A 
0.75 DRR1; TU3A; FLJ45473 NM_007177 family with sequence similarity 107, member A 
TBC1D1
6 
0.75 FLJ20748; MGC25062 NM_019020 TBC1 domain family, member 16 
SLC27A
5 
0.749 ACSB; FATP5; ACSVL6; FACVL3; VLACSR; 
VLCSH2; VLCS-H2; FLJ22987 
NM_012254 solute carrier family 27 (fatty acid transporter), member 5 
DONSO
N 
0.749 B17; C21orf60; DKFZP434M035 NM_017613 downstream neighbor of SON 
HS6ST2 0.749 MGC130022; MGC130023 NM_147175 heparan sulfate 6-O-sulfotransferase 2 
NR4A1 0.749 HMR; N10; TR3; NP10; GFRP1; NAK-1; NGFIB; 
NUR77; MGC9485 
NM_173158 nuclear receptor subfamily 4, group A, member 1 
CHCHD
1 
0.748 C2360; C10orf34; FLJ25854 NM_203298 coiled-coil-helix-coiled-coil-helix domain containing 1 
ST3GAL
4 
0.747 STZ; SAT3; CGS23; SIAT4; NANTA3; SIAT4C; 
FLJ11867; ST3GalIV; ST3Gal IV 
NM_006278 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 
LSG1 0.747 FLJ11301 NM_018385 large subunit GTPase 1 homolog (S. cerevisiae) 
PCDHA
C2 
0.747 MGC71598; PCDH-ALPHA-C2 NM_031883 protocadherin alpha subfamily C, 2 
NDUFS
2 
0.747 DCTN2 NM_004550 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
ABI1 0.747 E3B1; ABI-1; NAP1BP; SSH3BP; SSH3BP1 NM_001012
752 
abl-interactor 1 
DCX 0.746 DC; DBCN; LISX; SCLH; XLIS NM_178151 doublecortex; lissencephaly, X-linked (doublecortin) 
ANK3 0.746 FLJ45464; ANKYRIN-G NM_001149 ankyrin 3, node of Ranvier (ankyrin G) 
HIRIP3 0.746 CYP2U1 NM_003609 HIRA interacting protein 3 




0.745 MGC16279; MGC104828 NM_032916 family with sequence similarity 86, member B1 
ZFP36L
1 
0.745 BRF1; ERF1; cMG1; ERF-1; Berg36; TIS11B; 
RNF162B 
NM_004926 zinc finger protein 36, C3H type-like 1 
CDC42B
PA 
0.744 MRCK; MRCKA; PK428; FLJ23347; KIAA0451; 
DKFZp686L1738; DKFZp686P1738 
NM_014826 CDC42 binding protein kinase alpha (DMPK-like) 
PSMD13 0.744 p40.5; HSPC027 NM_002817 proteasome (prosome, macropain) 26S subunit, non-ATPase, 13 
FTSJ3 0.744 EPCS3; FLJ20062 NM_017647 FtsJ homolog 3 (E. coli) 
NEF3 0.744 NFM; NEFM; NF-M NM_005382 neurofilament 3 (150kDa medium) 
BOC 0.744 BOC NM_033254 Boc homolog (mouse) 
NFIC 0.744 CTF; NFI; CTF5; NF-I; MGC20153 NM_205843 nuclear factor I/C (CCAAT-binding transcription factor) 
C8ORF5
3 
0.744 MGC14595 NM_032334 chromosome 8 open reading frame 53 
ABCA2 0.742 ABC2 NM_001606 ATP-binding cassette, sub-family A (ABC1), member 2 
UHRF1 0.742 Np95; ICBP90; RNF106; huNp95; FLJ21925; 
MGC138707 
NM_013282 ubiquitin-like, containing PHD and RING finger domains, 1 
BAT4 0.742 G5; D6S54E NM_033177 HLA-B associated transcript 4 
LOC126
295 
0.742 ZNF424 NM_173480 zinc finger protein 57 
CENPF 0.741 CENF; PRO1779 NM_016343 centromere protein F, 350/400ka (mitosin) 
GFRA2 0.741 NTNRA; RETL2; TRNR2; GDNFRB; NRTNR-
ALPHA 
NM_001495 GDNF family receptor alpha 2 
TRIAP1 0.74 WF-1; P53CSV; HSPC132 NM_016399 TP53 regulated inhibitor of apoptosis 1 
CPEB1 0.74 CPEB; FLJ13203 NM_030594 cytoplasmic polyadenylation element binding protein 1 
KIAA17
27 
0.739 KIAA1727 NM_033393 KIAA1727 protein 
RHBDL
1 
0.739 RRP; RHBDL NM_003961 rhomboid, veinlet-like 1 (Drosophila) 
ZMYM1 0.739 MYM; FLJ23151; FLJ43753; RP11-181E22.4 NM_024772 zinc finger, MYM-type 1 
MRPL19 0.739 RLX1; RPML15; MRP-L15; KIAA0104; 
MGC20675 
NM_014763 mitochondrial ribosomal protein L19 
FAM29
A 
0.738 MGC102696; MGC138798; MGC138799; RP11-
296P7.3 
NM_017645 family with sequence similarity 29, member A 
TPARL 0.738 TPARL; TMPT27 NM_018475 transmembrane protein 165 
PRKG2 0.738 cGKII; PRKGR2 NM_006259 protein kinase, cGMP-dependent, type II 
FSD1 0.737 MIR1; GLFND; MGC3213 NM_024333 fibronectin type III and SPRY domain containing 1 
YPEL4 0.737 FLJ30213; MGC102723; MGC138324 NM_145008 yippee-like 4 (Drosophila) 
MINA 0.737 MDIG; NO52; MINA53; FLJ14393; 
DKFZp762O1912 
NM_032778 MYC induced nuclear antigen 
DNMT3
B 
0.737 ICF; M.HsaIIIB NM_006892 DNA (cytosine-5-)-methyltransferase 3 beta 
GRHL2 0.736 BOM; DFNA28; TFCP2L3; FLJ11172; FLJ13782 NM_024915 grainyhead-like 2 (Drosophila) 
NSMAF 0.736 FAN NM_003580 neutral sphingomyelinase (N-SMase) activation associated factor 
TAF9 0.735 AK6; CIP; CINAP; TAF2G; AD-004; CGI-137; 
MGC1603; MGC3647; MGC5067; TAFII31; 
TAFII32; MGC:1603; MGC:3647; MGC:5067; 
TAFIID32 
NM_016283 TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa 
PTCD2 0.735 FLJ12598 NM_024754 pentatricopeptide repeat domain 2 
FLJ4385
5 
0.735   NM_198857   
PDZK3 0.735 AIPC; PIN1; PAPIN; PDZK3; KIAA0300 NM_178140 PDZ domain containing 2 
ZBTB20 0.734 HOF; DPZF; ODA-8S; ZNF288; DKFZp566F123 NM_015642 zinc finger and BTB domain containing 20 
URG4 0.733 URG4; DKFZp666G166; DKFZp686O0457 NM_017920 up-regulated gene 4 
TESK2 0.733 TESK2 NM_007170 testis-specific kinase 2 




0.731 C6orf169; FLJ13018; dJ230I3.1 NM_001029
858 
solute carrier family 35, member F1 
MYOZ1 0.731 CS-2; FATZ; MYOZ NM_021245 myozenin 1 
KIF22 0.73 KID; OBP; KNSL4; OBP-1; OBP-2 NM_007317 kinesin family member 22 
RNF123 0.73 KPC1; FP1477; FLJ12565; DKFZp686C2222 NM_022064 ring finger protein 123 
SLC4A4 0.73 KNBC; NBC1; NBC2; pNBC; HNBC1; hhNMC; 
SLC4A5; DKFZp781H1314 
NM_003759 solute carrier family 4, sodium bicarbonate cotransporter, 
member 4 
INSM1 0.73 IA1; IA-1 NM_002196 insulinoma-associated 1 
POLQ 0.729 POLH; PRO0327; DKFZp781A0112 NM_199420 polymerase (DNA directed), theta 





sphingomyelin phosphodiesterase, acid-like 3B 
MSH2 0.728 FCC1; COCA1; HNPCC; HNPCC1 NM_000251 mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli) 
DPP7 0.728 QPP; DPP2; DPPII NM_013379 dipeptidyl-peptidase 7 
TCF21 0.727 POD1 NM_003206 transcription factor 21 
ABCB7 0.727 ABC7; ASAT; Atm1p; EST140535 NM_004299 ATP-binding cassette, sub-family B (MDR/TAP), member 7 
JAM2 0.727 JAMB; CD322; JAM-B; VEJAM; PRO245; VE-
JAM; C21orf43 
NM_021219 junctional adhesion molecule 2 
HMX2 0.726 H6L; Nkx5-2 NM_005519 homeobox (H6 family) 2 
EIF2AK
4 
0.726 GCN2; KIAA1338 NM_001013
703 
eukaryotic translation initiation factor 2 alpha kinase 4 
SULT1C
1 
0.725 ST1C1; ST1C2; SULT1C#1; humSULTC2 NM_001056 sulfotransferase family, cytosolic, 1C, member 1 
UNQ943
3 
0.724 UNQ9433 NM_207413 RPLK9433 
ADAMT
S2 
0.724 NPI; PCINP; PCPNI; hPCPNI; ADAM-TS2; 
ADAMTS-3 
NM_014244 ADAM metallopeptidase with thrombospondin type 1 motif, 2 
PLK1 0.724 PLK; STPK13 NM_005030 polo-like kinase 1 (Drosophila) 
LOC966
10 
0.723 LOC96610 NM_080926 hypothetical protein similar to KIAA0187 gene product 
PGF 0.723 PLGF; PlGF-2 NM_002632 placental growth factor, vascular endothelial growth factor-
related protein 
LYK5 0.723 LYK5; STRAD; FLJ90524 NM_001003
786 
protein kinase LYK5 
SCMH1 0.723 Scml3 NM_001031
694 
sex comb on midleg homolog 1 (Drosophila) 
ZNF294 0.723 RNF160; C21orf10; C21orf98; FLJ11053; 
KIAA0714 
NM_015565 zinc finger protein 294 
LOC150
223 
0.723 LOC150223; MGC133160 NM_001017
964 




0.723 MGC40612; RP11-396A22.1 NM_018527 NMDA receptor regulated 1-like 
PAP2 0.722 PAP2D; PAP2 NM_001010
861 
phosphatidic acid phosphatase type 2 
GOT1 0.722 GIG18 NM_002079 glutamic-oxaloacetic transaminase 1, soluble (aspartate 
aminotransferase 1) 
HBQ1 0.72 HBG1 NM_005331 hemoglobin, theta 1 
NAGLU 0.72 NAG; MPS3B; UFHSD; MPS IIIB NM_000263 N-acetylglucosaminidase, alpha- (Sanfilippo disease IIIB) 
C1ORF1
98 
0.719 FLJ14525; FLJ16283; FLJ38847; MGC10710; 
DKFZp667D152 
NM_032800 chromosome 1 open reading frame 198 
AMBP 0.719 HCP; ITI; UTI; ITIL NM_001633 alpha-1-microglobulin/bikunin precursor 
CRYBB
1 
0.719 CRYBB1 NM_001887 crystallin, beta B1 
EIF3S10 0.718 EIF3; P167; p180; p185; EIF3A; KIAA0139; eIF3-
p170; eIF3-theta 
NM_003750 eukaryotic translation initiation factor 3, subunit 10 theta, 
150/170kDa 
SHMT1 0.718 SHMT; CSHMT; MGC15229; MGC24556 NM_148918 serine hydroxymethyltransferase 1 (soluble) 
MAP2K
3 
0.717 MEK3; MKK3; MAPKK3; PRKMK3 NM_145110 mitogen-activated protein kinase kinase 3 
BFSP1 0.717 CP94; CP115; LIFL-H; FILENSIN NM_001195 beaded filament structural protein 1, filensin 
CD109 0.717 CPAMD7; FLJ38569; FLJ41966; RP11-525G3.1; 
DKFZp762L1111 
NM_133493 CD109 molecule 
KIAA04
04 
0.717 KIAA0404; MGC117153 NM_015104 hypothetical protein LOC23130 
MYOZ3 0.716 CS3; CS-3; FRP3 NM_133371 myozenin 3 
C13ORF
23 
0.716 FLJ12661; FLJ23780; bA50D16.2; RP11-50D16.2 NM_025138 chromosome 13 open reading frame 23 
BAIAP2
L1 
0.716 IRTKS NM_018842 BAI1-associated protein 2-like 1 
C20ORF
59 
0.715 FLJ23412 NM_022082 chromosome 20 open reading frame 59 
SYT11 0.715 SYT12; KIAA0080; MGC10881; MGC17226; 
DKFZp781D015 
NM_152280 synaptotagmin XI 
B4GAL
T6 




0.714 DHFRP4; FLJ16119 NM_176815 dihydrofolate reductase-like 1 
ESM1 0.714 endocan NM_007036 endothelial cell-specific molecule 1 
OPRS1 0.714   NM_147160   
NOVA1 0.714 Nova-1 NM_006491 neuro-oncological ventral antigen 1 
ETHE1 0.714 HSCO; YF13H12 NM_014297 ethylmalonic encephalopathy 1 
MDS028 0.713 MDS028 NM_018463 integrin alpha FG-GAP repeat containing 2 
SORCS2 0.713 WFDC2 NM_020777 sortilin-related VPS10 domain containing receptor 2 
ADH5 0.713 FDH; ADHX; ADH-3 NM_000671 alcohol dehydrogenase 5 (class III), chi polypeptide 
ACTN1 0.713 FLJ40884 NM_001102 actinin, alpha 1 
GNL3L 0.713 FLJ10613; RP11-353K22.1 NM_019067 guanine nucleotide binding protein-like 3 (nucleolar)-like 
KIAA08
63 
0.713 KIAA0863 NM_014913 zinc finger protein 508 
RLN2 0.712 H2; RLXH2; bA12D24.1.1; bA12D24.1.2 NM_005059 relaxin 2 
IRAK1B
P1 
0.712 AIP70; SIMPL; MGC138458; MGC138460 NM_001010
844 
interleukin-1 receptor-associated kinase 1 binding protein 1 
DNAPT
P6 
0.712 DNAPTP6; DKFZp564A2416 NM_015535 DNA polymerase-transactivated protein 6 
MSH3 0.712 DUP; MRP1 NM_002439 mutS homolog 3 (E. coli) 
ARL4 0.711 ARL4 NM_212460 ADP-ribosylation factor-like 4A 
KCNAB
1 
0.711 hKvb3; AKR6A3; KCNA1B; Kvb1.3; hKvBeta3; 
KV-BETA-1 
NM_172159 potassium voltage-gated channel, shaker-related subfamily, beta 
member 1 
PAGE5 0.711 GAGEE1; PAGE-5 NM_130467 P antigen family, member 5 (prostate associated) 
DCLRE
1A 
0.711 PSO2; SNM1; KIAA0086 NM_014881 DNA cross-link repair 1A (PSO2 homolog, S. cerevisiae) 
VTI1B 0.71 VTI1; VTI2; VTI1L NM_006370 vesicle transport through interaction with t-SNAREs homolog 1B 
(yeast) 
PNMA2 0.71 MA2; MM2; RGAG2; KIAA0883 NM_007257 paraneoplastic antigen MA2 
SARS2 0.71 SYS; SARS; SERS; SARSM; SerRSmt; mtSerRS; 
FLJ20450 
NM_017827 seryl-tRNA synthetase 2 
PES1 0.709 PES NM_014303 pescadillo homolog 1, containing BRCT domain (zebrafish) 
FJX1 0.709 FLJ22416 NM_014344 four jointed box 1 (Drosophila) 
WDR4 0.709 TRM82 NM_033661 WD repeat domain 4 
C3ORF1
4 
0.709 HT021 NM_020685 chromosome 3 open reading frame 14 
IPO4 0.708 Imp4; FLJ23338; MGC131665 NM_024658 importin 4 
SC65 0.708 SC65; NOL55 NM_006455 synaptonemal complex protein SC65 
WDR53 0.708 MGC64882 NM_182627 WD repeat domain 53 
RAMP2 0.707 TSPO NM_005854 receptor (calcitonin) activity modifying protein 2 
FAIM3 0.707 TOSO NM_005449 Fas apoptotic inhibitory molecule 3 
BMS1L 0.707 KIAA0187 NM_014753 BMS1-like, ribosome assembly protein (yeast) 
TNFSF1
1 
0.707 ODF; OPGL; sOdf; CD254; RANKL; TRANCE; 
hRANKL2 
NM_003701 tumor necrosis factor (ligand) superfamily, member 11 
TGOLN
2 
0.707 TGN38; TGN46; TGN48; TGN51; TTGN2; 
MGC14722 
NM_006464 trans-golgi network protein 2 
PPARG
C1B 
0.707 PERC; PGC1B; PGC-1(beta) NM_133263 peroxisome proliferative activated receptor, gamma, coactivator 
1, beta 
ROBO1 0.707 SAX3; DUTT1; FLJ21882; MGC131599; 
MGC133277 
NM_133631 roundabout, axon guidance receptor, homolog 1 (Drosophila) 
RFC1 0.706 A1; RFC; PO-GA; RECC1; MHCBFB; RFC140; 
MGC51786 
NM_002913 replication factor C (activator 1) 1, 145kDa 
PCDH19 0.706 KIAA1313; DKFZp686P1843 NM_020766 protocadherin 19 
FXYD5 0.706 RIC; IWU1; KCT1; OIT2; IWU-1; dysad; 
HSPC113; PRO6241 
NM_144779 FXYD domain containing ion transport regulator 5 
FLJ2062
8 
0.705 FLJ20628; DKFZp564I2178 NM_017910 hypothetical protein FLJ20628 
ABHD8 0.705 MGC2512; FLJ11743; MGC14280 NM_024527 abhydrolase domain containing 8 
RPL7 0.705 humL7-1 NM_000971 ribosomal protein L7 
BMP6 0.705 VGR; VGR1 NM_001718 bone morphogenetic protein 6 
ARHGE
F12 
0.705 LARG; PRO2792; KIAA0382; DKFZp686O2372 NM_015313 Rho guanine nucleotide exchange factor (GEF) 12 
NIN 0.704 KIAA1565 NM_016350 ninein (GSK3B interacting protein) 
 253
SSBP2 0.704 HSPC116; DKFZp686F03273 NM_012446 single-stranded DNA binding protein 2 
TMEM8
7A 
0.702 DKFZP564G2022 NM_015497 transmembrane protein 87A 
KIAA08
59 
0.702 CGI-01; FLJ10310; 5630401D24Rik NM_015935 KIAA0859 
BCL11A 0.702 EVI9; CTIP1; BCL11A-L; BCL11A-S; FLJ10173; 
FLJ34997; KIAA1809; BCL11A-XL 
NM_138559 B-cell CLL/lymphoma 11A (zinc finger protein) 
GPATC
4 
0.702 RPIA NM_182679 G patch domain containing 4 
OGFRL
1 
0.701 FLJ21079; MGC102783; dJ331H24.1 NM_024576 opioid growth factor receptor-like 1 
NUDT2
2 
0.7 MGC13045 NM_032344 nudix (nucleoside diphosphate linked moiety X)-type motif 22 
LRRC34 0.699 FLJ27346; MGC27085 NM_153353 leucine rich repeat containing 34 
HARS2 0.699 DUEB; C20orf88; MGC41905; MGC119131; 
bA379J5.3; bA555E18.1 
NM_080820 histidyl-tRNA synthetase 2 
MKKS 0.699 KMS; MKS; BBS6; HMCS NM_018848 McKusick-Kaufman syndrome 
SRI 0.699 SCN; FLJ26259 NM_003130 sorcin 
SLC9A1 0.698 APNH; NHE1; FLJ42224 NM_003047 solute carrier family 9 (sodium/hydrogen exchanger), member 1 
(antiporter, Na+/H+, amiloride sensitive) 
SLC13A
3 
0.698 NADC3; SDCT2 NM_001011
554 
solute carrier family 13 (sodium-dependent dicarboxylate 
transporter), member 3 
EIF5A2 0.698 EIF-5A2; eIF5AII NM_020390 eukaryotic translation initiation factor 5A2 
KISS1 0.698 KiSS-1; MGC39258 NM_002256 KiSS-1 metastasis-suppressor 
SLC35D
3 
0.697 FRCL1; MGC102873; bA55K22.3 NM_001008
783 
solute carrier family 35, member D3 
BPNT1 0.697 PIP NM_006085 3'(2'), 5'-bisphosphate nucleotidase 1 
LOC906
24 
0.697 FLJ20796; MGC24679 NM_181705 chromosome 5 open reading frame 31 
ATRN 0.697 MGCA; DPPT-L; KIAA0548; MGC126754 NM_139322 attractin 
HHLA1 0.697 UTS2 NM_005712 Urotensin 2 
CCRL1 0.696 PPR1; CCBP2; CCR10; CCR11; VSHK1; CKR-
11; CCX-CKR; CC-CKR-11 
NM_178445 chemokine (C-C motif) receptor-like 1 
MSTO1 0.696 MST; LST005; FLJ10504; RP11-29H23.3; 
DKFZp686B1757; DKFZp686I01261 
NM_018116 misato homolog 1 (Drosophila) 
FLJ4184
1 
0.696 FLJ41841 NM_207499 FLJ41841 protein 
C9ORF1
40 
0.696 C9orf140 NM_178448 chromosome 9 open reading frame 140 
FKBP9 0.696 FKBP60; FKBP63; PPIase; MGC126772; 
MGC138258; DKFZp586B1723 
NM_007270 FK506 binding protein 9, 63 kDa 
DPEP3 0.696 MBD3 NM_022357 dipeptidase 3 
PLEKH
A9 
0.696 FLJ14156 NM_015899 pleckstrin homology domain containing, family A 
(phosphoinositide binding specific) member 9 
WDFY1 0.695 WDF1; FENS-1; ZFYVE17 NM_020830 WD repeat and FYVE domain containing 1 
HHLA3 0.694 ARL4A NM_001031
693 
HERV-H LTR-associating 3 
TSEN2 0.694 SEN2; SEN2L; MGC2776; MGC4440 NM_025265 tRNA splicing endonuclease 2 homolog (S. cerevisiae) 
EIF3S8 0.694 eIF3-p110 NM_003752 eukaryotic translation initiation factor 3, subunit 8, 110kDa 
C20ORF
11 
0.694 TWA1 NM_017896 chromosome 20 open reading frame 11 
HAPLN
3 
0.694 EXLD1; HsT19883 NM_178232 hyaluronan and proteoglycan link protein 3 
ARHGE
F19 
0.694 WGEF; FLJ33962; RP4-733M16.1 NM_153213 Rho guanine nucleotide exchange factor (GEF) 19 
KLF10 0.694 EGRA; TIEG; TIEG1 NM_005655 Kruppel-like factor 10 
MTCP1 0.693 C6.1B NM_001018
025 
mature T-cell proliferation 1 
C5ORF1
6 
0.693 FLJ90583 NM_173828 chromosome 5 open reading frame 16 
KIAA06
72 
0.693 KIAA0672 NM_014859 KIAA0672 gene product 
ARHGA
P1 
0.693 RHOGAP; RHOGAP1; CDC42GAP; p50rhoGAP NM_004308 Rho GTPase activating protein 1 
KIAA15
24 
0.692 FLJ12850 NM_020890 KIAA1524 
MID1 0.692 OS; FXY; OSX; OGS1; XPRF; BBBG1; GBBB1; 
RNF59; ZNFXY; TRIM18 
NM_000381 midline 1 (Opitz/BBB syndrome) 
TREX1 0.691 AGS1; DRN3; ATRIP; FLJ12343; 
DKFZp434J0310 
NM_032166 three prime repair exonuclease 1 
FBXL15 0.691 PSD; Fbl15; FBXO37; FLJ16137; MGC11279 NM_024326 F-box and leucine-rich repeat protein 15 
SLC4A1
1 
0.691 BTR1; CHED2; NABC1; MGC126418; 
MGC126419; dJ794I6.2 
NM_032034 solute carrier family 4, sodium bicarbonate transporter-like, 
member 11 
ACACB 0.69 ACC2; ACCB; HACC275 NM_001093 acetyl-Coenzyme A carboxylase beta 
KLHL7 0.689 KLHL6; SBBI26 NM_001031
710 
kelch-like 7 (Drosophila) 
NFIA 0.689 NFI-L; KIAA1439; DKFZp434L0422 NM_005595 nuclear factor I/A 
KIAA12
12 
0.689 APE; GIV; GRDN; HkRP1; DKFZp686D0630 NM_018084 KIAA1212 
C9ORF3
7 
0.689 C9orf37 NM_032937 chromosome 9 open reading frame 37 
ACAD8 0.689 ACAD-8; FLJ22590 NM_014384 acyl-Coenzyme A dehydrogenase family, member 8 
HSD17B
6 
0.689 HSE; RODH NM_003725 hydroxysteroid (17-beta) dehydrogenase 6 
MKLN1 0.688 FLJ11162 NM_013255 muskelin 1, intracellular mediator containing kelch motifs 
CCL11 0.688 SCYA11; MGC22554 NM_002986 chemokine (C-C motif) ligand 11 
CCDC21 0.688 FLJ13976; FLJ22000; DKFZp434P232; 
DKFZP434L0117 
NM_022778 coiled-coil domain containing 21 
FYN 0.688 SLK; SYN; MGC45350 NM_153047 FYN oncogene related to SRC, FGR, YES 
SIX6 0.688 Six9; OPTX2; MCOPCT2 NM_007374 sine oculis homeobox homolog 6 (Drosophila) 
CYB5D
2 
0.688 MGC32124 NM_144611 cytochrome b5 domain containing 2 
SIVA 0.688 SIVA; CD27BP NM_006427 CD27-binding (Siva) protein 
CSTF1 0.687 CstF-50; CstFp50 NM_001033
521 
cleavage stimulation factor, 3' pre-RNA, subunit 1, 50kDa 





0.687 FLJ41960; bA373N18.1; RP11-373N18.1 NM_145247 chromosome 10 open reading frame 78 
ZC3H12
A 
0.687 MCPIP; FLJ23231; dJ423B22.1; RP3-423B22.1 NM_025079 zinc finger CCCH-type containing 12A 
PSMD2 0.687 S2; P97; TRAP2; MGC14274 NM_002808 proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 
QPCTL 0.687 FLJ20084 NM_017659 glutaminyl-peptide cyclotransferase-like 
CXORF
45 
0.686   NM_024810   
CHST10 0.686 HNK1ST; HNK-1ST; MGC17148 NM_004854 carbohydrate sulfotransferase 10 
RPUSD2 0.686 C18B11; C15orf19; FLJ31409 NM_152260 RNA pseudouridylate synthase domain containing 2 
ATM 0.686 AT1; ATA; ATC; ATD; ATE; ATDC; TEL1; 
MGC74674; DKFZp781A0353 
NM_000051 ataxia telangiectasia mutated (includes complementation groups 
A, C and D) 
LHX6 0.686 LHX6.1; MGC119542; MGC119544; 
MGC119545 
NM_199160 LIM homeobox 6 
JSRP1 0.686 JP-45; FLJ32416 NM_144616 junctional sarcoplasmic reticulum protein 1 
CDC25
A 
0.686 CDC25A2 NM_001789 cell division cycle 25A 





chromosome 1 open reading frame 31 
MFSD2 0.685 FP1147; PP10484; FLJ14490; FLJ35904; 
HMFN0656; RP3-342P20.1 
NM_032793 major facilitator superfamily domain containing 2 
NAG6 0.685 NAG6; MGC129657; DKFZP434G156 NM_022742 hypothetical protein DKFZp434G156 
POR 0.684 CPR; CYPOR; P450R; FLJ26468; 
DKFZp686G04235 
NM_000941 P450 (cytochrome) oxidoreductase 
TRUB2 0.684 CLONE24922; RP11-339B21.1 NM_015679 TruB pseudouridine (psi) synthase homolog 2 (E. coli) 
YPEL3 0.684 MGC10500 NM_031477 yippee-like 3 (Drosophila) 
ARSG 0.683 KIAA1001 NM_014960 arylsulfatase G 
DNASE
2 
0.683 DNL; DNL2; DNASE2A NM_001375 deoxyribonuclease II, lysosomal 
ACAA1 0.683 ACAA; THIO; PTHIO NM_001607 acetyl-Coenzyme A acyltransferase 1 (peroxisomal 3-oxoacyl-
Coenzyme A thiolase) 
HSPC17
1 
0.683 HSPC171 NM_014187 HSPC171 protein 
ECHDC
3 
0.683 FLJ20909 NM_024693 enoyl Coenzyme A hydratase domain containing 3 
ATAD3
A 
0.682 FLJ10709 NM_018188 ATPase family, AAA domain containing 3A 
LPHN3 0.682 LEC3; CIRL3 NM_015236 latrophilin 3 
MRPL47 0.682 NCM1; CGI-204; MGC45403 NM_020409 mitochondrial ribosomal protein L47 
WDR3 0.681 FLJ12796 NM_006784 WD repeat domain 3 
CHST6 0.681 MCDC1 NM_021615 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6 
FAM72
A 
0.68 GCUD2; MGC57827; RP11-312O7.1 NM_207418 family with sequence similarity 72, member A 
C12ORF
31 
0.68 MGC14817; MGC104302 NM_032338 chromosome 12 open reading frame 31 
R3HDM
1 
0.68 R3HDM; FLJ23334; KIAA0029 NM_015361 R3H domain containing 1 





0.68 CML66; FLJ14991 NM_032869 NudC domain containing 1 
CSPG5 0.68 NGC; MGC44034 NM_006574 chondroitin sulfate proteoglycan 5 (neuroglycan C) 
HAS3 0.679 HAS3 NM_005329 hyaluronan synthase 3 
FLJ3236
3 
0.679 FLJ32363; MGC46448 NM_198566 FLJ32363 protein 
SLC25A
28 
0.679 MRS4L; MRS3/4; NPD016; DKFZp547C109 NM_031212 solute carrier family 25, member 28 
C12ORF
30 
0.678 FLJ13089; DKFZp667K2112 NM_024953 chromosome 12 open reading frame 30 
SNX8 0.678 SNX8 NM_013321 sorting nexin 8 
BTN3A3 0.678 BTF3 NM_006994 butyrophilin, subfamily 3, member A3 
CDC45L 0.677 CDC45; CDC45L2; PORC-PI-1 NM_003504 CDC45 cell division cycle 45-like (S. cerevisiae) 
AIM1 0.676 ST4 NM_001624 absent in melanoma 1 
KCTD17 0.676 FLJ12242 NM_024681 potassium channel tetramerisation domain containing 17 
PPIAL4 0.675 COAS2 NM_178230 peptidylprolyl isomerase A (cyclophilin A)-like 4 
TRIM9 0.675 RNF91; SPRING; KIAA0282 NM_015163 tripartite motif-containing 9 
ACTR3
B 
0.675 ARP11; ARP3BETA; DKFZp686O24114 NM_020445 ARP3 actin-related protein 3 homolog B (yeast) 
ADAMT
SL1 
0.675 ADAMTSR1; MGC40193 NM_052866 ADAMTS-like 1 
PHLPPL 0.675 KIAA0931 NM_015020 PH domain and leucine rich repeat protein phosphatase-like 
TSC22D
1 
0.675 TSC22; TGFB1I4; MGC17597; RP11-269C23.2; 
DKFZp686O19206 
NM_183422 TSC22 domain family, member 1 
MAN2B
2 
0.674 KIAA0935 NM_015274 mannosidase, alpha, class 2B, member 2 
KIAA05
64 
0.674 KIAA0564; FLJ21779 NM_001009
814 
KIAA0564 protein 
APOM 0.674 G3a; NG20; HSPC336; MGC22400 NM_019101 apolipoprotein M 
VDAC1 0.673 PORIN; MGC111064; PORIN-31-HL NM_003374 voltage-dependent anion channel 1 
NARG1
L 
0.673 MGC40612; RP11-396A22.1 NM_024561 NMDA receptor regulated 1-like 
VKORC
1L1 
0.672 DKFZp762H0113 NM_173517 vitamin K epoxide reductase complex, subunit 1-like 1 
RTP1 0.672 MGC35450 NM_153708 receptor transporter protein 1 
BCL2L1
2 
0.672 MGC120313; MGC120314; MGC120315 NM_138639 BCL2-like 12 (proline rich) 
UBL7 0.672 TCBA1; BMSC-UbP; MGC14421 NM_201265 ubiquitin-like 7 (bone marrow stromal cell-derived) 
OLFM1 0.671 AMY; NOE1; OlfA; NOELIN; NOELIN1; 
NOELIN1_V1; NOELIN1_V2; NOELIN1_V4; 
NOELIN1_V5 
NM_006334 olfactomedin 1 
VWCE 0.671 VWC1; URG11; FLJ32009 NM_152718 von Willebrand factor C and EGF domains 
POLR3
G 
0.671 RPC7; RPC32 NM_006467 polymerase (RNA) III (DNA directed) polypeptide G (32kD) 
LRRC47 0.671 KIAA1185; RP1-286D6.3 NM_020710 leucine rich repeat containing 47 
 255
GNLY 0.671 519; LAG2; NKG5; LAG-2; D2S69E; TLA519; 
lymphokine 
NM_006433 granulysin 
G6PD 0.67 G6PD1 NM_000402 glucose-6-phosphate dehydrogenase 
FBP1 0.67 FBP NM_000507 fructose-1,6-bisphosphatase 1 
CAPN11 0.669 calpain11 NM_007058 calpain 11 
BNC1 0.669 BNC; BSN1; HsT19447 NM_001717 basonuclin 1 
NUP35 0.668 MP44; NP44 NM_138285 nucleoporin 35kDa 
C14ORF
130 
0.668 MGC9518; FLJ10483 NM_018108 chromosome 14 open reading frame 130 
PABPC3 0.668 PABP3; PABPL3 NM_030979 poly(A) binding protein, cytoplasmic 3 





0.667 FLJ41618; MGC45866 NM_152259 chromosome 15 open reading frame 42 
FVT1 0.667 FVT1 NM_002035 follicular lymphoma variant translocation 1 
GLRX2 0.666 GRX2; bA101E13.1 NM_197962 glutaredoxin 2 
HLA-G 0.666 MHC-G NM_002127 HLA-G histocompatibility antigen, class I, G 
FAM46
A 
0.666 XTP11; C6orf37; FLJ20037; FLJ31495 NM_017633 family with sequence similarity 46, member A 
OACT5 0.666 C3F; OACT5; nessy NM_005768 membrane bound O-acyltransferase domain containing 5 
C1ORF1
35 
0.666 MGC2603; FLJ14264 NM_024037 chromosome 1 open reading frame 135 
C12ORF
32 
0.665 HKMT1188; MGC13204 NM_031465 chromosome 12 open reading frame 32 
FAM98
C 
0.665 FLJ44669 NM_174905 family with sequence similarity 98, member C 
IFIH1 0.665 Hlcd; MDA5; MDA-5; IDDM19; MGC133047 NM_022168 interferon induced with helicase C domain 1 
KIAA19
04 
0.664 KIAA1904; dJ63G5.3 NM_052906 KIAA1904 protein 
MPP2 0.664 DLG2; DKFZp686J2189; DKFZp761D0712; 
DKFZp686A06252 
NM_005374 membrane protein, palmitoylated 2 (MAGUK p55 subfamily 
member 2) 
CCNA2 0.664 CCN1; CCNA NM_001237 cyclin A2 
GCN1L1 0.664 GCN1; GCN1L; KIAA0219 NM_006836 GCN1 general control of amino-acid synthesis 1-like 1 (yeast) 
TPX2 0.664 DIL2; p100; DIL-2; HCTP4; FLS353; HCA519; 
REPP86; C20orf1; C20orf2; GD:C20orf1 
NM_012112 TPX2, microtubule-associated, homolog (Xenopus laevis) 
MBNL2 0.663 MBLL; MBLL39; PRO2032; MGC120625; 
MGC120626; MGC120628; DKFZp781H1296; 
RP11-128N14.1 
NM_144778 muscleblind-like 2 (Drosophila) 
SART2 0.663 SART2 NM_013352 squamous cell carcinoma antigen recognized by T cells 2 
RIMS3 0.663 NIM3; RIM3; KIAA0237 NM_014747 regulating synaptic membrane exocytosis 3 
OLIG2 0.662 BHLHB1; OLIGO2; RACK17; PRKCBP2 NM_005806 oligodendrocyte lineage transcription factor 2 
ZNF226 0.662 ZNF226 NM_001032
374 
zinc finger protein 226 
BTN2A2 0.662 BTF2; BT2.2 NM_181531 butyrophilin, subfamily 2, member A2 
MIR16 0.662 MIR16; GDE1; 363E6.2 NM_016641 membrane interacting protein of RGS16 
WDR67 0.661 Gm85; MGC21654; MGC104222; MGC126773; 
MGC138159 
NM_145647 WD repeat domain 67 
ABI3BP 0.661 TARSH; NESHBP; FLJ41743; FLJ41754 NM_015429 ABI gene family, member 3 (NESH) binding protein 
PDXK 0.66 PKH; PNK; C21orf97 NM_003681 pyridoxal (pyridoxine, vitamin B6) kinase 
CCDC25 0.66 CCDC25 NM_001031
708 
synonym: FLJ10853; Homo sapiens coiled-coil domain 
containing 25 (CCDC25), mRNA. 
C1ORF1
12 
0.66 FLJ10706; FLJ13470; MGC130018; MGC130019; 
RP1-97P20.1 
NM_018186 chromosome 1 open reading frame 112 
OSTAL
PHA 
0.66 OSTalpha; MGC39807 NM_152672 organic solute transporter alpha 
PRIM2A 0.66 p58; PRIM2; MGC75142 NM_000947 primase, polypeptide 2A, 58kDa 
LAMB3 0.659 LAMNB1 NM_000228 laminin, beta 3 
AURKC 0.659 AIE2; AIK3; AurC; STK13; aurora-C NM_001015
878 
aurora kinase C 
ELL3 0.659 FLJ22637 NM_025165 elongation factor RNA polymerase II-like 3 
TDP1 0.658 FLJ11090; MGC104252 NM_018319 tyrosyl-DNA phosphodiesterase 1 
HRIHFB
2122 
0.658 TARA; DFNB28; KIAA1662; dJ37E16.4; 
HRIHFB2122 
NM_138632 TRIO and F-actin binding protein 
CARD1
0 
0.658 BIMP1; CARMA3; MGC142219 NM_014550 caspase recruitment domain family, member 10 
LRRC49 0.658 FLJ20156 NM_017691 leucine rich repeat containing 49 
DTYMK 0.658 CDC8; TMPK; TYMK NM_012145 deoxythymidylate kinase (thymidylate kinase) 
OVOL2 0.658 ZNF339; EUROIMAGE566589 NM_021220 ovo-like 2 (Drosophila) 
HIBCH 0.658 HIBYL-COA-H NM_014362 3-hydroxyisobutyryl-Coenzyme A hydrolase 
EDG2 0.657 LPA1; LPAR1; edg-2; vzg-1; Gpcr26; Mrec1.3; 
rec.1.3 
NM_057159 endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 2 
DDEF1 0.657 PAP; PAG2; AMAP1; ASAP1; ZG14P; 
KIAA1249 
NM_018482 development and differentiation enhancing factor 1 
LANCL
1 
0.657 p40; GPR69A NM_006055 LanC lantibiotic synthetase component C-like 1 (bacterial) 
SACS 0.657 ARSACS; DKFZp686B15167 NM_014363 spastic ataxia of Charlevoix-Saguenay (sacsin) 
DNAJA
3 
0.656 TID1; hTid-1 NM_005147 DnaJ (Hsp40) homolog, subfamily A, member 3 
RAD54
B 
0.656 FSBP NM_012415 RAD54 homolog B (S. cerevisiae) 
UNQ194
0 
0.656 UNQ1940 NM_205855 HWKM1940 
ZWILC
H 
0.655 KNTC1AP; hZwilch; FLJ10036; FLJ16343; 
MGC111034 
NM_017975 Zwilch, kinetochore associated, homolog (Drosophila) 
WDR51
A 
0.655 MGC131902; DKFZP434C245 NM_015426 WD repeat domain 51A 
SNTB2 0.655 SNT3; SNTL; SNT2B2; EST25263; D16S2531E NM_006750 syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, 
basic component 2) 
ABL1 0.655 ABL; JTK7; p150; c-ABL; v-abl NM_007313 v-abl Abelson murine leukemia viral oncogene homolog 1 
IRX4 0.654 MGC131996 NM_016358 iroquois homeobox protein 4 
ZSCAN
2 
0.654 ZFP29; FLJ20595 NM_001007
072 
zinc finger and SCAN domain containing 2 
CRIM1 0.654 S52; MGC138194 NM_016441 cysteine rich transmembrane BMP regulator 1 (chordin-like) 
DNMT1 0.654 DNMT; MCMT; CXXC9; FLJ16293; 
MGC104992 
NM_001379 DNA (cytosine-5-)-methyltransferase 1 




0.654 CGI-67; RP11-409O11.2 NM_001025
780 
chromosome 9 open reading frame 77 
CD83 0.653 BL11; HB15 NM_004233 CD83 molecule 
ATG4C 0.653 APG4C; AUTL1; AUTL3; APG4-C; FLJ14867 NM_032852 ATG4 autophagy related 4 homolog C (S. cerevisiae) 
DUSP23 0.653 VHZ; LDP-3; DUSP25; FLJ20442; RP11-
190A12.1 
NM_017823 dual specificity phosphatase 23 
ANKRD
28 
0.653 PITK; KIAA0379 NM_015199 ankyrin repeat domain 28 
RAC1 0.653 MIG5; TC-25; p21-Rac1; MGC111543 NM_018890 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP 
binding protein Rac1) 
CTH 0.653 MGC9471 NM_153742 cystathionase (cystathionine gamma-lyase) 
SPON1 0.652 KIAA0762; MGC10724; f-spondin NM_006108 spondin 1, extracellular matrix protein 
TPP1 0.652 CLN2; GIG1; LINCL; TPP I; TPP-I NM_000391 tripeptidyl peptidase I 
EIF2S1 0.652 EIF2; EIF-2; EIF2A; EIF-2A; EIF-2alpha NM_004094 eukaryotic translation initiation factor 2, subunit 1 alpha, 35kDa 
SORT1 0.651 NT3; Gp95 NM_002959 sortilin 1 
HADHA 0.651 GBP; HADH; MTPA; LCHAD; MGC1728; TP-
ALPHA 
NM_000182 hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme 
A thiolase/enoyl-Coenzyme A hydratase (trifunctional protein), 
alpha subunit 
GALK2 0.651 GK2; MGC1745 NM_001001
556 
galactokinase 2 





ASAH1 0.65 AC; PHP; ASAH; PHP32; FLJ21558; FLJ22079 NM_177924 N-acylsphingosine amidohydrolase (acid ceramidase) 1 
PVRL1 0.65 ED4; PRR; HIgR; HVEC; OFC7; PRR1; PVRR; 
CD111; PVRR1; SK-12; CLPED1; MGC16207; 
nectin-1; MGC142031 
NM_203286 poliovirus receptor-related 1 (herpesvirus entry mediator C; 
nectin) 
BTN3A1 0.65 BTF5; BT3.1; CD277 NM_007048 butyrophilin, subfamily 3, member A1 
AP3B1 0.65 PE; HPS; HPS2; ADTB3; ADTB3A NM_003664 adaptor-related protein complex 3, beta 1 subunit 
SCARA
3 
0.649 CSR; APC7; CSR1; MSLR1; MSRL1 NM_182826 scavenger receptor class A, member 3 
SYDE1 0.649 7h3; FLJ13511 NM_033025 synapse defective 1, Rho GTPase, homolog 1 (C. elegans) 
JPH1 0.649 JP1; JP-1; DKFZp762L0313 NM_020647 junctophilin 1 
CD164 0.649 MGC-24; MUC-24; endolyn NM_006016 CD164 molecule, sialomucin 
ALDH1
A1 
0.649 ALDC; ALDH1; PUMB1; ALDH11; RALDH1; 
ALDH-E1; MGC2318 
NM_000689 aldehyde dehydrogenase 1 family, member A1 
PLK4 0.648 SAK; STK18 NM_014264 polo-like kinase 4 (Drosophila) 
PVRL1 0.648 ED4; PRR; HIgR; HVEC; OFC7; PRR1; PVRR; 
CD111; PVRR1; SK-12; CLPED1; MGC16207; 
nectin-1; MGC142031 




0.647 FLJ25053 NM_173505 ankyrin repeat domain 29 
SNAPC5 0.647 SNAP19 NM_006049 small nuclear RNA activating complex, polypeptide 5, 19kDa 
FOXRE
D1 
0.646 H17; FP634 NM_017547 FAD-dependent oxidoreductase domain containing 1 
HERC6 0.645 FLJ20637 NM_001013
005 
hect domain and RLD 6 
KLF10 0.645 EGRA; TIEG; TIEG1 NM_005655 Kruppel-like factor 10 
FLJ1128
6 
0.645 FLJ11286; FLJ40743 NM_018381 hypothetical protein FLJ11286 
MCM6 0.644 Mis5; P105MCM; MCG40308 NM_005915 MCM6 minichromosome maintenance deficient 6 (MIS5 
homolog, S. pombe) (S. cerevisiae) 
TRMT1 0.644 FLJ20244 NM_017722 TRM1 tRNA methyltransferase 1 homolog (S. cerevisiae) 
PLA2G3 0.644 GIII-SPLA2 NM_015715 phospholipase A2, group III 
MANSC
1 
0.644 FLJ10298; LOH12CR3; 9130403P13Rik NM_018050 MANSC domain containing 1 
UNC5D 0.644 Unc5h4; FLJ16019; KIAA1777; PRO34692 NM_080872 unc-5 homolog D (C. elegans) 
LRRC15 0.644 LIB NM_130830 leucine rich repeat containing 15 
PUS1 0.643 MLASA; MGC11268 NM_025215 pseudouridylate synthase 1 
PXN 0.643 FLJ16691 NM_002859 paxillin 
C18ORF
54 
0.642 MGC33382 NM_173529 chromosome 18 open reading frame 54 
BCOR 0.642 MAA2; ANOP2; MCOPS2; FLJ20285; FLJ38041; 
KIAA1575; MGC71031; MGC131961 
NM_017745 BCL6 co-repressor 
OSAP 0.642 OSAP; MGC125827; MGC125828 NM_032623 ovary-specific acidic protein 
KIAA09
71 
0.642 KIAA0971 NM_014929 FAST kinase domains 2 
ETV5 0.641 ERM NM_004454 ets variant gene 5 (ets-related molecule) 
RIN1 0.641 RIN1 NM_004292 Ras and Rab interactor 1 
CCNE1 0.641 CCNE NM_001238 cyclin E1 
SYNGR
1 
0.641 MGC:1939 NM_145738 synaptogyrin 1 
SLC41A
1 
0.641 MgtE NM_173854 solute carrier family 41, member 1 
PPM1G 0.64 PP2CG; PPP2CG; MGC1675; MGC2870; 
PP2CGAMMA 
NM_002707 protein phosphatase 1G (formerly 2C), magnesium-dependent, 
gamma isoform 
FBL 0.64 FIB; FLRN; RNU3IP1 NM_001436 fibrillarin 
GPR23 0.64 P2Y9; LPAR4; P2RY9; P2Y5-LIKE NM_005296 G protein-coupled receptor 23 
LIAS 0.64 LAS; LIP1; HUSSY-01; MGC23245 NM_006859 lipoic acid synthetase 
HLA-
DMB 
0.639 RING7; D6S221E NM_002118 major histocompatibility complex, class II, DM beta 
SNX5 0.639 FLJ10931 NM_014426 sorting nexin 5 
DNAJC1
2 
0.639 JDP1; RP11-57G10.2 NM_021800 DnaJ (Hsp40) homolog, subfamily C, member 12 
SLITL2 0.638 SLITL2 NM_138440 vasorin 
STK4 0.638 KRS2; MST1; YSK3; DKFZp686A2068 NM_006282 serine/threonine kinase 4 
NOP5/N
OP58 
0.638 NOP5/NOP58; HSPC120 NM_015934 nucleolar protein NOP5/NOP58 
PLAC9 0.638 MGC104710 NM_001012
973 
placenta-specific 9 
LARS 0.638 LRS; LEUS; LARS1; LEURS; PIG44; RNTLS; 
HSPC192; hr025Cl; FLJ10595; FLJ21788 
NM_020117 leucyl-tRNA synthetase 
MMP25 0.638 MMP20; MT-MMP6; MT6-MMP NM_022718 matrix metallopeptidase 25 
IGSF21 0.638 MGC15730; RP11-121A23.1 NM_032880 immunoglobin superfamily, member 21 
SRP46 0.637 SRP46 NM_032102 splicing factor, arginine/serine-rich 2B 
C16ORF
58 




0.636 FAM31D; KIAA1277 NM_015689 DENN/MADD domain containing 2A 
RHEBL
1 
0.636 RHEBL1c; FLJ25797; MGC34869 NM_144593 Ras homolog enriched in brain like 1 
SPIB 0.635 SPI-B NM_003121 Spi-B transcription factor (Spi-1/PU.1 related) 
RNF175 0.635 FLJ34190 NM_173662 ring finger protein 175 
TNS3 0.634 TEM6; TENS1; FLJ13732; FLJ35545; 
MGC88434; H_NH049I23.2; DKFZp686M1045 
NM_022748 tensin 3 
PIGS 0.634 FLJ45226; DKFZp686K20216 NM_033198 phosphatidylinositol glycan anchor biosynthesis, class S 
GFOD1 0.634 C6orf114 NM_018988 glucose-fructose oxidoreductase domain containing 1 




0.633 TMEM24L; MGC71445; C21orf258; 
DKFZp686O198; DKFZP586F0422 
NM_199050 chromosome 21 open reading frame 25 
UQCRH 0.633 MGC111572 NM_006004 ubiquinol-cytochrome c reductase hinge protein 
PPRC1 0.632 PRC; KIAA0595; MGC74642; RP11-302K17.6 NM_015062 peroxisome proliferative activated receptor, gamma, coactivator-
related 1 
PPIL1 0.632 CYPL1; hCyPX; MGC678; PPIase; CGI-124 NM_016059 peptidylprolyl isomerase (cyclophilin)-like 1 
AGA 0.632 GA; AGU; ASRG NM_000027 aspartylglucosaminidase 
KIAA05
86 
0.632 Talpid3 NM_014749 KIAA0586 
CCT4 0.632 SRB; Cctd; MGC126164; MGC126165 NM_006430 chaperonin containing TCP1, subunit 4 (delta) 
PSMF1 0.631 PI31 NM_178578 proteasome (prosome, macropain) inhibitor subunit 1 (PI31) 
PELP1 0.631 HMX3; MNAR; P160 NM_014389 proline, glutamic acid and leucine rich protein 1 
ANKRA
2 
0.631 ANKRA NM_023039 ankyrin repeat, family A (RFXANK-like), 2 
SLC27A
1 
0.631 FATP; FATP1; ACSVL5; FLJ00336; MGC71751 NM_198580 solute carrier family 27 (fatty acid transporter), member 1 
E2F2 0.63 E2F-2 NM_004091 E2F transcription factor 2 
KIF15 0.63 HKLP2; KNSL7; FLJ25667; NY-BR-62 NM_020242 kinesin family member 15 
EIF5B 0.63 IF2; FLJ10524; KIAA0741; DKFZp434I036 NM_015904 eukaryotic translation initiation factor 5B 
METAP
1 
0.63 KIAA0094; DKFZp781C0419 NM_015143 methionyl aminopeptidase 1 
LRRC17 0.63 P37NB NM_001031
692 
leucine rich repeat containing 17 
VARS 0.63 G7A; VARS2 NM_006295 valyl-tRNA synthetase 
C6ORF1
68 
0.629 MGC2817; dJ273F20 NM_032511 chromosome 6 open reading frame 168 
FLJ1171
2 
0.629 AGS2; DLEU8; FLJ11712 NM_024570 ribonuclease H2, subunit B 
METTL
3 
0.629 M6A; Spo8; MT-A70; MGC4336 NM_019852 methyltransferase like 3 
ITGB1B
P1 
0.629 ICAP1; ICAP1A; ICAP1B; ICAP-1A; ICAP-1B; 
DKFZp686K08158 
NM_022334 integrin beta 1 binding protein 1 
KIAA12
74 
0.628 PALD NM_014431 KIAA1274 
PRKCH 0.628 PKCL; PKC-L; PRKCL; MGC5363; MGC26269; 
nPKC-eta 
NM_006255 protein kinase C, eta 
TATDN
1 
0.628 CDA11 NM_032026 TatD DNase domain containing 1 
ARMCX
2 
0.628 ALEX2; MGC8742; KIAA0512; MGC13343 NM_177949 armadillo repeat containing, X-linked 2 
C12ORF
52 
0.627 FLJ14827 NM_032848 chromosome 12 open reading frame 52 
TCEAL1 0.627 p21; SIIR; pp21 NM_004780 transcription elongation factor A (SII)-like 1 
CACNA
1F 





similar to F-box only protein 2 
UNG 0.626 DGU; UDG; UNG1; HIGM4; UNG15; 
DKFZp781L1143 
NM_080911 uracil-DNA glycosylase 
TMEM9
B 
0.624 C11orf15 NM_020644 TMEM9 domain family, member B 
TRIM47 0.624 GOA; RNF100 NM_033452 tripartite motif-containing 47 
MGC13
114 
0.624 MGC13114; JFP2 NM_032366 hypothetical protein MGC13114 
FLJ4298
6 
0.624   NM_207403   
COQ2 0.623 CL640; FLJ26072 NM_015697 coenzyme Q2 homolog, prenyltransferase (yeast) 
NCOR2 0.623 SMRT; CTG26; SMRTE; TRAC1; TNRC14; 
TRAC-1; SMRTE-tau 
NM_006312 nuclear receptor co-repressor 2 
PPIL5 0.623 LRR-1; 4-1BBLRR; MGC20689 NM_152329 peptidylprolyl isomerase (cyclophilin)-like 5 
LOC571
46 
0.623 TMEM159 NM_020422 transmembrane protein 159 
MFNG 0.622 MFNG NM_002405 manic fringe homolog (Drosophila) 
DNAJC1
2 
0.622 JDP1; RP11-57G10.2 NM_201262 DnaJ (Hsp40) homolog, subfamily C, member 12 
CEBPA 0.622 CEBP; C/EBP-alpha NM_004364 CCAAT/enhancer binding protein (C/EBP), alpha 
FUT4 0.622 CD15; ELFT; FCT3A; FUC-TIV NM_002033 fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-
specific) 
PDCD2 0.621 RP8; ZMYND7; MGC12347 NM_144781 programmed cell death 2 
RAB38 0.621 rrGTPbp; NY-MEL-1 NM_022337 RAB38, member RAS oncogene family 
CDX4 0.62 CDX4 NM_005193 caudal type homeobox transcription factor 4 
MYLIP 0.62 MIR NM_013262 myosin regulatory light chain interacting protein 
ENPP2 0.619 ATX; NPP2; ATX-X; PDNP2; LysoPLD; 
FLJ26803; PD-IALPHA 
NM_006209 ectonucleotide pyrophosphatase/phosphodiesterase 2 (autotaxin) 
C14ORF
4 
0.619 IRF2BPL; KIAA1865 NM_024496 chromosome 14 open reading frame 4 
EPB41L
4B 
0.619 CG1; EHM2; FLJ21596; DKFZp761N1814 NM_018424 erythrocyte membrane protein band 4.1 like 4B 
SOD2 0.619 IPO-B; MNSOD; Mn-SOD NM_000636 superoxide dismutase 2, mitochondrial 
C1ORF7
1 
0.617 FLJ32001; MGC18089; RP11-452J6.1 NM_152609 chromosome 1 open reading frame 71 
SNAP23 0.617 SNAP23A; SNAP23B; HsT17016 NM_003825 synaptosomal-associated protein, 23kDa 
CCDC77 0.617 MGC13183 NM_032358 coiled-coil domain containing 77 
MST150 0.617 MST150; NID67; MGC117221; MGC126887; NM_032947 MSTP150 
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MGC126889 
PINK1 0.616 BRPK; PARK6; FLJ27236 NM_032409 PTEN induced putative kinase 1 
ZNF323 0.616 ZNF310P; FLJ23407; ZNF20-Lp; dJ874C20.2 NM_145909 zinc finger protein 323 
LAMC2 0.616 B2T; EBR2; BM600; EBR2A; LAMB2T; 
LAMNB2; MGC138491; MGC141938 
NM_018891 laminin, gamma 2 
FLJ2194
5 
0.616 PP384; FLJ21945 NM_025203 chromosome 2 open reading frame 44 
C10ORF
77 
0.616 FLJ22529; bA18I14.8; RP11-18I14.8 NM_024789 chromosome 10 open reading frame 77 
PCDH11
X 
0.615 PCDHX; PCDHY; PCDH-X; PCDH11 NM_032967 protocadherin 11 X-linked 
PODXL
2 
0.615 PODLX2 NM_015720 podocalyxin-like 2 
ATP6V1
E2 
0.614 VMA4; ATP6E1; ATP6EL2; MGC9341; 
ATP6V1EL2 
NM_080653 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E2 
CCNH 0.613 CAK; p34; p37 NM_001239 cyclin H 
EXT2 0.613 SOTV NM_000401 exostoses (multiple) 2 
OCRL 0.613 LOCR; NPHL2; OCRL1; INPP5F NM_000276 oculocerebrorenal syndrome of Lowe 
SURF6 0.613 FLJ30322 NM_006753 surfeit 6 
ELP3 0.612 FLJ10422 NM_018091 elongation protein 3 homolog (S. cerevisiae) 
ANGEL
1 
0.612 KIAA0759 NM_015305 angel homolog 1 (Drosophila) 
SLC25A
21 
0.612 ODC; ODC1; MGC126570 NM_030631 solute carrier family 25 (mitochondrial oxodicarboxylate carrier), 
member 21 
DIXDC1 0.611 CCD1; KIAA1735 NM_033425 DIX domain containing 1 
STC2 0.611 STC-2; STCRP NM_003714 stanniocalcin 2 
ADCY9 0.611 HLA-DRB1 NM_001116 adenylate cyclase 9 
PIGB 0.61 MGC21236 NM_004855 phosphatidylinositol glycan anchor biosynthesis, class B 
ST8SIA
5 
0.61 SIAT8E; ST8Sia V; MGC119670; MGC119671 NM_013305 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 
LOC221
955 
0.61 DAGLBETA; KCCR13L NM_139179 diacylglycerol lipase beta 
MRPL4 0.61 L4mt; CGI-28; MGC2681; MGC16367 NM_015956 mitochondrial ribosomal protein L4 
TXLNA 0.609 TXLN; MGC118870; MGC118871; RP4-622L5.4; 
DKFZp451J0118 
NM_175852 taxilin alpha 
DEF6 0.609 IBP NM_022047 differentially expressed in FDCP 6 homolog (mouse) 
FAM43
B 
0.609 FLJ44952 NM_207334 family with sequence similarity 43, member B 
CENTD
3 
0.609 ARAP3; DRAG1; FLJ21065 NM_022481 centaurin, delta 3 
LARGE 0.609 MDC1D; KIAA0609 NM_004737 like-glycosyltransferase 
C1ORF1
87 
0.609 UNQ3119; AGPA3119; FLJ34999; MGC117222 NM_198545 chromosome 1 open reading frame 187 
SVIL 0.609 DKFZp686A17191 NM_003174 supervillin 
CHAC1 0.608 MGC4504 NM_024111 ChaC, cation transport regulator-like 1 (E. coli) 
SFRS10 0.608 TRA2B; SRFS10; TRA2-BETA; Htra2-beta; 
DKFZp686F18120 
NM_004593 splicing factor, arginine/serine-rich 10 (transformer 2 homolog, 
Drosophila) 
TFF3 0.608 ITF; TFI; HITF; hP1.B NM_003226 trefoil factor 3 (intestinal) 
ARHGA
P11A 
0.608 KIAA0013; MGC70740; GAP (1-12) NM_199357 Rho GTPase activating protein 11A 
FLJ1398
4 
0.608 TIP; FLJ13984; FLJ42098 NM_024770 methyltransferase like 8 
MPDZ 0.608 MUPP1; FLJ25909; FLJ34626; FLJ90240; 
DKFZp781P216 
NM_003829 multiple PDZ domain protein 
IMP3 0.608 BRMS2; MRPS4; C15orf12; FLJ10968; 
DKFZp586L0118 
NM_018285 IMP3, U3 small nucleolar ribonucleoprotein, homolog (yeast) 
USP9X 0.608   NM_004652   
RRM1 0.607 R1; RR1; RIR1 NM_001033 ribonucleotide reductase M1 polypeptide 
C12ORF
62 
0.607 MGC14288 NM_032901 chromosome 12 open reading frame 62 
LSM6 0.607 YDR378C NM_007080 LSM6 homolog, U6 small nuclear RNA associated (S. cerevisiae) 
M6PR 0.607 SMPR; MPR46; CD-MPR NM_002355 mannose-6-phosphate receptor (cation dependent) 
WRN 0.606 RECQ3; RECQL2; RECQL3; DKFZp686C2056 NM_000553 Werner syndrome 
AURKA
IP1 
0.606 AIP; AKIP; FLJ20608 NM_017900 aurora kinase A interacting protein 1 
CCDC34 0.606 L15; RAMA3; NY-REN-41 NM_030771 coiled-coil domain containing 34 
NXT2 0.606 P15-2 NM_018698 nuclear transport factor 2-like export factor 2 
ULBP2 0.606 N2DL2; RAET1H NM_025217 UL16 binding protein 2 
DLST 0.606 DLTS NM_001933 dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-
glutarate complex) 
RIC8B 0.605 RIC8; hSyn; FLJ10620; MGC39476 NM_018157 resistance to inhibitors of cholinesterase 8 homolog B (C. 
elegans) 
CYB5A 0.605 CYB5; MCB5 NM_148923 cytochrome b5 type A (microsomal) 
NRK 0.604 NESK; FLJ16788; MGC131849; 
DKFZp686A17109 
NM_198465 Nik related kinase 
NUP155 0.604 N155; KIAA0791 NM_004298 nucleoporin 155kDa 
ARL1 0.603 ARFL1 NM_001177 ADP-ribosylation factor-like 1 
NGLY1 0.602 PNG1; FLJ11005; FLJ12409 NM_018297 N-glycanase 1 
IGSF1 0.601 IGCD1; IGDC1; INHBP; PGSF2; KIAA0364; 
MGC75490 
NM_205833 immunoglobulin superfamily, member 1 
ACAD1
0 
0.601 MGC5601 NM_025247 acyl-Coenzyme A dehydrogenase family, member 10 
UAP1 0.601 AgX; AGX1; SPAG2 NM_003115 UDP-N-acteylglucosamine pyrophosphorylase 1 
IGSF1 0.601 IGCD1; IGDC1; INHBP; PGSF2; KIAA0364; 
MGC75490 
NM_001555 immunoglobulin superfamily, member 1 
C14ORF
29 
0.6 c14_5314; MGC129926; MGC129927 NM_181533 chromosome 14 open reading frame 29 
TBC1D8 0.6 AD3; VRP; HBLP1 NM_007063 TBC1 domain family, member 8 (with GRAM domain) 
WDR35 0.6 KIAA1336; MGC33196 NM_001006
657 
WD repeat domain 35 
CRYBA
4 
0.6 KLK4 NM_001886 crystallin, beta A4 
PCSK1N 0.6 SAAS; PROSAAS NM_013271 proprotein convertase subtilisin/kexin type 1 inhibitor 
RAB3C 0.6 RAB3C NM_138453 RAB3C, member RAS oncogene family 
KCNJ2 0.599 IRK1; LQT7; SQT3; HHIRK1; KIR2.1; HHBIRK1 NM_000891 potassium inwardly-rectifying channel, subfamily J, member 2 
PDPR 0.599 PDPR; FLJ10079; DKFZp686A088; NM_017990 pyruvate dehydrogenase phosphatase regulatory subunit 
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DKFZp686D16130 
ACBD6 0.598 MGC2404 NM_032360 acyl-Coenzyme A binding domain containing 6 
DPH2 0.597 DPH2L2 NM_001384 DPH2 homolog (S. cerevisiae) 
PCMTD
1 
0.597 FLJ10883 NM_052937 protein-L-isoaspartate (D-aspartate) O-methyltransferase domain 
containing 1 
GFM1 0.597 EFG; GFM; EFG1; EFGM; EGF1; hEFG1; 
FLJ12662; FLJ13632; FLJ20773 
NM_024996 G elongation factor, mitochondrial 1 
TOR1B 0.597 DQ1; MGC4386 NM_014506 torsin family 1, member B (torsin B) 
GCNT2 0.596 II; IGNT; ULG3; GCNT5; GCNT2C; NACGT1; 
NAGCT1; bA421M1.1; bA360O19.2 




0.595 FLJ32906 NM_145263 spermatogenesis associated 18 homolog (rat) 
NIP7 0.595 KD93; CGI-37; HSPC031; FLJ10296 NM_016101 nuclear import 7 homolog (S. cerevisiae) 
KIAA04
06 
0.595 ABHD2 NM_014657 KIAA0406 
SIAE 0.595 LSE; YSG2; CSE-C; MGC87009 NM_170601 sialic acid acetylesterase 
KDELC
1 
0.595 EP58; KDEL1; MGC5302 NM_024089 KDEL (Lys-Asp-Glu-Leu) containing 1 
POPDC3 0.594 POP3; MGC22671; bA355M14.1 NM_022361 popeye domain containing 3 
IKIP 0.593 IKIP; FLJ31051 NM_201612 IKK interacting protein 
ETV5 0.593 ERM NM_004454 ets variant gene 5 (ets-related molecule) 
TBPL1 0.593 TLF; TLP; STUD; TRF2; MGC:8389; MGC:9620 NM_004865 TBP-like 1 
CDCA5 0.592 MGC16386 NM_080668 cell division cycle associated 5 
PTP4A1 0.592 HH72; PRL1; PRL-1; PTPCAAX1; PTP(CAAX1); 
DKFZp779M0721 
NM_003463 protein tyrosine phosphatase type IVA, member 1 
EDG7 0.592 GPCR; LPA3; Edg-7; LP-A3; LPAR3; HOFNH30; 
RP4-678I3 
NM_012152 endothelial differentiation, lysophosphatidic acid G-protein-
coupled receptor, 7 
STAT1 0.592 ISGF-3; STAT91; DKFZp686B04100 NM_007315 signal transducer and activator of transcription 1, 91kDa 
FAM54
A 
0.592 DUFD1 NM_138419 family with sequence similarity 54, member A 
PEMT 0.592 PNMT; PEAMT; PEMPT; PEMT2; MGC2483 NM_148173 phosphatidylethanolamine N-methyltransferase 
HSPC19
6 
0.591 HSPC196 NM_016464 transmembrane protein 138 
CRYGD 0.591 CACA; CCA3; CRYG4; cry-g-D NM_006891 crystallin, gamma D 
PTRH1 0.591 PTH1; C9orf115; MGC51999 NM_001002
913 
peptidyl-tRNA hydrolase 1 homolog (S. cerevisiae) 
EBI2 0.59 SGCE NM_004951 Epstein-Barr virus induced gene 2 (lymphocyte-specific G 
protein-coupled receptor) 
RPL13 0.59 BBC1; D16S444E; FLJ27453; FLJ27454; 
MGC71373; MGC117342 
NM_033251 ribosomal protein L13 
AIF1 0.59 IBA1; AIF-1; IRT-1 NM_001623 allograft inflammatory factor 1 
WDR42
A 
0.59 H326; FLJ35857; MGC99640; MGC117276; 
MGC118891; DKFZp781G1096 
NM_015726 WD repeat domain 42A 
TNKS1
BP1 
0.59 TAB182; FLJ45975; KIAA1741 NM_033396 tankyrase 1 binding protein 1, 182kDa 
MARVE
LD3 
0.589 MARVD3; MRVLDC3; FLJ32280 NM_052858 MARVEL domain containing 3 
RFWD3 0.588 RNF201; FLJ10520 NM_018124 ring finger and WD repeat domain 3 
TTLL12 0.588 FLJ41795; KIAA0153; dJ526I14.2 NM_015140 tubulin tyrosine ligase-like family, member 12 
MLKL 0.588 FLJ34389 NM_152649 mixed lineage kinase domain-like 
CTSL 0.588 MEP; CATL; FLJ31037 NM_001912 cathepsin L 
ASS 0.588 ASS; CTLN1 NM_054012 argininosuccinate synthetase 1 
FRAG1 0.588 FRAG1; PGAP2; MGC799 NM_014489 FGF receptor activating protein 1 
TCP1 0.588 CCT1; CCTa; D6S230E; CCT-alpha; TCP-1-alpha NM_030752 t-complex 1 
C6ORF7
2 
0.587 dJ12G14.2 NM_138785 chromosome 6 open reading frame 72 
RASAL
2 
0.587 nGAP; MGC129919 NM_170692 RAS protein activator like 2 
IRF1 0.587 MAR; IRF-1 NM_002198 interferon regulatory factor 1 
NPAS1 0.586 MOP5; PASD5 NM_002517 neuronal PAS domain protein 1 
C20ORF
103 
0.585 C20orf103 NM_012261 chromosome 20 open reading frame 103 
RNF150 0.585 MGC125502 NM_020724 ring finger protein 150 
SCRL 0.585 SCRL; MGC33947; PLAL6978; PRO21961 NM_152358 chromosome 19 open reading frame 41 
PPAP2C 0.584 LPP2; PAP-2c; PAP2-g NM_177543 phosphatidic acid phosphatase type 2C 
LGP2 0.584 LGP2; D11lgp2e NM_024119 likely ortholog of mouse D11lgp2 
PDCD1
LG2 
0.584 B7DC; Btdc; PDL2; CD273; PD-L2; PDCD1L2; 
MGC142238; MGC142240; bA574F11.2 
NM_025239 programmed cell death 1 ligand 2 
NOMO2 0.584 PM5; Nomo NM_173614 NODAL modulator 2 
FAM8A
1 
0.584 AHCP; FLJ23721 NM_016255 family with sequence similarity 8, member A1 
C19ORF
19 
0.583 FLJ40059; MGC129962; MGC129963 NM_182577 chromosome 19 open reading frame 19 
MARVE
LD3 
0.583 MARVD3; MRVLDC3; FLJ32280 NM_001017
967 
MARVEL domain containing 3 
TNFRSF
10D 
0.583 DCR2; CD264; TRUNDD; TRAILR4 NM_003840 tumor necrosis factor receptor superfamily, member 10d, decoy 
with truncated death domain 
IFI30 0.583 GILT; IP30; IFI-30; MGC32056 NM_006332 interferon, gamma-inducible protein 30 
C14ORF
94 
0.582 FLJ20424 NM_017815 chromosome 14 open reading frame 94 
THBD 0.582 TM; THRM; CD141 NM_000361 thrombomodulin 
LRP16 0.582 LRP16 NM_014067 LRP16 protein 
PPA1 0.581 PP; PP1; IOPPP; MGC111556; SID6-8061 NM_021129 pyrophosphatase (inorganic) 1 
AP3M2 0.581 P47B; AP47B; CLA20 NM_006803 adaptor-related protein complex 3, mu 2 subunit 
MGC17
624 
0.581 MGC17624 NM_206967 chromosome 16 open reading frame 74 
WDR36 0.581 GLC1G; UTP21; TAWDRP; TA-WDRP; 
DKFZp686I1650 
NM_139281 WD repeat domain 36 
ENPP5 0.58 KIAA0879 NM_021572 ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative 
function) 
EYA3 0.58   NM_172098   
C9ORF4
5 
0.58   NM_030814   
LRRFIP
2 
0.58 HUFI-2; FLJ20248; FLJ22683; DKFZp434H2035 NM_017724 leucine rich repeat (in FLII) interacting protein 2 
BACE2 0.579 ASP1; BAE2; DRAP; AEPLC; ALP56; ASP21; NM_012105 beta-site APP-cleaving enzyme 2 
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CDA13; CEAP1 
TAP2 0.578 APT2; PSF2; ABC18; ABCB3; RING11; 
D6S217E 
NM_018833 transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 
C14ORF
93 
0.578 FLJ12154 NM_021944 chromosome 14 open reading frame 93 
C21ORF
63 
0.578 B18; SUE21; PRED34 NM_058187 chromosome 21 open reading frame 63 
TNFRSF
12A 
0.577 FN14; CD266; TWEAKR NM_016639 tumor necrosis factor receptor superfamily, member 12A 
ATP6V0
E2L 
0.577 C7orf32 NM_145230 ATPase, H+ transporting V0 subunit E2-like (rat) 
CSPG2 0.577 VERSICAN; DKFZp686K06110 NM_004385 chondroitin sulfate proteoglycan 2 (versican) 
CHRNA
5 
0.577 CHRNA5 NM_000745 cholinergic receptor, nicotinic, alpha 5 
EXOSC
7 
0.576 p8; EAP1; RRP42; Rrp42p; hRrp42p; FLJ26543; 
KIAA0116 
NM_015004 exosome component 7 
MULK 0.576 AGK; FLJ10842 NM_018238 multiple substrate lipid kinase 
VAV1 0.576 VAV NM_005428 vav 1 oncogene 
APP 0.576 AAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; 
CTFgamma 
NM_000484 amyloid beta (A4) precursor protein (peptidase nexin-II, 
Alzheimer disease) 
RRS1 0.576 KIAA0112 NM_015169 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 
MRPL3 0.575 MRL3; RPML3 NM_007208 mitochondrial ribosomal protein L3 
DKC1 0.575 DKC; NAP57; NOLA4; XAP101; dyskerin NM_001363 dyskeratosis congenita 1, dyskerin 
LOC112
937 
0.574   NM_138416   
TTF2 0.573 HuF2 NM_003594 transcription termination factor, RNA polymerase II 
TACC2 0.573 AZU-1; ECTACC NM_006997 transforming, acidic coiled-coil containing protein 2 
KCNQ2 0.573 EBN; BFNC; EBN1; ENB1; HNSPC; KV7.2; 
KCNA11; KVEBN1 
NM_172109 potassium voltage-gated channel, KQT-like subfamily, member 2 
BCL11A 0.573 EVI9; CTIP1; BCL11A-L; BCL11A-S; FLJ10173; 
FLJ34997; KIAA1809; BCL11A-XL 
NM_022893 B-cell CLL/lymphoma 11A (zinc finger protein) 
GCDH 0.573 GCD; ACAD5 NM_013976 glutaryl-Coenzyme A dehydrogenase 
KIAA18
04 
0.573 KIAA1804; MLK4; dJ862P8.3; RP5-862P8.2 NM_032435 mixed lineage kinase 4 
FUCA1 0.573 G6PD NM_000147 fucosidase, alpha-L- 1, tissue 
KATNB
1 
0.571 KAT NM_005886 katanin p80 (WD repeat containing) subunit B 1 
CLIC4 0.571 H1; huH1; p64H1; CLIC4L; FLJ38640; 
DKFZP566G223 
NM_013943 chloride intracellular channel 4 
FAT 0.571 ME5; FAT1; CDHF7; hFat1 NM_005245 FAT tumor suppressor homolog 1 (Drosophila) 
MRPS35 0.571 MDS023; MRPS28; MRP-S28; HDCMD11P; 
MGC104278; DKFZp762P093 
NM_021821 mitochondrial ribosomal protein S35 
HNRPD
L 
0.571 HNRNP; JKTBP; JKTBP2; laAUF1 NM_031372 heterogeneous nuclear ribonucleoprotein D-like 
CLN5 0.571 NCL; FLJ90628 NM_006493 ceroid-lipofuscinosis, neuronal 5 
PSD3 0.571 EFA6R; HCA67; DKFZp761K1423 NM_206909 pleckstrin and Sec7 domain containing 3 
COQ3 0.571 bA9819.1; UG0215E05 NM_017421 coenzyme Q3 homolog, methyltransferase (S. cerevisiae) 
PARP14 0.571 BAL2; KIAA1268 NM_017554 poly (ADP-ribose) polymerase family, member 14 
MLLT7 0.571 AFX; AFX1; FOXO4; MGC120490 NM_005938 myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 7 
SDF4 0.571 Cab45; RP5-902P8.6 NM_016547 stromal cell derived factor 4 
FLJ1098
6 
0.571 FLJ10986; RP11-242B9.1 NM_018291 hypothetical protein FLJ10986 
HADHS
C 
0.57 HAD; HHF4; HADH1; SCHAD; HADHSC; 
M/SCHAD; MGC8392 
NM_005327 hydroxyacyl-Coenzyme A dehydrogenase 
FLJ4590
9 
0.57 FLJ45909; FLJ44131 NM_198445 FLJ45909 protein 
BUB3 0.569 BUB3L; hBUB3 NM_004725 BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) 
MGC32
07 
0.568 MGC3207 NM_032285 hypothetical protein MGC3207 
COQ9 0.568 C16orf49; DKFZP434K046 NM_020312 coenzyme Q9 homolog (S. cerevisiae) 
SEMA4
B 
0.568 SemC; SEMAC; KIAA1745; MGC131831 NM_020210 sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4B 
OXCT2 0.568 FKSG25; SCOT-T; FLJ00030 NM_022120 3-oxoacid CoA transferase 2 
MGC32
65 
0.567 MGC3265 NM_024028 prenylcysteine oxidase 1 like 
HIST1H
2BE 
0.567 H2B.h; H2B/h; H2BFH; H2BFN; dJ221C16.8 NM_003523 histone 1, H2be 
NEFH 0.567 NFH NM_021076 neurofilament, heavy polypeptide 200kDa 
EXOSC
2 
0.566 p7; RRP4; Rrp4p; hRrp4p NM_014285 exosome component 2 
AGPAT
5 
0.566 LPAAT-e; 1-AGPAT5; LPAAT-epsilon NM_018361 1-acylglycerol-3-phosphate O-acyltransferase 5 (lysophosphatidic 
acid acyltransferase, epsilon) 
MRPL12 0.566 5c5-2; L12mt; MRPL7; RPML12; MGC8610; 
MRPL7/L12; MRP-L31/34 
NM_002949 mitochondrial ribosomal protein L12 
CDT1 0.566 DUP; RIS2 NM_030928 chromatin licensing and DNA replication factor 1 
BLM 0.565 BS; RECQ2; RECQL2; RECQL3; MGC126616; 
MGC131618; MGC131620 
NM_000057 Bloom syndrome 
ITPR2 0.565 IP3R2 NM_002223 inositol 1,4,5-triphosphate receptor, type 2 
OGDHL 0.565 IARS NM_018245 oxoglutarate dehydrogenase-like 
GAL3ST
3 
0.565 GAL3ST2; MGC142112; MGC142114 NM_033036 galactose-3-O-sulfotransferase 3 
CSDA 0.565 DBPA; CSDA1; ZONAB NM_003651 cold shock domain protein A 
MTHFD
2 
0.564 NMDMC NM_006636 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
MRS2L 0.564 HPT; MRS2; MGC78523 NM_020662 MRS2-like, magnesium homeostasis factor (S. cerevisiae) 
PRP2 0.564 PRP2 NM_173490 transmembrane protein 171 
ZCCHC
7 
0.564 AIR1; HSPC086; FLJ22611; RP11-397D12.1 NM_032226 zinc finger, CCHC domain containing 7 
SUV420
H1 
0.564 CGI-85; MGC703; MGC21161; MGC118906; 
MGC118909 
NM_016028 suppressor of variegation 4-20 homolog 1 (Drosophila) 
GNS 0.564 G6S; MGC21274 NM_002076 glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) 
MET 0.563 HGFR; RCCP2 NM_000245 met proto-oncogene (hepatocyte growth factor receptor) 
WBSCR
27 
0.563 MGC40131 NM_152559 Williams Beuren syndrome chromosome region 27 
MYBBP 0.563 P160; PAP2; FLJ37886 NM_014520 MYB binding protein (P160) 1a 
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1A 
NARG1 0.561 Ga19; NAT1; NATH; TBDN100 NM_057175 NMDA receptor regulated 1 
DEPDC
1B 
0.561 XTP1; FLJ11252 NM_018369 DEP domain containing 1B 
SERTA
D4 
0.561 DJ667H12.2 NM_019605 SERTA domain containing 4 
LTBP1 0.56 LTBP1 NM_000627 latent transforming growth factor beta binding protein 1 
H2BFS 0.559 H2BFS NM_017445 H2B histone family, member S 
CHAF1
B 
0.559 CAF1; MPP7; CAF-1; CAF1A; CAF1P60; CAF-
IP60; MPHOSPH7 
NM_005441 chromatin assembly factor 1, subunit B (p60) 




protein phosphatase 1B (formerly 2C), magnesium-dependent, 
beta isoform 
ADCK1 0.559 FLJ39600 NM_020421 aarF domain containing kinase 1 
RFC5 0.558 RFC36; MGC1155 NM_007370 replication factor C (activator 1) 5, 36.5kDa 
MRPL16 0.558 L16mt; FLJ20484; PNAS-111 NM_017840 mitochondrial ribosomal protein L16 




0.558 KEPI; NY-BR-81; CPI17-like NM_030949 protein phosphatase 1, regulatory (inhibitor) subunit 14C 
AKAP12 0.558 AKAP250; DKFZp686M0430; DKFZp686O0331 NM_005100 A kinase (PRKA) anchor protein (gravin) 12 
TJP2 0.558 ZO2; X104; ZO-2; MGC26306 NM_201629 tight junction protein 2 (zona occludens 2) 
PAQR8 0.558 MPRB; LMPB1; C6orf33; FLJ32521; FLJ46206 NM_133367 progestin and adipoQ receptor family member VIII 
TUBB4 0.557 TUBB5; beta-5 NM_006087 tubulin, beta 4 
MLF1IP 0.557 CENPU; KLIP1; CENP-U; CENP-50; FLJ23468; 
CENP-U(50) 
NM_024629 MLF1 interacting protein 
ARHGE
F10 
0.556 GEF10; MGC131664; DKFZp686H0726 NM_014629 Rho guanine nucleotide exchange factor (GEF) 10 




0.556 KIAA0523 NM_015253 KIAA0523 protein 
AYTL2 0.556 lpcat; LPCAT1; PFAAP3; FLJ12443 NM_024830 acyltransferase like 2 
KLRG1 0.556 2F1; MAFA; MAFA-L; MAFA-2F1; MGC13600 NM_005810 killer cell lectin-like receptor subfamily G, member 1 
HOOK1 0.556 HK1; MGC10642 NM_015888 hook homolog 1 (Drosophila) 
BAIAP2
L2 
0.555 FLJ22582 NM_025045 BAI1-associated protein 2-like 2 
KIAA19
70 
0.555 MSE1; KIAA1970 NM_133451 glutamyl-tRNA synthetase 2 (mitochondrial)(putative) 
NDUFV
2 
0.555 NDUFV2 NM_021074 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 
IMP4 0.555 BXDC4; MGC19606 NM_033416 IMP4, U3 small nucleolar ribonucleoprotein, homolog (yeast) 
FYN 0.554 SLK; SYN; MGC45350 NM_002037 FYN oncogene related to SRC, FGR, YES 
PENK 0.554 MYLK NM_006211 proenkephalin 
FAM86
A 
0.554 SB153; MGC19636 NM_201400 family with sequence similarity 86, member A 
PRO185
3 
0.554 PRO1853 NM_144736 hypothetical protein PRO1853 
SNX5 0.553 FLJ10931 NM_152227 sorting nexin 5 
CCDC25 0.553 FLJ10853 NM_018246 coiled-coil domain containing 25 
LRCH4 0.553 LRN; LRRN1; LRRN4; SAP25; PP14183; 
FLJ40101; FLJ46315 




0.552 FLJ32549 NM_152440 hypothetical protein FLJ32549 
VAMP1 0.552 SYB1; VAMP-1; DKFZp686H12131 NM_016830 vesicle-associated membrane protein 1 (synaptobrevin 1) 
RASD1 0.552 AGS1; DEXRAS1; MGC:26290 NM_016084 RAS, dexamethasone-induced 1 
CIRH1A 0.552 NAIC; CIRHIN; TEX292; FLJ14728; KIAA1988 NM_032830 cirrhosis, autosomal recessive 1A (cirhin) 
PRMT3 0.551 HRMT1L3 NM_005788 protein arginine methyltransferase 3 
CSPG4 0.55 NG2; MCSP; MCSPG; MSK16; MEL-CSPG NM_001897 chondroitin sulfate proteoglycan 4 (melanoma-associated) 
TTK 0.55 ESK; PYT; MPS1L1; FLJ38280 NM_003318 TTK protein kinase 
LOC816
91 
0.55 LOC81691; DKFZp434J0315 NM_030941 exonuclease NEF-sp 
PNPLA2 0.55 ATGL; FP17548; TTS-2.2; DKFZp667M109; 
1110001C14Rik 
NM_020376 patatin-like phospholipase domain containing 2 
HERC4 0.549 KIAA1593; DKFZP564G092 NM_015601 hect domain and RLD 4 
IMPDH1 0.549 IMPD; RP10; IMPD1; sWSS2608; 
DKFZp781N0678 
NM_000883 IMP (inosine monophosphate) dehydrogenase 1 
CLYBL 0.549 CLB; bA134O15.1 NM_206808 citrate lyase beta like 
CBR1 0.548 CBR; hCBR1 NM_001757 carbonyl reductase 1 
MICAL2 0.548 KIAA0750; MICAL2PV1; MICAL2PV2; 
DKFZp686H2469; DKFZp686H03148 
NM_014632 microtubule associated monoxygenase, calponin and LIM domain 
containing 2 
Sep-02 0.548 DIFF6; NEDD5; hNedd5; KIAA0158 NM_001008
491 
septin 2 
TGFBR3 0.548 TGFBR3 NM_003243 transforming growth factor, beta receptor III (betaglycan, 
300kDa) 
ARG2 0.547 ARG2 NM_001172 arginase, type II 
HNRPA
1 
0.547 HNRNPA1; MGC102835 NM_002136 heterogeneous nuclear ribonucleoprotein A1 
KIAA09
22 
0.547 FLJ10592; TMEM131L; DKFZp586H1322 NM_015196 KIAA0922 
C6ORF8
5 
0.547 FLJ22174; DKFZP434F011 NM_021945 chromosome 6 open reading frame 85 
C1ORF1
81 
0.547 FLJ20729; FLJ20760; NY-BR-75; MGC131963 NM_017953 chromosome 1 open reading frame 181 
CDC42E
P2 
0.547 CEP2; BORG1 NM_006779 CDC42 effector protein (Rho GTPase binding) 2 
EVA1 0.547 EVA; MPZL2 NM_005797 epithelial V-like antigen 1 
ANKRD
25 
0.546 SIP; MXRA3; FLJ20004; KIAA1518; 
MGC119707; DKFZp434N161 
NM_015493 ankyrin repeat domain 25 
RHOU 0.546 ARHU; WRCH1; hG28K; CDC42L1; FLJ10616; 
DJ646B12.2; fJ646B12.2 
NM_021205 ras homolog gene family, member U 
CD19 0.545 B4; MGC12802 NM_001770 CD19 molecule 
LEPRE1 0.544 P3H1; GROS1; MGC117314 NM_022356 leucine proline-enriched proteoglycan (leprecan) 1 
ACACA 0.544   NM_000664   
LRRFIP
2 
0.543 HUFI-2; FLJ20248; FLJ22683; DKFZp434H2035 NM_006309 leucine rich repeat (in FLII) interacting protein 2 
EHBP1 0.543 NACSIN; KIAA0903 NM_015252 EH domain binding protein 1 
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chromosome 18 open reading frame 56 
TCP1 0.542 CCT1; CCTa; D6S230E; CCT-alpha; TCP-1-alpha NM_030752 t-complex 1 
WDHD1 0.542 AND-1 NM_001008
396 
WD repeat and HMG-box DNA binding protein 1 
RAB3B 0.541 RAB3B NM_002867 RAB3B, member RAS oncogene family 
PIK3CD 0.541 p110D NM_005026 phosphoinositide-3-kinase, catalytic, delta polypeptide 
CPT1C 0.541 CATL1; CPTIC; FLJ23809 NM_152359 carnitine palmitoyltransferase 1C 
SEMA3
A 
0.54 SemD; SEMA1; SEMAD; SEMAL; coll-1; 
Hsema-I; SEMAIII; sema III; Hsema-III 
NM_006080 sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3A 
ZNF323 0.539 ZNF310P; FLJ23407; ZNF20-Lp; dJ874C20.2 NM_030899 zinc finger protein 323 
ICA1 0.538   NM_022308   
USP28 0.538 KIAA1515 NM_020886 ubiquitin specific peptidase 28 
EREG 0.537 ER NM_001432 epiregulin 
HEATR
1 
0.537 BAP28; FLJ10359; MGC72083; RP11-385F5.3 NM_018072 HEAT repeat containing 1 
MRPS12 0.537 RPS12; RPMS12; RPSM12; MPR-S12; MT-
RPS12 
NM_033363 mitochondrial ribosomal protein S12 
RFC3 0.537 RFC38; MGC5276 NM_002915 replication factor C (activator 1) 3, 38kDa 
IL27RA 0.536 CRL1; TCCR; WSX1; IL27R; zcytor1 NM_004843 interleukin 27 receptor, alpha 
C20ORF
27 
0.536   NM_017874   
SAC3D1 0.536 SHD1; HSU79266 NM_013299 SAC3 domain containing 1 
TFPI 0.536 EPI; TFI; LACI NM_001032
281 
tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor) 
PELI2 0.535 PELI2 NM_021255 pellino homolog 2 (Drosophila) 
KRTCA
P3 
0.535 KCP3; MRV222; PRO9898; MGC126736; 
MGC126738 
NM_173853 keratinocyte associated protein 3 
CACNG
6 
0.535 CACNG7 NM_031897 calcium channel, voltage-dependent, gamma subunit 6 
FAM111
A 
0.534 FLJ22794; KIAA1895; DKFZp686A06175 NM_022074 family with sequence similarity 111, member A 
STOX2 0.534 DKFZp762K222 NM_020225 storkhead box 2 
STOM 0.534 BND7; EPB7; EPB72 NM_004099 stomatin 
PHF19 0.534 PCL3; MGC23929; MGC131698 NM_015651 PHD finger protein 19 
SLC43A
1 
0.534 LAT3; PB39; POV1; R00504 NM_003627 solute carrier family 43, member 1 
RNASE
T2 
0.533 RNASE6PL; bA514O12.3; RP11-514O12.3 NM_003730 ribonuclease T2 
TRIM8 0.533 GERP; RNF27 NM_030912 tripartite motif-containing 8 
SEC24D 0.532 FLJ43974; KIAA0755 NM_014822 SEC24 related gene family, member D (S. cerevisiae) 
SERBP1 0.532 CGI-55; CHD3IP; HABP4L; PAIRBP1; 
FLJ90489; PAI-RBP1; DKFZp564M2423 
NM_001018
068 
SERPINE1 mRNA binding protein 1 
GEMIN
6 
0.532 FLJ23459 NM_024775 gem (nuclear organelle) associated protein 6 
MAN1C
1 
0.532 HMIC; MAN1C; MAN1A3; pp6318 NM_020379 mannosidase, alpha, class 1C, member 1 
ST7 0.532 HELG; RAY1; SEN4; TSG7; ETS7q; FAM4A1; 
DKFZp762O2113 
NM_018412 suppression of tumorigenicity 7 
TSPAN9 0.531 NET-5; PP1057 NM_006675 tetraspanin 9 
ZSCAN
2 
0.531 ZFP29; FLJ20595 NM_181877 zinc finger and SCAN domain containing 2 
LARP6 0.531 FLJ11196 NM_197958 La ribonucleoprotein domain family, member 6 
C19ORF
4 
0.531 BSMAP NM_012109 chromosome 19 open reading frame 4 
SHC1 0.529 SHC; p66; SHCA; p52SHC; p66SHC; FLJ26504 NM_003029 SHC (Src homology 2 domain containing) transforming protein 1 
RPP40 0.529 RNASEP1; bA428J1.3 NM_006638 ribonuclease P 40kDa subunit 
IMPA2 0.529 CDK6 NM_014214 inositol(myo)-1(or 4)-monophosphatase 2 
ZSCAN
2 
0.528 ZFP29; FLJ20595 NM_001007
072 
zinc finger and SCAN domain containing 2 
SLC16A
9 
0.527 MCT9; C10orf36; FLJ43803 NM_194298 solute carrier family 16, member 9 (monocarboxylic acid 
transporter 9) 




0.526 FLJ43600; dJ310O13.5 NM_080625 chromosome 20 open reading frame 160 
CABLE
S1 
0.526 HsT2563; FLJ35924 NM_138375 Cdk5 and Abl enzyme substrate 1 
PYCAR
D 
0.526 ASC; TMS1; CARD5; MGC10332 NM_145183 PYD and CARD domain containing 
CD82 0.526 R2; 4F9; C33; IA4; ST6; GR15; KAI1; SAR2; 
TSPAN27 
NM_002231 CD82 molecule 
TCEA1 0.526 SII; TCEA; TF2S; GTF2S; TFIIS NM_006756 transcription elongation factor A (SII), 1 
PPP3CA 0.526 CALN; CCN1; CNA1; CALNA; PPP2B; 
CALNA1 
NM_000944 protein phosphatase 3 (formerly 2B), catalytic subunit, alpha 
isoform (calcineurin A alpha) 
FLJ2067
4 
0.525 FLJ20674 NM_019086 hypothetical protein FLJ20674 
FZD9 0.524 FZD3 NM_003508 frizzled homolog 9 (Drosophila) 
TCF4 0.524 E2-2; ITF2; SEF2; SEF2-1; SEF2-1A; SEF2-1B NM_003199 transcription factor 4 
ERCC5 0.524 XPG; UVDR; XPGC; ERCM2 NM_000123 excision repair cross-complementing rodent repair deficiency, 
complementation group 5 (xeroderma pigmentosum, 
complementation group G (Cockayne syndrome)) 
CHPT1 0.524 CPT; CPT1 NM_020244 choline phosphotransferase 1 
PSME3 0.524 Ki; PA28G; REG-GAMMA; PA28-gamma NM_005789 proteasome (prosome, macropain) activator subunit 3 (PA28 
gamma; Ki) 
NAT5 0.524 ARD1; NAT3; dJ1002M8.1 NM_181528 N-acetyltransferase 5 
PAK1IP
1 
0.523 PIP1; MAK11; WDR84; hPIP1; FLJ20624; 
bA421M1.5; RP11-421M1.5 
NM_017906 PAK1 interacting protein 1 
TMEM1
08 
0.523 MGC3040 NM_023943 transmembrane protein 108 
ANAPC
1 
0.523 APC1; MCPR; TSG24 NM_022662 anaphase promoting complex subunit 1 
SAR1B 0.523 CMRD; GTBPB; SARA2 NM_016103 SAR1 gene homolog B (S. cerevisiae) 
ASMTL 0.521 ASTML; ASMTLX; ASMTLY NM_004192 acetylserotonin O-methyltransferase-like 
TUFM 0.521 EFTU; EF-TuMT NM_003321 Tu translation elongation factor, mitochondrial 
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AZIN1 0.52 OAZI; OAZIN; ODC1L; MGC691; MGC3832 NM_015878 antizyme inhibitor 1 
PKIA 0.52 PRKACN1 NM_006823 protein kinase (cAMP-dependent, catalytic) inhibitor alpha 
MAN2A
1 
0.52 MANA2; MANII NM_002372 mannosidase, alpha, class 2A, member 1 
CHAC2 0.519 LMBRD2 NM_001008
708 
ChaC, cation transport regulator-like 2 (E. coli) 
ETV6 0.518 TEL NM_001987 ets variant gene 6 (TEL oncogene) 
MGC33
926 
0.518 MGC33926 NM_152390 hypothetical protein MGC33926 
ACP5 0.516 TRAP; MGC117378 NM_001611 acid phosphatase 5, tartrate resistant 
LFNG 0.516   NM_002304   
IL10RB 0.516 CRFB4; CRF2-4; D21S58; D21S66; CDW210B; 
IL-10R2 
NM_000628 interleukin 10 receptor, beta 
HLA-
DMA 
0.515 DMA; HLADM; RING6; D6S222E NM_006120 major histocompatibility complex, class II, DM alpha 
ZNF589 0.515 SZF1 NM_016089 zinc finger protein 589 
SMTN 0.515 FLJ35365; FLJ38597 NM_006932 smoothelin 
DET1 0.515 FLJ10103; MGC126156; MGC126157 NM_017996 de-etiolated homolog 1 (Arabidopsis) 
PHLDB
1 
0.515 LL5A; FLJ00141; FLJ90266; KIAA0638; 
MGC111531; DKFZp686H039; 
DKFZp686O24210 
NM_015157 pleckstrin homology-like domain, family B, member 1 
TRIP13 0.515 16E1BP NM_004237 thyroid hormone receptor interactor 13 
QTRT1 0.514 TGT; FP3235 NM_031209 queuine tRNA-ribosyltransferase 1 (tRNA-guanine 
transglycosylase) 
CDC14B 0.514 CDC14B3; Cdc14B1; Cdc14B2; hCDC14B NM_003671 CDC14 cell division cycle 14 homolog B (S. cerevisiae) 
ELOVL
4 
0.514 ADMD; STGD2; STGD3 NM_022726 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 4 
RPL41 0.513 RPL41 NM_021104 ribosomal protein L41 
MPP4 0.513 DLG6; ALS2CR5 NM_033066 membrane protein, palmitoylated 4 (MAGUK p55 subfamily 
member 4) 
TIMP2 0.512 CSC-21K NM_003255 TIMP metallopeptidase inhibitor 2 
AKR1A
1 
0.511 ALR; ALDR1; MGC1380; MGC12529 NM_006066 aldo-keto reductase family 1, member A1 (aldehyde reductase) 
MPHOS
PH1 
0.511 MPP1; KRMP1; MPP-1; DKFZp434B0435; 
DKFZp434P0810 
NM_016195 M-phase phosphoprotein 1 
HOXC6 0.51 CP25; HOX3; HOX3C; HHO.C8 NM_153693 homeobox C6 
RBPSU
H 
0.51 csl; CBF1; KBF2; RBP-J; RBPJK; IGKJRB; 
IGKJRB1; MGC61669 
NM_203284 recombining binding protein suppressor of hairless (Drosophila) 
SLC19A
3 
0.51 SLC19A3 NM_025243 solute carrier family 19, member 3 
RBPSU
H 
0.51 csl; CBF1; KBF2; RBP-J; RBPJK; IGKJRB; 
IGKJRB1; MGC61669 
NM_203284 recombining binding protein suppressor of hairless (Drosophila) 
MGC24
08 
0.51 MGC2408 NM_032331 hypothetical protein MGC2408 
GMNN 0.509 Gem; RP3-369A17.3 NM_015895 geminin, DNA replication inhibitor 
TXNDC 0.508 TMX; TXNDC1; DKFZP564E1962 NM_030755 thioredoxin domain containing 
PSRC1 0.508 DDA3; FP3214; MGC1780; RP11-297O4.2 NM_001005
290 
proline/serine-rich coiled-coil 1 
CMTM7 0.507 CKLFSF7; FLJ30992 NM_138410 CKLF-like MARVEL transmembrane domain containing 7 
UNG 0.507 DGU; UDG; UNG1; HIGM4; UNG15; 
DKFZp781L1143 
NM_080911 uracil-DNA glycosylase 
KIF2C 0.507 MCAK; KNSL6 NM_006845 kinesin family member 2C 
KIAA05
28 
0.506 DKFZp779N2044 NM_014802 KIAA0528 
RSU1 0.506 RSP-1; FLJ31034 NM_152724 Ras suppressor protein 1 
SKP2 0.505 FBL1; FLB1; FBXL1; MGC1366 NM_032637 S-phase kinase-associated protein 2 (p45) 
IVD 0.505 ACAD2 NM_002225 isovaleryl Coenzyme A dehydrogenase 
FAM113
B 





meteorin, glial cell differentiation regulator-like 
PLA2G4
C 
0.505 CPLA2-gamma; DKFZp586C0423 NM_003706 phospholipase A2, group IVC (cytosolic, calcium-independent) 
CENTB
1 
0.505 ACAP1; KIAA0050 NM_014716 centaurin, beta 1 
RBPMS 0.504 HERMES NM_001008
712 
RNA binding protein with multiple splicing 
NDE1 0.504 NUDE; NUDE1; FLJ20101; HOM-TES-87 NM_017668 nudE nuclear distribution gene E homolog 1 (A. nidulans) 
LIAS 0.503 LAS; LIP1; HUSSY-01; MGC23245 NM_006859 lipoic acid synthetase 
PRIM1 0.503 p49; MGC12308 NM_000946 primase, polypeptide 1, 49kDa 
RPL29 0.502 HIP; HUMRPL29; MGC88589 NM_000992 ribosomal protein L29 
KPNA2 0.502 QIP2; RCH1; IPOA1; SRP1alpha NM_002266 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 
SCG2 0.502 SN; CHGC; SgII NM_003469 secretogranin II (chromogranin C) 
DCC1 0.502 DCC1; MGC5528 NM_024094 defective in sister chromatid cohesion homolog 1 (S. cerevisiae) 
GOLPH
2 
0.502 GP73; PSEC0257 NM_016548 golgi phosphoprotein 2 
RPUSD3 0.502 FLJ34707; MGC29784 NM_173659 RNA pseudouridylate synthase domain containing 3 
TFB2M 0.501 Hkp1; FLJ22661; FLJ23182 NM_022366 transcription factor B2, mitochondrial 
CENPH 0.501 C12orf52 NM_022909 centromere protein H 
EIF2S2 0.5 EIF2; EIF2B; MGC8508; EIF2beta; 
DKFZp686L18198 
NM_003908 eukaryotic translation initiation factor 2, subunit 2 beta, 38kDa 
SLCO4
A1 
0.5 POAT; OATP1; OATP-E; OATP4A1; OATPRP1; 
SLC21A12 
NM_016354 solute carrier organic anion transporter family, member 4A1 
RHOQ 0.5 ARHQ; TC10; TC10A; RASL7A NM_012249 ras homolog gene family, member Q 
CD55 0.499 CR; TC; DAF NM_000574 CD55 molecule, decay accelerating factor for complement 
(Cromer blood group) 
PDE4B 0.499 DPDE4; PDEIVB; MGC126529; 
DKFZp686F2182 
NM_002600 phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 
dunce homolog, Drosophila) 




0.498 MGC34695; MGC131934 NM_173555 trypsin domain containing 1 
C20ORF
72 
0.498 FLJ14597; bA504H3.4 NM_052865 chromosome 20 open reading frame 72 
LYPLA1 0.498 LPL1; APT-1; LYSOPLA NM_006330 lysophospholipase I 




0.498 CDC50B; MGC126775 NM_001017
970 
transmembrane protein 30B 
LAP3 0.498 LAP; PEPS; LAPEP NM_015907 leucine aminopeptidase 3 
PHYH2 0.498 HPCL; HPCL2; PHYH2; 2-HPCL NM_012260 2-hydroxyacyl-CoA lyase 1 
PAPSS2 0.497 SK2; ATPSK2 NM_001015
880 
3'-phosphoadenosine 5'-phosphosulfate synthase 2 
CUL1 0.497 CDK6 NM_003592 cullin 1 
PHF17 0.497 JADE1; FLJ22479; KIAA1807 NM_024900 PHD finger protein 17 
KCNG3 0.496 KV6.3; KV10.1 NM_172344 potassium voltage-gated channel, subfamily G, member 3 
SNCA 0.496 PD1; NACP; PARK1; PARK4; MGC110988 NM_007308 synuclein, alpha (non A4 component of amyloid precursor) 
KLHL3 0.496 KIAA1129; MGC44594 NM_017415 kelch-like 3 (Drosophila) 
AKNA 0.496 KIAA1968; RP11-82I1.4 NM_030767 AT-hook transcription factor 
SRI 0.496 SCN; FLJ26259 NM_003130 sorcin 
PACSIN
1 
0.494 SDPI; KIAA1379 NM_020804 protein kinase C and casein kinase substrate in neurons 1 
NFKB1 0.494 KBF1; EBP-1; MGC54151; NFKB-p50; NFKB-
p105; NF-kappa-B; DKFZp686C01211 
NM_003998 nuclear factor of kappa light polypeptide gene enhancer in B-cells 
1 (p105) 
GMDS 0.493 GMD NM_001500 GDP-mannose 4,6-dehydratase 
LOC571
49 
0.492 A211C6.1 NM_020424 LYR motif containing 1 
CBLC 0.492 CBL-3; RNF57; CBL-SL NM_012116 Cas-Br-M (murine) ecotropic retroviral transforming sequence c 
LTBP3 0.492 LTBP2; LTBP-3; pp6425; FLJ33431; FLJ39893; 
DKFZP586M2123 
NM_021070 latent transforming growth factor beta binding protein 3 
PIAS2 0.492 miz; MIZ1; SIZ2; MGC102682; PIASX-BETA; 
PIASX-ALPHA 
NM_173206 protein inhibitor of activated STAT, 2 
LEPREL
2 
0.49 GRCB; P3H3; HSU47926 NM_014262 leprecan-like 2 
SPRYD3 0.49 FLJ14800 NM_032840 SPRY domain containing 3 
RASIP1 0.49 RAIN; FLJ20401 NM_017805 Ras interacting protein 1 
MTHFD
1 
0.49 MTHFC; MTHFD NM_005956 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, 




0.49 LOC139886; MGC133224 NM_001012
968 
hypothetical protein LOC139886 
C9ORF1
0 
0.489 C9orf10; DNAPTP1; DNAPTP5; MGC111527; 
MGC133257 
NM_014612 family with sequence similarity 120A 
HSPA4L 0.489 APG-1; Osp94 NM_014278 heat shock 70kDa protein 4-like 





0.488 E3; ALDH4; ALDH7; ALDH9; TMABADH NM_000696 aldehyde dehydrogenase 9 family, member A1 
RGMB 0.488 DRAGON; FLJ90406; MGC86970 NM_001012
761 
RGM domain family, member B 
CYTL1 0.488 C17 NM_018659 cytokine-like 1 
EPDR1 0.487 UCC1; MERP1; MERP-1 NM_017549 ependymin related protein 1 (zebrafish) 
MCM7 0.487 MCM2; CDC47; P85MCM; P1CDC47; PNAS-
146; CDABP0042; P1.1-MCM3 
NM_182776 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) 
FLJ2541
6 
0.487 FLJ25416; FLJ13936 NM_145018 hypothetical protein FLJ25416 
TM7SF3 0.486 TM7SF3 NM_016551 transmembrane 7 superfamily member 3 
STXBP6 0.486 amisyn; HSPC156; FLJ39638 NM_014178 syntaxin binding protein 6 (amisyn) 
MGC45
840 
0.485 MGC45840; MGC88858 NM_173584 EF-hand calcium binding domain 4A 
HSPC11
1 
0.485 HSPC111; HSPC185 NM_016391 hypothetical protein HSPC111 
UST 0.485 2OST NM_005715 uronyl-2-sulfotransferase 
EBNA1
BP2 
0.484 P40; EBP2; NOBP NM_006824 EBNA1 binding protein 2 
WDR12 0.484 YTM1; FLJ10881; FLJ12719; FLJ12720 NM_018256 WD repeat domain 12 
PCDH18 0.483 PCDH68L; KIAA1562; DKFZP434B0923 NM_019035 protocadherin 18 
NCLN 0.483 SCARB1 NM_020170 nicalin homolog (zebrafish) 
EDNRB 0.483 ETB; ETRB; HSCR; ABCDS; HSCR2 NM_003991 endothelin receptor type B 
VKORC
1 
0.482 VKOR; MST134; MST576; VKCFD2; EDTP308; 
MGC2694; FLJ00289; IMAGE3455200 
NM_024006 vitamin K epoxide reductase complex, subunit 1 
MGST1 0.482 MGST; GST12; MGST-I; MGC14525 NM_020300 microsomal glutathione S-transferase 1 
C1GAL
T1C1 




C1GALT1-specific chaperone 1 
SSPN 0.481 KRAG; SPN1; SPN2 NM_005086 sarcospan (Kras oncogene-associated gene) 
SDHA 0.481 FP; SDH2; SDHF NM_004168 succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 
SERPIN
B8 
0.481 PI8; CAP2 NM_001031
848 
serpin peptidase inhibitor, clade B (ovalbumin), member 8 
NLN 0.48 AGTBP; KIAA1226; DKFZp564F123 NM_020726 neurolysin (metallopeptidase M3 family) 
SORBS1 0.479 CAP; FLAF2; R85FL; SH3D5; SORB1; SH3P12; 
FLJ12406; KIAA1296; DKFZp451C066; 
DKFZp586P1422 
NM_015385 sorbin and SH3 domain containing 1 
ARHGE
F6 
0.479 PIXA; COOL2; MRX46; Cool-2; KIAA0006; 
alphaPIX; alpha-PIX 
NM_004840 Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 
CHAF1
A 
0.477 CAF1; P150; CAF-1; CAF1B; CAF1P150; 
MGC71229 
NM_005483 chromatin assembly factor 1, subunit A (p150) 
EIF4E3 0.476 MGC39820; MGC86971 NM_173359 eukaryotic translation initiation factor 4E member 3 
HMMR 0.476 CD168; IHABP; RHAMM; MGC119494; 
MGC119495 
NM_012485 hyaluronan-mediated motility receptor (RHAMM) 
KIAA19
14 





0.476 p12B; RRP46; RRP41B; Rrp46p; hRrp46p; 
MGC12901; MGC111224 
NM_020158 exosome component 5 
UGT3A
2 
0.476 MGC119426; MGC119429 NM_174914 UDP glycosyltransferase 3 family, polypeptide A2 
CDR2 0.475 Yo; CDR62 NM_001802 cerebellar degeneration-related protein 2, 62kDa 
DYNLT
3 
0.475 RP3; TCTE1L; TCTEX1L NM_006520 dynein, light chain, Tctex-type 3 
AP1S1 0.474 AP19; CLAPS1; SIGMA1A NM_057089 adaptor-related protein complex 1, sigma 1 subunit 
MGST1 0.474 MGST; GST12; MGST-I; MGC14525 NM_020300 microsomal glutathione S-transferase 1 
TNNC2 0.473 TNNC2 NM_003279 troponin C type 2 (fast) 
BID 0.473 MGC15319; MGC42355 NM_001196 BH3 interacting domain death agonist 
THYN1 0.473 MY105; THY28; MDS012; HSPC144; NM_199298 thymocyte nuclear protein 1 
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THY28KD; MGC12187 
TPST2 0.473 TPST2 NM_001008
566 
tyrosylprotein sulfotransferase 2 
PBK 0.471 SPK; TOPK; Nori-3; FLJ14385 NM_018492 PDZ binding kinase 
GAJ 0.47 GAJ NM_032117 meiotic nuclear divisions 1 homolog (S. cerevisiae) 
GRAMD
3 
0.47 NS3TP2; FLJ21313 NM_023927 GRAM domain containing 3 
IRS1 0.47 HIRS-1 NM_005544 insulin receptor substrate 1 
RASL11
B 
0.47 MGC2827; MGC4499 NM_023940 RAS-like, family 11, member B 
TYK2 0.469 JTK1 NM_003331 tyrosine kinase 2 
HEXB 0.469 ENC-1AS NM_000521 hexosaminidase B (beta polypeptide) 
SRPK1 0.469 SFRSK1 NM_003137 SFRS protein kinase 1 
TEAD4 0.468 RTEF1; TEF-3; EFTR-2; RTEF-1; TEFR-1; 
MGC9014; TCF13L1; hRTEF-1B 
NM_201441 TEA domain family member 4 
HSD17B
8 
0.468 KE6; FABG; HKE6; FABGL; RING2; H2-KE6; 
D6S2245E; dJ1033B10.9 
NM_014234 hydroxysteroid (17-beta) dehydrogenase 8 
SLC6A1
5 
0.467 V7-3; NTT73; hv7-3; FLJ10316; MGC87066; 
DKFZp761I0921 
NM_182767 solute carrier family 6, member 15 
GMPS 0.467 CFB NM_003875 guanine monphosphate synthetase 
ZNF483 0.466 ZNF483 NM_001007
169 
zinc finger protein 483 
PSAT1 0.465 PSA; MGC1460 NM_021154 phosphoserine aminotransferase 1 
ST7 0.465 HELG; RAY1; SEN4; TSG7; ETS7q; FAM4A1; 
DKFZp762O2113 
NM_018412 suppression of tumorigenicity 7 
BXDC1 0.465 RPF2; FLJ21087; bA397G5.4 NM_032194 brix domain containing 1 
ALDH4
A1 
0.465 P5CD; ALDH4; P5CDh; P5CDhL; P5CDhS NM_170726 aldehyde dehydrogenase 4 family, member A1 
MCM7 0.464 MCM2; CDC47; P85MCM; P1CDC47; PNAS-
146; CDABP0042; P1.1-MCM3 
NM_005916 MCM7 minichromosome maintenance deficient 7 (S. cerevisiae) 
FRAT2 0.464 MGC10562 NM_012083 frequently rearranged in advanced T-cell lymphomas 2 




inositol polyphosphate-5-phosphatase, 145kDa 
ACYP1 0.464 ACYPE NM_203488 acylphosphatase 1, erythrocyte (common) type 
KATNA
L2 
0.462 MGC33211; DKFZP667C165 NM_031303 katanin p60 subunit A-like 2 
PARP9 0.462 BAL; BAL1; FLJ26637; MGC:7868; 
DKFZp666B0810; DKFZp686M15238 
NM_031458 poly (ADP-ribose) polymerase family, member 9 
XPC 0.461 XP3; XPCC NM_004628 xeroderma pigmentosum, complementation group C 
CXORF
12 
0.461 ITBA1; DXS9878E NM_003492 chromosome X open reading frame 12 
MCCC2 0.461 MCCB NM_022132 methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 
DKK3 0.461 REIC NM_013253 dickkopf homolog 3 (Xenopus laevis) 
STRBP 0.46 SPNR; MGC3405; FLJ11307; FLJ14223; 
FLJ14984; MGC21529; DKFZp434N214 
NM_018387 spermatid perinuclear RNA binding protein 
LMO4 0.46 LMO4 NM_006769 LIM domain only 4 
MFSD1 0.459 FLJ14153; UG0581B09 NM_022736 major facilitator superfamily domain containing 1 
NME1 0.457 AWD; GAAD; NM23; NDPKA; NM23-H1 NM_198175 non-metastatic cells 1, protein (NM23A) expressed in 
ABLIM1 0.457 ABLIM; LIMAB1; LIMATIN; MGC1224; 
FLJ14564; KIAA0059; DKFZp781D0148 
NM_006720 actin binding LIM protein 1 
PHB 0.457 PHB NM_002634 prohibitin 
POLE2 0.456 DPE2 NM_002692 polymerase (DNA directed), epsilon 2 (p59 subunit) 
SATB2 0.456 FLJ21474; FLJ32076; KIAA1034; MGC119474; 
MGC119477 
NM_015265 SATB family member 2 
EPB41L
4B 
0.455 CG1; EHM2; FLJ21596; DKFZp761N1814 NM_018424 erythrocyte membrane protein band 4.1 like 4B 
PARP1 0.454 PARP; PPOL; ADPRT; ADPRT1; PARP-1; 
pADPRT-1 
NM_001618 poly (ADP-ribose) polymerase family, member 1 
TRAF3I
P2 
0.453 ACT1; CIKS; C6orf4; C6orf5; C6orf6; MGC3581; 
DKFZP586G0522 
NM_147200 TRAF3 interacting protein 2 
DAZAP
1 
0.452 MGC19907 NM_018959 DAZ associated protein 1 
TMEM5 0.452 HP10481 NM_014254 transmembrane protein 5 
CD74 0.452 DHLAG; HLADG; Ia-GAMMA; protein 41 NM_001025
158 
CD74 molecule, major histocompatibility complex, class II 
invariant chain 
CSRP2 0.451 CRP2; LMO5; SmLIM NM_001321 cysteine and glycine-rich protein 2 
GPR160 0.449 GPCR1; GPCR150 NM_014373 G protein-coupled receptor 160 
TRAP1 0.449 HSP75; HSP90L NM_016292 TNF receptor-associated protein 1 
NPFFR2 0.447 GPR74; NPFF2; NPGPR NM_053036 neuropeptide FF receptor 2 




0.446 ERP18; ERP19; TLP19 NM_015913 thioredoxin domain containing 12 (endoplasmic reticulum) 
NOL6 0.446 NRAP; UTP22; FLJ21959; MGC14896; 
MGC14921; MGC20838; bA311H10.1 
NM_022917 nucleolar protein family 6 (RNA-associated) 
VRK1 0.446 MGC117401; MGC138280; MGC142070 NM_003384 vaccinia related kinase 1 
REEP5 0.446 DP1; TB2; D5S346; C5orf18; MGC70440 NM_005669 receptor accessory protein 5 
WDSOF
1 
0.446 Gm83; HSPC064; MGC126859; MGC138247; 
DKFZP564O0463 
NM_015420 WD repeats and SOF1 domain containing 
SYT1 0.445 P65; SYT; SVP65; DKFZp781D2042 NM_005639 synaptotagmin I 
NOX4 0.442 KOX; KOX-1; RENOX NM_016931 NADPH oxidase 4 
PHGDH 0.44 PDG; PGD; PGAD; PGDH; SERA; 3PGDH; 3-
PGDH; MGC3017 
NM_006623 phosphoglycerate dehydrogenase 
STAT1 0.44 ISGF-3; STAT91; DKFZp686B04100 NM_139266 signal transducer and activator of transcription 1, 91kDa 
PYGL 0.438 RB1 NM_002863 phosphorylase, glycogen; liver (Hers disease, glycogen storage 
disease type VI) 
SLC7A1 0.436 ERR; ATRC1; CAT-1; HCAT1; REC1L NM_003045 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 1 
F12 0.435 HAF NM_000505 coagulation factor XII (Hageman factor) 
LYAR 0.434 LYAR; FLJ20425 NM_017816 hypothetical protein FLJ20425 
CEBPD 0.433 CELF; CRP3; C/EBP-delta; NF-IL6-beta NM_005195 CCAAT/enhancer binding protein (C/EBP), delta 
CHGA 0.432 CGA NM_001275 chromogranin A (parathyroid secretory protein 1) 
PTN 0.432 HARP; HBNF; HBGF8; NEGF1 NM_002825 pleiotrophin (heparin binding growth factor 8, neurite growth-
promoting factor 1) 
TIMM8
A 
0.431 DDP; MTS; DDP1; DFN1; MGC12262 NM_004085 translocase of inner mitochondrial membrane 8 homolog A 
(yeast) 
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SF3A3 0.431 PRP9; PRPF9; SAP61; SF3a60 NM_006802 splicing factor 3a, subunit 3, 60kDa 
EFNB2 0.431 HTKL; EPLG5; Htk-L; LERK5; MGC126226; 
MGC126227; MGC126228 
NM_004093 ephrin-B2 
HHLA2 0.431 CERK NM_007072 HERV-H LTR-associating 2 
NES 0.43 FLJ21841; Nbla00170 NM_006617 nestin 




0.43 FLJ39106 NM_173629 chromosome 18 open reading frame 26 
LAD1 0.43 LadA; MGC10355 NM_005558 ladinin 1 
DPYSL2 0.43 DRP2; CRMP2; DRP-2; DHPRP2 NM_001386 dihydropyrimidinase-like 2 
WIPI1 0.428 Atg18; WIPI49; FLJ10055 NM_017983 WD repeat domain, phosphoinositide interacting 1 
OLFM1 0.427 AMY; NOE1; OlfA; NOELIN; NOELIN1; 
NOELIN1_V1; NOELIN1_V2; NOELIN1_V4; 
NOELIN1_V5 
NM_014279 olfactomedin 1 
CORO2
B 
0.426 CLIPINC; KIAA0925 NM_006091 coronin, actin binding protein, 2B 
FBXO22 0.426 FBX22; FLJ13986 NM_012170 F-box protein 22 
MCM5 0.426 CDC46; MGC5315; P1-CDC46 NM_006739 MCM5 minichromosome maintenance deficient 5, cell division 
cycle 46 (S. cerevisiae) 
ISOC2 0.425 TMEM101 NM_024710 isochorismatase domain containing 2 
NAP1L3 0.425 MB20; NPL3; MGC26312 NM_004538 nucleosome assembly protein 1-like 3 
SEMA4
D 
0.425 CD100; SEMAJ; coll-4; M-sema G; M-sema-G NM_006378 sema domain, immunoglobulin domain (Ig), transmembrane 
domain (TM) and short cytoplasmic domain, (semaphorin) 4D 
BUB1B 0.424 SSK1; BUBR1; Bub1A; MAD3L; hBUBR1; 
BUB1beta 




0.424 HDL; 11-DH; HSD11; HSD11B; HSD11L; 
MGC13539; 11-beta-HSD1 
NM_181755 hydroxysteroid (11-beta) dehydrogenase 1 
AP1S1 0.424 AP19; CLAPS1; SIGMA1A NM_001283 adaptor-related protein complex 1, sigma 1 subunit 
C12ORF
24 
0.424 HSU79274 NM_013300 chromosome 12 open reading frame 24 
RPS7 0.423 RPS7 NM_001011 ribosomal protein S7 
FLJ3120
4 
0.423 FLJ31204; RP11-479E16.1 NM_174912 amidase domain containing 
RAI14 0.422 RAI13; NORPEG; KIAA1334; DKFZp564G013 NM_015577 retinoic acid induced 14 
F2RL1 0.422 PAR2; GPR11 NM_005242 coagulation factor II (thrombin) receptor-like 1 
VAMP4 0.422 VAMP24 NM_003762 vesicle-associated membrane protein 4 
SLC24A
6 
0.421 NCLX; NCKX6; FLJ22233 NM_024959 solute carrier family 24 (sodium/potassium/calcium exchanger), 
member 6 
ATP5G1 0.421 ATP5A; ATP5G NM_001002
027 
ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C1 (subunit 9) 
PANX1 0.421 MRS1; UNQ2529; MGC21309 NM_015368 pannexin 1 
EXTL3 0.419 REG; RPR; REGR; botv; EXTR1; KIAA0519; 
DKFZp686C2342 
NM_001440 exostoses (multiple)-like 3 
MRPL24 0.419 MGC9831; MRP-L18; FLJ20917; MGC22737 NM_024540 mitochondrial ribosomal protein L24 
ASPH 0.419 BAH; HAAH; JCTN; junctin; CASQ2BP1 NM_020164 aspartate beta-hydroxylase 
ACO1 0.419 IRP1; IREB1; IREBP NM_002197 aconitase 1, soluble 
RIN2 0.419 RASSF4 NM_018993 Ras and Rab interactor 2 
HBA1 0.419 CD31; MGC126895; MGC126897 NM_000558 hemoglobin, alpha 1 
DBC1 0.419 FAM5A; DBCCR1 NM_014618 deleted in bladder cancer 1 
ZNF206 0.418 ZSCAN10; FLJ14549 NM_032805 zinc finger protein 206 
LYN 0.418 JTK8; FLJ26625 NM_002350 v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
ARIH2 0.417 ARI2; TRIAD1; FLJ10938; FLJ33921 NM_006321 ariadne homolog 2 (Drosophila) 
ASCC3 0.416 RNAH; HELIC1; ASC1p200; MGC26074; 
DJ467N11.1; dJ121G13.4 
NM_006828 activating signal cointegrator 1 complex subunit 3 
MICB 0.416 PERB11.2 NM_005931 MHC class I polypeptide-related sequence B 
GLTP 0.415 GLTP NM_016433 glycolipid transfer protein 
ASPHD
1 
0.414 ASPHD1 NM_181718 aspartate beta-hydroxylase domain containing 1 
GART 0.414 AIRS; GARS; PAIS; PGFT; PRGS; GARTF; 
MGC47764 
NM_000819 phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
DNAJB6 0.413 MRJ; HSJ2; HHDJ1; HSJ-2; MSJ-1; MGC1152; 
FLJ42837; MGC117297; DKFZp566D0824 
NM_005494 DnaJ (Hsp40) homolog, subfamily B, member 6 
RAB7L1 0.413 RAB7L; DKFZp686P1051 NM_003929 RAB7, member RAS oncogene family-like 1 
SMS 0.412 SRS; SpS; MRSR; SPMSY NM_004595 spermine synthase 
NQO1 0.412 DTD; QR1; DHQU; DIA4; NMOR1; NMORI NM_000903 NAD(P)H dehydrogenase, quinone 1 
LOXL3 0.412 LOXL NM_032603 lysyl oxidase-like 3 
ISG20L1 0.412 AEN; pp12744; FLJ12484; FLJ12562 NM_022767 interferon stimulated exonuclease gene 20kDa-like 1 
HK1 0.412 HKI; HXK1; HK1-ta; HK1-tb NM_033500 hexokinase 1 
LCK 0.411 YT16; p56lck; pp58lck NM_005356 lymphocyte-specific protein tyrosine kinase 
BCAS4 0.41 FLJ20495 NM_017843 breast carcinoma amplified sequence 4 
CMTM8 0.41 CKLFSF8 NM_178868 CKLF-like MARVEL transmembrane domain containing 8 
RARRE
S2 
0.41 TIG2; HP10433 NM_002889 retinoic acid receptor responder (tazarotene induced) 2 
FLJ9023
1 
0.41   NM_173581   
MGC26
856 
0.409 PRO7434; ALKN2972; MGC26856 NM_152779 GLI pathogenesis-related 1 like 1 
MGC41
72 
0.409 MGC4172; ARPG836; FLJ39232 NM_024308 short-chain dehydrogenase/reductase 
CYP2S1 0.408 CYP2S1 NM_030622 cytochrome P450, family 2, subfamily S, polypeptide 1 
FKBP11 0.406 FKBP19; MGC54182 NM_016594 FK506 binding protein 11, 19 kDa 
C3ORF2
6 
0.406 MGC4308 NM_032359 chromosome 3 open reading frame 26 
PDGFR
B 
0.406 JTK12; PDGFR; CD140B; PDGFR1; PDGF-R-
beta 
NM_002609 platelet-derived growth factor receptor, beta polypeptide 
ANK3 0.406 FLJ45464; ANKYRIN-G NM_001149 ankyrin 3, node of Ranvier (ankyrin G) 
RPL8 0.406 RPL8 NM_033301 ribosomal protein L8 
CCRN4
L 
0.405 NOC; CCR4L; MGC78549; MGC142054; 
MGC142060; MGC4120817 
NM_012118 CCR4 carbon catabolite repression 4-like (S. cerevisiae) 
RAB31 0.403 Rab22B NM_006868 RAB31, member RAS oncogene family 
PFS2 0.403 PSF2; Pfs2; HSPC037 NM_016095 GINS complex subunit 2 (Psf2 homolog) 
TPM2 0.402 DA1; TMSB; AMCD1 NM_213674 tropomyosin 2 (beta) 
GNG4 0.402 VPS13B NM_004485 guanine nucleotide binding protein (G protein), gamma 4 
NSBP1 0.4 NSBP1 NM_030763 nucleosomal binding protein 1 
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LAMC1 0.4 LAMB2; MGC87297 NM_002293 laminin, gamma 1 (formerly LAMB2) 
RNMTL
1 
0.399 HC90; FLJ10581 NM_018146 RNA methyltransferase like 1 
ORC1L 0.398 ORC1; PARC1; HSORC1 NM_004153 origin recognition complex, subunit 1-like (yeast) 
SULF1 0.398 SULF-1; HSULF-1; FLJ38022; FLJ41750; 
KIAA1077 
NM_015170 sulfatase 1 
TFPI 0.397 EPI; TFI; LACI NM_006287 tissue factor pathway inhibitor (lipoprotein-associated 
coagulation inhibitor) 
SESN1 0.395 PA26; SEST1; MGC138241; MGC142129; RP11-
787I22.1 
NM_014454 sestrin 1 
MAD2L
2 
0.394 REV7; MAD2B NM_006341 MAD2 mitotic arrest deficient-like 2 (yeast) 
DTL 0.393 RAMP; L2DTL NM_016448 denticleless homolog (Drosophila) 
TNC 0.392 TN; HXB NM_002160 tenascin C (hexabrachion) 
SLC17A
5 
0.392 SD; AST; NSD; SLD; ISSD; SIASD; SIALIN; 
FLJ22227; FLJ23268 
NM_012434 solute carrier family 17 (anion/sugar transporter), member 5 
GRM4 0.391 mGlu4; GPRC1D; MGLUR4 NM_000841 glutamate receptor, metabotropic 4 
RPS15 0.391 RIG; MGC111130 NM_001018 ribosomal protein S15 
FLJ2070
1 
0.391 FLJ20701; HMFN2073 NM_017933 hypothetical protein FLJ20701 
REXO2 0.39 RFN; SFN; CGI-114; MGC111570; 
DKFZP566E144 
NM_015523 REX2, RNA exonuclease 2 homolog (S. cerevisiae) 
GULP1 0.39 CED6; GULP; CED-6; FLJ31156 NM_016315 GULP, engulfment adaptor PTB domain containing 1 
IDH3A 0.39 PXDN NM_005530 isocitrate dehydrogenase 3 (NAD+) alpha 
SIX4 0.39 AREC3; MGC119450; MGC119452; MGC119453 NM_017420 sine oculis homeobox homolog 4 (Drosophila) 
FKBP4 0.389 HBI; p52; Hsp56; FKBP52; FKBP59; PPIase NM_002014 FK506 binding protein 4, 59kDa 
CALD1 0.388 CDM; H-CAD; L-CAD; NAG22; MGC21352 NM_004342 caldesmon 1 
MCEE 0.388 RPL12 NM_032601 methylmalonyl CoA epimerase 
AP1S1 0.387 AP19; CLAPS1; SIGMA1A NM_001283 adaptor-related protein complex 1, sigma 1 subunit 
PCNXL
2 
0.387 FLJ11383; KIAA0435 NM_024938 pecanex-like 2 (Drosophila) 
C3ORF5
4 
0.387 MGC20416 NM_203370 chromosome 3 open reading frame 54 
SLC7A8 0.386 LAT2; LPI-PC1 NM_012244 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 8 
BRP44 0.385 MGC125752; MGC125753; DKFZP564B167 NM_015415 brain protein 44 
HNT 0.384 HNT; NTM; MGC60329 NM_016522 neurotrimin 
CDCP1 0.382 CD318; TRASK; SIMA135 NM_178181 CUB domain containing protein 1 
WWC1 0.382 KIBRA; FLJ10865; FLJ23369; KIAA0869 NM_015238 WW, C2 and coiled-coil domain containing 1 
TRAM2 0.382 KIAA0057 NM_012288 translocation associated membrane protein 2 
TNFRSF
8 
0.381 CD30; KI-1; D1S166E NM_001243 tumor necrosis factor receptor superfamily, member 8 
MAPRE
2 
0.379 EB1; EB2; RP1 NM_014268 microtubule-associated protein, RP/EB family, member 2 
JARID2 0.378 JMJ NM_004973 Jumonji, AT rich interactive domain 2 
FAM98
A 
0.378 DKFZP564F0522; DKFZp686O03192 NM_015475 family with sequence similarity 98, member A 
SLC25A
19 




0.376 LRRC5; FLJ10470; FLJ20403 NM_018103 leucine rich repeat containing 8 family, member D 
PRPS1 0.375 PRSI; PRS I; KIAA0967 NM_002764 phosphoribosyl pyrophosphate synthetase 1 
SLC6A1
5 
0.375 V7-3; NTT73; hv7-3; FLJ10316; MGC87066; 
DKFZp761I0921 
NM_018057 solute carrier family 6, member 15 
ADCY3 0.375 AC3; KIAA0511 NM_004036 adenylate cyclase 3 
LNK 0.372 LNK NM_005475 SH2B adaptor protein 3 
H2AFJ 0.37 MGC921; FLJ10903 NM_177925 H2A histone family, member J 
IGSF1 0.368 IGCD1; IGDC1; INHBP; PGSF2; KIAA0364; 
MGC75490 
NM_205833 immunoglobulin superfamily, member 1 
FXYD5 0.368 RIC; IWU1; KCT1; OIT2; IWU-1; dysad; 
HSPC113; PRO6241 
NM_014164 FXYD domain containing ion transport regulator 5 
BTBD11 0.367 FLJ33957; FLJ42845 NM_152322 BTB (POZ) domain containing 11 
LRP11 0.367 MANSC3; FLJ14735; MGC39092; bA350J20.3 NM_032832 low density lipoprotein receptor-related protein 11 
TIMP2 0.366 CSC-21K NM_003255 TIMP metallopeptidase inhibitor 2 
CIT 0.366 CRIK; STK21; KIAA0949 NM_007174 citron (rho-interacting, serine/threonine kinase 21) 
TSPAN5 0.366 NET-4; TM4SF9; TSPAN-5 NM_005723 tetraspanin 5 
HRASL
S3 
0.366 HREV107; HREV107-3; MGC118754; H-
REV107-1 
NM_007069 HRAS-like suppressor 3 
LOC134
147 
0.366 FLJ23617 NM_138809 carboxymethylenebutenolidase-like (Pseudomonas) 
MCM4 0.364 CDC21; CDC54; hCdc21; MGC33310; P1-CDC21 NM_005914 MCM4 minichromosome maintenance deficient 4 (S. cerevisiae) 
LOC387
882 
0.363 LOC387882 NM_207376 hypothetical protein 
HPRT1 0.363 HPRT; HGPRT NM_000194 hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) 
FOS 0.362 c-fos NM_005252 v-fos FBJ murine osteosarcoma viral oncogene homolog 
L2HGD
H 
0.362 FLJ12618; C14orf160 NM_024884 L-2-hydroxyglutarate dehydrogenase 
SYT6 0.36 SYT6 NM_205848 synaptotagmin VI 
CEBPZ 0.359 CBF2; HSP-CBF NM_005760 CCAAT/enhancer binding protein zeta 
MIMITI
N 
0.357 MMTN; B17.2L; mimitin NM_174889 NDUFA12-like 
FHL2 0.357 DRAL; AAG11; SLIM3 NM_001450 four and a half LIM domains 2 
PLEKH
F1 
0.355 APPD; MGC4090; PHAFIN1; ZFYVE15 NM_024310 pleckstrin homology domain containing, family F (with FYVE 
domain) member 1 
PARD6
A 
0.352 PAR6; PAR6C; TAX40; PAR-6A; TIP-40; 
PAR6alpha 
NM_016948 par-6 partitioning defective 6 homolog alpha (C.elegans) 
C13ORF
3 
0.352 RAMA1; MGC4832 NM_145061 chromosome 13 open reading frame 3 
SLC39A
10 
0.35 LZT-Hs2; MGC126565; MGC138428; 
DKFZp781L10106 
NM_020342 solute carrier family 39 (zinc transporter), member 10 
PROK2 0.35 BV8; PK2; MIT1 NM_021935 prokineticin 2 
NASP 0.349 FLB7527; MGC2297; PRO1999; FLJ31599; 
FLJ35510; MGC19722; MGC20372; 
DKFZp547F162 
NM_002482 nuclear autoantigenic sperm protein (histone-binding) 




0.346 MGC35274; DKFZp686I2243 NM_153374 LysM, putative peptidoglycan-binding, domain containing 2 
LRRN6
A 
0.345 LERN1; LINGO1; UNQ201; FLJ14594; 
MGC17422 
NM_032808 leucine rich repeat neuronal 6A 
P2RY5 0.344 P2Y5; MGC120358 NM_005767 purinergic receptor P2Y, G-protein coupled, 5 
CASP3 0.343 CPP32; SCA-1; CPP32B NM_032991 caspase 3, apoptosis-related cysteine peptidase 
TCEAL2 0.342 my048; MY0876G05 NM_080390 transcription elongation factor A (SII)-like 2 
PUNC 0.341 HsT18880 NM_004884 putative neuronal cell adhesion molecule 
FDXR 0.34 ADXR NM_024417 ferredoxin reductase 
SASH1 0.34 KIAA0790; dJ323M4.1; RP3-323M4.1 NM_015278 SAM and SH3 domain containing 1 
SCG3 0.339 SGIII; FLJ90833 NM_013243 secretogranin III 
FZD10 0.338 FzE7; FZ-10; hFz10 NM_007197 frizzled homolog 10 (Drosophila) 
INHBE 0.336 MGC4638 NM_031479 inhibin, beta E 
TIMP4 0.334 TIMP4 NM_003256 TIMP metallopeptidase inhibitor 4 
UBE2L6 0.332 RIG-B; UBCH8; MGC40331 NM_004223 ubiquitin-conjugating enzyme E2L 6 
PCOLC
E 
0.332 PCPE NM_002593 procollagen C-endopeptidase enhancer 
PFTK1 0.331 KIAA0834; PFTAIRE1 NM_012395 PFTAIRE protein kinase 1 
TM4SF1
8 
0.331 L6D NM_138786 transmembrane 4 L six family member 18 
DPPA5 0.331 Esg1 NM_001025
290 
developmental pluripotency associated 5 
KCNN2 0.33 SK2; hSK2; SKCA2; KCa2.2 NM_170775 potassium intermediate/small conductance calcium-activated 
channel, subfamily N, member 2 
TMBIM
4 
0.327 S1R; ZPRO; CGI-119 NM_016056 transmembrane BAX inhibitor motif containing 4 
FGF19 0.325 FGF19 NM_005117 fibroblast growth factor 19 
MGC24
665 
0.325 MGC24665 NM_152308 chromosome 16 open reading frame 75 
STOM 0.324 BND7; EPB7; EPB72 NM_004099 stomatin 
SOX8 0.324 MGC24837 NM_014587 SRY (sex determining region Y)-box 8 
PHC1 0.323 EDR1; HPH1; RAE28 NM_004426 polyhomeotic-like 1 (Drosophila) 
STEAP1 0.323 STEAP; PRSS24; MGC19484 NM_012449 six transmembrane epithelial antigen of the prostate 1 
DCAMK
L1 
0.323 DCLK; KIAA0369 NM_004734 doublecortin and CaM kinase-like 1 
HEY2 0.321 GRL; CHF1; HRT2; HERP1; HESR2; MGC10720 NM_012259 hairy/enhancer-of-split related with YRPW motif 2 
DUT 0.321 dUTPase; FLJ20622 NM_001025
248 
dUTP pyrophosphatase 




0.319 SCA12; MGC24888; PR55-BETA; PP2A-PR55B; 
PR2AB-BETA; PR2AB55-BETA; PR2APR55-
BETA 
NM_181676 protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 
52), beta isoform 
SEPHS1 0.315 SPS; SELD; SPS1; MGC4980 NM_012247 selenophosphate synthetase 1 
FLJ2580
1 
0.314 FLJ25801; MGC138164; MGC138166 NM_173553 hypothetical protein FLJ25801 
PSMB8 0.314 LMP7; D6S216; RING10; D6S216E; MGC1491 NM_148919 proteasome (prosome, macropain) subunit, beta type, 8 (large 
multifunctional peptidase 7) 
CABC1 0.312 COQ8; ADCK3; MGC4849 NM_020247 chaperone, ABC1 activity of bc1 complex like (S. pombe) 
OCIAD2 0.312 MGC45416; DKFZp686C03164 NM_001014
446 
OCIA domain containing 2 
KCND2 0.309 RK5; KV4.2; KIAA1044; MGC119702; 
MGC119703 




0.309 FLJ22662 NM_024829 hypothetical protein FLJ22662 
GFPT2 0.306 GFAT2; FLJ10380 NM_005110 glutamine-fructose-6-phosphate transaminase 2 
FGD5 0.306 ZFYVE23 NM_152536 FYVE, RhoGEF and PH domain containing 5 
PAK1 0.305 PAKalpha; MGC130000; MGC130001 NM_002576 p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 
ITGB1B
P3 
0.304 MIBP; NRK2; MGC126624 NM_170678 integrin beta 1 binding protein 3 
OAZ2 0.303 OAZ2 NM_002537 ornithine decarboxylase antizyme 2 
AKAP7 0.3 AKAP18 NM_016377 A kinase (PRKA) anchor protein 7 
APCDD
1 
0.296 B7323; DRAPC1; FP7019 NM_153000 adenomatosis polyposis coli down-regulated 1 
CTGF 0.294 CCN2; NOV2; HCS24; IGFBP8; MGC102839 NM_001901 connective tissue growth factor 
PRDM1
4 
0.292 PFM11; MGC59730 NM_024504 PR domain containing 14 
C7ORF2
4 
0.29 MGC3077; FLJ11717 NM_024051 chromosome 7 open reading frame 24 
NELL2 0.289 NRP2 NM_006159 NEL-like 2 (chicken) 
SMPDL
3B 
0.289 ASML3B NM_014474 sphingomyelin phosphodiesterase, acid-like 3B 
HSPA2 0.289 HSPA2 NM_021979 heat shock 70kDa protein 2 
SCGB3
A2 
0.288 LU103; PNSP1; UGRP1 NM_054023 secretoglobin, family 3A, member 2 
ICAM3 0.286 CD50; CDW50; ICAM-R NM_002162 intercellular adhesion molecule 3 
UGP2 0.284 UDPG; UGPP2; UDPGP2; pHC379 NM_006759 UDP-glucose pyrophosphorylase 2 
CHST7 0.281 C6ST-2 NM_019886 carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 7 
OCIAD2 0.277 MGC45416; DKFZp686C03164 NM_152398 OCIA domain containing 2 
CXCL12 0.275 PBSF; SDF1; SDF1A; SDF1B; TPAR1; SCYB12; 
SDF-1a; SDF-1b; TLSF-a; TLSF-b 
NM_001033
886 




0.269 FP1188; DKFZP434I2117 NM_031478 family with sequence similarity 57, member B 
SMPDL
3B 
0.268 ASML3B NM_014474 sphingomyelin phosphodiesterase, acid-like 3B 
SEMA6
A 
0.265 VIA; SEMA; HT018; SEMAQ; SEMA6A1; 
KIAA1368; sema VIa 
NM_020796 sema domain, transmembrane domain (TM), and cytoplasmic 
domain, (semaphorin) 6A 
FABP5 0.264 EFABP; E-FABP; PAFABP; PA-FABP NM_001444 fatty acid binding protein 5 (psoriasis-associated) 
RTN4IP
1 
0.264 NIMP; MGC12934 NM_032730 reticulon 4 interacting protein 1 
KIAA07
46 
0.264 KIAA0746; FLJ21629; DKFZp781J1697 NM_015187 KIAA0746 protein 
MT1A 0.261 MT1; MTC; MT1S; MGC32848 NM_005946 metallothionein 1A (functional) 
DIAPH2 0.26 DIA; POF; DIA2; POF2; FLJ11167 NM_007309 diaphanous homolog 2 (Drosophila) 
CCND1 0.259 BCL1; PRAD1; U21B31; D11S287E NM_053056 cyclin D1 
DNMT3 0.256 ICF; M.HsaIIIB NM_006892 DNA (cytosine-5-)-methyltransferase 3 beta 
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B 
NANOG 0.255 FGA NM_024865 Nanog homeobox 
IQGAP2 0.25 ARIH2 NM_006633 IQ motif containing GTPase activating protein 2 
CYP2S1 0.249 CYP2S1 NM_030622 cytochrome P450, family 2, subfamily S, polypeptide 1 
NFE2L3 0.243 NRF3 NM_004289 nuclear factor (erythroid-derived 2)-like 3 
ADAM1
5 
0.241 MDC15 NM_207195 ADAM metallopeptidase domain 15 (metargidin) 
MT1X 0.241 MT1; MT-1l NM_005952 metallothionein 1X 
DPPA2 0.237 PESCRG1 NM_138815 developmental pluripotency associated 2 
DPPA4 0.234 FLJ10713; 2410091M23Rik NM_018189 developmental pluripotency associated 4 
ITGB1B
P3 
0.23 MIBP; NRK2; MGC126624 NM_014446 integrin beta 1 binding protein 3 
MMP9 0.228 GELB; CLG4B NM_004994 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa 
type IV collagenase) 
HPCAL
1 
0.227 BDR1; HLP2; VILIP-3 NM_002149 hippocalcin-like 1 
GLDC 0.226 GCE; NKH; GCSP; HYGN1; MGC138198; 
MGC138200 
NM_000170 glycine dehydrogenase (decarboxylating) 
CKMT1
B 
0.225 CKMT; CKMT1; UMTCK NM_020990 creatine kinase, mitochondrial 1B 
TERF1 0.223 TRF; PIN2; TRF1; TRBF1; t-TRF1; hTRF1-AS NM_017489 telomeric repeat binding factor (NIMA-interacting) 1 
CDCA7
L 
0.223 R1; RAM2; DKFZp762L0311 NM_018719 cell division cycle associated 7-like 
AASS 0.22 LKRSDH; LORSDH; LKR/SDH NM_005763 aminoadipate-semialdehyde synthase 
DACT1 0.217 DPR1; FRODO; HDPR1; DAPPER; THYEX3; 
DAPPER1 
NM_016651 dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) 
SILV 0.21 SI; SIL; ME20; gp100; PMEL17; D12S53E NM_006928 silver homolog (mouse) 
UBE2L6 0.204 RIG-B; UBCH8; MGC40331 NM_004223 ubiquitin-conjugating enzyme E2L 6 





CH25H 0.204 C25H NM_003956 cholesterol 25-hydroxylase 
SCNN1
A 
0.201 ENaCa; SCNEA; SCNN1; FLJ21883; ENaCalpha NM_001038 sodium channel, nonvoltage-gated 1 alpha 
FLJ1250
5 
0.199 FLJ12505; RP11-275G3.1 NM_024749 vasohibin 2 
FAH 0.191 FAH NM_000137 fumarylacetoacetate hydrolase (fumarylacetoacetase) 
POU5F1 0.187 OCT3; OTF3; OTF4; Oct4; MGC22487 NM_203289 POU domain, class 5, transcription factor 1 
PTPRZ1 0.175 PTPZ; HPTPZ; PTP18; PTPRZ; RPTPB; 
HPTPzeta; RPTPbeta 
NM_002851 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 
FAM46
B 
0.175 MGC16491; MGC20845; RP11-344H11.8 NM_052943 family with sequence similarity 46, member B 
HAS3 0.164 HAS3 NM_005329 hyaluronan synthase 3 
USP44 0.158 FLJ14528; DKFZP434D0127 NM_032147 ubiquitin specific peptidase 44 
POU5F1 0.147 OCT3; OTF3; OTF4; Oct4; MGC22487 NM_002701 POU domain, class 5, transcription factor 1 
VSNL1 0.146 HLP3; VILIP; HPCAL3; HUVISL1; VILIP-1 NM_003385 visinin-like 1 
CKMT1
A 
0.139 CKMT1; UMTCK NM_001015
001 
creatine kinase, mitochondrial 1A 


































Gene Name Fold 
Change 
Common Genbank Description 
CD1D 2.844 R3; CD1A; MGC34622 NM_001766 CD1d molecule 
C2ORF34 2.622 FLJ23451 NM_024766 chromosome 2 open reading frame 34 
PPP2R2C 2.4 PR52; IMYPNO; IMYPNO1; 
MGC33570 
NM_181876 protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), gamma isoform 
VANGL1 2.349 LPP2; STB2; MGC5338 NM_138959 vang-like 1 (van gogh, Drosophila) 
IFRD1 2.203 PC4; TIS7 NM_001550 interferon-related developmental regulator 1 
HES1 2.14 HHL; HRY; HES-1; FLJ20408 NM_005524 hairy and enhancer of split 1, (Drosophila) 
SLC2A1 2.088 GLUT; GLUT1; MGC141895; 
MGC141896 
NM_006516 solute carrier family 2 (facilitated glucose 
transporter), member 1 
TMEPAI 2.024 STAG1; PMEPA1 NM_020182 transmembrane, prostate androgen induced 
RNA 
NTS 2.005 NN; NT; NT/N; NTS1; NMN-125 NM_006183 neurotensin 
IL17RD 1.974 SEF; IL-17RD; IL17RLM; 
FLJ35755; MGC133309; 
DKFZp434N1928 
NM_017563 interleukin 17 receptor D 
GPR64 1.974 HE6; TM7LN2; FLJ00282; 
MGC104454; MGC138738; 
MGC138739 
NM_005756 G protein-coupled receptor 64 
PPT2 1.917 G14; NG3; C6orf8; 
DKFZp564P1516 
NM_138717 palmitoyl-protein thioesterase 2 
KAL1 1.902 HHA; KAL; KMS; ADMLX; 
KALIG-1 
NM_000216 Kallmann syndrome 1 sequence 
ADAMTS18 1.9 ADAMTS21 NM_199355 ADAM metallopeptidase with 
thrombospondin type 1 motif, 18 
SLC36A2 1.875 PAT2; TRAMD1; FLJ16051; 
MGC119658; MGC119660 
NM_181776 solute carrier family 36 (proton/amino acid 
symporter), member 2 
SHB 1.873 bA3J10.2; RP11-3J10.8 NM_003028 Src homology 2 domain containing adaptor 
protein B 
SON 1.866   NM_138926   
ZNF278 1.861 ZSG; MAZR; PATZ; RIAZ; 
ZBTB19; dJ400N23 
NM_032051 zinc finger protein 278 
ANGPT1 1.854 AGP1; AGPT; ANG1 NM_001146 angiopoietin 1 
KLF5 1.84 CKLF; IKLF; BTEB2 NM_001730 Kruppel-like factor 5 (intestinal) 
GDF3 1.786 GDF3 NM_020634 growth differentiation factor 3 
CHRD 1.751   NM_177978   
C17ORF39 1.738 MGC3048 NM_024052 chromosome 17 open reading frame 39 
CROP 1.725 CROP; LUC7A; OA48-18 NM_016424 cisplatin resistance-associated overexpressed 
protein 
KIAA1944 1.704 MOLT; KIAA1944; MGC138770; 
MGC138771 
NM_133448 transmembrane protein 132D 
NEBL 1.701 LNEBL; bA56H7.1; MGC119746; 
MGC119747 
NM_006393 nebulette 
JOSD3 1.697 MGC5306 NM_024116 Josephin domain containing 3 
RNF44 1.692 KIAA1100 NM_014901 ring finger protein 44 
GAD1 1.68 GAD NM_000817 glutamate decarboxylase 1 (brain, 67kDa) 
CLK2 1.673 hCLK2; MGC61500 NM_001291 CDC-like kinase 2 
SS18L1 1.66 CREST; LP2261; KIAA0693; 
MGC26711; MGC78386 
NM_015558 synovial sarcoma translocation gene on 
chromosome 18-like 1 
MATR3 1.628 MGC9105; KIAA0723; 
DKFZp686K0542; 
DKFZp686K23100 
NM_018834 matrin 3 
RBM35A 1.615 FLJ20171 NM_017697 RNA binding motif protein 35A 
BCOR 1.612 MAA2; ANOP2; MCOPS2; 
FLJ20285; FLJ38041; KIAA1575; 
MGC71031; MGC131961 
NM_020926 BCL6 co-repressor 
C10ORF47 1.609 MGC35403 NM_153256 chromosome 10 open reading frame 47 
C9ORF77 1.607 CGI-67; RP11-409O11.2 NM_016014 chromosome 9 open reading frame 77 
CCNG2 1.606 SCOTIN NM_004354 cyclin G2 
ZNF202 1.605 ZNF202 NM_003455 zinc finger protein 202 
BTBD6 1.604 BDPL NM_033271 BTB (POZ) domain containing 6 
ZNF498 1.603 ZNF498 NM_145115 zinc finger protein 498 
ANK2 1.601 LQT4; FLJ38277; 
DKFZp686P0948; 
DKFZp686M09125 
NM_020977 ankyrin 2, neuronal 
EGLN1 1.591 PHD2; SM20; ECYT3; SM-20; 
HIFPH2; ZMYND6; C1orf12; 
DKFZp761F179 
NM_022051 egl nine homolog 1 (C. elegans) 
NRIP1 1.582 RIP140 NM_003489 nuclear receptor interacting protein 1 
NPY5R 1.568 NPYR5 NM_006174 neuropeptide Y receptor Y5 
PPARGC1A 1.56 LEM6; PGC1; PGC1A; PGC-1v; 
PPARGC1; PGC-1(alpha) 
NM_013261 peroxisome proliferative activated receptor, 
gamma, coactivator 1, alpha 
TNMD 1.553 TEM; CHM1L; BRICD4; tendin; 
myodulin; CHM1-LIKE 
NM_022144 tenomodulin 
NUDT10 1.541 DIPP3a; hDIPP3alpha NM_153183 nudix (nucleoside diphosphate linked moiety 
X)-type motif 10 
ZNF435 1.54 ZNF392; ZSCAN16; FLJ22191; 
dJ265C24.3 
NM_025231 zinc finger protein 435 
ANP32C 1.505 PP32R1 NM_012403 acidic (leucine-rich) nuclear phosphoprotein 
32 family, member C 
GABBR1 1.492 hGB1a; GPRC3A; GABABR1; 
GABBR1-3; GABAB(1e); 





KIAA1468 1.491 HsT885; HsT3308; FLJ33841 NM_020854 KIAA1468 
ATF4 1.487 CREB2; TXREB; CREB-2; 
TAXREB67 
NM_001675 activating transcription factor 4 (tax-
responsive enhancer element B67) 
DOCK1 1.48 ced5; DOCK180 NM_001380 dedicator of cytokinesis 1 
RYR2 1.478 ARVC2; ARVD2; VTSIP NM_001035 ryanodine receptor 2 (cardiac) 
ZSWIM3 1.472 C20orf164 NM_080752 zinc finger, SWIM-type containing 3 
TP53RK 1.472 PRPK; Nori-2; Nori-2p; C20orf64 NM_033550 TP53 regulating kinase 
ZNF350 1.466 ZFQR; ZBRK1 NM_021632 zinc finger protein 350 
C20ORF10 1.465 CLG01; TP53TG5 NM_014477 chromosome 20 open reading frame 10 
FUT11 1.462 MGC33202; MGC119338; 
MGC119339 
NM_173540 fucosyltransferase 11 (alpha (1,3) 
fucosyltransferase) 
ATP7B 1.454 WD; PWD; WC1; WND NM_000053 ATPase, Cu++ transporting, beta polypeptide 
SIAH1 1.454 Siah-1; hSIAH1; HUMSIAH; 
Siah-1a 
NM_001006610 seven in absentia homolog 1 (Drosophila) 
NR2C1 1.443 TR2; TR2-11 NM_001032287 nuclear receptor subfamily 2, group C, 
member 1 
ANKHD1 1.43 MASK NM_017747 ankyrin repeat and KH domain containing 1 
SNTB1 1.427 A1B; SNT2; BSYN2; 59-DAP; 
DAPA1B; SNT2B1; TIP-43; 
FLJ22442; MGC111389 
NM_021021 syntrophin, beta 1 (dystrophin-associated 
protein A1, 59kDa, basic component 1) 
FGF12 1.427 FHF1; FGF12B NM_004113 fibroblast growth factor 12 
C1ORF84 1.42 FLJ34502; RP11-506B15.1 NM_001012960 chromosome 1 open reading frame 84 
ZBED4 1.42 GON4L NM_014838 zinc finger, BED-type containing 4 
SCAND2 1.417 SCAND2 NM_033640 SCAN domain containing 2 
CRY1 1.415 PHLL1 NM_004075 cryptochrome 1 (photolyase-like) 
FLJ22639 1.401   NM_024796   
WDR19 1.399 ORF26; PWDMP; FLJ23127; 
KIAA1638 
NM_025132 WD repeat domain 19 
COL4A4 1.396 CA44 NM_000092 collagen, type IV, alpha 4 
KIAA1434 1.394 KIAA1434; FLJ11085; 
MGC26147; RP5-1022P6.2 
NM_019593 hypothetical protein KIAA1434 
EDNRA 1.388 ETA; ETRA NM_001957 endothelin receptor type A 
JRK 1.387 JH8; FLJ45729; 
DKFZp686C24207 
NM_003724 jerky homolog (mouse) 
PHF16 1.386 JADE3; KIAA0215; MGC138748; 
MGC138749 
NM_014735 PHD finger protein 16 
RCE1 1.386 FACE2; RCE1A; RCE1B NM_001032279 RCE1 homolog, prenyl protein peptidase (S. 
cerevisiae) 
CSAG2 1.382 TRAG3; MGC149851; 
MGC149852 
NM_004909 CSAG family, member 2 
PCF11 1.379 KIAA0824 NM_015885 PCF11, cleavage and polyadenylation factor 
subunit, homolog (S. cerevisiae) 
GMEB1 1.373 PIF96; P96PIF NM_006582 glucocorticoid modulatory element binding 
protein 1 
FLJ14768 1.365 ZNF798; FLJ14768 NM_032836 FLT3-interacting zinc finger 1 
MARS2 1.365 MetRS; mtMetRS NM_138395 methionine-tRNA synthetase 2 
(mitochondrial) 
MAN1A2 1.359 MAN1B NM_006699 mannosidase, alpha, class 1A, member 2 
THAP1 1.343 FLJ10477; MGC33014 NM_199003 THAP domain containing, apoptosis 
associated protein 1 
HDHD3 1.34 C9orf158; MGC12904; 
2810435D12Rik 
NM_031219 haloacid dehalogenase-like hydrolase domain 
containing 3 
ALDH1A3 1.338 ALDH6; RALDH3; ALDH1A6 NM_000693 aldehyde dehydrogenase 1 family, member A3 
CEP27 1.337 C15orf25; FLJ10460; HsT17025 NM_018097 centrosomal protein 27kDa 
BRSK2 1.332 SAD1; STK29; PEN11B; C11orf7 NM_003957 BR serine/threonine kinase 2 
CTDSP1 1.331 SCP1; NLIIF NM_182642 CTD (carboxy-terminal domain, RNA 
polymerase II, polypeptide A) small 
phosphatase 1 
MRPL27 1.331 L27mt; MGC23716 NM_148571 mitochondrial ribosomal protein L27 




NM_198330 inositol polyphosphate-5-phosphatase F 
RET 1.319 PTC; MTC1; HSCR1; MEN2A; 
MEN2B; RET51; CDHF12; RET-
ELE1 
NM_020630 ret proto-oncogene (multiple endocrine 
neoplasia and medullary thyroid carcinoma 1, 
Hirschsprung disease) 
ZNF16 1.314 KOX9 NM_001029976 zinc finger protein 16 
ATF2 1.309 HB16; CREB2; TREB7; CRE-
BP1; MGC111558 
NM_001880 activating transcription factor 2 
ZNF93 1.307 TF34; HPF34; HTF34; ZNF505 NM_001004126 zinc finger protein 93 
RNF170 1.304 FLJ38306; DKFZP564A022 NM_030954 ring finger protein 170 
ZNF233 1.304 FLJ38032 NM_181756 zinc finger protein 233 
WWOX 1.302 FOR; WOX1; FRA16D; 
HHCMA56; PRO0128; WWOX 
v8; D16S432E 
NM_130844 WW domain containing oxidoreductase 
BTRC 1.302 FWD1; FBW1A; bTrCP; 
FBXW1A; bTrCP1; MGC4643; 
betaTrCP; BETA-TRCP 
NM_003939 beta-transducin repeat containing 
MESDC1 1.301 MGC99595 NM_022566 mesoderm development candidate 1 
NR2C2 1.298 TR4; TAK1; TR2R1; hTAK1 NM_003298 nuclear receptor subfamily 2, group C, 
member 2 
HLA-DQB1 1.298 IDDM1; CELIAC1; HLA-DQB; 
HLA DQB1 
NM_002123 major histocompatibility complex, class II, 
DQ beta 1 
ZNFN1A5 1.297 PEGASUS; ZNFN1A5; 
FLJ22973; DKFZp781B0249 
NM_022466 IKAROS family zinc finger 5 (Pegasus) 
HNRPK 1.296 CSBP; TUNP; HNRNPK NM_031263 heterogeneous nuclear ribonucleoprotein K 
IFRD1 1.293 PC4; TIS7 NM_001007245 interferon-related developmental regulator 1 
YWHAZ 1.292 KCIP-1; MGC111427; 
MGC126532; MGC138156 
NM_003406 tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
ZNF71 1.29 EZFIT NM_021216 zinc finger protein 71 
MAML3 1.288 GDN; MAM2; CAGH3; ERDA3; 
MAM-2; TNRC3 
NM_018717 mastermind-like 3 (Drosophila) 
ARL5B 1.287 ARL8 NM_178815 ADP-ribosylation factor-like 5B 
GLCCI1 1.287 GIG18; FAM117C NM_138426 glucocorticoid induced transcript 1 
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CDK10 1.286 PISSLRE NM_052988 cyclin-dependent kinase (CDC2-like) 10 
ING3 1.284 Eaf4; ING2; p47ING3; FLJ20089 NM_198267 inhibitor of growth family, member 3 
FAM24B 1.281 MGC45962; DKFZp667I0323 NM_152644 family with sequence similarity 24, member B 
NOL9 1.274 FLJ23323; MGC131821; 
MGC138483 
NM_024654 nucleolar protein 9 
ZNF586 1.274 FLJ20070 NM_017652 zinc finger protein 586 
KCNG1 1.274 K13; kH2; KCNG; KV6.1; 
MGC12878 
NM_172318 potassium voltage-gated channel, subfamily 
G, member 1 
PITX2 1.271 RS; RGS; ARP1; Brx1; IDG2; 
IGDS; IHG2; PTX2; RIEG; 
IGDS2; IRID2; Otlx2; RIEG1; 
MGC20144; MGC111022 
NM_000325 paired-like homeodomain transcription factor 
2 
KLHL4 1.266 KHL4; DKELCHL; KIAA1687 NM_057162 kelch-like 4 (Drosophila) 
IL23A 1.265 P19; SGRF; IL-23; IL-23A; 
IL23P19; MGC79388 
NM_016584 interleukin 23, alpha subunit p19 
SOCS6 1.263 CIS4; SSI4; SOCS4; STAI4; 
STAT4; STATI4; HSPC060 
NM_004232 suppressor of cytokine signaling 6 
SMURF1 1.26 KIAA1625 NM_181349 SMAD specific E3 ubiquitin protein ligase 1 
KCR1 1.257 KCR1; ALG10 NM_001013620 asparagine-linked glycosylation 10 homolog B 
(yeast, alpha-1,2-glucosyltransferase) 
COX11 1.252 COX11P NM_004375 COX11 homolog, cytochrome c oxidase 
assembly protein (yeast) 
GTF2I 1.252 DIWS; SPIN; IB291; BAP135; 
BTKAP1; TFII-I; WBSCR6; BAP-
135 
NM_033001 general transcription factor II, i 
BTNL2 1.248 BTL-II; HSBLMHC1 NM_019602 butyrophilin-like 2 (MHC class II associated) 
ACHE 1.246 YT; ARACHE; N-ACHE NM_015831 acetylcholinesterase (Yt blood group) 
GOLPH3L 1.245 GPP34R; FLJ10687 NM_018178 golgi phosphoprotein 3-like 
ZNF607 1.245 FLJ14802; MGC13071 NM_032689 zinc finger protein 607 
GABRE 1.241 GABRE NM_021990 gamma-aminobutyric acid (GABA) A 
receptor, epsilon 
FLJ11171 1.24 FLJ11171 NM_018348 hypothetical protein FLJ11171 
ZNF675 1.237 TIZ; TBZF; FLJ36350 NM_138330 zinc finger protein 675 
SLC40A1 1.233 FPN1; HFE4; MTP1; IREG1; 
MST079; MSTP079; SLC11A3 
NM_014585 solute carrier family 40 (iron-regulated 
transporter), member 1 
OR2A7 1.231 OR2A21; HSDJ0798C17 NM_001005328 olfactory receptor, family 2, subfamily A, 
member 7 
TMEM16J 1.22 PIG5; TP53I5 NM_001012302 transmembrane protein 16J 
LOC112869 1.219 FLJ32446 NM_138414 coiled-coil domain containing 101 
DSCR1L1 1.217 CSP2; RCN2; MCIP2; hRCN2; 
ZAKI-4 
NM_005822 Down syndrome critical region gene 1-like 1 
ZNF419 1.211 ZNF419; FLJ23233 NM_024691 zinc finger protein 419A 
ZNF197 1.211 P18; VHLaK; ZNF20; ZNF166; 
D3S1363E 
NM_001024855 zinc finger protein 197 
PLA2G6 1.211 GVI; PLA2; INAD1; iPLA2; 
PNPLA9; CaI-PLA2 
NM_003560 phospholipase A2, group VI (cytosolic, 
calcium-independent) 
RANBP2L1 1.21 RGP5; BS-63; DKFZp686I1842 NM_005054 RANBP2-like and GRIP domain containing 5 
KIAA1414 1.207 KIAA1414 NM_019024 KIAA1414 protein 
IFIT1L 1.205 bA149I23.6; DKFZp781M1841 NM_001010987 interferon-induced protein with 
tetratricopeptide repeats 1-like 
F7 1.202 F7 NM_000131 coagulation factor VII (serum prothrombin 
conversion accelerator) 
FTSJ2 1.201   NM_177442   
AGPAT4 1.194 1-AGPAT4; dJ473J16.2; LPAAT-
delta; RP3-473J16.2 
NM_001012733 1-acylglycerol-3-phosphate O-acyltransferase 
4 (lysophosphatidic acid acyltransferase, 
delta) 
NUP43 1.194   NM_024647   
GSTZ1 1.193 MAI; MAAI; GSTZ1-1; 
MGC2029 
NM_001513 glutathione transferase zeta 1 
(maleylacetoacetate isomerase) 
EPB41L5 1.192 BE37; FLJ12957; KIAA1548 NM_020909 erythrocyte membrane protein band 4.1 like 5 
MXD1 1.191 MAD; MAD1; MGC104659 NM_002357 MAX dimerization protein 1 
ZSWIM3 1.19 C20orf164 NM_080752 zinc finger, SWIM-type containing 3 
HIP2 1.189 LIG; HYPG; UBE2K NM_005339 huntingtin interacting protein 2 
PCGF6 1.187 MBLR; RNF134; MGC15678; 
MGC17541 
NM_032154 polycomb group ring finger 6 
GLUL 1.182 GS; GLNS; PIG43 NM_001033044 glutamate-ammonia ligase (glutamine 
synthetase) 
FBXO9 1.176 FBX9; VCIA1; KIAA0936; NY-
REN-57; dJ341E18.2; 
DKFZp434C0118 
NM_033481 F-box protein 9 
EIF5 1.175 EIF-5A NM_183004 eukaryotic translation initiation factor 5 
LOC399900 1.174 LOC399900 NM_001013667 hypothetical gene supported by AK093779 
TMPRSS3 1.169 DFNB8; DFNB10; ECHOS1; 
TADG12 
NM_032401 transmembrane protease, serine 3 
ATG16L1 1.168 WDR30; APG16L; ATG16L; 
FLJ00045; FLJ10035; FLJ10828; 
FLJ22677 
NM_030803 ATG16 autophagy related 16-like 1 (S. 
cerevisiae) 
MLL4 1.167 MLL4; HRX2; MLL2; TRX2; 
KIAA0304 
NM_014727 myeloid/lymphoid or mixed-lineage leukemia 
4 
C11ORF35 1.167 MGC35138 NM_173573 chromosome 11 open reading frame 35 
ZDHHC18 1.164 DKFZp667O2416 NM_032283 zinc finger, DHHC-type containing 18 
WASF1 1.164 WAVE; SCAR1; WAVE1; 
FLJ31482; KIAA0269 
NM_003931 WAS protein family, member 1 
LRP2 1.164 gp330 NM_004525 low density lipoprotein-related protein 2 
STARD4 1.164 STARD4 NM_139164 START domain containing 4, sterol regulated 
MAPK14 1.163 RK; p38; EXIP; Mxi2; CSBP1; 
CSBP2; CSPB1; PRKM14; 
PRKM15; SAPK2A; p38ALPHA 
NM_139013 mitogen-activated protein kinase 14 
ARHGAP29 1.16 PARG1; RP11-255E17.1 NM_004815 Rho GTPase activating protein 29 
ST14 1.159 HAI; MTSP1; SNC19; MT-SP1; 
MTSP-1; PRSS14; TADG-15 
NM_021978 suppression of tumorigenicity 14 (colon 
carcinoma) 
KIF19 1.159 KIF19A; FLJ37300 NM_153209 kinesin family member 19 
IFITM5 1.158 IFITM5 NM_001025295 interferon induced transmembrane protein 5 
FLRT2 1.156 KIAA0405 NM_013231 fibronectin leucine rich transmembrane 
protein 2 
NCOA2 1.151 TIF2; GRIP1; NCoA-2; NM_006540 nuclear receptor coactivator 2 
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MGC138808 
EPS8L1 1.15 DRC3; EPS8R1; MGC4642; 
PP10566; FLJ20258; MGC23164 
NM_133180 EPS8-like 1 
SLA/LP 1.149 SLA/LP NM_016955 soluble liver antigen/liver pancreas antigen 
GGA3 1.147 KIAA0154 NM_138619 golgi associated, gamma adaptin ear 
containing, ARF binding protein 3 
DKFZP686I15217 1.146 DKFZp686I15217 NM_207495 hypothetical protein DKFZp686I15217 
LPIN3 1.145 SMP2; LIPN3L; dJ450M14.2; 
dJ450M14.3; dJ620E11.2 
NM_022896 lipin 3 
FANCC 1.141 FA3; FAC; FACC; FLJ14675 NM_000136 Fanconi anemia, complementation group C 
RET 1.14 PTC; MTC1; HSCR1; MEN2A; 
MEN2B; RET51; CDHF12; RET-
ELE1 
NM_020975 ret proto-oncogene (multiple endocrine 
neoplasia and medullary thyroid carcinoma 1, 
Hirschsprung disease) 
C13ORF6 1.139 C13orf6; FLJ14906; MGC27058; 
bA153I24.2; RP11-153I24.2 
NM_032859 abhydrolase domain containing 13 
RFX4 1.138 NYD-SP10 NM_213594 regulatory factor X, 4 (influences HLA class 
II expression) 
SUV39H2 1.133 FLJ23414 NM_024670 suppressor of variegation 3-9 homolog 2 
(Drosophila) 
GPR12 1.132 GPCR12; GPCR21; MGC138349; 
MGC138351 
NM_005288 G protein-coupled receptor 12 
LOC389118 1.131 LOC389118; PRO34300 NM_001007540 VLLR9392 





PSD 1.13 TYL; KIAA2011 NM_002779 pleckstrin and Sec7 domain containing 
HTN3 1.126 HIS2; HTN2; HTN5 NM_000200 histatin 3 
RNPEPL1 1.122 FLJ10806; FLJ26675; MGC99544 NM_018226 arginyl aminopeptidase (aminopeptidase B)-
like 1 
TREML1 1.122 TLT1; TLT-1; PRO3438; 
GLTL1825; MGC119173; 
dJ238O23.3 
NM_178174 triggering receptor expressed on myeloid 
cells-like 1 
LGALS2 1.121 HL14; MGC75071 NM_006498 lectin, galactoside-binding, soluble, 2 
(galectin 2) 
HAAO 1.119 HAO; 3-HAO NM_012205 3-hydroxyanthranilate 3,4-dioxygenase 
WBSCR23 1.118   NM_025042   
ARTN 1.118 EVN; NBN NM_057160 artemin 
PSCDBP 1.116 HE; B3-1; CASP; CYBR; CYTIP NM_004288 pleckstrin homology, Sec7 and coiled-coil 
domains, binding protein 
FAM91A1 1.115 FLJ23790; DKFZp666B104 NM_144963 family with sequence similarity 91, member 
A1 
PCDHA11 1.114 CNR7; CNRN7; CNRS7; CRNR7; 
PCDH-ALPHA11 
NM_031861 protocadherin alpha 11 
MYH3 1.107 HEMHC; SMHCE; MYHSE1; 
MYHC-EMB 
NM_002470 myosin, heavy polypeptide 3, skeletal muscle, 
embryonic 
C8ORF37 1.105 FLJ30600 NM_177965 chromosome 8 open reading frame 37 
SPTB 1.104 HSpTB1 NM_001024858 spectrin, beta, erythrocytic (includes 
spherocytosis, clinical type I) 
TSHB 1.103 TSH-BETA NM_000549 thyroid stimulating hormone, beta 
RFNG 1.102 RFNG NM_002917 radical fringe homolog (Drosophila) 
LOC390667 1.095 LOC390667 NM_001013658 similar to Neuronal pentraxin II precursor 
(NP-II) (NP2) 
KA21 1.094 KA21; MGC45562 NM_152349 keratin 222 pseudogene 
TAS2R4 1.093 T2R4 NM_016944 taste receptor, type 2, member 4 
MMP28 1.091 MM28; MMP25 NM_001032278 matrix metallopeptidase 28 
C1ORF157 1.09 FLJ40343; MGC120329; 
MGC120330; MGC120332 
NM_182579 chromosome 1 open reading frame 157 
CRYM 1.09 THBP; DFNA40 NM_001014444 crystallin, mu 
CLUL1 1.088 RA337M NM_199167 clusterin-like 1 (retinal) 
LTBP1 1.084 LTBP1 NM_206943 latent transforming growth factor beta binding 
protein 1 
NUP155 1.083 N155; KIAA0791 NM_153485 nucleoporin 155kDa 
CMIP 1.081 CMIP; KIAA1694 NM_198390 c-Maf-inducing protein 
PLEC1 1.081 HD1; PCN; EBS1; EBSO; PLTN; 
PLEC1b 
NM_201380 plectin 1, intermediate filament binding 
protein 500kDa 
FLJ36492 1.08 FLJ36492; MGC126634 NM_182568 hypothetical protein FLJ36492 
GHRHR 1.078 GRFR; GHRFR; GHRHRpsv NM_001009824 growth hormone releasing hormone receptor 
ARHGAP11A 1.078 KIAA0013; MGC70740; GAP (1-
12) 
NM_014783 Rho GTPase activating protein 11A 
PRKCABP 1.074 PRKCABP; MGC15204 NM_012407 protein interacting with PRKCA 1 
FYTTD1 1.069 DKFZp761B1514 NM_001011537 forty-two-three domain containing 1 
HIST1H2BI 1.066 H2B/k; H2BFK NM_003525 histone 1, H2bi 
OR52A4 1.064 OR52A4 NM_001005222 olfactory receptor, family 52, subfamily A, 
member 4 
TIGD1 1.059 EEYORE NM_145702 tigger transposable element derived 1 
LOC400986 1.058 LOC400986 NM_001010914 synonym: HEM1; Homo sapiens protein 
immuno-reactive with anti-PTH polyclonal 
antibodies (LOC400986), mRNA. 
SPG7 1.057 CAR; PGN; CMAR; MGC126331; 
MGC126332 
NM_199367 spastic paraplegia 7, paraplegin (pure and 
complicated autosomal recessive) 
SUCNR1 1.044 GPR91 NM_033050 succinate receptor 1 
ELA2A 1.04 ELA2A; ELA1; PE-1 NM_033440 elastase 2A 
MAP4 1.035 MGC8617; DKFZp779A1753 NM_030884 microtubule-associated protein 4 
DLX3 1.034 TDO NM_005220 distal-less homeobox 3 
KIAA0513 1.033 KIAA0513 NM_014732 KIAA0513 
GLYAT 0.972 CAT; GAT; ACGNAT NM_005838 glycine-N-acyltransferase 
KRTAP10-10 0.97 KAP10.10; KAP18.10; 
KRTAP18-10; KRTAP18.10 
NM_181688 keratin associated protein 10-10 
UNQ9217 0.964 UNQ9217 NM_205548 AASA9217 
KRTAP1-1 0.961 HB2A; KAP1.1; KAP1.6; 
KAP1.7; KAP1.1A; KAP1.1B; 
KRTAP1A; hKAP1.7; KRTAP1.1 
NM_030967 keratin associated protein 1-1 
TSKS 0.944 TSKS; TSKS1 NM_021733 testis-specific kinase substrate 
CC2D1A 0.941 MRT3; FREUD-1; FLJ20241; 
FLJ41160 
NM_017721 coiled-coil and C2 domain containing 1A 
SHOX 0.94 SS; GCFX; PHOG; SHOXY NM_000451 short stature homeobox 
 274
STAG3 0.936 STAG3 NM_012447 stromal antigen 3 
TNPO1 0.936 MIP; TRN; IPO2; MIP1; KPNB2 NM_002270 transportin 1 
GUCY1A2 0.935 GC-SA2; GUC1A2 NM_000855 guanylate cyclase 1, soluble, alpha 2 
MLL2 0.928 ALR; AAD10 NM_003482 myeloid/lymphoid or mixed-lineage leukemia 
2 
F11 0.92 FXI NM_000128 coagulation factor XI (plasma thromboplastin 
antecedent) 
PPP1R14D 0.92 GBPI-1; FLJ20251; MGC119014; 
MGC119016; CPI17-like 
NM_017726 protein phosphatase 1, regulatory (inhibitor) 
subunit 14D 
UACA 0.919 NUCLING; FLJ10128; 
KIAA1561; MGC141967; 
MGC141969 
NM_018003 uveal autoantigen with coiled-coil domains 
and ankyrin repeats 
CIB3 0.919 KIP3; MGC96922; MGC138405; 
MGC142151 
NM_054113 calcium and integrin binding family member 3 
ST8SIA4 0.919 PST; PST1; SIAT8D; MGC34450; 
MGC61459; ST8SIA-IV 
NM_175052 ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 4 
ZDHHC9 0.918 DHHC9; CGI-89; ZNF379 NM_016032 zinc finger, DHHC-type containing 9 
LZTFL1 0.917 RAPH1 NM_020347 leucine zipper transcription factor-like 1 
C20ORF135 0.914 MGC42974; dJ591C20.1 NM_080622 chromosome 20 open reading frame 135 
FLJ42393 0.913 FLJ42393 NM_207488 FLJ42393 protein 
RDH8 0.912 PRRDH NM_015725 retinol dehydrogenase 8 (all-trans) 
FLJ23447 0.91 SLRR5B; FLJ23447 NM_024825 podocan-like 1 
CUBN 0.907 IFCR; MGA1; gp280; FLJ90055; 
FLJ90747 
NM_001081 cubilin (intrinsic factor-cobalamin receptor) 
EEFSEC 0.902 SELB; EFSEC NM_021937 eukaryotic elongation factor, selenocysteine-
tRNA-specific 
Sep-06 0.901 SEP2; KIAA0128; MGC16619; 
MGC20339; RP5-876A24.2 
NM_145799 septin 6 
TCP11 0.9 D6S230E; KIAA0229; 
MGC111103 
NM_018679 t-complex 11 (mouse) 
OSR2 0.9 FLJ90037 NM_053001 odd-skipped related 2 (Drosophila) 
PPFIA1 0.894 LIP1; LIP.1; LIPRIN; MGC26800 NM_177423 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein 
(liprin), alpha 1 
CATSPER2 0.893 MGC33346 NM_172097 cation channel, sperm associated 2 
ASCC3 0.891 RNAH; HELIC1; ASC1p200; 
MGC26074; DJ467N11.1; 
dJ121G13.4 
NM_022091 activating signal cointegrator 1 complex 
subunit 3 
FLJ42102 0.888 FLJ42102 NM_001001680 FLJ42102 protein 
ZNF658 0.886 FLJ32813; MGC35232; 
DKFZp572C163 
NM_033160 zinc finger protein 658 
PROP1 0.884 PROP1 NM_006261 prophet of Pit1, paired-like homeodomain 
transcription factor 
ATR 0.882 FRP1; MEC1; SCKL; SCKL1 NM_001184 ataxia telangiectasia and Rad3 related 
BICD1 0.88 BICD NM_001714 bicaudal D homolog 1 (Drosophila) 
POMZP3 0.877 POM121; MGC8359; POM-ZP3 NM_012230 POM (POM121 homolog, rat) and ZP3 fusion 
KLHL4 0.876 KHL4; DKELCHL; KIAA1687 NM_019117 kelch-like 4 (Drosophila) 
BHMT 0.875 BHMT NM_001713 betaine-homocysteine methyltransferase 
MAP4K3 0.874 GLK; MAPKKKK3; RAB8IPL1 NM_003618 mitogen-activated protein kinase kinase kinase 
kinase 3 
LOC51315 0.87 FLJ22333 NM_016618 lysine-rich coiled-coil 1 
MAWBP 0.868 MAWBP; FLJ35507 NM_001033083 MAWD binding protein 
SSH1 0.866 SSH-1; FLJ38102; KIAA1298 NM_018984 slingshot homolog 1 (Drosophila) 
IGSF4B 0.865 BIgR; NECL1; TSLL1; Necl-1; 
synCAM3; FLJ10698 
NM_021189 immunoglobulin superfamily, member 4B 
PRKCB1 0.865 PKCB; PRKCB; PRKCB2; 
MGC41878; PKC-beta 
NM_212535 protein kinase C, beta 1 
MAGI1 0.862 AIP3; BAP1; WWP3; BAIAP1; 
MAGI-1; TNRC19 
NM_001033057 membrane associated guanylate kinase, WW 
and PDZ domain containing 1 
NPAS2 0.861 MOP4; PASD4; FLJ23138; 
MGC71151 
NM_002518 neuronal PAS domain protein 2 
IQCG 0.853 FLJ11667; FLJ23571; 
DKFZp434B227 
NM_032263 IQ motif containing G 
CCBE1 0.851 FLJ30681; MGC50861 NM_133459 collagen and calcium binding EGF domains 1 
UXT 0.849 ART-27 NM_153477 ubiquitously-expressed transcript 
RSHL2 0.847 RSP3; dJ111C20.1 NM_031924 radial spokehead-like 2 
NAT2 0.846 AAC2 NM_000015 N-acetyltransferase 2 (arylamine N-
acetyltransferase) 
INSIG1 0.845 CL-6; MGC1405 NM_198336 insulin induced gene 1 
PRKAA1 0.844 AMPK; AMPKa1; MGC33776; 
MGC57364 
NM_206907 protein kinase, AMP-activated, alpha 1 
catalytic subunit 
ABCB4 0.843 MDR3; PGY3; ABC21; MDR2/3; 
PFIC-3 
NM_000443 ATP-binding cassette, sub-family B 
(MDR/TAP), member 4 
BLOC1S2 0.84 BLOS2; FLJ30135; MGC10120; 
RP11-316M21.4 
NM_001001342 biogenesis of lysosome-related organelles 
complex-1, subunit 2 
GABRD 0.839 MGC45284 NM_000815 gamma-aminobutyric acid (GABA) A 
receptor, delta 
ASTN2 0.837 KIAA0634; bA67K19.1 NM_198188 astrotactin 2 
RBL2 0.832 Rb2; P130; FLJ26459 NM_005611 retinoblastoma-like 2 (p130) 
DNM1 0.831 DNM NM_004408 dynamin 1 
FA2H 0.83 FAAH; FAXDC1; FLJ25287 NM_024306 fatty acid 2-hydroxylase 
HOXA11 0.829 HOX1; HOX1I NM_005523 homeobox A11 
CPZ 0.826 MGC99682 NM_001014447 carboxypeptidase Z 
NDUFB4 0.826 B15; CI-B15; MGC5105 NM_004547 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 4, 15kDa 
MSRB3 0.821 FLJ36866; DKFZp686C1178 NM_001031679 methionine sulfoxide reductase B3 
KCNH2 0.819 ERG1; HERG; LQT2; SQT1; 
HERG1; Kv11.1 
NM_172056 potassium voltage-gated channel, subfamily H 
(eag-related), member 2 
MOCS1 0.818 MIG11; MOCOD; MOCS1A; 
MOCS1B; KIAA0381 
NM_138928 molybdenum cofactor synthesis 1 
PEX11A 0.816 MGC138534; PEX11-ALPHA NM_003847 peroxisomal biogenesis factor 11A 
UNQ2541 0.815 UNQ2541 NM_203347 MSFL2541 
C6ORF167 0.814 FLJ46180; KIAA1900; 
dJ39B17.2; DKFZp781C2113; 
DKFZp686C20164 
NM_198468 chromosome 6 open reading frame 167 
MCAM 0.814 CD146; MUC18 NM_006500 melanoma cell adhesion molecule 
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FAM112B 0.814 FLJ32942 NM_144594 family with sequence similarity 112, member 
B 
PLEKHQ1 0.813 PP1628; pp9099; FLJ38884; 
DKFZp761K2312 
NM_025201 pleckstrin homology domain containing, 
family Q member 1 
PPIL6 0.813 MGC41939; bA425D10.6; 
dJ919F19.1 
NM_173672 peptidylprolyl isomerase (cyclophilin)-like 6 
GATA2 0.807 NFE1B; MGC2306 NM_032638 GATA binding protein 2 
EBF 0.806 COE1; EBF1; OLF1; O/E-1 NM_024007 early B-cell factor 
KLK7 0.806 SCCE; PRSS6 NM_139277 kallikrein 7 (chymotryptic, stratum corneum) 
NOX5 0.806 NOX5A; NOX5B NM_024505 NADPH oxidase, EF-hand calcium binding 
domain 5 
COL13A1 0.805 COL13A1 NM_080805 collagen, type XIII, alpha 1 
KARS 0.802 KARS2; KIAA0070 NM_005548 lysyl-tRNA synthetase 
USP48 0.802 USP31; RAP1GA1; MGC14879; 
MGC132556; DKFZp762M1713 
NM_001032730 ubiquitin specific peptidase 48 
DNTTIP2 0.8 ERBP; TdIF2; HSU15552; LPTS-
RP2; RP4-561L24.1 
NM_014597 deoxynucleotidyltransferase, terminal, 
interacting protein 2 
SEZ6 0.8 ZC3HC1 NM_178860 seizure related 6 homolog (mouse) 
BTN3A3 0.799 BTF3 NM_006994 butyrophilin, subfamily 3, member A3 
PTPRE 0.798 PTPE; HPTPE; DKFZp313F1310; 
R-PTP-EPSILON 
NM_006504 protein tyrosine phosphatase, receptor type, E 
FLJ45121 0.797 FLJ45121 NM_207451 FLJ45121 protein 
C9ORF132 0.795 EEIG1; C9orf132; MGC50853; 
bA203J24.7 
NM_203305 family with sequence similarity 102, member 
A 
WDR63 0.793 FLJ30067; NYD-SP29; RP11-
507C22.2 
NM_145172 WD repeat domain 63 
DOK4 0.793 FLJ10488 NM_018110 docking protein 4 
SELO 0.792 SELO; MGC131879 NM_031454 selenoprotein O 
SEZ6L2 0.785 PSK-1; FLJ90517 NM_201575 seizure related 6 homolog (mouse)-like 2 
HIST1H2BJ 0.784 H2B/r; H2BFR NM_021058 histone 1, H2bj 
C3ORF34 0.782 MGC14126 NM_032898 chromosome 3 open reading frame 34 
RWDD2 0.781 MGC13523; MGC138208; 
dJ747H23.2 
NM_033411 RWD domain containing 2 
SLC35A2 0.78 UGT; UGAT; UGT1; UGT2; 
UGTL; UGALT 
NM_005660 solute carrier family 35 (UDP-galactose 
transporter), member A2 
PPFIA3 0.777 LPNA3; KIAA0654; 
MGC126567; MGC126569 
NM_003660 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein 
(liprin), alpha 3 
C14ORF28 0.774 DRIP1; c14_5270 NM_001017923 chromosome 14 open reading frame 28 
CARS 0.773 CYSRS; MGC:11246 NM_001751 cysteinyl-tRNA synthetase 
ACADS 0.772 SCAD; ACAD3 NM_000017 acyl-Coenzyme A dehydrogenase, C-2 to C-3 
short chain 
GRHL3 0.771 SOM; TFCP2L4; MGC46624 NM_021180 grainyhead-like 3 (Drosophila) 
PPM1F 0.771 FEM-2; POPX2; hFEM-2; 
CaMKPase; KIAA0015 
NM_014634 protein phosphatase 1F (PP2C domain 
containing) 
CYP51A1 0.768 LDM; CP51; CYP51; CYPL1; 
P450L1; P450-14DM 
NM_000786 cytochrome P450, family 51, subfamily A, 
polypeptide 1 
KRT17 0.768 PC; K17; PC2; PCHC1 NM_000422 keratin 17 
KCTD13 0.767 PDIP1; FKSG86; POLDIP1 NM_178863 potassium channel tetramerisation domain 
containing 13 
LOC196463 0.766 LOC196463 NM_173542 hypothetical protein LOC196463 
SLC25A20 0.766 CAC; CACT NM_000387 solute carrier family 25 
(carnitine/acylcarnitine translocase), member 
20 
C1ORF33 0.766 dJ657E11.4 NM_016183 chromosome 1 open reading frame 33 
ADC 0.765 ODC-p; ODC1L; KIAA1945 NM_052998 arginine decarboxylase 
EGFL6 0.762 W80; MAEG; DKFZp564P2063 NM_015507 EGF-like-domain, multiple 6 
CRI1 0.761 EID1; EID-1; RBP21; PTD014; 
C15orf3; PNAS-22; IRO45620; 
MGC138883; MGC138884 
NM_014335 CREBBP/EP300 inhibitor 1 
WDR23 0.759 GL014; PRO2389; 
DKFZp779A1629 
NM_025230 WD repeat domain 23 
ZDHHC24 0.759 ZDHHC24 NM_207340 zinc finger, DHHC-type containing 24 
PNKD 0.755 MR1; PDC; DYT8; FPD1; MR-1; 
BRP17; FKSG19; TAHCCP2; 
KIAA1184; KIPP1184; 
MGC31943; DKFZp564N1362 
NM_022572 paroxysmal nonkinesiogenic dyskinesia 
CPA4 0.755 CPA3 NM_016352 carboxypeptidase A4 
C1ORF24 0.755 C1orf24 NM_022083 synonyms: NIBAN, FLJ38228; isoform 2 is 
encoded by transcript variant 2; cell growth 
inhibiting protein 39; Homo sapiens 
chromosome 1 open reading frame 24 
(C1orf24), transcript variant 2, mRNA. 
POU2F3 0.754 OCT11; PLA-1; Epoc-1; Skn-1a; 
FLJ40063; MGC126698 
NM_014352 POU domain, class 2, transcription factor 3 
RRAD 0.751 RAD; RAD1; REM3 NM_004165 Ras-related associated with diabetes 
KIAA1324 0.75 RP11-352P4.1 NM_020775 KIAA1324 
BICD2 0.748 KIAA0699; bA526D8.1 NM_001003800 bicaudal D homolog 2 (Drosophila) 
HTR3A 0.747 HTR3; 5HT3R; 5-HT-3; 5-HT3A; 
5-HT3R 
NM_000869 5-hydroxytryptamine (serotonin) receptor 3A 
ABCA8 0.747 KIAA0822 NM_007168 ATP-binding cassette, sub-family A (ABC1), 
member 8 
C1ORF83 0.742 FLJ32112; FLJ39169; RP4-
758J24.3 
NM_153035 chromosome 1 open reading frame 83 
UPF3B 0.735 UPF3X; HUPF3B; RENT3B NM_080632 UPF3 regulator of nonsense transcripts 
homolog B (yeast) 
PRKCB1 0.73 PKCB; PRKCB; PRKCB2; 
MGC41878; PKC-beta 
NM_212535 protein kinase C, beta 1 
RIPK5 0.723 RIP5; DustyPK; HDCMD38P; 
KIAA0472 
NM_015375 receptor interacting protein kinase 5 
KLHL13 0.721 BKLHD2; FLJ10262; KIAA1309; 
MGC74791 
NM_033495 kelch-like 13 (Drosophila) 
GDF6 0.719 CDMP2 NM_001001557 growth differentiation factor 6 
HSD17B2 0.714 HSD17; EDH17B2 NM_002153 hydroxysteroid (17-beta) dehydrogenase 2 
ARL3 0.711 ARFL3 NM_004311 ADP-ribosylation factor-like 3 
GSTM5 0.711 GTM5; GSTM5-5 NM_000851 glutathione S-transferase M5 
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NOXO1 0.709 P41NOX; P41NOXA; P41NOXB; 
P41NOXC; SH3PXD5; 
MGC20258 
NM_144603 NADPH oxidase organizer 1 
NUDT6 0.707 gfg; bFGF; FGF-2; gfg-1; 
ASFGF2; FGF-AS; FGF2AS 
NM_198041 nudix (nucleoside diphosphate linked moiety 
X)-type motif 6 
RAB11FIP4 0.707 FLJ00131; KIAA1821; 
MGC11316; MGC126566; 
RAB11-FIP4 
NM_032932 RAB11 family interacting protein 4 (class II) 
CD36 0.702 FAT; GP4; GP3B; GPIV; PASIV; 
SCARB3 
NM_001001548 CD36 molecule (thrombospondin receptor) 
APS 0.702 APS NM_020979 SH2B adaptor protein 2 
PTGER1 0.7 EP1 NM_000955 prostaglandin E receptor 1 (subtype EP1), 
42kDa 
CRH 0.7 CRF NM_000756 corticotropin releasing hormone 
AHNAK 0.699 AHNAKRS; MGC5395 NM_024060 AHNAK nucleoprotein (desmoyokin) 
STARD8 0.698 KIAA0189; DKFZp686H1668 NM_014725 START domain containing 8 
FLJ10260 0.692 SLFN3; FLJ10260 NM_018042 schlafen family member 12 
APBB1IP 0.69 RIAM; INAG1; PREL1; RARP1 NM_019043 amyloid beta (A4) precursor protein-binding, 
family B, member 1 interacting protein 
MGC31967 0.689 MGC31967; RP11-331F9.6 NM_174923 coiled-coil domain containing 107 
SERPING1 0.688 C1IN; C1NH; HAE1; HAE2; 
C1INH 
NM_000062 serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1, (angioedema, 
hereditary) 
RARRES3 0.687 RIG1; TIG3; HRASLS4; 
MGC8906 
NM_004585 retinoic acid receptor responder (tazarotene 
induced) 3 
C4ORF18 0.685 AD021; AD036; FLJ38155; 
DKFZp434L142 
NM_016613 chromosome 4 open reading frame 18 
TGFB1I1 0.684 HIC5; ARA55; HIC-5; TSC-5 NM_015927 transforming growth factor beta 1 induced 
transcript 1 
ETV1 0.684 ER81; MGC104699; 
MGC120533; MGC120534; 
DKFZp781L0674 
NM_004956 ets variant gene 1 
ATG4A 0.679 APG4A; AUTL2 NM_052936 ATG4 autophagy related 4 homolog A (S. 
cerevisiae) 
IL11RA 0.677 MGC2146 NM_004512 interleukin 11 receptor, alpha 
C1ORF116 0.677 SARG; MGC2742; MGC4309; 
FLJ36507; DKFZp666H2010 
NM_023938 chromosome 1 open reading frame 116 
CNN1 0.674 SMCC; Sm-Calp NM_001299 calponin 1, basic, smooth muscle 
SYAP1 0.666 PRO3113; FLJ14495; FLJ44185; 
DKFZp686K221 
NM_032796 synapse associated protein 1, SAP47 homolog 
(Drosophila) 
DOC1 0.664 DOC1; GIP90 NM_182909 downregulated in ovarian cancer 1 
MYL9 0.663 LC20; MLC2; MRLC1; MYRL2; 
MGC3505 
NM_006097 myosin, light polypeptide 9, regulatory 
MEIS2 0.659 MRG1; MGC2820; HsT18361 NM_020149 Meis1, myeloid ecotropic viral integration site 
1 homolog 2 (mouse) 
C20ORF18 0.654 XAP4; RBCK2; RNF54; 
ZRANB4; C20orf18; UBCE7IP3 
NM_006462 RanBP-type and C3HC4-type zinc finger 
containing 1 
TNFRSF10A 0.652 DR4; APO2; CD261; MGC9365; 
TRAILR1; TRAILR-1 
NM_003844 tumor necrosis factor receptor superfamily, 
member 10a 
GSTM3 0.652 GST5; GSTB; GTM3; GSTM3-3; 
MGC3310; MGC3704 
NM_000849 glutathione S-transferase M3 (brain) 
F2RL2 0.652 PAR3 NM_004101 coagulation factor II (thrombin) receptor-like 
2 
FBXO32 0.645 Fbx32; MAFbx; ATROGIN1; 
FLJ32424; MGC33610 
NM_148177 F-box protein 32 








NM_014988 hypothetical protein 
PTGDS 0.638 PDS; PGD2; PGDS; PGDS2 NM_000954 prostaglandin D2 synthase 21kDa (brain) 
FLI1 0.637 EWSR2; SIC-1 NM_002017 Friend leukemia virus integration 1 
AMPD3 0.633 DUT NM_001025389 adenosine monophosphate deaminase 
(isoform E) 
CDKN1A 0.629 P21; CIP1; SDI1; WAF1; CAP20; 
CDKN1; MDA-6; p21CIP1 
NM_078467 cyclin-dependent kinase inhibitor 1A (p21, 
Cip1) 
GNA15 0.628 GNA16 NM_002068 guanine nucleotide binding protein (G 
protein), alpha 15 (Gq class) 
HEXA 0.626 TSD; MGC99608 NM_000520 hexosaminidase A (alpha polypeptide) 
ACPP 0.626 PAP; ACP3; ACP-3 NM_001099 acid phosphatase, prostate 
CFH 0.616 FH; HF; HF1; HF2; HUS; FHL1; 
CFHL3; MGC88246 
NM_001014975 complement factor H 
BHMT2 0.615 FLJ20001 NM_017614 betaine-homocysteine methyltransferase 2 
AK5 0.612 AK6; MGC33326 NM_174858 adenylate kinase 5 
ATP1B2 0.609 AMOG NM_001678 ATPase, Na+/K+ transporting, beta 2 
polypeptide 
IDS 0.607 MPS2; SIDS NM_000202 iduronate 2-sulfatase (Hunter syndrome) 
HOXA10 0.605 PL; HOX1; HOX1H; HOX1.8; 
MGC12859 
NM_153715 homeobox A10 
ELLS1 0.604 Ells1; FLJ25903 NM_152793 chromosome 7 open reading frame 41 
PTMA 0.602 TMSA; MGC104802 NM_002823 prothymosin, alpha (gene sequence 28) 
DOC1 0.601 DOC1; GIP90 NM_014890 downregulated in ovarian cancer 1 
AHNAK 0.598 AHNAKRS; MGC5395 NM_024060 AHNAK nucleoprotein (desmoyokin) 
MYEOV 0.597 OCIM NM_138768 myeloma overexpressed gene (in a subset of 
t(11;14) positive multiple myelomas) 
LRP10 0.597 LRP9; MST087; MGC8675; 
MSTP087; MGC142274; 
MGC142276; DKFZP564C1940 
NM_014045 low density lipoprotein receptor-related 
protein 10 
COL11A1 0.595 STL2; COLL6; CO11A1 NM_080629 collagen, type XI, alpha 1 
A4GALT 0.592 P1; PK; A14GALT; A4GALT1 NM_017436 alpha 1,4-galactosyltransferase 
(globotriaosylceramide synthase) 
IL6ST 0.592 CD130; GP130; CDw130; IL6R-
beta; GP130-RAPS 
NM_002184 interleukin 6 signal transducer (gp130, 
oncostatin M receptor) 
C9ORF89 0.589 BinCARD; MGC11115; NM_032310 chromosome 9 open reading frame 89 
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MGC110898; bA370F5.1 
TGM2 0.578 TG2; TGC NM_198951 transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
TRPM4 0.578 TRPM4B; FLJ20041 NM_017636 transient receptor potential cation channel, 
subfamily M, member 4 
BMP1 0.577 PCP; TLD; PCOLC; FLJ44432 NM_006129 bone morphogenetic protein 1 
ABCC3 0.574   NM_020037   
PTPRN 0.566 IA2; IA-2; ICA512; R-PTP-N; 
FLJ16131; IA-2/PTP 
NM_002846 protein tyrosine phosphatase, receptor type, N 
NRG1 0.557 GGF; HGL; HRG; NDF; ARIA; 
GGF2; HRG1; HRGA; SMDF 
NM_013960 neuregulin 1 
H2AFY 0.542 H2A.y; H2A/y; H2AFJ; mH2A1; 
H2AF12M; MACROH2A1.1; 
macroH2A1.2 
NM_138609 H2A histone family, member Y 
ATP2B4 0.537 MXRA1; PMCA4; ATP2B2; 
DKFZp686M088; 
DKFZp686G08106 
NM_001684 ATPase, Ca++ transporting, plasma 
membrane 4 
SGCE 0.526 ESG; DYT11 NM_003919 sarcoglycan, epsilon 
MYO1D 0.518 myr4; KIAA0727 NM_015194 myosin ID 
ALCAM 0.517 MEMD; CD166; FLJ38514; 
MGC71733 
NM_001627 activated leukocyte cell adhesion molecule 
TICAM1 0.515 TRIF; PRVTIRB; TICAM-1; 
MGC35334 
NM_182919 toll-like receptor adaptor molecule 1 
IL1A 0.513 IL1; IL-1A; IL1F1; IL1-ALPHA NM_000575 interleukin 1, alpha 
STAT1 0.495 ISGF-3; STAT91; 
DKFZp686B04100 
NM_139266 signal transducer and activator of transcription 
1, 91kDa 
FLJ90166 0.493 FLJ90166; MGC126807; 
MGC126809; RP4-685L9.2 
NM_153360 adenomatosis polyposis coli down-regulated 
1-like 
CEECAM1 0.474 CerCAM; GLT25D3; 
MGC149620; MGC149621 
NM_016174 cerebral endothelial cell adhesion molecule 1 
IL24 0.471 C49A; FISP; MDA7; ST16; IL-24; 
IL10B; Mob-5; mda-7 
NM_006850 interleukin 24 
DHRS3 0.461 SDR1; RDH17; Rsdr1; retSDR1 NM_004753 dehydrogenase/reductase (SDR family) 
member 3 
JAK1 0.46 JAK1A; JAK1B NM_002227 Janus kinase 1 (a protein tyrosine kinase) 
DEGS1 0.457 MLD; DEGS; DES1; Des-1; 
FADS7; MIG15; MGC5079 
NM_003676 degenerative spermatocyte homolog 1, lipid 
desaturase (Drosophila) 
NRP1 0.447 NRP; CD304; VEGF165R; 
DKFZp781F1414; 
DKFZp686A03134 
NM_001024629 neuropilin 1 
HSDL2 0.426 C9orf99; FLJ25855; MGC10940 NM_032303 hydroxysteroid dehydrogenase like 2 
COMT 0.417 COMT NM_000754 catechol-O-methyltransferase 
DFNA5 0.407 ICERE-1 NM_004403 deafness, autosomal dominant 5 
THRA 0.404 AR7; EAR7; ERBA; ERBA1; 
NR1A1; THRA1; THRA2; 
THRA3; EAR-7.1; EAR-7.2; 




NM_003250 thyroid hormone receptor, alpha 
(erythroblastic leukemia viral (v-erb-a) 
oncogene homolog, avian) 
GPR177 0.401 MRP; WLS; C1orf139; FLJ23091; 
MGC14878; MGC131760 
NM_024911 G protein-coupled receptor 177 
LIMA1 0.395 EPLIN; SREBP3; MGC131726 NM_016357 LIM domain and actin binding 1 
LOC388610 0.381 LOC388610 NM_001013642 hypothetical LOC388610 
ECM1 0.368 ECM1 NM_004425 extracellular matrix protein 1 
S100A4 0.359 42A; 18A2; CAPL; MTS1; P9KA; 
PEL98 
NM_002961 S100 calcium binding protein A4 
S100A4 0.358 42A; 18A2; CAPL; MTS1; P9KA; 
PEL98 
NM_002961 S100 calcium binding protein A4 
FAP 0.351 FAPA; DPPIV; SEPRASE; 
DKFZp686G13158 
NM_004460 fibroblast activation protein, alpha 
EDG2 0.346 LPA1; LPAR1; edg-2; vzg-1; 
Gpcr26; Mrec1.3; rec.1.3 
NM_001401 endothelial differentiation, lysophosphatidic 
acid G-protein-coupled receptor, 2 
CCL20 0.333 CKb4; LARC; ST38; MIP3A; 
MIP-3a; SCYA20 
NM_004591 chemokine (C-C motif) ligand 20 
SPARC 0.333 ON NM_003118 secreted protein, acidic, cysteine-rich 
(osteonectin) 
TGM2 0.313 TG2; TGC NM_004613 transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) 
HS3ST3A1 0.29 30ST3A1; 3OST3A1 NM_006042 heparan sulfate (glucosamine) 3-O-
sulfotransferase 3A1 
CASP4 0.228 TX; ICH-2; Mih1/TX; ICEREL-II; 
ICE(rel)II 
NM_033306 caspase 4, apoptosis-related cysteine peptidase 
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